

MRFF Initiative	Grant Opportunity	Organisation	Organisation Type	State or Territory	Project Name	Project Summary	Chief Investigator A/Project Lead	Chief Investigator Team	Type of Grant	Contract Start Date	Contract End Date	Field of Research Category	Field(s) of Research	Total Funding
Australian Brain Cancer Mission	2018 Enhanced Capacity of the Australian and New Zealand Children's Haematology Oncology Group (ANZCHOG) Program	Monash University	University	VIC	Australian and New Zealand Children's Haematology/Oncology Group	Development and implementation of an Australian Research Agenda that identifies current and upcoming leading international trials of high potential relevance/significance to Australian paediatric brain cancer patients; Increased access to, and participation in, trials for Australian patients and sites in brain cancer clinical trials; Expedited time to start-up in Australia, through support provided and coordinated nationally; Structures and approaches in place to translate findings in practice; Close collaboration and cohesion of effort and activity by national brain cancer research groups and key research groups working in brain cancer and under the Australian Brain Cancer Mission, to maximise impact of effort and investments under the Mission; Working with the Australian Brain Cancer Mission, through Cancer Australia, in its initial analysis of existing brain cancer platforms and technologies, and efforts to expand and coordinate these assets based on the outcomes of the analysis.	Not applicable	Not available	One-off/ad hoc	25/09/2018	28/09/2024	Not available	Not available	\$ 3,010,000.00
Australian Brain Cancer Mission	2018 Enhanced Capacity of the Cooperative Trials Group for Neuro-Oncology (COGNO) Program	University of Sydney	University	NSW	Cooperative Trials Group for Neuro-Oncology	Development and implementation of an Australian Research Agenda that identifies current and upcoming leading international trials of high potential relevance/significance to Australian adult brain cancer patients; Increased access to and participation in trials for Australian patients and sites in brain cancer clinical trials; Expedited time to start-up in Australia, through support provided and coordinated nationally; Structures and approaches in place to translate findings in practice; Close collaboration and cohesion of effort and activity by national brain cancer research groups and key research groups working in brain cancer and under the Australian Brain Cancer Mission, to maximise impact of effort and investments under the Mission; Working with the Australian Brain Cancer Mission in its initial analysis of existing brain cancer platforms and technologies, and efforts to expand and coordinate these assets based on the outcomes of the analysis.	Not applicable	Not available	One-off/ad hoc	28/09/2018	28/09/2023	Not available	Not available	\$ 2,500,000.00
Australian Brain Cancer Mission	2018 Zero Childhood Brain Cancer	University of New South Wales	University	NSW	Zero Childhood Brain Cancer program	The purpose of the Zero Childhood Brain Cancer program is to support research activities which enable the provision of a personalised medicine program to improve outcomes for Australian children with high risk or relapsed brain cancers with the ultimate goal of improving survival outcomes for Australian children with high risk brain cancers.	Professor Michelle Haber	Not available	One-off/ad hoc	27/06/2018	30/06/2023	Not available	Not available	\$ 5,002,023.00
Australian Brain Cancer Mission	2019 Brain Cancer Survivorship	University of Sydney	University	NSW	Brain cancer Rehabilitation, Assessment, Intervention of survivor Needs	The innovative BRAIN program addresses care targets for brain cancer survivorship through a comprehensive multifaceted approach which recognises the enormous range of impacts of brain cancer for the individual and their carers. Through a systematic approach to screening for distress, symptoms, and needs of patients and caregivers in routine clinical practice we will achieve immediate improvements in our understanding of the frequency and severity of symptoms and need in the population across the country. Knowledge generated will underpin development of improved models of care coordination in this high-need population.	Not applicable	Not available	Open competitive	30/06/2020	31/08/2023	Not available	Not available	\$ 4,973,026.00
Australian Brain Cancer Mission	2019 Brain Cancer Survivorship	University of New South Wales	University	NSW	A new nurse-led intervention to re-engage childhood brain cancer survivors (Engage Brain)	Almost all childhood brain cancer survivors have health problems after they finish cancer treatment. Unfortunately, most Australian survivors are not receiving the care they need to manage these problems. The Grantee has developed the Re-engage program to help childhood brain cancer survivors improve their confidence to manage their health and to improve their quality of life. Reengage offers survivors two telehealth nurse consults and careful case review by an expert team. The nurses create a care package for survivors which includes a summary of their care needs, a letter for their GP, referrals to specialists and education about healthy lifestyles. This trial will test the impact of Re-engage and will help us to roll-out Re-engage across Australia.	Not applicable	Not available	Open competitive	30/06/2020	29/06/2024	Not available	Not available	\$ 1,941,576.00
Australian Brain Cancer Mission	2019 Innovative Clinical Trials	University of Sydney	University	NSW	LUMOS (Low & Intermediate Grade Glioma Umbrella Study of Molecular Guided Therapies)	LUMOS (Low & Intermediate Grade Glioma Umbrella Study of Molecular Guided Therapies) is a multi-year innovative precision oncology umbrella research study for patients with relapsed Grade 2 and 3 (G2/3) glioma. These patients have a very poor prognosis, with no established standard of care treatment. Umbrella studies are a new approach whereby patients within one disease group are allocated to different treatments based on a biological rationale. This approach is particularly relevant for the use of targeted agents, in which the presence of the target is required for efficacy.	Associate Professor Hui Gan	Not available	One-off/ad hoc	26/06/2019	30/06/2022	Not available	Not available	\$ 502,558.00
Australian Brain Cancer Mission	2019 Innovative Clinical Trials	La Trobe University	University	VIC	Prospective, multicentre trial evaluating FET-PET in high grade glioma (FIG Study)	The Prospective, Multicentre Trial Evaluating FET-PET in High Grade Glioma (FIG Study) is a highly innovative, multi-centre Australian research study which will evaluate the role of amino-acid imaging with 18F-FET positron emission tomography (PET PET) in patients with glioblastoma (GBM). This study addresses an area of urgent unmet clinical need in GBM patients, where standard imaging techniques may not be effective in accurately defining tumour volume prior to chemoradiation treatment, and also in accurately assessing true response vs pseudoprogression in patients following initial treatment - both scenarios impacting on clinical management decisions, and patient care.	Professor Andrew Scott	Not available	One-off/ad hoc	27/06/2019	30/06/2022	Not available	Not available	\$ 1,246,611.80
Australian Brain Cancer Mission	2020 Brain Cancer Survivorship	University of Melbourne	University	VIC	Responding to need: technology-enhanced brain cancer survivorship	In 2020, 2,000 Australians will be diagnosed with brain cancer. Less than a quarter (22%) will be alive in 5 years. Lack of access to tailored survivorship care, connectivity with the treating team and peers is common, due to centralisation of care in metropolitan hospitals. This research will develop and demonstrate impact of an online survivorship platform, co-produced with brain cancer survivors and carers, to streamline access to treating teams, peer support, and evidence-informed supportive care, in a private and secure environment.	Professor Kate Drummond	Professor Kate Drummond, Doctor James Whittle, Doctor Heidi McAlpine, Professor Mark Rosenthal, Professor Wendy Chapman, Associate Professor Ann Borda, Doctor Daniel Capurro, Professor Mei Krishnasamy, Doctor Verena Schredewaldt, Mr Rana Dhillon, Associate Professor Kathleen Grey	Open competitive	30/06/2021	29/06/2024	Not available	Not available	\$ 2,615,278.00
Australian Brain Cancer Mission	2021 Brain Cancer Research	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	"GLUMMER" - Glioma Liquid biopsy and Multiomic-Monitoring Enabled Research platform	Glioblastoma (GBM) is an aggressive brain cancer with a dismal 5-year survival rate of 5%. Our collaborative research program GLUMMER (Glioma Liquid biopsy and Multi-omic Monitoring Enabled Research platform) will address the lack of effective treatment options with a pipeline of early to late translational science. The impact of this program will improve survival outcomes, quality of life and avoid unnecessary health burdens for this devastating disease.	Doctor James Whittle	Doctor James Whittle, Associate Professor Mitty Jenkins, Doctor Saskia Freytag, Doctor Sarah Best, Associate Professor Andrew Monokoff, Doctor David Goode, Doctor Stephen Wong, Professor Sean Grimmond, Professor Stephen Fox, Professor Sarah-Jane Dawson, Doctor Lucy Gately, Professor Katharine Drummond, Professor David Eisenstat, Associate Professor Lucy Palmer	Targeted competitive	1/11/2022	31/12/2027	Genetics	Genetics, Genomics, Immunology, Applied Immunology (incl. Antibody Engineering), Xenotransplantation And T-Cell Therapies, Oncology And Carcinogenesis, Molecular Targets	\$ 4,550,471.30
Australian Brain Cancer Mission	2021 Brain Cancer Research	University of New South Wales	University	NSW	A new targeted combination therapy with matched biomarker to treat intractable glioblastoma	Glioblastoma (GBM) is the most aggressive and fatal of all brain cancers. GBM tumours contain aggressive cells that are able to hide from therapies. These cells express androgen (male hormone) receptors, which provides a new way to target them. Using a unique model of growing patient tumours in the lab, and mice, this study will define whether anti-androgen drugs improve the effect of standard-of-care therapies. This will enable rapid results leading to clinical trials to improve GBM outcomes.	Professor Jeffrey Holst	Professor Jeffrey Holst, Associate Professor Christine Chaffer, Associate Professor Elizabeth Hovey, Associate Professor Eng Siew Koh, Doctor Sylvia Chung, Doctor Beatriz Perez San Juan, Doctor Rajesh Reddy, Doctor Michael Rodriguez, Doctor Kanu Wahi, Associate Professor Luke Sethi, Doctor Rebecca Ormsby, Doctor Grant Buchanan, Doctor Benjamin Dhall	Targeted competitive	1/11/2022	31/10/2024	Oncology And Carcinogenesis	Oncology And Carcinogenesis, Molecular Targets	\$ 582,686.40
Australian Brain Cancer Mission	2021 Brain Cancer Research	The Council of the Queensland Institute of Medical Research	Medical Research Institute	QLD	"Off-the-shell" CAR-T cell immunotherapy for brain cancer	Over the last two decades the overall survival of brain cancer patients have remained largely unchanged. Our group has previously shown that adoptive T cell therapy directed to a common herpesvirus, CMV can be safely used for the treatment of brain cancer patients and this therapy can offer clinical benefit to some patients. In this project we are aiming to assess a novel dual targeting T cell therapy which is specifically designed to target tumour-nourishing cancer stem-cells.	Professor Rajiv Khanna	Professor Rajiv Khanna, Doctor Paulo Martins, Associate Professor Corey Smith, Associate Professor David Walker	Targeted competitive	1/11/2022	31/10/2024	Immunology	Immunology, Applied Immunology (incl. Antibody Engineering, Xenotransplantation And T-Cell Therapies)	\$ 329,489.00

Australian Brain Cancer Mission	2022 Australian Brain Cancer Research Infrastructure	University of Sydney	University	NSW	Supporting Australian Brain Cancer Research with an integrated network of platforms	To deliver better treatment and care for Australian brain cancer patients we will establish three national, interlinked platforms: an Australian Brain Cancer Registry to reduce unwarranted variation in patient care; a Registry Trials platform to facilitate data-driven trials and patient access of data and specimens to research; and a Biobanking and Organoid platform to standardise operating procedures and enable collaborative translational research.	Associate Professor Rosalind Jeffree	Associate Professor Rosalind Jeffree, Doctor Adrian Lee, Doctor Alexander Yulle, Professor Andrew Scott, Doctor Anthony Nguyen, Doctor Benjamin Kong, Professor Bryan Day, Doctor Cassie Turner, Professor Claire Vajdic, Doctor Craig Geddy, Ms Danica Cossio, Doctor David Hansen, Associate Professor David Ziegler, Ms Donna Turan, Associate Professor Eng-Siew Koh, Doctor Ganesan Kichenadasse, Mr Gary Francois, Doctor Guillermo Gomez, Doctor Hao-Wen Sim, Professor Hui Gan, Doctor James Whittle, Doctor Jamie Gabriel, Professor Joanne Ashers, Professor Joanne Dickinson, Professor John Simes, Professor John Zalcberg, Professor Jordan Hamford, Professor Katherine Drummond, Doctor Kimberley Alexander, Professor Leonie Quinn, Doctor Lucy Gately, Associate Professor Mark Pinkham, Professor Shera Agar, Associate Professor Michael Buckland, Doctor Mythily Sachchidanathan, Mr Norm Good, Doctor Rebecca Ormsby, Ms Robyn Leonard, Doctor Rosemary Harrop, Doctor Ryan Sullivan, Professor Stuart Pison, Professor Sue Evans, Professor Terence O'Brien, Doctor Wayne Ng, Doctor Wee Chin, Professor Wendy Upworth, Associate Professor Wenny Vinkart, Associate Professor Zannie Lwin	Targeted competitive	1/01/2023	31/12/2027	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Oncology And Carcinogenesis, Oncology And Carcinogenesis Not Elsewhere Classified	\$	5,991,219.44
Cardiovascular Health Mission	2019 Accelerated Research - Congenital Heart Disease	Queensland University of Technology	University	QLD	CHD LIFE+ family-centred care models supporting long-term neurodevelopment	This multidisciplinary project will produce actionable intelligence to help health services implement efficient models of care that empower children who receive open heart surgery and their families to access the right assessments and treatments in the right location for their circumstances at the right time for optimal prevention and treatment of neurodevelopmental complications according to contemporary clinical recommendations and child/family circumstances (CHD LIFE+). This will be achieved through mixed methods research incl. complex health service model simulations, implementation science, and co-design processes. This project includes leading academics, clinicians and all Australian services who perform paediatric open heart surgery.	Professor Steven McPhail	Not available	Open competitive	29/06/2020	30/06/2025	Not available	Not available	\$	2,997,256.00
Cardiovascular Health Mission	2019 Accelerated Research - Congenital Heart Disease	The University of Adelaide	University	SA	Maternal exposures, congenital heart defects, and child development	We shall identify non-genomic factors across gestation that are associated with congenital heart disease (CHD). Using government and other data, we have assembled a cohort comprising all births in South Australia (1986-2015, n=580,000) linked to birth defects reported to age 5 years. Prescription medicines have been added to maternal exposures that are routinely registered. We will identify contributions to CHD from 1) specific maternal health problems and pregnancy complications 2) selected prescription medicines 3) medical interventions to treat infertility. We will assess special needs and educational performance in children with CHDs across their school years. This work will be replicated in a comparable Canadian cohort.	Professor Michael Davies	Not available	Open competitive	26/06/2020	31/12/2024	Not available	Not available	\$	3,037,417.00
Cardiovascular Health Mission	2019 Accelerated Research - Congenital Heart Disease	The University of Queensland	University	QLD	Gene Expression to Predict Long-Term Outcome in Infants After Heart Surgery	We will identify gene expression patterns predicting patient-centred short- and long-term outcomes in infants undergoing heart surgery. The study is an expansion of our existing large trial of infants under 2 years of age undergoing open heart surgery on cardiopulmonary bypass across all paediatric heart surgery centres in Australia and New Zealand. Using cutting-edge gene expression studies, we will investigate the individual response to cardiopulmonary bypass. A state-of-the-art neuropsychological assessment is performed in all children until school entry age. The aim is to understand and predict the adverse impact of heart surgery on infants with heart disease to improve long term outcomes for children with childhood heart disease.	Associate Professor Luregn Schlagbach	Not available	Open competitive	26/06/2020	30/06/2025	Not available	Not available	\$	3,068,742.00
Cardiovascular Health Mission	2019 Accelerated Research - Congenital Heart Disease	University of Sydney	University	NSW	An Australian Study of the Outcomes and Burden of Congenital Heart Disease	This national multi-disciplinary project addresses the critical need to improve health outcomes across the Congenital Heart Disease (CHD) life-course. The research program proposes a "two level" approach to generating important and clinically relevant research outcomes: (i) through generating data from 25,000 child and adult cases of CHD from sites across Australia, with linkage to survival and health care utilisation (a National CHD Registry) and (ii) applying comprehensive phenotyping to 2,400 paediatric/adult cases living with CHD that provides the information required to target critical psychological, mental health, neurocognitive and quality of life outcomes in CHD patients and the parents of CHD children.	Professor David Selemajer	Not available	Open competitive	26/06/2020	31/12/2024	Not available	Not available	\$	3,994,175.00
Cardiovascular Health Mission	2019 Accelerated Research - Congenital Heart Disease	University of Sydney	University	NSW	Congenital Heart Fitness Intervention Trial: CH-FIT	Most Australians who have congenital heart disease (CHD) survive to adulthood but often live with complex medical problems and reduced exercise capacity. Although regular exercise is well-recognised to be of benefit for physical and mental health in many health conditions, research investigating the health impact of exercise and the best way to help adults and children living with CHD to lead active lives is lacking. This project will address that gap with a 12 month exercise training and lifestyle education program designed to improve exercise capacity and quality of life in children and adults living with CHD. This will be largest and most definitive exercise trial ever performed in this population which will inform practice worldwide.	Doctor Rachel Cordina	Not available	Open competitive	26/06/2020	30/06/2025	Not available	Not available	\$	3,328,569.00
Cardiovascular Health Mission	2019 Accelerated Research - Congenital Heart Disease	University of Sydney	University	NSW	Personalised Pulmonary Valved Conduits: reducing re-operations in CHD	We address the unmet need for a durable, biocompatible right ventricle to pulmonary artery valved tube, used in reconstructive surgery for congenital heart disease. Currently available animal and donated human products fail in just a few years, requiring replacement open heart surgery every 5-10 years. This has patient safety, psychological and financial implications for the individual, family and health system. Our team of doctors, scientists and engineers is bringing together recent developments in polymer science and computational engineering to build a solution tailored to the individual that will allow the tube to 'grow' with the child, maintain good valve function, avoiding reoperation, improving heart function and quality of life.	Professor Fariba Dehghani	Not available	Open competitive	30/06/2020	31/12/2024	Not available	Not available	\$	2,081,761.00
Cardiovascular Health Mission	2019 Cardiovascular Health	Monash University	University	VIC	Using Polygenic Risk Scores to Target Statin Therapy in Primary Prevention	Calculation scores by examining multiple genes predict the chance of having a heart attack. It is unknown whether they can guide use of treatments to prevent heart attacks. This clinical trial will determine whether statins, medications commonly used to lower cholesterol, will have a protective effect on the growth of plaques within blood vessels, in patients with different levels of polygenic risk. The findings will help to define how to best use polygenic risk scores in clinical practice.	Professor Stephen Nicholls	Professor Stephen Nicholls, Professor Christopher Semerari, Associate Professor Dennis Wong, Professor Sophia Zoungas, Associate Professor Jodie Ingles, Doctor Adam Nelson	Targeted competitive	1/06/2020	31/05/2023	Cardiorespiratory Medicine And Haematology	Cardiology (Ind. Cardiovascular Diseases)	\$	1,416,095.00
Cardiovascular Health Mission	2019 Cardiovascular Health	University of Melbourne	University	VIC	A randomised controlled trial of ultra-early, minimally invasive surgery for intracerebral haemorrhage (EVACUATE)	Intracerebral haemorrhage (stroke caused by bleeding in the brain) is a major cause of death and disability and treatment options are limited. Surgery was not effective in past trials but was performed relatively late and used open brain surgery techniques that disrupt surrounding brain tissue. We propose a globally unique randomised controlled trial of minimally invasive surgery within 8 hours of stroke onset with the aim of reducing disability through early effective removal of blood clot.	Professor Bruce Campbell	Professor Bruce Campbell, Professor Timothy Kheng, Associate Professor John Lidlaw, Associate Professor Amal Abu-Hamden, Professor Leonid Churlov, Professor J Mocco, Associate Professor Christopher Kellner, Doctor Lan Gao, Professor Stephen Davis	Targeted competitive	1/06/2020	31/05/2025	Neurosciences	Central Nervous System	\$	2,138,226.00
Cardiovascular Health Mission	2019 Cardiovascular Health	University of New South Wales	University	NSW	Novel deep learning methods for large-scale cardiovascular risk screening using Australian digital health data	Through two synergistic studies using routinely collected data and novel deep learning methods, we will deliver: (1) The world's first dynamic cardiovascular risk prediction algorithm that uses clinical text data and longitudinal event sequences; and (2) The world's first mammography-derived cardiovascular risk prediction algorithm.	Professor Louisa Jorm	Professor Louisa Jorm, Doctor Clare Annett, Doctor Sebastiano Barbieri, Professor Patrick Brennan, Professor Anthony Rodgers, Professor Mark Woodward, Doctor Katrina Poppe, Doctor Ziba Gandomir, Associate Professor Blanca Gallego Lujan, Professor Kinty Douglas	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Health Information Systems (Ind. Surveillance)	\$	1,467,090.60
Cardiovascular Health Mission	2019 Cardiovascular Health	University of New South Wales	University	NSW	Total Cardiac Care - STROKE: A randomised controlled trial of a comprehensive smartphone application-centric model of care to improve outcomes in stroke patients	One in three patients are re-admitted to hospital within 6 months of successful treatment for stroke. We have developed a smartphone-based "hospital in the home" system that allows patients, GPs and specialists to monitor blood pressure, heart rhythm, activity, and medication use daily. Patients and medical teams are alerted when signs indicate treatment changes are needed. Our study is aimed at proving this system can reduce the number of patients re-admitted to hospital after stroke.	Professor Ken Butcher	Professor Ken Butcher, Doctor Sae Yuan Ooi, Professor Nigel Lovell, Professor Kim Delbarno, Professor Zhao Yang Dong, Emerita Professor Branka Celler, Professor Sallie-Anne Pearson, Doctor Thomas Lung, Emeritus Professor Siaw-Teng Liaw, Doctor Jennifer Yu	Targeted competitive	1/06/2020	31/05/2024	Clinical Sciences	Clinical Sciences Not Elsewhere Classified	\$	1,629,905.00
Cardiovascular Health Mission	2019 Cardiovascular Health	University of New South Wales	University	NSW	The SaltSwitch Online Grocery Shopping (OGS) Trial: A Novel Method for Reducing Blood Pressure among Individuals with Hypertension	High blood pressure is a leading cause for heart diseases and stroke in Australia, and reducing salt intake to lower blood pressure is strongly recommended by guidelines. Online grocery shopping is transformative for how Australians obtain food and offers an opportunity for nutrition intervention. We propose to test the efficacy and implementation of a scalable online grocery shopping intervention called SaltSwitch to help consumers choose lower salt products and reduce their blood pressure.	Associate Professor Jason Wu	Associate Professor Jason Wu, Professor Bruce Neal, Professor Cliona Ni Mhurchu, Associate Professor Adrian Cameron, Associate Professor Mark Huffman, Doctor Kathy Trieu, Mr Fraser Taylor	Targeted competitive	1/06/2020	31/05/2023	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	1,687,990.14
Cardiovascular Health Mission	2019 Cardiovascular Health	University of Sydney	University	NSW	Calcitriol After Stroke to Prevent Event Recurrence (CASPER) Study	Inflammation plays a critical role in the rupture of artery plaques, leading to acute stroke. Despite current best treatments, many people remain at high risk of recurrent stroke events, predominantly because current therapies do not specifically target the inflammatory component of arterial disease. This project investigates the ability of calcitriol, a safe and commonly used anti-inflammatory drug, to inhibit vascular disease-associated inflammation, thereby improving clinical outcomes.	Professor Anthony Keech	Professor Anthony Keech, Professor Geoffrey Cloud, Associate Professor Sanjay Patel, Doctor Carlos Garcia Espartero, Professor John Simes, Professor Rachel Morton, Doctor Kristi Robledo, Doctor Andrzej Januszewski, Professor Val Gobecki, Professor Lisa Aslake	Targeted competitive	1/06/2020	30/11/2024	Cardiorespiratory Medicine And Haematology	Cardiology (Ind. Cardiovascular Diseases)	\$	2,997,908.45

Cardiovascular Health Mission	2020 Cardiovascular Health	Monash University	University	VIC	Statins and Progression of Coronary Atherosclerosis in Melanoma Patients Treated with Immune Checkpoint Inhibitors	Checkpoint inhibitors are used in an increasing number of melanoma patients. Recent data has suggested that checkpoint inhibitor use may associate with both a greater risk of heart attack and stroke, which may relate to greater growth of plaques in blood vessels. In this clinical trial we will compare the effects of statins (drugs commonly used to lower cholesterol) and placebo on plaque growth in melanoma patients treated with checkpoint inhibitors.	Professor Stephen Nicholls	Professor Stephen Nicholls, Professor Eva Segelov, Professor Mark Shackleton, Professor Grant McDermid, Associate Professor Andrew Hayden, Professor Sophia Zoungas, Associate Professor Victoria Mar, Doctor Nibesh Nerlekar, Professor Nimma Lawe, Doctor Elizabeth Almon	Targeted competitive	1/06/2021	31/05/2025	Cardiorespiratory Medicine And Haematology	Cardiology (Incl. Cardiovascular Diseases)	\$	1,669,300.28
Cardiovascular Health Mission	2020 Cardiovascular Health	The University of Newcastle	University	NSW	Stroke in patients with large ischaemic Core: Assessment of Reperfusion therapy Impact on Outcome (SICARIO)	Endovascular thrombectomy (EVT) is validated and in routine clinical use for ischaemic stroke patients and provides one of the largest treatment effects in medicine. However, the foundational trials where highly selective, meaning EVT is only offered to a third of stroke patients. We propose a trial of rapid progressors to identify if these patients can still benefit from EVT. The proposed trial will address large knowledge gaps to deliver practice changing data.	Professor Christopher Levi	Professor Christopher Levi, Associate Professor Andrew Iward, Professor Mark Parsons, Professor Leonid Churilov, Professor Ken Butcher, Professor Marjory Moodie, Associate Professor Elizabeth Wadley, Professor Neil Spratt, Professor Christopher Bladin, Professor Bernard Yan	Targeted competitive	1/06/2021	31/05/2025	Cardiorespiratory Medicine And Haematology	Cardiovascular Medicine And Haematology Not Elsewhere Classified	\$	1,515,113.87
Cardiovascular Health Mission	2020 Cardiovascular Health	University of Sydney	University	NSW	Safety and Tolerability of AZD6482 in Reperfusion for Stroke (STAR5)	Stroke is a leading cause of death/disability worldwide. Identification of novel drugs that can improve clot lysis without causing bleeding would represent a major advance in stroke treatment. The Safety and Tolerability of AZD6482 in Reperfusion for Stroke (STAR5) study - describes a Phase 2a, dose escalation study evaluating safety/tolerability of a novel anti-clotting drug (AZD6482) with promising preclinical safety/efficacy data, in adults with acute ischaemic stroke.	Professor Shaun Jackson	Professor Shaun Jackson, Doctor Candice Delcourt, Professor Craig Anderson, Associate Professor Gian Luca Di Tanna, Associate Professor Simone Schoenwaelder, Doctor Timothy Ang	Targeted competitive	1/06/2021	31/05/2025	Cardiorespiratory Medicine And Haematology	Cardiology (Incl. Cardiovascular Diseases)	\$	2,706,533.13
Cardiovascular Health Mission	2020 Cardiovascular Health	The University of Adelaide	University	SA	The SPRINTs Project: Stroke - Prevention of Reperfusion Injury and Neuroinflammation - a Therapeutic Strategy	Stroke is a major clinical problem, with the impacts not limited to the acute management phase. Stroke is a leading cause of adult disability and dementia. Such issues are associated with an inflammatory reaction in the brain that follows the restoration of blood flow. Our team are reformulating an existing drug treatment to use to manage the inflammatory reaction in the brain to reduce complications and improve patient outcomes.	Associate Professor Renee Turner	Associate Professor Renee Turner, Professor Henry Ma, Professor Alan Nimmo, Associate Professor Connie Wong, Professor James Bourne, Doctor Nicholas Veldhuis, Professor Jonathan Baell, Professor Michelle McIntosh, Doctor Daniel Peale	Targeted competitive	1/06/2021	31/08/2025	Neurosciences	Central Nervous System	\$	2,563,915.78
Cardiovascular Health Mission	2020 Cardiovascular Health	University of Sydney	University	NSW	Lesiologic	Heart rhythm disorders are common worldwide, with 240,000 people suffering from atrial fibrillation (AF) alone in Australia and doubling by 2034. Radiofrequency (RF) catheter ablation has become the standard of care but many surgeries fail due to a lack of real-time monitoring. Our team of cardiologists at Westmead Hospital and Biomedical Engineers at University of Sydney have solved this problem by creating Lesiologic, a non-invasive system to visualise cardiac RF ablation in real-time.	Professor Alistair McEwan	Professor Alistair McEwan, Doctor Pierre Qian, Doctor M.A. (Tony) Barry, Doctor Luping Zhou, Doctor Anusha Withana, Doctor Aravinda Thangam, Associate Professor Stuart Thomas, Michael Cegnar, Doctor Warren Smith, Professor Qihui Li	Targeted competitive	1/06/2021	28/02/2025	Cardiorespiratory Medicine And Haematology	Cardiology (Incl. Cardiovascular Diseases)	\$	1,102,873.15
Cardiovascular Health Mission	2020 Cardiovascular Health	University of New South Wales	University	NSW	Development of novel, clinically viable strategies for reducing cardiac damage and preventing future events in myocardial infarction (MI) survivors by targeting inflammation	People that have a heart attack enter an inflamed state that increases the likelihood of having a second event. This project will use small, biodegradable nanoparticles that target and remove inflamed white blood cells and reduce the likelihood that heart attack survivors will have another event in the short term. To prevent future events in the long term, we plan to couple longer lasting anti-inflammatory molecules and peptides to the nanoparticles for delivery to inflamed cells and tissues.	Professor Kerry-Anne Rye	Professor Kerry-Anne Rye, Professor Nicholas King, Associate Professor Shane Thomas, Professor Mark Juellet, Professor Anthony Keech, Professor Madhav Devalaraja, Professor Pall Thordarson, Associate Professor Laurence Macia, Doctor Se-Yuan Ooi	Targeted competitive	1/06/2021	31/01/2026	Cardiorespiratory Medicine And Haematology	Cardiology (Incl. Cardiovascular Diseases)	\$	2,849,891.71
Cardiovascular Health Mission	2020 Cardiovascular Health	University of Melbourne	University	VIC	REACHING FOR YOUR WORDS: A Phase II umbrella trial of integrated Upper limb & Language Impairment and Functional Training (UPLIFT) after stroke	Losing the ability to use your arm and communicate is extremely debilitating. It affects 1 in 6 survivors at 3 months post-stroke and remains unmet long-term. We propose a new model of rehabilitation: integrated Upper limb & Language Impairment and Functional Training (UPLIFT) during community living. Using a novel trial design we will efficiently identify the most promising UPLIFT interventions(), which will directly impact how we organise and deliver rehabilitation in Australia.	Doctor Kathryn Hayward	Doctor Kathryn Hayward, Professor Leonid Churilov, Associate Professor Erin Godecke, Professor Trevor Russell, Professor Julie Bernhardt, Associate Professor Ruth Barker, Professor Vincent Thij, Professor Bruce Campbell, Doctor Sonia Brownsett, Professor Geoffrey Denman	Targeted competitive	1/06/2021	29/02/2024	Clinical Sciences	Rehabilitation And Therapy (Excl. Physiotherapy)	\$	992,634.36
Cardiovascular Health Mission	2020 Cardiovascular Health	Monash University	University	VIC	ECMO Rehab: A Randomised Controlled Trial of Early Cardiac Rehabilitation to Improve Survival and Recovery in Critically-ill Patients on ECMO	The ECMO Rehab trial will compare the effect of early rehabilitation, involving physical activity and mobilisation, with standard care on disability and recovery in critically ill adult patients requiring extracorporeal membrane oxygenation (ECMO). These patients are at significant risk of ICU-acquired weakness due to prolonged immobility, and this weakness is associated with substantial morbidity and mortality. Early rehabilitation may reduce this weakness and improve patient outcomes.	Professor Carol Hodgson	Professor Carol Hodgson, Doctor Alisa Higgins, Professor Michael Bailey, Associate Professor Vincent Pellegrino, Associate Professor Priya Nair, Professor David McGiffin, Associate Professor Jeffrey Presswell, Doctor Mark Dennis, Professor Eddy Fan, Doctor Sandra Braaf	Targeted competitive	1/06/2021	31/05/2024	Clinical Sciences	Intensive Care	\$	662,648.57
Cardiovascular Health Mission	2020 Cardiovascular Health	University of New South Wales	University	NSW	CardiAI: Deep learning to predict and prevent secondary cardiovascular events	Individuals who have suffered a heart event are at much higher risk of further episodes than the general population. Many of these events can be prevented with risk factor control. However, not all patients have the same level of risk and calculation of risk is not part of routine hospital care. This project will use hospital data to develop an automated risk calculator to inform clinicians of a patient's risk profile at discharge from hospital so that targeted interventions can be given.	Associate Professor Blanca Gallego Lusan	Associate Professor Blanca Gallego Lusan, Professor Louisa Jorm, Doctor Se-Yuan Ooi, Doctor Jennifer Yu, Professor Nigel Lovell, Professor Deborah Lupton, Doctor Juan Quinto	Targeted competitive	1/06/2021	31/01/2024	Cardiorespiratory Medicine And Haematology	Cardiology (Incl. Cardiovascular Diseases)	\$	544,978.65
Cardiovascular Health Mission	2020 Cardiovascular Health	University of Sydney	University	NSW	Digital solutions for heart failure best practice care	Care of heart failure in Australia remains patchy and varies widely between localities. Our digital solution will provide doctors and their patients with a confidential personalised recommendation for treatment consistent with each individual's needs and clinical circumstances. Allowing both patients and doctors access to the recommendations from international guidelines will provide patients with the confidence that they are receiving optimal treatment and best outcomes.	Professor Anthony Keech	Professor Anthony Keech, Doctor Sean Lai, Professor Peter Macdonald, Doctor Caleb Ferguson, Christopher Ryan, Professor Alicia Jenkins, Doctor Kathleen Dempsey, Professor Clara Chow, Doctor Rachel O'Connell, Associate Professor Gary Kilov	Targeted competitive	1/06/2021	31/07/2024	Public Health And Health Services	Preventive Medicine	\$	936,836.88
Cardiovascular Health Mission	2020 Cardiovascular Health	University of Melbourne	University	VIC	Improving life after stroke with tailored support: Innovation in use of national registry data	Using data from the Australian Stroke Clinical Registry, we have identified factors associated with an increased risk of returning to hospital and poor quality of life. We will co-design with clinicians, survivors of stroke and health administrators a nurse-led, outpatient-based service to review and manage people we identify as vulnerable. The service will be tested for feasibility in a pilot randomised control trial. Innovation in the use of registry data to improve health will be shown.	Professor Dominique Cadilhac	Professor Dominique Cadilhac, Professor Sandy Middleton, Associate Professor Monique Killemby, Professor Timothy Keinig, Associate Professor Rohan Grimley, Doctor Joosup Kim	Targeted competitive	1/06/2021	31/05/2024	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	505,704.36
Cardiovascular Health Mission	2020 Cardiovascular Health	University of Sydney	University	NSW	Guardian Angel: Implementation of a peer support program for people with heart disease	Heart disease causes nearly 20% of deaths around the world. Sadly, the ongoing care people receive after they leave hospital has not kept up with medical advances. We will evaluate implementation of a peer support program (in-person and digital options) via a phased roll-out in 25 local areas (>1350 patients) across Australia. The project will empower survivors to harness their lived experience to support others in similar situations thereby reducing the escalating heart disease burden.	Professor Julie Redfern	Professor Julie Redfern, Professor Robyn Gallagher, Emeritus Professor Adrian Bauman, Professor Gemma Figtree, Professor Thomas Briffa, Professor Andrew Malarina, Professor Marie Hackett, Doctor Karan Heyn, Doctor Qi Gu Law	Targeted competitive	1/06/2021	30/11/2023	Public Health And Health Services	Preventive Medicine	\$	655,522.17
Cardiovascular Health Mission	2020 Cardiovascular Health	The University of Queensland	University	QLD	Measuring, Monitoring, and Motivating Adherence to Self-Managed Aphasia Treatment	Every 53 minutes someone in Australia has a stroke. A third of those who survive will have aphasia—difficulty speaking, understanding, reading, writing. Aphasia makes daily life difficult. Everyday activities like having a chat or reading an email become impossible challenges. Depression is common and quality of life is very poor. We will develop iChat, a smartphone app that puts engaging, effective therapy in the pockets of stroke survivors, empowering them to take control of their recovery.	Doctor Sarah Wallace	Doctor Sarah Wallace, Professor David Copland, Professor Janet Wiley, Associate Professor Anthony Angwin, Associate Professor Victoria Palmer, Doctor Peter Worthing, Doctor Anne Hill, Doctor Barbara Timmer, Associate Professor Matthew Gullo	Targeted competitive	1/06/2021	30/11/2023	Clinical Sciences	Rehabilitation And Therapy (Excl. Physiotherapy)	\$	388,521.10
Cardiovascular Health Mission	2020 Cardiovascular Health	The University of Newcastle	University	NSW	Yarning up After Stroke	Yarning up After Stroke (YuaS) aims to reduce the inequity in health care and improve the long-term recovery and survivorship of Aboriginal and/or Torres Strait people living with stroke. YuaS will (i) identify the needs and wants of Aboriginal people (ii) produce a co-designed evidence and strengths based conversation tool to support stroke recovery, and (iii) determine the effect this tool has on disability and quality of life of Aboriginal and/or Torres Strait people living with stroke.	Professor Christopher Levi	Professor Christopher Levi, Professor Kim Usher, Doctor Heidi Janssen, Reakeeta Smallwood, Professor Neil Spratt, Professor Michael Nilsson, Doctor Carlos Garcia Espartero, Associate Professor Elizabeth Holliday, Ms Rachel Peake, Professor Natalie Ciccone	Targeted competitive	1/06/2021	31/05/2023	Cardiorespiratory Medicine And Haematology	Cardiology (Incl. Cardiovascular Diseases)	\$	485,061.66
Cardiovascular Health Mission	2020 Cardiovascular Health	The University of Queensland	University	QLD	Development of drugs to prevent ischaemic injuries of the heart and brain	This project develops new drugs to prevent injuries caused by heart attacks. The leading cause of death in the world for which there are no drugs currently available. We will address this failing of modern medicine by combining the expertise of scientists and clinicians across research institutions and hospitals in Australia. The drugs we plan to develop will provide socioeconomic benefits to Australia by saving lives, improving the quality-of-life for survivors, and reducing healthcare costs.	Doctor Nathan Palant	Doctor Nathan Palant, Professor Glenn King	Targeted competitive	1/06/2021	31/05/2024	Biochemistry And Cell Biology	Cell Development, Proliferation And Death	\$	1,499,560.20
Cardiovascular Health Mission	2020 Cardiovascular Health	Monash University	University	VIC	New models of rehabilitation to improve work and health outcomes after stroke	Our team has designed a hybrid implementation study which will investigate new models of vocational rehabilitation after stroke in Australia. In this trial, we will test the translation and feasibility of delivering two different models of vocational rehabilitation, both shown to be effective outside of Australia, and explore the key elements required for their delivery so as to enable implementation across organisations, geographical locations and between states to enable future scalability.	Professor Natasha Lamin	Professor Natasha Lamin, Associate Professor Kathryn Radford, Professor Maria Croty, Professor Anusha Martin, Professor Anne Holland, Doctor Dana Wong, Doctor Laura Joffe, Professor Geoffrey Cloud	Targeted competitive	1/06/2021	31/12/2023	Clinical Sciences	Rehabilitation And Therapy (Excl. Physiotherapy)	\$	999,056.20
Cardiovascular Health Mission	2020 Childhood Stroke	National Stroke Foundation	Corporation	VIC	The Australian Paediatric Acute Code Stroke (PACS) study	The objective of this project is to improve survival outcomes after paediatric stroke, bridging the inequity gap between adults and children in accessing reperfusion therapies through implementation of the Paediatric Acute Code Stroke (PACS) protocol.	Not applicable	Not available	One-off/ad hoc	30/06/2020	30/06/2025	Not available	Not available	\$	4,000,000.00
Cardiovascular Health Mission	2020 Strategic Research	National Heart Foundation of Australia	Corporation	VIC	2020 Strategic Research Grants	The project will fund innovative research in the four areas of predictive modelling, cardio-oncology, secondary prevention, and women and heart disease.	Not applicable	Not available	One-off/ad hoc	30/06/2020	30/06/2024	Not available	Not available	\$	4,000,000.00
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Sydney	University	NSW	Renal Factors Modify HEART disease Study - REFORM HEARTS	Approximately 10% of Australians have chronic kidney disease (CKD). As kidney function deteriorates, the risk of cardiovascular disease rises sharply. CKD is an independent risk factor for cardiovascular death, but few effective therapies are available. We will address this area of unmet need by identifying a new cohort that contributing to the burden of cardiovascular disease - CKD patients. Our research will provide new knowledge and potential therapeutic opportunities for development.	Professor Natasha Rogers	Associate Professor Natasha Rogers, Doctor Rebecca Kozor, Daniel Menjies, Professor Karen Dwyer, Professor Lisa Thomas, Professor Angela Webster, Doctor Ella Patrick, Doctor Soheil Julavi	Targeted competitive	1/06/2022	31/05/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases), Clinical Sciences, Nephrology And Urology	\$	865,396.80
Cardiovascular Health Mission	2021 Cardiovascular Health	University of New South Wales	University	NSW	Investigating Mechanisms of Alcohol-Induced Heart Disease	Moderate to high levels of alcohol consumption can damage many organs in the body including the heart. Whether a person's genetic makeup influences the risk of alcohol-induced heart disease is currently unknown. Our research will use a multi-faceted approach that spans from human cohorts to computational and laboratory studies to understand how alcohol and genes act and interact to affect the heart's structure and function. This will inform new strategies for disease treatment and prevention.	Professor Diane Fatkin	Professor Diane Fatkin, Associate Professor Eleni Giannoulatos, Professor Steven Niederer, Doctor Christopher Wong, Carolyn Stubley, Doctor Renee Johnson, Professor Nigel Turner, Associate Professor Andrew Jabbar, Doctor Jim Poulipoulas, Professor Michael Farrell, Doctor Celina Santiago, Professor Robert Bryson-Richardson	Targeted competitive	1/06/2022	30/09/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases)	\$	999,995.60

Cardiovascular Health Mission	2021 Cardiovascular Health	University of Melbourne	University	VIC	Treating the impact of seizures on cardiac function to reduce death	Patients with epilepsy are at risk of dying suddenly. An impact of seizures on heart function is likely to be the cause of death in some patients. How the brain and heart interact during a seizure is not well understood. In this grant, we will use models of seizures and record both brain and heart function to better understand this interaction. We will also test therapeutic interventions to see if we can protect the heart from seizures with the aim of motivating clinical studies.	Professor Christopher Reid	Professor Samuel Barlow, Associate Professor Yugesha Lankadeva, Doctor Lindsay Booth, Professor Clive May	Targeted competitive	1/06/2022	31/10/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases), Genetics, Neurogenetics, Neurosciences, Autonomic Nervous System	\$	847,479.70
Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	University	VIC	Atheroma Progression In Clonal Haematopoiesis Investigation with Imaging, Biomarkers and Genomic Sequencing (ARCHMEDES)	Heart disease (heart attack, heart failure, stroke) is Australia's biggest killer. Recently, an abnormality in white blood cells, the cells within your bone marrow and blood, which fight disease, has been linked with increased risk of heart disease. Known as clonal haematopoiesis of indeterminate potential (CHIP) is common in older adults (over 60 years), and identifying patients with this abnormality may allow us to treat their heart disease earlier, and better.	Professor Stephen Nicholls	Professor Stephen Nicholls, Doctor Kristen Bubb, Doctor James Green, Doctor Adam Nelson, Doctor Timothy Sargent, Professor Roger Milne, Professor Jake Shortt, Professor Melissa Southey, Professor Sophia Zoungas, Doctor Nish Netherker, Professor Timothy Hughes	Targeted competitive	1/06/2022	31/05/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiovascular Medicine And Haematology Not Elsewhere Classified	\$	996,384.68
Cardiovascular Health Mission	2021 Cardiovascular Health	The University of Newcastle	University	NSW	Cardiovascular disease and cancer: identifying shared disease pathways and pharmacological management	Recent advances in cancer prevention and management have led to a marked increase in cancer survivors. Cardiovascular disease (CVD) has become the leading cause of morbidity and mortality for these people, due to effects of their cancer therapy and shared risk factors between cancer and CVD. We aim to reduce the burden of CVD in cancer patients by developing better, more personalised treatments that can be used both to treat cancer and prevent CVD, and move them closer towards clinical trials.	Associate Professor Aaron Sverdlow	Associate Professor Aaron Sverdlow, Professor Michael Kelso, Kerry Doyle, Doctor James Lynam, Doctor Tali Hong Hing, Associate Professor Craig Gedyes, Doctor Heather Lee, Associate Professor Anoop Enjeti, Doctor Susan Dent, Associate Professor Nicole Verrilli, Professor Murray Cairns, Professor John Attia, Daniel Tillet, Associate Professor Dean Neo	Targeted competitive	1/06/2022	31/05/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases), Oncology And Carcinogenesis, Oncology And Carcinogenesis Not Elsewhere Classified	\$	999,998.00
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Sydney	University	NSW	Non-invasive imaging of atherosclerotic plaque: quantification of disease activity for improved identification of patients with residual cardiovascular risk	At present, some 50% of heart attacks are caused by the rupture of "high-risk" plaques that cannot be detected by currently available routine, non-invasive tests. We discovered that the activity of the enzyme myeloperoxidase (MPO) in arteries can be used to identify and differentiate high-risk from "low-risk" plaques (which currently can be detected and treated). This project will assess a novel non-invasive imaging tool that measures MPO activity for its ability to identify high-risk plaque.	Professor Roland Stocker	Professor Roland Stocker, Associate Professor John Chen, Professor Sanjay Patel, Professor Christopher Loni, Professor David Coleman, Professor Hosni Khat, Doctor James Nadel, Doctor Kristy Robledo, Professor Anthony Keech, Associate Professor Peter Liu, Professor Mark Parsons, Doctor Christopher Blair, Associate Professor Imran Rashid	Targeted competitive	1/06/2022	31/05/2026	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases), Clinical Sciences, Nuclear Medicine	\$	999,631.42
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Western Australia	University	WA	Alloantibody in kidney transplant recipients: is this the missing link to reduce the risk of heart disease? (AN-INSPIRE STUDY)	Kidney transplant patients experienced a very high burden of heart disease complications. Recent evidence suggests that the development of new proteins directed against the donor genes occurring post-transplant may predispose transplant patients to a higher risk of heart disease complications. This study will definitively address this uncertainty and improve our current understanding of whether this novel risk factor contributes to the excess risk of heart disease in this population.	Professor Wai Lim	Professor Wai Lim, Professor Charmaine Lok, Associate Professor Brendan McDougall, Doctor Lucy Sullivan, Associate Professor Andrea Vecelli, Associate Professor Lloyd D'Orologa, Professor Peter Thompson, Associate Professor Helen Pilmore, Professor Armando Twesira-Pinto, Associate Professor Heloise Cardinal, Professor Germaine Wong, Doctor Esther Ooi, Associate Professor James Chong, Doctor Anna Francis, Asst Professor Caroline Lamarche	Targeted competitive	1/06/2022	31/05/2025	Clinical Sciences	Clinical Sciences, Nephrology And Urology, Cardiorespiratory Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases), Immunology, Transplantation Immunology	\$	996,354.00
Cardiovascular Health Mission	2021 Cardiovascular Health	The University of Adelaide	University	SA	The Asialoglycoprotein Receptor 1 (ASGR1): a novel target for atherosclerosis	Our group have revealed an exciting new role for protein 'ASGR1' in the development of fatty deposits in blood vessels that cause heart attack and stroke. We will determine if levels of ASGR1 in the blood predicts the presence of fatty deposits in heart and neck vessels of patients. We will also characterise the sugar communication network in these patients. This project will pave the way to a novel blood-based marker for heart disease and stroke that will be supported by novel <u>pre-clinical studies</u> .	Associate Professor Christine Bursill	Associate Professor Christina Bursill, Doctor Arun Everett-Dass, Associate Professor Peter Pavlitis, Professor Robert Firdinge, Professor Nicole Packer, Doctor Joanne Tan	Targeted competitive	1/06/2022	30/12/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases)	\$	999,989.20
Cardiovascular Health Mission	2021 Cardiovascular Health	Macquarie University	University	NSW	Early Atrial Fibrillation Screening for Indigenous people (EAS)	The EAS study co-designs screening of Indigenous people for atrial fibrillation (AF) in primary care, evaluates the patient pathway and develops a framework to build scale. Our earlier work found Indigenous people need to be screened 10 years earlier than current guidelines and that tech-based, community screening was acceptable and feasible. Earlier screening for AF for Indigenous people (<55 years) will ensure early detection and timely treatment and ultimately reduce the rate of AF stroke.	Doctor Kylie Gwynne	Doctor Kylie Gwynne, Doctor Josephine Gwynn, Debbie McCowen, Doctor Jessica Orchard, Doctor John Skinner, Doctor Nicole Lowies, Associate Professor Christian Nailliah, Ms Katrina Ward, Professor Bronwyn Carlson, Mr Boe Rambadindri, Professor Ben Freedman	Targeted competitive	1/06/2022	31/05/2024	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health, Cardiorespiratory Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases)	\$	574,883.90
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Sydney	University	NSW	Identifying and addressing barriers and enablers to implementing best-practice cardiac rehabilitation: the Quality Improvement in Cardiac Rehabilitation (QUICR) Cluster Randomised Controlled Trial	Cardiac rehabilitation prevents further heart attacks and hospital admissions, but participation is low and quality variable. We have shown that collaborative quality improvement programs can address barriers and enable improvement in care quality and delivery in primary care. In this clinical trial, we will work with partners to determine if a quality improvement approach, supported by an electronic data platform, enhances cardiac rehabilitation quality of care and improves patient outcomes.	Professor Robyn Gallagher	Professor Robyn Gallagher, Professor David Bringer, Professor Thomas Riffle, Emerita Professor Adrian Bauman, Doctor Michelle Curich, Professor Julie Redfern, Doctor Susan Cartledge, Professor Robyn A Clark, Professor Gemma Figueres, Professor Adrienne O'Neil, Doctor Karice Hyun	Targeted competitive	1/06/2022	31/07/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases), Public Health And Health Services, Health And Community Services	\$	894,507.20
Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	University	VIC	Addressing the poor medication adherence in prevention of cardiovascular mortality and morbidity in Australia: development of a clinical decision support tool	The proposed study will help to contribute to a better understanding of nonadherence behaviours. Despite the strong evidence of the impact of pharmaceutical interventions, there remains a considerable gap between ideal treatment goals and current treatment in cardiovascular disease (and other related chronic disease areas). These gaps lead to reductions in the potential positive impacts of such interventions, losses of health outcomes for individuals, and downstream impacts on health systems	Doctor Stella Talic	Doctor Stella Talic, Doctor Jenni Ikonaki, Ms Sean Lybrand, Doctor Ella Zomer, Professor Simon Bell, Professor Danny Lew, Professor Sally Simon, Professor Christopher Reid, Associate Professor Janifia Ademi, Doctor Danielle Benavise	Targeted competitive	1/06/2022	31/05/2026	Public Health And Health Services	Public Health And Health Services, Primary Health Care	\$	706,241.60
Cardiovascular Health Mission	2021 Cardiovascular Health	James Cook University	University	QLD	Supervised Home Exercise for Peripheral Artery Disease	Blocked leg arteries (PAD) affect >1 million Australians, causing walking impairment and poor quality of life (QoL). Supervised exercise therapy is an effective PAD treatment by improving walking and QoL and reducing risk of major adverse events, but is not widely available in Australia. This trial will test the effectiveness of our novel exercise program delivered completely by telehealth, as compared to the current standard of care (centre-based exercise). Our program could transform PAD care.	Professor Jonathan Golledge	Professor Jonathan Golledge, Professor Clare Teal, Doctor Elizabeth Austin, Associate Professor Robyn Clay-Williams, Associate Professor Belinda Parmenter, Doctor Aaron Doward, Doctor Joseph Moon, Associate Professor Richard Norman, Associate Professor Christopher Askew, Doctor Nicola Burton, Associate Professor Clare Arnot, Professor Rachel Neale, Doctor Dylan Morris, Ms Jenna Pritchard	Targeted competitive	1/06/2022	31/05/2026	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases)	\$	999,999.71
Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	University	VIC	Love Your Brain: A stroke prevention digital platform	Many Australians experience stroke. There is huge public demand for information about how to stop stroke, which can be met by our "Love Your Brain" digital platform. The platform comprises an online course and messaging system on risk factor management, leveraging an existing Stroke Foundation program. We will test the effectiveness of this platform for helping more people in the community identify and manage their risk factors. This platform will reduce the prevalence of stroke in Australia.	Associate Professor Monique Kilkenny	Associate Professor Monique Kilkenny, Professor Timothy Kleinig, Associate Professor Janet Bray, Professor Dominique Cadilhac, Professor Mark Nelson, Doctor Mustapha Olaysi, Doctor Hoang Phan, Professor Amanda Thrift, Associate Professor Seana Gail, Ms Tara Purvis, Doctor Lisa Murphy, Doctor Jan Cameron	Targeted competitive	1/06/2022	31/12/2025	Public Health And Health Services	Public Health And Health Services, Health Promotion	\$	944,787.90
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Sydney	University	NSW	Enhancing engagement with eHealth approaches to prevent cardiovascular disease among adolescents: The Triple E Project	E-Health approaches (e.g. websites, mobile apps) have significant potential to help adolescents make health behaviour changes that will reduce their risk of developing CVD later in life, but more research is needed. This research will address a critical knowledge gap by increasing our understanding of how eHealth CVD prevention approaches can better engage adolescents, and translate this knowledge by engaging adolescents across Australia with a free preventive mobile app for CVD.	Doctor Louise Thornton	Doctor Louise Thornton, Doctor Katrina Champion, Professor Debra Richwood, Professor Nicola Newton, Doctor Milena Heinrich, Professor Frances Kay-Lambkin, Professor Maree Tesson, Professor Bonnie Spring, Associate Professor Sarah Zaman, Doctor Stephanie Parridge, Associate Professor Matthew Sunderland, Doctor Lauren Gardner	Targeted competitive	1/06/2022	31/05/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases), Public Health And Health Services, Preventive Medicine, Paediatrics And Reproductive Medicine, Paediatrics And Reproductive Medicine Not Elsewhere Classified	\$	993,682.00
Cardiovascular Health Mission	2021 Cardiovascular Health	The University of Newcastle	University	NSW	Using existing digital infrastructure for the national scale-up of an effective school nutrition program to reduce population CVD risk	SWAP-IT is a healthy lunchbox, text-message based program delivered by schools to parents mobile phones using software schools routinely use to contact parents. It was found to be effective in improving student diet and healthy weight. This research tests a strategy to increase the adoption of the SWAP-IT program by schools across Australia. It has the potential to influence millions of student lunches each week and reduce the risk of future cardiovascular disease and stroke.	Professor Luke Wolfenden	Professor Luke Wolfenden, Doctor Rachel Sutherland, Doctor Jannah Jones, Doctor Andrew Mlat, Professor Philip Morgan, Professor Heather McKay, Doctor Li Kheng Chai, Professor Corneel Vandekerkotte, Doctor Nicole Neilhan	Targeted competitive	1/06/2022	31/05/2025	Public Health And Health Services	Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	997,350.60
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Tasmania	University	TAS	Improving cardiovascular health through increased transport-related physical activity: A co-designed randomised controlled trial	Regular physical activity plays a key role in cardiovascular disease and stroke prevention, yet over one third of Australians are insufficiently active. This project aims to establish the impact on physical activity of a novel incentives-based strategy to increase public transport use through a single-linked parallel group randomised controlled trial. Findings will provide public health and transport authorities with evidence to inform decisions around the use of incentives-based strategies.	Associate Professor Verity Cleland	Associate Professor Verity Cleland, Doctor Lisa Stafford, Professor Christopher Blizard, Professor Anna Timperio, Professor Stephen Greaves, Doctor Kim Jose	Targeted competitive	1/06/2022	31/05/2025	Public Health And Health Services	Public Health And Health Services, Health Promotion	\$	767,132.85
Cardiovascular Health Mission	2021 Cardiovascular Health	Menzies School of Health Research	Medical Research Institute	NT	Non Expert Acquisition and Remote Expert Review of Screening echocardiography images from Child health and Antenatal clinics (NEARER SCAN)	Rheumatic heart disease (RHD) affects many children and pregnant women in Aboriginal and Torres Strait Islander communities in Northern Australia. Echocardiographic screening can identify RHD and facilitate earlier access to treatment. We will evaluate implementation of a novel approach to incorporating echocardiographic screening for RHD into routine antenatal care and child health checks in communities by briefly trained non-expert practitioners with support from offsite experts.	Associate Professor Joshua Francis	Associate Professor Joshua Francis, Doctor Jeffrey Cannon, Doctor Emma Haynes, Doctor Bo Remenyi, Ms Vicki Wade, Associate Professor Judith Katzenellenbogen, Associate Professor Natasha Howard, Professor Anna Ralph, Doctor James Marangou, Doctor Paul Jones, Doctor Nicole Canuto, Doctor Jennifer Yan, Professor Bart Currie, Doctor Holger Unger, Doctor Daniel Engelman	Targeted competitive	1/06/2022	31/05/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases)	\$	999,764.40
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Melbourne	University	VIC	Use of Artificial Intelligence-Guided Echocardiography to Guide Cardiovascular Management in Rural and Remote Australia	Heart failure and valvular heart disease are disproportionate problems in rural and remote Australia (RAA). Echocardiography is the best imaging investigation, and essential for management, but access to this essential test shows huge geographic variations, primarily because of dependence on expert acquisition. This trial seeks to demonstrate the effectiveness of artificial intelligence-based echocardiography for triage and management of patients with known or suspected heart disease in RAA.	Professor Thomas Marwick	Professor Thomas Marwick, Professor Graham Hillis, Doctor Benedict Costello, Doctor Leah Wright, Doctor Quan Huynh, Sudhir Wahi, Doctor Christopher Yu, Angus Baumann, Professor Kazuki Nishigaki, Professor Paul Scuffham	Targeted competitive	1/06/2022	31/05/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiovascular Medicine And Haematology Not Elsewhere Classified, Cardiorespiratory Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases), Cognitive Science, Knowledge Representation And Machine Learning	\$	999,996.60

Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	University	VIC	Combining Novel Imaging Biomarkers with AI-Accelerated Diagnosis for Equitable Patient Selection To Proactive Treatment With Middle Meningeal Artery Embolisation To Improve Outcomes in cSDH	Chronic subdural haematoma (cSDH) is a disease of the elderly that can cause severe disability and death due to brain compression. This project focuses on using new imaging biomarkers + AI-technology to enable equitable selection of patients to a pro-active, minimally invasive treatment 'called' 'middle meningeal artery embolisation' to stop haematoma growth. The main impact of our research outcomes are: fewer patients who need surgery and fewer patients with disability.	Professor Roland Bammer	Professor Roland Bammer, Professor Katharine Drummond, Associate Professor Tony Goldschlager, Professor Wen Lim, Associate Professor Ronil Chandra, Doctor Shalini Amulakutwa, Professor Vincent Thijs	Targeted competitive	1/06/2022	31/12/2025	Clinical Sciences	Clinical Sciences, Radiology And Organ Imaging	\$	999,865.70
Cardiovascular Health Mission	2021 Cardiovascular Health	Flinders University	University	SA	Impact of non-invasive coronary angiography on suspected acute coronary syndromes with low concentration troponin elevation	Increased sensitivity of modern troponin assays, which are used to detect cardiac injury, has led to identification of a new cohort with low level troponin elevations. Amongst this cohort, where the risk of a blockage in coronary vessels which requires treatment is lower, traditional investigative approaches such as invasive coronary angiography may not be of benefit. CT coronary angiography may be a less invasive, equally safe alternative imaging approach for this large newly identified cohort.	Associate Professor Sam Lehman	Associate Professor Sam Lehman, Professor Harvey White, Associate Professor Stephen Quinn, Professor John French, Ms Kristina Lambiris, Professor Derek Chew, Professor Jonathan Karnon	Targeted competitive	1/06/2022	31/05/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Ind. Cardiovascular Diseases)	\$	999,542.50
Cardiovascular Health Mission	2021 Cardiovascular Health	Queensland University of Technology	University	QLD	CTCA-POC: CT Coronary Angiography Inspired Point-of-Care Technology for Enhanced Diagnosis and Monitoring of Coronary Artery Disease	We are developing a novel point-of-care technology to better diagnose and monitor patients with coronary artery disease. This technology integrates CT coronary angiography with computational analysis and microfabrication techniques to create a microfluidic device for individual patients. It will not only enable clinicians to identify the high-risk patients more accurately, but also allow individual patients to monitor their risk of excessive blood clotting to prevent unexpected heart attacks.	Professor Zhiyong Li	Professor Zhiyong Li, Professor Gemma Ffytres, Professor Stuart Grieve, Doctor Liming Ju	Targeted competitive	1/06/2022	31/05/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Ind. Cardiovascular Diseases)	\$	999,995.90
Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	University	VIC	Precision Ecmo in Cardiogenic Shock Evaluation: PRECISE Study	ECMO is a form of mechanical heart support used in patients with cardiogenic shock. Although lifesaving, many patients still die and survivors often have complications. Supported by the national ECMO network, the PRECISE study will recruit 236 patients to investigate whether biomarkers can better identify which patients will derive the best long term benefit from ECMO, potentially leading to more targeted ECMO support and improved patient care.	Doctor Aidan Burrell	Doctor Aidan Burrell, Professor Alistair Nichol, Associate Professor Priya Nair, Associate Professor Vincent Pellegrino, Associate Professor Kiran Shekar, Professor Carol Hodgson, Doctor Mark Dennis, Doctor Alisa Higgins, Associate Professor Jessica Kasza, Associate Professor Zoe McQuillen, Professor Silvana Marasco, Associate Professor Dion Stub, Alain Combes, Doctor Ary Serpa Neto, Professor John Fraser	Targeted competitive	1/06/2022	31/05/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Ind. Cardiovascular Diseases)	\$	999,778.40
Cardiovascular Health Mission	2021 Cardiovascular Health	James Cook University	University	QLD	Transforming clinical pathways for abdominal aortic aneurysm through use of blood and imaging biomarkers	Patients with weakening of the main abdominal artery are at high risk of major adverse events. In this project we use biomarkers to develop improved models of care for this condition. Blood and imaging biomarkers will be discovered and validated. These will be incorporated into practical tools to inform management. Two promising repurposed drugs will also be tested. The findings could transform care from a focus on surgery to an individualised management pathways offering multiple treatments.	Professor Jonathan Gollidge	Professor Jonathan Gollidge, Associate Professor Catherine Rush, Doctor Rebecca Evans, Associate Professor Robyn Clay-Williams, Doctor Aaron Doward, Professor Gregory Jones, Professor Thomas Gasser, Associate Professor Matthew Field, Doctor Joseph Moon, Professor Aletta Schulte, Associate Professor Clare Arnett, Associate Professor Troyen Tran, Doctor Dylan Morris, Professor Switha Venkatesh, Ms Jenna Pinchbeck	Targeted competitive	1/06/2022	31/05/2026	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiovascular Medicine And Haematology, Not Elsewhere Classified	\$	999,999.60
Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	University	VIC	Using co-design to improve accessibility and acceptability of cardiac services for vulnerable populations: The Equal Hearts Study	Australians who live with social disadvantage are more likely to have heart disease. Health services can help address this burden, by ensuring they are accessible to all (i.e. easy to navigate and understand). This research will work closely with patients and health workers to improve accessibility of hospital-based cardiac services. We will first explore factors affecting accessibility and then co-design and test an intervention that addresses these factors.	Doctor Alison Beauchamp	Doctor Alison Beauchamp, Professor Stephen Nicholls, Associate Professor Annkarin Wong Shee, Doctor Jason Talewi, Associate Professor Romulo Oqupe, Doctor Lavanya Sharma, Doctor Rebecca Jessup, Professor William van Gaal	Targeted competitive	1/06/2022	1/10/2025	Public Health And Health Services	Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	597,104.30
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Sydney	University	NSW	Beyond Country of Birth: Transforming approaches to quantifying ethnic inequalities in access to best care for CVD	This project will identify inequalities in the way that people use the health system or are managed inside and outside of hospital for cardiovascular disease based on their ethnicity, or related factors such as English language proficiency and Visa class. We will carry out our research by linking data from the Australian Census and migration dataset to Commonwealth and NSW State health data, to quantify and determine drivers of ethnic inequalities in best care for cardiovascular diseases.	Associate Professor Fiona Stanaway	Associate Professor Fiona Stanaway, Associate Professor Patrick Kelly, Doctor Benjamin Hsu, Professor Louisa Jorm, Doctor Carmen Hudak Schneider, Professor Andrew Wilson, Doctor Saman Khalabati Soltani, Professor Leonard Kitharides, Associate Professor Michelle Dickson, Doctor Sarah Alkhatib	Targeted competitive	1/06/2022	31/05/2025	Public Health And Health Services	Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	782,008.00
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Canberra	University	ACT	A very brief intervention for physical activity behaviour change in cardiac rehabilitation: the 'Measure It' trial	Cardiac rehabilitation attendance finds it difficult to adhere to important physical activity guidelines. We have found that when clinicians regularly measure physical activity (taking <5 minutes), this simple intervention can increase physical activity levels in insufficiently active adults. Here we will find the optimum frequency of physical activity measurement within cardiac rehabilitation to increase activity levels of people with heart disease, reducing their risk of repeat cardiac events.	Associate Professor Nicole Freene	Associate Professor Nicole Freene, Associate Professor Theophilus Nyongesa, Professor Rachel Davey, Professor Robyn Gallagher, Doctor Christian Verdicchio, Associate Professor Richard Kegan, Doctor Zephania Tyack, Doctor Breanne Kunstler, Professor Walter Abhayaratna, Professor Steven McDermid	Targeted competitive	1/06/2022	31/01/2025	Public Health And Health Services	Public Health And Health Services, Health Promotion, Cardiorespiratory Medicine And Haematology, Cardiology (Ind. Cardiovascular Diseases), Clinical Sciences, Rehabilitation And Therapy (Excl. Physiotherapy)	\$	510,069.60
Cardiovascular Health Mission	2021 Cardiovascular Health	The University of Adelaide	University	SA	Next Generation Precision Health Platform to support Atrial Fibrillation Management	We investigate the use of behaviour change driven by digital technology to transform care of AF patients. This will be achieved by instilling clinical health literacy, use of precision tools to support patients through lifestyle changes and shared decision making. This novel approach makes for a paradigm shift from a scarcely available, resource intensive specialised AF Clinics to a widely available one emphasizing health literacy and behaviour change to improve cardiovascular outcomes.	Associate Professor Rajiv Mahajan	Associate Professor Rajiv Mahajan, Associate Professor Satupa Mukherjee, Associate Professor Saurabh Kumar, Doctor Nathan O'Callaghan, Doctor Timothy Luthman, Professor Mark Boyd, Associate Professor Han Lim	Targeted competitive	1/06/2022	31/08/2024	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Ind. Cardiovascular Diseases)	\$	791,555.40
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Western Australia	University	WA	Towards Remote Patient Monitoring of Heart Failure Using Event-Driven AI Systems	The objective of our study is to develop an artificial intelligence based system that is capable of estimating the central venous pressure based on the skin motion acquired using different camera techniques. Our device will be adopted into a mobile system and its performance will be assessed in real life situations in a prospective study. This research has the potential to improve patient outcomes and also reduce hospital readmissions by diagnosing heart failure at early onset.	Professor Girish Dawideti	Professor Girish Dawideti, Doctor Abdul Rahman Indayil, Professor Graham Hills, Professor Sarjap Patel, Professor Mohammed Benamoun, Doctor Omid Kavehei, Professor Farid Bousaid, Doctor Jason Eshraghian, Professor Gemma Ffytres	Targeted competitive	1/06/2022	31/05/2024	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Ind. Cardiovascular Diseases)	\$	583,551.20
Cardiovascular Health Mission	2021 Cardiovascular Health	Flinders University	University	SA	Yolngu Heart Health for Life: Person-centred, co-designed and student-assisted cardiac rehabilitation in East Arnhem Land	The project team will work with the local Yolngu peoples of East Arnhem to develop, implement and evaluate a new cardiac rehabilitation program. It will use senior allied health students on clinical placements to deliver the program. It will build on existing National Heart Foundation resources (The 'My Heart My Family Our Culture' (MHMFQC) resources) designed for Aboriginal and Torres Strait Islander peoples but be culturally adapted for the local East Arnhem context.	Professor Chris Rissel	Professor Chris Rissel, Doctor Alice Cairns, Associate Professor Ruth Barker, Patricia Field, Mrs Kylie Stothers, Doctor Karla Canuto, Associate Professor Narelie Campbell, Professor Robyn A Clark, Doctor Claire Balaban	Targeted competitive	1/06/2022	31/05/2024	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health	\$	633,589.00
Cardiovascular Health Mission	2021 Cardiovascular Health	The University of Queensland	University	QLD	The Right Treatment for the Right Person at the Right Time: Driving High-Value Aphasia Care through Meaningful Health System Monitoring	Every 10 minutes someone in Australia has a stroke. A third of those who survive will have aphasia—difficulty speaking, understanding, reading, writing. Aphasia makes everyday life difficult and activities like reading an email, become impossible challenges. Depression is common and quality of life is very poor. We will monitor aphasia services to understand what helps someone to have a 'good recovery', and develop an approach that empowers survivors with knowledge about their therapy progress.	Doctor Sarah Wallace	Doctor Sarah Wallace, Associate Professor Monique Kilbenny, Doctor Kristine Strickland, Doctor Anne Hill, Doctor Robyn O'Halloran, Associate Professor Erin Godceke, Professor David Copland, Doctor Mudeen Olajoy, Professor Deborah Hersh, Professor Carolyn Unsworth	Targeted competitive	1/06/2022	30/11/2024	Clinical Sciences	Clinical Sciences, Rehabilitation And Therapy (Excl. Physiotherapy)	\$	451,221.00
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Sydney	University	NSW	Discovery of new platelet targets to improve the management of coronary artery disease	Only 1 in 4 patients who have suffered from a heart attack will receive long term protection with available treatments. There is a need to find new targets for monitoring and treating patients after their first event. Our research will identify targets on platelets which are blood cells responsible for blood clotting. Using a small amount of blood, we will profile platelet markers from patients recovering from a heart attack. These markers will be used to discover new therapies.	Doctor Freda Passam	Doctor Freda Passam, Doctor James Weaver, Associate Professor Vivien Chen, Doctor Mark Laranca	Targeted competitive	1/06/2022	31/05/2024	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiovascular Medicine And Haematology Not Elsewhere Classified	\$	659,293.00
Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	University	VIC	Improving short- and long-term outcomes in cardiac bypass surgery by preventing acute kidney injury	During cardiac bypass surgery, there is a substantial drop in blood flow to the organs. This induces acute kidney injury, especially in individuals with pre-existing conditions such as diabetes, resulting in poor short- and long-term outcomes. This project will develop a new pre-clinical model of reduced blood pressure in diabetic animals to understand the mechanisms of how kidneys are injured, and to test novel therapies to prevent this happening in patients undergoing cardiac surgery.	Professor David Nikolic-Paterson	Professor David Nikolic-Paterson, Doctor Frank Ma, Doctor Keren Grynberg, Associate Professor William Mulvey, Professor Julian Smith	Targeted competitive	1/06/2022	31/05/2024	Clinical Sciences	Clinical Sciences, Nephrology And Urology	\$	511,208.00
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Melbourne	University	VIC	Novel targeted anti-inflammatory and anti-thrombotic mRNA therapies: Establishing innovative technologies to combat cardiovascular diseases	We designed mRNA-based strategies will provide safe and long-lasting therapeutic benefits for 3 chronic cardiovascular diseases with unmet therapeutic needs. Upstream nanoparticles will be designed for disease-specific delivery or be responsive to ultrasonic stimulus, thereby providing controlled release of the mRNA payload. These novel approaches will result in dose-reduction, eliminate off-targeted effects, and can be easily translated to benefit all other medical fields.	Associate Professor Xiaowei Wang	Associate Professor Xiaowei Wang, Professor Harshal Nandurkar, Professor Karlheinz Peter	Targeted competitive	1/06/2022	31/05/2024	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Ind. Cardiovascular Diseases)	\$	689,854.82
Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	University	VIC	Discovery of new molecular targets for stroke-Associated pneumonia to improve recovery	Pneumonia is highly prevalent and often deadly in stroke patients, raising the possibility of weakened lung immunity after stroke. The focus of this project is to explore if the release of small membrane-bound vesicles, termed exosomes, after stroke remotely regulate and impair host defence. We propose revealing exosomal content will offer novel biomarkers to identify high-risk stroke patients who will require targeted therapy to limit infectious complications and improve patient recovery.	Associate Professor Connie Wong	Associate Professor Connie Wong, Professor Henry Ma, Doctor Justin Ireda, Associate Professor Raif Schittenhelm, Doctor Shu Wen Wen	Targeted competitive	1/06/2022	31/12/2024	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Ind. Cardiovascular Diseases), Medical Biochemistry And Metabolomics, Medical Biochemistry And Metabolomics Not Elsewhere Classified, Immunology, Cellular Immunology	\$	663,217.60
Cardiovascular Health Mission	2021 Cardiovascular Health	Flinders University	University	SA	Real-time measurement of renewal rate constants in pulsed field ablation of atrial fibrillation	Atrial fibrillation is the most common heart rhythm disorder in the Australian community. The current approach to treatment of AF, called ablation, has high failure rates in persistent AF. In an academic-industry partnership, in this application, we (i) develop a new monitoring technology for intra-procedural monitoring of the effectiveness of AF ablation; and (ii) perform AF ablations using a novel form of ablation, known as pulse electrical field ablation.	Associate Professor Anand Ganesan	Associate Professor Anand Ganesan, Doctor Dhani Dhamparani, Mr Darius Chapman, Doctor Shahid Ullah, Mr Ian Fong, Doctor Andrew May, Professor Jonathan Karnon	Targeted competitive	1/06/2022	31/05/2024	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Ind. Cardiovascular Diseases)	\$	604,305.60

Cardiovascular Health Mission	2021 Cardiovascular Health	University of Melbourne	University	VIC	Translating novel mechanism-guided therapeutics to improve functional recovery of the brain and kidneys after open-heart surgery	Acute brain and kidney injury often occur after heart surgery; the reasons for this are unclear, and there are no effective treatments. During heart surgery, we found that blood can spill to the brain and kidneys are depleted but can be restored using our new candidate drugs that deliver zinc into cells. We will provide the scientific rational for future clinical trials of this novel therapy to improve the recovery of the brain and kidneys after heart surgery to improve patient health outcomes.	Associate Professor Yugeesh Lankadeva	Associate Professor Yugeesh Lankadeva	Targeted competitive	1/06/2022	31/03/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (incl. Cardiovascular Diseases), Cardiorespiratory Medicine And Haematology, Cardiovascular Medicine And Haematology Not Elsewhere Classified, Medical Physiology, Systems Physiology	\$	998,224.25
Cardiovascular Health Mission	2021 Cardiovascular Health	St Vincent's Institute of Medical Research	Medical Research Institute	VIC	Sustained delivery of stem cell secretome for cardiac repair	Heart disease is the leading cause of death worldwide. Stem cells have the potential to treat heart disease by producing beneficial soluble factors and membrane-bound particles. This project aims to accelerate the development of a new, safe and minimally invasive method to deliver the beneficial proteins of stem cells to patients, using a retrievable encapsulation device that protects the transplanted cells, to allow long-term treatment for effective cardiac repair.	Doctor Shiang Lim	Doctor Shiang Lim, Professor Thomas Loudovaris, Professor Janina Morrison, Doctor Kellan Kelly, Doctor Jack Darby, Professor Derek Haseley	Targeted competitive	1/06/2022	31/05/2024	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (incl. Cardiovascular Diseases), Medical Biotechnology, Regenerative Medicine (incl. Stem Cells And Tissue Engineering), Medical And Biomedical Chemistry, Biologically Active Molecules	\$	958,504.12
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Melbourne	University	VIC	Targeting no-reflow to augment tissue salvage in stroke	Ischemic stroke is due to a blocked major brain artery. Half of patients who receive acute treatment do not improve for unclear reasons. We will study one potential reason, the "no-reflow phenomenon", where micro-blockages in small vessels stop blood reaching the brain despite unblocking the major artery. We will test how to reduce no-reflow in mice, and how it affects humans. Our ultimate aim is to develop a clinical trial for no-reflow to help brain tissue receive blood more efficiently.	Doctor Felix Ng	Doctor Felix Ng, Associate Professor Brad Sutherland, Professor Patricia Desmond, Professor Stephen Davis, Professor Geoffrey Doman, Professor Bruce Campbell, Doctor Hannah Johns, Professor Vincent Thijs, Associate Professor Reece Turner, Professor Robert Medcalf	Targeted competitive	1/06/2022	31/03/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiovascular Medicine And Haematology Not Elsewhere Classified	\$	999,978.19
Cardiovascular Health Mission	2021 Cardiovascular Health	University of South Australia	University	SA	The feasibility and potential of a novel robotic gait biosynthesis for people with severe gait impairment post-stroke	People after stroke often have problems walking due to weakness and poor coordination. However in order to recover, they need to intensively practice the things they find difficult. This presents a problem when walking itself is extremely unsafe or needs a lot of help. We have devised a new sensor and exoskeleton system that may allow people to practise walking safely with less reliance on other people. We need to test this for safety and acceptability first with our stroke survivor partners.	Professor Susan Hillier	Professor Susan Hillier, Professor Timothy Kleinig, Mr Robert Trotter, Professor Mark Jenkinson, Professor Karen Reynolds, Doctor Brenton Hordacre, Doctor David Hobbs, Mr Anthony Fox	Targeted competitive	1/06/2022	31/05/2024	Clinical Sciences	Clinical Sciences, Physiotherapy, Neurosciences, Central Nervous System, Clinical Sciences, Radiology And Organ Imaging	\$	513,102.80
Cardiovascular Health Mission	2021 Cardiovascular Health	University of New South Wales	University	NSW	Developing a holistic machine learning based rapid response system and end of life care system in preventing cardiac arrests and preventable deaths and improving end of life care in acute hospitals	Our research aims to develop and implement a holistic dual machine learning (ML) based systems (rapid response system (RRS) and end of life (EoL) care system) in combining the new care models for preventing cardiac arrests and related deaths among in hospital patients and continuing shared decision making end-of-life care both during and after hospitalisation.	Associate Professor Jack Chen	Associate Professor Jack Chen, Associate Professor Deepak Bhongari, Professor Anden Anemian, Associate Professor Arthas Baburao, Professor Michael Parr, Professor Daniel Chan, Professor Kenneth Hillman, Doctor Liwei Du	Targeted competitive	1/06/2022	31/05/2024	Public Health And Health Services	Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	700,583.20
Cardiovascular Health Mission	2021 Cardiovascular Health	University of New South Wales	University	NSW	Outcome Prediction in IntraCerebral haemorrhage Study (OPTICS) with machine learning	Patients with spontaneous brain haemorrhage or intracerebral haemorrhage (ICH), are often critically unwell and at high risk of death and disability, where clinicians face decisions over providing intensive care, surgery, or palliation. However, there are few reliable tools available to guide clinicians in such outcome prediction. We aim to enhance outcome prediction in ICH by using deep learning, a form of artificial intelligence, in analysis of a unique patient database of 3000+ brain images.	Professor Craig Anderson	Professor Craig Anderson, Professor Laurent Billot, Doctor Mengyu Ouyang, Doctor Sebastiano Barbieri	Targeted competitive	1/06/2022	31/05/2024	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (incl. Cardiovascular Diseases), Clinical Sciences, Intensive Care, Neurosciences, Central Nervous System	\$	404,190.00
Cardiovascular Health Mission	2022 Cardiovascular Health	University of New South Wales	University	NSW	The Elusive Hearts Study: Using genomics to diagnose and manage inherited cardiovascular diseases	Our understanding of how genetic variants lead to cardiac diseases is limited, and only 40% of families receive a genetic diagnosis. We seek to develop a national cohort of patients with heritable cardiovascular diseases where current genetic testing has failed to identify a cause, and apply advanced, state of the art research-based sequencing and analysis methods to identify a cause. This will give the family a diagnosis, allow more accurate risk prediction and provide mechanistic insights.	Associate Professor Jodie Ingles	Associate Professor Jodie Ingles, Associate Professor Robert Weintraub, Professor Julie McGaughan, Professor Jamie Vandenberg, Associate Professor Owen Siggs, Doctor Ira Deveson, Professor Jonathan Skinner, Professor John Atherton, Professor Daniel MacArthur, Doctor Richard Nagel, Doctor Belinda Gray, Associate Professor Dominica Zentner, Professor Zorritza Stark, Professor Christopher Semanjan, Professor Igor Konstantinov	Targeted competitive	1/02/2023	31/01/2027	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Cardiovascular Medicine And Haematology, Cardiology (incl. Cardiovascular Diseases)	\$	1,499,286.00
Cardiovascular Health Mission	2022 Cardiovascular Health	Deakin University	University	VIC	Early detection of insulin-resistance with a mixed meal challenge - The REFINE study	Insulin resistance is a precursor to type 2 diabetes, heart disease and stroke. We have developed a new more sensitive test for doctors to use to screen people with insulin resistance. Detecting people in the community with insulin resistance can help doctors inform patient care to prevent people from developing these chronic diseases.	Associate Professor Michelle Keske	Associate Professor Michelle Keske, Professor Thomas Marwick, Professor Jo Salmon, Professor Itamar Levinger, Doctor Gavin Abbott, Doctor Lewas Parker, Professor Glenn Wadley	Targeted competitive	1/02/2023	30/06/2027	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Cardiovascular Medicine And Haematology, Cardiovascular Medicine And Haematology Not Elsewhere Classified	\$	1,498,740.60
Cardiovascular Health Mission	2022 Cardiovascular Health	Queensland University of Technology	University	QLD	Clinical and health economics implications of routine CTCA for emergency department assessment of Abnormal and Torres Strait Islander people at risk of acute coronary syndrome	A new model of care will be implemented and evaluated for First Nation Australians who present to emergency in Far North Queensland with chest pain. The strategy, co-designed with First Nations Australians, includes access to Computed Tomography Coronary Angiography (CTCA) to detect heart disease and provide culturally safe test information. The aims are to improve diagnosis of heart disease, increase uptake of preventive therapies, and determine acceptability and feasibility of the strategy.	Professor Louise Cullen	Professor Louise Cullen, Doctor Soham Cramb, Professor Ray Mahoney, Doctor Victoria McCrea, Professor Graham Hillis, Doctor Abdul Rahman Isahayid, Mr Andrew Goodman, Professor William Pansarage, Professor Derek Chew, Doctor Andrea McKivett, Doctor Zephania Tyeck, Associate Professor Iain Greenleide, Professor Gemma Figtree, Ms Laura Stephenson, Doctor Gregory Skarney	Targeted competitive	1/02/2023	31/01/2027	Health Sciences	Health Sciences, Public Health, Health Equity, Biomedical And Clinical Sciences, Cardiovascular Medicine And Haematology, Cardiology (incl. Cardiovascular Diseases), Indigenous Studies, Aboriginal And Torres Strait Islander Health And Wellbeing, Aboriginal And Torres Strait Islander Health Services	\$	1,488,717.70
Cardiovascular Health Mission	2022 Cardiovascular Health	University of Sydney	University	NSW	Evaluation of a Standardised Clinical Pathway to improve Equity and outcomes in Cardiac Shock (ESCAPE-CS)	Cardiogenic shock (CS) is a common and lethal condition. Care of CS patients in Australia must modernise to ensure all patients have equal access and chance of survival. The ESCAPE-CS trial aims to implement and assess a comprehensive system of CS care that includes a streamlined pathway for referring patients, a specialist shock team, and protocols to guide treatment. The trial is a necessary step in developing a comprehensive system delivering the best possible CS care to all Australians.	Doctor Pankaj Jain	Doctor Pankaj Jain, Doctor MH Nguyen, Professor Ian Marschner, Associate Professor Priya Nair, Associate Professor Brian Burns, Professor Anthony Keech, Associate Professor Caleb Ferguson, Associate Professor Andrew Forrest, Doctor Mark Dennis, Mr Karan Shah, Associate Professor Chi Kin Law, Professor Christopher Hayward, Professor Peter Macdonald, Doctor Kavitha Mulhiah	Targeted competitive	1/02/2023	31/01/2027	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Cardiovascular Medicine And Haematology, Cardiology (incl. Cardiovascular Diseases)	\$	971,931.94
Cardiovascular Health Mission	2022 Cardiovascular Health	The University of Newcastle	University	NSW	Increasing the capacity of Community Managed Organisations to provide preventive care to people with a mental health condition	The aim of this study is to assess the effectiveness of practice change strategies designed to increase preventive care provision for cardiovascular disease risk behaviours to clients with a mental health condition within CMO settings. This research will support people with a mental health condition to make positive changes to their cardiovascular disease risk behaviour, with the potential to reduce the physical health inequity experienced by this population group.	Professor Jennifer Bowman	Professor Jennifer Bowman, Professor David Castle, Professor Russell Roberts, Professor John Wiggins, Professor Luke Woffenden, Mr Mark Orr, Professor Sharon Lawn, Associate Professor Flora Tzelepis, Doctor Christopher Oldmeadow, Doctor Melanie Ringland, Doctor Kate Bartlett, Doctor Penny Reeves, Doctor Elizabeth Campbell, Doctor Caitlin Fehily, Ms Sumathi Govindasamy	Targeted competitive	1/02/2023	30/06/2027	Health Sciences	Health Sciences, Health Services And Systems, Health And Community Services, Health Sciences, Public Health, Preventative Health Care	\$	1,135,281.00
Cardiovascular Health Mission	2022 Cardiovascular Health	Edith Cowan University	University	WA	Investigating genetic and lifestyle determinants of abdominal aortic calcification, and their relationship with cardiovascular disease	This project will use a newly developed state-of-the-art algorithm to detect and quantify a novel structural measure of blood vessel disease from widely-available bone density machine images. Using these results in large studies with detailed genetic and lifestyle information, we will explore why and how disease occurs. Ultimately, enabling new and better approaches to target genes, lifestyle factors and chronic diseases causing cardiovascular hospitalisations and deaths in older Australians.	Associate Professor Joshua Lewis	Associate Professor Joshua Lewis, Doctor Syed Zulqarnain Gilani, Emeritus Professor Joseph Hung, Doctor John Kemp, Professor Carl Schultz, Professor Nicholas Harvey, Professor Richard Woodman, Doctor Nicola Bondonio, Doctor Marc Sim, Professor John Schousboe, Doctor Cassandra Smith, Professor Wai Lin, Professor Emma Duncan, Doctor Anne Ezzine Lagnedok, Farminder Raina	Targeted competitive	1/02/2023	31/01/2027	Biological Sciences	Biological Sciences, Genetics, Genomics, Biomedical And Clinical Sciences, Clinical Sciences, Radiology And Organ Imaging, Health Sciences, Epidemiology, Nutritional Epidemiology	\$	1,202,212.80
Cardiovascular Health Mission	2022 Cardiovascular Health	James Cook University	University	QLD	Activation of AMPK to treat abdominal aortic aneurysm (SA)	Twenty million people worldwide, and 100,000 Australians, have weakening of the main abdominal artery which can lead to sudden death or the need for hazardous surgery. Currently the only treatment for this disease is surgery but this has durability and safety limitations. This integrated laboratory and clinical research project tests a promising novel drug to treat this disease.	Professor Jonathan Golledge	Professor Jonathan Golledge, Professor Norielle Daly, Doctor Sonia Shah, Doctor Sandra Galic, Professor Gregory Jones, Doctor Joseph Moon, Doctor Dylan Morris, Associate Professor Catherine Rush, Emer Professor Rhonda Jones, Ms Jenna Prochaska, Associate Professor Jon Oshill, Doctor Tejas Singh, Professor Phil Tsao	Targeted competitive	1/02/2023	31/01/2028	Health Sciences	Health Sciences, Other Health Sciences, Other Health Sciences Not Elsewhere Classified	\$	1,044,836.20
Cardiovascular Health Mission	2022 Cardiovascular Health	University of Sydney	University	NSW	Clinical imaging inspired point-of-care microtechnology for enhanced diagnosis and monitoring of recurrent stroke	In collaboration with NSW Telestroke Service, we introduce a low-cost, portable, standardised, point-of-care microdevice for stroke recurrent risk assessment. It particularly benefits the large and disadvantaged populations, including regional, aged, pregnant, handicapped, and indigenous. We envisage the standardised microchip will expand future applications to tailor intervention requirements, assess bleeding risk after surgery, and long-term monitor antithrombotic treatment and prognosis.	Doctor Liming Ju	Doctor Liming Ju, Professor Ken Butcher, Doctor Hongxia Lu, Doctor Timothy Ang, Doctor Freda Passam, Professor Zhiyong Li, Doctor Leon Edwards, Doctor Ann-Na Cho, Y. Shrike Zhang, Lunkyung Ko	Targeted competitive	1/02/2023	30/04/2027	Engineering	Engineering, Biomedical Engineering, Biomechanical Engineering, Engineering, Fluid Mechanics And Thermal Engineering, Microfluidics And Nanofluidics, Biomedical And Clinical Sciences, Cardiovascular Medicine And Haematology, Cardiovascular Medicine And Haematology Not Elsewhere Classified	\$	1,199,996.00
Cardiovascular Health Mission	2022 Cardiovascular Health	University of Sydney	University	NSW	Replenishing enzymatic cofactor NAD+ in Heart Failure: Rescuing an engine out of fuel	Although it is well known that the failing heart is "an engine out of fuel", no heart failure therapies target the heart's capacity to generate fuel. This program identified a mechanism common to the major forms of heart failure, whereby a key molecule that helps the heart's fuel generating machinery is depleted. Restoring levels of this molecule were able to recover the heart from heart failure in model systems, which will now be tested in patients in this application.	Doctor John O'Sullivan	Doctor John O'Sullivan, Doctor Sean Lal, Doctor Yen Chie Kwai, Doctor Andrew Philp, Professor Sally Inglis, Rong Tian	Targeted competitive	1/02/2023	31/01/2027	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Cardiovascular Medicine And Haematology, Cardiology (incl. Cardiovascular Diseases)	\$	1,499,523.00
Cardiovascular Health Mission	2022 Cardiovascular Health	Monash University	University	VIC	Advancing preclinical development of novel GPCR-targeted therapeutics for heart failure	Heart failure with preserved ejection fraction (where compliance of heart muscle is decreased, making the heart stiffer) is now the most prevalent form of heart failure, particularly women. Traditional heart failure drugs are ineffective here - new innovations in drug discovery are required. We have identified a novel drug discovery approach to target heart failure with preserved ejection fraction that has the potential to effectively address this urgent, unmet clinical need in women and men.	Professor Rebecca Ritchie	Professor Rebecca Ritchie, Doctor Chengxue Helena Qin, Doctor Lauren May, Professor Jean Yang, Professor Grant Dineley, Professor Andrew Taylor, Doctor Kristen Bubb, Professor Stephen Nicholls, Doctor Alexander Pinto, Emeritus Professor John Horowitz, Professor Jonathan Baell, Professor Gemma Figtree, Doctor David Shuckford, Associate Professor Gabriele Schiattarella, Hooi Hooi Ng	Targeted competitive	1/02/2023	31/01/2026	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Cardiovascular Medicine And Haematology, Cardiology (incl. Cardiovascular Diseases)	\$	1,496,862.61

Cardiovascular Health Mission	2022 Cardiovascular Health	University of Sydney	University	NSW	Gap Junction Modulation: A Novel Molecular Target in the Management of Ventricular Arrhythmia in Ischaemic Cardiomyopathy	Although decreased electrical conduction in the heart has been identified as a mechanism for ventricular arrhythmia that underlies sudden cardiac death following heart attack, there are no current treatment modalities that target this mechanism directly. We have developed novel therapeutic approaches to address this issue. Through this proposal, we will continue to expand our trajectory towards the clinical translation of this discovery by utilising gene therapy and other advanced therapeutics.	Associate Professor Eddy Kizana	Associate Professor Eddy Kizana, Associate Professor Leszek Lisowski, Associate Professor Sarab Kumar, Professor Ian Alexander, Doctor Dhama Ravindran	Targeted competitive	1/02/2023	31/01/2027	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Cardiovascular Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases)	\$	1,104,168.00
Cardiovascular Health Mission	2022 Cardiovascular Health	Baker Heart and Diabetes Institute	Medical Research Institute	VIC	Novel, targeted therapies for heart failure with preserved ejection fraction	Heart failure with preserved ejection fraction (HFpEF) is the predominant form of heart failure with no effective treatment currently available. Inflammation and oxidative stress are the key factors driving HFpEF pathologies. The enzyme, namely, ASK1, is the convergent point of HFpEF pathologies and a potential therapeutic target. ASK1 inhibitors to be developed in this study will provide new treatment improving the management and quality of life for HFpEF patients.	Professor David Kaye	Professor David Kaye, Doctor Guy Krippner, Associate Professor Bing Wang	Targeted competitive	1/02/2023	31/01/2027	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Cardiovascular Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases)	\$	998,334.81
Cardiovascular Health Mission	2022 Cardiovascular Health	University of Melbourne	University	VIC	Post-thrombectomy intra-arterial tenecteplase for Acute management of Non-retrievable thrombus and no-reflow in Emergent Stroke (EXTEND-AGNES-TNK)	The EXTEND-AGNES-TNK multicentre study will test whether adding tenecteplase, a powerful clot busting medication, during clot retrieval procedure will improve recovery by dissolving smaller and inaccessible blockages in the small arteries across 18 Australian major stroke centres. If effective, the study will bring a new treatment that can be immediately used in Australia to significantly maximise the effectiveness of current stroke treatment and improve stroke patients' outcome.	Doctor Felix Ng	Doctor Felix Ng, Professor Geoffrey Donnay, Professor Timothy Klasing, Professor Helen Dewey, Professor Stephen Davis, Doctor Ian Gao, Professor Vincent Thip, Professor Leonid Churlov, Professor Peter Mitchell, Doctor Jans Alamegeel, Professor Patricia Desmond, Doctor Kathryn Hayward, Professor Bruce Campbell, Alice Ma	Targeted competitive	1/02/2023	31/07/2029	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Cardiovascular Medicine And Haematology, Cardiovascular Medicine And Haematology Not Elsewhere Classified	\$	3,885,416.16
Cardiovascular Health Mission	2022 Cardiovascular Health	University of Melbourne	University	VIC	Impact of Total Arterial Revascularisation in Coronary Artery Surgery on cardiovascular, cerebrovascular and multiorgan outcomes - an RCT (TA Trial)	Coronary artery disease affects 4 million Australians annually and occurs in patients with multiple coexisting cardiovascular comorbidities undergoing coronary artery bypass surgery. Complications are related to failure of bypass grafts to remain open (patent). This multi-centre RCT proposes that the exclusive use of arterial grafts, vs some use of venous grafts (in addition to arterial grafts, - the current standard of care) will lead to improved patient outcomes and survival.	Professor Alistair Royce	Professor Alistair Royce, Professor Paul Bannan, Associate Professor Baime Liu, Doctor Andrea Bower, Doctor Sandy Clarke-Evry, Professor Julian Smith, Professor Michael Valley, Professor Christopher Reid, Professor Rinaldo Bellomo, Professor Colin Royce, Associate Professor David Eccleston, Professor Guy Ludbrook, Doctor David Tian	Targeted competitive	1/02/2023	31/01/2029	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Clinical Sciences, Surgery	\$	4,958,416.40
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	La Trobe University	University	VIC	Prospective, multicentre trial evaluating FET-PET in high grade brain glioma	This prospective multicentre trial will be the largest study performed to date, aiming to develop a novel imaging test (FET-PET) for the accurate evaluation of residual or recurrent disease in patients with high grade brain cancer. We also aim to establish the prognostic ability of FET-PET in patients with high grade glioma.	Professor Andrew Scott	Professor Andrew Scott, Professor Anna Nowak, Associate Professor Roslyn Francis, Professor Hui Gan, Professor Rodney Hicks, Associate Professor Farshad Forouzi, Associate Professor Eng-Siew Koh, Professor Mark Rosenblat, Associate Professor Mustafa Khawar, Professor Martin Ebert	Restricted competitive	26/06/2018	15/08/2024	Oncology And Carcinogenesis	Cancer Diagnosis	\$	1,564,187.71
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	Monash University	University	VIC	A collaborative study of the Interfant network (Australian sites): the feasibility, safety and efficacy of the addition of Blinatumomab to the Interfant 06 backbone in infants with MLL-rearranged Acute lymphoblastic leukaemia (The Blin-fant Study)	Infants (<1 year of age) diagnosed with acute lymphoblastic leukaemia (ALL) is rare but devastating. Most have a distinct genetic change which makes them even more likely to die from their disease. This international study will examine if a novel drug, blinatumomab, can be safely added to the standard chemotherapy used to treat infants with ALL, and if it is better than chemotherapy alone. The results from this study will be used to develop the first worldwide trial for infant ALL.	Doctor Rishi Kotecha	Associate Professor Rishi Kotecha, Doctor Luciano Dalla-Pozza, Associate Professor Andrew Moore, Doctor Seung Lin Khaw, Associate Professor Rosemary Sutton, Doctor Inge van der Sluis	Restricted competitive	13/06/2018	31/12/2023	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	314,771.57
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	Monash University	University	VIC	A registry-linked national platform trial to improve precision-based outcomes using novel therapies in acute myeloid leukaemia (AML)	Acute myeloid leukaemia (AML) is a rare disease, affecting 4.1/100,000 in the population. It is also a lethal blood cancer, with 5-year overall survival only 24.5%. Despite intensive chemotherapy relapse risk is high. Using next-generation sequencing (NGS) and droplet digital PCR (ddPCR), it is now possible to identify and track clonal variants in almost all patients. This proposal will create an integrated national clinical trial program in AML focused on precision diagnosis, treatment and monitoring. This will be achieved by establishing a network of laboratories to perform NGS-based risk stratification and minimal residual disease (MRD) tracking within the Australasian Leukaemia and Lymphoma Group framework. Using this established trials group, we propose to develop an adaptive 3-stage platform study to enable discovery of novel target directed therapies. A Master Protocol will randomise patients in first remission to multiple investigational agents, compared to a central arm. The study will be perpetual, with promising arms graduating to larger efficacy studies and ineffectual arms replaced with new agents. Serial MRD quantitation of clonal disease by RT-qPCR and digital PCR will be used in stage 1 to identify promising drugs, relative to observation. In the second stage, promising arms will be adaptively expanded to estimate leukaemia-free survival. Arms showing sufficient promise in phase 2 will be expanded seamlessly to stage 3, to validate the effect on overall survival. The BCL-2 inhibitor venetoclax has shown great promise in elderly patients with AML, in combination with low-dose cytarabine. We hypothesize that targeting BCL-2 will suppress MRD and prolong survival of AML patients with diverse genomic profiles. The outcomes from this proposal include a world first maintenance platform trial in AML and the first examination of the effectiveness of targeting BCL-2 to eliminate MRD linked to an enduring framework to efficiently screen novel drugs.	Associate Professor Andrew Wei	Professor Andrew Wei, Professor Mark Dawson, Associate Professor John Breckels, Professor Stefan Bohlander, Doctor Adam Ivey	Restricted competitive	18/06/2018	31/12/2023	Clinical Sciences	Clinical Sciences Not Elsewhere Classified	\$	1,507,785.35
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	Monash University	University	VIC	CAST - A Randomised Phase 3 Trial of Cyclophosphamide after Sibling Allogeneic Haematopoietic Stem Cell Transplant	Bone marrow transplant is an important curative treatment for patients with blood cancers. Unfortunately, 40% of patients will develop a life-threatening complication called graft versus host disease (GVHD). In this study, we will compare two strategies to prevent GVHD - the standard drugs used for almost 30 years and a new treatment. We predict that this new treatment will have the risk of serious GVHD, leading to improved survival, quality of life and reduced health costs to the community.	Associate Professor David Curtis	Professor David Curtis, Professor Geoffrey Hill, Professor David Gottlieb, Doctor Suresh Parthi, Professor David Ritchie, Professor Madeleine King, Professor C. Oria Morrissey	Restricted competitive	13/06/2018	15/02/2023	Cardiorespiratory Medicine And Haematology	Haematology	\$	1,570,198.12
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	Monash University	University	VIC	The BLENDER Trial - Blend to Limit Oxygen in ECMO: A randomised Controlled Registry Trial	The sickest patients with heart & lung failure sometimes require extracorporeal membrane oxygenation (ECMO). ECMO pumps blood into the body with very high oxygen levels. High oxygen levels may be harmful. A more conservative oxygen level is possible. We will randomly allocate 286 ECMO patients to a high or conservative oxygen target and measure improvement in patient outcomes. If effective this therapy will improve Australian lives, transform clinical practice, and yield major savings.	Professor David Pilcher	Professor David Pilcher, Professor Carol Hodgson, Professor John Fraser, Professor David Cooper, Doctor Adrian Burnell, Associate Professor Vincent Pellegrini, Professor Andrew Udy, Associate Professor David Gattas, Professor Michael Bailey, Doctor Alisa Higgins	Restricted competitive	13/06/2018	31/12/2023	Clinical Sciences	Intensive Care	\$	753,355.46
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	Monash University	University	VIC	The DIAMOND study: Diagnosis of aplastic anaemia, management, and outcomes utilising a national dataset	Aplastic anaemia (AA) is a bone marrow disorder leading to profound anaemia, low platelet counts (risk of major bleeding) and low white blood cell counts (risk of serious infection). Mortality is as bad as many cancers. Better diagnosis and treatment is needed. This trial of a new agent, avatrombopag, which stimulates blood cell production, along with bone marrow laboratory studies and comprehensive genomic assessments, will help better understand and treat this life-threatening condition.	Associate Professor Erica Wood	Professor Erica Wood, Associate Professor Stephen Ting, Associate Professor Zee McQuillen, Professor Jeff Sier, Doctor Devendra Hwase, Professor John McNeil, Doctor Paul Laczar, Doctor Piers Blombery, Doctor Anthony Mills	Restricted competitive	13/06/2018	15/02/2024	Cardiorespiratory Medicine And Haematology	Haematology	\$	1,750,726.49
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	Murdoch Children's Research Institute	Medical Research Institute	VIC	The efficacy of rehabilitation for hereditary ataxia - a randomised controlled trial	The hereditary cerebellar ataxias (HCAs) result in worsening incoordination and loss of the ability to walk. Many reduce lifespan. There are no medications proven to improve symptoms for most HCAs. We have shown some evidence of benefit from rehabilitation to improve symptoms of HCAs and here propose a larger study to definitively answer the question of whether rehabilitation does indeed improve the ability of individuals with HCAs to perform basic tasks required to live independently.	Professor Martin Delatycki	Professor Martin Delatycki, Professor Joshua Burns, Associate Professor Louise Corbett, Doctor David Samulewicz, Doctor Anna Grebler, Doctor Sarah Milne, Professor Philipp Lamont, Doctor Christina Liang	Restricted competitive	28/06/2018	30/11/2022	Neurosciences	Central Nervous System	\$	1,227,417.66
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	The University of Adelaide	University	SA	Treatment of Severe Early Onset Intrahepatic Cholestasis of Pregnancy	Severe early onset intrahepatic cholestasis of pregnancy, a rare disorder, associated with itching and increased concentrations of serum bile acids, has increased risks of stillbirth, fetal anaemia and compromise, pre-term birth, pre-eclampsia and gestational diabetes. Treatment is not well established: we will test ursodeoxycholic acid vs rifampicin. There are few long term data on the offspring health.	Professor William Hague	Professor William Hague, Professor Jodie Dodd, Professor Jonathan Morris, Associate Professor Michael Stark, Professor Michael Peak, Associate Professor Philipp Middleton, Doctor Antonia Shand, Professor John Newnham, Professor Leonie Callaway, Professor Susan Walker	Restricted competitive	8/06/2018	31/12/2023	Paediatrics And Reproductive Medicine	Obstetrics And Gynaecology	\$	1,191,768.95
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	The University of Queensland	University	QLD	A platform clinical trial approach to the management of Mycobacterium abscessus complex (MABSC)	Mycobacterium abscessus complex are multi-drug resistant organisms that are now seen more frequently and can result in severe lung infection in vulnerable individuals. There is no current evidence base on which to determine management. Treatment regimens that are currently used are complex, expensive and are often very poorly tolerated and outcomes are variable. This application seeks to set up a platform trial that will provide evidence on which to base management in the future.	Professor Claire Wainwright	Professor Claire Wainwright, Professor Scott Bell, Doctor James Wason, Associate Professor Robert Thomson, Professor Jason Roberts, Professor Lachlan Coan, Associate Professor Joshua Byrnes, Professor Ham Tiddens, Professor Keith Grimwood, Professor Susannah Ahern	Restricted competitive	26/06/2018	30/06/2024	Other Medical And Health Sciences	Medical And Health Sciences Not Elsewhere Classified	\$	2,091,178.43
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	The University of Queensland	University	QLD	An Open Label, Multicentre, Phase I study of Ibrutinib, Ruxitinab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies	Although brain lymphomas are devastating, a number of innovative therapies are in clinical trials to try and improve outcomes. Unfortunately these trials exclude a rare subset of virus driven brain lymphomas that occur in the meninges that for which no therapy exists. Based on our research, we propose an innovative triple therapy regimen that targets the unique biology of viral driven brain lymphomas as which we believe will be effective and well-tolerated.	Professor Maher Gandhi	Professor Maher Gandhi, Professor Chan Yoon Cheah, Professor Riccardo Dolcetti, Associate Professor Mark Polizzotto, Doctor Colin Keane, Associate Professor Peter Meli, Professor Monica Slavin, Associate Professor Benjamin Teh, Associate Professor Lutz Krause, Professor Paul Scuffham	Restricted competitive	26/06/2018	15/11/2024	Oncology And Carcinogenesis	Haematological Tumours	\$	1,642,389.26
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	The University of Queensland	University	QLD	Medicinal Cannabis to Relieve Symptom Burden in the Palliative Care of Patients with Advanced Cancer	Medicinal cannabis has proven helpful for symptom relief in a few chronic diseases, but there is limited evidence regarding the benefits and safety for patients with advanced cancer. We will conduct the first clinical trial to rigorously evaluate the efficacy, safety and acceptability of medicinal cannabinoids for symptom relief in advanced cancer patients. The study will define the role of medicinal cannabis in the care of patients with cancer undergoing palliative care.	Professor Janet Hardy	Professor Janet Hardy, Professor Philip Good, Professor Nicholas Linzer, Professor Jennifer Martin, Professor Patsy Yates, Professor Richard Chye, Doctor Alison Haywood, Associate Professor Rebecca Dixon	Restricted competitive	24/06/2018	30/06/2023	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	1,363,040.02

Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	University of Sydney	University	NSW	BEAT-CF: Bayesian Evidence-Adaptive Trial to optimise management of Cystic Fibrosis	For rare diseases like Cystic Fibrosis (CF), there is an urgent need to know which treatments work, which don't, and in whom. Most trials only compare two treatments at a time, assigning a fixed number of patients to each option even when evidence is accumulating that one is better than the other. We will simultaneously evaluate a range of CF treatments, progressively eliminating those found to be worse than available alternatives. We expect to show this approach can efficiently improve care for complex diseases.	Associate Professor Thomas Snelling	Professor Thomas Snelling, Doctor Scott Berry, Professor Adam Jaffe, Doctor Jule Marsh, Ms Anne McKenzie, Professor Sarah Rangnathan, Associate Professor Andre Schultz, Professor Stephen Stick, Professor Peter Warf, Professor Steve Webb	Restricted competitive	6/06/2018	31/05/2024	Clinical Sciences	Clinical Sciences Not Elsewhere Classified	\$	3,545,904.97
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	University of Melbourne	University	VIC	SpeechAte: A rater-blinded randomised controlled trial of intensive home-based speech treatment for aphasia	Progressive brain disorders often lead to profound difficulties speaking. No medical treatments are known to reverse the effects of neurodegeneration. Patients are desperate for an evidenced based treatment to reverse the effects of decline. We aim to evaluate the effectiveness of intensive, home-based rehabilitation using biofeedback for improving speech in adults with cerebral disease. Outcomes will be immediately available to patients and clinicians.	Associate Professor Adam Vogel	Professor Adam Vogel, Professor Matthias Synofzik, Professor Deborah Theodosis, Professor Ludwig Schoel, Professor Paul Maruff, Professor Gary Rance, Doctor Athanasios Tsanas	Restricted competitive	26/06/2018	31/12/2022	Clinical Sciences	Rehabilitation And Therapy (Excl. Physiotherapy)	\$	498,627.29
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	University of Melbourne	University	VIC	STOP-MSU Stopping haemorrhage with Tranexamic acid commenced Prehospital in a Mobile Stroke Unit	A minority of stroke patients (15%) have intracerebral haemorrhage (ICH) but it is associated with a higher mortality and worse outcomes than ischaemic stroke. STOP-MSU will be a Phase II trial of 50 patients, recruited < 1 hour from onset, based on non-contrast CT showing ICH, but not requiring demonstration of the spot sign. Patients will be randomized 1:1 to Tranexamic acid or placebo. The primary outcome will be reduction of hematoma growth from ambulance to the 24 hr follow-up scan.	Professor Stephen Davis	Professor Stephen Davis, Professor Mark Parsons, Professor Bruce Campbell, Professor Bernard Van, Professor Stan Skafidas, Professor Patricia Desmond	Restricted competitive	26/06/2018	30/06/2023	Neurosciences	Neurology And Neuromuscular Diseases	\$	1,285,820.00
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	University of New South Wales	University	NSW	CRISTAL: Cluster Randomised Trial of Aspirin versus low molecular weight heparin for venous thromboembolism prophylaxis in joint replacement surgery, a registry-nested study	Hip and knee replacement surgery may be complicated by blood clots in the leg or lung. Due to a lack of evidence, there is uncertainty about the role of aspirin in preventing clots, compared to the most common drug (heparin). There is considerable variation in practice in Australia. This study will use patients recruited to the National Joint Replacement Registry to test the effectiveness and safety of (cheap) aspirin tablets in preventing clots compared to (more expensive) heparin injections.	Professor Ian Harris	Professor Ian Harris, Professor Stephen Groves, Professor Rachelle Buchbinder, Associate Professor Justine Naylor, Associate Professor Nicole Pratt, Professor Richard de Steiger, Professor Beng Chong, Associate Professor Iana Scherman, Associate Professor Sam Adie, Professor Anthony Harris	Restricted competitive	28/06/2018	30/06/2022	Clinical Sciences	Orthopaedics	\$	934,847.73
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	University of New South Wales	University	NSW	Immunotherapy Targeting of Cytomegalovirus antigens in Glioblastoma: INTERGATE-GBM	Glioblastoma (GBM) is uniformly lethal, and these tumours now represent the most frequent cause of cancer death in children and young adults. Current therapy is inappreciating and produces a median overall survival of <15 months because of limits defined by poor systemic toxicity. We will clinically test a peptide vaccine that specifically targets patient GBM and redirects patients' own immune cells to recognise and destroy tumours.	Associate Professor Kerrie McDonald	Associate Professor Kerrie McDonald, Professor John Sampson, Associate Professor Elizabeth Hovey, Doctor Gerald Archer	Restricted competitive	28/06/2018	15/06/2023	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	1,446,001.78
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	University of Sydney	University	NSW	A randomised controlled trial, of N-Acetyl Cysteine, for premanifest Huntington gene expansion carriers (NAC-preHD)	NAC-preHD is a clinical trial for people who are Huntington Disease (HD) genetic expansion carriers, who have not yet developed clinical manifestations. Participants will be randomly allocated either to an oral nutritional supplement N-Acetylcysteine or placebo, assessed clinically and using brain imaging, over 3 years. This will be the largest clinical trial for premanifest HD expansion carrier in the world, and if found to be effective, can be rapidly implemented in the community.	Associate Professor Clement Loy	Professor Clement Loy, Professor Michael Berk, Professor Julie Stout, Doctor Rachael Scallin, Professor Anthony Hannan, Professor Peter Rangang, Professor Amanda Toxtree-Pinto, Associate Professor John O'Sullivan, Doctor Yifat Gilkman-Johnston, Miss Robyn Kato	Restricted competitive	20/06/2018	15/09/2025	Neurosciences	Cellular Nervous System	\$	1,905,262.52
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	University of Sydney	University	NSW	The BEST-Fluids study: Better Evidence for Selecting Transplant Fluids	End-stage kidney disease (ESKD) is a major health problem worldwide. Kidney transplantation is the best treatment, however not all kidney transplants work well. At the time of kidney transplantation, patients receive fluid through a drip and this fluid may affect how well the kidney works. The BEST-Fluids study will determine which fluid (PlasmaLyte or normal saline) produces the best results, particularly how long the transplant takes to work well and how this affects long term survival.	Professor Steven Chadban	Professor Steven Chadban, Doctor Michael Collins, Doctor Colin McArthur, Professor Philip O'Connell, Professor Patrick Coates, Professor Carmel Hawley, Associate Professor Laurence Weinberg, Associate Professor Peter Mount, Associate Professor Philip Clayton, Doctor Magid Fahim	Restricted competitive	20/06/2018	31/12/2023	Clinical Sciences	Nephrology And Urology	\$	1,117,350.38
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity	Murdoch Children's Research Institute	Medical Research Institute	VIC	A randomised placebo-controlled trial of combined mitochondrial agents for the treatment of fatigue and depression in multiple sclerosis with an assessment of the impact on kynurenine pathway metabolomics	Recent work implicates mitochondrial function problems as determinants of brain damage and symptoms in multiple sclerosis. Mitochondria are the powerhouses of brain cells and they are very vulnerable to oxidant damage. Specific antioxidant regimens can rescue damaged mitochondria. This clinical trial will evaluate how a newly developed Australian combined mitochondrial therapy alleviates fatigue and depression among people with relapsing remitting multiple sclerosis and fatigue.	Professor Anne-Louise Ponsonby	Professor Anne-Louise Ponsonby, Professor Robyn Lucas, Professor Bruce Taylor, Professor Ingrid van der Mei, Professor Felice Jacka, Doctor Brian Fernandes, Professor Simon Broadley, Professor Jeannette Lechner-Scott, Doctor Damjan Vukusic, Professor John Christodoulou	Restricted competitive	25/10/2019	15/02/2023	Public Health And Health Services	Epidemiology	\$	887,072.22
Clinical Trials Activity	2017 Lifting Clinical Trials and Registries Capacity - Clinical Trials Networks Program	Australian Clinical Trials Alliance	Corporation	VIC	Strengthening the capacity, efficiency and effectiveness of Clinical Trials Networks through the Australian Clinical Trials Alliance	ACTA will expand and strengthen its capacity to provide collaborative and strategic leadership and practical support for Clinical Trials Networks (CTNs), and the coordinating centres (CCs) and clinical quality registries (CQRs) that enable, support, and inform their work through facilitating the development and implementation of a national capacity-building framework (the framework) to provide a comprehensive, evidence-based foundation and strategic roadmap to expand the capacity, capability, efficiency and effectiveness of CTNs in Australia, and building on strategic partnerships with stakeholders, including Government, working with members and Alliance partners to address clinical priorities, and facilitating effective sharing of experience, capacity and resources between CTNs to accelerate the impact of research as a core part of a self-improving health system.	Not Applicable	Not available	One-off	16/06/2017	29/11/2021	Not available	Not available	\$	5,000,000.00
Clinical Trials Activity	2018 International Clinical Trial Collaborations (Round 18.1)	Murdoch Children's Research Institute	Medical Research Institute	VIC	A randomised control trial of positive end-expiratory pressure levels during resuscitation of preterm infants at birth (The PQLAA Trial)	Preterm birth is a major public health problem. The fragile preterm lung is prone to collapse and injury from the very first breaths of life. We have shown that positive end-expiratory pressure (PEEP) at birth is essential to support the preterm lung. Clinicians have no guidance on how to optimally use PEEP at birth. This project will conduct the first large clinical trial of PEEP strategies in preterm infants, providing guidance to clinicians across all healthcare settings worldwide.	Associate Professor David Tingay	Associate Professor David Tingay, Associate Professor Louise Owen, Professor Peter Davis, Professor Anton van Kam, Professor Harsh Kirpalani, Doctor Camille Omar Kamli, Associate Professor Andrew Gill, Professor Martin Kessler, Professor Sherry Courtney, Mrs Francesca Orsini	Restricted competitive	1/04/2019	31/03/2024	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine Not Elsewhere Classified	\$	1,387,651.75
Clinical Trials Activity	2018 International Clinical Trial Collaborations (Round 18.1)	The George Institute for Global Health	Medical Research Institute	NSW	The SAHARA Trial: Understanding the best red cell transfusion practice in patients with intracranial bleeding from a ruptured aneurysm	Aneurysmal subarachnoid hemorrhage (aSAH) is the result of a burst artery in the brain. It affects young people (40-60 years), nearly half of whom will die, and a third will have permanent disability. Managing these patients is challenging because the recovering brain is very sensitive and at great risk of further injury (like new strokes) from a lack of blood flow. This study will provide the answer to this common and important question. It will help doctors better manage patients with aSAH.	Associate Professor Anthony Delaney	Associate Professor Anthony Delaney, Associate Professor Shane English, Professor Simon Inffer, Professor John Myburgh, Doctor Naah Assad, Associate Professor Luanalya McIntyre, Professor Dean Ferguson, Doctor Judith Bellagat, Ms Emily Fitzgerald, Doctor Christopher Andersen	Restricted competitive	1/04/2019	31/03/2024	Cardiorespiratory Medicine And Haematology	Cardiovascular Medicine And Haematology Not Elsewhere Classified	\$	902,752.20
Clinical Trials Activity	2018 International Clinical Trial Collaborations (Round 18.1)	University of Western Australia	University	WA	The Early valve replacement in severe Aortic regurgitation (EARV AS) trial	Severe narrowing of the aortic heart valve (aortic stenosis; AS) is a very common condition. If AS is causing problems then the valve needs to be replaced. Most people with AS do not, however, have any symptoms. Traditionally these patients with severe but asymptomatic AS are followed up carefully and only have surgery if they become unwell. It is not clear, however, whether it would be better to replace the valve earlier. This large clinical trial will test which is the best approach.	Professor Graham Hills	Professor Graham Hills, Professor Paul Myles, Professor Julian Smith, Professor Clara Chow, Professor Thomas Marwick, Professor Thomas Britz, Professor Stephen Jan, Professor Joseph Selvanayagam, Professor Gerald McCann, Professor David Newby	Restricted competitive	1/04/2019	31/03/2024	Cardiorespiratory Medicine And Haematology	Cardiology (Incl. Cardiovascular Diseases)	\$	1,827,443.20
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	Deakin University	University	VIC	The Candestart Adjunctive bipolar Depression Trial -CADET	The CADET trial will evaluate the rem-in-angiotensin system as a new therapeutic target for mood disorders compared to a placebo. The trial will highlight compelling atheoretical genetic drug discovery, preclinical, epidemiological and clinical data supporting the need of a novel drug, candestart, a drug that decreases the inflammatory effects of angiotensin II by blocking its receptor.	Professor Michael Berk	Professor Michael Berk, Professor Gin Malhi, Professor Che Ng, Professor Malcolm Hopwood, Doctor Brian Fernandes, Doctor Sheila Gwini, Associate Professor John Amerena, Doctor Mary Lou Chatterton, Professor Trisha Suppes, Associate Professor Lana Williams	Restricted competitive	1/04/2019	30/09/2025	Clinical Sciences	Psychiatry (Incl. Psychotherapy)	\$	2,428,397.10
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	La Trobe University	University	VIC	Improving muscle strength in young people with Prader-Willi syndrome	This trial, which includes health economic analysis, will investigate if community-based strength training improves muscle strength in people with Prader-Willi syndrome (PWS). Outcomes will be assessed at baseline, 6 and 12 months. This trial's outputs will result in: improved health outcomes for people with PWS, completion of the largest Australian trial in PWS, improved infrastructure to facilitate future Australian PWS trials and high-quality evidence to underpin National Disability Insurance Scheme funding for people with PWS.	Professor Nora Shields	Professor Nora Shields, Professor Kim Bennell, Professor Nicholas Taylor, Doctor Lauren Kien, Associate Professor Tania Matic, Professor Christine Egbly, Associate Professor Jennifer Watts, Professor Luke Prendergast	Restricted competitive	1/04/2019	31/03/2024	Public Health And Health Services	Care For Disabled	\$	874,175.45
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	Menzies School of Health Research	Medical Research Institute	NT	Improving outcomes of children and young adults with primary ciliary dyskinesia (PCD): a multi-centre, double-blind, double-dummy, 2x2 factorial, randomised controlled trial (RCT)	This trial will test if 12 months of treatment with the antibiotic azithromycin and the mucolytic, edosteine can reduce acute respiratory exacerbations in children and young adults with primary ciliary dyskinesia (PCD), while also assessing cost effectiveness, effects on quality of life, potential for antimicrobial resistance, safety and the effect of individual cilia ultrastructure on outcomes. Further this study will use a whole exome sequencing approach to search for new genetic markers of PCD that may be useful for diagnosis of the disease.	Professor Anne Chang	Professor Anne Chang, Associate Professor Philip Robinson, Associate Professor Lucy Morgan, Professor Keith Grimwood, Professor Emma Duncan, Associate Professor Mark Chaffield, Doctor Yuesen Zhao, Associate Professor Paul Peo, Associate Professor Andre Schultz, Doctor Gabrielle McCallum	Restricted competitive	1/04/2019	31/03/2025	Paediatrics And Reproductive Medicine	Paediatrics	\$	2,375,118.40
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	Monash University	University	VIC	COZMOS: Phase I/II trial of Combined 5'-azacitidine and carboplatin for recurrent/refractory paediatric brain and solid tumours	Relapsed and recurrent brain tumours in children are almost universally fatal, with limited treatment options beyond radiation therapy. The COZMOS trial has been developed by researchers in Canada, and will test the safety and preliminary efficacy of 5-azacitidine (DNMTi) combined with carboplatin in children up to 18 years of age. Paediatric cancer centres across Australia will open this study, which will provide the first evidence for this new treatment strategy, and ultimately may provide a much needed option to children diagnosed with these brain tumours.	Doctor Jordan Hanford	Associate Professor Jordan Hanford, Doctor Vijay Ramaswamy, Doctor Santosh Vakil, Professor Stewart Kelle	Restricted competitive	1/04/2019	31/03/2024	Oncology And Carcinogenesis	Chemotherapy	\$	125,354.50
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	Monash University	University	VIC	Erythropoietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multicentre, stratified, double-blind, placebo randomised controlled trial. (The EPO-TRAUMA trial)	This study will evaluate whether epoetin alfa (EPO) prevents mortality and reduces severe disability in critically injured trauma patients six months after injury. It will assess the effect of EPO compared to placebo.	Associate Professor Craig French	Associate Professor Craig French, Professor Alistair Nichol, Professor Rinaldo Bellomo, Professor David Cooper, Professor Michael Bailey, Doctor Alisa Higgins, Doctor Colin McArthur, Professor Carol Hodges	Restricted competitive	1/04/2019	31/03/2025	Clinical Sciences	Intensive Care	\$	3,509,303.10

Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	Monash University	University	VIC	Evaluating the effectiveness and safety of sodium selenate as a disease modifying treatment for patients with behavioural variant Frontotemporal Dementia (bvFTD)	This trial will provide novel evidence of a potential disease modifying treatment (sodium selenate) for behavioural variant frontotemporal dementia (bvFTD). It will also identify biomarkers to help predict the outcome and response to treatment in bvFTD patients; this information will help inform future trials.	Professor Terence O'Brien	Professor Terence O'Brien, Doctor Charles Malpas, Professor Dennis Velakoulis, Professor Amy Broadmann, Professor Olivier Piguet, Professor Tomas Kalinic, Professor Mark Walterfang, Associate Professor Rebekah Ahmed, Professor Ashley Bush, Associate Professor David Darby	Restricted competitive	1/04/2019	31/03/2024	Neurosciences	Neurology And Neuromuscular Diseases	\$	1,604,184.40
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	Monash University	University	VIC	FaR-RMS: Frontline And Relapse study in Rhabdomyosarcoma	This clinical trial is designed to simultaneously examine multiple aspects of treatment, seeking to improve survival and quality of life for all Rhabdomyosarcoma (RMS) patients. The areas of research include the addition of new agents to standard chemotherapy backbones, extension of maintenance chemotherapy, optimisation of radiotherapy dosing and timing, identification of genetic biomarkers for risk stratification and new prognostic biomarkers.	Doctor Martin Campbell	Doctor Martin Campbell, Professor Michael Sullivan, Professor Angela Hong, Doctor Jeremy Lewin, Doctor Tilly Trahair, Doctor Meriel Jenney	Restricted competitive	1/04/2019	31/03/2025	Oncology And Carcinogenesis	Solid Tumours	\$	1,353,514.40
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	Novel Venetoclax Combinations to Improve Outcomes in Unfit Older Patients with Acute Myeloid Leukaemia	This nationwide study will collaborate with the Australasian Leukaemia and Lymphoma Group to evaluate the benefit of particular chemotherapies on the remission rates and survival of unfit older patients with acute myeloid leukaemia (AML). The therapies will use low-dose cytarabine and venetoclax with FLT3 inhibition in AML patients with intermediate risk, and histone deacetylase inhibitors in AML patients with adverse risk.	Associate Professor Andrew Wei	Professor Andrew Wei, Associate Professor John Reynolds, Professor David Ritchie, Doctor Michelle Ananda-Rajah	Restricted competitive	1/04/2019	31/03/2024	Oncology And Carcinogenesis	Molecular Targets	\$	1,380,297.60
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	Monash University	University	VIC	SI-EUOT: SI Jude - Phase I Evaluation of LY2606368, Molecularly-Targeted CHK2/2i Therapy, in Combination with Cyclophosphamide or Gemtacinib for Children and Adolescents with Refractory or Recurrent Medulloblastoma Brain Tumours	The SI-EUOT trial will test treatment for children and adolescents with refractory or recurrent Medulloblastoma Brain Tumours. Participants will be assigned to one of two interventions: checkpoint kinase inhibitor LY2606368 and cyclophosphamide, or LY2606368 and gemtacinib. The trial will determine the maximum tolerated dose of the doublet therapies in children, evaluate pharmacokinetics and evaluate preliminary efficacy in a small number of patients. The trial will also test the feasibility of adapting treatments to distinct subtypes of medulloblastoma brain tumour and assess biologic data with the potential to aid identification of new disease biomarkers.	Associate Professor Nicholas Gottardo	Associate Professor Nicholas Gottardo, Doctor Gilles Robinson, Professor Amar Gajjar, Professor Stefan Pfister, Professor Olaf Witt, Doctor Radene Enderby, Doctor Clinton Stewart	Restricted competitive	1/04/2019	31/03/2024	Oncology And Carcinogenesis	Chemotherapy	\$	226,283.60
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	The University of Queensland	University	QLD	A Randomised Phase II Trial of Adjuvant Avelumab in Patients with Early Stage Merkel Cell Carcinoma	This trial will address an unmet need in patients with early stage Merkel Cell Carcinoma, a rare cancer where no current adjuvant systemic therapy is available. It will investigate the efficacy and safety of concurrent radiation with adjuvant avelumab immunotherapy.	Doctor Wen Xu	Doctor Wen Xu, Professor Michael Paulsen, Associate Professor Victoria Atkinson, Professor Gerald Fogarty, Professor Michael Venn, Professor Bernard Smithers, Associate Professor David Gyorki, Associate Professor Victoria Mar, Associate Professor Julie Howle, Associate Professor Alexander Gurniak	Restricted competitive	1/04/2019	31/03/2025	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	1,632,095.75
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	The University of Queensland	University	QLD	An Open Label, Multicentre, Phase One Study Incorporating Early Application of CAR T cells for Primary Refractory Aggressive Lymphoma	This Australian Leukaemia and Lymphoma Group led phase I study will use a proven positron emission tomography - computed tomography (PET-CT) trial design for rapid identification of primary refractory aggressive lymphoma patients, to permit generation and early application of autologous chimeric antigen receptor (CAR) T-cells targeted against the malignant B-cell clone.	Professor Maher Gandhi	Professor Maher Gandhi, Professor David Gottlieb, Professor Mark Hertzberg, Doctor Kenneth Mickelthwait, Doctor Piers Blombery, Doctor Colin Keane, Associate Professor Ann-Maree Patch, Associate Professor Eliza Hawkes, Professor Chan Yoon Cheah, Professor Riccardo Dolcetti	Restricted competitive	1/04/2019	31/03/2025	Oncology And Carcinogenesis	Haematological Tumours	\$	3,596,966.90
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	The University of Queensland	University	QLD	The TEACH PD study: a Targeted Education Approach to Improve Peritoneal Dialysis Outcomes	This trial will determine whether delivery of the TEACH PD training curriculum, rather than an existing program, is an inexpensive intervention that improves health outcomes for peritoneal dialysis (PD) patients by reducing PD-related infection burden, hospitalisation, technique failure, and healthcare costs.	Professor David Johnson	Professor David Johnson, Professor Neil Boudville, Professor Josephine Chow, Professor Robert Walker, Associate Professor Young-Jee Cho, Ms Elaine Pascoe, Professor Matthew Jose, Associate Professor Genevieve Steiner, Associate Professor Rachael Walker, Associate Professor Philip Clayton	Restricted competitive	1/04/2019	31/12/2025	Clinical Sciences	Nephrology And Urology	\$	2,383,206.90
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	University of Canberra	University	ACT	Evaluation of a bush medicine-based treatment for scabies in Australian Aboriginal children	This randomised controlled trial will examine the clinical efficacy of a simple and low-cost bush medicine (tea tree oil, TTO) treatment against scabies and the prevention of associated secondary bacterial infections. TTO has shown promising results as a scabicide in preliminary in vitro studies, and has been used previously as an adjunctive treatment for crusted scabies by the Royal Darwin Hospital.	Doctor Jackson Thomas	Doctor Jackson Thomas, Doctor Daniel Engelman, Professor Thomas Calma, Professor Gregory Peterson, Associate Professor Shelley Walton, Professor Mark Daniel, Doctor Tim Spelman, Associate Professor Iyde McKillen, Professor Andrew Steer	Restricted competitive	1/04/2019	31/10/2023	Complementary/Alternative Medicine	Traditional Aboriginal And Torres Strait Islander Medicine And Treatments	\$	1,294,542.05
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	University of Melbourne	University	VIC	The AIM2 Study: Genomically Guided Novel Combination Treatment of Mantle Cell Lymphoma	This trial will evaluate the efficacy and safety of rationally-designed novel drug combinations in patients with poor-prognosis Mantle Cell Lymphoma. The trial will add a monoclonal anti-CD20 antibody in all patients from Day 1, and in those patients who carry genetic features in their cancer predicting for primary resistance to IV, also add the anti-BCR-κ drug navitoclax.	Doctor Constantine Tam	Professor Constantine Tam, Professor Andrew Roberts, Professor John Seymour, Professor Sarah-Jane Dawson, Professor Mark Dawson, Doctor Mary Ann Anderson, Professor Paula Marlon, Associate Professor Bryce Kain	Restricted competitive	1/04/2019	31/07/2025	Other Medical And Health Sciences	Medical And Health Sciences Not Elsewhere Classified	\$	2,005,391.40
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	University of New South Wales	University	NSW	The ACHIEVE Study brings together a robust international collaboration to definitively address whether spironolactone can improve outcomes in dialysis patients (both haemodialysis and peritoneal dialysis). It is a randomised, controlled trial that examines the effect of spironolactone compared to placebo upon a composite outcome of cardiovascular death and heart failure.	Associate Professor Martin Gallagher	Professor Martin Gallagher, Associate Professor Michael Walsh, Professor Kevin Polkinghorne, Professor Vivekanand Jha, Doctor Lai Seong Hooi, Associate Professor Min Jun	Restricted competitive	1/04/2019	31/03/2024	Cardiorespiratory Medicine And Haematology	Cardiovascular Medicine And Haematology Not Elsewhere Classified	\$	2,850,898.40	
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	University of Sydney	University	NSW	BEAT-Calc (Better Evidence And Translation in Calciphylaxis)	The BEAT-Calc adaptive trial will determine whether, in people with End Stage Kidney Disease receiving haemodialysis therapy developing Calciphylaxis, treatment initiated with one of three active therapies is superior to placebo-based therapy for wound healing, survival and avoidance of amputation or new lesions.	Associate Professor Meg Jardine	Professor Meg Jardine, Associate Professor Laurent Billot, Professor Carmel Hawley, Professor Vincent Brandenburg, Associate Professor Nigel Toussaint, Associate Professor Rathika Krishnasamy, Associate Professor Sagar Nigwekar, Professor Grahame Elder, Doctor Smeeta Sinha	Restricted competitive	1/04/2019	31/03/2024	Clinical Sciences	Nephrology And Urology	\$	2,201,943.70
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	University of New South Wales	University	NSW	Does Withholding Enteral Feeds Around blood Transfusion reduce the incidence of necrotising enterocolitis (NEC) in very preterm infants? The international WHEAT Study	The "With Holding or continuing Enteral Feeds Around blood Transfusion" (WHEAT) trial will evaluate which feeding policy reduces Transfusion-Associated Necrotising Enterocolitis in pre-term infants born after less than 30 weeks gestation. The WHEAT trial will be embedded in care and is the first-ever neonatal multi-site registry trial (or point of care trial) globally.	Professor Kei Lui	Professor Kei Lui, Doctor Christopher Gale, Professor William Tarnow-Mordi, Doctor Tim Schindler, Professor Georgina Chambers, Associate Professor Andrew Martin, Associate Professor Malcolm Battin, Deborah Harris, Ms Melinda Cruz	Restricted competitive	1/04/2019	31/12/2025	Paediatrics And Reproductive Medicine	Paediatrics	\$	1,606,825.80
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	University of New South Wales	University	NSW	MEMOIR: A multi-site placebo-controlled trial of memantine and graded motor imagery for complex regional pain syndrome	The MEMOIR study will test the effectiveness of two promising interventions in improving Complex Regional Pain Syndrome patient outcomes: an N-methyl D-aspartate antagonist (memantine) therapy, and a Graded Motor Imagery physiotherapy intervention.	Associate Professor James McAuley	Professor James McAuley, Associate Professor Sylvia Gustin, Professor G. Lorimer Moseley, Professor Andrew McLachlan, Professor Benedict Ward, Professor Sallie Lamb, Doctor Neil O'Connell, Doctor Jigini Lee	Restricted competitive	1/04/2019	31/03/2023	Other Medical And Health Sciences	Medical And Health Sciences Not Elsewhere Classified	\$	922,314.05
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	University of Sydney	University	NSW	ALS Trials Australia (ALSTIA) - to develop precision medicine	The Amyotrophic Lateral Sclerosis (ALS) Trials Australia network will integrate research and clinical services to assess the efficacy and safety of teficdera immunotherapy in patients with ALS. Teficdera is an immunotherapy currently in use for the treatment of relapsing-remitting multiple sclerosis, targeting neuroinflammation. The trial will provide high quality evidence for the utility of teficdera in ALS, establish a clinical trials register to enhance recruitment into future trials and an integrated clinical trials data collection system, generate genomic biomarker data for trial patients to enable understanding of variability in treatment response, and expand clinical trials activity in Australia.	Professor Matthew Kiernan	Professor Matthew Kiernan, Professor Ostojia Vucic, Professor Naomi Wray, Associate Professor Paul Talman, Professor Merlene Needham, Associate Professor David Schultz, Professor Michael Barnett, Associate Professor Susanna Park	Restricted competitive	1/04/2019	31/03/2024	Neurosciences	Neurology And Neuromuscular Diseases	\$	1,704,432.20
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	University of Sydney	University	NSW	MAGMA: Multi-Arm Glioblastoma Australasia Trial	The MAGMA trial utilises a novel clinical trial design to test different glioblastoma treatments simultaneously against a common control group. This design is more efficient, reducing patient numbers, the time taken to complete the study, and by exposing fewer patients to the control arm more patients can test experimental arms. Experimental arms may involve novel surgery, radiation, drugs, novel sequences or administration strategies, or biomarker directed therapy. The initial trial arms are: 1. Intensive neoadjuvant temozolomide (TMZ) soon after surgery, before radiation. 2. Prolonged TMZ until progression, rather than the current standard of six months.	Doctor Craig Gedye	Associate Professor Craig Gedye, Professor Anna Nowak, Associate Professor Elizabeth Hovey, Associate Professor Eng-Siew Koh, Doctor Rosemary Harris, Doctor Jonathan Parsons, Ms Elizabeth Barnes, Associate Professor Rosalind Jeffree	Restricted competitive	1/04/2019	30/09/2024	Oncology And Carcinogenesis	Chemotherapy	\$	1,273,632.05
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	University of Sydney	University	NSW	NAVMAN TRIAL: A multi-centre, dynamic, waitlist randomised controlled trial of patient navigators in children with chronic kidney disease	The NAVMAN trial will assess the overall health benefits and costs of a patient navigator program in children with chronic kidney disease (CKD) stages 3-5, on dialysis and with kidney transplants and/or low socioeconomic backgrounds. The key objectives of the trial are to: assess the impact of a patient navigator program on the overall health and wellbeing of children with CKD; compare the cost-benefits ratio of patient-navigator program with standard care; and identify the barriers and facilitators of developing and implementing a patient navigator program in clinical practice.	Associate Professor Germaine Wong	Professor Germaine Wong, Associate Professor Patricia Caldwell, Professor Kirsten Howard, Professor Allison Tong, Professor Jonathan Craig, Professor Armando Teixeira-Pinto, Doctor Martin Howell, Doctor Hugh McCarthy, Doctor Michelle Irving	Restricted competitive	1/04/2019	31/03/2024	Clinical Sciences	Nephrology And Urology	\$	1,093,680.90
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	University of Sydney	University	NSW	PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma	This trial in newly diagnosed advanced follicular lymphoma (FL) patients builds on evidence provided by an Australian-led collaboration that demonstrates the powerful predictive value of post-treatment positron emission tomography-computed tomography (PET-CT) status on survival. In this trial, patients will receive standard R-chemotherapy, followed by a PET/CT scan which will be used to separate the patients into two groups (PET positive or negative). Patients will further receive rituximab maintenance treatment with or without lenalidomide treatment, or no further treatment, depending on their assigned group.	Associate Professor Judith Trotman	Professor Judith Trotman, Professor Michael Fulham, Professor Andrew Pettitt, Professor Stephen Opat, Doctor Anna Johnston	Restricted competitive	1/04/2019	31/03/2024	Oncology And Carcinogenesis	Haematological Tumours	\$	787,068.85
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - General	University of Sydney	University	NSW	PICCOG: PARP and Immune Checkpoint inhibitor Combination for relapsed IDH-mutant high-grade Glioma	Globally there is no standard treatment for patients with relapsed high-grade glioma. The PICCOG study will assess the safety and efficacy of rucaparib plus nivolumab in patients with relapsed isocitrate dehydrogenase (IDH)-mutant high-grade glioma.	Doctor Hao-Wen Sim	Doctor Hao-Wen Sim, Doctor Helen Wheeler, Associate Professor Zarnie Lwin, Doctor Kathryn Field, Doctor Benjamin Chua, Mr David Espinoza, Associate Professor Michael Buckland, Doctor Kimberley Alexander-Kaufman	Restricted competitive	1/04/2019	31/12/2026	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	1,391,472.20

Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - Low Survival Cancers and Diseases	La Trobe University	University	VIC	A Basket Study of Low Survival Cancers Treated with EGFR-ADCs	Monoclonal antibodies against Epidermal Growth Factor Receptor (EGFR) are proven treatments in some tumours, although there is a lack of biomarkers and toxicity is nearly universal due to concomitant normal tissue targeting. Ci Gan and Scott have pioneered the development of a tumour-specific anti-EGFR antibody, called mA806 then ABT-806, which has no normal tissue binding. This tumour specificity has allowed it to be used as the backbone for a tumour-specific anti-EGFR antibody drug conjugate (ADC) called ABT-414. This biomarker-driven basket study will target a group of low survival cancers which are EGFR dysregulated (amplified, mutated or autonomously activated through inappropriate autocrine loops) and likely to benefit from ABBV-321 treatment, and which are not part of the Pharma-sponsored ABBV-321 Phase 1 program. All cancers with a 5-year survival of less than 50% which show EGFR dysregulation will be eligible. Nine tumour types with low survival will be recruited including anus, gallbladder, stomach, liver, oesophagus, pancreas, lung, mesothelioma and triple-negative breast cancer. Selecting sites in multiple Australian capital cities will provide maximal patient access. Exploratory endpoints will include exploratory tissue and biomarkers of efficacy and resistance. A sub-study looking at imaging will be undertaken at selected participating sites.	Associate Professor Hui Gan	Professor Hui Gan, Professor Andrew Scott, Professor Anna Nowak, Associate Professor Ella Hawkes, Professor Niall Tebbutt, Associate Professor Thomas John, Associate Professor Jayesh Desai, Doctor Belinda Yeo, Associate Professor Zarnie Lwin, Professor Leontie Churlish	Restricted competitive	28/03/2019	31/12/2024	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	1,658,626.31
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - Low Survival Cancers and Diseases	Monash University	University	VIC	Brain Oxygen Neuromonitoring In Australia And New Zealand Assessment (BONANZA) Trial	Severe traumatic brain injury (TBI) is a disease with high morbidity and mortality, up to 50% of severe TBI victims have died by 6 months post-injury. This is significantly higher than the observed mortality in any other trauma cohorts, or critical illness syndromes. TBI also disproportionately affects Indigenous Australians, with hospitalisation rates due to head injury 21 times that of non-Indigenous peoples. The goal of the project is to improve survival post severe TBI and reduce long-term healthcare costs (currently \$58 AUD per annum), by conducting an international, multicentre, randomised controlled trial of an innovative precision-medicine neuro-intensive care management protocol. This clinical trial will involve collaboration with NIH-funded US investigators. The involvement of Australian participants is essential to ensure the trial is adequately powered to assess mortality.	Associate Professor Andrew Udy	Professor Andrew Udy, Professor David Cooper, Professor Alisdair Nichol, Professor Jeffrey Rosenfeld, Professor David Menon, Professor Michael Bailey, Professor Katharine Drummond, Doctor Alisa Higgins	Restricted competitive	3/01/2019	30/11/2024	Clinical Sciences	Intensive Care	\$	1,084,852.43
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - Low Survival Cancers and Diseases	Monash University	University	VIC	Frailty-stratified randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma - the FRAIL-M study	Multiple myeloma (MM) is a low survival cancer, and is a heterogeneous, debilitating and incurable haematological cancer with a relative 5 year survival of 48.5% among newly diagnosed patients, the 14th worst 5 year relative survival of 34 cancers. The population being studied in the FRAIL-M study are older patients with MM who have worse outcomes, with 5 year survival in those 65 or older only 27% compared with 56% if less than 65 years. However, survival of MM patients is likely worse than reported due to misclassification of the precursor condition monoclonal gammopathy of uncertain significance (MGUS) as MM. The erroneous inclusion of MGUS patients may artificially bolster survival statistics for MM. The project will conduct a stratified randomised controlled trial to identify which competing treatment options are more appropriate in transplant-ineligible myeloma patients according to frailty status. It will enrol transplant-ineligible myeloma patients and stratify them into three groups (fit, intermediate-fit or frail) based on a standardised and validated frailty assessment. Each stratum will be randomised to a bortezomib-based vs a lenalidomide-based regimen, with dose adjusted according to frailty stratum. The co-primary endpoints are achievement of an overall response after four cycles of treatment and incidence of dose-limiting toxicity. Key secondary endpoints will include event-free survival, overall survival, infection and patient-reported outcome measure at baseline and following treatment. In each arm a Bayesian Optimal Phase II design will be used to jointly monitor efficacy and toxicity, and further adjust the dose or close individual treatment arms if they appear either too toxic or ineffective.	Professor Andrew Spencer	Professor Andrew Spencer, Associate Professor Zoe McCullough, Professor HANG QUACH, Associate Professor Peter Mollee, Professor Erica Wood, Associate Professor John Reynolds, Professor Ruth Wabnitz, Associate Professor Richard De Alencar Lourenco	Restricted competitive	3/01/2019	30/09/2023	Oncology And Carcinogenesis	Haematological Tumours	\$	1,682,835.68
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - Low Survival Cancers and Diseases	Monash University	University	VIC	Improving survival in myelofibrosis	Myelofibrosis (MF) is a rare incurable blood cancer. It can develop from a pre-existing myeloproliferative disorder. Patients with high risk MF have a median survival of less than 3 years and some less than 5 years. Moreover, the quality of life for patients is poor with a high symptom burden and frequent hospital admissions for blood transfusions and management of infections. About 50% of patients with MF carry the identical mutation in JAK2 (i.e. V617F) which drives the disease. Most of the other 50% carry mutations in other components of cytokine signalling pathways that activate JAK2. The JAK2/J inhibitor, ruxitinib, is available in Australia on the PBS for treatment of high risk and low risk MF based primarily on two large phase 3 placebo controlled trials. Most patients show initial clinical improvement but then slowly progress. There are no effective alternative drugs currently available in Australia. The molecular genetics of MF and MPNs has advanced greatly in the past 5 years. Many second mutations which adversely influence the risk of progression to acute leukaemia and impact on long term survival are now known. These mutations are mostly in epigenetic regulators. Genetic profiling of patients is becoming increasingly important for accurate prognosis and for personalized treatment options. This grant will build a registry-linked national platform trial to improve precision-based outcomes, based on low cost genomic profiling, for patients with MF and using novel therapies.	Professor Andrew Perkins	Professor Andrew Perkins, Associate Professor David Ross, Associate Professor Steven Lane, Doctor Cecily Forsyth, Professor Andrew Wei, Professor David Curtis, Associate Professor Jake Shortt, Professor Wendy Erber, Associate Professor William Stevenson	Restricted competitive	3/01/2019	31/12/2023	Cardiorespiratory Medicine And Haematology	Haematology	\$	1,733,327.17
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - Low Survival Cancers and Diseases	University of Melbourne	University	VIC	Combination of Avelumab with Peptide Receptor Radionuclide Therapy (PRRT) or Conventional Fractionated Radiotherapy (RT) in Metastatic Merkel Cell Carcinoma (MCC)	Merkel cell carcinoma (MCC) is a rare and highly aggressive neuroendocrine tumour of the skin affecting 300 Australians each year, and the 5-year survival rate is 13%. MCC is highly responsive to radiotherapy (RT) and radiation has been shown to enhance the anti-tumour effects of immunotherapy. Seventy percent of MCCs express somatostatin receptors (SSTR), and are potential candidates for peptide receptor radionuclide therapy (PRRT) such as 177Lu-DOTATATE that uses a SSTR-targeting peptide to deliver a payload of radiation to sites of disease expressing SSTR. The DOTAM trial is an adaptive, biomarker-driven, signal-seeking, three-arm clinical trial designed to develop the novel combination of avelumab, with either 177Lu-DOTATATE or RT in mMCC depending on the expression of SSTR as defined by 68Ga-DOTATE PET scans. The project will develop the first ever anti-PD-L1 + PRRT / RT combination for mMCC as well as provide new insights into predictors of response and drug resistance via the embedded translational studies.	Doctor Shahneen Sandhu	Associate Professor Shahneen Sandhu, Associate Professor Richard Tothill, Professor Richard Scholey, Associate Professor Alexander Guminski, Professor Jürgen Becker, Professor Michael Poulsen, Associate Professor Victoria Atkinson, Associate Professor Paul Nesson, Professor Mark Shackleton, Associate Professor David Pattison	Restricted competitive	16/01/2019	15/05/2023	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	1,812,005.42
Clinical Trials Activity	2018 Rare Cancers, Rare Diseases and Unmet Need - Low Survival Cancers and Diseases	University of Sydney	University	NSW	mHOLFRINOX and STEReotactic body radiotherapy (SBRT) for pancreatic cancer with high-risk and Locally Advanced disease (MASTERPLAN): a multicentre, randomised phase II study of the Australian Gastrointestinal Trials Group (AGTG)	In recognition of the need to redress the low survival of pancreatic cancer (PC) which has a five year overall survival rate of 8%, international consensus guidelines recommend clinical trials that explore new treatment paradigms including stereotactic body radiotherapy (SBRT). SBRT is a highly innovative treatment that utilizes significant technological advances in radiotherapy treatment to enable safe radiotherapy dose escalation, increasing tumour cell death and the potential to reduce LMR rates. SBRT has demonstrated encouraging outcomes, including high margin-negative resection rates and LMR rates less than 30%, without increasing postoperative complication rates. This study evaluates whether SBRT in addition to modern chemotherapy is superior to the current standard of chemotherapy alone. The primary endpoint of MASTERPLAN is the 12 month LMR rate. This study is a comprehensive multidisciplinary collaboration of leading pancreatic scientists and clinicians around the country in the context of a randomised phase II trial addressing a cancer with extremely low survival.	Associate Professor Andrew Kneebone	Professor Andrew Kneebone, Professor Jasvinder Samra, Associate Professor Hen Le, Associate Professor Nam Nguyen, Professor David Goldstein, Professor Minoti Apte, Professor Andrew Barbour, Doctor Andrew Orr, Doctor Sarah Chander, Mr David Espinoza	Restricted competitive	1/02/2019	31/12/2023	Oncology And Carcinogenesis	Radiation Therapy	\$	1,512,807.76
Clinical Trials Activity	2019 International Clinical Trial Collaborations (Round 19-1)	Macquarie University	University	NSW	The Australian multidomain Approach to Reduce dementia Risk by protecting brain health With lifestyle intervention (AU-ARROW) study	The AU-ARROW trial is part of an international clinical trial of an innovatively structured, multi-modal treatment plan to improve or maintain brain function in older adults at risk of cognitive decline and dementia. We will conduct tests related to memory and brain functioning and investigate changes in the biological markers of Alzheimer's disease in the brain and blood to provide, high quality, evidence-based data for cost-effective deployment in a clinical setting.	Professor Ralph Martins	Professor Ralph Martins, Professor Kaarin Anstey, Professor Sharon Nalsmith, Associate Professor Laura Baker, Professor Mia Kivipelto, Associate Professor Torki Sammour, Associate Professor Hossein Afzali, Doctor Bree Stephenson, Associate Professor Amanda Dawson, Doctor Thomas Arthur	Restricted competitive	1/10/2019	30/09/2025	Neurosciences	Neurosciences Not Elsewhere Classified	\$	3,115,066.90
Clinical Trials Activity	2019 International Clinical Trial Collaborations (Round 19-1)	The University of Newcastle	University	NSW	Sunrise Australia - A randomised clinical trial of Single Use Negative pressure dressings for Reduction in Surgical site infection following Emergency laparotomy	Surgical Site Infections (wound infections) affect at least 1 in 4 patients who have emergency abdominal (belly) surgery. New types of dressings might reduce infections, but they also usually cost more than older types. Single Use Negative Pressure Dressings (DUNPD) have a pump within them that removes fluid from the wound, which may reduce the infection rate. This trial will test whether the extra cost of these dressings produces benefits for patients in reducing the infection rate.	Doctor Peter Pockney	Associate Professor Peter Pockney, Professor David Watson, Professor Toby Richards, Associate Professor Vijayaraghavan Muralidharan, Associate Professor Torki Sammour, Associate Professor Hossein Afzali, Doctor Bree Stephenson, Associate Professor Amanda Dawson, Doctor Thomas Arthur	Restricted competitive	1/10/2019	30/09/2022	Clinical Sciences	Surgery	\$	782,256.00
Clinical Trials Activity	2019 International Clinical Trial Collaborations (Round 19-2)	Murdoch Children's Research Institute	Medical Research Institute	VIC	Pragmatic Paediatric Trial of Balanced versus Normal Saline Fluid in Sepsis (PROMPT-BOLUS)	Sepsis is the most common cause of multiple organ failure and hospital death in children. In adult and in animal studies there are concerns that normal saline (the standard resuscitation fluid) is worse than a balanced fluid (which is more like blood). By enrolling 8,800 children across Australia, New Zealand, US and Canada, this large study will provide definitive evidence for which fluid is better, with the potential to save the lives of thousands of children's lives worldwide.	Professor Franz Bahl	Professor Franz Bahl, Associate Professor Edward Oakley, Professor Stuart Daise, Professor Meredith Borland, Emeritus Professor Nathan Kupperman, Associate Professor Scott Weiss, Associate Professor Fran Balamuth, Doctor Elliot Long	Restricted competitive	1/02/2020	31/01/2027	Clinical Sciences	Emergency Medicine	\$	3,055,620.00

Clinical Trials Activity	2019 International Clinical Trial Collaborations (Round 19.2)	University of Sydney	University	NSW	POLEM Trial: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage II dMMR or POLE exonuclease domain mutant cancer: A phase III randomised study	Most people with stage II colon cancer are treated with surgery then chemotherapy to prevent cancer coming back. In some patients, unfortunately cancer does come back. This study is being conducted to assess whether adding a new drug to standard chemotherapy could reduce the risk of cancer returning. This new drug, called avelumab is an immunotherapy drug that helps the immune system attack and kill cancer cells. If positive this trial could change treatment worldwide for this patient group.	Professor Timothy Price	Professor Timothy Price, Professor Niall Tebbutt, Associate Professor Jeanne Tie, Professor Christos Karapetis, Professor Stephen Ackland, Doctor Connie Diakos, Doctor Matthew Burgis, Doctor Naureen Starling, Doctor Tony Dhillon	Restricted competitive	1/02/2020	31/07/2025	Oncology And Carcinogenesis	Molecular Targets	\$	981,312.50
Clinical Trials Activity	2019 International Clinical Trial Collaborations (Round 19.2)	University of Sydney	University	NSW	Apixaban Twice Daily vs Rivaroxaban Once Daily for the Treatment of Venous Thromboembolism: A randomised controlled trial (COBRA)	Blood clots in leg veins and lung arteries decrease quality of life of patients and may cause death. The best way to prevent recurrent clots is with blood thinning medications. A side effect of blood thinning is bleeding. Two new drugs which prevent recurrent clots are accepted as standard of care. However, it is not clear which drug results in fewer bleeding events. We will study patients with blood clots to determine which of these drugs is safer and results in less bleeding events.	Doctor Vivien Chen	Doctor Vivien Chen, Associate Professor Lana Castellucci, Doctor Timothy Brighton, Professor Huyn Tran, Professor Marc Rodger, Professor Gregoire Le Gal, Professor Susan Kahn, Professor John Simes, Doctor Caroline Reddel, Professor Rachael Morton	Restricted competitive	1/02/2020	31/07/2024	Cardiorespiratory Medicine And Haematology	Haematology	\$	1,057,839.75
Clinical Trials Activity	2019 International Clinical Trial Collaborations (Round 19.3)	University of Melbourne	University	VIC	Transfusion Triggers in Cardiac Surgery Australia trial (TRICS-IV)	In Australia, over 11,000 adults undergo cardiac surgery annually with blood transfusion being common (over 40% overall). The decision-point for when to transfuse to balance the risks associated with anaemia versus transfusion remains unclear for some patients. Our research has identified that while it may be safe for older patients to have restricted blood transfusions (thus decreasing transfusion risk and saving resources), younger patients might actually benefit from more liberal transfusion.	Professor David Scott	Professor David Scott, Professor Alistair Royse, Doctor Raymond Hu, Professor John Fraser, Professor Cyril David Mauer, Doctor Nadine Shehata, Professor Paul Bannon, Professor James Ibbister	Restricted competitive	1/06/2020	31/01/2024	Cardiorespiratory Medicine And Haematology	Cardiovascular Medicine And Haematology Not Elsewhere Classified	\$	869,565.96
Clinical Trials Activity	2019 International Clinical Trial Collaborations (Round 19.3)	University of Melbourne	University	VIC	Circulating tumour DNA guided Therapy for stage IIB/C BRAF mutant positive Melanoma after surgical resection (DETECTION)	DETECTION is a phase III, international trial that will enrol 1500 patients with stage IIB/C melanoma. It will examine whether a blood test containing tumour DNA (ctDNA) will be able to identify patients at high risk of recurrence following their curative surgery even though their scans appear normal. It will also evaluate if treating these patients early with immunotherapy based on the ctDNA positive result will improve overall survival.	Doctor Shaheen Sandhu	Associate Professor Shaheen Sandhu, Professor Sarah-Jane Dawson, Professor Georgina Long, Associate Professor Matteo Carino, Associate Professor Alexander Menzies, Professor Richard Soyer, Professor Helen Riess, Professor Paul Lorigan, Associate Professor Victoria Atkinson, Professor Michael Henderson	Restricted competitive	1/06/2020	30/11/2025	Oncology And Carcinogenesis	Molecular Targets	\$	3,230,670.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Childhood Brain Cancer	Monash University	University	VIC	CONNECT 1903: A Pilot and Surgical Study of Larotrectinib for Disease Control in Children with Newly-Diagnosed High-Grade Glioma with NTRK Fusion	High grade gliomas (HGGs) are deadly brain cancers. Some HGGs in children have been found to have a genetic change, called a fusion, in a specific receptor which drives cancer growth. Larotrectinib is a new drug which targets this fusion and has shown remarkable results in children with cancers that have this fusion. CONNECT-1903 is an international study that will assess if treatment with larotrectinib is safe and can control the growth of HGGs that contain this fusion in children.	Associate Professor Nicholas Gottardo	Associate Professor Nicholas Gottardo, Doctor Neelima Manoharan, Doctor Santosh Valvi, Doctor Maryam Fouladi, Ms Robyn Strong	Targeted competitive	1/06/2020	31/5/2024	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	323,898.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Childhood Brain Cancer	Monash University	University	VIC	MET-MED Trial: A phase II randomised double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients	Medulloblastoma is the most common brain cancer in children, requiring aggressive treatment to survive. Unfortunately, most patients are left with long-term brain damage, including memory and intellectual problems. Studies using metformin to promote brain repair have shown promising preliminary results. The MET-MED trial will be the first time metformin is comprehensively examined as a brain recovery agent in children diagnosed with medulloblastoma.	Doctor Jordan Hanford	Associate Professor Jordan Hanford, Doctor Cinzia De Luca, Doctor Donald Mabbott, Professor Eric Boufflet, Michelle Carl, Doctor Janelle Jones, Doctor Paul Wood	Targeted competitive	1/06/2020	31/05/2026	Oncology And Carcinogenesis	Oncology And Carcinogenesis Not Elsewhere Classified	\$	879,903.50
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Childhood Brain Cancer	Monash University	University	VIC	The TINT Trial: A phase II clinical trial of trametinib in paediatric patients with neurofibromatosis type 1 associated progressive optic pathway gliomas	Neurofibromatosis type 1 (NF1) is a genetic disorder in children that can sometimes result in the development of a brain tumour in the optic nerves (Optic Pathway Gliomas, OPG). The TINT clinical trial will discover if trametinib - a targeted therapy that is effective in some cancers - can be used to treat children with NF1-associated OPG. We will investigate if trametinib can reduce the size of the tumours as well as improve vision, quality of life, behaviour and neurodevelopment.	Associate Professor Geoffrey McCowage	Associate Professor Geoffrey McCowage, Doctor Andrew Doddguth, Associate Professor Jonathan Payne, Doctor Belinda Raine, Doctor Gabriel Dabschek, Doctor Kathryn Kinross	Targeted competitive	1/06/2020	31/05/2027	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	761,210.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Childhood Brain Cancer	University of New South Wales	University	NSW	LOGGIC: A phase III, randomised international multicentre trial for Low Grade Glioma in Children and adolescents	Low Grade Gliomas are the most common brain tumour of childhood. If they cannot be removed surgically they are often difficult to manage and often require years of treatment with chemotherapy. In this international trial we will, for the first time, assess the efficacy of a new targeted treatment that specifically shuts off the genetic driver of these tumours. We will compare this treatment with standard chemotherapy to define the best treatment for children with this intractable disease.	Associate Professor David Ziegler	Associate Professor David Ziegler, Professor Stefan Pfister, Professor Claire Wakefield, Professor Olaf Witt, Doctor Dong-Anh Khuong-Chung	Targeted competitive	1/06/2020	31/05/2026	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	1,128,497.50
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	Monash University	University	VIC	Australasian Resuscitation in Sepsis Evaluation: Fluid or Vasopressors in Emergency Department Sepsis (ARISE-Fluids) Trial	Sepsis is a life-threatening condition, where the body's response to infection results in organ damage. Patients with sepsis may develop severely low blood pressure. It is not known if it is better to treat this with large volumes of intravenous fluid, or to give less fluid and introduce medication to raise the blood pressure earlier. The ARISE-Fluids trial will investigate which of these strategies will save more lives.	Professor Sandra Peake	Professor Sandra Peake, Associate Professor Stephen Macdonald, Associate Professor Anthony Delaney, Professor Gerben Keijzers, Professor Andrew Udy, Associate Professor Glenn Arendts, Professor Diana Egerton-Warbuton, Professor Daniel Fatovich, Doctor Alisa Higgins, Doctor Elissa Milford	Targeted competitive	1/06/2020	31/05/2026	Clinical Sciences	Emergency Medicine	\$	2,335,540.20
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	Monash University	University	VIC	Bone Loss Prevention with Zoledronic Acid or Denosumab in Critically Ill Women - A Randomised Controlled Trial (Bone Zone)	Women over 50 years of age are at high risk of osteoporosis and fragility fractures after life-threatening critical illness. There are effective medications to prevent this, however few women receive them during critical illness. This study aims to test 2 commonly used anti-fracture medications in 450 critically ill women over 50-years of age in Australia. If shown to be effective, this could transform clinical practice, and the recognition and prevention of bone loss in critically ill women.	Associate Professor Neel Orford	Associate Professor Neel Orford, Professor Jacqueline Center, Associate Professor Priya Nair, Professor David Cooper, Professor Carol Hodgson, Professor Mark Kotowicz, Professor Julie Pasco, Professor Michael Bailey, Professor Bale Venkatesh, Professor John Mavrouk	Targeted competitive	1/06/2020	31/05/2025	Clinical Sciences	Intensive Care	\$	1,905,282.70
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	Murdoch Children's Research Institute	Medical Research Institute	VIC	Clinical efficacy of ulbrashort (1 dose) intravenous antibiotics compared to traditional duration (3 days) for children with complicated urinary tract infections: a multicentre randomised controlled trial	Complicated urinary tract infections are common reasons for hospital admissions and constitute a major burden for healthcare systems. However, research into the optimal treatment for children with urinary tract infections have only focused on those with an uncomplicated clinical course, neglecting those with a more complicated course. This trial will address this unmet need by conducting the first trial to investigate the optimal treatment for this group, 1 day or 3 days of drip antibiotics.	Associate Professor Penelope Bryant	Associate Professor Penelope Bryant, Doctor Laila Ibrahim, Professor Stuart Dzelic, Professor Simon Craig, Doctor Sandy Hopper, Mrs Francesca Onini, Associate Professor Katherine Quinlan, Doctor Amit Kochar, Doctor Sarah McChab	Targeted competitive	1/06/2020	31/05/2025	Paediatrics And Reproductive Medicine	Paediatrics	\$	1,643,669.50
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	Murdoch Children's Research Institute	Medical Research Institute	VIC	Does cannabidiol reduce severe behavioural problems in youth with intellectual disability? A randomised placebo-controlled trial	Many children with intellectual disability (ID) show severe behavioural problems (SBP). At present the main treatment for this involves psychiatric medications, which often cause side effects. This study aims to investigate whether cannabidiol, a non-toxic component of cannabis, is effective in reducing SBP in children aged 6-18 years with ID. Participants will take either cannabidiol or placebo. Response to treatment will be evaluated by parent report of behavioural symptoms after 8 weeks.	Associate Professor Daryl Eron	Associate Professor Daryl Eron, Professor Katrina Williams, Doctor Jeremy Freeman, Professor Elizabeth Elliott, Associate Professor Noel Cranwick, Associate Professor Jonathan Payne, Professor Andrew Davidson, Chidambaram Prakash, Professor Katherine Lee, Doctor Lauren Rice	Targeted competitive	1/06/2020	31/05/2023	Paediatrics And Reproductive Medicine	Paediatrics	\$	883,484.50
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	The Council of the Queensland Institute of Medical Research	Medical Research Institute	QLD	PhoCESS: Pancreatic cancer Relatives Counselling and Education Support Service trial. Assessing the effect of nurse-led counselling, compared with information alone, on participant-reported outcomes and use of medical services	Family carers of people with pancreatic cancer are highly distressed and feel unsupported. Their unmet needs are compounded by the short time-line from diagnosis to death (average 5 months). PhoCESS is a randomised-counselling intervention for pancreatic cancer carers on various outcomes including anxiety and cost-effectiveness. The trial will apply real-world delivery of support to carers through the Auser Pancreatic Cancer Foundation.	Associate Professor Vanessa Beesley	Associate Professor Vanessa Beesley, Professor Rachel Neale, Professor Margaret Turner, Professor Patsy Yates, Associate Professor David Wyll, Professor Raymond Chan, Associate Professor Louisa Gordon	Targeted competitive	1/06/2020	31/07/2024	Public Health And Health Services	Health Counselling	\$	801,229.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	The University of Adelaide	University	SA	Precision Medicine for Chronic Myelomonocytic Leukaemia: Phase II Trial Studying the Efficacy of Lenicumbab or High Dose Ascorbate plus Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort	Chronic myelomonocytic leukaemia is a rare and neglected blood cancer that rapidly progresses to acute leukaemia within 28-32 months and has no approved therapy. Based on our extensive data we will treat high-risk newly diagnosed patients with a new monoclonal antibody Lenicumbab and metabolic interventions (including high dose ascorbate) plus standard of care azacitidine and assess the percentage of patients that have not progressed and still alive.	Professor Timothy Hughes	Professor Timothy Hughes, Doctor Devendra Hwasae, Associate Professor David Ross, Associate Professor Daniel Thomas, Associate Professor David Young, Associate Professor Steven Lane, Associate Professor Agnes Yang, Professor Angel Lopez, Doctor Timothy Hecus, Associate Professor John Reynolds	Targeted competitive	1/06/2020	31/05/2023	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	1,619,122.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	The University of Notre Dame Australia	University	WA	Optimism in IBM: A dbRCT Phase III trial of Srolimus in patients with Inclusion Body Myositis, to slow or stabilise otherwise relentless disease progression, as measured by the IBM Functional Rating Scale (IBMFRS)	Inclusion Body Myositis (IBM) is a rare muscle disease, causing progressive muscle weakness, disability, loss of independence and major lifestyle changes. At present there are no effective treatments available. This trial will pursue a promising new treatment, Srolimus, shown to stabilise disease in a pilot study in France, and will address unmet needs in this population. This is an Australian-led, international collaborative Phase III clinical trial, offering hope to IBM patients.	Professor Merrilee Needham	Professor Merrilee Needham, Associate Professor Robert Henderson, Associate Professor Alistair Corbett, Associate Professor Stephen Reddel, Doctor Christina Liang, Doctor Katrina Reardon, Doctor Roula Ghaoui, Professor Max Bulsara, Professor Maaz Bimachkie	Targeted competitive	1/06/2020	31/05/2025	Neurosciences	Neurology And Neuromuscular Diseases	\$	1,883,014.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	The University of Queensland	University	QLD	Implementation of Metformin therapy to Ease Decline of kidney function in PKD - the IMPEDE-PKD trial	Autosomal dominant polycystic kidney disease, ADPKD, is a painful genetic disease that impacts quality of life. In ADPKD, large cysts develop and enlarge on both kidneys, which eventually causes the kidneys to fail. The IMPEDE-PKD trial will test if Metformin (a low cost and well known drug) will slow down the rate of kidney failure in people with ADPKD.	Associate Professor Andrew Mallett	Professor Andrew Mallett, Professor David Johnson, Doctor Ragada El-Damrawi, Professor Satorina Palmer, Associate Professor Gopala Rangam, Professor Vivekanand Jha, Professor Carol Pollock, Ms Elaine Pascoe, Associate Professor Alison Haynes, Doctor Amal Mullaewarachi	Targeted competitive	1/06/2020	31/05/2027	Clinical Sciences	Nephrology And Urology	\$	2,572,402.50
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	The University of Queensland	University	QLD	The TELD-SCOPE study: Attenuating Telomere Attrition with Danazone. Is there Scope to Dramatically Improve Health Outcomes for Adults and Children with Pulmonary Fibrosis?	The genomic revolution is finally starting to pay its promised health outcome dividends. One of the greatest opportunities in non-malignant disease is in children and adults with lung fibrosis due to genetic mutations (prevalence 1:14,000) who generally die within 2 years of diagnosis. The TELD-SCOPE clinical trial exploits exciting new genomic information to transform life expectancy and quality of life for these Australians, by repurposing an existing, inexpensive drug.	Professor Daniel Chambers	Professor Daniel Chambers, Associate Professor Tamer Certe, Professor Adam Jaffe, Associate Professor Ian Glaspie, Professor Peter Hopkins, Associate Professor Nicole Goh, Associate Professor Christopher Gearing, Doctor John Macintosh, Professor Hiran Sevaluradi	Targeted competitive	1/06/2020	31/05/2025	Cardiorespiratory Medicine And Haematology	Respiratory Diseases	\$	1,828,445.50
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	The University of Queensland	University	QLD	Can intrapartum SideEffects safely Avert the Risks of Contraction-induced Hypoxia in labour? SEARCh - a pragmatic Phase 3 Randomised Controlled Trial	Globally, lack of oxygen during labour is a major cause of stillbirth and neonatal deaths, brain injury and cerebral palsy. Many babies suffer these complications often without any warning or risk factors. We have shown that sideEffects can reduce the rate of operative delivery. The SEARCh trial may also improve neonatal outcomes. We wish to test this hypothesis in a randomised trial. It raises the possibility of a simple, affordable treatment to improve neonatal outcomes.	Professor Saleesh Kumar	Professor Saleesh Kumar, Professor Ben W. Mol, Professor William Tarnow-Mordi, Professor Vicki Flensay, Professor Helen Lyle, Professor John Badaway, Professor Susan Walker, Professor Jon Hyett, Professor Lisa Askie, Associate Professor Emily Callender	Targeted competitive	1/06/2020	31/05/2024	Paediatrics And Reproductive Medicine	Obstetrics And Gynaecology	\$	3,418,152.00

Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	The University of Queensland	University	QLD	Targeting the gut microbiome as a treatment for Primary Sclerosing Cholangitis: The Queensland Clinical Network Study	Primary sclerosing cholangitis (PSC) is a rare, immune-mediated chronic cholestatic liver disease with a poor prognosis without liver transplantation. New data from Australia suggest that therapies targeting the gut microbiome improve outcomes for patients with PSC. This randomised placebo-controlled trial aims to generate knowledge to change clinical practice and provide a cure for these patients.	Professor Gerald Holtmann	Professor Gerald Holtmann, Professor Mark Morrison, Doctor Ayesha Shah, Doctor Natasha Kokosi, Associate Professor Graeme Macdonald, Professor Michael Jones, Associate Professor Peter Lewindon, Doctor Katherine Stuart, Professor Simon Keely, Professor James O'Beirne	Targeted competitive	1/06/2020	31/05/2024	Clinical Sciences	Gastroenterology And Hepatology	\$	1,631,020.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	The University of Queensland	University	QLD	Ataxia-telangiectasia: treating mitochondrial dysfunction with a novel form of anaerobiosis	A-T is a rare genetic disease with ~40 known cases in Australia. They have neuro-degenerative disease, immune deficiency, and cancer, life expectancy is ~25years. There is no treatment for A-T. We have identified that altered calcium transport into mitochondria (cell batteries) leads to cell death, that treating A-T cells with Theophylline (C7) corrects these defects. C7 has been used safely for 15 years in other metabolic diseases. We intend to conduct a trial of C7 in A-T patients.	Professor David Coman	Professor David Coman, Professor Martin Lavri, Professor Peter Sy, Professor Claire Wainwright, Professor Ernst Wolvetang, Doctor katharine sindari, Associate Professor Susan Dowling	Targeted competitive	1/06/2020	30/11/2023	Paediatrics And Reproductive Medicine	Paediatrics	\$	2,459,666.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	University of Melbourne	University	VIC	Evaluation of Fibroblastic Activation Protein Inhibitors (FAPi) as a novel radiopharmaceutical targeting cancer-associated fibroblasts for the diagnosis and treatment of patients with Cancer of Unknown Primary: the FAPi-CUP trial	The FAPi-CUP trial seeks to address the unmet need for more effective diagnosis and treatment options for people with Cancer of Unknown Primary (CUP). We will investigate the role of a protein called fibroblast activation protein (FAP). We will test whether using a new type of PET scan that looks for whether or not cancer cells are expressing FAP will help us to find the primary cancer in patients with CUP. We will also test a new type of treatment using a radionuclide therapy that targets FAP.	Associate Professor Linda Mileshkin	Professor Linda Mileshkin, Professor Rodney Hicks, Associate Professor Richard Tophill, Professor David Bowtell, Doctor Hui Li Wong, Professor Penelope Schofield, Professor Sean Grimmond	Targeted competitive	1/06/2020	31/08/2025	Oncology And Carcinogenesis	Cancer Diagnosis	\$	2,387,924.50
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	University of Melbourne	University	VIC	A multi-centre randomised controlled trial of polysomnographic titration of non-invasive ventilation in motor neurone disease	Non-invasive ventilation (NIV) to help people breathe as they get weaker with Motor Neurone Disease (MND) increases survival by 4 times more than the best drug we have (Riluzole). Our team have demonstrated that a sleep study that optimises NIV, can increase how many people can use NIV well and thus further improve survival. However, an overnight sleep study can be difficult for people with MND. This current study will test whether the same benefit can be seen in more centres across Australia.	Professor David Berlowitz	Professor David Berlowitz, Professor Dominic Rowe, Associate Professor Mark Howard, Associate Professor Amanda Piper, Doctor Marnie Graco, Miss Sabine Braat, Professor Bhajan Singh, Doctor Tanara Vieira Sousa, Professor Natsaba Lamin	Targeted competitive	1/06/2020	31/12/2025	Neurosciences	Neurology And Neuromuscular Diseases	\$	3,480,676.55
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	University of New South Wales	University	NSW	AZA+ A multi-site phase 1/2 dose escalation/expansion trial combining azacitidine and defactibine for high-risk myelodysplastic syndrome patients who fail to respond to azacitidine alone	AZA+ A multi-site phase 1/2 dose escalation/expansion trial combining azacitidine and defactibine for high-risk myelodysplastic syndrome patients who fail to respond to azacitidine alone	Professor John Pimanda	Professor John Pimanda, Associate Professor Mark Polizzotto, Professor Mark Hertzberg, Professor Andrew Wei, Professor Mark Dawson, Professor Richard Lock, Doctor Ashwin Unnikrishnan, Professor Jake Olivier, Doctor Chun Yew Feng, Doctor Peter Campbell	Targeted competitive	1/06/2020	31/12/2025	Oncology And Carcinogenesis	Haematological Tumours	\$	3,328,735.50
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	University of Sydney	University	NSW	Structured exercise program to reduce fatigue in patients receiving dialysis: a preference stratified adaptive trial (NE-FIT)	End-stage kidney disease is rare and life-limiting. For patients receiving dialysis, fatigue is a common and debilitating symptom associated with an increased risk of mortality and cardiovascular disease. Exercise is a research priority for patients and clinicians. The NE-FIT trial will determine if a patient-centred exercise program is an efficacious and cost-effective in reducing fatigue, hospitalisation, and improving health outcomes in people receiving dialysis.	Professor Allison Tong	Professor Allison Tong, Professor Carmel Hawley, Professor Armando Teixeira Pinto, Professor Kevin Polkinghorne, Professor Thomas Seeling, Professor Jonathan Craig, Doctor Martin Howell, Doctor Angela Ju, Mrs Nicole Scholes-Robertson, Professor Jeff Coombes	Targeted competitive	1/06/2020	31/05/2027	Clinical Sciences	Nephrology And Urology	\$	1,957,499.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - General	University of Sydney	University	NSW	Optimising Q fever vaccination in Australia: Protecting our rural adolescents	Q fever is a serious disease and effects rural populations predominantly. This risk of infection is especially higher in highly effective Q fever vaccine but it is only recommended for those 15 years and older. In this grant we will study the safety and effectiveness of Q fever vaccine in children aged 10-14 years. The goal is to widen the age recommendation for the Q fever vaccine and ultimately protect more rural adolescents.	Associate Professor Nicholas Wood	Associate Professor Nicholas Wood, Associate Professor Kerry Ann O'Brien, Professor David Durham, Professor Stephen Graves, Doctor Peter Massey, Penelope Hutchinson, Professor Kristine McArthur, Associate Professor Heather Gidding	Targeted competitive	1/06/2020	30/11/2023	Clinical Sciences	Infectious Diseases	\$	1,772,624.41
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Neurological Disorders	Curtin University	University	WA	A randomised control trial in subjects with early Alzheimer's disease in exploring if probiotic supports cognitive function through improved cerebrovascular function	We have identified that leakage from blood-into-brain of fat/protein complexes can trigger Alzheimer's disease (AD). Moreover, we have also identified an historic drug that inhibits the production and leakage into brain of these toxic fat/protein moieties. The drug of interest is well tolerated and has an excellent safety profile, providing rapid translational opportunities. This study may provide a completely new treatment opportunity for patients with AD.	Professor John Mamo	Professor John Mamo, Professor Leon Flicker, Associate Professor Roger Garnett, Professor Gerald Watts, Professor Nicola Lautenschlager, Doctor Carolyn Orr, Associate Professor Roddy Francis, Associate Professor Michael Byrnes, Professor Christopher Reid, Associate Professor Ravula Tebbel	Targeted competitive	1/06/2020	31/05/2024	Neurosciences	Central Nervous System	\$	1,720,000.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Neurological Disorders	Deakin University	University	VIC	Does repetitive transcranial magnetic stimulation (rTMS), compared to sham rTMS, improve social communication in adolescents and young adults with autism spectrum disorder (ASD)?	This is a multisite clinical trial to assess whether a form of non-invasive brain stimulation, repetitive transcranial magnetic stimulation (rTMS), can safely improve social symptoms in adolescents and young adults with autism spectrum disorder (ASD). rTMS has been established as a safe and effective treatment for a range of brain-based conditions, including depression, migraine, and obsessive compulsive disorder, and there is evidence to suggest it could be effective in ASD.	Professor Peter Enticott	Professor Peter Enticott, Professor Paul Fitzgerald, Professor Karen Barlow, Professor Ian Hickie, Doctor Melissa Luzzi, Doctor Nigel Rogach, Professor Christl Middeldorp, Associate Professor Scott Clark, Doctor Ann-Maree Valiente, Doctor Kevlin Boulton	Targeted competitive	1/06/2020	31/10/2024	Psychology	Biological Psychology (Neuropsychology, Psychopharmacology, Physiological Psychology)	\$	1,903,208.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Neurological Disorders	Monash University	University	VIC	Sodium Selenate as a Disease Modifying Treatment for Progressive Supranuclear Palsy (Sodium Selenate for PSP)	Progressive supranuclear palsy (PSP) is a fatal, neurodegenerative disease that affects people >40 years. Patients suffer progressive loss of balance, abnormal eye movements and reduced thinking ability, particularly planning, organisation and language. There is currently no cure or treatment that targets the underlying cause. This clinical trial will test the effectiveness of sodium selenate as a new treatment to slow or stop the progression of patients affected by this devastating disease.	Professor Terence O'Brien	Professor Terence O'Brien, Doctor Kelly Bertram, Doctor Lucy Wisah, Doctor Andrew Burns, Associate Professor Thomas Kirkham, Associate Professor John O'Sullivan, Doctor Charles Malpas, Associate Professor Jaume Fielding, Professor Dennis Velakoulis, Professor Meng Law	Targeted competitive	1/06/2020	31/05/2025	Neurosciences	Central Nervous System	\$	2,639,490.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Neurological Disorders	Monash University	University	VIC	Autoimmune Encephalitis - a rare and debilitating neurological illness affecting the Australian population. A study of the Australian Autoimmune Encephalitis Consortium	Autoimmune encephalitis are a collection of diseases where the immune system incorrectly attacks brain tissue causing inflammation & nerve damage. Individuals with this disease can have seizures, memory, behavioural & mood problems, affecting their quality of life and longevity. This project is the largest of its kind in Australia, bringing national experts to examine this disease with the hope of making improvements in early recognition, diagnosis & treatment of this debilitating condition.	Doctor Mastura Monif	Doctor Mastura Monif, Professor Helmut Butkuvien, Associate Professor Stephen Reddel, Professor Tomas Kalnik, Professor David Tarlinton, Associate Professor Uday Seneviratne, Professor Jayashri Kulkarni, Doctor Katherine Buzzard, Professor Bruce Taylor	Targeted competitive	1/06/2020	31/05/2025	Clinical Sciences	Clinical Sciences Not Elsewhere Classified	\$	2,092,824.80
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Neurological Disorders	Monash University	University	VIC	The Long-term Outcomes of Lidocaine Infusions for persistent PostOperative Pain in patients undergoing breast surgery (LULIPOP) Trial	Long lasting pain is common after breast cancer surgery. It is a common side effect of successful treatment, and is very difficult to treat. No intervention has been shown to prevent its occurrence. The LULIPOP trial is a personalised medicine trial. It is a large study examining whether a local anaesthetic drug, lidocaine, given intravenously during and after surgery, will alter the risk of developing long-term pain in the wound of patients who undergo breast cancer surgery.	Professor Tomas Corcoran	Professor Tomas Corcoran, Professor Paul Myles, Doctor Andrew Toner, Professor Christobel Saunders, Professor Andrew Forbes, Professor Philip Peyton, Professor Kate Leslie, Professor Stephan Schug, Professor David Story, Professor David Scott	Targeted competitive	1/06/2020	31/05/2025	Neurosciences	Sensory Systems	\$	4,334,375.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Neurological Disorders	Murdoch Children's Research Institute	Medical Research Institute	VIC	Study of Neck Injury Imaging in Children (SONIC): Improving the Diagnosis of Spinal Cord, Bone and Ligament Injuries Compared With Current Practice	Neck injuries to spinal cord, bones and ligaments need to be carefully considered in children presenting to emergency departments as missed injuries may have devastating consequences. Clinical decision rules are used to guide which adult patients should receive neck imaging, but no guidance currently exists for children. This study of 30,000 children in emergency departments with possible neck injuries aims to investigate the best way to accurately predict which children require neck imaging.	Professor Franz Babi	Professor Franz Babi, Associate Professor Edward Oakley, Professor Stuart Dalziel, Professor Meredith Bartard, Doctor Natalie Phillips, Associate Professor Susan Donath, Professor Stacy Gorgen, Professor Gwan Davis, Professor Geoffrey Askin	Targeted competitive	1/06/2020	31/01/2026	Clinical Sciences	Emergency Medicine	\$	2,528,025.70
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Neurological Disorders	The University of Adelaide	University	SA	Iodine supplementation in pregnancy to improve early childhood neurodevelopment: how much is enough?	The Australian Government recommends women take iodine supplements during pregnancy to optimise their child's development. However, our studies suggest that too much iodine during pregnancy may lower children's performance on tests of cognitive development. We will test if limiting iodine intake from prenatal supplements in pregnant women who already get enough iodine from food can protect the cognitive development of their children.	Professor Maria Makrides	Professor Maria Makrides, Professor Timothy Green, Associate Professor Rosalie Grivell, Professor Jeanne Cheong, Doctor Shao Zhou, Doctor Thomas Sullivan, Associate Professor Hossein Afari, Doctor Karen Best, Doctor Jacqueline Gould, Doctor Dorothy McElduff	Targeted competitive	1/06/2020	30/11/2025	Nutrition And Dietetics	Public Nutrition Intervention	\$	3,235,960.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Neurological Disorders	University of Melbourne	University	VIC	Endovascular Brain Computer Interface for Independent Communication	This project seeks to support a first in human clinical trial using an implantable brain computer interface as a hands-free controller for personal computers and devices that restore lost function to patients with severe paralysis, due to spinal cord injury, stroke, motor neuron disease and muscular dystrophy.	Associate Professor Thomas Oxley	Associate Professor Thomas Oxley, Associate Professor Nicholas Dipe, Professor Peter Mitchell	Targeted competitive	1/06/2020	31/12/2023	Neurosciences	Central Nervous System	\$	1,481,180.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Neurological Disorders	The University of Newcastle	University	NSW	Reducing debilitating fatigue after stroke to improve Quality of Life	We will undertake a clinical trial aimed at improving the quality of life for stroke survivors by targeting and treating fatigue. Post stroke fatigue has been rated as the number one unmet medical need of stroke survivors. We have previously had significant success in a phase 2 trial of modified to treat post stroke fatigue, and we now seek to perform a similar trial on a larger, international cohort in order to change clinical practice.	Professor Christopher Levi	Professor Christopher Levi, Associate Professor Andrew Beard, Professor Mark Parsons, Professor Geoffrey Donnan, Professor James Khan, Professor Marjory Moodie, Professor Beata Bajarek, Professor Ken Butcher, Professor Hugh Markus, Professor Michael Nilsson	Targeted competitive	1/06/2020	31/05/2025	Neurosciences	Central Nervous System	\$	1,006,075.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Neurological Disorders	University of Sydney	University	NSW	Evaluation of a new Brief Intervention for Childhood Autism Spectrum Disorders	This study will evaluate the first integrated, brief parenting intervention for children with Autism Spectrum Disorder. The intervention works to maximise outcomes for children with ASD by improving the children's social communication and engagement, reduce the child's externalising behaviour disturbances, and enhance parental and family coping, skills, teamwork and self-care.	Professor Mark Dadds	Professor Mark Dadds, Emeritus Professor Bruce Tonge, Doctor Lucy Tully	Targeted competitive	1/06/2020	31/05/2024	Clinical Sciences	Psychiatry (Incl. Psychotherapy)	\$	837,447.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Reproductive Cancers	The University of Queensland	University	QLD	Enhancing treatment outcomes after gynaecological cancer (AQUIMEN): Using exercise to promote health after cancer therapy	Exercise is a potent aid to recovery after reproductive cancer treatment. However, many women are not sufficiently active to achieve its benefits or have no access to the support that enables safe exercise. This innovative study will assist women recovering from reproductive cancer treatment to safely integrate exercise into their lives in a practical way. It will thereby improve women's quality of life and function and reduce their risk of treatment-related chronic disease.	Professor Alexandra McCarthy	Professor Alexandra McCarthy, Professor Margaret Turner, Professor Debra Anderson, Associate Professor Assad Khan, Doctor Tim Kim, Doctor Jayviree Steeds, Professor Leone Young, Associate Professor Hatham Tufaha	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Preventive Medicine	\$	2,211,455.00
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Reproductive Cancers	University of Sydney	University	NSW	PARAGON-II: Phase 2 basket study of an Alk inhibitor plus PI3KA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms	PARAGON-II is a trial for women with gynaecological cancers whose tumours are potentially treatable with hormonal treatment. These patients must have cancers that have recurred or metastasised. For patients whose cancer has a genetic mutation called PI3KCA, they will be treated with letrozole hormonal treatment and abirateride that targets PI3KCA. For those without PI3KCA mutation, these patients will be treated with letrozole and ribocicli, another new oral targeted treatment.	Doctor Chee Khoo Lee	Associate Professor Chee Khoo Lee, Professor Michael Friedlander, Professor Clare Scott, Professor Theresa Lee, Doctor Tarek Mansour, Doctor David Jeffrey Goh, Professor Anna de'Azio, Professor Alicia Jenkins, Doctor Alison Davis, Doctor Rachel O'Connell	Targeted competitive	1/06/2020	31/05/2023	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	1,995,422.30

Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Reproductive Cancers	University of Sydney	University	NSW	Adjuvant Tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk endometrial cancer: the ADELLE study	This clinical trial seeks to improve outcomes for women with high-risk endometrial cancer, who have a significant risk of relapse after standard post-operative treatment with chemotherapy & radiotherapy. The trial will find out if relapse rates can be lowered by adding immunotherapy to a current standard therapy. Women will be randomly assigned to receive the new treatment combination or existing standard treatment, then followed up to see if outcomes are improved and what side-effects occur.	Associate Professor Linda Mileschkin	Professor Linda Mileschkin, Doctor Yeh Chen Lee, Professor Martin Stockler, Associate Professor Roland Ameli, Doctor Pearly Shaw, Associate Professor Pamela Pollock, Ms Elizabeth Barnes, Doctor Paul Cohen, Doctor Michelle Wilson, Doctor Elizabeth Christie	Targeted competitive	1/06/2020	31/05/2023	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	1,633,241.35
Clinical Trials Activity	2019 Rare Cancers, Rare Diseases and Unmet Need - Reproductive Cancers	University of Sydney	University	NSW	HYNOVA - A randomised study comparing Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial ovarian, fallopian tube and primary peritoneal cancer	HYNOVA is a clinical trial comparing the effect of heated chemotherapy given into the abdominal cavity at a temperature of 42°C (HIPEC) to that given at body temperature of 37°C (NIPEC) at the time of surgery to women with advanced cancer of the ovary, fallopian tube or peritoneum. A recent study showed better survival in this group after treatment with HIPEC compared with no HIPEC. However, oncologists remain undecided about the potential benefit and harm of applying heat to the chemotherapy.	Doctor Rhonda Farrell	Associate Professor Rhonda Farrell, Associate Professor Alison Brand, Associate Professor Orla McNealy, Associate Professor Caroline Ford, Associate Professor Jermaine Coward, Associate Professor Sumita Ananda, Doctor Kristy Robblee, Doctor Rebecca Merceia-Beeber, Associate Professor Cherry Koh, Doctor Michelle Harrison	Targeted competitive	1/06/2020	31/05/2023	Oncology And Carcinogenesis	Chemotherapy	\$	686,674.00
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.1)	Queensland University of Technology	University	QLD	Oral bacterial lysate to prevent persistent wheeze in infants after severe bronchiolitis; a randomised placebo controlled trial (BLUPA: Bacterial Lysate in Preventing Asthma)	Preventing the development of wheeze in preschool children would produce major health benefits, but to date no therapies have proved to be effective. A group of infants who are at very high risk of developing preschool wheeze and subsequent asthma, are infants who are hospitalised with bronchiolitis. We are partnering leaders in the United Kingdom in this study which will examine whether boosting the immune system by giving granules of lysed dead bacteria can prevent future childhood asthma.	Professor Anne Chang	Professor Anne Chang, Professor Keith Grimwood, Professor Jonathan Grigg, Doctor Danielle Wurzel, Professor Steven McPhail, Professor Brian Selvalarasu, Professor Allan Cripps, Doctor Gabrielle McCallum, Professor Debby Bogaert	Targeted competitive	1/05/2021	30/04/2026	Cardiorespiratory Medicine And Haematology	Respiratory Diseases	\$	1,598,380.42
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.1)	University of Melbourne	University	VIC	AMEND-CRT trial	Cardiac resynchronization therapy (CRT) is an accepted treatment option in patients with heart failure. CRT 're-tunes' the contraction of the heart so that it beats efficiently, and successful CRT can improve cardiac function and survival. However, the CRT selection process is currently imprecise, with many patients failing to benefit. We seek to show that an echocardiographic selection process may reduce the non-responder rate without limiting the selection of patients who will benefit.	Professor Thomas Marwick	Professor Thomas Marwick, Professor Jens-Uwe Voigt, Professor David Kaye, Professor Jonathan Kalman, Professor Lisa Thomas, Professor Prashanthan Sanders, Associate Professor David Prior, Professor Kazuaki Negishi, Professor Paul Souffam	Targeted competitive	1/05/2021	30/04/2026	Cardiorespiratory Medicine And Haematology	Cardiology (Incl. Cardiovascular Diseases)	\$	991,197.80
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.1)	Curtin University	University	WA	Nasal high-flow Oxygen Therapy After Cardiac Surgery: NOTACS	Patients undergoing cardiac surgery often suffer lung complications. NOTACS will test an oxygen delivery strategy called nasal high flow oxygen as a way of reducing these complications and shortening the time needed to recover in hospital. Because indigenous patients needing cardiac surgery experience disproportionately worse outcomes, NOTACS will focus on Aboriginal and Torres Strait Islander study participation, innovative and inclusive trial methods, and research leadership development.	Doctor Edward Litton	Associate Professor Edward Litton, Doctor Andrew Klein, Doctor Julianne Coombes, Associate Professor Rachel Parke, Professor Andrew Maionara, Professor Christopher Reid, Doctor Yi Da Chiu, and Professor David Plicker, Mr Sumit Yadav, Doctor Mahesh Kamanan	Targeted competitive	1/05/2021	30/04/2025	Clinical Sciences	Intensive Care	\$	1,460,861.70
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.1)	University of Sydney	University	NSW	AGITG and Scandinavian Sarcoma Group International Trial Collaboration, SSG XVIII: International randomised phase III multicenter study of 3 v 5 years of adjuvant imatinib as treatment of patients with operable GIST with high risk for recurrence	This international trial compares the effect of giving imatinib for 5 years compared the current standard of 3 years to people who have undergone surgery for gastrointestinal stromal tumours (GIST). The aim is to prevent tumours from returning. At present it is not known whether GIST patients benefit from being on treatment for longer than 3 years and half of the participants will be allocated to 2 years extra imatinib. Results could change standards to 5 years or confirm 3 years is optimal.	Professor John Zalcberg	Professor John Zalcberg, Doctor Katrin Spjut, Professor Nail Tebbout, Professor Desmond Yip, Associate Professor Jayesh Desai, Professor Timothy Price, Associate Professor Lara Lipton, Doctor Connie Diakos, Associate Professor Sumita Ananda, Doctor Ch-Siu Lau	Targeted competitive	1/05/2021	30/04/2026	Oncology And Carcinogenesis	Chemotherapy	\$	1,036,125.09
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.1)	University of Sydney	University	NSW	SAFER (AUG) Trial: Screening for Atrial Fibrillation with ECG to Reduce stroke - a randomised controlled trial	Atrial fibrillation (AF) is a common heart condition causing an irregular heartbeat, and is responsible for about 1 in 3 strokes. 'Blood thinning' tablets (anticoagulants) prevent AF-strokes. AF often has no symptoms. 1 in 10 people with stroke are unaware they have AF. Early identification of AF could prevent strokes. This research in general practices will find out if AF screening of people aged over 70 can prevent strokes without excess side effects, and if it represents good value for money.	Professor Saul Freedman	Professor Saul Freedman, Professor Mark Nelson, Associate Professor Charlotte Heape, Professor Dominique Cadilhac, Mr Jonathan Marti, Doctor Michael Sweeting, Professor Vincent Thys, Professor John Sims	Targeted competitive	1/05/2021	30/04/2026	Cardiorespiratory Medicine And Haematology	Cardiology (Incl. Cardiovascular Diseases)	\$	1,782,949.60
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.2)	Macquarie University	University	NSW	Determining the impact of a new primary care model for low back pain: A cluster randomised trial	The study will determine the effectiveness of integrating a musculoskeletal clinician (physiotherapist or chiropractor) within general practitioner's (GPs) clinics for patients with low back pain. The study will evaluate the effect of this new approach on patient health, health system, and societal outcomes. The results will inform decision-makers about whether physiotherapists or chiropractors should be integrated within GPs' clinics more widely.	Professor Simon French	Professor Simon French, Professor Mark Hancock, Professor Nicholas Zwick, Associate Professor Jordan Miller, Associate Professor Monica Tallaard, Doctor Petra Graham, Professor Terrence Harnes, Professor Fiona Blyth, Doctor Katie de Luca	Targeted competitive	1/06/2021	30/06/2026	Public Health And Health Services	Primary Health Care	\$	2,107,805.90
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.2)	University of Melbourne	University	VIC	The C*STEROID Trial: An international, randomised placebo-controlled trial to determine the effect of antenatal corticosteroids on newborn health when given prior to planned caesarean section birth from 35+0 to 39+6 weeks of pregnancy	Babies born by caesarean section (CS) have an increased risk of breathing problems. Antenatal corticosteroids (ACS) before preterm birth reduce the risk of breathing problems. There is limited research to determine whether ACS before planned CS are beneficial. There are also some concerns that they may cause harm by lowering the blood sugar levels in babies. The C*STEROID trial will assess the effects of ACS prior to planned CS at or near term to determine if this treatment is safe and effective.	Associate Professor Joanne Said	Associate Professor Joanne Said, Associate Professor Katie Groen, Professor Caroline Crowther, Professor Jonathan Morris, Professor Lex Doyle, Professor Dale Foster, Doctor Nikolaos Zepi, Professor Jane Hardwick, Associate Professor Amanda Henry, Doctor Clare Whitehead	Targeted competitive	1/06/2021	31/05/2025	Paediatrics And Reproductive Medicine	Obstetrics And Gynaecology	\$	2,151,495.00
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.2)	University of Sydney	University	NSW	RADAR: A randomised PET-adapted study of bleomycin-free treatment of early stage Hodgkin Lymphoma	RADAR is a phase III randomised trial in patients with untreated, early stage Hodgkin Lymphoma. It will test if bleomycin (B) can be replaced by an antibody treatment called brentuximab vedotin (A) combined with the standard chemotherapy AVD. Patients with an early complete response on PET scan will need fewer total chemotherapy cycles and no radiotherapy, reducing toxicity of treatment including future heart disease and secondary cancer while maintaining excellent control of the lymphoma.	Professor Judith Trotman	Professor Judith Trotman, Doctor Nicole Wong Doo, Professor John Radford, Doctor Leanne Berkahn, Professor Sally Barrington, Professor Maher Gandhi, Professor Stephen Opat, Associate Professor Eita Hawkes, Associate Professor Tara Cochran, Doctor Anna Johnston	Targeted competitive	1/06/2021	31/05/2026	Oncology And Carcinogenesis	Haematological Tumours	\$	1,395,462.00
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	La Trobe University	University	VIC	I-124 PET Directed Radioiodine Therapy for Radioiodine Refractory Thyroid Cancer: the I-TRIST Study	While current treatments for thyroid cancer are usually effective, a subset of patients will stop responding or become less sensitive to 131I treatment. The outcome for these patients is poor and further treatment options may not be effective or have significant toxicity. This prospective multicentre trial will use cutting edge imaging to evaluate the ability of drugs to "resensitize" the tumour to 131I therapy. We will also determine the affordability of bringing this therapy to the clinic.	Professor Andrew Scott	Professor Andrew Scott, Professor Bruce Robinson, Associate Professor David Pattison, Professor Christopher Gilliland, Associate Professor Kendrick Clifton, Professor Dale Bailey, Associate Professor Roslyn Francis, Ms Elizabeth Barnes, Professor Benjamin Solomon, Associate Professor Brendan Mulligan	Targeted competitive	1/06/2021	31/05/2026	Clinical Sciences	Nuclear Medicine	\$	2,708,660.70
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	The Council of the Queensland Institute of Medical Research	Medical Research Institute	QLD	MeST-Lly (Molecular Screening and Therapeutics in Leukemia and lymphoma)	The MeST-Lly clinical trial program will provide a new model of care with rapid molecular screening linked to targeted innovative treatments for the management of high-risk blood cancer in patients in Australia who have exhausted treatment options. MRFF funding will allow this screening and targeted treatment blood cancer screening program to be rolled out nationally, increase trials activity and offer hope to patients with limited treatment options.	Associate Professor Steven Lane	Associate Professor Steven Lane, Professor Hamish Scott, Associate Professor David Ross, Doctor Carolyn Grove, Associate Professor Nada Hamad, Associate Professor Anna Brown, Doctor Rosemary Harnup, Professor Richard D'Andrea	Targeted competitive	1/06/2021	31/05/2026	Oncology And Carcinogenesis	Haematological Tumours	\$	2,688,736.40
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	University of Melbourne	University	VIC	A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with high risk Retroperitoneal Sarcoma (STRASS 2)	Retroperitoneal sarcomas (RPS) are a diverse group of cancers that arise at the back of the abdominal cavity. The STRASS 2 study is designed to find out if a course of chemotherapy prior to surgery for RPS will reduce the risk of cancer recurrence and increase cure rates after surgery. It is the 1st study to look specifically at only 3 sarcoma types with the highest risk of cancer spreading. It also uses different chemotherapy drugs for each sarcoma type to ensure the best chance of response.	Associate Professor David Gyorki	Associate Professor David Gyorki, Associate Professor Peter Gimison, Professor Michael Hofman, Doctor Prunella Blimham, Professor Andrew Barbour, Professor Alessandro Gronchi, Doctor Hayden Snow	Targeted competitive	1/06/2021	31/05/2026	Oncology And Carcinogenesis	Solid Tumours	\$	901,695.00
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	University of Sydney	University	NSW	An adaptive, randomised controlled trial to treat polycysemia infections (BKPvY) in kidney and kidney pancreas transplant recipients (BEAT-BK) trial	BK polycysemia (BKPvY) infection is a feared outcome for kidney and kidney pancreas (SPK) transplant recipients because it can lead to significant kidney graft function dysfunction and graft loss. Apart from immunosuppression reduction, there are no effective treatments for BKPvY infection. The BEAT-BK trial will be the first-in-the world, adaptive randomization trial of intravenous immunoglobulin and immunosuppression reduction/modification in patients with kidney and SPK recipients.	Associate Professor Germaine Wong	Professor Germaine Wong, Professor Carmel Hawley, Professor Allison Tong, Doctor Julie Marsh, Professor Jonathan Craig, Professor Thomas Snelling, Associate Professor Helen Plimore, Doctor Martin Howell, Associate Professor Kate Wyburn, Mrs Nicole Scholtes-Robertson	Targeted competitive	1/06/2021	31/05/2027	Public Health And Health Services	Epidemiology	\$	2,894,169.05
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	Monash University	University	VIC	Preventing bone loss and restoring sexual function in women with premature ovarian insufficiency: a randomised, double-blind, placebo-controlled clinical trial	Women who have loss of function of their ovaries before the age of 40, or 'premature ovarian insufficiency' (POI), have estrogen and testosterone depletion. Despite treatment with estrogen women with POI still lose bone and have sexual difficulties. We will test if, compared with placebo, adding testosterone to standard estrogen therapy after POI prevents bone loss and improves sexual function. The findings will immediately inform the clinical care of women with POI.	Professor Susan Davis	Professor Susan Davis, Associate Professor Amanda Vincent, Professor Brynwyn Stuckey, Professor Peter Ebeling, Professor Robin Bell	Targeted competitive	1/06/2021	31/05/2026	Clinical Sciences	Endocrinology	\$	912,511.66
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	University of Melbourne	University	VIC	Targeted therapies for vascular malformations	Vascular malformations are rare congenital lesions which can cause lifelong pain, deformity and diminished quality of life. The recent, surprising discovery that they arise through similar genetic mechanisms to many cancers, suggests that drugs already in the clinic for cancer treatment should be effective in these conditions. A 'precision medicine' approach will give children and adults with the most severe vascular malformations their first opportunity to benefit from a clinical trial.	Professor Anthony Penington	Professor Anthony Penington, Doctor Stephen Luen, Associate Professor Michael Milesley, Doctor Jayesh Desai, Professor Mark Rosenthal, Doctor Natasha Brown, Associate Professor Jordan Hansford	Targeted competitive	1/06/2021	30/11/2026	Oncology And Carcinogenesis	Molecular Targets	\$	1,699,252.60
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	University of Melbourne	University	VIC	POST-ETERNAL: Extending the time window for Tenecteplase by Effective Recanalization of Basilar artery thrombus in patients with POSTerior circulation stroke	Basilar artery occlusion is a rare (~1% of all strokes) but devastating (80-90% disability and mortality) stroke caused by a blockage in the basilar artery, a blood vessel in the back of the brain. POST-ETERNAL is a clinical trial of a new clot-dissolving medicine called tenecteplase administered within 24 hours of symptom onset in patients with a stroke due to basilar artery occlusion. The main outcome of this trial is the proportion of patients at 3 months who are free from disability.	Doctor Fana Alemseged	Doctor Fana Alemseged, Professor Bruce Campbell, Professor Peter Mitchell, Associate Professor Nawaf Yassi, Professor Ken Butcher, Doctor Wouter Schonewille, Professor Stephen Davis	Targeted competitive	1/06/2021	31/05/2027	Neurosciences	Central Nervous System	\$	2,860,248.50
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	University of New South Wales	University	NSW	StoPain: A randomised placebo-controlled trial to investigate the efficacy of an advanced interactive brain-computer interface neuromodulation treatment for spinal cord injury neurogenic pain	Neuropathic pain (NP) is a debilitating secondary condition for persons with spinal cord injury (SCI) and effective pharmacological and nonpharmacological treatments remain elusive. We will test whether an advanced Brain-Computer Interface Neuromodulation (BCI-N) treatment offers sustained pain relief for SCI NP. This trial is expected to provide a major sustainable advance in SCI NP management that has tangible implications in the improvement of quality of life of individuals living with SCI NP.	Associate Professor Sylvia Gustin	Associate Professor Sylvia Gustin, Professor James McAuley, Professor James Middleton, Professor Chin Teng Lin, Professor Mark Jensen, Professor Ashley Craig, Professor Paul Glare, Associate Professor Toby Newton-John, Professor G. Lorimer Moseley, Doctor Negin Hesam-Sharati	Targeted competitive	1/06/2021	31/05/2027	Clinical Sciences	Rehabilitation And Therapy (Excl. Physiotherapy)	\$	1,780,269.60

Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	Monash University	University	VIC	Third Degree Burn Wound Closure using Engineered Skin - Phase I Clinical Trial	Over 40% of burn survivors live with pain and disability caused by scarring of skin grafts and their donor sites. Development of a reliable skin graft substitute to be tested in this study will save lives and improve the quality of life for survivors of severe burn injury by minimisation of the need to use patients' own unburned skin to graft burns. We will treat patients with severe burns with bioengineered skin developed in our laboratory and grown from small samples of their own skin.	Associate Professor Heather Cleland	Associate Professor Heather Cleland, Doctor Shiva Akbarzadeh, Mr Cheng Lo, Associate Professor Denise Marks, Professor Caroline Gargett	Targeted competitive	1/06/2021	31/05/2026	Clinical Sciences	Surgery	\$	2,363,239.15
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	La Trobe University	University	VIC	Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma	Hodgkin Lymphoma (HL) is a rare malignancy, with 500 new cases annually in young Australians. While 70% of patients are cured with front line treatment, 30% of patients require second line therapy which often fails resulting in death. Immunotherapy and targeted therapies have dramatically improved survival in haematological malignancies. This study will combine two agents currently approved in recurrent HL the second line setting, earlier to maximise survival of these young Australians.	Associate Professor Eliza Hawkes	Associate Professor Eliza Hawkes, Professor Judith Trotman, Professor Kerry Savage, Doctor Colm Keane, Associate Professor See Ting Lee, John Kuruvilla, Associate Professor Tara Cochrane, Professor Chan Yoon Cheah, Doctor Gareth Gregory, Doctor Anna Johnston	Targeted competitive	1/06/2021	31/05/2025	Oncology And Carcinogenesis	Haematological Tumours	\$	1,225,487.40
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	The University of Queensland	University	QLD	Testing a sinonasal microbiome transplant as a therapy for Chronic Rhinosinusitis by randomised controlled trial	Chronic sinus infections place a significant burden on quality of life. Recently our team undertook a promising study treating 25 chronic sinus patients with a nasal time containing nasal secretions from healthy donors. The patients' sinus symptoms decreased significantly after treatment; their symptom scores went from 57 out of 110 to 35 out of 110, a statistically significant improvement. This project will test the nasal secretion treatment more rigorously comparing it to a placebo.	Professor Anders Cervin	Professor Anders Cervin, Professor David Paterson, Professor Navia Huggens, Doctor Joanne Kemmer	Targeted competitive	1/06/2021	31/05/2024	Clinical Sciences	Infectious Diseases	\$	707,954.00
Clinical Trials Activity	2021 Clinical Trials Activity	University of Sydney	University	NSW	The EZCAR Trial:A Phase I clinical trial to evaluate administration of EphA2 targeted CAR T cells to children with sarcoma	Solid tumour sarcomas in children are rare cancers that can recur, become treatment resistant, or spread in the patient by the time of diagnosis. Immunotherapies which direct a patient's immune system to attack their cancer can be curative in childhood leukaemias, but untested against sarcomas. The EZCAR trial will test the administration of immunotherapy to children with incurable sarcomas as a first step in developing effective curative treatments to offer when standard therapies have failed.	Associate Professor Geoffrey McCowage	Associate Professor Geoffrey McCowage, Professor Geraldine O'Neill, Professor Ian Alexander, Doctor Caroline Bateman	Targeted competitive	1/02/2023	31/01/2028	Oncology And Carcinogenesis	Oncology And Carcinogenesis, Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	2,386,848.24
Clinical Trials Activity	2021 Clinical Trials Activity	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	ADAPT (Achieving Durable remission via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia)	This proposal will create a new trial called ADAPT to establish novel regimens to enhance outcomes among older patients with acute myeloid leukaemia who have a sub-optimal response to venetoclax, which was pioneered by this research team. We will also investigate how to deliver therapy more safely, ceasing treatment in those with a low chance of relapse guided by sensitive technologies and optimising use of antibiotics to manage low blood counts to reduce the risk of antibiotic resistance.	Professor Andrew Wei	Professor Andrew Wei, Ing So Tsing, Doctor Chong Chyn Chua, Doctor Michelle Tew	Targeted competitive	1/02/2023	31/01/2027	Oncology And Carcinogenesis	Oncology And Carcinogenesis, Haematological Tumours	\$	2,980,478.10
Clinical Trials Activity	2021 Clinical Trials Activity	Monash University	University	VIC	Generating new evidence to reduce complications and improve the safety and efficacy of extracorporeal membrane oxygenation (ECMO) in patients with severe cardiac and respiratory failure: THE RECOMMEND Platform Trial	Patients in Australia who are admitted to intensive care with very severe failure of the heart or lungs may receive extracorporeal membrane oxygenation (ECMO) if other forms of life support fail. ECMO is a device that acts like a heart lung bypass, but over 50% of these patients die and survivors are often left with significant disabilities. This trial will determine the optimal treatments for patients on ECMO to improve survival and reduce disability.	Professor Carol Hodgson	Professor Carol Hodgson, Associate Professor Neil Orford, Professor David J. (Jamie) Cooper, Associate Professor Zoe McCutcheon	Targeted competitive	1/02/2023	31/01/2028	Clinical Sciences	Clinical Sciences, Intensive Care	\$	2,985,992.73
Clinical Trials Activity	2021 Clinical Trials Activity	University of Sydney	University	NSW	Optimising the treatment of antibiotic resistant urinary tract infections in children: The FOSU/TI Trial	Urinary tract infections (UTIs) are one of the most common bacterial infections affecting children worldwide, and increasingly, these are caused by drug-resistant infections as antibiotic resistance spreads globally. Currently, children require admission to hospital to be treated with antibiotics (via a drip) to treat these infections. We aim to show that a safe, tolerable antibiotic (fosfomycin) can be used to treat UTIs in children, with just a single oral dose required for most infections.	Doctor Phoebe Williams	Doctor Phoebe Williams, Doctor Shannon McKim, Doctor Martin Howell, Doctor Philip Britton	Targeted competitive	1/02/2023	31/01/2028	Clinical Sciences	Clinical Sciences, Infectious Diseases, Paediatrics And Reproductive Medicine, Paediatrics, Pharmacology And Pharmaceutical Sciences, Clinical Pharmacology And Therapeutics	\$	1,534,478.05
Clinical Trials Activity	2021 Clinical Trials Activity	University of Melbourne	University	VIC	The Cannabidiol First-Episode Psychosis Study	Two thirds of young people with psychosis do not respond to antipsychotic medication during initial treatment and therefore are switched to a second or third antipsychotic with a similar mechanism of action. Since cannabidiol, a non-intoxicating part of the Cannabis plant, does not appear to degenerate on the same mechanism, this agent may represent a new class of treatment psychosis when treatment with conventional antipsychotic medication as sole antipsychotic agent has a low success rate.	Professor G. Paul Amminger	Professor G. Paul Amminger, Professor Alison Yung, Professor Andrew Thompson, Professor Patrick McGorry	Targeted competitive	1/02/2023	31/01/2026	Clinical Sciences	Clinical Sciences, Psychiatry (incl. Psychotherapy)	\$	2,604,231.90
Clinical Trials Activity	2021 Clinical Trials Activity	Monash University	University	VIC	A Phase 2, double-blind, placebo-controlled trial of sodium selenate as a disease modifying treatment for chronic drug resistant temporal lobe epilepsy (SELECT Trial)	We propose the world's first clinical trial of a drug treatment (sodium selenate) to reduce the severity of a common and poorly controlled type of epilepsy – Temporal Lobe Epilepsy (TLE). Current medical treatments for this condition fail to control the seizures in at least 30% of patients. This trial will investigate whether 6 months treatment will have a longer-term effect to reduce the number of seizures, and improve wellbeing and quality of life.	Professor Terence O'Brien	Professor Terence O'Brien, Professor Mark Cook, Professor Dennis Velakoulis, Doctor John-Paul Nicola	Targeted competitive	1/02/2023	31/01/2028	Neurosciences	Neurosciences, Central Nervous System	\$	2,961,326.74
Clinical Trials Activity	2021 Clinical Trials Activity	Monash University	University	VIC	Interfant-21: A new international clinical trial for infants diagnosed with KMT2A-rearranged acute lymphoblastic leukaemia	Infants diagnosed with acute lymphoblastic leukaemia (ALL) have poor outcomes. Rearrangements of the KMT2A gene are present in up to 80% of infants with ALL and have exceptionally low survival rates of less than 40%. Interfant-21 is an international clinical trial that will test whether the addition of a novel immunotherapeutic agent, blinatumomab, to standard chemotherapy can improve survival in infants diagnosed with KMT2A-rearranged ALL.	Associate Professor Rishi Kotucha	Associate Professor Rishi Kotucha, Doctor Seong Lin Khaw, Doctor Michelle Henderson, Ms Robyn Strong	Targeted competitive	1/02/2023	31/01/2028	Oncology And Carcinogenesis	Oncology And Carcinogenesis, Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	718,933.55
Clinical Trials Activity	2021 Clinical Trials Activity	The University of Queensland	University	QLD	PilotT1: Pre-venting chronic pain after whiplash Road Traffic Injury	After a whiplash injury sustained in a road traffic crash, up to 50% of people will develop chronic pain and disability. Doctors are increasingly using pregabalin for acute whiplash, even though it is not a recommended treatment. Our pilot trial showed promising effects of pregabalin to prevent chronic pain after whiplash injury. We will conduct a large and definitive trial to determine if these effects are real.	Professor Michele Sterling	Professor Michele Sterling, Professor Chung-Wei Christine Lin, Associate Professor Jane Nikles, Professor Paul Hodges	Targeted competitive	1/02/2023	30/09/2028	Clinical Sciences	Clinical Sciences, Clinical Sciences Not Elsewhere Classified	\$	2,035,691.85
Clinical Trials Activity	2021 Clinical Trials Activity	Queensland University of Technology	University	QLD	Preventing bronchiectasis in children: A multicentre randomised controlled trial and cohort study	Our consumer co-designed proposal responds to internationally identified clinical needs and research gaps. In children with chronic wet cough, we will link carefully collected clinical characteristics with novel omics data obtained from blood and airway specimens using state-of-the-art technology. We will also undertake a multi-centre randomised controlled trial aimed to prevent bronchiectasis and other clinical outcomes of children with chronic wet cough who have high-risk traits.	Professor Anne Chang	Professor Anne Chang, Professor Steven McPhail, Associate Professor Stephanie Yerkovich, Professor Shyamali Dharmage	Targeted competitive	1/02/2023	31/08/2028	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Respiratory Diseases	\$	2,621,218.26
Clinical Trials Activity	2021 Clinical Trials Activity	The University of Newcastle	University	NSW	Individualised blood pressure targets versus standard care among critically ill patients with shock - a multicentre randomised controlled trial	Shock is a common cause of death in ICU. Nearly all patients with shock need medications to support their blood pressure (BP). Current practice of standard BP target is a one-size-fits-all approach. Targeting patients' usual pre-illness BP in ICU has not been tested in an RCT. Therefore, we aim to investigate whether BP targets that approximate patients' own pre-illness BP readings can potentially improve the rates of death and major adverse kidney events at day 14 among ICU patients with shock.	Doctor Rakshit Panwar	Doctor Rakshit Panwar, Doctor Shailesh Bihari, Associate Professor Kiran Shekar, Doctor Mahesh Raman	Targeted competitive	1/02/2023	31/01/2028	Clinical Sciences	Clinical Sciences, Intensive Care	\$	2,823,845.94
Clinical Trials Activity	2021 Clinical Trials Activity	The University of Queensland	University	QLD	INCremental dialysis to improve Health in people starting Haemodialysis (INCH-HD)	When, and how often, to start haemodialysis (HD) is an important decision. Most patients start HD three times per week (conventional HD), however this approach may not be suitable for all patients; there is some evidence it may actually be harmful. An alternative approach is to start a less frequent twice-weekly (incremental) HD routine. The INCH-HD trial will test if incremental HD preserves the quality of life of patients and families and is a safe, practical, cost effective treatment option.	Professor David Johnson	Professor David Johnson, Doctor Ginger Chu, Associate Professor Matthew Roberts, Associate Professor Rathika Krishnamany	Targeted competitive	1/02/2023	31/01/2028	Clinical Sciences	Clinical Sciences, Nephrology And Urology	\$	2,679,683.25
Clinical Trials Activity	2021 Clinical Trials Activity	University of New South Wales	University	NSW	Neurostimulation to improve walking after spinal cord injury	This randomised controlled trial (RCT) will determine if transcutaneous spinal electrical stimulation combined with locomotor training can restore walking ability in people with spinal cord injury. The trial will include people with incomplete SCI from Sydney, Melbourne, and Perth. We will also examine the effects on neurological function, spasticity, neuropathic pain and quality of life. We expect that any physical improvements will also improve mental wellbeing and functional independence.	Professor Jane Butler	Professor Jane Butler, Doctor Elizabeth Bye, Professor Lisa Harvey, Doctor Martin Herx	Targeted competitive	1/02/2023	30/09/2028	Clinical Sciences	Clinical Sciences, Physiotherapy, Neurosciences, Neurosciences Not Elsewhere Classified	\$	2,994,189.70
Clinical Trials Activity	2021 Clinical Trials Activity	University of Melbourne	University	VIC	Restoration of Respiratory and Upper Limb function after cervical spinal cord injury (RRULI)	Exercise for people with longstanding spinal cord injury makes weak muscles stronger, but weakness returns when exercise training stops. We have early evidence that both electrical stimulation of the spinal cord through the skin, and breathing very short bursts of low oxygen levels, when added to exercise training, may produce longer lasting benefits. This trial will determine which combinations of these treatments shows the most promise.	Professor David Berlowitz	Professor David Berlowitz, Professor Janet Taylor, Associate Professor Mark Howard, Doctor Claire Boswell-Ruys	Targeted competitive	1/02/2023	30/09/2028	Neurosciences	Neurosciences, Neurosciences Not Elsewhere Classified, Clinical Sciences, Physiotherapy	\$	2,993,843.40
Clinical Trials Activity	2021 Clinical Trials Activity	Deakin University	University	VIC	Randomized E-Hypnotherapy for Chronic Pelvic Pain Syndrome Trial (REST)	Chronic pelvic pain syndrome impacts up to 20% of Australians. It is associated with poor quality of life and psychological health, but the effective treatment is lacking. Hypnotherapy is known to improve mental health and pain. Our pilot studies showed that hypnotherapy might help to treat depression, anxiety and pelvic pain. This study will examine whether hypnotherapy improves pain, mental health, and quality of life as compared to relaxation alone and a waitlist group over 12 months.	Professor Antonina Mikocka-Walus	Professor Antonina Mikocka-Walus, Doctor Nikki McAffrey, Doctor Sabindra Evans, Associate Professor Simon Knowles	Targeted competitive	1/02/2023	31/05/2028	Psychology	Psychology, Health, Clinical And Counselling Psychology, Paediatrics And Reproductive Medicine, Obstetrics And Gynaecology, Clinical Sciences, Gastroenterology And Hepatology	\$	1,300,459.86
Clinical Trials Activity	2021 Clinical Trials Activity	University of South Australia	University	SA	ReconNECKT: A randomised placebo-controlled trial to test the safety, clinical and cost effectiveness of a new treatment for chronic neck pain	Chronic neck pain is a common problem that comes at great personal, economic and social cost. It has been recognised as a high priority problem by consumers, industry and government. Our project is a randomised clinical trial to test the safety and effects on pain, function and quality of life, and cost-effectiveness of a new treatment for chronic neck pain that is based on modern neuroscience. We will compare our treatment to a carefully designed placebo treatment.	Professor G. Lorimer Mosley	Professor G. Lorimer Mosley, Doctor Emma Karan, Associate Professor Natasha Stanton, Professor James Mculey	Targeted competitive	1/02/2023	31/01/2028	Clinical Sciences	Clinical Sciences, Physiotherapy	\$	1,470,061.06
Clinical Trials Activity	2021 Clinical Trials Activity	Australian National University	University	ACT	Modulating stem cell differentiation in individuals with high risk clonal haematopoiesis: the MOSAIC trial	Throughout life, our blood stem cells acquire mutations in their genes. Some mutations allow those stem cells to dominate blood cell production, a phenomenon called clonal haematopoiesis. Many complications of ageing, including blood cancers, heart disease, and infections, are connected to these mutations. We will attempt to reverse the effects of these mutations using a new treatment we developed to restore normal stem cell production, with the goal of preventing the complications of ageing.	Professor Mark Polizzotto	Professor Mark Polizzotto, Teresa Neeman, Tracy Murphy, Yogen Sauntharajah	Targeted competitive	1/02/2023	31/01/2028	Oncology And Carcinogenesis	Oncology And Carcinogenesis, Haematological Tumours	\$	2,971,763.69

Clinical Trials Activity	2021 Clinical Trials Activity	Australia New Zealand Gynaecological Oncology Group	Corporation	NSW	Tailored adjuvant therapy in POLEmut & NSMP early stage endometrial cancer (TAPER)	The number of endometrial (uterine) cancer (EC) cases in Australia is rising rapidly. Research advances mean biological (molecular) markers in tumour samples can identify a specific group of EC patients who will have exceptionally good survival, and who might not need either chemotherapy or radiotherapy after surgery, saving the patient long term side effects and reducing treatment costs overall. This clinical trial will implement molecular testing of EC to avoid unnecessary toxic therapies.	Associate Professor Alison Brand	Associate Professor Alison Brand, Professor Jessica McAlpine, Ms Kathryn Cornthwaite, Doctor Bryony Simcock	Targeted competitive	1/02/2023	31/01/2028	Oncology And Carcinogenesis	Oncology And Carcinogenesis, Molecular Targets	\$	1,271,471.61
Clinical Trials Activity	2021 Clinical Trials Activity	University of New South Wales	University	NSW	Targeted, Adaptive Genomics for Ethical, Evidence-based Expansion of Newborn Screening: a type II hybrid effectiveness-implementation trial	Every year thousands of Australians suffer unnecessary death or disability from treatable genetic conditions because effective screening is unavailable. We have developed and tested a way to screen newborns using genomics for 53 treatable health conditions. This project will introduce this screening approach into healthcare to see how effective it is at identifying treatable genetic conditions in newborns, the impact on parents, and what health system factors contribute to its success.	Associate Professor Natalie Taylor	Associate Professor Natalie Taylor, Doctor Ronny Parkinson, Doctor Lillian Downie, Doctor Jacobus Ungerer	Targeted competitive	1/02/2023	31/01/2026	Genetics	Genetics, Genomics, Public Health And Health Services, Preventive Medicine, Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	2,993,818.99
Clinical Trials Activity	2021 Clinical Trials Activity	University of Sydney	University	NSW	Delayed cord clamping in babies born before 37 weeks gestation to prevent anaemia, death and disability (WARM - Wait a Minute or More): a pragmatic stepped-wedge implementation trial	Every year, more than 25,000 Australians are born preterm, before 37 weeks of pregnancy. A few of them need immediate help to breathe. But for the others, waiting to clamp the umbilical cord 60 seconds or more after birth reduces anaemia and improves healthy long term survival. This project will involve staff and parents in maternity hospitals across Australia. It will test how to bring the benefits of "waiting a minute or more" before clamping the cord to as many preterm babies as possible.	Professor William Tarnow-Mordi	Professor William Tarnow-Mordi, Doctor Naomi Spotswood, Associate Professor Amy Keir, Doctor Kirsty Robledo	Targeted competitive	1/02/2023	30/06/2026	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine, Obstetrics And Gynaecology	\$	2,975,545.90
Clinical Trials Activity	2021 Clinical Trials Activity	St Vincent's Institute of Medical Research	Medical Research Institute	VIC	A Randomised Controlled Trial to Assess if the Implementation of an Artificial Intelligence Mammogram Reader Improves Breast Cancer Screening	One million women annually are screened for breast cancer. Early detection reduces the risk of dying however mammographic interpretation is challenging. The project will provide implementation evidence of the effectiveness of an AI mammogram reader in breast cancer screening to improve accuracy and experience. Ultimately this can enable a more effective and personalised BreastScreen service to women.	Associate Professor Helen Frazer	Associate Professor Helen Frazer, Associate Professor Michelle Reinalls, Professor Gustavo Carneiro, Professor Dennis Petrie	Targeted competitive	1/02/2023	30/06/2027	Oncology And Carcinogenesis	Oncology And Carcinogenesis, Cancer Diagnosis, Clinical Sciences, Radiology And Organ Imaging, Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	2,994,374.19
Clinical Trials Activity	2021 Clinical Trials Activity	University of Western Australia	University	WA	Identifying Advanced Liver Fibrosis in Primary Care	Significant scarring of the liver typically causes no symptoms until life-threatening complications occur such as liver cancer and liver failure when it is too late to treat its cause or provide care to prevent complications. This trial will examine whether using computer software integrated into a general practice and combined with new diagnostic tests will increase the detection of advanced liver fibrosis in patients with risk factors for liver disease who attend their general practitioner.	Associate Professor Leon Adams	Associate Professor Leon Adams, Associate Professor Jo-Anne Marsini-Nankervis, Professor Jon Emery	Targeted competitive	1/02/2023	31/01/2027	Clinical Sciences	Clinical Sciences, Gastroenterology And Hepatology	\$	2,550,696.32
Clinical Trials Activity	2021 Clinical Trials Activity	Monash University	University	VIC	Just Say No to the Just in Case Cannula: An Implementation Science Trial with Roadmap for National Roll Out	Have you or your family ever waited for care in an ED and wondered what the nurses and doctors were doing? They may have been inserting a 'Just in Case Cannula' (Jv), in the belief that they were being safe, caring clinicians. However, JVs are painful to insert, have serious side-effects and come at a high cost. Up to half of JVs are not used for any treatment. We plan to improve cannula use and safety in EDs nationally. We will ensure value for money, reduce waste and drive national uptake.	Professor Diana Egerton-Warbuton	Professor Diana Egerton-Warbuton, Associate Professor Lisa Kuhn, Professor Gerben Keijzers, Professor Helena Teede	Targeted competitive	1/02/2023	31/01/2028	Clinical Sciences	Clinical Sciences, Emergency Medicine, Applied Economics, Health Economics, Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	2,890,281.87
Clinical Trials Activity	2021 Clinical Trials Activity	Monash University	University	VIC	The CONSEP trial: Implementing screening for a hidden cause of hypertension	One in 3 adult Australians have high blood pressure (HBP) and 10% of them have a condition called primary aldosteronism (PA). PA makes HBP hard to control and leads to strokes, heart attacks and kidney failure. While easy to detect with a blood test, GPs hardly ever order this test to check for PA in patients with HBP. CONSEP will test a new strategy to help GPs find patients living with PA, opening the door to better outcomes for those living with this very treatable condition.	Associate Professor Jun Yang	Associate Professor Jun Yang, Associate Professor Gang Chen, Professor Mark Nelson, Doctor Angela Meider	Targeted competitive	1/02/2023	31/01/2027	Clinical Sciences	Clinical Sciences, Endocrinology, Public Health And Health Services, Primary Health Care, Cardiorespiratory Medicine And Haematology, Cardiology (Ind. Cardiovascular Diseases)	\$	2,299,203.19
Clinical Trials Activity	2021 Clinical Trials Activity	University of Western Australia	University	WA	A programme to improve medical follow-up and health outcomes for First Nations children hospitalised with lung infections	First Nations children have high rates of lung disease. Those who have been hospitalised with a lung infection are at higher risk. Our research aims to reduce this burden of chronic lung disease. With a culturally secure, cooperative approach, parents will be empowered to recognise key symptoms and seek help. The research will also improve how this condition is managed by clinicians in primary care and hospitals. The goal is improved lung health outcomes for First Nations children.	Doctor Pamela Laird	Doctor Pamela Laird, Associate Professor Raz Walker, Associate Professor Fennell Giff, Professor Maree Toombs	Targeted competitive	1/02/2023	31/01/2027	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine, Paediatrics, Public Health And Health Services, Health And Community Services, Clinical Sciences, Clinical Sciences Not Elsewhere Classified	\$	1,970,716.29
Clinical Trials Activity	2021 Clinical Trials Activity	Deakin University	University	VIC	CoDefendo: Co-Designing, Evaluating, and Implementing Supportive Care for Endometriosis	Impacting 1 in 10 women, endometriosis is under-recognised. Usual care, comprised of hormone and pain medications, has limited efficacy, is associated with considerable side effects, and discontinued by 40% of patients. Surgery often fails to prevent recurrence of disease. Comprehensive management of chronic pain is urgently needed to address the poor QoL of 830,000 Australians with endometriosis. This project will evaluate and implement a person-focused supportive care model for endometriosis.	Professor Antonina Mikocka-Walus	Professor Antonina Mikocka-Walus, Professor Felice Jaska, Doctor Nikki Mc Caffrey, Professor Jason	Targeted competitive	1/02/2023	31/08/2028	Public Health And Health Services	Public Health And Health Services, Preventive Medicine	\$	1,470,988.82
Clinical Trials Activity	2021 Clinical Trials Activity	University of New South Wales	University	NSW	Comparative Effectiveness of Ketamine and Esketamine in Treatment Resistant Depression	Ketamine is a highly effective new treatment for treatment-resistant depression. Two main forms of ketamine are available in Australia, a patented new drug, and a generic form of ketamine widely available at low cost. This will be the first study to directly compare these two forms of ketamine, in terms of effectiveness, acceptability, safety and cost effectiveness.	Professor Colleen Loo	Professor Colleen Loo, Ms Karen Wells, Professor Nicholas Glozier, Professor Christopher Davey	Targeted competitive	1/02/2023	31/01/2027	Clinical Sciences	Clinical Sciences, Psychiatry (Ind. Psychotherapy)	\$	2,989,718.53
Clinical Trials Activity	2021 Clinical Trials Activity	Deakin University	University	VIC	iCare – An interactive online portal to improve health and wellbeing for people living with complex cancers, and their informal carers: a Phase II randomised controlled trial	Our proposed study addresses an area of high-urgent need related to chronic, complex cancers. Our Phase II trial will test the feasibility and acceptability of a co-designed interactive web-based portal, that supports people with upper GI cancers, the burden experienced by carers, and the urgent needs of both groups. The results will inform a hybrid implementation trial to deliver meaningful health impacts to carers and people with cancer.	Professor Patricia Livingston	Professor Patricia Livingston, Doctor Anna Uglade, Professor Alison Hutchison, Doctor David Watson	Targeted competitive	1/02/2023	30/06/2026	Public Health And Health Services	Public Health And Health Services, Health Counseling	\$	826,731.86
Clinical Trials Activity	2021 Clinical Trials Activity	University of Melbourne	University	VIC	Sugamadex, neostigmine and postoperative pulmonary complications	Pneumonia and other lung complications after surgery are common, distressing and costly. Muscle weakness after surgery increases the risk of lung complications. Sugamadex reverses muscle relaxant drug better than neostigmine. We propose a large study of surgical patients aged 40 years and over to determine if sugamadex reduces the risk of lung complications compared with neostigmine. This study has the potential to improve outcomes for millions of patients and health services worldwide.	Professor Kate Leslie	Professor Kate Leslie, Miss Sabine Braat, Professor David Story, Professor Tomas Corcoran	Targeted competitive	1/02/2023	30/04/2027	Clinical Sciences	Clinical Sciences, Anaesthesiology	\$	2,948,208.65
Clinical Trials Activity	2021 Clinical Trials Activity	University of New South Wales	University	NSW	Enhancing point-of-care testing for hepatitis C infection: the OPTIMISE study	Hepatitis C testing and treatment has declined in Australia, slowing elimination progress. Point-of-care testing for active hepatitis C infection provides results in an hour, enabling same-visit diagnosis and treatment. But, this test is more costly and has a longer time to result than point-of-care antibody testing. This MHF Project will conduct a comparative effectiveness trial to assess the effectiveness, cost effectiveness, and acceptability of point-of-care hepatitis C testing strategies.	Professor Jason Grebely	Professor Jason Grebely, Professor Carla Treloar, Doctor Marianne Martiniello, Doctor Melanie Kingsland	Targeted competitive	1/02/2023	31/01/2026	Public Health And Health Services	Public Health And Health Services, Epidemiology	\$	2,066,438.73
Clinical Trials Activity	2021 Clinical Trials Activity	Macquarie University	University	NSW	A comparative effectiveness trial of digital mental health care models for adults with epilepsy	This clinical trial will compare the acceptability and effectiveness of two models (guided vs unguided) of delivering a digital psychological intervention aimed at improving mental health and functional outcomes in adults with epilepsy. The guided model delivers the intervention with support from mental health specialist. Whereas the unguided model offers the intervention in a standalone, self-directed format. This trial will inform the public health potential of these two approaches to care.	Doctor Milena Gandy	Doctor Milena Gandy, Doctor Eyal Karni, Doctor Kaitlyn Parratt, Professor Blake Dear	Targeted competitive	1/02/2023	31/01/2028	Public Health And Health Services	Public Health And Health Services, Mental Health	\$	973,195.11
Clinical Trials Activity	2021 Clinical Trials Activity	The University of Newcastle	University	NSW	A comprehensive digital solution to empower asthma and comorbidity self-management	Asthma control and self-management via existing asthma care models remain low. New, cost-effective, and evidence-based models of care with better reach and higher uptake are needed. This trial will demonstrate the effectiveness of a comprehensive, national, digital asthma care program compared to usual care in achieving asthma control. The findings will have direct healthcare system implications and if effective can be upscaled nationally to assist millions of people with asthma.	Professor Peter Gibson	Professor Peter Gibson, Doctor John Fardy, Doctor Rebecca McLaughlin, Doctor Rebecca Wyse	Targeted competitive	1/02/2023	31/01/2028	Public Health And Health Services	Public Health And Health Services, Health Promotion	\$	2,415,561.62
Clinical Trials Activity	2021 Innovative Therapies for Mental Illness	University of Sydney	University	NSW	A randomised, double-blind, controlled trial of MDMA-assisted exposure therapy for comorbid alcohol use disorder and post-traumatic stress disorder. This study will generate high level efficacy and cost-efficacy data for these life-threatening problems.	There is a high rate of comorbidity between alcohol use disorders and post traumatic stress disorder which is associated with greater clinical impairment, poorer prognosis and greater treatment attrition. This trial will be an internally unique study which will examine the efficacy of MDMA-assisted therapy to treat concurrent alcohol use disorder and post traumatic stress disorder. This study will generate high level efficacy and cost-efficacy data for these life-threatening problems.	Associate Professor Kirstin Morley	Associate Professor Kirstin Morley, Professor Katherine Mills, Professor Paul Haber, Professor Daniel Lubman, Professor Maree Tesson, Doctor Shalini Annangi, Professor Andrew Ballie, Doctor Yong Yi Lee, Doctor Alyssa Morse, Professor Sude Beck	Targeted competitive	1/01/2022	31/12/2025	Clinical Sciences	Psychiatry (Ind. Psychotherapy)	\$	1,951,246.45
Clinical Trials Activity	2021 Innovative Therapies for Mental Illness	University of Sydney	University	NSW	PANORDEXA: A clinical trial of psilocybin-assisted psychotherapy in anorexia nervosa	Anorexia nervosa is a deadly eating disorder that is often resistant to treatment. Psilocybin is a psychedelic drug, found in mushrooms, that has shown to be effective in a range of mental illnesses, especially depression and anxiety, which very commonly co-occur with anorexia nervosa. There is emerging evidence that psychedelics may improve the mental wellbeing of individuals with this illness. This study will investigate 3 doses of psilocybin assisted therapy in adults with anorexia nervosa.	Professor Stephen Touyz	Professor Stephen Touyz, Associate Professor Sloane Madden, Professor Ian McGorry, Doctor Sarah Maguire, Professor David Nutt, Meg Spriggs, Doctor Samuel Banister	Targeted competitive	1/02/2022	31/12/2025	Pharmacology And Pharmaceutical Sciences	Clinical Pharmacology And Therapeutics	\$	1,175,522.20
Clinical Trials Activity	2021 Innovative Therapies for Mental Illness	University of Melbourne	University	VIC	A Randomised Controlled Trial of MDMA-Assisted Psychotherapy for Treatment-Resistant Social Anxiety in Young Adults with Autism Spectrum Disorder	Social anxiety is common in young adults with autism. It compounds the core symptoms of autism, contributing to disability and distress. Current treatments are often ineffective. MDMA-assisted psychotherapy is a novel treatment shown to be safe and possibly effective in a pilot study. We propose a clinical trial of MDMA-assisted psychotherapy for treatment-resistant social anxiety in young adults with autism. Results may provide an efficacious new treatment option for this disabling condition.	Associate Professor Gill Bedi	Associate Professor Gill Bedi, Professor Adam Guastella, Professor David Cahill, Professor Stephen Wood, Professor Patrick McGorry, Professor Andrew Chanen, Professor Ian Hickie, Doctor Rick Pan Yuen, Doctor Keshie Boulton, Mr Alexandre Guerin	Targeted competitive	1/01/2022	31/12/2026	Clinical Sciences	Psychiatry (Ind. Psychotherapy)	\$	3,762,327.90
Clinical Trials Activity	2021 Innovative Therapies for Mental Illness	Australian National University	University	ACT	Evaluating the efficacy of psilocybin-assisted psychotherapy in treatment-resistant depression	Psychotic-like assisted psychotherapy using psilocybin, has been investigated in several small studies for its capacity to aid in the recovery of patients with depression. This form of treatment appears to have antidepressant benefits but there are considerable limitations with the studies that have been conducted to date. We aim to conduct a substantive study evaluating the use of this treatment in patients with depression who have failed to respond to other antidepressant medications.	Professor Paul Fitzgerald	Professor Paul Fitzgerald, Professor Kate Hoy, Professor Jayashree Kulkarni, Professor Michael Berk, Doctor Neil Bailey, Professor Stephanie Herlihy, Doctor Jeggan Tiego, Professor Nicholas Glozier	Targeted competitive	1/01/2022	31/07/2027	Clinical Sciences	Psychiatry (Ind. Psychotherapy)	\$	2,727,173.50
Clinical Trials Activity	2021 Innovative Therapies for Mental Illness	University of Melbourne	University	VIC	Clinical Trial of Cannabidiol for Treatment Resistant Anxiety Disorders in Youth	Anxiety disorders are the most common psychiatric conditions in youth. With current treatments only around 50% of young people remit from their anxiety disorders. Cannabidiol (CBD) is the major non-intoxicating constituent of cannabis; it has anxiolytic properties and excellent tolerability and safety as demonstrated by our successful pilot study. We now aim to test whether CBD can reduce anxiety severity in youth who did not respond to standard treatments in a larger placebo-controlled study.	Professor G. Paul Amminger	Professor G. Paul Amminger, Associate Professor Ashleigh Lin, Associate Professor Simon Rice, Professor C. Barnaby Nelson, Professor Allison Yung, Doctor Maximus Berger, Doctor Magenta Simmons	Targeted competitive	1/01/2022	30/06/2025	Clinical Sciences	Psychiatry (Ind. Psychotherapy)	\$	1,745,708.55

Clinical Trials Activity	2021 Innovative Therapies for Mental Illness	University of Melbourne	University	VIC	Dimethyltryptamine (DMT)-Assisted Psychological Therapy for Treatment-Resistant Major Depression, Alcohol Use Disorder, and Dual Diagnosis	Alcohol use disorder (AUD) and major depressive disorder (MDD) are disorders which commonly occur together, being associated with immense psychosocial impact. A potential novel treatment involves the use of the psychedelic formulation of the compound Dimethyltryptamine (known as 'DMT'). Research has revealed that DMT may alleviate depression, also having an addictive effects. We propose to conduct a clinical trial using DMT for adults with AUD and/or MDD.	Professor Jerome Sarris	Professor Jerome Sarris, Associate Professor Yvonne Bonomo, Doctor Daniel Perkins, Doctor James Rucker, Professor Allan Young, Professor Daniel Hoyer, Doctor Margaret Ross, Doctor Carolyn Le, Doctor Simon Ruffell, Professor Andrew Lawrence	Targeted competitive	1/01/2022	31/12/2025	Clinical Sciences	Psychiatry (Ind. Psychotherapy)	\$	1,977,354.90
Clinical Trials Activity	2021 Innovative Therapies for Mental Illness	University of Melbourne	University	VIC	Pulicycbin-assisted therapy for refractory Functional Neurological Disorder	Functional Neurological Disorder (FND) is a mental disorder that presents with neurological symptoms, such as paralysis, which are of psychological origin. Many patients do not respond to standard therapy, and potentially face lifelong disability as a result. We believe that adding pulicycbin to standard therapy will allow them to recover completely. We will test this using a randomised controlled trial of pulicycbin plus standard therapy compared to placebo plus standard therapy.	Professor Richard Kanaan	Professor Richard Kanaan, Professor David Berlowitz, Professor Olivia Carter, Ms Sabine Braat, Doctor Glenn Nielsen, Doctor Alexander Bryson	Targeted competitive	1/01/2022	30/09/2027	Clinical Sciences	Psychiatry (Ind. Psychotherapy)	\$	1,448,343.80
Clinical Trials Activity	2021 International Clinical Trial Collaborations (Round 21.1)	University of Sydney	University	NSW	Anticoagulation for Stroke Prevention in Patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial	Many people have major surgery, and about 3% will develop atrial fibrillation (AF) transiently in the perioperative period. These people have a higher risk of stroke and adverse outcomes. We know that anticoagulation reduces stroke risk in people with established AF, but it is unclear whether perioperative AF causes stroke by the same mechanisms and hence whether treating perioperative AF with anticoagulation will produce benefit to patients or harm, because of the increased risk of bleeding.	Professor Clara Chow	Professor Clara Chow, Professor Graham Hillis, Professor David Bruger, Associate Professor Aaron Sverdlow, Professor John Atherton, Professor Lisa Thomas, Professor Richard Lindley, Associate Professor Gail Fergusson, Professor PJ Devereaux, Associate Professor David Conen	Targeted competitive	1/02/2022	31/01/2027	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology Cardiology (Ind. Cardiovascular Diseases)	\$	1,816,175.10
Clinical Trials Activity	2021 International Clinical Trial Collaborations (Round 21.1)	University of New South Wales	University	NSW	Dopagliflozin in advanced chronic kidney disease and kidney failure: The RENAL LIFE/CYLE trial	Patients with advanced stages of chronic kidney disease and kidney failure receiving kidney replacement therapy with dialysis or kidney transplantation suffer from significant burden of heart disease, which shortens their life. The RENAL LIFE/CYLE trial will evaluate whether dopagliflozin, a medication previously used for lowering blood glucose level, would improve clinical outcomes related to heart and kidney disease in patients with advanced chronic kidney disease and kidney failure.	Associate Professor Sunil Badve	Associate Professor Sunil Badve, Doctor Clare Annot, Professor Viado Perkovic, Doctor Brendon Neuen, Professor Bruce Neal, Doctor Rebecca Kozor, Margaret Kelley, Ms Helen Monaghan, Associate Professor Laurent Billot, Professor Hiddo Lambers Heersink	Targeted competitive	1/02/2022	31/01/2027	Clinical Sciences	Clinical Sciences, Nephrology And Urology, Cardiorespiratory Medicine And Haematology, Cardiology (Ind. Cardiovascular Diseases)	\$	2,229,409.70
Clinical Trials Activity	2021 International Clinical Trial Collaborations (Round 21.1)	The University of Adelaide	University	SA	The single dose of antenatal corticosteroids (SNACS) randomised trial for women at risk for preterm birth	Each year across the world, 15 million babies are born early before 37 weeks. Exposure to two doses of antenatal corticosteroids (ACS) before early birth improves baby's lung and brain development. Despite ACS being used since the 1970's, the optimal dose has not been determined. We hypothesise that a single dose (rather than 2 doses) of ACS is sufficient for lung maturation with fewer long term side effects. We will conduct an international, multi-centre randomised trial to evaluate this.	Professor Jodie Dodd	Professor Jodie Dodd, Doctor Amanda Popreczay, Associate Professor Amy Kiri, Doctor Jennie Lausie, Doctor Cecelia O'Brien, Associate Professor Amanda Henry, Associate Professor Joanne Said, Professor Annette Riley, Doctor Kellie Murphy, Doctor Sarah McDonald	Targeted competitive	1/02/2022	31/07/2027	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine, Obstetric And Gynaecology	\$	3,025,898.90
Clinical Trials Activity	2021 International Clinical Trial Collaborations (Round 21.1)	University of New South Wales	University	NSW	Enhanced Control of Hypertension and Thrombectomy Stroke Study (ENCHANTED-MT)	Mechanical thrombectomy (MT), the insertion of a device to remove a clot and restore blood flow in a blocked artery in the brain, is a standard procedure to improve recovery from acute ischaemic stroke. Blood pressure is important in determining success, but the optimal level of control is uncertain. We wish to include Australian patients in the large clinical trial we have designed and initiated in China, to reliably evaluate the benefits and risks of different BP control targets in MT.	Professor Craig Anderson	Professor Craig Anderson, Doctor Lili Song, Ms Xiaoying Chen, Professor Mark Parsons, Associate Professor Pengfei Yang, Professor Thompson Robinson, Doctor Xia Wang, Professor Ken Butcher, Professor Jiamin Lu, Professor Bruce Campbell	Targeted competitive	1/02/2022	31/07/2025	Clinical Sciences	Clinical Sciences, Clinical Sciences Not Elsewhere Classified	\$	2,029,360.80
Clinical Trials Activity	2021 International Clinical Trial Collaborations (Round 21.1)	Monash University	University	VIC	Adaptive platform trial for severe community acquired pneumonia: new interventions for severe CAP and influenza	This application proposes to add new treatments to REMAP-CAP, an existing trial for patients admitted to an Intensive Care Unit because of life-threatening pneumonia. The trial utilises innovative methods to allow simultaneous evaluation of multiple different treatment approaches. The new treatments that will be tested are levofloxacin (a drug that is used for a type of chronic leukaemia) and drugs that modulate the immune response, which will be tested in a sub-group with influenza.	Professor Steve Webb	Professor Steve Webb, Associate Professor Zoe McQuillan, Professor Alistair Nichol, Doctor Thomas Hills, Doctor Alisa Higgins, Doctor Aidan Burrell, Ms Anne McKenzie, Professor Allen Cheng, Professor Ian Seppelt, Doctor Colin McArthur	Targeted competitive	1/06/2022	31/05/2026	Clinical Sciences	Clinical Sciences, Intensive Care	\$	2,824,703.40
Clinical Trials Activity	2021 International Clinical Trial Collaborations (Round 21.2)	University of Melbourne	University	VIC	PET/CT for Staphylococcus aureus bloodstream infections: an international, multicentre, randomised controlled trial	Bloodstream infections due to Staphylococcus aureus (golden staph) are common (~5,000 episodes per year in Australia) and deadly (20% mortality rate). Key to treatment is finding where the infection is lodged in the body. The SNAP-PET trial will determine whether using a nuclear medicine imaging PET/CT can detect previously unrecognised foci of infection and results in changes to clinical management (surgical drainage of infection and optimal antibiotic duration) and improved patient outcomes.	Professor Steven Tong	Professor Steven Tong, Professor Joshua Davis, Professor Andrew Scott, Associate Professor Roslyn Francis, Associate Professor Anna Goodman, Professor Gary Cook, Professor Mital Paul, Doctor Julie Marsh, Doctor Anna McGlothlin	Targeted competitive	1/06/2022	31/05/2027	Clinical Sciences	Clinical Sciences, Infectious Diseases	\$	998,222.40
Clinical Trials Activity	2021 International Clinical Trial Collaborations (Round 21.2)	University of New South Wales	University	NSW	Sedation, Temperature and Pressure after Cardiac Arrest and Resuscitation (STEP CARE) trial	Two thousand Australians are hospitalised after a cardiac arrest each month; only 240 will survive to hospital discharge. Survivors have impaired physical and brain health, impacting their lives and their community. In a single clinical trial, we will evaluate three every day intensive care practices (sedative, temperature and blood pressure strategy) to assess their effect on improving survival and brain health.	Doctor Manoj Saxena	Doctor Manoj Saxena, Associate Professor Niklas Nielsen, Associate Professor Naomi Hammond, Professor Anders Asenman, Associate Professor Clare Annot, Professor Bala Venkatesh, Doctor Candice Delcourt, Associate Professor Anthony Delaney, Professor Stephen Bernard, Markus Skrifvars	Targeted competitive	1/06/2022	31/05/2027	Clinical Sciences	Clinical Sciences, Intensive Care	\$	844,764.00
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Newcastle	University	NSW	A precision medicine clinical trial platform to BEAT CF	Cystic Fibrosis (CF) is caused by over 2000 gene defects. Medications have been developed that improve outcomes in CF. These medicines have been shown to work in 80% of people with CF. For the remaining 20% there is uncertainty, use will be limited due to expense, some will miss out and others may receive treatment that is not needed. We have developed a personalised avatar using cells from each person that can predict accurately who will and will not benefit from these medicines.	Professor Peter Wark	Professor Peter Wark, Professor Thomas Stelling, Professor Adam Jaffe, Doctor Gerard Kailo, Doctor Shafigh Waters, Professor James McGree, Associate Professor Andre Schultz	Targeted competitive	1/01/2022	31/05/2025	Cardiorespiratory Medicine And Haematology	Respiratory Diseases	\$	2,107,804.40
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of Melbourne	University	VIC	Augmenting dietary protein during critical illness: A cluster randomised cross-sectional double cross-over clinical trial	A small proportion of Australians become so sick that require admission to an Intensive Care Unit (ICU) for life support. As part of their care these patients receive liquid nutrition via a tube into their stomach. The ideal amount of dietary protein to administer is, however, unknown. This large pragmatic trial will inform how much dietary protein these critically ill patients should receive whilst in ICU receiving life support.	Associate Professor Adam Deane	Associate Professor Adam Deane, Professor Marianne Chapman, Professor Sandra Peake, Doctor Lee-Anne Chapple, Associate Professor Jeffrey Pressnell, Professor Rinaldo Bellomo, Professor Paul Young, Doctor Emma Ridley, Doctor Amalia Karahalios, Doctor An Tran-Duy	Targeted competitive	1/02/2022	31/01/2026	Nutrition And Dietetics	Nutritional Physiology	\$	1,992,218.00
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Edith Cowan University	University	WA	A Multicomponent Exercise Medicine Programme in Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy (the EXPAN trial): A Two-armed Phase I Randomised Controlled Trial	Pancreatic cancer has the third lowest survival rate in Australia. Although treatment advances have improved chances of long-term survival in patients with borderline resectable or locally advanced tumours, the rate remains low due to inoperability and poor physical condition after pre-operative therapy. This trial will examine if exercise is feasible to implement during pre-operative therapy and if it is beneficial to patients' physical and mental health as well as their response to treatment.	Professor Dennis Taaffe	Professor Dennis Taaffe, Associate Professor Colin Tang, Professor Daniel Galvas, Professor Robert Newton, Professor Suzanne Chambers, Professor Nigel Spry, Doctor Carolyn McIntyre	Targeted competitive	1/02/2022	31/01/2026	Oncology And Carcinogenesis	Oncology And Carcinogenesis Not Elsewhere Classified	\$	561,910.00
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Monash University	University	VIC	More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT 2 trial	Treatment of multiple myeloma (MM, a blood cancer) is now very complex and costly. However, survival benefits achieved with new therapies in clinical trials are not being seen in clinical practice, in part because many MM patients stop therapy early, often due to side-effects. The MY-PROMPT-2 trial tests whether real-time symptom feedback using patient-reported outcome measures improves duration on treatment, leading to better patient outcomes and more efficient use of these high-cost medicines.	Professor Andrew Spencer	Professor Andrew Spencer, Associate Professor Claudia Rutherford, Associate Professor John Reynolds, Professor Phoebe Ioy Ho, Associate Professor Zoe McQuillan, Doctor Elizabeth Moore, Doctor Tracy King, Professor Erica Wood, Professor Simon Harrison, Doctor Adam Irving	Targeted competitive	1/02/2022	31/01/2027	Oncology And Carcinogenesis	Chemotherapy	\$	1,678,493.00
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Flinders University	University	SA	A randomised controlled trial of Standard Of Care versus RadioAblation in Early Stage HCC (The SOCRATES HCC Study)	This proposed study will investigate the ability of a new radiotherapy technique (SBRT) to treat liver cancer more effectively than current standards of care. Recent advances in radiotherapy techniques have enabled radiotherapy to be delivered more precisely using higher dose but fewer treatment sessions, in a safe way. The current treatments for small liver cancers have some significant problems. We aim to compare this modern radiotherapy technique to the current, invasive standards of care.	Professor Alan Wigg	Professor Alan Wigg, Associate Professor David Pryor, Doctor Katherine Stuart, Associate Professor Helen Le, Professor Stuart Roberts, Professor John Olymki, Jonathan Tibbatts, Professor Jared Martin, Professor Annette Haworth, Professor Richard Woodman	Targeted competitive	1/02/2022	31/01/2027	Oncology And Carcinogenesis	Radiation Therapy	\$	2,352,018.80
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Adelaide	University	SA	HEPATA: Hereditary Pancreatitis and Autoleak Transplant Trials in Australia	The aim of this project is to collect the evidence required for TP-IAT to become a reimbursed medical procedure for the treatment of hereditary pancreatitis (HP). In order to achieve this 24 HP patients will undergo TP-IAT and the impact on disease progression, quality of life, reduction in pain medication, hospitalisations, health costs and economic impacts will be determined. This will allow a formal application to the government for assessment of TP-IAT to become a reimbursed medical procedure.	Professor Patrick Coates	Professor Patrick Coates, Professor Henry Pleakis, Richard Cooper, John Chen, Doctor Santa De Sousa, Mr Sanjeev Khurana, Professor Lyle Palmer, Professor Alex Brown, Associate Professor Natasha Rogers, Professor David Torpy	Targeted competitive	1/02/2022	31/01/2027	Clinical Sciences	Gastroenterology And Hepatology	\$	2,014,561.20
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of Melbourne	University	VIC	Driving functional recovery after spinal cord injury using transcutaneous electrical spinal cord neuromodulation (TESCON)	This project addresses a significant unmet need for people who have lost the use of their arm and hand after spinal cord injury. Regaining this is ranked as their highest priority. An early phase flexible design trial will investigate whether a novel non-invasive method of spinal cord stimulation in early and late stages post-injury improves upper limb function. Recovery of arm and hand function would have a substantial impact on potential for employment, independence and quality of life.	Professor Mary Galea	Professor Mary Galea, Victor Edgerton, Doctor Parag Gad, Professor David Grayden, Associate Professor Andrew Nunn, Doctor Maya Pantsef, Professor Leonid Churilov, Professor James Middleton	Targeted competitive	1/02/2022	31/01/2027	Neurosciences	Central Nervous System	\$	2,038,621.80
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Monash University	University	VIC	REDEM: A Randomised Controlled Trial of ECMO to Desaturate, Extracate Early and Mobilise in severe acute respiratory infection	The EVEREST trial is an Australian-initiated, registry-based, multicentre, randomised controlled trial to determine if early ECMO (with desaturation, early extracorporeal, and mobilisation), in comparison to standard care (including continuing mechanical ventilation), improves key patient centred outcomes, and reduces health care costs. The EVEREST trial is a pivotal study that will guide the treatment of respiratory failure globally - for COVID-19, as well as for future pandemics.	Doctor Aidan Burrell	Doctor Aidan Burrell, Professor David J. Daniel Cooper, Professor Carol Hodgson, Professor John Fraser, Associate Professor Priya Nair, Associate Professor Vincent Pellegrino, Professor Christine McDonald, Doctor Jessica Kassa, Professor Eddy Fan, Professor Andrew Lidy	Targeted competitive	1/01/2022	31/01/2027	Clinical Sciences	Intensive Care	\$	2,534,432.00
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of New South Wales	University	NSW	Improving the lives of people with Phantom Limb Pain - the TITAN trial (graded moTor Imagery for phantom limb pain)	Phantom Limb Pain is the most distressing and disabling of all chronic pain conditions, 75% report suicidal thoughts. No treatment is supported by high quality evidence meaning that people with Phantom Limb Pain have few options for interventions that can be dangerous. We have conducted a series of pilot studies on the most promising non-pharmacological intervention for Phantom Limb Pain. This trial will determine whether this promising intervention is effective for Phantom Limb Pain.	Professor James McAuley	Professor James McAuley, Professor G. Lorimer Moseley, Associate Professor Sylvia Gustin, Professor Rob Jensen, Professor Hens Flax, Associate Professor Natasha Stanton, Doctor Melita Giummarra, Professor Stephen Goodall, Doctor Aidan Cashin	Targeted competitive	1/02/2022	31/01/2027	Clinical Sciences	Clinical Sciences Not Elsewhere Classified	\$	1,531,130.80

Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Monash University	University	VIC	INTER-EWING - 1 - International clinical research program to improve outcomes in newly diagnosed Ewing Sarcoma patients - Trial 1.	Ewing sarcoma (ES) is a rare cancer, which has a dismal survival rate once it has spread (30%) demonstrating an urgent need to improve outcomes. INTER-EWING-1 (a phase III international trial) will investigate the impact of three interventions on survival for all newly diagnosed ES patients: 1. Adding a novel agent to standard chemotherapy 2. Optimising radiotherapy doses 3. Adding extra chemotherapy at the end of treatment. It will open in Australia, New Zealand, United Kingdom and Europe.	Associate Professor Geoffrey McCowage	Associate Professor Geoffrey McCowage, Associate Professor Jayesh Desai, Associate Professor Marianne Phillips, Doctor Jessica Ryan, Professor Angela Hong, Doctor Jeremy Lewis, Doctor Maria Kirby, Professor Bernadette Brennan, Ms Robyn Strong, Associate Professor Paul Stalley	Targeted competitive	1/02/2022	31/01/2027	Oncology And Carcinogenesis	Solid Tumours	\$	998,608.80
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Adelaide	University	SA	REMIT: An international, multi-centre, randomised clinical trial to compare Obinutuzumab + Calcineurin inhibitor to Corticosteroid + Cyclophosphamide treatment regimens in Primary Membranous Nephropathy	Primary Membranous Nephropathy is a kidney disease that causes leakage of protein in the urine and consequently severe swelling of the body. Some patients develop kidney failure. Currently, treatment involves giving corticosteroid and cyclophosphamide. Unfortunately, this treatment has many undesirable side effects. Hence, we need to find better treatment with less side effects. This trial will compare new treatment comprising of obinutuzumab and calcineurin inhibitor to the old treatment.	Professor Chen Au Peh	Professor Chen Au Peh, Doctor Bhadrans Bose, Professor David Johnson, Professor Vivekanand Jha, Professor David Jayne, Doctor Elasma Milanti, Professor Megan Griffith, Professor Jack Wetzels, Doctor Andreas Kronbicher, Doctor Adrian Liew	Targeted competitive	1/01/2022	31/05/2027	Clinical Sciences	Nephrology And Urology	\$	2,904,210.20
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Flinders University	University	SA	Implementing a Nurse-Enabled, Shared-Care Model to Address Unmet Needs of People with Neuroendocrine Tumours: the AUS-NET Trial	People with neuroendocrine tumours have significant unmet care needs and impaired quality of life. This research will implement and evaluate an integrated, shared-care model that provide facilitation and coordination for the optimal involvement of the patient's GP and community health practitioners. This study will improve the quality of life and reduce unmet needs of people with neuroendocrine tumours, with cost effectiveness and implementation learnings to inform future research translation.	Professor Raymond Chan	Professor Raymond Chan, Professor Jon Emery, Professor Michael Jeffery, Doctor Nicolas Hart, Professor Gillian Harvey, Associate Professor David Wild, Doctor David Chan, Professor Michelle Miller, Associate Professor Sanjeeva Kularatna, Miss Lee Jone	Targeted competitive	1/01/2022	31/01/2027	Oncology And Carcinogenesis	Solid Tumours	\$	2,374,220.10
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Monash University	University	VIC	Fibrinogen Early In Severe Trauma Study II (FESTY II)	Yearly, 8000 Australians suffer severe trauma and bleeding caused by trauma is a major cause of death. Trauma results the inability to form clots to stop bleeding. Fibrinogen is a clotting factor that bind clots together. Fibrinogen can be replaced using cryoprecipitate, a frozen blood product made from healthy donors, or fibrinogen factor concentrate which is easier to use and has a long shelf life. FESTY II will investigate fibrinogen replacement in severely injured bleeding trauma patients.	Associate Professor Zoe McQuilten	Associate Professor Zoe McQuilten, Doctor James Winearts, Professor David J. (Jamie) Cooper, Professor Michael Reade, Associate Professor Craig French, Associate Professor Jeffrey Pressnell, Doctor Alisa Higgins, Professor Zohal Balogh, Professor Stephanie Heritier, Professor Erica Wood	Targeted competitive	1/02/2022	31/01/2027	Clinical Sciences	Emergency Medicine	\$	3,162,379.40
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Adelaide	University	SA	The AIRSPACE Trial: Anti-MRSA PhAge Cocktail treatment via Acoustic Enhanced Nebulisers	Previous research in our team has shown promise for the use of bacteriophage, a virus that kills bacteria, for the treatment of infections of the sinuses. However, delivery of bacteriophage to the sinuses using devices, resulting in 97% of phage. This is unacceptable as manufacturing of phage is expensive. In this project we will conduct a trial to see whether treatments with bacteriophage delivered using a specific device is more effective than antibiotics to kill those bacteria.	Professor Peter-John Wormald	Professor Peter-John Wormald, Associate Professor Sarah Vreugde, Professor Alkis Psaltis, Doctor Sandra Porteous Morales, Doctor Ousou Roumegas, Professor Benjamin Cazzolato, Professor Maizur Arjomandi, Doctor Jennie Louise, Ms Camille Schubert	Targeted competitive	1/02/2022	30/06/2026	Clinical Sciences	Otorhinolaryngology	\$	1,712,340.60
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Monash University	University	VIC	SCANPatient: Synoptic reporting of CT scans assessing cancer of the pancreas	There are approximately 4000 people diagnosed with pancreatic cancer (PC) annually in Australia. People with PC are treated according to the extent of their disease at diagnosis. One of the problems that doctors face is adequately distinguishing patients who should receive chemotherapy before surgery versus surgery alone. In this study, we will test whether a structured radiology report can improve the accuracy of reporting of CT scans in PC to optimise care.	Associate Professor Charles Pilgrim	Associate Professor Charles Pilgrim, Associate Professor Samantha Ellis, Associate Professor David Cavallucci, Doctor Mark Goodwin, Professor Neil Merrett, Doctor Jessica Yang, Doctor Lorraine Chantrell, Professor John Zalcberg, Doctor Lane Ioannou, Doctor Jessica Kasza	Targeted competitive	1/02/2022	31/01/2027	Oncology And Carcinogenesis	Cancer Diagnosis	\$	2,970,301.10
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of New South Wales	University	NSW	A Platform trial of combination precision guided therapies for high risk childhood cancer	Zero Childhood Cancer is a world leading program that uses genomic sequencing to identify new treatment strategies for children with the most aggressive cancers. Here we will develop a companion clinical trial which will test new combinations of targeted drugs, to treat high risk childhood cancers based on each child's individual tumour profile.	Associate Professor David Ziegler	Associate Professor David Ziegler, Associate Professor Paul Ebert, Mrs Chelsea Mayoah, Professor Glenn Marshall, Doctor Dong-Anh Khuong-Quang, Professor Michelle Jeffrey, Doctor Marion Mateos, Doctor David Jones, Doctor Cornelis Martinus van Tilburg, Doctor Daniel Morgenstern	Targeted competitive	1/02/2022	31/01/2027	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	1,515,180.00
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of Sydney	University	NSW	LUMOS: Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies	Low and anaplastic grade gliomas are brain tumours that are universally fatal with limited treatment options at recurrence and almost no access to clinical trials. We will perform comprehensive genomic profiling on resected tumour samples and then match them with the best available treatments. Lastly, we will collect an invaluable resource of biological samples before and after treatment for future research into better therapies.	Professor Hui Gan	Professor Hui Gan, Associate Professor Eng-Siew Koh, Professor John Simes, Doctor Subhojit Thakreswaran, Doctor Hao-Wen Sim, Associate Professor Rosalind Jeffery, Associate Professor Craig Gedy, Associate Professor Zarnie Lwin, Associate Professor Benhur Amanuel, Doctor Sonia Yip	Targeted competitive	1/02/2022	31/01/2027	Oncology And Carcinogenesis	Cancer Genetics	\$	1,982,681.32
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Queensland	University	QLD	Optimising Care: Phase III trial in women with metastatic breast cancer to improve quality of life via exercise and diet	Women with metastatic breast cancer (MBC) have a poor prognosis (30% five-year survival) and poor quality of life (QoL). While many programs and services are available to support women with MBC, most are due to a large evidence-base. Few, if any, supportive care interventions are available for women facing a terminal diagnosis of MBC. This world-first trial will evaluate whether an exercise and dietary intervention can improve the QoL of women with MBC compared to current practice.	Professor Marina Reeves	Professor Marina Reeves, Professor Sandra Hayes, Professor Frances Boyle, Professor Gail Garvey, Associate Professor Louise Gordon, Professor Elizabeth Eakin, Doctor Michelle Morris, Associate Professor Nicole McCarthy, Associate Professor Mark Chaffield, Associate Professor Sean Jordan	Targeted competitive	1/02/2022	31/01/2027	Oncology And Carcinogenesis	Oncology And Carcinogenesis Not Elsewhere Classified	\$	2,044,955.10
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Queensland	University	QLD	An early phase, open label, multi-centre trial of front line therapy for EBV-associated lymphomas – TREBL-2	In this ground-breaking Australasian Leukaemia Lymphoma Group Phase 1 study, we will use front line immunotherapy in an innovative trial that targets the unique viral-immuno biological features of a rare but devastating type of rarely driven lymphoma. It is called 'EBV-associated Diffuse large B-cell lymphoma'. The aim of our proposal is to provide a highly targeted but relatively well-tolerated therapy, that eradicates disease and prevents relapse by restoring immunity.	Professor Maher Gandhi	Professor Maher Gandhi, Associate Professor Emily Blyth, Doctor Colin Keane, Doctor Piers Blombery, Associate Professor Tara Ochrane, Doctor Anna Johnstone, Associate Professor Gunter Hartel, Doctor Alexandre Cristiano, Associate Professor Ann-Marie Patch	Targeted competitive	1/01/2022	31/01/2027	Oncology And Carcinogenesis	Haematological Tumours	\$	2,844,744.60
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of Melbourne	University	VIC	Eliminating HIV that persists on antiretroviral therapy through treatment with the BCL-2 antagonist, venetoclax	The main barrier to curing HIV is persistence of the virus in a latent for in long-lived cells. This is partly driven by changes in cell death pathways, which can be targeted with venetoclax, a drug recently approved for cancer treatment. We aim to establish safety of venetoclax in people living with HIV without cancer and determine whether venetoclax can eliminate HIV infected cells. This will clarify whether venetoclax may contribute to a safe and effective cure for HIV.	Professor Sharon Lewin	Professor Sharon Lewin, Associate Professor Thomas Rasmussen, Professor Marc Pellegrini, Associate Professor James McMahon, Professor Andrew Roberts, Associate Professor Daniel Gray	Targeted competitive	1/01/2022	31/01/2025	Clinical Sciences	Infectious Diseases	\$	1,400,752.00
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Murdoch Children's Research Institute	Medical Research Institute	VIC	Is oral antibiotic treatment alone non-inferior to standard care for children with bone and joint infections?	Bone and joint infections are common in children and can lead to severe disability. Usually these infections are treated with antibiotics given through the child's vein for a few days followed by antibiotics given by mouth. This research will find out if giving antibiotics just by mouth works as well as the current treatment. If it does, it would prevent the risks of giving antibiotics through the vein and, importantly, allow children to have all their treatment at home.	Associate Professor Amanda Gwee	Associate Professor Amanda Gwee, Professor Nigel Curtis, Professor Franz Babi, Professor Cheryl Jones, Associate Professor Asha Brown, Professor Stephen Duffell, Associate Professor Catherine Sattler, Doctor Brendan McMillan, Doctor Anna Grobler, Doctor Li Huang	Targeted competitive	1/02/2022	31/01/2026	Paediatrics And Reproductive Medicine	Paediatrics	\$	1,230,723.80
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Queensland University of Technology	University	QLD	Improving clinical outcomes for children and adults with bronchiectasis: a multi-centre randomised controlled trial using a novel mucolytic with a discovery biomarker	We plan a study that looks at a novel therapy, erdostrine, for children/young adults with bronchiectasis (BE). Our study addresses several unmet needs as they are no current therapies (other than antibiotics) for children with BE. Our goal is to improve the outcomes of children/young adults with BE by using erdostrine and understanding underlying causes and contributors to acute disease flare-ups. Our study, informed by consumers, will improve the future outcomes of people with BE if successful.	Professor Anne Chang	Professor Anne Chang, Professor Keith Grimwood, Professor Allan Cripps, Professor Steven McPhail, Associate Professor Lucy Morgan, Associate Professor Julie Marchant, Associate Professor Lucy Burr, Associate Professor Mark Chaffield, Doctor Vikas Goyal, Associate Professor Andre Schultz	Targeted competitive	1/02/2022	31/01/2027	Cardiorespiratory Medicine And Haematology	Respiratory Diseases	\$	2,069,492.72
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Monash University	University	VIC	Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (CAPPOS): multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery	Infections following surgery lead to significant patient suffering and healthcare costs. The administration of antibiotics at the time of surgery is an important strategy to prevent infections. In patients undergoing heart surgery we do not know whether there is an additional benefit to giving longer courses of antibiotics following surgery to help prevent infections or if this will lead to patient harm, such as drug-resistant infections. This project will answer these important questions.	Associate Professor Trisha Peel	Associate Professor Trisha Peel, Professor Paul Myles, Professor David McGiffin, Professor Julian Smith, Professor Andrew Forbes, Professor Silvana Mirasol, Professor David Pitcher, Associate Professor Andrew Stewardson, Associate Professor Dennis Petrie, Professor Anton Peleg	Targeted competitive	1/02/2022	31/05/2027	Clinical Sciences	Infectious Diseases	\$	7,979,999.10
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of Melbourne	University	VIC	Accelerating clot lysis in ischemic stroke with Denagase with an Umbrella Bayesian Optimised Phase 2 trial	Stroke remains a major cause of disability. Clot-dissolving medicines targeting fibrin can be rapidly delivered at most Australian hospitals. DNA extruded by white blood cells is another key structural component of clot. Denagase, an approved medicine for other diseases, dissolves DNA and we showed accelerated clot dissolving when combined with standard treatment. Our trial will test whether denagase can accelerate restoration of blood flow to improve outcomes in up to 300 patients with stroke.	Professor Bruce Campbell	Professor Bruce Campbell, Professor Leonid Churilov, Professor Robert Medcalf, Doctor Fana Alkermesh, Professor Timothy Heneghan, Professor Helen Dewey, Doctor Candice Decourt, Professor Peter Mitchell, Professor Geoffrey Donnan, Professor Stephen Davis	Targeted competitive	1/02/2022	31/01/2026	Neurosciences	Central Nervous System	\$	1,453,336.70
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of Melbourne	University	VIC	Look before you leap: How transthoracic ECHOCardiography before fractured Neck Of Femur saves lives in frail older people – the proposed Pragmatic ECHONOF III trial	Hip fracture surgery is a major world health care burden that is worsening as the average age increases, causing major suffering to the patients and their families. This randomised controlled trial will confirm whether or not our preliminary studies are correct which have suggested that an ultrasound of the heart performed before hip fracture surgery results in saving lives and reducing health care costs. Bedside ultrasound results in increased effectiveness of care of these very frail patients.	Professor Colin Royle	Professor Colin Royle, Associate Professor David Camy, Professor Alistair Royle, Professor Andre Demaut, Associate Professor Dina LoGiudice, Associate Professor David Eccleston, Doctor Andrea Bowyer, Professor Daniel Sessler, Doctor Sandy Clarke-Errey, Professor Andrew Palmer	Targeted competitive	1/02/2022	31/01/2027	Clinical Sciences	Surgery	\$	3,686,076.20
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Queensland	University	QLD	SWIMS - Schizophrenia Weights, Metformin and Semaglutide: A double blind double dummy placebo controlled multi-centre RCT	Antipsychotics are the mainstay of treatment for schizophrenia. However, antipsychotics are linked with obesity and diabetes, which increase the risk of heart disease. Our preliminary research suggests that the diabetes drug semaglutide and metformin can reduce antipsychotic-related obesity. We now propose to undertake a rigorous multi-site national clinical trial, to establish the role of semaglutide and metformin in meaningfully reducing weight among these people taking antipsychotics.	Professor Dan Skidnd	Professor Dan Skidnd, Associate Professor Anthony Russell, Professor Michael Berk, Professor Alison Yang, Professor Anthony Hart, Doctor Julia Lapin, Professor Steve Kisely, Associate Professor Klaus Oliver Schubert, Doctor Mahesh Jayaram, Doctor Urska Arnautovska	Targeted competitive	1/01/2022	31/01/2028	Clinical Sciences	Psychiatry (Ind. Psychotherapy)	\$	3,839,117.60

Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Queensland	University	QLD	The Siročán study: A multi-centre randomised double blind placebo-controlled trial of 1% topical sirolimus in the chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients	Upon receiving an organ transplantation, recipients are at very high risk of skin cancer. This can lead to hundreds of surgeries to the death of the patient. This clinical trial proposes to explore topical sirolimus, a cream commonly used for other indication, in this setting to reduce the burden of disease. This will provide transplant recipients at risk of skin cancer with a viable option to reduce the morbidity of the disease as well as the cost burden.	Professor Kiarash Khoursethrani	Professor Kiarash Khoursethrani, Associate Professor Scott Campbell, Professor Daniel Chambers, Associate Professor Louisa Gordon, Professor Angela Webster, Associate Professor Victoria Mar, Professor Diana Damian, Alvin Chong, Associate Professor Helmut Schaidler, Doctor Nicole Isabel	Targeted competitive	1/02/2022	31/01/2027	Clinical Sciences	Dermatology	\$	2,486,489.20
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of New South Wales	University	NSW	4CAST: A phase IIb study evaluating the safety and efficacy of VT-464 in combination with chemotherapy in patients with metastatic breast cancer	With no curative therapies for patients with treatment refractory triple-negative breast cancer, there is an urgent need to develop new therapeutic strategies to improve survival outcomes. We discovered that blocking the androgen receptor prevents and treats chemotherapy-resistant triple-negative breast cancer. When combined with chemotherapy, overall survival is significantly improved in pre-clinical models. We have now developed a clinical trial to test this new therapy in the clinic.	Associate Professor Christine Chaffer	Associate Professor Christine Chaffer, Associate Professor Anthony Iozhva, Doctor Rachel Dear, Professor Frances Boyle, Doctor Leonard Goldstein	Targeted competitive	1/01/2022	31/12/2024	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	668,444.00
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of Melbourne	University	VIC	Addressing the poor outcomes of young women with hormone receptor-positive, HER2-negative (HR+/HER2-) early breast cancer	Young women diagnosed with breast cancer have a higher rate of recurrence and death from breast cancer. The reasons for this are until now unknown. We have previously conducted a genomic analysis of 1293 breast cancer samples diagnosed from young women.	Professor Sherene Loi	Professor Sherene Loi, Professor Prudence Francis, Professor Stephen Fox, Associate Professor Nicholas Wilcken, Associate Professor Nicole McCarthy, Associate Professor Andrew Redfern, Doctor Nicholas Zdenkowski	Targeted competitive	1/01/2022	31/12/2026	Oncology And Carcinogenesis	Oncology And Carcinogenesis Not Elsewhere Classified	\$	4,909,215.00
Clinical Trials Activity	2022 International Clinical Trial Collaborations (Round 22.1)	Monash School of Health Research	Medical Research Institute	NT	Neonatal probiotics to prevent early-onset acute respiratory infections (ARIs) in high-risk children: A multisite randomised controlled trial (RCT)	Acute respiratory infections (ARIs) are a leading cause of hospitalisation and preventable death among Aboriginal infants. The first microbes encountered by the infant gut shape systemic immune development and future susceptibility to infection. Through an international partnership, we propose a randomised controlled trial to determine if neonatal probiotics can reduce the risk of ARI in the first year of life. Secondary aims will evaluate safety, the gut microbiome and immune development.	Doctor Michael Blinks	Doctor Michael Blinks, Professor Peter Morris, Associate Professor Peter Richmond, Ms Amy Bleskeley, Professor Anne Chang, Professor Mike Taylor, Doctor Celestine Aho, Professor William Pomat, Doctor Dennis Bonney, Doctor Anita van den Biggelaar, Doctor Robyn Marsh, Ms Adrienne Kirby	Targeted competitive	1/02/2023	31/01/2028	Health Sciences	Health Sciences, Public Health, Preventative Health Care, Indigenous Studies, Aboriginal and Torres Strait Islander Health And Wellbeing, Aboriginal and Torres Strait Islander Child Health And Wellbeing, Indigenous Studies, Pacific Peoples Health And Wellbeing, Pacific Peoples Mothers And Babies Health And Wellbeing	\$	2,428,288.66
Clinical Trials Activity	2022 International Clinical Trial Collaborations (Round 22.1)	University of New South Wales	University	NSW	Strategies and Treatments for Respiratory Infections and Viral Emergencies (STRIVE)	Despite highly active treatments for people with early COVID-19 infection, therapies for people who have severe disease are much less effective. A global master platform study called STRIVE has commenced to study the most effective treatments and strategies in people who are hospitalised with severe respiratory illness. The first trial in this platform will study a novel antiviral drug for COVID-19. This application aims to support ten Australian sites to join this new international network.	Professor Gail Matthews	Professor Gail Matthews, Professor Mark Boyd, Associate Professor Janine Trevillyan, Associate Professor Stuart Turville, Doctor Susan Maddocks, Associate Professor James Robinson, Doctor Nila Dharan, Associate Professor Bridget Barber, Professor Gregory Dore, Associate Professor Benjamin Rogers, Associate Professor Claudia Dabler, Professor Anthony Kelleher, Associate Professor James McMahon, Professor Steven Tong, Professor Virginia Wieman	Targeted competitive	1/02/2023	31/01/2027	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Infectious Diseases	\$	1,993,166.40
Clinical Trials Activity	2022 International Clinical Trial Collaborations (Round 22.1)	Western Sydney University	University	NSW	Title Closed-loop Insulin delivery by glucose Responsive ComPUter algorithms in Type 1 diabetes pregnancies (CIRCUIT)	Many (>50%) newborns of pregnant women with type 1 diabetes (T1D) are harmed by abnormal glucose exposure in the womb. With Canadian researchers, we will randomly assign women to use a new automated insulin delivery approach or standard insulin delivery and test whether blood glucose is improved, birth complications reduced and diabetes self-care demands lessened. Findings could result in more effective and easier ways for women with T1D to have healthier pregnancies and children.	Professor David Simmons	Professor David Simmons, Doctor Sarah Pries, Associate Professor Glyris Ross, Doctor Waddad Tannous, Doctor Ariane Sweeting, Professor Dhammitra Pasupathy, Professor Christopher Nolan, Doctor Melinda Morrison, Ms Simone Marschner, Professor Ngai Cheung Renza Schilla, Professor Denise Feig, Mrs Romina Zappulla, Professor Lois Fitzmaurice	Targeted competitive	1/02/2023	31/01/2026	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Clinical Sciences, Endocrinology, Biomedical And Clinical Sciences, Medical Biotechnology, Medical Biotechnology Not Elsewhere Classified, Biomedical And Clinical Sciences, Reproductive Medicine, Obstetrics And Gynaecology	\$	763,386.00
Clinician Researchers	2017 Next Generation Clinical Researchers	Australian National University	University	ACT	Implementation of a peer worker-led mental health recovery program	Australia faces a shortage of mental health services and mental health workers. In particular, there is a lack of clearly embedded roles for people who have a lived experience of mental health issues, peer workers. Peer workers have a unique role, connecting with people experiencing mental health issues to promote recovery. This project will evaluate a trial of a peer worker-led group recovery program in Australia.	Doctor Michelle Barfield	Not applicable	Targeted or restricted competitive	1/07/2018	30/06/2021	Public Health And Health Services	Mental Health	\$	179,118.00
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Melbourne	University	VIC	Improving patient management pathways in age-related macular degeneration	Age related macular degeneration (AMD) is the most common cause of vision impairment in Australians aged over 50 years. In recent years, there have been a number of diagnostic tests and new interventions developed for AMD, but it has proven challenging to communicate this information to all primary eye care practitioners. This project will investigate the reasons management guidelines are not always being followed, and develop online training to provide direct bench-to-bedside AMD education.	Doctor Lauren Ayton	Not applicable	Targeted or restricted competitive	1/04/2019	30/09/2021	Ophthalmology And Optometry	Ophthalmology	\$	179,118.00
Clinician Researchers	2017 Next Generation Clinical Researchers	Flinders University	University	SA	Enhancing the capacity of mental health services to review, personalise and intervene early through implementation of real-time outcome monitoring	By monitoring functioning and symptom changes experienced by severe mental illness patients in their living environments, mental health services can identify those experiencing decline earlier and hence deliver appropriate and timely interventions. However, monitoring is currently poorly implemented in Australian mental health services and inadequately supported by national policy. The applicant proposes to address this evidence-practice gap through a mobile phone-based monitoring system.	Associate Professor Niranjan Bidargadi	Not applicable	Targeted or restricted competitive	16/01/2018	31/12/2021	Public Health And Health Services	Mental Health	\$	179,118.00
Clinician Researchers	2017 Next Generation Clinical Researchers	Flinders Institute of Neuroscience and Mental Health	Medical Research Institute	VIC	Mild traumatic brain injury and the risk of long-term neurodegenerative and neurobehavioural disease	Considerable media attention surrounds the potential for long-term problems in individuals with high exposure to head impacts such as seen in sporting, civilian and/or military contexts. This study examines the long-term effects of mild traumatic brain injury (mTBI) and helps close the current knowledge gap of the impact of this disorder on individuals. There are no long term trials to answer the critical question of whether mild TBI causes long term problems in the brain.	Associate Professor Paul McCrory	Not applicable	Targeted or restricted competitive	22/03/2018	31/12/2022	Neurosciences	Central Nervous System	\$	577,188.50
Clinician Researchers	2017 Next Generation Clinical Researchers	The Garvan Institute of Medical Research	Medical Research Institute	NSW	Improving outcomes in osteoporosis and bone health	Osteoporotic fractures are a common and increasing problem as the population ages. They are associated with increased risk of re-fracture and early death yet most patients remain untreated. This proposal will identify which fracture patients are at highest risk of re-fracture and premature death (b) identify whether osteoporosis treatment decreases this risk and (c) increase osteoporosis awareness and treatment uptake by general practitioners with an integrated fracture risk prediction tool.	Professor Jacqueline Center	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2022	Clinical Sciences	Endocrinology	\$	343,682.50
Clinician Researchers	2017 Next Generation Clinical Researchers	La Trobe University	University	VIC	Implementing appropriate exercise and education for Australians with knee osteoarthritis	Knee osteoarthritis (OA) affects 4% of the population. It is effectively treated with physiotherapy led exercise and education. Most Australian's with OA do not receive these treatments, and many physiotherapists lack the required knowledge and capability to provide exercise and education. I will develop a program involving workshops and online resources to teach physiotherapists how to provide exercise and education to knee OA patients, and support patients with online education resources.	Doctor Christian Barton	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2022	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	179,118.00
Clinician Researchers	2017 Next Generation Clinical Researchers	Monash University	University	VIC	Cognitive Phenotyping and Personalised Treatment for Methamphetamine Addiction	Prevention and treatment of addiction to stimulants such as methamphetamine is imperative for community health and safety. This fellowship will enable me to apply my expertise in impulsivity and addiction to identify people at risk of increasing methamphetamine use and to develop and evaluate cognitive training therapies that will empower people with methamphetamine related problems to control their drug use. Outcomes include a risk identification and triage tool and three novel therapies.	Associate Professor Antonio Verdejo-Garcia	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2021	Psychology	Biological Psychology (Neuropsychology) Psychopharmacology, Physiological Psychology	\$	476,728.00
Clinician Researchers	2017 Next Generation Clinical Researchers	Monash University	University	VIC	Generating and translating evidence into practice in women's health and beyond	Obesity is increasing with major reproductive and metabolic health impacts for women and the next generation. This fellowship focuses on prevention of obesity and optimal diagnosis and management of obesity related reproductive and metabolic conditions in women including before and during pregnancy. Translation is vital to deliver health benefits from research. Here Professor Teede will generate new evidence and translate this into practice in women's health and beyond to deliver tangible impact.	Professor Helena Teede	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2022	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	494,733.00
Clinician Researchers	2017 Next Generation Clinical Researchers	Monash University	University	VIC	Improving outcomes for critically ill patients after traumatic brain injury and blood transfusion	The Fellowship will support an academic clinician to lead the Alfred Intensive Care Department, and the Monash ANZIC Research Centre. Two pivotal NMBAC supported clinical trials, led by the Fellow, are each the largest and most definitive trials in their fields, and will complete during Fellowship and provide extensive data for research outputs. Concurrently, a new research program to improve patients function and quality of life after critical illness, will be supported.	Professor David Cooper	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2022	Clinical Sciences	Intensive Care	\$	412,277.50
Clinician Researchers	2017 Next Generation Clinical Researchers	Monash University	University	VIC	Improving outcomes in low back pain: Targeting specific therapies to patient subgroups	Low back pain is a major health problem worldwide. There is a lack of effective treatments and a "one size fits all" approach to treatment is being used. This innovative research program aims to change the way back pain is treated, by identifying specific types of back pain, determining the effectiveness of treatments for these types of back pain, and translating a targeted approach to management into clinical practice to improve the health of individuals with back pain.	Doctor Donna Urquhart	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2023	Clinical Sciences	Clinical Sciences Not Elsewhere Classified	\$	429,055.20
Clinician Researchers	2017 Next Generation Clinical Researchers	Monash University	University	VIC	Novel targeted onco-therapeutic nanoparticles for personalised therapy and real-time monitoring	I will develop novel specific cancer therapies using next generation nanoparticles. These particles will deliver highly potent drugs to cancerous tissue avoiding damage to healthy organs. My project has the potential to increase the quality of life and survival of patients suffering from the most invasive/malignant cancers, including breast and prostate cancer.	Doctor Karen Alt	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2021	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	431,000.00
Clinician Researchers	2017 Next Generation Clinical Researchers	Monash University	University	VIC	Optimising Emergency and Trauma Systems through evidence based pathways	Developing systems for emergency and trauma care based on strong evidence and robust data systems is crucial to the acute health sector. Through an extensive, well recognised collaboration of research groups at The Alfred, Monash and the National Trauma Research Institute, we aim to undertake world leading systems development both locally and globally, focusing on prehospital, emergency and trauma clinical care pathways significantly reducing mortality and improving functional outcomes.	Professor Peter Cameron	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2022	Public Health And Health Services	Health And Community Services	\$	412,277.50

Clinician Researchers	2017 Next Generation Clinical Researchers	Monash University	University	VIC	Precision medicine for epilepsy and beyond: from discovery to implementation and evaluation	The theme of this Fellowship is to improve treatment outcomes using a genomic-based Precision Medicine approach. This goal will be achieved by 3 closely linked projects that harness the power of gene sequencing and advances in bioassay technology, coupled with careful clinical and health economic evaluation. While the emphasis is on epilepsy, the research will extend to other major disease areas of global health significance. The potential socioeconomic impact of these innovations is enormous.	Professor Patrick Kwan	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2022	Neurosciences	Central Nervous System	\$	481,155.50
Clinician Researchers	2017 Next Generation Clinical Researchers	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	Translational Research Program to Advance Clinical Outcomes in Acute Myeloid Leukaemia	Five-year survival in acute myeloid leukaemia (AML) is only 27%, placing it amongst the worst-ranked cancers for clinical outcome. Improved patient outcomes will be achieved through implementation of a Translational Research Program to support novel agent drug testing, early phase and randomised clinical trials and a national clinical registry to audit outcomes. New insights into leukaemic stem cell function and mechanisms of drug resistance will inform the design of future clinical trials.	Associate Professor Andrew Wei	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2022	Oncology And Carcinogenesis	Haematological Tumours	\$	412,419.00
Clinician Researchers	2017 Next Generation Clinical Researchers	Murdoch Children's Research Institute	Medical Research Institute	VIC	Improving the health and development of high risk preterm newborns	Preterm children have more health and developmental problems than those born full term. Although we know the problems faced by those tiniest and most immature, more questions remain. What problems do they face as adults? What new treatments are available to improve their outcomes? Are the more "mature" preterms at risk as well? My research program aims to address these questions through the efforts of the Victorian Infant Collaborative Study team, a large research team that I lead.	Associate Professor Jeanie Cheong	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2021	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine Not Elsewhere Classified	\$	333,709.60
Clinician Researchers	2017 Next Generation Clinical Researchers	Murdoch Children's Research Institute	Medical Research Institute	VIC	Improving upper limb function in Hereditary Cerebellar Ataxia	Friedreich ataxia (FRDA) causes incoordination and muscle weakness which may result in the affected person being unable to walk or use their arms effectively. Incoordination is a result of destruction of nerves in the spine and the area of the brain that controls movement (cerebellum). This study will assess the use of brain stimulation to improve coordination and function in people with FRDA. The results of this study may also result in treatments for similar inherited cerebellar ataxias.	Doctor Louise Corben	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2022	Neurosciences	Neurology And Neuromuscular Diseases	\$	431,000.00
Clinician Researchers	2017 Next Generation Clinical Researchers	Murdoch Children's Research Institute	Medical Research Institute	VIC	Significance of low-level mosaicism to intellectual disability in paediatric disorders	My vision for the next 4 years is to improve outcomes for children and their families with inherited disorders associated with intellectual disability (ID) and autism through earlier diagnosis and intervention. This is of great importance with annual costs of ID close \$14.72 billion to the Australian health system, and missed or delayed diagnoses being a significant problem, as ID is found in 1.7% of births, where a specific cause is currently identified in less than half.	Doctor David Godler	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2021	Genetics	Epigenetics (incl. Genome Methylation And Epigenomics)	\$	476,728.00
Clinician Researchers	2017 Next Generation Clinical Researchers	The University of Queensland	University	QLD	Personalised early detection of melanoma	The incidence of melanoma in Australia continues to increase, with Queensland having the highest incidence worldwide. This research uses latest advances in genomics, imaging technologies and microscopy devices to develop a personalised screening program for high-risk individuals, with the aim of improving early detection, and reducing the burden of melanoma.	Professor H. Peter Soyer	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2022	Clinical Sciences	Dermatology	\$	577,188.50
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Melbourne	University	VIC	Closing the communication gap in chronic disease	Some patients with chronic disease struggle to look after their condition at home. An educational approach called teach-back has been shown to improve people's understanding of how to manage their condition. Teach-back is not commonly used in Australia, but is recommended by key policy documents. This project will develop and test a process for integrating teach-back into pre-discharge care of hospital patients with chronic conditions, by training nurses to act as teach-back mentors.	Doctor Alison Beauchamp	Not applicable	Targeted or restricted competitive	1/02/2018	31/01/2020	Nursing	Clinical Nursing: Secondary (Acute Care)	\$	179,118.00
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Melbourne	University	VIC	Elimination of Hepatitis C Virus (HCV) as a Public Health Threat	This Practitioner Fellowship will support studies that will contribute directly to the efforts to eliminate HCV infection from Australia. The research program aims to reduce transmission of HCV infection by evaluating the best models of care for i) engaging and treating high risk individuals with HCV infection, including people who inject drugs and prisoners, ii) preventing reinfection with HCV, and iii) re-treatment of individuals who fail treatment due to drug resistance.	Professor Alexander Thompson	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2022	Clinical Sciences	Gastroenterology And Hepatology	\$	481,155.50
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Melbourne	University	VIC	Examining new treatments and developing new treatment biomarkers for youth with severe depression	Antidepressant medications and psychotherapy have been the mainstays of depression treatment in young people, but given their modest effectiveness, there is a pressing need for new treatment strategies. During this fellowship I aim to examine better treatments for depression, and develop better predictors about who is likely to benefit from them.	Associate Professor Christopher Davey	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2021	Clinical Sciences	Psychiatry (Ind. Psychotherapy)	\$	333,709.60
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Melbourne	University	VIC	Neuroimaging in mental health: the quest for clinically useful biomarkers	To ultimately improve treatment of mental illness, this research program aims to detect robust and reliable neuroimaging markers that are associated with affective disorders by pooling data from many samples across the world. Moreover, this research aims to develop alternative biological-based classifications of mental illness in young people, and evaluate their clinical value by examining their predictive value for treatment response and disease course.	Assistant Professor Lianne Schmaal	Not applicable	Targeted or restricted competitive	1/01/2018	30/04/2022	Clinical Sciences	Psychiatry (Ind. Psychotherapy)	\$	431,000.00
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Melbourne	University	VIC	Optimising interventions for Staphylococcus aureus and skin infections	Staphylococcal and streptococcal infections are major causes of illness and death, particularly in Indigenous Australians. These include invasive bloodstream infections and skin infections that lead to chronic kidney and heart disease. I will conduct clinical trials to optimise the management of staphylococcal bloodstream infections using novel trial methods, and use genomics and mathematical modelling to understand and reduce the burden of skin infections in Indigenous communities.	Associate Professor Steven Tong	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2021	Clinical Sciences	Infectious Diseases	\$	333,709.60
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Melbourne	University	VIC	Precision therapy for neurological diseases	Multiple sclerosis is the most common cause of neurological disability among young adults. The patients' individual response to therapy is highly variable. The research vision completed during this Fellowship will generate novel evidence enabling individually-tailored research of multiple sclerosis. Through the newly established Clinical Outcomes Research Unit at the Royal Melbourne Hospital, the expertise from observational data in multiple sclerosis will be applied in other areas of neurology.	Doctor Tomas Kalincik	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2021	Neurosciences	Neurology And Neuromuscular Diseases	\$	476,728.00
Clinician Researchers	2017 Next Generation Clinical Researchers	University of New South Wales	University	NSW	Catch them when they fall: Providing best evidence care after a suicide attempt	A previous suicide attempt is the strongest predictor of death by suicide. There is a strong evidence base for the key changes required to care after a suicide attempt: implementing evidence-based care is estimated to reduce suicide attempts at the population level by approximately 12%. Yet this is an area of health services that has been difficult to reform. This project is aimed at implementing best-evidence practice in four regions of NSW, where I have established partnerships.	Doctor Fiona Shand	Not applicable	Targeted or restricted competitive	1/01/2018	29/02/2020	Public Health And Health Services	Mental Health	\$	179,118.00
Clinician Researchers	2017 Next Generation Clinical Researchers	University of New South Wales	University	NSW	Determinants of the outcomes from infectious diseases	This Fellowship will allow Professor Lloyd to continue clinical and laboratory research in two areas: firstly, in relation to prevention of transmission of hepatitis C infection, and scale up of antiviral treatments, particularly amongst prisoners. Secondly, in studies investigating the biological basis of chronic fatigue states following acute infection or cancer treatment, and also in development of effective treatment for chronic fatigue states.	Professor Andrew Lloyd	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2022	Clinical Sciences	Infectious Diseases	\$	577,188.50
Clinician Researchers	2017 Next Generation Clinical Researchers	The University of Newcastle	University	NSW	Discovery to therapy implementation in acute stroke	Advances in acute stroke therapies are occurring rapidly but challenges remain in their safe and effective delivery to stroke sufferers. This research focuses on testing a potentially superior 'clot busting' drug therapy for acute stroke and on identifying reasons why one of the most widely used current therapies carries a risk of significant harm due to bleeding into the brain. The work also investigates how to better implement the newest form of acute therapy, mechanical blood clot extraction.	Professor Christopher Levi	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2022	Neurosciences	Neurology And Neuromuscular Diseases	\$	577,188.50
Clinician Researchers	2017 Next Generation Clinical Researchers	University of New South Wales	University	NSW	Improving internet-delivered psychological therapies for depression and anxiety	Depression and anxiety affect 3 million Australians. While effective psychological treatments exist, even the best only help 50% recover, and relapse is common. My research aims to improve the treatment of adult depression and anxiety, through developing more effective, efficient and accessible internet-delivered psychological therapies and identifying the conditions that promote optimal long-term outcomes.	Doctor Jill Newby	Not applicable	Targeted or restricted competitive	21/03/2018	31/12/2021	Psychology	Health, Clinical And Counselling Psychology	\$	431,000.00
Clinician Researchers	2017 Next Generation Clinical Researchers	University of New South Wales	University	NSW	Reducing the burden of dialysis catheter complications - a national approach	Kidney disease patients on dialysis are especially susceptible to infections due to their frequent use of healthcare services, their immune deficient state and their exposure to dialysis catheters. My project is the basis of a national initiative to reduce the burden of dialysis catheter associated bacteraemia, the most expensive healthcare acquired infection in the highest risk patient group, and drive savings of life and money.	Doctor Sadra Kotwal	Not applicable	Targeted or restricted competitive	10/05/2018	31/03/2020	Other Medical And Health Sciences	Medical And Health Sciences Not Elsewhere Classified	\$	179,118.00
Clinician Researchers	2017 Next Generation Clinical Researchers	University of New South Wales	University	NSW	Sepsis Outcomes Research	Sepsis is a major cause of hospitalization and ICU admission in Australia population corresponding to more than 15700 new cases each year. Every year more than 3000 people die from sepsis in Australia which is greater than the annual national road toll and breast, prostate or colorectal cancer. The research outlined in this proposal to study the effect of steroids and vitamin D to improve patient's recovery from sepsis and also understand the genetic basis behind their ability to survive sepsis.	Professor Bala Venkatesh	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2022	Clinical Sciences	Intensive Care	\$	278,795.25
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Sydney	University	NSW	Understanding and optimising the delivery of chronic disease care for better cardiovascular outcomes	The proposed research program will undertake research that utilises existing clinical information and structures. This information will provide evidence in a cost effective manner. A particular project will examine current treatment delivered to people with chronic disease. A second project will embed a study of the optimum level of sodium exposure in dialysis within routine clinical practice. The outcome will be a cost-efficient study that will potentially lead to improve outcomes.	Associate Professor Meg Jardine	Not applicable	Targeted or restricted competitive	21/03/2018	31/12/2021	Clinical Sciences	Nephrology And Urology	\$	476,728.00
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Sydney	University	NSW	Decreasing unnecessary surgery for low back pain	Low back pain affects one in four people in Australia and is responsible for over \$8 billion spent on treatments and work loss every year. Surgery is a popular treatment approach for this multifactorial condition but we still lack high quality science to support the role of surgery for low back pain. We also lack research capacity in this field. In my Fellowship, I propose to conduct high quality studies to generate and implement scientific knowledge in this field.	Associate Professor Manuela Ferreira	Not applicable	Targeted or restricted competitive	21/03/2018	31/12/2021	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	476,728.00

Clinician Researchers	2017 Next Generation Clinical Researchers	University of Sydney	University	NSW	Improving health outcomes for disadvantaged children	I am a paediatrician researcher dedicated to improving health and quality of life for ill and disadvantaged children. The focus of my Fellowship will be research in three areas: rare childhood diseases, fetal alcohol spectrum disorder, and vaccine-preventable disease, with attention to diagnosis, treatment and prevention. Alignment of my research and clinical work and my experience in evidence-based medicine will facilitate adoption of my research into clinical care and health policy.	Professor Elizabeth Elliot	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2022	Paediatrics And Reproductive Medicine	Paediatrics	\$	577,188.50
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Sydney	University	NSW	Vaccine safety research in understudied and at risk groups: critical knowledge to inform practice and policy	Vaccines are typically given to healthy individuals and therefore safety issues loom high on the list of public concerns. Vaccine hesitancy due to safety concerns is an issue of increasing global interest and threatens to lower vaccine uptake. My research aims to understand why some people experience adverse reactions to vaccines, do genetic markers exist? what are the long term outcomes of a vaccine reaction and how best to communicate vaccine risk/safety to the Australian community.	Associate Professor Nicholas Wood	Not applicable	Targeted or restricted competitive	21/03/2018	31/12/2021	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine Not Elsewhere Classified	\$	286,036.80
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Tasmania	University	TAS	Improving musculoskeletal pain by matching the right treatment with the right patient	Musculoskeletal pain is common, disabling, and costly in Australia. Current treatment options are poor. This program of research uses clinical trials to investigate new therapy options for osteoarthritis and chronic low back pain. These studies aim to provide new effective treatment options for patients that can improve pain, slow joint damage and decrease the overall burden of musculoskeletal disease.	Doctor Dawn Aitken	Not applicable	Targeted or restricted competitive	21/03/2018	31/12/2023	Clinical Sciences	Rheumatology And Arthritis	\$	431,000.00
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Tasmania	University	TAS	Sustaining oral and systemic health in Residential Aged Care Facilities	Poor oral health is associated with many health problems. Community of Practice members will educate nurse-carer champions who then train direct care staff. The care staff will oversee 2-minutes of teeth cleaning after meals using regular or timed electric toothbrushes, or daily denture care. There will be audits of daily oral care by nurse-carer champions assisted by students, examination of used toothbrushes, regular analyses of gum-based oral bacteria.	Associate Professor Leonard Crocombe	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2019	Public Health And Health Services	Aged Health Care	\$	179,118.00
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Western Australia	University	WA	Developing personalised treatment for retinal degeneration	Dr Chen seeks a clinical CDFI to support his ambition in combining his expertise in clinical management of retinal diseases with a growing track record of clinical trials and laboratory science to develop treatment for retinal degeneration. This is achieved through a patient-centred translational platform that he has established. In the next 5 years, He will identify the most suitable method for measuring progression and develop personalised therapy for a phase I clinical trial.	Doctor Fred Chen	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2021	Ophthalmology And Optometry	Ophthalmology	\$	258,600.00
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Western Australia	University	WA	Nutritional strategies for allergy prevention	Allergic disease affects more than one in five Australian children. What foods a mother eats during pregnancy and breastfeeding, as well as when to introduce solid foods to babies, is thought to be critical in reducing the increasing burden of allergy in our Australian community. I hope to use this Fellowship to discover what dietary factors put children at risk of developing a food allergy, and <u>ways we can reduce that risk</u> .	Doctor Debra Palmer	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2021	Immunology	Allergy	\$	431,000.00
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Western Australia	University	WA	Translational Research on Malignant Pleural Effusion and Pleural Infection	I am a leading researcher in pleural effusions (fluid build-up in the chest) from cancer and infection. I run a multicentre clinical trial team to answer important questions directly relevant to patient care, as well as a lab research group with proven record of discovery new treatment targets. This Fellowship will capitalise on platforms I have built and determine best approach to remove effusions, understand etiologic roles of the fluid ultimately to find ways to stop fluid from forming.	Professor Y C Gary Lee	Not applicable	Targeted or restricted competitive	1/01/2018	31/12/2022	Clinical Sciences	Clinical Sciences Not Elsewhere Classified	\$	481,155.50
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Wollongong	University	NSW	Implementing a health literacy focused dietetic outpatient model of care for people with chronic kidney disease	A special diet is essential for keeping people with chronic kidney disease well. However inadequate health literacy prevents many people from following this diet correctly. In this project we will redesign the way health services are provided to patients with inadequate health literacy. We will also evaluate whether altering the type of information provided and the method that it is delivered is more effective than the current model of care.	Ms Kelly Lambert	Not applicable	Targeted or restricted competitive	1/01/2018	29/02/2020	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	179,118.00
Clinician Researchers	2017 Next Generation Clinical Researchers	University of Sydney	University	NSW	Improving diagnosis, treatment and prevention of mitochondrial disease	The goal of this work is to use state-of-the-art research methods to improve clinical practice and the health outcomes for patients with mitochondrial disease and other neurological disorders. Professor Sue will undertake an integrated program involving clinical studies, bioinformatics, tissue culture and in vitro cell modelling to discover better ways to treat mitochondrial disease and other neurological diseases due to impaired mitochondrial function.	Professor Carolyn Sue	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2024	Neurosciences	Neurology And Neuromuscular Diseases	\$	257,388.25
Clinician Researchers	2018 Next Generation Clinical Researchers	National Ageing Research Institute	Medical Research Institute	VIC	Translating dignity principles into practice in aged care homes	Care dependent older people in aged care homes are at risk of violations to their personal dignity during continence care interactions, especially if they have dementia. Educating aged care staff about managing incontinence may protect residents' dignity and reduce conflicts in care. Informed by the Knowledge to Action Cycle, different research methods will be used to implement a multifaceted, evidence-based, feasible and sustainable person-centred 'Dignity in Continence Care Program'.	Doctor Joan Ostaszewicz	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2021	Nursing	Aged Care Nursing	\$	181,066.00
Clinician Researchers	2018 Next Generation Clinical Researchers	Burnet Institute	Medical Research Institute	VIC	Advancing diagnostics and vaccines for malaria elimination	This research will advance the development of new diagnostics and understanding about malaria immunity that will advance vaccine development.	Doctor Jack Richards	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2023	Clinical Sciences	Infectious Diseases	\$	437,036.00
Clinician Researchers	2018 Next Generation Clinical Researchers	Curtin University	University	WA	Pharmacy interventions for Naloxone Scale-Up (PNSU)	Deaths due to opioid overdose are preventable, yet increasing. The safe and effective treatment for opioid overdose is not easily available to those in need. Community pharmacies are accessible healthcare settings and are frequently in contact with the majority of opioid users. This project aims to implement feasible harm reduction interventions to increase the availability of opioid overdose treatment delivered through community pharmacy.	Doctor Joanna Moulin	Not applicable	Targeted or restricted competitive	1/07/2019	30/06/2022	Public Health And Health Services	Health And Community Services	\$	181,066.00
Clinician Researchers	2018 Next Generation Clinical Researchers	La Trobe University	University	VIC	Translating evidence to improve access to paediatric therapy services	Children with disabilities often face very long waiting lists to access therapy services. Delayed care for these children can lead to missed windows of opportunity when treatment is most effective. There is a substantial body of evidence that shows that there are strategies that can be used to reduce waiting times for health services. This project will translate evidence into practice to improve access to therapy services, leading to better outcomes for children and their families.	Doctor Katherine Harding	Not applicable	Targeted or restricted competitive	1/01/2019	30/06/2022	Public Health And Health Services	Community Child Health	\$	181,066.00
Clinician Researchers	2018 Next Generation Clinical Researchers	Monash University	University	VIC	A national cancer outcome strategy	This application is intended to establish a national cancer outcome strategy by creating and building on a platform of disease based clinical registries that allow measurement of and improvement in quality of care. These registries will also facilitate the conduct of clinical trials in real-world populations.	Professor John Zalcberg	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2023	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	487,893.00
Clinician Researchers	2018 Next Generation Clinical Researchers	Monash University	University	VIC	fungalAI: Breaking the mould of the traditional antifungal stewardship paradigm	Fungal pneumonia is an uncommon but serious infection in patients with impaired immunity. Cancer chemotherapy or transplantation are major risk factors. Treatments are limited and have significant side effects and cost. Hospitals need high quality data on these infections in real-time in order to best manage them. This has not been possible until now. This project using artificial intelligence to detect, diagnose and alert doctors to fungal pneumonia in order to best drive improvements in care.	Doctor Michelle Ananda-Rajah	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2020	Clinical Sciences	Infectious Diseases	\$	181,066.00
Clinician Researchers	2018 Next Generation Clinical Researchers	Monash University	University	VIC	Next Generation Targeting of DNA-Methylation in Poor Risk Lymphoid Cancer	Lymphoma and multiple myeloma (MM) are the most common blood cancers in Australia. Unfortunately, patients with T-cell lymphoma have much worse outcomes than those with B-cell lymphoma, and MM remains incurable. This Fellowship seeks to develop better treatments for MM and T-cell lymphoma. Laboratory experiments will evaluate a new class of drug designed to inhibit a target called VPRBP in the myeloma cell. Associate Professor Shortt will also conduct a clinical trial of a drug called SGI-110 in T-cell lymphoma.	Associate Professor Jake Shortt	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2022	Oncology And Carcinogenesis	Haematological Tumours	\$	218,518.00
Clinician Researchers	2018 Next Generation Clinical Researchers	Monash University	University	VIC	Reducing Brain Injury and Improving The Care Of High-Risk Newborn Infants	Associate Professor Wong is a consultant Neonatologist, with joint appointments at Monash Newborn and The Ritchie Centre. Her research program focuses on improving the care and outcome of sick newborn infants. While survival rates of preterm infants have improved, the problem of brain injury and long-term neuro-disability in these babies remains high. Associate Professor Wong's research combines studies both in preterm infants and animal models, to address clinical questions (bedside to bench), and then translate findings back to bedside.	Associate Professor Flora Wong	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2022	Paediatrics And Reproductive Medicine	Paediatrics	\$	241,702.00
Clinician Researchers	2018 Next Generation Clinical Researchers	Murdoch Children's Research Institute	Medical Research Institute	VIC	Implementing evidence based management for children with dystonic cerebral palsy	The aim of this TRIP fellowship is to improve the outcomes for children with cerebral palsy who have a complex and often misunderstood movement disorder called dystonia. Dystonia interferes significantly with everyday functioning causing pain and discomfort for children. This project will implement a care pathway and measurement toolkit, based on best-available evidence, into the major treatment centres around Australia that manage children with cerebral palsy.	Doctor Adrienne Harvey	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2020	Paediatrics And Reproductive Medicine	Paediatrics	\$	181,066.00
Clinician Researchers	2018 Next Generation Clinical Researchers	Queensland University of Technology	University	QLD	Embracing digital disruption in hospitals to improve outcomes among vulnerable people	Hospitals are transitioning to paperless systems and processes. Siloed clinical systems are being superseded with unprecedented investment in integrated digital communication technologies including integrated electronic medical records and data linkage warehouses. This research program seeks to embrace the digitisation of hospitals by using digital information recorded in electronic systems to better understand how we can improve trauma-related care for people hospitalised with injuries.	Associate Professor Steven McPhail	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2022	Other Medical And Health Sciences	Medical And Health Sciences Not Elsewhere Classified	\$	483,404.00
Clinician Researchers	2018 Next Generation Clinical Researchers	Sydney Local Health District	State government entity/local health district	NSW	Implementing fasting guidelines within an acute hospital surgical setting	Members of the community requiring surgical interventions are among the most vulnerable in the hospital. They are usually immobile, powerless and required to fast for procedures. Fasting guidelines exist to ensure positive clinical outcomes but the complexity of systems means patients are fasted excessively. This Fellowship aims to reduce pre-operative fasting to 6 hours in two tertiary hospitals. Effective implementation strategies targeted at changing clinician behaviour will be implemented.	Doctor Sharon Carey	Not applicable	Targeted or restricted competitive	1/01/2019	30/09/2022	Nutrition And Dietetics	Clinical And Sports Nutrition	\$	181,066.00

Clinician Researchers	2018 Next Generation Clinical Researchers	The University of Queensland	University	QLD	Early diagnosis and treatment of lung cancer	Lung cancer is the biggest cause of cancer deaths in Australia. At present most cases of lung cancer are diagnosed at a late stage when cure is sadly not possible. This work will develop new ways to prevent and detect early lung cancer so it can be treated effectively.	Professor Kwun Fong	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2023	Cardiorespiratory Medicine And Haematology	Respiratory Diseases	\$	487,893.00
Clinician Researchers	2018 Next Generation Clinical Researchers	The University of Queensland	University	QLD	IAx: Instant assessment and personalised feedback in alcohol use disorder	Alcohol Use Disorder is one of the most common mental disorders. Evidence-based treatment begins with a thorough assessment and ongoing monitoring of response to treatment. However, most practitioners do not use reliable, standardised instruments in these assessments because of the time it takes to score and interpret them. This project will develop and evaluate the implementation of a computerised instant assessment and feedback system (IAx) to increase the adoption of best-practice assessment.	Doctor Matthew Gullo	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2022	Psychology	Health, Clinical And Counselling Psychology	\$	181,066.00
Clinician Researchers	2018 Next Generation Clinical Researchers	Wesley Medical Research Limited	Medical Research Institute	QLD	Improving paediatric critical care outcome	The Fellowship research program will improve paediatric critical care for children and infants, focusing on respiratory support in intensive care, post-operative care for children and infants who have undergone open heart surgery, and tackling severe sepsis in children admitted to hospital.	Associate Professor Andreas Schnider	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2024	Paediatrics And Reproductive Medicine	Paediatrics	\$	348,495.00
Clinician Researchers	2018 Next Generation Clinical Researchers	The University of Queensland	University	QLD	Scaling, spreading, and sustaining The Systematized, Interdisciplinary Malnutrition Program for implementation and Evaluation (SIMPLE) - a multi-site implementation program	Malnutrition harms one in three patients and is costly. Hospital diets currently deliver individual malnutrition care to a select few. Care models are available that engage patients and hospitals to move to multidisciplinary nutrition care. This increases the proportion of patients receiving appropriate nutrition care without increasing costs. I will lead implementation of multidisciplinary malnutrition care across Queensland Hospitals to improve patient and healthcare outcomes.	Doctor Jack Bell	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2021	Nutrition And Dietetics	Clinical And Sports Nutrition	\$	181,066.00
Clinician Researchers	2018 Next Generation Clinical Researchers	University of Melbourne	University	VIC	Complex depression and anxiety in youth: Innovative e-therapy and biotherapy clinical trials	Depression and anxiety disorders are the most prevalent mental illnesses in Australian youth, however current treatments are only modestly effective. In this Fellowship Doctor Rice will lead 5 clinical studies with young people experiencing various illness stages of depression and anxiety. Of these, 3 studies will use a new online treatment delivered via a social media-based internet platform, with a further 2 studies testing new biological (i.e., medication and anti-inflammatory) approaches.	Doctor Simon Rice	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2022	Clinical Sciences	Psychiatry (incl. Psychotherapy)	\$	349,628.80
Clinician Researchers	2018 Next Generation Clinical Researchers	University of Melbourne	University	VIC	From simulation to translation: A new quality improvement program for antibiotic prescribing in general practice	Antimicrobial stewardship (AMS) strategies are required in general practice to optimise appropriate antibiotic prescribing. We will implement a quality improvement program consisting of a clinical decision support tool, audits and benchmarking in four general practices and explore its acceptability and effectiveness. This implementation study directly addresses key aims of the National Antimicrobial Resistance Strategy and will inform AMS strategies and health policy for general practice.	Doctor Jo-Anne Manski-Nankervis	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2021	Clinical Sciences	Infectious Diseases	\$	181,066.00
Clinician Researchers	2018 Next Generation Clinical Researchers	University of Melbourne	University	VIC	Optimising Respiratory Therapies to Improve Outcomes for Preterm Infants	Preterm birth is the leading cause of newborn deaths worldwide. The smallest, sickest babies are born extremely preterm before 28 weeks' gestation; 50% of survivors develop bronchopulmonary dysplasia (BPD), the chronic lung disease of prematurity. BPD is associated with worse long-term respiratory health and neurodevelopmental outcomes. Dr Manley's research aims to increase survival and reduce morbidity in preterm infants by finding new therapies to prevent BPD, and improving early respiratory supports.	Doctor Brett Manley	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2022	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine Not Elsewhere Classified	\$	305,924.00
Clinician Researchers	2018 Next Generation Clinical Researchers	University of Sydney	University	NSW	Clinical Trials To Improve Outcome of Cancer Patients	Several areas are currently of great interest in oncology including identification of effective new targeted and immunotherapies. The other area is to identify useful and reliable biomarkers to choose the best treatments for most appropriate patients. Associate Professor Khasraw will continue his research to develop a program to help cancer patients, influence clinical practice and health policy across various domains in cancer.	Associate Professor Mustafa Khasraw	Not applicable	Targeted or restricted competitive	1/01/2019	25/08/2019	Clinical Sciences	Clinical Sciences Not Elsewhere Classified	\$	483,404.00
Clinician Researchers	2018 Next Generation Clinical Researchers	University of Sydney	University	NSW	New approaches for treatment of alcohol use disorder	Alcohol use disorder (AUD) is a leading health problem in Australia with 5500 deaths annually. Current treatments are unsatisfactory and few people receive evidence based care. This Fellowship will develop better treatment and services to tackle this highly stigmatised disorder. I will conduct clinical trials of medications including topiramate, naltrexone and cannabis. I will work to overcome barriers to receiving effective care, aiming to increase the number of people receiving treatment.	Professor Paul Haber	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2023	Clinical Sciences	Clinical Sciences Not Elsewhere Classified	\$	418,050.00
Clinician Researchers	2018 Next Generation Clinical Researchers	University of Sydney	University	NSW	The role of cortical dysfunction in Amyotrophic Lateral Sclerosis (ALS) pathophysiology	Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease killing two Australians every day. The disease starts in one arm or leg, and then progresses rapidly to result in global weakness. Patients describe as being trapped in their bodies. We don't understand the reasons underlying the development of ALS or why the disease spreads very rapidly. This research will attempt to identify factors driving the rapid spread of disease, in the hope of developing effective therapies.	Professor Ostojic (Stevil) Vucic	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2023	Neurosciences	Central Nervous System	\$	585,270.00
Clinician Researchers	2018 Next Generation Clinical Researchers	University of Tasmania	University	TAS	Exercise is medicine so why don't General Practitioners prescribe it?	Exercise is medicine and General Practitioners are ideally placed to promote the benefits of regular exercise to their patients. Despite this advice about exercise is rarely provided in these GP consultations. This project will design, implement and evaluate the effectiveness of a series of tools designed to address the barriers to GPs recommending exercise as a treatment and increase the provision of exercise advice in this setting.	Associate Professor Andrew Williams	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2022	Clinical Sciences	Rehabilitation And Therapy (Excl. Physiotherapy)	\$	181,066.00
Clinician Researchers	2018 Next Generation Clinical Researchers	University of Western Australia	University	WA	Community-based studies of diabetes and infectious diseases	Diabetes and tropical/infectious diseases are globally important and increasingly encountered in Australia. The studies covered by this Fellowship application aim to continue to improve the clinical management of these diseases through epidemiological and intervention studies in key patient groups conducted by multidisciplinary research teams that I have developed and/or lead.	Professor Timothy Davis	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2023	Clinical Sciences	Endocrinology	\$	585,270.00
Clinician Researchers	2018 Next Generation Clinical Researchers	University of Western Australia	University	WA	Maximising health for older Australians	I am a clinical geriatrician whose interests span many facets of ageing including frailty, cognitive impairment, dementia, and falls. Funding from this Fellowship will allow me to focus on research activities related to these areas and related transitional activities.	Professor Leon Flicker	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2023	Clinical Sciences	Geriatrics And Gerontology	\$	585,270.00
Clinician Researchers	2018 Next Generation Clinical Researchers	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	Translational research to drive improved diagnosis and treatment of inflammatory diseases	I am a clinician researcher, focussed on improving the treatment of human inflammatory diseases. My research has shown that molecules best known as growth factors for blood cells also play important roles in many chronic inflammatory diseases. I research these new targets and have developed therapies that block their effects in human diseases. My leadership position in medical research facilitates this bench to bedside translation of new therapies and evidence based, patient-centred care.	Professor Ian Wicks	Not applicable	Targeted or restricted competitive	1/01/2019	31/12/2023	Immunology	Innate Immunity	\$	418,050.00
Clinician Researchers	2018 Next Generation Clinical Researchers	La Trobe University	University	VIC	Closing the evidence-practice gap in occupational health practices to prevent musculoskeletal disorders	Many musculoskeletal disorders (MSDs) are work-related, but occupational health practices targeting MSD risk are not evidence-based, focusing just on manual handling hazards with little worker input. This project will train and support workplace practitioners to implement a 'toolkit' (risk management tools) addressing all relevant hazards. New online resources will enable widespread toolkit use in future. Expected outcomes include fewer people with MSDs and lower costs to the healthcare system.	Associate Professor Jodi Oakman	Not applicable	Targeted or restricted competitive	1/08/2019	30/06/2023	Public Health And Health Services	Environmental And Occupational Health And Safety	\$	181,066.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of South Australia	University	SA	Evidence-based digital technologies for health behaviour	Poor lifestyle patterns (physical inactivity, excess sedentary behaviour, lack of sleep, poor diet) are leading modifiable causes of death and disease in Australia. It is vital we improve health behaviors in our communities, particular within high-risk groups. The rapid growth of technologies has created new possibilities for health interventions. Innovative research is needed to harness this potential by creating and translating personalised, scalable technology-based interventions.	Associate Professor Carol Maher	Not applicable	Targeted competitive	1/01/2021	31/12/2025	Public Health And Health Services	Preventive Medicine	\$	1,118,593.01
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	Macquarie University	University	NSW	Screening and Risk Reduction for Dementia in Primary Care	Without a cure for dementia, risk reduction is paramount. Co-designed with consumers and GPs, this project will evaluate the effectiveness of a structured screening and risk reduction tool for dementia implemented in primary care. This tool will enable identification of amenable risks, guide GP and consumer joint decision making about the most appropriate evidence-based interventions to reduce the identified risks, and facilitate interventions. The tool will be evaluated in a clinical trial.	Professor Viviana Wuthrich	Not applicable	Targeted competitive	1/01/2021	31/12/2025	Psychology	Health, Clinical And Counselling Psychology	\$	1,562,250.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	Advancing Personalised Treatment in Colorectal Cancer with Tissue and Liquid Biomarkers	I am leveraging my world leading studies of liquid biopsy (circulating tumour DNA) as recurrence marker in bowel cancer, where there are unique opportunities to further improve tissue and blood test based prognostication (by adding more markers), to move forward the field of "fear of cancer" (questionnaires to better understand and improve the patient experience), to collect cost of care data to demonstrate the cost-effectiveness of this approach, and to develop new treatment.	Associate Professor Jeanne Fie	Not applicable	Targeted competitive	1/01/2021	31/12/2025	Oncology And Carcinogenesis	Solid Tumour	\$	1,187,350.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Melbourne	University	VIC	Closing the critical knowledge gaps in perinatal genomics	Over the past decade, advances in genetics have impacted every aspect of medicine, including the care of pregnant women and their babies (perinatal medicine). "Genomics" is the modern term for genetics on a large scale: it is the study of a person's complete set of DNA, rather than individual genes. The application of genomics in perinatal medicine has created both benefits and concerns. This program will provide the essential evidence to guide responsible progress in perinatal genomics.	Associate Professor Lisa Hul	Not applicable	Targeted competitive	1/01/2021	31/12/2025	Paediatrics And Reproductive Medicine	Foetal Development And Medicine	\$	1,281,125.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Western Australia	University	WA	Preventing Bronchiectasis in Indigenous People	Aboriginal people are severely affected by lung disease. Much chronic disease can be prevented if early respiratory symptoms can be detected early and children are given optimal treatment. My research will apply knowledge translation and evaluation to close the gap between evidence and practice to ensure that the primary health workforce in Australia is skilled with, up to date, and apply current best practice in paediatric indigenous lung health.	Doctor Andre Schultz	Not applicable	Targeted competitive	1/01/2021	31/12/2025	Cardiorespiratory Medicine And Haematology	Respiratory Diseases	\$	1,131,125.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of New South Wales	University	NSW	Tackling it with Tech: Using novel internet solutions to overcome the burden of depression in youth	Depression is common in youth and suicide is a tragic and fatal outcome. My research explores how the internet can be used to detect young people in need of mental healthcare, deliver accessible and engaging treatments, and provide schools and professionals with new tools and services to proactively identify youth early so that they can get the right care at the right time. This research program will transform how young Australians receive care, significantly reducing the burden of depression.	Doctor Bridianne O'Dea	Not applicable	Targeted competitive	1/01/2021	31/12/2026	Public Health And Health Services	Mental Health	\$	620,205.00

Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Melbourne	University	VIC	Saving time, saving brain through prehospital stroke care	This research project aims to improve outcomes for stroke patients through new treatments that can be designed at the patient's doorstep. Projects include performing the world's first trial of a drug designed to halt bleeding into the brain on Australia's first treatment stroke ambulance. Other projects will include assessing outcomes for patients treated on the stroke ambulance and improving paramedic recognition of patients needing specialised interventional treatments.	Doctor Henry Zhao	Not applicable	Targeted competitive	1/01/2021	31/12/2025	Neurosciences	Central Nervous System	\$	645,205.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	Monash School of Health Research	Medical Research Institute	NT	Moving together towards the elimination of chronic Hepatitis B in the Northern Territory	Aboriginal and Torres Strait Islander Australians are disproportionately affected by chronic hepatitis B infection and liver cancer. As a specialist doctor and clinical-researcher, I am working in partnership with Aboriginal people to eliminate hepatitis B from the Aboriginal population of the Northern Territory (NT). Together with Aboriginal people in the NT, scientists and health professionals I will provide evidence for improved culturally safe care for people living with hepatitis B.	Doctor Jane Davies	Not applicable	Targeted competitive	1/01/2021	31/12/2025	Clinical Sciences	Infectious Diseases	\$	1,131,125.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	Monash University	University	VIC	Optimise Primary Aldosteronism Detection For Better Health Outcomes	Primary aldosteronism (PA) is a preventable, but often unrecognised cause of high blood pressure, strokes and heart diseases. However, doctors do not routinely screen for it. A simple blood test could mean the difference between receiving a cure or requiring chronic complex care. My research will determine how common PA is in our community and develop guidelines to improve its detection to benefit hundreds of thousands of Australians living with hidden PA.	Doctor Jun Yang	Not applicable	Targeted competitive	1/01/2021	31/12/2025	Clinical Sciences	Endocrinology	\$	570,205.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Western Australia	University	WA	Better penicillin, better hearts: improving secondary prevention of rheumatic heart disease	Getting 'the penicillin needle' every month is the only way we currently have to prevent RHD, but due to pain associated with injections given into the muscle, adherence to this is poor. An injection of penicillin given at a higher dose, but under the skin (subcutaneously) could allow us to schedule the needle every 3 months instead. To get the most from any new penicillin, we also need to know what level of penicillin is required to prevent the sore throats and skin infections that cause RHD.	Doctor Laurens Manning	Not applicable	Targeted competitive	1/01/2021	31/12/2025	Clinical Sciences	Infectious Diseases	\$	1,281,125.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	Flinders University	University	SA	Meeting psychological needs to improve the quality and safety of aged care	Improving the quality and safety of aged care is in best the interests of us all: two-thirds of us will access an aged care service in our lifetime. Innovative models of care that could achieve this aim exist, but a fundamental lack of expertise about how to implement them into the complex aged care sector gets in the way. This research will trial new approaches and identify the key ingredients to assist the aged care sector to implement the best-quality care.	Doctor Monica Cations	Not applicable	Targeted competitive	1/01/2021	31/12/2025	Public Health And Health Services	Aged Health Care	\$	420,078.91
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	Monash University	University	VIC	Using a purpose-built digital assessment tool to determine the mechanisms driving addictive behaviours and its utility to improve treatment engagement and outcomes	The clinical assessment of people with drug, alcohol or other behavioural addictions (e.g. gambling) has traditionally relied on measuring the frequency and severity of the behavior itself, and not the underlying brain-based processes that lead to these problems. This study will test a neurocognitive framework for addictions - derived from a panel of world leading experts in the field - to establish a unifying, scientifically-informed understanding of the core processes driving addictions.	Doctor See Lee	Not applicable	Targeted competitive	1/01/2021	31/12/2025	Psychology	Biological Psychology (Neuropsychology, Psychopharmacology, Physiological Psychology)	\$	645,205.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Melbourne	University	VIC	A Neural Systems Model to Optimize Treatment Outcomes in Binge Eating Populations	This project will use advanced brain imaging techniques to understand how people that binge eat process negative beliefs. Over the next 5 years, I will establish a research program that uses brain-based factors to predict which patients will respond to certain treatments and to develop personalized treatment options. The findings of this project will be used to improve treatment outcomes and help people that binge eat to obtain long-term recovery.	Doctor Trevor Steward	Not applicable	Targeted competitive	1/01/2021	31/12/2025	Clinical Sciences	Psychiatry (Ind. Psychotherapy)	\$	645,205.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	Murdoch Children's Research Institute	Medical Research Institute	VIC	Establishing the early diagnosis of atherosclerosis and cardiovascular risk factors in adults with repaired aortic arch obstruction: The key to decreasing premature death	Aortic arch obstruction is a condition where there is a narrowing in the aorta (main blood vessel from the heart supplying blood to the body) and usually requires surgery early in life. There is a high rate of death in young adults which is linked to accelerated heart disease. This research aims to establish a C T scan of the heart (coronary artery calcium scoring) can help us identify young adults at highest risk of heart disease before its development.	Doctor Melissa Lee	Not applicable	Targeted competitive	1/01/2021	31/12/2026	Cardiorespiratory Medicine And Haematology	Cardiology (Ind. Cardiovascular Diseases)	\$	329,041.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	The University of Newcastle	University	NSW	Sustaining the implementation of evidence-based chronic disease prevention programs in education	Governments invest considerable resources in implementing diet, physical activity and obesity prevention initiatives in education settings. However, unless they are sustained, the public health benefits of such investments are reduced. Over the next 5 years my research program will address key impediments to sustainability research by producing evidence on the determinants of, and effective strategies for, sustaining these interventions in educational settings.	Doctor Nicole Nathan	Not applicable	Targeted competitive	1/01/2021	31/12/2025	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	1,562,250.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	The University of Newcastle	University	NSW	Personalised biomarker-guided management of asthma during pregnancy	Asthma is common in pregnancy, and asthma attacks are associated with poor outcomes for the offspring. We developed a novel management strategy which halves asthma attacks in pregnancy and reduces bronchitis and asthma in children. This grant will test the implementation of this strategy into routine antenatal care, and determine the health and developmental benefits for offspring, to provide evidence to improve clinical practice in the area of asthma management in pregnancy.	Doctor Vanessa Murphy	Not applicable	Targeted competitive	1/01/2021	31/12/2025	Clinical Sciences	Clinical Sciences Not Elsewhere Classified	\$	1,562,250.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Sydney	University	NSW	Policy-driven research to improve the immunisation program for young children	Vaccines are the most effective way to prevent childhood diseases. Evidence-based policies are required to ensure vaccination strategies optimally benefit the Australian population. This project leverages a decade of quality research and aims to improve Australia's public health actions in the prevention of whooping cough, gastrointestinal infections and pneumonia.	Professor Thomas Snelling	Not applicable	Targeted competitive	1/01/2021	31/12/2025	Public Health And Health Services	Preventive Medicine	\$	1,062,555.48
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	Deakin University	University	VIC	Improving outcomes for children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) and their carers	Attention deficit hyperactivity disorder (ADHD) affects 5% of Australian young people. This investigator grant aims to improve outcomes for young people with ADHD through 1) a better understanding of long term outcomes and key factors associated with positive outcomes; 2) the development of new psychosocial interventions, and 3) community engagement research to create an international research agenda and to address stigma.	Associate Professor Emma Sciberras	Not applicable	Targeted competitive	1/06/2020	31/12/2025	Public Health And Health Services	Community Child Health	\$	1,544,073.15
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	The University of Queensland	University	QLD	Supporting adults to sit less and move more for chronic disease prevention and management	New guidelines now recommend adults move more AND sit less. My program of research will develop and test interventions to support adults to achieve this recommendation. It will also generate new knowledge on the associated health and wellbeing impact of doing so. The research will focus on two key populations: desk workers and adults with chronic disease. Findings will result in evidence-based programs that can be delivered at scale within the workplace and clinic setting.	Associate Professor Genevieve Healy	Not applicable	Targeted competitive	1/06/2020	31/05/2025	Human Movement And Sports Science	Human Movement And Sports Science Not Elsewhere Classified	\$	1,487,455.48
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Sydney	University	NSW	Innovative regenerative therapies for heart repair	The project aims to develop new therapies to regenerate the infarcted and failing heart. The interconnected themes include: 1) pluripotent stem cell derived cardiomyocyte grafts and 2) drug treatment to alter the heart matrix 3) prevention of sudden cardiac death by heart regeneration.	Associate Professor James Chong	Not applicable	Targeted competitive	1/06/2020	31/12/2025	Cardiorespiratory Medicine And Haematology	Cardiology (Ind. Cardiovascular Diseases)	\$	1,562,250.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	Murdoch Children's Research Institute	Medical Research Institute	VIC	Keeping children out of hospital by being smarter with antibiotics	Hospitals are not the best place for children. They have worse psychological outcomes and are at risk of hospital-associated adverse events. One of the commonest reasons children are admitted to hospital is to receive intravenous (IV, through a drip). The aim of this program is 1) to find out whether for some infectious children do just as well taking oral antibiotics, and 2) to find out whether for infections really needing IV antibiotics, children can be treated just as safely at home.	Associate Professor Penelope Bryant	Not applicable	Targeted competitive	1/06/2020	31/12/2025	Clinical Sciences	Infectious Diseases	\$	1,281,125.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Melbourne	University	VIC	Minimising infective complications in the era of immune-based cancer therapies through precision, prediction and prevention	New cancer treatments are based on enhancing the immune system. However infections continue to affect many patients; disrupting their care, removing survival benefits from new cancer treatments and causing early deaths. With immune based therapies, types of infections seem and how to prevent them are still unknown. The proposed research will gain new knowledge of infections, study new technologies to detect and predict future infection risk and better ways to prevent infections from occurring.	Doctor Benjamin Teh	Not applicable	Targeted competitive	1/06/2020	31/12/2025	Medical Microbiology	Medical Microbiology Not Elsewhere Classified	\$	1,165,633.42
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of New South Wales	University	NSW	Investigating novel therapies for heart failure with preserved ejection fraction	Patients with heart failure related to a 'stiff heart' often have poor quality of life, shortness of breath and repeat hospital admissions. Other conditions like high blood pressure and obesity can make this condition worse. Currently, there are no treatments to make these patients feel better or prevent them from becoming worse when they go to hospital. I aim to find a new treatment for these patients, which will help them feel better, lose weight and reduce hospitalisation.	Doctor Clare Amott	Not applicable	Targeted competitive	1/06/2020	31/12/2025	Cardiorespiratory Medicine And Haematology	Cardiology (Ind. Cardiovascular Diseases)	\$	387,123.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Melbourne	University	VIC	Putting 3D printing into the reality of surgery: an approach for regenerating joint cartilage within the body using one-step surgery	Injuries to articular joints represent a huge cost to the health system. As academic orthopaedic surgeon specialising in robotic and 3D bioprinting, I aim at regenerating the building block of articular joints, by replacing the damaged tissue directly at surgery. My Research Program, performed in one of the most advanced 3D bioprinting facilities in Australia, in collaboration with world leaders in bioengineering, can open the way for bioprinting in surgery to regenerate tissues and organs.	Doctor Claudia Di Bella	Not applicable	Targeted competitive	1/06/2020	31/05/2025	Biomedical Engineering	Biomedical Engineering Not Elsewhere Classified	\$	447,602.50
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	The University of Queensland	University	QLD	Immuno-genetic biomarkers of response in a prospective study of immune checkpoint therapy in primary CNS lymphoma	Primary Central Nervous System Lymphoma (PCNSL) is a rare brain cancer with poor outcomes using standard available therapies. Even if cured patients are left with significant problems due to the intense therapy. There is emerging evidence that cancer may develop due to the tumours ability to avoid immune detection in the brain and this study will try to understand how the immune system can be helped to eradicate the cancer cells.	Doctor Colm Keane	Not applicable	Targeted competitive	1/06/2020	31/12/2025	Oncology And Carcinogenesis	Haematological Tumours	\$	1,393,575.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	The University of Adelaide	University	SA	Understanding molecular pathogenesis of therapy related myeloid neoplasm	Some treated cancer patients develop aggressive blood cancers, most probably due to chemotherapy and radiotherapy for their primary cancer. Their survival is <12 months and they have very limited treatment choices. Hence, understanding of risk factors and mechanisms of treatment-related blood cancers is crucial. We aim to understand the complex interaction between chemotherapy induced damage to bone marrow cells and patient's genetic factors responsible for treatment related blood cancer.	Doctor Devendra Hiwase	Not applicable	Targeted competitive	1/06/2020	31/05/2025	Oncology And Carcinogenesis	Haematological Tumours	\$	620,205.00

Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Melbourne	University	VIC	Developing a coherent national approach to the clinical and public health management of invasive Streptococcus A disease	Public awareness of meningococcal disease is high, but most people don't know that another pathogen, Streptococcus A, kills more people every year in Australia. Invasive Streptococcus A – the deadliest form of this disease – can spread to those closest to a Streptococcus A case. Unlike meningococcal disease, there is no national approach to preventing or managing invasive Streptococcus A. Research during this fellowship will result in a consistent approach to managing and preventing invasive Streptococcus A in Australia.	Doctor Katherine Gibney	Not applicable	Targeted competitive	1/06/2020	31/12/2025	Public Health And Health Services	Epidemiology	\$	1,449,800.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	Monash University	University	VIC	Blood based detection and monitoring of pre-malignant clonal haematopoiesis to predict clinical outcomes in the immunocompromised	Clonal haematopoiesis is when genetic mutations (alterations in the DNA) can be detected in blood stem cells of an individual and can increase the risk of cancer, heart disease, stroke and death. This study looks to explore how clonal haematopoiesis is formed and how it leads to adverse health outcomes. We will identify risk factors for clonal haematopoiesis which will guide the development of future screening programs and research into how this process can be better managed.	Doctor Paul Yeh	Not applicable	Targeted competitive	1/06/2020	31/12/2025	Cardiorespiratory Medicine And Haematology	Haematology	\$	620,734.77
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	The University of Newcastle	University	NSW	A big problem needs a big solution: Advancing the science of scaling up chronic disease prevention interventions	Chronic disease are responsible for 90% of deaths in Australia. Years of research has produced a range of policies and programs which could prevent the onset of chronic diseases. However, too few of these programs are ever scaled up to reach the communities they were intended for. Targeting children and families, my research aims to advance the evidence of how to effectively scale up policies and programs within the school setting so they can prevent the onset of chronic disease.	Doctor Rachel Sutherland	Not applicable	Targeted competitive	1/06/2020	31/05/2025	Public Health And Health Services	Health Promotion	\$	1,562,250.00
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Melbourne	University	VIC	The male experience of eating and body image disorders	Eating and body image disorders are devastating psychological conditions suffered by millions of Australian boys and men. However, despite overwhelming evidence that males experience eating and body image disorders in fundamentally different ways to women, there are no early-intervention or prevention programs designed specifically for males. My research program will develop new early-intervention and prevention programs to help this under-studied and under-served group.	Doctor Scott Griffiths	Not applicable	Targeted competitive	1/06/2020	31/12/2025	Psychology	Health, Clinical And Counselling Psychology	\$	1,562,250.00
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	Queensland Rural Medical Education Limited	Corporation	QLD	Assessing cultural safety in GP consultations for Indigenous Australians	Significant health disparities exist for Australian Aboriginal and Torres Strait Islander people. Training a culturally safe health workforce is vital to address this issue. Despite recognition that the definition of cultural safety must be determined by Indigenous people and communities, there are currently no tools to assess cultural safety within consultations based on community-derived data. This project will explore cultural safety as described by Australian Indigenous people, with the aim of developing a tool to assess general practitioners cultural safety based on their insights. As an organisation involved in medical education, this project will allow us to assess cultural safety more appropriately in medical learners.	Associate Professor Kay Brumpton	Associate Professor Kay Brumpton, Associate Professor Raeline Ward, Professor Tarun Sen Gupta, Doctor Hannah Woodall	Open competitive	14/04/2022	31/03/2025	Not available	Not available	\$	120,320.00
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	University of Melbourne	University	VIC	Strengthening care for rural children: stepped wedge trial in primary care	Across NSW and Victoria, 860,000 children, 30% of the States' population, live in rural areas. Although 19% of these children live with a chronic illness, there are fewer GPs per capita and paediatric specialty care is often lacking. Strengthening Care for Rural Children (SCARC), a model where paediatrician and GP's work together in GP practices, aims to deliver and rigorously evaluate a primary health care system strengthening programme that can bridge the gaps in access to health services and health outcomes between children living in rural Australia and their urban peers. It aims to improve the health of children by increasing capacity of the existing rural GP workforce to assess and effectively manage paediatric conditions.	Professor Lena Sanci	Professor Lena Sanci, Professor Raghu Lingam, Professor Harriet Hiscock, Associate Professor John Preddy, Doctor Kylie Vuong, Professor Michael Brydon, Doctor Bianca Forrester, Doctor James Best, Doctor David Tickell, Doctor Kathleen McDoskey, Doctor Joanne Grog, Doctor Michael Forrester, Associate Professor Faye McMillan, Doctor Maya Eamus	Open competitive	14/04/2022	31/03/2025	Not available	Not available	\$	2,996,188.00
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	The University of Queensland	University	QLD	RELEASE: Reducing Long-Term Antidepressant Use in General Practice	Our project is a cluster randomised controlled effectiveness-implementation trial in general practice to determine effectiveness of RELEASE compared to usual care on decreased antidepressant use and improved quality of life, and to evaluate our implementation strategy. Australians are among the highest users of antidepressants in the world (around 1 in 10 adults), due mostly to increasing long-term use against clinical guidelines. RELEASE targets people on long-term (>12 months) antidepressants with no indication for continued use (no depression/anxiety) and provides both doctors and patients with the information and resources needed to safely taper and stop these drugs to minimise adverse drug effects and improve quality of life.	Associate Professor Katharine Wallis	N/A	Open competitive	14/04/2022	31/03/2025	Not available	Not available	\$	1,912,691.00
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	University of Melbourne	University	VIC	The Australian New Zealand Oncofertility Clinical Trials Network	Many children and young people diagnosed with cancer receive treatment that renders them infertile. This is of major concern to families. This research will enable wide-scale implementation of new digital tools, guidance and models of oncofertility care across 9 Australian New Zealand Haematology Oncology (ANZHO) cancer centres in order to raise benchmarks of patient-centred oncofertility care. Families will receive discussion of the risks to fertility, and potential fertility preservation options (freezing of eggs/sperm or gonadal tissue) in the critical window between cancer diagnosis and cancer treatment. This will offer clinicians new models of care and young cancer survivors the chance of future parenthood.	Associate Professor Yasmin Jayasinghe	Associate Professor Yasmin Jayasinghe, Doctor Antonette Anazodo, Professor Michael Sullivan, Doctor Lisa Orme, Professor Margaret Zacharin, Associate Professor Maria McCarthy, Associate Professor Cathryn Stern, Doctor Daniel Lantsberg, Professor Richard Anderson, Professor Veronica Gomez-Lobo, Doctor Jacqueline Yano Maher, Doctor Mark Winstanley, Doctor Leanne Super, Doctor Liane Lockwood, Professor John Heath, Doctor Jessica Ryan, Professor William Ledger, Doctor Anne Ryan, Doctor Shital Julania, Doctor Tamara Hunter, Doctor Paola Kabanian Baeza, Doctor Rebecca Manuathane, Doctor Sally Reid, Doctor Dylan Wanigasekera, Doctor Marlene Skolim, Doctor Genia Rozem, Associate Professor Anusuchirawan	Open competitive	14/04/2022	31/03/2025	Not available	Not available	\$	2,999,970.00
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	University of New South Wales	University	NSW	Enhancing prison-to-community mental healthcare for Aboriginal prisoners	Aboriginal and/or Torres Strait Islander people are incarcerated at an alarming rate and those in prison often suffer with significant mental health need associated with elevated risk of poor outcomes before and after return to the community. The proposed research project aims to test the effectiveness of a new culturally-enhanced and release-focused mental health intervention designed to improve both mental health care in prison and to support the critical prison-to-community transition for Aboriginal and/or Torres Strait Islander men and women. The project is led by clinicians and Aboriginal Health workers, and additionally aims to build clinical research capacity in this vitally important field.	Professor Kimberlie Dean	Professor Kimberlie Dean, Doctor Vindya Nanyakkara, Doctor Sarah-Jane Spencer, Doctor Trevor Ma, Ms Nicole Johnson	Open competitive	14/04/2022	31/03/2025	Not available	Not available	\$	1,180,613.00
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	Monash University	University	VIC	Equipping Tertiary Care for the Optimal Diagnosis of Primary Aldosteronism	Primary aldosteronism (PA) is a common and potentially curable cause of hypertension that confers a high risk of heart disease and stroke if not diagnosed and treated. Its diagnosis requires specialised tests in the hospital. However, our hospitals are not yet equipped with cutting edge technology for a speedy diagnosis nor have the capacity to diagnose hundreds of thousands of affected patients in a timely manner. This project will establish modern tools and efficient pipelines to optimise the capacity of our hospitals to accurately diagnose PA. The outcomes of this research project are expected to set the standard for high quality guidelines for the diagnosis of PA and transform clinical practice in health services across Australia.	Doctor Jun Yang	Doctor Jun Yang, Professor Peter Fuller, Professor Michael Stowasser, Professor Paul Glenndinning, Associate Professor Lu Zhong, Associate Professor Chong Winston, Professor Andrea Rita Horwath, Professor Zoltan Endra, Doctor Moe Thuar, Doctor Jimmy Shen, Doctor Ian Jong	Open competitive	14/04/2022	31/03/2025	Not available	Not available	\$	2,993,294.00
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	University of Melbourne	University	VIC	CURE-NG: A Human Challenge Model to Develop New Treatments for Gonorrhoea	The CURE-NG project will undertake translational research to develop treatments that will address the rising incidence of gonorrhoea and the critical threat of drug resistant infection. Develop and implement a controlled human infection model (CHIM) of male gonorrhoea urethritis and a first-in-human oropharyngeal gonorrhoea CHIM. Transform how biomedical interventions for gonorrhoea are developed; Accelerate antimicrobial and vaccine development for gonorrhoea; Substantially build Australia's clinical trial capability and leadership; Embed the emerging technology of microbial genomics into CHIM translational research; Enhance translational workforce capability and specific capacity to use CHIMs for clinical translation.	Professor James McCarthy	Professor James McCarthy, Professor Deborah Williams, Professor Christopher Fairley, Associate Professor Marcus Chen, Professor Andrew Steer, Doctor Joshua Oswicki, Doctor Elise Williams, Doctor Euebiuz Jamack, Professor Sharon Lewin	Open competitive	14/04/2022	31/03/2025	Not available	Not available	\$	2,300,321.00
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	University of Melbourne	University	VIC	Transforming Clinical Research to Improve Outcomes for Preterm Infants	15 million babies are born preterm each year. Preterm birth is the leading cause of death and disability among children < 5 years. There is urgent need for interventions to reduce complications of prematurity and improve outcomes. Traditional trials are often resource intense and may take many years. Adaptive Platform Trials are innovative allowing multiple interventions to be evaluated simultaneously. This project will develop an Australian Adaptive Platform Trial to Improve Preterm Birth Outcomes. The project will identify research priorities and core outcomes important to families and the health service. It will build the infrastructure and expertise required to run the Platform trial and implement the findings into clinical practice.	Doctor Clare Whitehead	Doctor Clare Whitehead, Associate Professor Brett Manley, Associate Professor Katie Groom, Professor Peter Davis, Professor Ben Mai, Professor John Newnham, Professor Steve Webb, Professor Jonathan Morris, Professor Della Forster, Professor Kai Lu, Professor Jeanie Cheung, Doctor Kirsten Palmer, Professor Salim Kuper, Professor Adrienne Gordon, Associate Professor Michael Stark, Associate Professor Tobias Strunk, Professor Peter Dargaville, Doctor Holger Unger, Doctor Kiama Brown	Open competitive	14/04/2022	31/03/2025	Not available	Not available	\$	2,642,199.00
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	Monash University	University	VIC	Intensive physiotherapy to lower hospital length of stay after hip fracture	This clinical trial will test whether intensive physiotherapy delivered early following hip fracture can accelerate physical recovery and reduce hospital days. We will recruit 620 participants from 8 acute hospitals across 5 Australian states. Intervention participants receive intensive physiotherapy 3 times/day for 7 days during their acute hospital stay. The primary outcome is length of stay, with secondary outcomes of physical mobility, health-related quality of life and falls. Longer-term impact and health care costs will be quantified with 12-month follow up. We will embed implementation science methods to enhance translation of findings into routine care, and will build clinical research capacity in health services across Australia.	Professor Anne Holland	Professor Anne Holland, Doctor Lara Kimmell, Professor Ian Harris, Associate Professor Rana Ackerman, Professor Richard Page, Associate Professor Justine Naylor, Doctor Angela Burge	Open competitive	14/04/2022	31/03/2025	Not available	Not available	\$	2,930,647.00

Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	University of Melbourne	University	VIC	Validating cognitive screening for first-episode psychosis - CogScreen	Cognitive impairment is common in first-episode psychosis (FEP) and predicts poorer patient outcomes. Clinical guidelines recommend routine cognitive screening of patients with psychosis so that treatment is in line with the cognitive needs of the patient. The problem is that there are no well-validated cognitive screening tools for clinical use in FEP. The CogScreen study will establish the most accurate cognitive screening tool for patients attending Australian early psychosis services. CogScreen will provide clinicians with a rapid and cost-effective way of identifying cognitive impairment in FEP patients, so that they can refine diagnosis and deliver more effective treatments and services, leading to better outcomes for patients.	Associate Professor Kelly Allott	Associate Professor Kelly Allott, Doctor Shayden Bryce, Professor Andrew Thompson, Doctor Shona Francey, Professor Stephen Bowden, Associate Professor Scott Clark, Associate Professor Oliver Schubert, Professor Anthony Harris, Doctor Candice James, Ms Anna Scully, Doctor Christopher O'Halloran, Professor Scot Purdon	Open competitive	14/04/2022	31/03/2025	Not available	Not available	\$	2,294,990.00
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	Monash University	University	VIC	PROMOTE: a cluster-randomised implementation trial to promote evidence use	The PROMOTE randomised controlled trial will test the clinical benefit and cost effectiveness of an implementation package to increase clinician use of arm and stroke rehabilitation evidence in practice. We will recruit 14 hospitals across 3 Australian states to deliver arm rehabilitation to 238 patients after stroke. The primary outcome is clinician adherence to guidelines, with secondary outcomes of patient arm and hand movement, health-related quality of life and cost. In partnership with the Stroke Foundation, we will embed consumer involvement and employ implementation science methods to conduct a process evaluation alongside the trial. Together these will allow rapid translation of findings into routine stroke care.	Professor Natasha Lannin	Professor Natasha Lannin, Doctor Laura Jolliffe, Doctor Katherine Scrivener, Doctor Zoe Adey-Walkeing, Doctor Rania Abdulmalik, Doctor Brian Anthonis, Doctor Louis Baggio, Professor David Berlowitz, Doctor Carlos Garcia Espersen, Ms Alanna Grover, Doctor Owen Howlett, Ms Brynn Lewin	Open competitive	14/04/2022	31/03/2025	Not available	Not available	\$	2,996,464.00
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	The George Institute for Global Health	Medical Research Institute	NSW	Optimal Post rTPA-tx Monitoring in Ischaemic Stroke (OPTIMISMain)	The OPTIMISMain will compare standard monitoring versus low-intensity monitoring schedule for 24 hours following thrombolytic therapy for acute ischaemic stroke. The key difference in the monitoring schedule is over the 2- to 24-hour time period; there will be no difference in the frequency of monitoring over the first 2 hours when most bleeding complications tend to occur. This research will establish whether a widely applicable less-intensive monitoring schedule improves patient recovery, and allows freeing up of health care resources to engage in direct stroke management or care elsewhere, leading to avoidance of unnecessary intensive care unit stay, expedited stroke work-up, and reduced hospital stay.	Professor Craig Anderson	Professor Craig Anderson, Mrs Kylie Tastula, Professor Richard Lindley, Mrs Debbie Summers, Mrs Brenda Johnson, Associate Professor Victor Urrutia, Mrs Dianna Day, Professor Thompson Robinson	Open competitive	14/04/2022	31/03/2025	Not available	Not available	\$	1,774,988.00
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	University Of New South Wales	University	NSW	The Australian Endometriosis Clinicians Collaborative (AEECC)	Endometriosis affects 1 in 9 Australian women, has a diagnostic delay of 7 years and costs the economy \$9.7 billion annually. The AEECC is a prospective longitudinal clinical study that will: 1. compare imaging accuracy of endometriosis in general vs specialised settings; compare medical vs surgical treatment of endometriosis with regards to impact on pain, general health symptoms and quality of life using validated questionnaires 2. determine cost-effectiveness of both diagnostic imaging and treatment options 3. establish a national biobank of endometriosis for future research capacity. Outcomes will determine optimised diagnosis and treatment pathways for clinicians and that improve quality of life for women with endometriosis.	Professor Jason Abbott	Professor Jason Abbott, Doctor Rebecca Deans, Doctor Erin Nesbitt-Hawes, Professor Luk Rombauts, Doctor Mar Mathias, Associate Professor Krishnan Karthigaan, Doctor Danny Chou, Associate Professor Anusch Yazdani	Open competitive	14/04/2022	31/03/2025	Not available	Not available	\$	1,937,950.00
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	James Cook University	University	QLD	The Tele-Artery Trial (TEAL)	1 million Australians have blockage of their lower limb arteries, which causes leg pain and walking impairment that reduces quality of life and increases the risk of amputation and death. Based on a systematic review of past evidence, in collaboration with patients and other key stakeholders we have designed a remotely-supervised exercise program to improve function and quality of life of people with leg artery blockage. This controlled, randomised clinical trial will examine the efficacy of this novel program. Positive findings from this trial will be followed by wide dissemination of the program. This will benefit James Cook University through recognition for performing internationally leading health research of global significance.	Professor Jonathan Gollidge	Professor Jonathan Gollidge, Doctor Bernard Bourke, Doctor Juanita Muller, Doctor Frank Quigley, Doctor Ramesh Vedula, Doctor Mark Jackson, Doctor Erik Lu, Doctor Murray Ogg, Doctor John Bingley, Doctor Dylan Morris	Open competitive	14/04/2022	31/03/2025	Not available	Not available	\$	2,862,084.00
Clinician Researchers	2022 Clinician Researchers: Nurses, Midwives and Allied Health	Avondale University Limited	University	NSW	Hospital Acquired Pneumonia Prevention (HAPPEN study)	Pneumonia is the most common type of HAI, accounting for approximately one third of all HAIs, with non-ventilator healthcare-associated pneumonia (HAP) the most common. Remarkably, HAP receives little attention by policymakers, researchers and funders. There have been no randomised controlled studies exploring HAP prevention in hospital undertaken anywhere to date. We propose to undertake intervention involving improvements in oral care to reduce the incidence of HAP.	Professor Brett Mitchell	Professor Brett Mitchell, Professor Allen Cheng, Doctor Sonja Dawson, Doctor Julie McDonagh, Doctor Auvilla Madhuvu, Associate Professor Helen Rawson, Associate Professor Philip Russo, Associate Professor Jenny Sim, Associate Professor Andrew Stewardson, Doctor Nicole White, Professor Rhonda Wilson	Targeted competitive	1/02/2023	31/01/2027	Health Sciences	Health Sciences, Health Services And Systems, Patient Safety, Health Sciences, Nursing, Acute Care, Biomedical And Clinical Sciences, Infectious Diseases	\$	1,493,004.18
Clinician Researchers	2022 Clinician Researchers: Nurses, Midwives and Allied Health	University of Sydney	University	NSW	Nurse-Led improvements to the Quality and Safety of Residential Aged Care - Project HIRAID-AgedCare	Nurses in the aged care sector are underqualified and understaffed, leaving them ill-equipped to handle the complex clinical needs of older Australians. The proposed project aims to develop a new model of care: HIRAID-AGEDCARE, which will be based upon the existing HIRAID model (currently in use by emergency services across NSW hospitals). HIRAID-AGEDCARE will provide an evidence-based framework to help nurses perform their roles optimally and standardise nursing care across the aged care sector.	Professor Ramon Shaban	Professor Ramon Shaban, Professor Kate Curtis, Doctor Moira Dunsmore, Professor Margaret Fry, Professor Yun-Hee Jeon, Doctor Mary Lam, Professor Richard Lindley, Professor Lee-Fay Low, Professor Brendan McCormack, Ms Margherita Murgo, Professor Deborah Parker, Professor Donna Waters, Doctor Aaron Watson	Targeted competitive	1/02/2023	31/03/2027	Health Sciences	Health Sciences, Health Services And Systems, Aged Health Care, Health Sciences, Nursing, Aged Care Nursing, Health Sciences, Health Services And Systems, Residential Client Care	\$	1,494,519.50
Clinician Researchers	2022 Clinician Researchers: Nurses, Midwives and Allied Health	Menzies School of Health Research	Medical Research Institute	NT	Remote Aboriginal Communities Ending TB (REACT)	Tuberculosis (TB) is an important public health issue and cause of preventable illness and death in some remote Aboriginal communities in the Northern Territory. This project will listen to and work together with Aboriginal communities and health services to develop resources and strategies which increase awareness of TB to ensure it is diagnosed early, increase use of treatment to prevent TB, and enable the health system to provide supportive and culturally appropriate care to people with TB.	Christopher Lowbridge	Christopher Lowbridge, Joanne Duncum, Jessica Gatt, Doctor Vicki Krause, Professor Anna Ralph, Doctor Sean Taylor	Targeted competitive	1/02/2023	31/01/2027	Health Sciences	Health Sciences, Health Services And Systems, Rural And Remote Health Services, Health Sciences, Public Health, Preventative Health Care, Biomedical And Clinical Sciences, Infectious Diseases	\$	1,400,225.22
Clinician Researchers	2022 Clinician Researchers: Nurses, Midwives and Allied Health	Curtin University	University	WA	Melatonin supplementation to reduce the induction of labour rates in first time mothers: The MyTIME Trial	The rate of first-time mothers having their labour is induced is increasing. Induced labour can be associated with harm for mother and baby and contributes to rising health costs. Melatonin is a hormone produced naturally in the body. One of its actions is that it helps start childbirth. We will do a double-blind study to determine whether giving pregnant women oral melatonin may help with starting labour normally. This could be a simple and cost-effective way to decrease induction of labour.	Doctor Zoe Bradford	Doctor Zoe Bradford, Professor Dorota Doherty, Professor Jeffrey Keelan, Doctor Leela Kulkarni, Associate Professor Jane Warland, Doctor Scott White	Targeted competitive	1/02/2023	31/01/2027	Health Sciences	Health Sciences, Midwifery, Clinical Midwifery	\$	1,040,529.02
Clinician Researchers	2022 Clinician Researchers: Nurses, Midwives and Allied Health	University of Melbourne	University	VIC	IDC-IMPROVE: The co-design, implementation and evaluation of a care bundle to improve indwelling catheter care (IDC) in residential aged care homes	The priority health care issue this grant addresses is the gap in current services across Australia to support people with a long-term indwelling catheter who live in a residential aged care home. Long term catheter use is associated with high morbidity and places considerable demand on emergency services. This research will support the aged care workforce to address the needs of residents with catheters, consequently reducing problems associated with catheter use.	Doctor Joan Ostaszewicz	Doctor Joan Ostaszewicz, Associate Professor Frances Batchelor, Doctor Jessica Cecil, Ms Helen Crowe, Doctor Kathleen Hunter, Doctor Liza Lau, Professor Catherine Peterson, Doctor Mich Peters, Ashley Salway, Doctor Alison Sweeney, Janie Thompson, Ms Elizabeth Watt, Julie Westaway	Targeted competitive	1/02/2023	31/01/2026	Health Sciences	Health Sciences, Nursing, Nursing Workforce	\$	1,455,163.33
Clinician Researchers	2022 Clinician Researchers: Nurses, Midwives and Allied Health	Deakin University	University	VIC	SAFE-HF - translating heart Failure guidelines into practice: a RCT of a Nurse Practitioner primary care service	Heart failure (HF) is a common disease of the heart with a high rehospitalisation and mortality rate. HF patients rarely receive the full benefits of evidence-based care simply due to inaccessibility to a HF specialist team. HF nurse practitioners are a vital component of this specialist workforce. This translational and innovative project will determine the effectiveness and costs of a HF nurse practitioner in primary care. It has the potential to keep patients out of hospital and save lives.	Professor Andrea Driscoll	Professor Andrea Driscoll, Professor John Atherton, Associate Professor Ralph Auden, Doctor Alison Beauchamp, Doctor Susan Cartledge, Professor Alison Hutchinson, Doctor Graeme Lowe, Professor Philip Newton, Professor Lilana Orellana, Ms Amanda Pereira-Salgado, Ms Margaret Pollock, Doctor Ella Zomer	Targeted competitive	1/02/2023	31/07/2027	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Cardiovascular Medicine And Haematology, Cardiology (incl Cardiovascular Diseases)	\$	1,488,730.44
Clinician Researchers	2022 Clinician Researchers: Nurses, Midwives and Allied Health	The University of Queensland	University	QLD	Building capacity to prevent healthcare harm for hospitalised infants: A Type 1 Hybrid Randomised Controlled Trial	Our aim is to test the effectiveness of a new biosensor, to prevent babies developing a significant, preventable injury, known as extravasation (a chemical burn). This will help to make hospitals safer for babies, ensure our clinicians are using the best technology available, and build research links to allow us to do powerful research in the future.	Professor Amanda Ullman	Professor Amanda Ullman, Doctor Dianne August, Associate Professor Joshua Byrnes, Doctor Roni Cole, Professor Fiona Coyer, Professor Martha Carley, Professor Mark Davies, Associate Professor Lauren Kearney, Professor Samantha Keogh, Ms Tricia Kleidon, Associate Professor Nicole Marsh, Associate Professor Craig McBride, Ms Mari Takashima, Professor Robert Ware, Doctor Hu (Grace) Xu	Targeted competitive	1/02/2023	31/03/2026	Health Sciences	Health Sciences, Nursing, Acute Care	\$	1,491,791.12
Clinician Researchers	2022 Clinician Researchers: Nurses, Midwives and Allied Health	The University of Queensland	University	QLD	Implementing integrated psychological and physical care for Australians after road traffic injury	Our VISION is that all physiotherapists, nationwide, deliver effective early biopsychosocial care to improve health outcomes with rTBI. We will test an on-line implementation package (PICOT: Physiotherapists biopsychosocial On-line Training) compared to usual in-person training for broad implementation of physiotherapist-delivered integrated psychological and physical care for people after road traffic injury.	Professor Michele Sterling	Professor Michele Sterling, Doctor Rachel Elphinstone, Doctor Roma Forbes, Professor Nadine Foster, Associate Professor Jason Lodge, Doctor Johanna Lynch, Associate Professor Shaun O'Leary, Doctor Kerry Peek, Doctor Jennifer Setchell, Professor Helen Slater, Doctor Julia Treblehan, Associate Professor Haltham Tuffaha	Targeted competitive	1/02/2023	31/07/2027	Health Sciences	Health Sciences, Allied Health And Rehabilitation Science, Physiotherapy	\$	1,481,206.11
Clinician Researchers	2022 Clinician Researchers: Nurses, Midwives and Allied Health	University of Sydney	University	NSW	Responsible pre-operative Opioid use for Hip and Knee Arthroplasty (OpioidHALT) Study: Opioid tapering in patients prior to hip and knee arthroplasty	Hip and knee replacements are the most common joint replacement surgeries in Australia. Overuse of opioids in these patients appears to be common before surgery and have been associated with persistent opioid use after surgery, poorer post-operative pain, function and longer hospital stay. This research program will identify the effectiveness of a multidisciplinary pharmacist-led opioid tapering intervention to reduce persistent opioid use after hip and knee replacement surgery.	Doctor Jonathan Penn	Doctor Jonathan Penn, Associate Professor Sam Adie, Doctor Kylie Bailey, Doctor Bernadette Brady, Associate Professor Betty Charr, Mr Joseph Descallar, Professor Nicholas Lintzeris, Ms Shania Liu, Associate Professor Rebekah Moles, Professor Justine Napier, Doctor Claire O'Reilly, Professor Asad Patanawala, Doctor Carl Schneider, Associate Professor Lei Si, Associate Professor Jennifer Stevens	Targeted competitive	1/02/2023	31/01/2027	Health Sciences	Health Sciences, Allied Health And Rehabilitation Science, Allied Health And Rehabilitation Science Not Elsewhere Classified	\$	1,479,940.39

Clinician Researchers	2022 Clinician Researchers: Nurses, Midwives and Allied Health	University of Melbourne	University	VIC	Implementing uniVerSal Tele-prehabilitation into cancer care pathways STARRS trial	Abdominal surgery is the most frequent major surgical procedure performed in developed countries. Complications after surgery are strongly associated with poor patient recovery and increased healthcare costs. Patient education before surgery including the importance of deep breathing, oral care, physical activity, nutrition and pain management show promise in reducing these complications. We aim to establish this innovative management into routine care and measure its effectiveness.	Professor Linda Denery	Professor Linda Denery, Doctor Ianthe Boden, Doctor Lara Edbrooke, Associate Professor Helena Frawley, Associate Professor Catherine Granger, Claire Hackett, Professor Alexander Jarvis, Doctor Hilmy Ismail, Doctor Erin Laing, Professor Bernhard Riedel, Ms Catherine Sinton, Doctor Tim Spelman	Targeted competitive	1/02/2023	31/07/2027	Health Sciences	Health Sciences, Allied Health And Rehabilitation Science, Physiotherapy	\$	1,244,761.78
Clinician Researchers	2022 Clinician Researchers: Nurses, Midwives and Allied Health	The University of Queensland	University	QLD	E-PACT: Randomised Trial of Parenting Acceptance and Commitment therapy for Parents of children with neurodevelopmental disabilities	This project aims to have a lasting impact upon the lives of children with neurodevelopmental disabilities (NDD) and their families by growing parent capacity through parenting support. Based on five successful RCTs we have developed an online/telehealth solution - "e-PACT". In this study we will trial e-PACT with 300 families. We predict that e-PACT will improve parental capacity as measured by the parent-child relationships, with benefits for both parent and child physical and mental health.	Doctor Koa Whittingham	Doctor Koa Whittingham, Associate Professor Josephine Barbaro, Doctor Jacqueline Barloot, Professor Roslyn Boyd, Associate Professor Kristelle Hadley, Doctor Syed Afroze Karamat, Doctor Amy Mitchell, Professor Iona Novak, Doctor Natasha Reid	Targeted competitive	1/02/2023	31/01/2027	Psychology	Psychology, Clinical And Health Psychology, Clinical Psychology	\$	1,458,918.95
Clinician Researchers	2022 Clinician Researchers: Nurses, Midwives and Allied Health	The University of Newcastle	University	NSW	ESTEEM After Stroke: Improving access to stroke rehabilitation for regional Australians	This health Professionals-led research will improve regional stroke survivor's access to stroke care. Access will be improved by supporting non-government health care organisations to deliver the ESTEEM Program. The ESTEEM Program is a peer-supported program combining exercise, socialisation and creative art activities. This research will determine the effect that participation in the ESTEEM Program has on stroke survivor recovery and their and their carer's emotional health and quality of life.	Doctor Heidi Janssen	Doctor Heidi Janssen, Doctor Marie-Louise Bird, Professor Coralie English, Doctor Carlos Garcia-Espersen, Doctor Kristi Naras, Doctor Liam Johnson, Professor Christopher Levi, Professor Michael Nilsson, Doctor Christopher Oldmeadow, Doctor Christine Sherer, Doctor Dawn Simpson, Professor Neil Sprott	Targeted competitive	1/02/2023	31/01/2027	Health Sciences	Health Sciences, Health Services And Systems, Health And Community Services	\$	1,485,667.11
Clinician Researchers	2022 Clinician Researchers: Nurses, Midwives and Allied Health	Monash University	University	VIC	A national platform for improving quality of nutrition care for critically ill adults and children	We propose the first national platform to transform the future of nutrition care for critically ill adults and children in Australia. The primary aim of this proposal is to re-design and inform new models of nutrition care to ensure efficient and effective application of resources in the way consumers need. The impact will be improved quality of care and rapid reduction in complications associated with poor nutrition (for which critically ill patients are at high risk).	Doctor Emma Ridley	Doctor Emma Ridley, Doctor Darsini Aytan, Professor Michael Bailey, Professor Warwick Butt, Doctor Lee-anne Chapple, Doctor Kate Fetterplace, Doctor Amy Freeman-Sanderson, Professor Carol Hodgson, Victoria King, Professor Andrea Marshall, Professor Alastair Nichol, Professor Sandra Peake, Doctor Clara Tatuso, Professor Andrew Udy, Ms Jacinta Winderlich	Targeted competitive	1/02/2023	31/07/2027	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Clinical Sciences, Intensive Care	\$	1,494,950.90
Clinician Researchers	2022 Clinician Researchers: Nurses, Midwives and Allied Health	University of Sydney	University	NSW	Restructuring musculoskeletal health services to ensure equitable access to effective, affordable allied health care	Musculoskeletal conditions, such as back and neck pain, are extremely common and put a huge strain on the public healthcare system. This program of work is led by physiotherapists and aims to test new virtual models of care that improve the health of Australians, are preferred by patients & health Professionals, and use scarce healthcare money more efficiently. The new health services utilise virtual technology to reduce waiting times & ensure equitable access to effective, affordable care.	Doctor Joshua Zadro	Doctor Joshua Zadro, Professor Iana Ackerman, Doctor David Anderson, Professor Rachelle Buchsinder, Doctor Danielle Coombs, Professor Ian Harris, Professor Lisa Harvey, Doctor Gustavo Machado, Professor Chris Maher, Doctor Stephanie Matheson, Doctor Bethan Richards, Doctor Christina Abdel Shaheed, Professor Timothy Shaw, Doctor Michael Swain, Doctor Adrian Traeger	Targeted competitive	1/02/2023	31/07/2027	Health Sciences	Health Sciences, Allied Health And Rehabilitation Science, Physiotherapy	\$	1,491,473.01
Clinician Researchers	2022 Clinician Researchers: Nurses, Midwives and Allied Health	University of Sydney	University	NSW	Adoption, impact and sustainability of evidence-based practice into health care: Co-design and evaluation of projects, systems and processes	As allied health and nursing world-leaders in clinical, health services research and implementation science we will build evidence that supports effective adoption of evidence into health care. In partnership with consumers and stakeholders, we will develop and implement an efficient data collection system and systematically evaluate the funded Stream 1 and 2 projects led by nursing and allied health clinicians. These co-designed systems and resources will be transferable to other MRFF schemes.	Professor Julie Redfern	Professor Julie Redfern, Professor Andrew Baillie, Professor Raymond Chan, Associate Professor Caleb Ferguson, Professor Robyn Gallagher, Associate Professor Alexis Hure, Doctor Karlee Hynn, Professor Debra Jackson, Doctor Sarah Partridge, Doctor Mitchell Sarkies, Professor Catherine Sherrington	Targeted competitive	1/02/2023	31/01/2028	Health Sciences	Health Sciences, Health Services And Systems, Implementation Science And Evaluation	\$	299,118.94
Coronavirus Research Response	2020 Antiviral Development for COVID-19 (Stage One)	Monash University	University	VIC	Inhaled oligonucleotides to generate a decoy receptor for the SARS Coronavirus-2	The SARS-Coronavirus-2 gains access to the human body by binding to ACE2 on the surface of certain cells. We have found a practical way to change ACE2 so that it is no longer on the surface of cells, so can't be used as a conduit for virus entry. Moreover, by still being able to bind to this, this soluble ACE2 can act as a decoy receptor to prevent virus accessing other cells. This technology has been approved for use in humans, and represents a novel strategy for COVID-19.	Professor Merlin Thomas	Professor Merlin Thomas, Professor Stephen Willott, Doctor Julie McAuley, Doctor Raeline Pickering	Targeted competitive	1/06/2020	28/02/2021	Medicinal And Biomolecular Chemistry	Biologically Active Molecules	\$	297,057.90
Coronavirus Research Response	2020 Antiviral Development for COVID-19 (Stage One)	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	Biologics for the prophylaxis and treatment of COVID-19	Agents for treatments and prevention of COVID-19 infection are urgently needed. Antibodies are widely used to treat several infectious diseases, as well as autoimmune diseases and cancer. Using novel antibody discovery platforms and high-throughput screening approaches, our team of academic and industry partners is uniquely positioned to accelerate the discovery of an effective and safe antibody-based therapy to combat the new pandemic coronavirus.	Doctor Wai-Hong Tham	Associate Professor Wai-Hong Tham, Professor Stephen Kent, Doctor Mark Lidarment, Mr Peter Smith, Doctor Adam Wheatley, Doctor Amy Chung, Professor Dale Godfrey, Professor P. MARK Hogarth, Professor Miles Davenport, Doctor Daniel Layton	Targeted competitive	1/06/2020	28/02/2021	Medicinal And Biomolecular Chemistry	Biologically Active Molecules	\$	1,990,853.20
Coronavirus Research Response	2020 Antiviral Development for COVID-19 (Stage One)	University of New South Wales	University	NSW	Hyperimmune globulin: a rapid pathway to treatment of COVID-19	We have assembled a partnership to rapidly harness the body's successful immune responses in the form of antibodies in the blood, to pool them from many patients, purify them and then use them as an intravenous therapeutic to bring the infection under control in those who have progressive infection.	Professor Anthony Kelleher	Professor Anthony Kelleher, Professor Geoffrey Symonds, Associate Professor Mark Polizzotto, Professor Matthew Law, Doctor Matthew O'Sullivan, Associate Professor Stuart Turville, Doctor Louise Batta	Targeted competitive	1/06/2020	31/12/2022	Clinical Sciences	Infectious Diseases	\$	2,065,257.15
Coronavirus Research Response	2020 Antiviral Development for COVID-19 (Stage One)	Burnet Institute	Medical Research Institute	VIC	Novel inhibitors of SARS coronaviruses targeting ACE2	Antiviral therapies are urgently needed to improve the outcome of the many thousands of patients infected with SARS-CoV-2, who develop COVID-19 related respiratory failure. This project will determine the antiviral activity of peptide based inhibitors of the cellular receptor for SARS-coronaviruses, angiotensin-converting enzyme 2, and their mechanism of action. Inhibitors will be rapidly progressed into clinical studies in stage 2 to evaluate whether they improve patient outcomes.	Professor Heidi Drummer	Professor Heidi Drummer, Professor Robert Widdop, Professor Marie Isabel Aguilar, Professor Yahya Shehadi, Doctor Mark Del Borge, Associate Professor Pascal Coulibaly, Associate Professor James McMahon, Doctor Ketay Kulkarni, Mr Peter Lambert, Professor Michelle McIntosh	Targeted competitive	1/06/2020	31/08/2021	Medical Microbiology	Medical Virology	\$	296,956.50
Coronavirus Research Response	2020 Antiviral Development for COVID-19 (Stage One)	Griffith University	University	QLD	Targeting SARS-CoV-2 using Stealth nanoparticles loaded with gene silencing siRNAs	We have developed technology that turns off respiratory virus genes, resulting in a 99.9% reduction in virus growth in animal models. We have already used it against Hendra virus, RSV, and HMPV. These stealth nanoparticles, made from FDA approved materials, are able to deliver to the infected lung cells via the blood stream, bypassing the inflamed airway that blocks other medicines from working. Here we will explore this for COVID-19 virus.	Professor Nigel McMillan	Professor Nigel McMillan, Professor Kevin Morris, Doctor Ad Idris, Doctor Nicholas West, Professor Keith Grimwood, Professor Robert Ware, Professor Suresh Mahalingam	Targeted competitive	1/06/2020	28/02/2021	Medical Microbiology	Medical Virology	\$	317,694.00
Coronavirus Research Response	2020 Antiviral Development for COVID-19 (Stage One)	Monash University	University	VIC	Convalescent Plasma for COVID-19	This study will evaluate whether administration of plasma containing antibodies against COVID-19, collected from people who have recovered from the infection, is safe and improves outcomes for patients admitted to hospital or intensive care with COVID-19. In partnership with Australian Red Cross Lifeblood, we will establish the process to collect, test and administer the convalescent plasma. We will then test whether it is safe and effective in two large, multicentre, national clinical trials.	Associate Professor Zoe McQuilten	Associate Professor Zoe McQuilten, Professor David Cooper, Professor Erica Wood, Associate Professor Steven Tong, Doctor James Daly, Professor Ian Goshel, Professor Alastair Nichol, Professor Allen Cheng, Doctor Live Escourt, Professor Damian Barrett	Targeted competitive	1/06/2020	28/02/2021	Clinical Sciences	Infectious Diseases	\$	371,606.00
Coronavirus Research Response	2020 Antiviral Development for COVID-19 (Stage One)	Monash University	University	VIC	Ivermectin as an anti-viral against SARS-CoV-2	We have shown that the drug ivermectin, which is already used in humans to treat a number of parasite infections, is also very effective at preventing the virus that causes COVID-19 from replicating. We have shown this in virus infecting cells in a laboratory and now we will confirm whether it is able to be used in people suffering from COVID-19. As ivermectin is already safe for use, if it is effective against the virus at these safe concentrations it can be rapidly moved into human trials.	Doctor Kylie Wagstaff	Doctor Kylie Wagstaff, Professor David Jans, Doctor Julian Druce, Doctor Leon Cady, Associate Professor Justin Denholm	Targeted competitive	1/06/2020	28/02/2021	Medical Microbiology	Medical Virology	\$	344,458.70
Coronavirus Research Response	2020 Antiviral Development for COVID-19 (Stage One)	University of New South Wales	University	NSW	Monoclonal antibody therapy of COVID-19	The 2019/20 coronavirus (COVID-19) outbreak originating in the Wuhan province of China represents a major health emergency. In the earlier 2003 outbreak protective antibodies against the highly related SARS coronavirus have been described. Intriguingly, recent data indicate that these antibodies may not only be applicable to SARS, but also to COVID-19. Here we outline a strategy to develop these antibodies for COVID-19 therapy.	Professor Daniel Christ	Professor Daniel Christ, Professor William Rawlinson, Professor Christopher Goodnow, Professor Sean Emery	Targeted competitive	1/06/2020	28/02/2021	Clinical Sciences	Infectious Diseases	\$	594,420.08
Coronavirus Research Response	2020 Antiviral Development for COVID-19 (Stage One)	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	Targeting the double-strand break activity of Coronaviruses: the ViDUB programme	SARS-CoV-2 shares mechanisms to efficiently reproduce and infect human cells with previous coronaviruses. We propose to directly drug a viral enzyme, the Papain-like protease PLpro, required for this process. During Stage 1, the ViDUB program will deploy an accelerated approach to identify potent drugs disabling PLpro. During Stage 2, candidate antivirals will progress through already established clinical trials to offer benefit to patients and health professionals for prophylaxis and treatment.	Doctor David Komander	Professor David Komander, Professor Guillaume Lessene, Professor Marc Pellegri, Associate Professor Peter Czabotar	Targeted competitive	1/06/2020	28/02/2021	Medicinal And Biomolecular Chemistry	Molecular Medicine	\$	1,055,207.80
Coronavirus Research Response	2020 Antiviral Development for COVID-19 (Stage Two)	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	Biologics for the prophylaxis and treatment of COVID-19	Agents for treatments and prevention of COVID-19 infection are urgently needed. Antibodies are widely used to treat several infectious diseases, as well as autoimmune diseases and cancer. Using novel antibody discovery platforms and high-throughput screening approaches, our team of academic and industry partners is uniquely positioned to accelerate the discovery of an effective and safe antibody-based therapy to combat the new pandemic coronavirus.	Doctor Wai-Hong Tham	Associate Professor Wai-Hong Tham, Professor Stephen Kent, Doctor Mark Lidarment, Mr Peter Smith, Doctor Adam Wheatley, Doctor Amy Chung, Professor Dale Godfrey, Professor P. MARK Hogarth, Professor Miles Davenport, Doctor Daniel Layton	Targeted competitive	1/06/2020	28/02/2021	Medicinal And Biomolecular Chemistry	Biologically Active Molecules	\$	5,000,000.00
Coronavirus Research Response	2020 Australian COVID-19 (ASCOI) Trial	The University of Queensland	University	QLD	The Australian COVID-19 Trial (ASCOI) Trial	The world needs several trials of existing agents that are repurposed to treat COVID-19 disease and related complications. Of the currently known "repurposed" agents, hydroxychloroquine and lopinavir/ritonavir, appear to be promising. Preventing people infected with COVID-19 from developing severe enough symptoms to need mechanical ventilation or die is a major priority. If this therapy is proven conclusively to be effective, it will be used around the world. If it proves ineffective, other treatments will be explored emergently using the platform we (and other investigators) will establish.	Doctor Steven Tong	Doctor Steven Tong	Closed non-competitive	1/06/2020	30/06/2023	Not available	Not available	\$	350,000.00

Coronavirus Research Response	2020 Communication Strategies and Approaches During Outbreaks	Monash University	University	VIC	Effectiveness of tailored COVID-19 message for vulnerable Australians	Effective management of the COVID-19 pandemic in Australia requires the delivery of well-designed and relevant public health messages to all communities. This project will work with six of the most vulnerable Australian communities to ensure that suitable COVID-19 messages reach them. We will work to: 1) identify their COVID-19 information and communication needs; 2) co-design tailored communication strategies; and 3) evaluate the effectiveness of these communication strategies. This project will provide a better understanding of the unique COVID-19 information and communication needs of vulnerable Australian communities, and the materials required to ensure that no Australian is left behind in the effort to reduce the spread of COVID-19.	Professor Terry Haines	Not available	Open competitive	1/02/2021	30/09/2022	Not available	Not available	\$	315,961.00
Coronavirus Research Response	2020 Communication Strategies and Approaches During Outbreaks	Deakin University	University	VIC	Inclusive Health Communication in Specialist Disability Accommodation	Written and spoken health information is inaccessible for many people with intellectual disability. Building on our extensive work in inclusive communication, this study will identify communication priorities and effective supports for people with intellectual disability living in high risk specialist disability accommodation (SDA) during disease outbreaks. Using observations, interviews and a literature synthesis we will evaluate current engagement with COVID-19 messaging in SDA settings. A modified Delphi study will identify public health communication priorities and effective supports for this community across broader health and human service contexts, informing a scalable SDA communication strategy for public health events.	Doctor Kate Anderson	Not available	Open competitive	1/02/2021	31/10/2022	Not available	Not available	\$	109,047.00
Coronavirus Research Response	2020 Communication Strategies and Approaches During Outbreaks	Macquarie University	University	NSW	Harnessing the health communication power of the early childhood sector	This project investigates the quality and effectiveness of public health information used and communicated by the early childhood education (ECE) sector during the COVID-19 pandemic. A mixed method design will investigate how the ECE workforce accessed and communicated COVID-19 health information to families and staff, and examine the impact of attitudinal, behavioural and demographic characteristics on how information was sourced, interpreted and communicated. Findings will inform Best Practice Health Communication Guidelines and Recommendations to support the collective efforts of the health and ECE sector deliver a rapid and effective health communication response to future events that threaten the health of families and their educators.	Professor Sheila Degotardi	Not available	Open competitive	1/02/2021	30/06/2022	Not available	Not available	\$	174,992.00
Coronavirus Research Response	2020 COVID-19 Diagnosis Platform (CovID)	University of Sydney	University	NSW	Transforming recognition and assessment of COVID-19 in Australia using lung CT	COVID-19 is arguably the biggest health challenge facing Australia and the world for the last 100 years. Accurate assessment of the appearance of COVID-19 on lung CT scans is critically important to the management of patients and the disease. Research to date has shown large variability in clinicians' ability to recognise CT lesions. The current work will address this variability and builds on our previous research achievements which has built effective systems for other diseases. The result will be an innovative intelligent education solution with AI integration that will transform COVID-19 diagnostic efficacy.	Professor Patrick Brennan	Professor Patrick Brennan, Professor Stuart Grieve	Closed non-competitive	15/05/2020	30/06/2021	Not available	Not available	\$	1,042,698.00
Coronavirus Research Response	2020 COVID-19 Diagnostics	University of Melbourne	University	VIC	COVID-19 Strategic Planning and Delivery of Testing	This project consists of four key sub-projects that tackle the evolving pandemic, increase testing capability and control transmission of COVID-19. 1. 'One-stop' nucleic acid detection that saves on critical lab consumables and is rapid. 2. Post-market evaluation of TGA approved diagnostic tests before to ensure the quality, accuracy and sensitivity. 3. Development of new testing protocols to enable more individuals to be tested. 4. Testing and validation of serological POCT and assays.	Professor Sharon Lewin	Professor Sharon Lewis, Professor Benjamin Howden, Professor Tim Sinear, Professor Deborah Williamson, Doctor Mike Catton, Doctor Ian Monk, Doctor Roman Guerliot, Doctor Jean Lee, Doctor Norville Sherry, Doctor Katherine Bond	Closed non-competitive	1/05/2020	31/12/2022	Medical Microbiology	Medical Virology	\$	2,699,278.00
Coronavirus Research Response	2020 COVID-19 Immunological Studies	University of Melbourne	University	VIC	Defining immune responses in COVID-19 to understand susceptibility and target treatment	New vaccines and therapies are urgently needed for prevention and treatment of COVID-19. Our MHRF encompasses Australia's most advanced COVID-19 immunology program which will define protective and long-lasting immunity against SARS-CoV-2 and delineate detrimental immunopathology in COVID-19. Our in-depth immune studies in wide ranging cohorts will provide key insights into the rational design of vaccines and therapies to limit disease spread and protect high-risk groups.	Professor Katherine Kedzierska	Professor Katherine Kedzierska, Professor Stephen Kent, Professor Dale Godfrey, Professor James McCuskey, Doctor Adam Wheatley, Doctor Jennifer Juno, Doctor Amy Chung, Associate Professor Jane Davies, Professor Allen Cheng, Professor Deborah Williamson	Targeted competitive	1/11/2020	31/10/2022	Immunology	Cellular Immunology	\$	999,999.30
Coronavirus Research Response	2020 COVID-19 Immunological Studies	University of New South Wales	University	NSW	Cellular and molecular correlates to SARS-CoV2 immunity in convalescent patients	Studying the natural infection and the level of immunity across these patient groups with varying disease characteristics will support: understanding the immunological correlates of protection against SARS-CoV-2 infection - understanding how genetic variation between SARS-CoV-2 isolates (as the virus mutates) affects the immune response of different patient groups.	Associate Professor Stuart Turville	Associate Professor Stuart Turville, Professor Gail Matthews, Professor Miles Davenport, Doctor John Zauders, Professor Tri Phan, Associate Professor Fabio Luciani, Professor William Rawlinson, Professor Jan Gasbatt	Targeted competitive	1/11/2020	31/10/2023	Medical Microbiology	Medical Virology	\$	994,584.00
Coronavirus Research Response	2020 COVID-19 Immunological Studies	The Council of the Queensland Institute of Medical Research	Medical Research Institute	QLD	Defining SARS-CoV-2 immune maintenance in the Australian population	Control of viruses in humans is dependent on B cells that produce antibodies to recognise and neutralise virus particles, and T cells that recognise and remove virally infected cells. Currently, we do not know how these immune cells live for in individuals who have recovered from COVID-19. This must be determined in order to assess the risk of reinfection and identify which part of the population may benefit from vaccine boosters if a COVID-19 vaccine becomes available.	Associate Professor Corey Smith	Associate Professor Corey Smith, Professor Stephanie Gras, Doctor Kirsty Short, Associate Professor Kim Jacobson, Associate Professor Gunter Hartel, Doctor Helen Barrett, Professor Scott Kitchener	Targeted competitive	1/11/2020	31/10/2022	Immunology	Cellular Immunology	\$	998,876.00
Coronavirus Research Response	2020 COVID-19 Mental Health Research	University of Canberra	University	ACT	Implementing Artificial Intelligence (AI) to enhance Lifeline's crisis support service capacity in response to COVID-19 and emerging crises	Lifeline is Australia's national 24-hour crisis service for the general community. It featured heavily in the Australian Government's communications to encourage Australians to seek mental health support during COVID-19, with contacts surging 25 percent. This research aims to boost Lifeline's capacity by using artificial intelligence to enhance its ability to respond rapidly and effectively to emerging community mental health crises.	Professor Debra Rickwood	Professor Debra Rickwood, Professor Roland Goetsch, Doctor Mark Larsen, Professor Julian Epps, Professor Britt Klein, Doctor Abhinav Dhall, Doctor Jennifer Ma	Targeted competitive	1/11/2020	30/11/2022	Public Health And Health Services	Mental Health	\$	218,139.85
Coronavirus Research Response	2020 COVID-19 Mental Health Research	Monash University	University	VIC	Mobilising and empowering parents in the COVID-19 mental health response: A single-arm trial of an enhanced online parenting intervention to improve parent risk and protective factors for adolescent mental health	We aim to reduce the mental health impacts of COVID-19 and risk of longer-term adolescent mental health problems by enhancing their parents' ability to support them through this pandemic. We will involve parents in a co-designed process that learns and responds to their changing needs, to dynamically adapt an evidence-based parenting program integrated with an online peer-support network for parents. Our research will empower parents in their capacity to support their adolescents' mental health.	Associate Professor Marie Yap	Associate Professor Marie Yap, Emeritus Professor Anthony Iom, Professor Patrick Olivier, Doctor Rosin McNamey, Ling Wu, Doctor Mairied Cardamone-Breen, Doctor Thomas Barindade, Doctor Stephen Carbone, Associate Professor Sarah Whittle, Doctor Ori Schwartz	Targeted competitive	1/11/2020	31/12/2022	Public Health And Health Services	Mental Health	\$	610,922.75
Coronavirus Research Response	2020 COVID-19 Mental Health Research	University of Technology Sydney	University	NSW	Identifying the mental health effects and support needs of people bereaved during and following COVID-19: A Mixed Methods Project	The potential for significant mental health distress following bereavement has been recognised by the World Health Organisation. Bereavement is linked with mental health conditions such as major depression, anxiety and suicidal ideation. Many of the risk factors for poor mental health have been amplified by the COVID-19 pandemic: restrictions on gatherings and physical contact. This project will quantify the mental health outcomes and support needs of bereaved individuals impacted by COVID-19.	Professor Elizabeth Lobb	Professor Elizabeth Lobb, Doctor Fiona MacCallum, Professor Meera Agar, Professor Jane Phillips, Associate Professor Lauren Breen, Doctor Tim Luckett, Associate Professor Michelle Dilescio, Professor Jennifer Philip, Professor Jennifer Tienan, Associate Professor Annmarie Hosie	Targeted competitive	1/11/2020	31/10/2022	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	748,750.00
Coronavirus Research Response	2020 COVID-19 Mental Health Research	Deakin University	University	VIC	Evaluating the effectiveness of lifestyle therapy versus standard psychotherapy for reducing depression in adults with COVID-19 related distress: The CALM trial	The mental health of Australians has deteriorated since the COVID-19 outbreak. Our data show almost 1 in 2 Australians experienced depression during lockdown. CALM is an 8-week group-based, telehealth, lifestyle program for those with elevated psychological distress. It is delivered in Victoria as part of a partnership between Deakin University & Barwon Health's Mental Health, Drug & Alcohol Services. We anticipate CALM will be as effective and cost-effective as therapy for reducing depression.	Associate Professor Adrienne O'Neil	Associate Professor Adrienne O'Neil, Professor Felice Jada, Professor Must Yucel, Professor Jane Speight, Associate Professor Pivlicki Absate, Associate Professor Vincent Versace, Doctor Megan Tychenne, Associate Professor Simon Rosenbaum, Doctor Mary Lou Chatterton	Targeted competitive	1/11/2020	30/04/2022	Public Health And Health Services	Mental Health	\$	885,302.50
Coronavirus Research Response	2020 COVID-19 Mental Health Research	University of Wollongong	University	NSW	Narratives of Recovery - Practices supporting community mental health and well being post bush fire and COVID-19	Some communities have implemented their own strategies to address mental health problems following COVID-19. Local responses to community need are grounded in contextual knowledge and use existing resources. This project will investigate two different interventions delivered on the South Coast of NSW. The research will provide evidence about ways the interventions ameliorated crises. The outcomes will include recommendations for place-based, culturally safe approaches to mental health care.	Associate Professor Lynne Keewers	Associate Professor Lynne Keewers, Doctor Julianne Allan, Doctor Christopher Degeling, Mrs Maria Mackay, Mrs Kristine Falzon, Doctor Katerinya Olson, Doctor Kim Fox, Doctor Summer Finlay, Padmini Pai	Targeted competitive	1/11/2020	31/03/2023	Public Health And Health Services	Mental Health	\$	425,803.45
Coronavirus Research Response	2020 COVID-19 Mental Health Research	University of New South Wales	University	NSW	A novel text mining and data linkage approach to investigate the mental health needs of the population during the COVID-19 period	The impact of COVID-19 is expected to affect individuals with increases in mental illness, suicide, and self-harm events. The police are often the first to respond to these events, and their records contain reliable information that is not been used for mental health reporting purposes. This project will use a novel automated method to process police records of the last four years and investigate whether there have been any increases in mental illnesses before and during the COVID-19 crisis.	Professor Tony Butler	Professor Tony Butler, Doctor George Karystianis, Doctor Adrienne Whithall, Professor David Greenberg, Doctor Mandy Wilson, Professor Goran Nenadic, Professor Iain Buchan, Doctor Patricia Culcin	Targeted competitive	1/11/2020	30/04/2023	Public Health And Health Services	Mental Health	\$	232,159.00
Coronavirus Research Response	2020 COVID-19 PRO-COVER Trial	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	COVID-19 Prophylaxis with Hydroxychloroquine in Front-line Health and Allied Health Care Workers - The COVID-SHIELD Trial	As lock-down restrictions ease, there is potential for clusters of COVID-19 outbreaks. This places front-line healthcare workers at greater risk of becoming unknowingly infected or transmitting the SARS-CoV-2 virus that causes COVID-19. There is substantial international hype around the use of hydroxychloroquine (HCQ) as a prophylactic treatment, however, clear scientific evidence that it can prevent infection of SARS-CoV-2 is limited and a rigorous clinical trial is needed to determine if HCQ can provide benefit, harm or neither. The COVID-SHIELD trial will determine whether the drug hydroxychloroquine can protect healthcare workers from becoming infected with the SARS-CoV-2 virus.	Professor Marc Pellegrini	Professor Marc Pellegrini, Professor Ian Wicks, Associate Professor Mandana Nikpour, Professor Gairn Thurnhy, Doctor Maria Brown, Doctor Michelle Yong, Professor Monica Slavin	Closed non-competitive	15/05/2020	31/12/2021	Not available	Not available	\$	3,000,000.00
Coronavirus Research Response	2020 COVID-19 Vaccine Candidate Research (Round 1)	University of Melbourne	University	VIC	A safe, effective, and rapidly tunable SARS-CoV-2 vaccine	In response to the COVID-19 pandemic >200 vaccine candidates are in active development and >20 in clinical trials. While we hope that these 'first generation' vaccines will be safe and effective, there are sure to be challenges in deploying these vaccines to all parts of the globe, including Australia, in a timely manner. Accordingly, we have developed two vaccine candidates with significant novelty, tempered by realistic deployment imperatives, to be deployed in this global emergency.	Professor Dale Godfrey	Professor Dale Godfrey, Professor Damian Purcell, Professor David Jackson, Professor Gairn Thurnhy, Professor Sharon Lewin, Professor Terry Nolan, Professor Katherine Kedzierska, Doctor Amy Chung, Associate Professor Steven Rockman, Professor Robin Shaddock	Targeted competitive	1/10/2020	30/09/2023	Clinical Sciences	Infectious Diseases	\$	2,999,502.00

Coronavirus Research Response	2020 COVID-19 Vaccine Candidate Research (Round 1)	University of Sydney	University	NSW	Novel DNA based COVID-19 vaccine: A phase 1/1b trial for Australia	This phase 1/1b clinical COVID-19 vaccine trial aims to assess the safety and immune responses of a candidate DNA vaccine made by Bionet-Asia. 150 healthy volunteers aged 18 to 75 will be invited to participate. This is a partnership with 4 of Australia's most experienced academic vaccine trial sites, who form an Alliance, known as Vax4COVID and Bionet Asia. If successful larger phase 2 trials will follow. This trial is an important contribution to our goal of developing a COVID-19 vaccine.	Associate Professor Nicholas Wood	Associate Professor Nicholas Wood, Associate Professor Peter Richmond, Professor Helen Marshall, Doctor Anita van den Biggelaar, Professor Dominic Dwyer	Targeted competitive	1/10/2020	30/09/2023	Clinical Sciences	Infectious Diseases	\$	2,954,760.00
Coronavirus Research Response	2020 COVID-19 Vaccine Candidate Research (Round 2)	University of Sydney	University	NSW	A single dose, globally accessible vaccine to combat emerging SARS-CoV-2 variants	The emergence of highly transmissible SARS-CoV-2 variants threatens to derail COVID-19 control efforts. We have developed a next-generation vaccine, delivered as a single dose, that targets these variants. In this proposal we will undertake late-stage pre-clinical testing to determine the optimal vaccine formulation, define protective efficacy against SARS-CoV-2 infection and assess vaccine safety/tolerability. Outcomes will be used to fast track vaccine progression to clinical testing.	Professor James Triccas	Professor James Triccas, Doctor Claudio Counoupas, Professor Philip Hambro, Professor Nigel Curtis, Doctor Megan Stearn, Professor Gregory Fox, Doctor Angela Ferguson, Emeritus Professor Warwick Britton, Associate Professor Stuart Turville, Professor Wayne Haythorne	Targeted competitive	1/03/2021	31/08/2023	Medical Microbiology	Medical Virology	\$	1,556,560.00
Coronavirus Research Response	2020 COVID-19 Vaccine Candidate Research (Round 2)	University of South Australia	University	SA	Accelerated clinical development of a next generation COVID-19 vaccine using the established Semantics Copenhagen Vector platform system	In response to the global COVID-19 pandemic, the WHO have outlined the need for vaccines, which can address outbreaks, and provide population scale vaccination for the longer term. Our COVID-19 vaccine, based on a novel next-generation non-replicating viral vector vaccine technology, is advanced in development, and designed to deliver safe, broad, and long-lasting immunity. It can be produced economically and at scale to support these large-scale national and global vaccination programs.	Professor John Hayball	Professor John Hayball, Mr Peter Wulff, Doctor Paul Wabnitz	Targeted competitive	1/03/2021	30/06/2023	Immunology	Applied immunology (incl. Antibody Engineering, Xenotransplantation And T-Cell Therapies)	\$	2,983,909.00
Coronavirus Research Response	2020 COVID-19 Vaccine Candidate Research (Round 3)	University of Melbourne	University	VIC	AdaptiVax-CoV: A novel adaptable SARS-CoV-2 VLP vaccine to produce broad humoral and T cell responses to S, E and M viral proteins	In response to the COVID-19 pandemic over 20 vaccines are in clinical trials to test if these 'first generation' vaccines are safe and effective. However, whilst these vaccines may prove to be efficacious, they will only produce limited immune responses that will fail to protect against emerging coronaviruses. Accordingly, we have developed a significantly novel vaccine candidate that will produce broadly protective responses not only for COVID-19 but also future coronavirus global threats.	Professor Joseph Torresi	Professor Joseph Torresi, Professor William Heath, Professor Elizabeth Vincan, Professor Jason Macdonald, Professor Marc Pellegrini, Doctor Tim Adams, Doctor Peter Kelly, Professor Graham Le Gros	Targeted competitive	1/06/2021	31/12/2023	Clinical Sciences	Infectious Diseases	\$	2,999,862.00
Coronavirus Research Response	2020 COVID-19 Vaccine Candidate Research (Round 3)	University of Melbourne	University	VIC	Chimeric next generation COVID vaccines	New COVID vaccines to combat newly emerging strains are needed. However, simply remaking current vaccines with the new strains might not work since those vaccines are likely to boost only the same responses to the original strain, not make new immunity to the new strain. We have developed a 'CITE' COVID vaccine platform that will assess for 'focussing' of immunity to the new strain. Our goal is to test the immunity that 'future proofs' against the threat of newly emerging SARS-CoV-2 strains.	Professor Stephen Kent	Professor Stephen Kent, Professor Trent Munro, Professor Kanta Subbarao, Jason Lekleiter, Doctor Adam Wheatley, Doctor Jennifer Jung, Associate Professor Wai-Hong Tham, Doctor Kyle Quinn, Doctor Hyon Xhi Tan	Targeted competitive	1/06/2021	31/05/2024	Clinical Sciences	Infectious Diseases	\$	3,000,000.00
Coronavirus Research Response	2020 COVID-19 Vaccine Research	The University of Queensland	University	QLD	Rapid Acceleration of the UQ COVID-19 Vaccine Program	UQ is currently developing a vaccine for the COVID-19 outbreak based on its proprietary technology, the Molecular Clamp. We are requesting \$3M in funding from the Federal Government, in part support of achieving our ambitious goal to accelerate and advance this vaccine for the Australian and global population building on existing support from CEPI (Coalition for Epidemic Preparedness Innovations) and the Queensland Government.	Associate Professor Keith Chappell	Associate Professor Keith Chappell, Professor Trent Munro, Professor Paul Young	Closed non-competitive	1/06/2020	30/06/2023	Not available	Not available	\$	2,999,990.00
Coronavirus Research Response	2020 National COVID-19 Clinical Evidence Taskforce	Monash University	University	VIC	COVID-19 Clinical Evidence Taskforce	As clinicians work to provide the best possible care for Australians during the COVID-19 pandemic, we're working to keep them up-to-date with the latest evidence. The National COVID-19 Clinical Evidence Taskforce is a collaboration of over 25 national clinical groups, supporting Australia's healthcare professionals with continually updated, evidence-based clinical guidelines. In a world-first initiative, we use new technologies and methods to find and assess the latest research so we can update 'living' national guidelines every week. We provide the best evidence to support the best care for Australians during the COVID-19 crisis.	Associate Professor Julian Elliott	Associate Professor Julian Elliott, Professor Sally Green, Professor Jonathan Craig, Professor Sophia Zoungas, Professor Rachelle Buchbinder, Leanne Wells, Doctor Britta Tensdal, Associate Professors Joshua Vogel, Doctor Sarah Norris, Doctor Tani Turner	Closed non-competitive	15/05/2020	30/06/2021	Not available	Not available	\$	1,500,000.00
Coronavirus Research Response	2020 Novel Coronavirus Vaccine Development	The University of Queensland	University	QLD	Molecular Clamp Stabilized Spike Vaccine for Rapid Response	The Molecular Clamp platform is Australia's most advanced COVID-19 vaccine and is one of only four programs globally supported by CEPI for a rapid response to the outbreak. The strategic partners driving this application, The University of Queensland (UQ), The Doherty Institute (Doherty), and The Commonwealth Science Industrial Research Organisation (CSIRO), aim to complete pre-clinical evaluation of safety and protective efficacy in Q2 and Phase I human trials in Q3 2020. This will run in parallel with a separately proposed plan to expedite manufacturing at-scale. This ambitious approach has the potential to enable an Australian vaccine at an unprecedented pace, and have significant numbers of product in vial by the end of 2020 for further clinical and potential emergency distribution. If public health measures sufficiently slow infection rates, this increased speed has potential to have a major impact, especially for those at most risk, people with pre-existing medical conditions and the elderly. Given our recent progress, including identification of a candidate vaccine molecule, the funds requested in this proposal will be critical for studies designed to measure correlates of immune protection in COVID-19 patients during recovery and any immune responses associated with poor outcomes. Importantly, this work is also not covered by existing CEPI funding and fills a critical gap for vaccine development. Assays for these immune responses will be developed and used in animal vaccination studies and the human Phase I clinical trial. By directly comparing correlates of protection in natural infection with immune responses in the Phase I trial we will be able to optimise the vaccine dose and type of adjuvant to (i) ensure safety, (ii) elicit protection, and (iii) decrease antigen dose to inform future clinical or emergency use.	Doctor Keith Chappell	Doctor Keith Chappell, Professor Paul Young, Doctor Daniel Watterson, Professor Trent Munro, Professor Damian Purcell, Professor Katherine Kozienka, Doctor Chyng-Chung, Mr Trevor Drew, Professor Seshadi Vasan	Targeted competitive	1/06/2020	31/05/2023	Medical Microbiology	Medical Virology	\$	1,965,398.20
Coronavirus Research Response	2020 Rapid Response Digital Health Infrastructure	University of Sydney	University	NSW	Integrating remote monitoring technology into digital health infrastructure	We aim to improve the quality, safety and efficiency of remote patient monitoring in virtual hospitals using the experience of Sydney Local Health District's paviVital with pulse oximetry in COVID-19 patients. It is currently impossible to transfer data automatically from home devices to the CERNER Millennium electronic medical record (eMR). We will: (1) study the use and performance of pulse oximeters and their acceptability to staff and patients, and explore improvements; (2) develop and implement an application programming interface (API) to transfer pulse oximetry data to the eMR and a clinical interface for data extraction from the eMR; and (3) assess potential future applications of pulse oximeters. Results will apply Australia-wide.	Professor Andrew Wilson	Not available	Open competitive	12/04/2021	7/10/2022	Not available	Not available	\$	670,406.00
Coronavirus Research Response	2020 Rapid Response Digital Health Infrastructure	Monash University	University	VIC	Towards a national data management platform and Learning Health System	The Data Management Platform underpins the Learning Health System developed across NHMRC accredited Research Translation Centres nationally, with increased urgency under COVID-19. We draw on joint priorities, sustained investment and partnership across acute, ambulatory, primary and aged care services, government, industry and academia. Work packages include: governance, stakeholder and community engagement; data management processes, ethics, governance and consent; digital health tool co-development and adoption; data management pipeline co-development; digital tool implementation and integration; clinical trial cohort identification. Improved data management enables greater responsiveness to acute crises, recovery and beyond.	Professor Helena Teede	Not available	Open competitive	1/02/2021	30/06/2022	Not available	Not available	\$	1,922,584.00
Coronavirus Research Response	2020 Rapid Response Digital Health Infrastructure	Monash University	University	VIC	Real-time modelling of Australia's COVID-19 response	We will develop a modelling platform and simulation pipeline to model the COVID-19 pandemic across Australia in real-time for direct policy translation. Our platform will be distinguished by being modular, transparent, reliable, efficient and vividly communicated. Several of these features are already well-developed and will be markedly advanced over the grant period, during which time we will extend the platform into a full open-source collaboration open to external developers. Our models have already had a major influence on COVID-19 policy in Malaysia and the Philippines in collaboration with WHO, which will be extended to projections of epidemic burden and health system requirements in Victoria and other Australian jurisdictions.	Professor James Trauer	Not available	Open competitive	1/02/2021	29/07/2022	Not available	Not available	\$	810,300.00
Coronavirus Research Response	2020 Rapid Screening of Approved Drugs in Stem Cell Models for COVID-19	The Council of the Queensland Institute of Medical Research	Medical Research Institute	QLD	Preventing Cardiac Injury in Patients with COVID-19	COVID-19 can have fatal consequences in patients with underlying cardiovascular conditions, and cause cardiac injury even in patients without underlying heart conditions. The goal of the project is to rapidly screen for approved drugs that can be used to protect the heart in COVID-19 patients. We are applying a unique model of stem cell-derived human heart tissue developed in our lab that enables us to make rapid progress by being able to screen >100 conditions on a platform the size of a mobile phone.	Associate Professor James Hudson	Associate Professor James Hudson, Professor David James, Doctor Kelli Macdonald, Doctor Tobias Bald, Professor Christian Engwerda, Professor Mark Smyth	Closed non-competitive	1/06/2020	30/06/2021	Not available	Not available	\$	389,998.50
Coronavirus Research Response	2020 Rapid Screening of Approved Drugs in Stem Cell Models for COVID-19	University of Melbourne	University	VIC	Stem cell-derived human tissue models for the identification of drugs to treat COVID-19	This program is a collaboration between virologists at the Doherty Institute and stem cell biologists from the Murdoch Children's Research Institute, the University of Melbourne and Monash University to use models derived from human stem cells to test TGA/FDA approved drugs for antiviral activity against SARS-CoV-2 and enable their rapid repurposing to treat COVID-19. We will leverage our extensive knowledge of stem cell biology and virology to rapidly identify drugs that target the virus and to drugs that could be rapidly repurposed to protect against tissue damage in patients with COVID-19.	Professor Kanta Subbarao	Professor Kanta Subbarao, Associate Professor Enzo Porello, Doctor David Elliott, Professor Jose Polo, Professor Alastair Stewart, Doctor Jessica Vanslambrouk, Doctor Mariana Bax	Closed non-competitive	1/06/2020	31/01/2022	Not available	Not available	\$	610,000.00
Coronavirus Research Response	2020 Rare Cancers, Rare Diseases and Unmet Need COVID-19	Flinders University	University	SA	Prevention of SARS-CoV-2 transmission in aged care (PreSTAC): Effective evidence-based measures for rapid translation	Infection control measures in residential aged care facilities have proven insufficient to prevent COVID-19 outbreaks, with devastating consequences. We will compare an inexpensive and rapidly implementable germicidal ultraviolet air-treatment strategy, used in conjunction with existing infection control measures, with existing measures alone, as a means to reduce rates of respiratory viral infection in residential aged care facilities.	Professor Geraint Rogers	Professor Geraint Rogers, Professor Maria Crotty, Professor Lidia Morawska, Professor Scott Bell, Doctor Ming Qiao, Professor Richard Woodman, Associate Professor Craig Whitehead, Doctor Ivo Papanicolaou, Associate Professor Maria Inacio, Professor Caroline Miller	Targeted competitive	1/01/2021	31/12/2023	Medical Microbiology	Medical Virology	\$	1,366,094.00

Coronavirus Research Response	2020 Rare Cancers, Rare Diseases and Unmet Need COVID-19	University of Melbourne	University	VIC	Accelerated phase I trial of targeted and tunable SARS-CoV-2 spike protein receptor binding domain recombinant protein and mRNA vaccines	Two new 'next-generation' Australian COVID vaccines, soon to complete exhaustive MRFF-funded pre-clinical tests, will be studied in a first-in-human clinical trial. The vaccines target the virus receptor that attaches to human cells, and offer a number of potential advantages over first-generation vaccine candidates. The vaccines could be used separately, or together as a single dose not requiring a booster. This phase I study will be conducted in healthy Australian volunteers aged 18-75 years.	Professor Terry Nolan	Professor Terry Nolan, Professor Dale Godfrey, Professor Damian Purcell, Professor Colin Pouton, Professor David Jackson, Professor Julie Simpson, Associate Professor Steven Rockman, Miss Sabine Braat, Doctor Irani Ratnam	Targeted competitive	1/01/2021	31/12/2023	Clinical Sciences	Infectious Diseases	\$	1,588,283.00
Coronavirus Research Response	2020 Rare Cancers, Rare Diseases and Unmet Need COVID-19	University of New South Wales	University	NSW	Statins Treatment for COVID-19 to optimise Neurological Recovery (STRONGER) trial	COVID-19 can cause a range of complications to the brain. As well as predisposing patients to strokes from intense inflammation in the body and being critically ill, the virus may directly invade the brain to disrupt pathways. We aim to test whether statin treatment, widely prescribed to prevent strokes and improve cardiovascular health, has anti-inflammatory effects that can maintain memory and thinking after COVID-19 infection.	Professor Craig Anderson	Professor Craig Anderson, Professor Sophia Zoungas, Professor Sharon Naimism, Professor Meng Law, Professor Karin Leder, Doctor Ian Harding, Associate Professor Ruth Peters, Professor Mark Woodward, Associate Professor Julian Elliott, Doctor Cheryl Carrel	Targeted competitive	1/01/2021	31/12/2023	Cardiorespiratory Medicine And Haematology	Cardiology (incl. Cardiovascular Diseases)	\$	2,375,779.00
Coronavirus Research Response	2020 Rare Cancers, Rare Diseases and Unmet Need COVID-19	Flinders University	University	SA	3D-Printed Facial Guards to reduce P2/N95 respirator leak and protect health care workers from COVID-19	Face mask leak is a major problem for health care workers with existing P2/N95 respirators. The main reason for face mask leak is the individual variability in the shape of the human face. In this project we aim to test the effectiveness and feasibility of customised 3D-printed face guards used in conjunction with P2/N95 respirators as a way of reducing face mask leak. This is a rapidly scalable, customised technology that could quickly and feasibly be utilised around the world.	Associate Professor Anand Ganesan	Associate Professor Anand Ganesan, Professor Derek Chew, Professor Karen Reynolds, Mr Darius Chapman, Jane Parker, Doctor Shahid Ullah, Associate Professor Hossein Afzali	Targeted competitive	1/01/2021	31/12/2023	Biomedical Engineering	Biomedical Engineering Not Elsewhere Classified	\$	973,119.00
Coronavirus Research Response	2020 Rare Cancers, Rare Diseases and Unmet Need COVID-19	University of Melbourne	University	VIC	Use of Cardioprotective Therapy to Manage Persistent Cardiovascular Effects of COVID-19: A Pathway to Recognition and Treatment of Sclerotic Disease	COVID-19 disease starts as a respiratory infection, but heart and blood vessel involvement is common. Recent reports have shown heart muscle damage in not recovered patients after 2-3 months, suggesting that heart failure could develop as an important source of ongoing disability in patients who recover from the acute illness. This trial will define the value of medications and rehabilitation to prevent the progression to heart failure after recovery from COVID-19.	Professor Thomas Marxwick	Professor Thomas Marxwick, Doctor Erin Howden, Professor Graeme Maguire, Professor Kazuaki Negishi, Professor Lisa Thomas, Doctor Quan Huynh, Professor Paul Sciffham, Associate Professor Luke Burchill, Associate Professor Chiew Wong, Doctor Leah Wright	Targeted competitive	1/01/2021	31/12/2023	Cardiorespiratory Medicine And Haematology	Cardiology (incl. Cardiovascular Diseases)	\$	2,574,943.00
Coronavirus Research Response	2020 Rare Cancers, Rare Diseases and Unmet Need COVID-19	University of Melbourne	University	VIC	The Pomerium Trial: Protecting Aged Care Residents from the Pandemic via Specialised Nutritional Supplementation	Residents at aged care facilities are at much higher risk of infection and mortality associated with COVID-19. Other than complete isolation, there are not effective interventions to prevent this to happen. Here we propose to prepare residents for a pandemic via administration of a specialised nutritional supplement for at least 3 months. Benefits will include better protection against the disease, less associated complications, and stronger immune response to a future vaccine.	Professor Gustavo Duque	Professor Gustavo Duque, Doctor Sandra Iuliano-Burns, Professor Ralph Nanan, Doctor Ahmed Al Saei	Targeted competitive	1/01/2021	31/12/2023	Clinical Sciences	Geriatrics And Gerontology	\$	1,189,527.00
Coronavirus Research Response	2020 Respiratory Medicine Clinical Trials Research on COVID-19	Queensland University of Technology	University	QLD	Use of Therapeutic Drug Monitoring (TDM) optimise oral/enteral Hydroxychloroquine dosing in critically ill patients with COVID-19	The Royal Brisbane and Women's Hospital Intensive Care Unit Clinical Consultant Medical Staff, in agreement with the Infectious Diseases Department and the Pharmacy Department, have decided that all Covid-19 patients admitted to this unit should receive hydroxychloroquine as standard of care. This study is to determine whether therapeutic drug monitoring of hydroxychloroquine dosing in Covid-19 patients results in clinically significant alterations in the drug dosing regimen.	Professor Kevin Laupland	Professor Kevin Laupland, Professor Jason Roberts, Professor Michael Reade, Doctor Adam Stewart	Targeted competitive	1/06/2020	20/04/2021	Clinical Sciences	Intensive Care	\$	170,020.00
Coronavirus Research Response	2020 Respiratory Medicine Clinical Trials Research on COVID-19	Flinders University	University	SA	Precision antibiotic strategies to reduce invasive mechanical ventilation and mortality in COVID-19	We will investigate whether tracheal microbiology predicts duration of mechanical ventilation and death in COVID-19 patients, and determine whether antibiotic therapies can provide benefit through their impact on airway microbes.	Professor Geraint Rogers	Professor Geraint Rogers, Professor Marianne Chapman, Professor Andrew Bersten, Associate Professor David Shaw, Professor Steven Westewhagh, Professor David Gordon, Professor Richard Woodman, Doctor Lito Papanicolas, Doctor Kerry Jew, Doctor Ian Leese	Targeted competitive	1/06/2020	30/06/2021	Clinical Sciences	Intensive Care	\$	535,291.00
Coronavirus Research Response	2020 Respiratory Medicine Clinical Trials Research on COVID-19	The Council of the Queensland Institute of Medical Research	Medical Research Institute	QLD	Tocilizumab for treatment Of COVID-19 in intensive care patients ("TROCAR")	Severe illness from COVID-19 is associated with a high risk of death. Currently, no proven treatment exists. We will conduct a clinical trial to determine if tocilizumab, a drug used to reduce the adverse effects of inflammation, will improve clinical outcomes in critically ill patients with COVID-19. We will enrol 194 patients from intensive care units in Brisbane, and will determine if a single dose of tocilizumab reduces the duration of ventilatory support, and reduces the risk of death.	Associate Professor Bridget Barber	Associate Professor Bridget Barber, Associate Professor Jayesh Dhanani, Professor Christian Engwerda, Associate Professor Paul Griffin, Alexis Tabai, Stuart Baker, Associate Professor Gunter Hartel	Targeted competitive	1/06/2020	30/06/2021	Clinical Sciences	Intensive Care	\$	279,107.00
Coronavirus Research Response	2020 Respiratory Medicine Clinical Trials Research on COVID-19	University of Melbourne	University	VIC	ProTreat: an adaptive and rapid implementation trial of novel therapies to prevent and treat COVID-19 infection in high risk cancer patients	Coronavirus SARS-CoV-2; COVID-19 causes atypical pneumonia in infected people. Hospitalized patients have lymphopenia (drop in white blood cell counts and uncontrolled viral replication). The patients most likely to die from this disease are those that are immune-compromised including the elderly and those with immunosuppressive disease such as cancer. The aim of EnGeneRx nanocell therapy, is to boost the immune system of immune-compromised and elderly patients and resolve disease.	Professor Monica Slavin	Professor Monica Slavin, Professor Karin Thursky, Professor Grant McArthur, Professor Simon Harrison, Doctor Michelle Yong, Doctor Tim Spelman, Professor Mark Pellegrini, Professor Andrew Scott, Professor Julie Simpson, Professor Linda Mileshkin	Targeted competitive	1/06/2020	30/06/2022	Clinical Sciences	Infectious Diseases	\$	2,169,932.00
Coronavirus Research Response	2020 Respiratory Medicine Clinical Trials Research on COVID-19	The University of Queensland	University	QLD	Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OMS	Covid-19 causes severe respiratory infection, leading to death in some. Health care workers are at high risk of infection. To protect health care workers we propose a clinical trial to reduce respiratory illnesses using a drug called OMS that has been used safely in Europe for decades. We hypothesise that OMS will protect health care workers from developing the most serious respiratory infections, saving lives and allowing them to safely treat patients.	Professor Peter Sly	Professor Peter Sly, Professor Patrick Holt, Associate Professor Deborah Strickland, Doctor Anthony Bosco, Professor John Upham, Doctor Emmanuelle Fantin, Associate Professor David Reid, Professor Robert Ware, Doctor Adam Irwin	Targeted competitive	1/06/2020	30/06/2021	Cardiorespiratory Medicine And Haematology	Respiratory Diseases	\$	1,250,284.00
Coronavirus Research Response	2020 Respiratory Medicine Clinical Trials Research on COVID-19	University of Sydney	University	NSW	IMPACT-ICO: Trials of Immuno-Modulatory Particles and Colchicine To Improve COVID-19 Outcomes	The current coronavirus pandemic is highly contagious and carries a significant risk of death. We propose to test a commonly used inflammatory tablet Colchicine and a novel, biodegradable particle which reduces inflamed cells in the hope that this can improve outcomes. The trial will include 240 people needing oxygen treatment and hospital care for the infection. An expert committee together with consumer representatives will oversee the research.	Professor Anthony Keech	Professor Anthony Keech, Associate Professor Sanjay Patel, Associate Professor Edmund Lau, Professor Nicholas King, Professor Gregory King, Professor Alicia Jenkins, Professor Anthony Rodgers, Associate Professor David Sullivan, Professor Anthony Kelleher, Professor Ian Marschner	Targeted competitive	1/06/2020	30/06/2023	Cardiorespiratory Medicine And Haematology	Cardiology (incl. Cardiovascular Diseases)	\$	980,415.00
Coronavirus Research Response	2020 Respiratory Medicine Clinical Trials Research on COVID-19	University of Sydney	University	NSW	Repurposing existing medications to reduce severe acute respiratory distress in patients with COVID-19: the CLARITY trial	The CLARITY trial will test whether a group of common blood pressure medications reduce the duration and severity of lung failure due to COVID-19. These medications have been in clinical use for over 30 years. They protect against lung injury in animal studies, including injury from viruses like the COVID-19 virus although the effect in humans is not known. Existing medications that lessen the severity of COVID-19 lung disease could provide some relief for patients and hospitals.	Associate Professor Meg Jardine	Professor Meg Jardine, Professor Louise Burrell, Professor Carol Pollock, Professor Christine Jenkins, Professor Simon Finfer, Professor James McGree, Doctor Sadha Kotwal, Professor Sophia Zoungas, Doctor Angus Ritchie, Professor Angela Melvis	Targeted competitive	1/06/2020	31/12/2022	Cardiorespiratory Medicine And Haematology	Respiratory Diseases	\$	1,406,587.00
Coronavirus Research Response	2020 Stem Cell Therapies Mission	The Commonwealth Scientific and Industrial Research Organisation	Corporate Commonwealth entity	ACT	The sySTEMs initiative: systems biology-augmented, stem cell-derived, multi-tissue panel for rapid screening of approved drugs as potential COVID-19 treatments	Vaccines alone can't stop COVID-19 infections; we also need safe, effective and affordable COVID-19 treatments urgently. A great strategy is to repurpose drugs already approved for other diseases. To do that we need rapid, high-throughput drug screening in relevant tissues grown from 'stem cells'. However, this system needs improvement in its readouts, reproducibility and clinical correlation. We intend to achieve this and screen the 3 most promising repurposed drug candidates within a year.	Professor Seshadri Vasani	Professor Seshadri Vasani, Doctor Nathan Goble, Doctor Carmel O'Brien, Doctor Nageshkrumar Singanuralu Balasubramanian, Doctor David Beale, Professor Eugene Athan, Doctor Kim Bladell, Doctor Rohash Chandra, Doctor Laurence Wilson, Anu Kumar, Murugesan Sankaranarayanan, James Hudson, Moana Simpson	Targeted competitive	1/06/2021	31/10/2022	Biochemistry And Cell Biology	Systems Biology	\$	998,355.93
Coronavirus Research Response	2020 Tracking COVID-19 in Australia Using Genomics	University of New South Wales	University	NSW	Tracking COVID-19 using genomics	Pathogen genomics is a way of telling how the SARS-CoV-2 virus (which causes COVID-19) from one person is different from or similar to the SARS-CoV-2 viruses from other people. It is an important tool that can be used to understand the spread and evolution of the virus causing COVID-19 with the precision of specialty laboratory work including next-generation sequencing technology and advanced computing bioinformatics analyses. This project will be done by leading experts from around Australia, as part of the Communicable Diseases Genomics Network (CDGN). This is a genomics-focused network consisting of leading genomics laboratories across Australia. The use of COVID-19 pathogen genomics will provide insights into how virus moves from person to person (transmission) to help public health agencies better understand, track, and trace the transmissions of COVID-19, to reduce virus spread. This will become increasingly important as restrictions relax, and the Australian population returns to 'normal' activity.	Professor William Rawlinson	Professor William Rawlinson, Professor Benjamin Howden, Professor Vital Sintcheko, Associate Professor Amy Jenkinson, Professor Deborah Williamson, Associate Professor Torsten Seemann, Doctor Sebastian Duchene, Professor Margaret Kellner	Closed non-competitive	1/06/2020	31/12/2022	Not available	Not available	\$	3,269,101.60
Coronavirus Research Response	2021 COVID-19 Health Impacts and Vaccination Schedules	Murdoch University	University	WA	Molecular phenomic approaches to improve understanding of Post-Acute COVID-19 Syndrome – a biomarker-augmented strategy for risk-based stratification and targeted intervention to improve clinical outcomes	We will apply state-of-the-art phenomic methods to profile patients afflicted with PACS or 'long-COVID' to provide an objective classification of the condition. We will monitor these long-term biochemical changes in blood to determine the health trajectories of patients so that clinicians can best intervene to provide more precise treatment options.	Professor Jeremy Nicholson	Professor Jeremy Nicholson, Professor Elaine Holmes, Professor Toby Richards, Professor Paul Zimmet, Professor Bu Yeap, Professor Julian Wist, Doctor Zhonglin Chai, Associate Professor Jessica So	Targeted competitive	1/01/2022	31/12/2024	Medical Biochemistry And Metabolomics	Medical Biochemistry And Metabolomics Not Elsewhere Classified	\$	3,395,672.56
Coronavirus Research Response	2021 COVID-19 Health Impacts and Vaccination Schedules	University of Melbourne	University	VIC	Predicting the neurological impact of SARS-CoV-2 Variants of Concern-protecting Australians from long-COVID brain injury	As vaccination reduces the risk of death from SARS-CoV-2 infection, living with COVID-19 will require accepting that mild infection in vaccinated individuals will have an economic and health cost. Living with COVID-19 will require living with variants of concern of SARS-CoV-2 that evolve with time. Our focus will be to understand how SARS-CoV-2 variants affect the brain and develop a diagnostic test to identify patients at risk of chronic and debilitating brain injury from SARS-CoV-2 variants.	Associate Professor Victoria Lawson	Associate Professor Victoria Lawson, Doctor Julie McAuley, Professor Damian Purcell, Professor Andrew Hill, Doctor Lesley Cheng, Professor Steven Collins, Professor Sharon Lewin	Targeted competitive	1/01/2022	31/12/2024	Medical Microbiology	Medical Virology	\$	1,776,244.02
Coronavirus Research Response	2021 COVID-19 Health Impacts and Vaccination Schedules	University of New South Wales	University	NSW	Comparing Immunisation-boosting Regimens for COVID-19 Upon Initiation of Immunosuppressive Therapies (ORCUT Study)	We will determine the optimal timing of 3rd dose "booster" COVID-19 vaccines in previously fully-immunised patients who are commencing new immunosuppression for either a haematological malignancy or autoimmune/inflammatory condition. We will measure COVID-19 specific antibody levels over a 1 year follow-up period and determine the difference between the booster being administered immediately prior to starting immunosuppressive therapy or at 6 months after commencing immunosuppression.	Doctor Sarah Sasson	Doctor Sarah Sasson, Professor Anthony Kelleher, Associate Professor Kathy Pournomenos, Professor Miles Dawergor, Professor Judith Trotman, Associate Professor Fabienne Briot, Associate Professor Stuart Turville, Associate Professor Nada Hamad, Associate Professor Rowena Bull, Professor Golo Aghvassie	Targeted competitive	1/01/2022	31/12/2026	Immunology	Humoral Immunology And Immunochimistry	\$	2,752,966.61

Coronavirus Research Response	2021 COVID-19 Health Impacts and Vaccination Schedules	Monash University	University	VIC	Bringing Optimised COVID-19 vaccine Schedules to ImmunoCompromised populations (BOOST-IC)	COVID-19 vaccines prevent severe disease from SARS-CoV-2 infection but there are groups with poor immune systems due to their medical conditions at increased risk for severe disease despite being vaccinated. We will perform a clinical trial of different strategies of booster doses of mRNA COVID-19 vaccine in immunocompromised people. This will establish which boosting strategies, with one or two extra doses and the interval between those doses, are safe and the most protective from infection.	Associate Professor James McMahon	Associate Professor James McMahon, Professor Germaine Wong, Professor C. Orla Morrissey, Professor Thomas Snelling, Professor Sharon Lewin, Professor Allen Cheng, Professor Anthony Cunningham, Doctor Julie Marsh, Professor Kirsten Howard, Professor Kanta Subbarao	Targeted competitive	1/01/2022	31/12/2024	Clinical Sciences	Infectious Diseases	\$	2,911,774.24
Coronavirus Research Response	2021 COVID-19 Health Impacts and Vaccination Schedules	University of Western Australia	University	WA	The Platform trial in COVID-19 vaccine BOOSTing (PICOBOD)	The C-19 pandemic has had a devastating impact globally. It was hoped that vaccination would represent a cure, however emerging evidence now suggests that this will not be achievable. Consequently, booster C-19 vaccines, in addition to the primary series, are likely to be required to protect against the impacts of disease. We propose the Platform trial in COVID-19 vaccine BOOSTing (PICOBOD) to evaluate comparative booster vaccine strategies to inform best practice within Australia.	Associate Professor Peter Richmond	Associate Professor Peter Richmond, Doctor Charlie McLeod, Professor Katie Flanagan, Professor Magdalena Plebanek, Professor Thomas Snelling, Professor Helen Marshall, Professor Christopher Blyth, Mr Michael Dymock	Targeted competitive	1/01/2022	31/12/2026	Immunology	Humoral Immunology And Immunochimistry	\$	4,157,377.94
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	Australian Institute of Health and Welfare	Corporate Commonwealth entity	ACT	Towards an Australian COVID-19 Register and linked data set	This project aims to establish a national linked data platform that integrates COVID-19 case information with a range of relevant existing health data sets. This platform would strengthen evidence-based public health and health system planning and management. It will also be made available to external researchers, which would ultimately help improve the health and wellbeing of Australians affected by current and emerging global health threats.	Richard Juckes	Richard Juckes, Ms Claire Sparkle, Adrian Webster, Louise Gates, Louise York, Michelle Gourley, Doctor Lynette Moon, Doctor Fadwa Al-Yaman, Miss Bronie O'Donnel, Tyle Bayliss, Sarah Jones, Doctor Claudia Slimings	Restricted competitive	1/04/2022	31/03/2026	Public Health And Health Services	Public Health And Health Services, Epidemiology	\$	2,986,054.40
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	Monash University	University	VIC	A coordinated multipplatform randomised trial for hospitalised patients with COVID-19	This proposal supports two established adaptive platform trials, ASCOT-ADAPT and REMAP-CAP, to join together to identify effective treatments for COVID-19 as fast as possible. The new interventions that will be evaluated are optimal antiviral, the dose of dexamethasone; comparing two immune modulators (tocilizumab and baricitinib) to determine which is most effective, and convalescent plasma in patients who are immune suppressed.	Professor Steve Webb	Professor Steve Webb, Professor Alistair Nichol, Professor Jason Roberts, Professor Steven Tong, Professor Joshua Davis, Professor Bala Venkatesh, Doctor Alisa Higgins, Professor Justin Denholm, Associate Professor Zoe McCallum, Doctor Aidan Burrell, Mr James Totterdell, Ms Anne McKenzie, Associate Professor Naomi Hammond, Doctor Colin McArthur, Professor Allen Cheng	Targeted competitive	1/06/2022	30/05/2026	Clinical Sciences	Clinical Sciences, Intensive Care	\$	3,997,914.20
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	University of Melbourne	University	VIC	mRNA based antiviral therapeutics for SARS-CoV-2 using Cns13	SARS-CoV-2 emerged on the world stage with a mortality rate of ~2.0%. Rapid development of vaccines curbed the severity of the pandemic, however, development of antivirals that can be used as both treatment and prevention has been slow. We propose using antiviral mRNA packaged in lipid nanoparticles as a novel approach to treat and prevent SARS-CoV-2 infection. This pipeline could be used in the future to suppress any RNA virus of pandemic potential spread by the respiratory route.	Professor Sharon Lewin	Professor Sharon Lewin, Doctor Christina Cortez-Jungo, Professor Damian Purcell, Doctor Mohamed Farah, Professor Elizabeth Viccan, Professor Joseph Trajan, Professor Colin Pouton, Professor Frank Canas, Doctor Wei Zhao	Targeted competitive	1/06/2022	30/05/2025	Clinical Sciences	Clinical Sciences, Infectious Diseases, Medical Biotechnology, Medical Molecular Engineering Of Nucleic Acids And Proteins, Nanotechnology, Nanomedicine	\$	1,000,000.00
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	University of New South Wales	University	NSW	Development of antiviral RNA therapeutics targeting SARS-CoV-2 infection	There is an urgent need for antiviral treatments for COVID-19 infection due to evolving vaccine resistance and lack of adequate immune responses. This project develops direct acting antiviral RNA therapeutics to prevent and treat COVID-19 infection. The antiviral RNA will be delivered by inhaling nanoparticles that carry the therapeutic directly to targeted respiratory sites. The project will also provide pre-clinical data for accelerated translation to human proof of concept clinical trials.	Professor Anthony Kelleher	Professor Anthony Kelleher, Professor Daniela Train, Associate Professor Kathy Petooumenou, Cees van Rijn, Professor Maria Kavallaris, Professor Pall Thordarson, Associate Professor Stuart Turville, Professor Philip Hansbro, Doctor Charlotte Alenstiel, Doctor Minnao Liane	Targeted competitive	1/06/2022	30/05/2024	Medical Biochemistry And Metabolomics	Medical Biochemistry And Metabolomics, Medical Biochemistry: Nucleic Acids, Nanotechnology, Nanomedicine, Medical Microbiology, Medical Virology	\$	998,339.60
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	Curtin University	University	WA	Compound repurposing into novel therapeutics to treat SARS-CoV2 infection	With continued SARS-CoV-2 mutant variants causing death, it is imperative that repurposed medicines be use clinically where possible. We have identified a number of approved safe compounds with acceptable safety profiles to test. Using our 3D organotypic cell model, we will identify those most beneficial. Treatment with these agents may prevent infection, transmission, stop the cytokine storm, prevent the need for hospitalization, and reduce the overall healthcare burden caused by SARS-CoV-2.	Associate Professor Anthony Kicic	Associate Professor Anthony Kicic, Professor Christopher Blyth, Professor Stephen Stick, Professor Tobias Kollmann, Professor Robert Hancock	Targeted competitive	1/06/2022	30/05/2024	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Respiratory Diseases	\$	998,520.00
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	Monash University	University	VIC	Pre-clinical testing of novel inhaled RNA therapies for stability, safety and effectiveness against SARS-CoV-2 to demonstrate proof of concept	RNA can be used to treat human diseases. It can be used to provide a template to make a new protein, as in messenger RNA vaccines. RNA can also be used to selectively change the message and protein generated from a gene. We have shown that inhaled RNA can change the proteins made by the lungs in a way to protect them against SARS-CoV-2 and its associated hyper-inflammation in the lungs. In this project we will develop these new treatments in animal studies as a precursor to human trials.	Professor Merlin Thomas	Professor Merlin Thomas, Doctor Julie McAuley, Professor Stephen Willott, Doctor Raelyne Pickering	Targeted competitive	1/06/2022	30/05/2024	Medical Biotechnology	Medical Biotechnology, Gene And Molecular Therapy	\$	499,697.24
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	A lethal and irresistible combination: Simultaneous targeting of the SARS-CoV-2 proteases Mpro and Ppro	Drug development to fight the global pandemic caused by the SARS-CoV-2 virus has progressed at a lightning pace, thanks to effective vaccines. Anti-viral compounds are the final piece in this puzzle, but only 2 are currently available to patients. Our program will progress 2 new anti-viral molecules targeting distinct Achilles' heels of the virus and will demonstrate their efficacy, not only as single agents but also in combination, offering a treatment that avoids the emergence of resistance.	Professor Guillaume Lesenne	Professor Guillaume Lesenne, Doctor Melissa Call, Professor David Koster, Doctor Marc Pellegrini, Doctor Brad Steels, Associate Professor Peter Cabador, Professor Susan Chapman	Targeted competitive	1/06/2022	30/05/2024	Medicinal And Biomolecular Chemistry	Medicinal And Biomolecular Chemistry, Biologically Active Molecules, Medicinal And Biomolecular Chemistry, Medicinal And Biomolecular Chemistry Not Elsewhere Classified, Medical Microbiology, Medical Virology	\$	999,687.40
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	Esfam Biotech Pty Ltd	Corporation	VIC	Experimental Validation of the Target of ESFAM289 - a molecule with in vivo efficacy against SARS-CoV-2	Esfam has identified a molecule, ESFAM289, which has been demonstrated to be an effective treatment for COVID-19 in small animal studies. This project will generate data necessary to enable the commencement of clinical trials including information on how the molecule binds to its potential target and how it interrupts COVID-19 infection.	Professor Albert Frauman	Professor Albert Frauman	Targeted competitive	1/06/2022	30/05/2026	Biochemistry And Cell Biology	Biochemistry And Cell Biology, Structural Biology (incl. Macromolecular Modelling), Pharmacology And Pharmaceutical Sciences, Pharmacology And Pharmaceutical Sciences Not Elsewhere Classified, Biochemistry And Cell Biology, Biochemistry And Cell Biology Not Elsewhere Classified	\$	1,000,000.00
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	University of Melbourne	University	VIC	Intranasal TLR2/6 activation to prevent COVID infection in the elderly	Elderly Australians in aged care are highly vulnerable to COVID-19. Vaccines are essential but their protection fades with age and new vaccines can take over a year to make. We will test a new medicine called INNA-051 that strengthens natural defences against COVID-19 in the nose where infection starts. INNA-051 is highly effective in preventing respiratory viruses, is safe in the elderly and works on top of vaccines. It provides protection within a day that lasts about a week after each spray.	Professor Gary Anderson	Professor Gary Anderson, Professor Donald Campbell, Doctor Nicholas West, Professor Paul Monagle, Associate Professor Nathan Bartlett	Targeted competitive	1/06/2022	30/05/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Respiratory Diseases	\$	3,883,462.60
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	University of Western Australia	University	WA	The Platform Trial in COVID-19 Boosting: stage 2 (PICOBOD-2)	It is unclear whether periodic C-19 booster vaccination will be necessary in the future, and if so, whether this will be required for all Australians or select vulnerable groups. We will extend the platform trial in COVID-19 vaccine BOOSTing (PICOBOD) to evaluate optimal 3rd dose booster strategies in young children (5-11 years) and adolescents (12-17 years) and 4th dose booster strategies in pregnant women (18-49 years) and adults to inform national immunisation practice and policy.	Doctor Charlie McLeod	Doctor Charlie McLeod, Doctor Phoebe Williams, Mr Michael Dymock, Professor Christopher Blyth, Ms Suellen Nicholson, Doctor Ruth Thornton, Doctor Julie Marsh, Professor Sauf Fouat, Associate Professor Peter Richmond, Professor Katie Flanagan, Professor Magdalena Plebanek, Professor Thomas Snelling	Targeted competitive	1/06/2022	30/05/2025	Clinical Sciences	Clinical Sciences, Infectious Diseases	\$	3,830,631.40
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	University of Melbourne	University	VIC	Immune responses to SARS-CoV-2 variants across age groups and vulnerable populations	Understanding immune responses underpinning protection against emerging SARS-CoV-2 variants of concern is urgently needed. Our IRMF encompasses Australia's most advanced COVID-19 immunology program which will define protective and long-lasting immunity against emerging variants across age groups and vulnerable populations. Our in-depth immune studies in wide ranging cohorts will inform potential therapy and vaccine regimens for at-risk groups to limit disease spread and protect high-risk groups.	Professor Katherine Kedzierska	Professor Katherine Kedzierska, Doctor Thi Nguyen, Doctor Louise Kowtree, Doctor Amy Chung, Professor Paul Thomas, Associate Professor Jane Davies, Professor Jamie Rossjohn, Professor Stephen Kent, Associate Professor Jason Trubiano, Doctor Adam Wheatley, Doctor David Khoury, Doctor Jennifer Jans, Professor Miles Davenport, Associate Professor Benjamin Teh	Targeted competitive	1/06/2022	31/10/2025	Immunology	Immunology, Cellular Immunology	\$	3,001,424.40
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	Monash University	University	VIC	PROPHICCY: Profiling immune ResPonse in Paediatric and High-risk populations to SARS-CoV-2	COVID-19 vaccines protect against severe disease. However, people with underlying health conditions remain at risk of infection and associated complications. The PROPHICCY trial will evaluate antibodies and cellular immune responses after infection or vaccination in healthy and vulnerable people to evaluate their protection against future variants. These findings will inform future clinical care for COVID-19 and targeted approaches to enhance vaccine responses in the vulnerable patient groups.	Associate Professor Memo van Zelm	Associate Professor Memo van Zelm, Associate Professor Paul Licardi, Professor Anne Holland, Associate Professor Alberta Ioi, Associate Professor Ian Woolley, Associate Professor James McMahon, Professor David Curtis, Associate Professor Miles Sparrow, Doctor Gabriela Khoury, Associate Professor William Muller, Doctor Edward Giles, Professor Heidi Drummer, Associate Professor Benjamin Rogers, Doctor Samar Ojajimi, Associate Professor James Trauer	Targeted competitive	1/06/2022	30/05/2026	Immunology	Immunology, Humoral Immunology And Immunochimistry, Immunology, Cellular Immunology, Clinical Sciences, Infectious Diseases	\$	6,327,279.57
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	University of New South Wales	University	NSW	Aerosol transmission of SARS-CoV-2 experimentally and in an intensive care setting	This research uses a four-stage, multidisciplinary study design: real world, experimental & airflow modelling. In a hospital Intensive Care Unit (ICU), we will use air and surface sampling methods to detect SARS-CoV-2. We will do various experiments in 2 labs to get more understanding of how the virus travels through the air; and will model the movement of virus inside a hospital ICU ward using these data. It will help understand flow of air and virus within ICU and inform mitigation measures.	Professor Raina McIntyre	Professor Raina McIntyre, Professor Ian Seppelt, Doctor Charitha de Silva, Professor Mark Wilcox, Associate Professor Mark Nicholls, Professor Con Doolan	Targeted competitive	1/06/2022	30/05/2024	Public Health And Health Services	Public Health And Health Services, Environmental And Occupational Health And Safety	\$	992,908.20
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	University of Melbourne	University	VIC	Aerosol Infection Research: Better mOdelS to Reduce INdoor Exposure (AIRBORNE)	This project will bring together clinicians, virologists, aerosol scientists, engineers, epidemiologists and mathematical modelers to further our understanding of airborne transmission of SARS-CoV-2 in indoor spaces. Experiments will have to be done to gather more information about the infectiousness of individuals over time, how aerosolised particles and viruses move through complex spaces and effectiveness of mitigation measures. The information will be used to improve mathematical models.	Professor Kanta Subbarao	Professor Kanta Subbarao, Doctor Mariana Baz, Professor Jason Mority, Associate Professor Louis Irving, Doctor Simon Jones, Professor Kirsty Busing, Associate Professor Nicholas Geard, Associate Professor Sheena Sullivan, Associate Professor Forbes McGain, Doctor Robyn Schofield	Targeted competitive	1/06/2022	31/07/2025	Clinical Sciences	Clinical Sciences, Infectious Diseases, Medical Microbiology, Medical Virology, Cardiorespiratory Medicine And Haematology, Respiratory Diseases	\$	998,338.80

Coronavirus Research Response	2021 COVID-19 Vaccine-Associated Thrombosis With Thrombocytopenia Syndrome	Monash University	University	VIC	A national, multi-centre study evaluating Thrombotic Thrombocytopenia Syndrome (TTS) associated with ChAdOx1 (AZD1222) and other SARS-CoV-2 vaccines (viral vector and mRNA)	A condition of a blood clot with low platelets has been described in some patients after receiving COVID-19 vaccines, including the widely available ChAdOx1 vaccine. Known as thrombosis with thrombocytopenia syndrome (TTS), this condition presents with a wide spectrum of severity. Although it has an immunological basis, the underlying mechanisms is unknown and there are no known predictors for increased risk of TTS. Further understanding is needed to ensure safe COVID-19 vaccination.	Professor Huynh Tran	Professor Huynh Tran, Associate Professor Vivien Chen, Associate Professor Sanjeev Chinnai, Associate Professor Nicholas Wood, Professor Tri Phan, Professor Jim Buttery, Associate Professor Nigel Crawford, Professor Paul Monagle, Doctor Freda Passam, Doctor James McAden	Closed non-competitive	1/11/2021	31/10/2024	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	2,917,087.28
Dementia, Ageing and Aged Care Mission	2019 Accelerated Research - Clem Jones Centre for Ageing Dementia Research	The University of Queensland	University	QLD	Breaking through dementia - The Clem Jones Centre for Ageing Dementia Research	The Clem Jones Centre for Ageing Dementia Research (CICADR) brings together Australia's largest concentration of researchers focusing on research into the biological roots of the devastating neurodegenerative disorders such as Alzheimer's disease (AD). This project will support the development of an affordable and portable scanning ultrasound device, for the treatment of brain disorders including AD. Additionally, it will support the use of ultrasound to deliver immunotherapeutic agents to clear plaques and tangles, which are hallmarks of AD. In parallel, these outcomes will be underpinned by an extensive research base building an understanding of the mechanism of action of our proposed therapies and seeking to identify new drug targets and therapeutic strategies.	Not applicable	Not available	One-off ad hoc	1/04/2019	30/06/2023	Not available	Not available	\$	10,000,000.00
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	The University of Queensland	University	QLD	Alignment, Harmonisation, and Results: translating Care Outcome Measures to Improve Care (DOM-IC) for People Living with Dementia into Australian practice	We can't improve what we can't measure and improving quality of life and quality of care have been identified as key outcomes of programs designed for people living with dementia. In this project, we will bring together people living with dementia, caregivers, industry and funders to understand how to measure outcomes of care that matter to everyone. At the end of the project we will have a list of agreed outcomes to measure and guidelines for implementing these.	Associate Professor Tracy Comans	Associate Professor Tracy Comans, Professor Susan Kurrie, Professor Len Gray, Professor Leon Flicker, Professor Paula Williamson, Colin Cunningham, Doctor Kim-Hung Nguyen, Jack Hume, Dominic Treppe, Professor Oskiva Almeida, Judy Lovibond	Targeted competitive	1/06/2021	30/11/2023	Public Health And Health Services	Aged Health Care	\$	999,286.80
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	The University of Queensland	University	QLD	Technology Assisted and Remotely Delivered Anxiety Psychotherapy Intervention for People living with Dementia and Their Care Partners (Tech-CBT)	Anxiety is a rising concern and a largely unmet need in people living with dementia and their carers. This research evaluates whether a new technology assisted psychotherapy intervention to reduce anxiety in individuals with dementia and carers (Tech-CBT), is an effective, scalable and cost effective tool for improving quality of life and for decreasing adverse health outcomes for those living with dementia and their carers. We will also assess the potential and ease of its future uptake.	Doctor Nadeeka Dissanayaka	Doctor Nadeeka Dissanayaka, Doctor Peter Worthy, Doctor Deborah Brooks, Doctor Leander Mitchell, Mr Syed Afroz Keramat, Associate Professor Annette Broome, Associate Professor Mark Chatfield, Professor Gerard Byrne	Targeted competitive	1/06/2021	31/05/2025	Psychology	Health, Clinical And Counselling Psychology	\$	1,626,883.28
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	National Ageing Research Institute	Medical Research Institute	VIC	Drawing out care: Using animation and digital technologies to support Culturally and Linguistically Diverse (CALD) family carers and people living with dementia	This study aims to improve the lives of culturally and linguistically diverse (CALD) family carers and people living with dementia using animations, digital fact sheets, and a multilingual chat-bot - The Drawn Out Care project. Using co-produced and evaluated trial materials we will evaluate the clinical and cost effectiveness of Draw Care in reducing family carer's burden and improving their mood and quality of life, and the quality of life of the person living with dementia.	Associate Professor Bianca Bripath	Associate Professor Bianca Bripath, Associate Professor Tuan Anh Nguyen, Doctor Josefine Antoniadou, Professor Matthew Varghese, Professor Santosh Laganathan, Doctor Michaela Leticia Danjels Hill, Associate Professor Duncan Mortimer, Professor Nilmini Wickramasinghe, Doctor Andrew Gilbert	Targeted competitive	1/06/2021	30/11/2024	Public Health And Health Services	Family Care	\$	797,773.60
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	Monash University	University	VIC	Knowledge brokers for evidence translation to improve quality of life of medicines in residential aged care	The Royal Commission into Aged Care Quality and Safety has highlighted over-reliance on psychotropic medications as needing immediate action. Psychotropic medications can be inappropriately prescribed to people living with dementia in aged care. This project aims to trial the use of a 'knowledge broker' to implement new evidence based recommendations to improve the safe and effective use of psychotropic medications in people living with dementia and in aged care.	Professor Simon Bell	Professor Simon Bell, Doctor Adam La Caze, Doctor Amanda Cross, Professor Terrence Haines, Professor Sarah Haines, Constance Kourbells, Doctor Lakshmi Troung, Ms Lyntara Quirke	Targeted competitive	1/06/2021	31/05/2025	Public Health And Health Services	Aged Health Care	\$	1,952,566.00
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	The University of Queensland	University	QLD	SENtCog aged care: Hearing and vision support to improve quality of life for people living with dementia in residential aged care	Hearing & vision problems are common in people living with dementia in residential aged care. But hearing/vision problems often go unreported. Unreported hearing/vision problems increase the impact of dementia, cause social isolation, reduce independence and worsen quality of life. This study aims to improve quality of life for people with dementia by working with people with dementia, aged care and hearing/vision professionals to enable better ways of identifying and supporting hearing/vision needs.	Associate Professor Piers Dawes	Associate Professor Piers Dawes, Professor Johanna Westbrook, Professor Ralph Martins, Doctor Angelita Martini, Professor Lisa Key, Associate Professor racema Lero, Professor Colette Browning, Associate Professor Chyrisse Heine, Associate Professor Hamid Sobhani, Doctor Yuanyuan Guo	Targeted competitive	1/06/2021	31/05/2025	Clinical Sciences	Geriatrics And Gerontology	\$	1,200,710.20
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	Flinders University	University	SA	Creating partnership in support program to optimise carers' impact on dementia care	The aims of this study are to determine the effectiveness and cost-effectiveness of an innovative patient-centred dementia care approach, 'Partnership in Support program'. The program is designed to enhance support for carers and improve their ability to manage dementia at home. The expected outcomes are improved quality of life and health for carers and care recipients and reduced hospital admission, emergency department use and premature admission to aged care homes of care recipients.	Professor Lily Dongxia Xiao	Professor Lily Dongxia Xiao, Professor Julie Ratcliffe, Doctor Claudia Meyer, Doctor Michael Chapman, Ms Langhua Chen, Doctor Shuhui Ullah, Professor Alison Kilson, Doctor Andre Queiroz De Andrade	Targeted competitive	1/06/2021	31/05/2025	Nursing	Aged Care Nursing	\$	1,406,657.60
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	University of Melbourne	University	VIC	Music Attuned Technology Care eHealth (MATCH): A music based mobile eHealth solution to support care of people with dementia	We aim to develop and test the acceptability of a mobile eHealth technology that draws on the unique power of music to support the care of people with dementia. The technology teaches carers how to use music in a targeted way, to reduce agitation, stimulate autobiographical recall, and shared meaningful experiences. A feature of the eHealth solution will be its ability to monitor the agitation state of the person with dementia and adjust the music accordingly to meet the changing needs.	Professor Felicity Baker	Professor Felicity Baker, Associate Professor Mohanraj Karanath, Professor Nicola Lautenschlager, Associate Professor Jenny Wacott, Doctor Amit Lampki, Doctor Jeanette Tamplin, Doctor Christian Redd, Doctor Tanara Vieira Sousa, Doctor Karen Lamb, Professor Adam Vogel	Targeted competitive	1/06/2021	31/12/2025	Public Health And Health Services	Aged Health Care	\$	1,998,865.50
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	University of New South Wales	University	NSW	Development, validation and implementation of a computerised tool to assess instrumental activities of daily living	Instrumental activities of daily living (IADL) are essential to live independently. This project will develop and validate a computerised tool to assess IADL in older people with and without dementia. The tool is based on the existing Sydney Test of Everyday Activities in Memory Disorders (STEAM), which is a validated and internationally used instrument. Advantages of a computerised tool are better accessibility for both clinicians and patients, reduced costs, and shortened administration time.	Doctor Simone Reggumund	Doctor Simone Reggumund, Professor Henry Brodsky, Doctor Kanyo Numbers, Professor Lindy Clemson, Doctor Nicole Kochan, Professor Brian Draper, Professor Kim Delbaere, Professor Julian Trollor, Doctor Isewan Anupama Ginge, Doctor Jacqueline Wesson	Targeted competitive	1/06/2021	31/05/2025	Clinical Sciences	Geriatrics And Gerontology	\$	1,252,778.00
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	University of Melbourne	University	VIC	Blood testing to predict and discriminate dementias	A predictive blood test for Alzheimer's disease (AD) is urgently needed. Our project will bring together Australia's leading dementia researchers and the largest dementia-related research cohort ever assembled in this country to accelerate the use of blood tests in clinical settings (e.g. hospitals, memory clinics) that can help to diagnose, and predict the onset of, AD. We will also examine the impact of having a diagnostic blood test for AD on health and management outcomes.	Professor Ashley Bush	Professor Ashley Bush, Professor Christopher Rowe, Associate Professor Michelle Lupton, Doctor Jürgen Fripp, Professor Michael Breakspear, Doctor Samantha Loi, Professor Simon Laws, Professor Peter Melke, Professor Susannah Ahern, Doctor James Doche	Targeted competitive	1/06/2021	31/05/2026	Neurosciences	Central Nervous System	\$	3,999,909.28
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	University of Melbourne	University	VIC	Development and Implementation of the National Infection Surveillance Program for Aged Care (NISPAQ)	This project is focused on the implementation of an effective aged care infection surveillance program in all Australian aged care homes. These programs promote the systematic collection, management and analysis of infection data and the distribution of surveillance reports to those who need to know. The instigation of infection prevention and control strategies are based on these reports. The expected outcome is that the number of infections in high risk residents will significantly reduce.	Associate Professor Noleen Bennett	Associate Professor Noleen Bennett, Associate Professor Leon Worth, Professor Karin Thursky, Associate Professor Maria Inacio, Doctor Janet Suggitt, Ms Megan Corlis, Malcolm Clark, Emeritus Professor David Dunt, Doctor Ann Bull, Associate Professor Solomon Yu	Targeted competitive	1/06/2021	31/07/2024	Public Health And Health Services	Aged Health Care	\$	997,734.30
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	University of Melbourne	University	VIC	Implementing Effective infection prevention and control in Residential aged care (IMMERSE)	Older people living in aged care homes are susceptible to infections such as influenza. Our aim is to protect their health by promoting a strong focus on infection prevention and control (IPC). We will investigate gaps in IPC procedures such as how staff training is provided, how residents participate in IPC, and gaps in staff IPC practice, and identify solutions to address gaps. We will upskill IPC leads to drive change and co-design a network for IPC leads to share knowledge and experiences.	Professor Wen Lim	Professor Wen Lim, Professor Kirsty Buning, Professor Iliana Francis, Professor Desirée Fetherstonhaugh, Doctor Paul Yates, Associate Professor Douglas Johnson, Ms Joanne Tropea, Associate Professor Craig Abbotin, Doctor Jason Kwong, Associate Professor Caroline Marshall	Targeted competitive	1/06/2021	30/09/2024	Clinical Sciences	Geriatrics And Gerontology	\$	757,520.30
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	The University of Queensland	University	QLD	Unspoken, Unheard, Unmet: Improving Access to Preventative Health Care through Better Conversations about Care	Communication is important. We use it to express our needs, to connect with other people, to make choices, and to tell someone when something is wrong. Many older Australians who receive aged care services have difficulty communicating, but their care workers do not have the tools or resources to support them to express their needs, choices, or concerns. We will co-design and evaluate the "Better Conversations" program: resources and training to support important conversations about aged care.	Doctor Sarah Wallace	Doctor Sarah Wallace, Associate Professor Geoff Argus, Professor Joanne Wood, Doctor Kirstine Strudisole, Doctor Samantha Symonbalagalinga, Professor Louise Hickson, Associate Professor Nerina Scarrin, Professor Debra Fetherstonhaugh, Aparna Arjunan, Professor David Cripps, Professor Victoria Palmer, Doctor Peter Worthy, Associate Professor Anthony Angwin, Associate Professor Asad Khan	Targeted competitive	1/06/2022	30/11/2027	Public Health And Health Services	Public Health And Health Services, Aged Health Care	\$	2,014,394.33
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	The University of Queensland	University	QLD	Frailty KIT: An Australian Frailty Network to Create Knowledge, Implement Findings and Support Training	Programs to promote healthy ageing and reduce frailty work in research trials, but these are not widely available and where they are, people do not always join in. This study will compare ways to support older people to participate in frailty programs (e.g. health coach, online portal) to inform national implementation. We will form an Australian Frailty Network to oversee this and ensure all future work is coordinated and informed by the needs of older people, their families and caregivers.	Professor Ruth Hubbard	Professor Ruth Hubbard, Doctor Rosemary Saunders, Associate Professor Tracy Comans, Doctor Natasha Reid, Doctor Adrienne Young, Professor Michelle Miller, Professor Mark Morgan, Doctor Paul Yates, Doctor Emily Gordon, Professor Loretta Baldassar, Professor Maria Rataneone Singh, Professor Kenneth Rockwood, Professor Christopher Ebbertson-Kier, Professor Sarah Hillmer, Associate Professor Jason Ferris	Targeted competitive	1/06/2022	31/07/2027	Clinical Sciences	Clinical Sciences, Geriatrics And Gerontology, Public Health And Health Services, Aged Health Care	\$	4,993,238.54
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	University of Melbourne	University	VIC	The ENJOY Seniors Exercise Park IMP-ACT project: IMProving older people's health through physical Activity: a hybrid II implementation project design	The ENJOY IMP-ACT program is a translation research project built on an evidence based physical and social activity program. It aims to expand its impact on the community by incorporating an implementation framework to support local governments and the community to further engage older people in physical activity for better health. The program aims to enhance the physical and mental wellbeing and social connectedness of older people and build capacity and community engagement.	Professor Pazi Levinger	Professor Pazi Levinger, Doctor Andrew Gilbert, Professor Keith Hill, Doctor Lisa Burton, Emeritus Professor Adrian Bauman, Doctor Natasha Brusco, Doctor See-Ee Soh	Targeted competitive	1/06/2022	31/05/2026	Public Health And Health Services	Public Health And Health Services, Health And Community Services, Public Health And Health Services, Health Promotion	\$	2,011,748.53

Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	The University of Newcastle	University	NSW	A Preventative Care Program to optimise mental health during transition into residential aged care	The transition from living in the community to residential aged care (a nursing home), is a stressful experience for the person and their family that can lead to poor mental health. We designed a program to assist the new resident (PEARL), the family (aSTART), and to provide additional training for staff (Dignity of Choice). We expect the combination of programs will reduce and prevent symptoms of depression in the resident. We will evaluate the impact of the program to guide national rollout.	Doctor Michelle Kelly	Doctor Michelle Kelly, Doctor Jennifer White, Professor Briany Dow, Professor Claudia Cooper, Professor Mariko Carey, Doctor Anita Goh, Doctor Penny Rapagan, Doctor Joan O'Saizkiewicz, Doctor Kylie Wales, Associate Professor Joel Rhee, Doctor Jacqueline Wesson, Doctor Joanne Allen	Targeted competitive	1/06/2022	30/09/2023	Public Health And Health Services	Public Health And Health Services, Residential Client Care, Public Health And Health Services, Aged Health Care, Public Health And Health Services, Mental Health	\$	200,000.00
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	University of Melbourne	University	VIC	Implementation of a co-designed exercise and fall prevention program for older people from CALD backgrounds	There is strong evidence that exercise reduces falls in older people. Most older people do not meet physical activity guidelines and there are limited resources to support people from culturally and linguistically diverse (CALD) backgrounds. We will i) co-design an exercise and falls prevention program with older people from three culturally and linguistically diverse backgrounds and stakeholders and ii) evaluate the program in 630 older people from CALD backgrounds.	Associate Professor Catherine Said	Associate Professor Catherine Said, Doctor Cassie McDonald, Doctor Lidia Engel, Associate Professor Michele Calliaya, Professor Gustavo Duque, Ms Emily Ramage, Doctor Marlene Kiac, Professor Bianca Brinjath, Associate Professor Frances Batchelor	Targeted competitive	1/06/2022	1/01/2028	Clinical Sciences	Clinical Sciences, Physiotherapy, Clinical Sciences, Geriatrics And Gerontology, Public Health And Health Services, Aged Health Care	\$	200,000.00
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Monash University	University	VIC	Better Environment, Healthier Ageing	"Better environment, Healthier Ageing" project aims to measure major environmental risk factors comprehensively, to evaluate their health impacts in older Australians, and to develop, evaluate and implement intervention strategies that can mitigate the adverse impacts. The project will clarify the environmental enablers and barriers for achieving healthy ageing, and provide older Australians, aged care and health service providers with effective strategies to improve environmental health.	Professor Yuming Guo	Professor Yuming Guo, Associate Professor Yen Ying Lim, Associate Professor Shanshan Li, Associate Professor Joanne McKenzie, Professor Olly Jay, Professor Lidia Mowalewa, Doctor Rongkun Xu, Associate Professor Sean Cain, Associate Professor Joanne Ryan, Associate Professor Jiansheng Song, Associate Professor Zafina Adem, Associate Professor Helen Rawson, Professor Rachel Huxley, Professor Shyamali Dharmage	Targeted competitive	1/06/2022	31/05/2027	Public Health And Health Services	Public Health And Health Services, Epidemiology, Public Health And Health Services, Environmental And Occupational Health And Safety, Public Health And Health Services, Preventive Medicine	\$	200,000.00
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	James Cook University	University	QLD	MEformin for treating peripheral artery disease Related walking impairment Trial (MERIT)	MERIT is a randomised controlled trial to assess whether a cheap repurposed medication can treat blocked leg arteries (peripheral artery disease), a condition which adversely affects the quality of life and reduces the functional ability of over 1 million older Australians. Given the substantial prevalence of this disease in older people and the current absence of effective treatments, the findings of MERIT will have important implications for older people worldwide.	Professor Jonathan Golledge	Professor Jonathan Golledge, Professor Clare Heal, Associate Professor Belinda Parmenter, Doctor Aaron Ovardi, Professor Yvonne Cadee James, Professor Sarah Watkins, Mrs Rachel Daughley, Doctor Joseph Moxon, Professor Christopher Reid, Associate Professor Richard Norman, Associate Professor Christopher Ashew, Associate Professor Clare Arnott, Doctor Dylan Morris, Ms Jenna Finchbeck, Professor Edward Strivens	Targeted competitive	1/06/2022	31/05/2026	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiovascular Medicine And Haematology Not Elsewhere Classified	\$	1,215,182.04
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	University of Melbourne	University	VIC	No more shame: Changing health providers recognition and response to elder abuse to reduce Associated stigma	Elder abuse is a stigmatised. Older people feel shame disclosing it, health providers struggle to detect it. By improving health providers' recognition and response, the stigma of elder abuse can be reduced. Using co-design and trial methods, we evaluate our intervention's effectiveness in improving: (i) health providers' knowledge of elder abuse and ageing attitudes; (ii) sub-acute care sites' detection and responses; and (iii) older people's sense of safety, quality of life, and mental health.	Professor Bianca Brinjath	Professor Bianca Brinjath, Doctor Andrew Gilbert, Professor Briany Dow, Professor Elizabeth Manias, Professor Marion Ekers, Doctor Patricia Reyes, Brenda Appleton, Doctor Mueh Peters, Doctor Joanne Enticott, Peter Feldman, Associate Professor Duncan Mortimer, Doctor Josefina Antoniazis, Caronna Stevens, Doctor Joan Ostaszewicz	Targeted competitive	1/06/2022	31/05/2025	Public Health And Health Services	Public Health And Health Services, Aged Health Care, Public Health And Health Services, Mental Health, Public Health And Health Services, Health Community Services	\$	1,561,144.75
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	University of Sydney	University	NSW	Evaluation of primary care and help-seeking promotion programs to increase dementia diagnosis and early treatment	This project will test whether a public health-seeking campaign and a primary care practice change program increase dementia diagnosis and treatments and supports after diagnosis. The interventions will target dementia knowledge, stigma, and motivations. Interventions will be delivered in three regions. We will measure measure change through routinely collected health administration data, surveys and interviews. Results will be used to improve dementia training, public campaigns and policy.	Professor Lee-Fay Low	Professor Lee-Fay Low, Professor Henry Brodsky, Associate Professor Tracy Comans, Ms Caroline Gibson, Doctor Meredith Gresham, Associate Professor Mark Yates, Doctor Uliana Larnow, Professor Constance Pond, Doctor Edwin Tan, Associate Professor Lyn Phillips, Doctor Monica Catronis, Associate Professor Kate Laver, Associate Professor Mena J.	Targeted competitive	1/06/2022	31/08/2025	Public Health And Health Services	Public Health And Health Services, Primary Health Care, Public Health And Health Services, Health Promotion	\$	1,999,814.75
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	The University of Queensland	University	QLD	Navigating Fitness to Drive with Patients with Dementia in Primary Care: Delivering an Innovative Online Driver Safety Assessment and Management Package to Practitioners	We will deliver critical resources for primary care management of driving in patients with dementia. These resources include a validated off-road assessment of fitness to drive and protocols. These resources will empower GPs to begin a driving conversation early, assess confidently, and encourage their patients to plan early for eventual driving cessation. An approach that GPs and people living with dementia endorse as the optimal outcome in the inevitable transition to driving retirement.	Doctor Theresa Scott	Doctor Theresa Scott, Professor Mark Horswill, Doctor Andrew Hill, Professor Nancy Pachana, Emeritus Professor Geoffrey Mitchell	Targeted competitive	1/06/2022	31/01/2026	Public Health And Health Services	Public Health And Health Services, Primary Health Care	\$	1,316,765.43
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Monash University	University	VIC	The right to rehabilitation for people with dementia: tackling stigma and implementing evidence-based interventions	People with dementia are often denied treatments to help them maintain their everyday activities. This can be due to stigma and a lack of knowledge by health professionals. The overall aim of our project is to work with people with dementia, their care partners and service providers to develop and test resources and strategies to improve access to treatments that will assist people living with dementia maintain independence and wellbeing in the community for as long as possible.	Associate Professor Michele Calliaya	Associate Professor Michele Calliaya, Professor Velandri Sikanth, Professor Grant Russell, Doctor Taya Collyer, Professor Keith Hill, Professor Alan Petersen, Doctor Claire O'Carroll, Professor Terrence Haines, Doctor Natasha Layton, Ms Kate Swaffler, Doctor Barbara de Graaff	Targeted competitive	1/06/2022	31/07/2025	Clinical Sciences	Clinical Sciences, Geriatrics And Gerontology, Clinical Sciences, Rehabilitation And Therapy (Excl. Physiotherapy), Public Health And Health Services, Primary Health Care	\$	1,015,820.66
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Torrens University Australia Ltd	University	SA	IMPAACT: Improving the Participation of older Australians in policy decision-making on Ageing-related Conditions	In the future, more Australians will live with health conditions that are related to getting older. Some experts recommend that older people be screened for these conditions, yet many questions remain about how best to do this. Together with older people, we will conduct a process to incorporate older people's views into screening for ageing-related conditions. Our project will provide recommendations on how such screening should be offered within the community.	Doctor Rachel Ambaghsheer	Doctor Rachel Ambaghsheer, Associate Professor Matthew Leach, Professor Simon Stewart, Doctor Danielle Taylor, Professor Justin Bellby, Professor Annette Braunack-Mayer, Doctor Elsa Dent, Doctor Mark Thompson, Professor Renuka Viswanathan, Doctor Victoria Cornell, Doctor Michael Lawless	Targeted competitive	1/06/2022	31/05/2025	Public Health And Health Services	Public Health And Health Services, Aged Health Care, Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified, Public Health And Health Services, Primary Health Care	\$	584,430.14
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Monash University	University	VIC	EMBED: A stepped wedge cluster randomised trial of a tailored, integrated model of care to reduce symptoms of depression in home aged care	Older people who receive aged care services at home are at a high risk of depression but lack access to effective treatments. Aged care staff are mostly not trained to recognise or manage symptoms of depression. This research will evaluate Enhanced Management of home-Based Elders with Depression (EMBED)—a new model of care that is expected to reduce symptoms of depression, address stigma and enable older Australians to access evidence-based, tailored treatment at home.	Associate Professor Tanya Davison	Associate Professor Tanya Davison, Professor Anna Barker, Doctor Katy Numbers, Associate Professor Stephen Quinn, Professor Yun-Hee Jeon, Doctor Helena Williams, Associate Professor Tuan Anh Nguyen, Professor Leon Flicker, Doctor Rachel Milne, Associate Professor Leah Hees, Professor Osvaldo Almeida, Professor Viviana Wuthrich, Professor Sunil Bhar, Professor Penelope Schofield	Targeted competitive	1/06/2022	31/05/2025	Public Health And Health Services	Public Health And Health Services, Aged Health Care, Psychology, Health, Clinical And Counselling Psychology, Clinical Sciences, Psychiatry (incl. Psychotherapy)	\$	1,997,775.71
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Edith Cowan University	University	WA	Getting to the heart of healthy ageing: a behaviour change program to promote dietary pattern changes	Blood vessel disease is linked with risk of dementia, cardiovascular disease and falls. A large clinical trial will determine if a novel, low-cost, behaviour change program (knowledge of level of blood vessel disease, its links with risk of dementia, cardiovascular disease and falls, and the benefits of and how to follow a Mediterranean diet) will motivate an individual to make healthy lifestyle changes and will improve measures of risk for dementia, cardiovascular disease and falls.	Doctor Catherine Bordonaro	Doctor Catherine Bordonaro, Doctor Marc Sim, Professor Simon Laws, Professor Romola Bucks, Professor John Schuurbe, Professor Carl Schultz, Professor Richard Woodman, Professor James Dimmock, Professor Jonathan Hodgson, Associate Professor Joshua Lewis	Targeted competitive	1/06/2022	31/05/2025	Public Health And Health Services	Public Health And Health Services, Aged Health Care	\$	506,834.96
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Deakin University	University	VIC	Implementing innovative technology promoting self-awareness of brain health and self-determination in obtaining a timely dementia diagnosis	To delay decline, dementia needs to be diagnosed early. However, up to 76% of Australians diagnosed with dementia have advanced beyond the early stage. The Brain Health Journey app is designed to increase awareness of brain health and promote help-seeking for cognitive concerns. This research into the app use and influence on help-seeking, knowledge and beliefs about dementia will underpin widespread use of an evidence-based app by vulnerable older people to facilitate timely dementia diagnosis.	Professor Alison Hutchinson	Professor Alison Hutchinson, Doctor Lidia Engel, Professor Kon Mourakki, Doctor Loren Mowosowski, Associate Professor Benzie Hadley, Professor Tracey Bucknall, Doctor Eva Yuen, Doctor Terence Chong, Doctor Tanya Petrovich, Doctor Jessica Rivera Villana, Professor Uliana Orellana, Doctor Helen Macpherson, Professor Rajesh Vasa	Targeted competitive	1/06/2022	31/08/2025	Public Health And Health Services	Public Health And Health Services, Aged Health Care	\$	1,052,176.56
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Monash University	University	VIC	Residential Aged Care - Enhanced Dementia Diagnosis	The Royal Commission into Aged Care Quality and Safety found that 1 in 5 people have undiagnosed dementia. Our program provides education to residents, staff and families to address dementia stigma and uses blood tests and digital cognitive assessments to indicate which residents need a referral to specialists for a formal dementia diagnosis. This program will improve dementia knowledge and care leading to improved health and wellbeing for vulnerable people living in residential aged care.	Doctor Darsini Aytton	Doctor Darsini Aytton, Associate Professor Yen Ying Lim, Professor Amy Brodman, Professor Catherine Mihailopoulos, Associate Professor Samantha Loi, Associate Professor Michael Woodward, Doctor Anita Goh, Doctor Barbara Barbera, Associate Professor Scott Aytton, Doctor Ella Zomer, Associate Professor Jessica Kasza, Professor Helen Skouteris, Professor Paul Manliff, Doctor See-E Soh, Doctor Kathleen Doherty	Targeted competitive	1/06/2022	31/05/2025	Public Health And Health Services	Public Health And Health Services, Aged Health Care	\$	200,000.00
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	University of South Australia	University	SA	The Australian Consortium for Aged Care - Quality Measurement Toolbox (ACAC-QMOT): Improving Quality of Care through Better Measurement and Evaluation	The Australian Consortium for Aged Care (ACAC) will improve the quality of care provided to older Australians by defining what constitutes high quality care and the tools needed to monitor this across care settings. ACAC will generate the best quality evidence to inform the key components needed to provide high quality person-centred care. Our work will help care providers and the government understand the delivery of care quality and drive quality improvement to improve health and wellbeing.	Professor Maria Inacio	Professor Maria Inacio, Associate Professor Tracy Comans, Associate Professor Peter Hilbert, Professor Maria Croty, Professor Jeffrey Braithwaite, Professor Steven Wesselingh, Doctor Stephanie Ward, Doctor Narelle Walsh, Doctor Janet Sluggert, Professor Johanna Westbrook, Associate Professor Gillian Caughey, Professor Len Gray	Targeted competitive	1/06/2022	30/09/2025	Public Health And Health Services	Public Health And Health Services, Aged Health Care	\$	2,999,445.80

Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Macquarie University	University	NSW	Transforming residential aged care through evidence based informatics	Poor medication management is a critical and, to date, intractable problem in aged care, impacting residents' wellbeing. Informatics approaches have enormous potential to improve medication management, reduce the workload of resident care staff, & support residents and families access timely information. This project will demonstrate how informatics can support monitoring of medication quality, provide decision support to guide decision-making & support consumers with real-time information.	Professor Johanna Westbrook	Professor Ishanna Westbrook, Professor Nicholas Zwar, Doctor Karla Seaman, Professor Elizabeth Marais, Associate Professor Ling Li, Doctor Magdalene Raban, Professor Jeffrey Ikin, Associate Professor Tracy Bucknall, Professor Ian Cameron, Professor Simon Bell, Professor Mark Morgan, Doctor Nasir Wade, Professor Christopher Etherington, Professor Enrico Cioera	Targeted competitive	1/06/2022	31/08/2024	Public Health And Health Services	Public Health And Health Services, Residential Client Care	\$	992,386.00
Dementia, Ageing and Aged Care Mission	2022 Dementia, Ageing and Aged Care	The University of Queensland	University	QLD	Home hearing and vision care to improve quality of life for people with dementia and carers	Home care helps people with dementia continue to live in their own homes, rather than a aged care home. But over 70% of people have hearing or vision problems that worsen the impact of dementia, reduce quality of life and ability to live independently. Effective hearing and vision support is available, but most hearing and vision problems are not properly supported. We will work with older people to understand the barriers, then develop and test interventions to improve hearing and vision care.	Professor Piers Dawes	Professor Piers Dawes, Professor Brenda Gannon, Associate Professor Hamid Sohrabi, Doctor Carly Meyer, Professor Judy Lowthian, Doctor John Newall, Professor Lisa Kray, Professor Nancy Pachana, Doctor Yanyuan Gu, Doctor Shweta Kumaraan, Associate Professor Racem Lesoi, Professor Chyrisse Heine, Doctor Angelita Martini, Doctor Marianne Coleman, Doctor Sabrina Lensen	Targeted competitive	1/02/2023	31/03/2026	Health Sciences	Health Sciences, Health Services And Systems, Aged Health Care	\$	1,361,891.80
Dementia, Ageing and Aged Care Mission	2022 Dementia, Ageing and Aged Care	The University of Newcastle	University	NSW	Increasing days living in the community and improving quality of life among people living with dementia and their carers	There is a need to support people living with dementia to connect with needed health care and other services and proactively plan their care. This study will test the impact of a nurse led intervention on increasing the days spent in the community, and the quality of life of people living with dementia and their family carers using a randomised controlled design. Outcomes will be assessed for both the person with dementia and their family carer at baseline, 6 and 12 months follow-up.	Professor Mariko Carey	Professor Mariko Carey, Doctor Kay Khaing, Professor Constantine Pord, Professor John Attia, Professor Yun-Hee Jeon, Professor Anna Williams, Professor Balakrishnan Nair, Mr Simon Deeming, Doctor Michelle Kelly, Associate Professor Joel Rhee, Doctor Jennifer White, Doctor Kyle Wales	Targeted competitive	1/02/2023	31/01/2027	Health Sciences	Health Sciences, Health Services And Systems, Primary Health Care	\$	1,691,490.59
Dementia, Ageing and Aged Care Mission	2022 Dementia, Ageing and Aged Care	University of Canberra	University	ACT	Enhancing allied health services for people with dementia in residential aged care: an integrated, transdisciplinary model	Complications due to falls and injury after falls in people with dementia is a significant problem in Residential Aged Care Facilities (RACFs) in Australia. The project will utilise existing General Practice networks based at a RACF to coordinate a suite of evidence based allied health services including occupational therapy, physiotherapy, speech pathology, dietetics and pharmacy and opportunity to residents in a RACF in Canberra	Associate Professor Stephen Isbel	Associate Professor Stephen Isbel, Assistant Professor Nathan D Cunha, Associate Professor Jane Kelleet, Associate Professor Faran Salehi, Associate Professor Sam Kosari, Professor Rachel Davey, Associate Professor Angela Fearon, Doctor Parash Daxda, Professor Michelle Lissola, Professor Diane Gibson, Professor Mark Naughton, Doctor Jennifer Hewitt, Doctor Claire Pearce, Associate Professor Helen Southwood, Professor Pip Logan	Targeted competitive	1/02/2023	31/01/2027	Health Sciences	Health Sciences, Health Services And Systems, Aged Health Care	\$	647,854.40
Dementia, Ageing and Aged Care Mission	2022 Dementia, Ageing and Aged Care	Australian National University	University	ACT	To know me is to understand me: Digital life story packages in dementia care transitions	To Know Me is to Understand Me (2KMUM) trains healthcare students to conduct reminiscence sessions with aged care residents with dementia in order to produce a 4 minute life story video and poster to capture the resident's identity and preferences. We will compare 2KMUM with usual care to find out if 2KMUM helps aged care and health staff understand how to provide personalised care and support for the resident, improving the resident and their family carer's quality of life during transitions.	Doctor Katrina Anderson	Doctor Katrina Anderson, Ms Catherine Bateman, Associate Professor Tracy Comans, Ms Annaliese Blair, Professor Victoria Traynor, Professor Sunil Bhat, Professor Ian Cameron, Professor Susan Kurrie, Doctor Michael Bird	Targeted competitive	1/02/2023	30/06/2027	Health Sciences	Health Sciences, Health Services And Systems, Aged Health Care	\$	1,349,944.20
Dementia, Ageing and Aged Care Mission	2022 Dementia, Ageing and Aged Care	The University of Adelaide	University	SA	Connecting aged care, health care and social services systems to support older Aboriginal and Torres Strait Islander people to live their best lives	An Aboriginal-informed System Connector Model for Ageing Well will link individuals to services and create or strengthen relationships between aged care, health care and social services, thereby increasing timely access to consistent, quality services across systems to support older Aboriginal people in South Australia to age well. Our project will generate evidence that is currently lacking on models of care that prevent ill health and improve quality of life for older Indigenous people.	Associate Professor Odette Pearson	Associate Professor Odette Pearson, Ms Kim Morrey, Doctor Adriana Parnella, Doctor Courtney Ryder, Mr Kurt Towers, Associate Professor Natasha Howard, Doctor Rachel Kelly, Professor Saravana Kumar, Ms Trishia Ritchie, Ms Sone Waters, Doctor Jennifer Caruso	Targeted competitive	1/02/2023	31/01/2027	Health Sciences	Health Sciences, Health Services And Systems, Aged Health Care	\$	1,497,743.50
Dementia, Ageing and Aged Care Mission	2022 Dementia, Ageing and Aged Care	The Sax Institute	Corporation	NSW	Evaluating the implementation and uptake of prevention programs to support healthy ageing amongst Aboriginal people	Aboriginal Community Controlled Health Services (ACCHS) run holistic and culturally safe preventive healthy ageing programs for their communities. This collaborative project will examine the reach and uptake of prevention programs at three ACCHS in NSW. It will identify opportunities to optimise reach, with each community selecting an optimisation strategy which will be tested to assess impact on uptake in the community. Findings will be shared to support decision making, policy and practice.	Ms Sandra Bailey	Ms Sandra Bailey, Associate Professor Sumithra Muthyaya, Mr James Newman, Professor Christine Paul, Professor Rebecca Ivers, Professor Junita Sherwood, Doctor Michelle Kennedy, Ms Simone Sheriff, Ms Paulene Mackell, Mr Darryl Wright	Targeted competitive	1/02/2023	31/01/2027	Indigenous Studies	Indigenous Studies, Aboriginal And Torres Strait Islander Health And Wellbeing, Aboriginal And Torres Strait Islander Health And Wellbeing Not Elsewhere Classified, Health Sciences, Health Services And Systems, Implementation Science And Evaluation, Health Sciences, Public Health, Preventative Health Care	\$	1,493,993.80
Dementia, Ageing and Aged Care Mission	2022 Dementia, Ageing and Aged Care	University of Sydney	University	NSW	Active Women over 50 in rural, regional and remote areas: an effectiveness-implementation trial	Women aged 50+ are a priority for targeted physical activity programs, since capacity starts to decline at this age, and women aged 50+ have unique barriers to becoming active. The Active Women over 50 program combines website information, health coaching, Facebook group and SMS or email motivational messages, to promote physical activity. This research will test the effectiveness, cost-effectiveness and implementation potential of this virtually delivered physical activity promotion program.	Professor Anne Tiedemann	Professor Anne Tiedemann, Associate Professor Leonne Hassett, Associate Professor Simon Rosenbaum, Associate Professor Georgina Luscombe, Professor Kirsten Howard, Doctor Dominka Kawrakita, Professor Nehmat Housami, Emerita Professor Adrian Bauman, Professor Phylarath Phongsavan, Ms Geraldine Wallbank, Doctor Heidi Gildrist, Doctor Grace McKeon, Doctor Raul Ikhore Biwase	Targeted competitive	1/02/2023	31/01/2027	Health Sciences	Health Sciences, Public Health, Health Promotion	\$	1,218,977.20
Dementia, Ageing and Aged Care Mission	2022 Dementia, Ageing and Aged Care	The University of Queensland	University	QLD	Oral Health in Aged Care: Addressing Oral Health Inequity and Unmet Dental Care Needs in Vulnerable Populations	This program aims to evaluate and implement an intervention package that can reduce severe symptoms and functional limitations associated with untreated dental decay, a highly prevalent and debilitating unmet health need in residential aged care residents with dementia. The intervention will help improving quality of life and daily activities of those impacted residents and deliver a cost-effective and feasible approach to help this vulnerable population to maintain a healthy aging.	Professor Loc Do	Professor Loc Do, Doctor Diep Ha, Doctor Nicole Stormon, Helena Schuch, Professor Andrew Georginos, Doctor Kristiana Ludlow, Mr Christopher Sexton, Doctor Claudia Lopez Silva, Emeritus Professor Laurence Walsh, Professor Saso Ivanovski, Doctor Matthew Nangle, Professor Stephen Birch, Professor Julie Henry	Targeted competitive	1/02/2023	30/04/2026	Health Sciences	Health Sciences, Public Health, Public Health Not Elsewhere Classified, Health Sciences, Health Services And Systems, Mental Health Services, Health Sciences, Health Services And Systems, Residential Client Care	\$	1,425,890.90
Dementia, Ageing and Aged Care Mission	2022 Dementia, Ageing and Aged Care	Edith Cowan University	University	WA	BEFRIENDING with GENIE: An intervention to reduce loneliness and increase social support and service access for people living with dementia and their caregivers from CalD backgrounds	The BEFRIENDING with GENIE project aims to improve the quality of life of people living with dementia and their caregivers from Culturally and Linguistically Diverse (CaLD) backgrounds by reducing loneliness, increasing social support networks and improving access to, and knowledge about, appropriate services. It combines a successful BEFRIENDING program with a proven online social support network and engagement tool (GENIE) that will be piloted with 100 participants living in four states.	Professor Loretta Baldassar	Professor Loretta Baldassar, Doctor Manonita Ghosh, Doctor Jacques Raubenheimer, Professor Sunil Bhat, Doctor Simone Marino, Ms Mary Gurgeme, Associate Professor Danni Young, Doctor Sanetta du Toit, Doctor Catrina Stevens, Associate Professor Yavio Vassilev, Professor Colleen Doyle, Associate Professor Jade Cartwright, Doctor Anita Goh, Doctor Rosemary Saunders	Targeted competitive	1/02/2023	31/01/2027	Health Sciences	Health Sciences, Health Services And Systems, Aged Health Care, Health Sciences, Health Services And Systems, Health And Community Services, Human Society, Sociology, Sociology Of Migration, Ethnicity And Multiculturalism	\$	1,480,064.60
Dementia, Ageing and Aged Care Mission	2022 Dementia, Ageing and Aged Care	University of Melbourne	University	VIC	Implementation and evaluation of a co-designed exercise program to reduce falls in older people from culturally and linguistically diverse communities	Falls are the second leading cause of disability in older people. There is strong evidence that exercise reduces falls, however most older people do not meet physical activity guidelines. We are currently co-designing a program, Move Together, to increase the uptake of exercise to reduce falls with older people from Italian, Arab and Chinese communities. This study will evaluate the effectiveness and cost effectiveness of Move Together, and develop strategies to support implementation.	Associate Professor Catherine Said	Associate Professor Catherine Said, Doctor Lilla Engel, Associate Professor Frances Batchelor, Ms Emily Ramage, Doctor Cassie McDonald, Associate Professor Michelle Callaway, Professor Jillian Francis, Doctor Marlena Klatic, Doctor Sara Virgin, Doctor Jesse Zanker, Professor Wen Lim	Targeted competitive	1/02/2023	31/01/2028	Health Sciences	Health Sciences, Allied Health And Rehabilitation Science, Physiotherapy, Biomedical And Clinical Sciences, Clinical Sciences, Geriatrics And Gerontology, Health Sciences, Public Health, Injury Prevention	\$	1,498,604.40
Dementia, Ageing and Aged Care Mission	2022 Dementia, Ageing and Aged Care	University of Western Australia	University	WA	Strengthening and enhancing the utility of a neuropsychological tool for dementia in First Nations peoples	The Kimberley Indigenous Cognitive Assessment (KICA) is the only neuropsychological tool for dementia in Australia's First Nations peoples. Reviews, feedback and research have identified gaps that are impacting KICA access and use. To address these gaps the project will review, revise and test the KICA-R in diverse communities. A training package will be co-developed to inform use. It is critical that we address this dementia research priority to improve dementia care for First Nations peoples.	Doctor Kate Smith	Doctor Kate Smith, Ms Roslyn Malay, Associate Professor Sarah Russell, Professor Leon Flicker, Professor Dawn Bestman, Associate Professor Dina Logiudice, Doctor Zoe Hyde, Professor Edward Stevens, Associate Professor Carmela Pestell, Betty Santi	Targeted competitive	1/02/2023	31/03/2027	Health Sciences	Health Sciences, Health Services And Systems, Aged Health Care, Health Sciences, Health Services And Systems, Health Services And Systems Not Elsewhere Classified	\$	1,972,394.80
Dementia, Ageing and Aged Care Mission	2022 Dementia, Ageing and Aged Care	University of Sydney	University	NSW	A new tool to optimise the early and accurate diagnosis of frontotemporal dementia	This project aims to improve the accurate diagnosis of frontotemporal dementia (FTD): a debilitating form of younger-onset dementia. Aphedonia (a loss of interest) was recently identified as a key marker of FTD. This project will create a new clinical tool that captures early features of FTD and those at high risk of dementia throughout the course of their Parkinson's disease. Earlier diagnosis of FTD and to improve treatment outcomes for those affected.	Professor Muirneam Irish	Professor Muirneam Irish, Doctor David Fone, Professor Yun-Hee Jeon, Professor Dennis Velakoulis, Professor Gail Robinson, Doctor Alexis Whitton, Professor Lee Fay Low, Associate Professor Fiona Kumfor, Associate Professor Rebekah Ahmed, Professor Olivier Piguet	Targeted competitive	1/02/2023	30/04/2027	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Clinical Sciences, Geriatrics And Gerontology	\$	1,789,025.10
Dementia, Ageing and Aged Care Mission	2022 Dementia, Ageing and Aged Care	The University of Queensland	University	QLD	Enhancing utility of neuropsychological evaluation for earlier and effective diagnosis of dementia in Parkinson's disease	Dementia is a major concern for people living with Parkinson's disease; however, there are limited opportunities for early diagnosis. This research will assess a new intervention that includes 1) best practice guidelines for cognitive evaluation, and 2) a technology platform, to help clinicians to effectively identify dementia and those at high risk of dementia throughout the course of their Parkinson's disease. Earlier diagnosis of dementia will improve access to support and quality of life.	Associate Professor Nadeeka Dissanayaka	Associate Professor Nadeeka Dissanayaka, Doctor Jacqueline Liddle, Associate Professor Mark Chaffield, Associate Professor John O'Sullivan, Professor Gerard Byrne, Doctor Isander Mitchell, Doctor Kirstine Shrubsole, Professor Nancy Pachana, Doctor Michelle McMaster, Professor Martin Lesuire Verreynne, Doctor Ji Hyun Yang, Doctor Peter Worthy, Doctor Syed Afroz Keramat, Doctor Deborah Brooks, Associate Professor Annette Broome	Targeted competitive	1/02/2023	30/04/2027	Psychology	Psychology, Clinical And Health Psychology, Clinical Neuropsychology	\$	2,000,000.00

Dementia, Ageing and Aged Care Mission	2022 Dementia, Ageing and Aged Care	Flinders University	University	SA	Spatial navigation assessment: pathway to clinical translation and early diagnosis of dementia	Current clinical tests for Alzheimer's disease are not sensitive enough to detect brain changes that begin 10-20 years before memory symptoms appear. Our team has developed novel tests of spatial navigation (how we navigate our surroundings) that are highly sensitive to these early brain changes. This project will optimise the tests for rollout in clinical services, enabling timely, accurate diagnosis that will fast-track access to early interventions and improve outcomes for those affected.	Doctor Stephanie Wong	Doctor Stephanie Wong, Professor Mark Jenkinson, Associate Professor Victor Roger Schinazi, Associate Professor Tobias Loetscher, Doctor Michelle Kelly, Professor Maria Crotty, Professor Psychology, Applied And Developmental Psychology, Testing, Assessment And Psychometrics	Targeted competitive	1/02/2023	30/04/2027	Psychology	Psychology, Clinical And Health Psychology, Clinical Neuropsychology, Psychology, Biological Psychology	\$	1,999,825.50
Dementia, Ageing and Aged Care Mission	2022 Dementia, Ageing and Aged Care	Monash University	University	VIC	An Integrated Method for the Assessment and Monitoring of Dementia and Cognitive Impairment: The Cognition - Optimised, Digitised, And Harmonised (C-ODH) platform	Neuropsychological testing is key to dementia diagnosis, but barriers such as time, cost, and geographical access, can limit the access of such tests. Utilising novel technologies, and with our Australian industry partners, we will develop and optimize digital assessments, and systems for the deployment, analysis and reporting. By the end of this study, we will have a 10 assessment platform that will enable earlier, and more effective dementia diagnosis with greater geographical access.	Associate Professor Yen Ying Lim	Associate Professor Yen Ying Lim, Professor Sateenah Ahern, Doctor Inga Mehrani, Associate Professor Scott Ayton, Doctor Rachel Buckley, Doctor Roushi Shihaghe, Doctor Darshini Ayton, Professor Paul Maruff, Associate Professor Jane Alty, Professor Velanda Lirkhath, Professor Sharon Naismith, Doctor Laura Bird, Doctor Jurgen Frapp	Targeted competitive	1/02/2023	31/01/2027	Psychology	Psychology, Clinical And Health Psychology, Clinical Neuropsychology, Psychology, Biological Psychology, Neuroscience, Neurology And Neuromuscular Diseases, Health Sciences, Health Services And Systems, Implementation Science And Evaluation	\$	1,997,763.20
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	University of Sydney	University	NSW	Developing a promoter-less gene therapy approach for haemophilia A	Haemophilia A (Factor VIII deficiency) is a bleeding disorder that affects around 3,000 people in Australia. Gene therapy can tackle such deficiencies by delivering the corrective genes to the patient's cells. However, questions on the durability of such therapies are common. In this proposal, we plan to harness the cellular natural DNA repair process to provide a precise and durable therapy, by safely inserting the correct copy of Factor VIII into a highly expressed region of the human genome.	Doctor Marti Cabanes Creus	Doctor Marti Cabanes Creus, Doctor Suzanne Scott	Targeted competitive	1/02/2023	31/01/2025	Medical Biotechnology	Medical Biotechnology, Gene And Molecular Therapy	\$	513,720.11
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	University of Sydney	University	NSW	Reducing medication-related harm in people living with dementia through community action: Development and testing of novel co-designed medication management resources across care settings	Poor medication management is one of the most common causes of hospital admission in people living with dementia, and is often avoidable. This project will educate, empower and support people with dementia and their carers to manage their medications safely by developing, and testing co-designed medication management guidance resources for use in the community and during the transition into aged care.	Doctor Mouna Sawan	Doctor Mouna Sawan, Doctor Natali Iokanovic, Doctor Jacqueline Wesson, Doctor Karen Watson, Doctor Amanda Cross	Targeted competitive	1/02/2023	31/01/2025	Pharmacology And Pharmaceutical Sciences	Pharmacology And Pharmaceutical Sciences, Clinical Pharmacy And Pharmacy Practice	\$	664,384.24
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	The University of Queensland	University	QLD	Running for Health: community-based adaptive exercise for cardiorespiratory health in young people with moderate to severe cerebral palsy	In Australia, 420 children are born annually with cerebral palsy (CP), making it the most common physical disability. Of these, 40% will have moderate to severe motor disability, greater pain, lower levels of physical activity, and early death. We have promising data on a new adaptive physical activity called Frame Running which we will test in a trial of 90 children with moderate to severe CP.	Doctor Sarah Redman	Doctor Sarah Redman, Doctor Syed Afroz Keramat, Doctor Ellen Armstrong, Doctor Iain Dutta, Doctor Matthew Alwash, Doctor David Williams, Stina Ofsted, Doctor Andrea Burgess, Associate Professor Leanne Sakzewski, Doctor Dayna Pool	Targeted competitive	1/02/2023	31/01/2025	Clinical Sciences	Clinical Sciences, Physiotherapy, Clinical Sciences, Rehabilitation And Therapy (incl. Physiotherapy), Paediatrics And Reproductive Medicine, Paediatrics	\$	768,886.64
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	The Council of the Queensland Institute of Medical Research	Medical Research Institute	QLD	Treatment of Obsessive-Compulsive Disorder with Transcranial Focused Ultrasound	Obsessive-compulsive disorder (OCD) is a mental illness that can be very difficult to treat and causes significant disability and suffering. In this research, we plan to understand how focused ultrasound sound waves can be used to change brain activity in a circuit that we think is crucial to persistent symptoms. We plan to show that this is a safe, tolerable and effective therapy and anticipate that it will prove to be a new option for people with OCD who have not responded to other treatments.	Doctor Philip Mosley	Doctor Philip Mosley, Doctor Luke Hearne	Targeted competitive	1/02/2023	31/01/2025	Clinical Sciences	Clinical Sciences, Psychiatry (incl. Psychotherapy)	\$	289,870.25
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	University of New South Wales	University	NSW	Harnessing nanopore sequencing technology to improve diagnosis of human disease	Nanopore sequencing is an emerging technology that enables cheap, fast, portable analysis of long DNA/RNA molecules. There are countless opportunities to streamline, improve or reimagine the diagnosis of human disease using nanopore technology. We outline a series of new tests that address unsolved challenges in genetic disease diagnosis, clinical RNA sequencing and cancer surveillance. In each case, we propose experiments to establish the advantages of nanopore sequencing over existing methods.	Doctor Ira Devoson	Doctor Ira Devoson, Doctor Amali Mallawaarachchi, Doctor Khore Kumar, Doctor Pak Lung Cheong, Doctor Hasindu Gamaarachchi, Doctor Andre Luiz Martins Reis	Targeted competitive	1/02/2023	31/01/2025	Genetics	Genetics, Genomics, Clinical Sciences, Medical Genetics (Excl. Cancer Genetics), Biochemistry And Cell Biology, Bioinformatics	\$	954,947.75
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	The University of Adelaide	University	SA	Plasma Flash: translating cold plasma technology as an antimicrobial wound irrigation towards clinical trials	Superbug, or antibiotic-resistant bacteria, cause recurring infections after surgery and in non-healing wounds as existing antibiotics fail to effectively kill them. We developed a novel sterilisation approach using cold plasma technology. Use lightning striking water, plasma charges liquids with ions and radicals that effectively destroy bacteria, regardless of their antibiotic resistance. We will show proof-of-concept of this innovation to improve infection control and wound care.	Doctor Katharina Richter	Doctor Katharina Richter, Doctor Guilherme Pena, Doctor Adrian Abdo	Targeted competitive	1/02/2023	28/02/2025	Clinical Sciences	Clinical Sciences, Infectious Diseases, Medical Microbiology, Medical Bacteriology, Clinical Sciences, Podiatry	\$	758,437.60
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	St Vincent's Institute of Medical Research	Medical Research Institute	VIC	Repurposing approved drugs for Friedreich's ataxia heart disease	Friedreich's ataxia is a genetic disorder and heart disease is the leading cause of premature death in Friedreich's ataxia patients. There is currently no treatment for Friedreich's ataxia heart disease. Using a disease-in-a-dish model of Friedreich's ataxia heart disease we will identify and repurpose safe, FDA-approved compounds (an approach that is faster than new drug development) that can prevent and reverse the symptoms of Friedreich's ataxia heart disease and facilitate clinical trials.	Doctor Jarmion Lees	Doctor Jarmion Lees, Doctor Mark Xiang Li	Targeted competitive	1/02/2023	30/06/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (incl. Cardiovascular Diseases)	\$	570,744.47
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	University of Sydney	University	NSW	Learning health systems approach to the diagnosis and management of lower respiratory tract infections in children	Chest infections are the most common cause of hospital visits among young children. It can be hard for doctors to tell if a chest infection is caused by bacteria, viruses, or both. Our team will develop a digital tool that can be used in the clinic to help doctors tell which children have bacterial infections and need antibiotics, from which children who do not. This will reduce unnecessary testing and use of antibiotics and help improve the quality of care for these children.	Doctor Parveen Fatima	Doctor Parveen Fatima, Doctor Jannah Baker, Doctor Rama Kishore, Doctor Phyllis Williams, Doctor Sarjay Jayasinghe Wadamballi Archagechi, Doctor Adam Bartlett, Doctor Laurelle McLeod, Doctor Yue Wu	Targeted competitive	1/02/2023	31/07/2025	Public Health And Health Services	Public Health And Health Services, Epidemiology, Cognitive Science, Decision Making, Paediatrics And Reproductive Medicine, Paediatrics	\$	958,403.57
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	The University of Queensland	University	QLD	Broad-spectrum vaccine design for flaviviruses and hantaviruses	Given the continual emergence of viral infections, there is a need for vaccines that provide immunity against several viruses within a family. We propose constructing vaccines based on ancestral viruses that display common key features that would confer protective immunity against present existing viruses. This strategy could allow for broad-spectrum immunity against current pathogens and help prepare the world for future viral outbreaks.	Doctor Natalie Newton	Doctor Natalie Newton, Doctor Christopher McMillan, Doctor Jessica Harrison, Doctor Ariel Isaacs, Doctor Yu Shang Law, Doctor Gabriel Foley, Doctor Rhye Parry, Doctor Nughah Modhiran	Targeted competitive	1/02/2023	31/01/2025	Medical Microbiology	Medical Microbiology, Medical Virology	\$	936,701.61
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	Monash University	University	VIC	A national critical care research platform to ensure high-quality sepsis care in Australian ICUs	Our vision is to improve the care provided to those with sepsis on a national scale, by: (1) improving access to data and generating time efficient knowledge, via greater participation in, and provision of multicentre trials and cohort studies; (2) disseminating knowledge, via improved links to, and in partnership with, peak consumer, critical care academic, research, quality assurance, and vocational training organisations; and (3) translating knowledge into real-world policy and practice.	Professor Andrew Udy	Professor Andrew Udy, Professor Paul Young, Associate Professor Kiran Shekar, Doctor Arya Serpa Neto, Professor Daryl Jones, Associate Professor Adam Deane, Associate Professor Zoe McQuillen, Doctor Kelly Thompson, Doctor Manoj Saxena, Associate Professor Naomi Hammond	Targeted competitive	1/02/2023	31/01/2028	Clinical Sciences	Clinical Sciences, Intensive Care	\$	4,899,778.81
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	The University of Queensland	University	QLD	Obstructive sleep apnoea diagnosis and management in First Nations communities: community co-design, local capacity building and place-based models for sustainable success	Obstructive Sleep Apnoea (OSA) is a highly prevalent yet under-recognised health condition affecting many First Nations peoples. Logistical and financial issues in accessing non-local specialist services result in high rates of undiagnosed/unreated OSA in First Nations communities. This project includes five work packages focused on co-designing OSA services, upskilling the local workforce and educating community members to bring a transformative shift in OSA care in First Nations communities.	Doctor Yaqoot Fatima	Doctor Yaqoot Fatima, Doctor Michelle Olaithe, Doctor Simon Joosten, Doctor Bushra Nasir, Doctor Tracy Woodroffe, Doctor Mark Robinson, Doctor Kathleen Maddison, Doctor Lauren Lawson, Doctor Scott Coussens, Doctor Shannon Edmed	Targeted competitive	1/02/2023	31/01/2028	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health, Public Health And Health Services, Primary Health Care	\$	4,063,176.88
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	University of Western Australia	University	WA	Mandivall: Effectiveness and Consequences of Australia's COVID-19 Vaccine Mandates	Governments can best implement and maintain effective vaccination policy by drawing on strong evidence regarding what works, as well as mitigating against unintended consequences. Understanding the successes and failures of COVID-19 vaccine mandates in Australia and comparing them to similar policies in France and Italy is crucial to the continued management of COVID-19, for designing strategies for future pandemics, as well as for maintaining public confidence in routine vaccines.	Associate Professor Katie Attwell	Associate Professor Katie Attwell, Doctor Jane Williams, Doctor Jessica Kaufman, Doctor Huong Le, Professor Christopher Blyth, Doctor Annette Regan, Doctor Jeremy Ward, Doctor Marco Rizi, Doctor Uwana Evers, Doctor Meelin Genie	Targeted competitive	1/02/2023	30/09/2027	Public Health And Health Services	Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	4,754,183.37
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	University of New South Wales	University	NSW	Transition Compass - Optimising transition from paediatric to adult healthcare services: A randomised controlled trial	Transition to adult care is a high risk time for young adults with chronic medical conditions to lose contact with specialist healthcare teams. This project will develop a transition support package, combining 1) insights from lived experience, 2) a model of care which has been proven to be effective and 3) technology. We will assess the impact of this approach in terms of post-transition medical contacts and participant experience, aiming to embed the initiative in clinical practice if effective.	Doctor Jordana McLoone	Doctor Jordana McLoone, Doctor Angela Gialamas, Doctor Samantha Lahn, Doctor Harley Smithers-Sheedy, Doctor Cara Bailey, Doctor Shaelee Lee, Doctor Cella Moore, Jemma Anderson, Doctor Michael Hodgins, Associate Professor Susan Woodliff	Targeted competitive	1/02/2023	31/01/2028	Clinical Sciences	Clinical Sciences, Clinical Sciences Not Elsewhere Classified	\$	4,704,635.53
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	University of Melbourne	University	VIC	MEGA-dose sCOPRiate for Sepsis (MEGASCOPRES): An interdisciplinary research program to transform management of sepsis in intensive care units	One in five people die due to sepsis when infection causes organ failure. Ascorbic acid (vitamin C) may be an effective therapy, but clinical trials to date have failed to show benefit, likely due to inadequate dosing and acidity. We reported a dramatic reversal of sepsis when mega-doses of the sodium salt of ascorbic acid were used in a series of studies in animals and then humans to define how sodium ascorbate reverses sepsis and whether this translates to saving lives.	Associate Professor Yugesh Lankadeva	Associate Professor Yugesh Lankadeva, Doctor Laura Cook, Doctor Neil Glasford, Professor Antoine Riqually, Doctor Mark Plummer, Doctor Lindsey Booth, Doctor Samantha Smith, Doctor Alexander Wood, Doctor Pei Chen Connie Ow, Doctor Shu Wen Wen	Targeted competitive	1/02/2023	31/03/2028	Clinical Sciences	Clinical Sciences, Intensive Care	\$	4,897,652.65
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	University of Western Australia	University	WA	The missing heritability of human disease: discovery to implementation	Most patients and families with rare diseases remain without a genetic diagnosis following clinical genetic testing. Targeted therapies can only be designed and tested once an accurate genetic cause is found. Our research team will use a range of complementary computational approaches to genomic technologies to identify the missing genetics of rare diseases. We will work to implement these approaches into routine clinical care for the benefit of all Australian rare disease patients.	Doctor Gaianna Ravenscroft	Doctor Gaianna Ravenscroft, Doctor Claire Homan, Doctor Peter Arts, Doctor Parvathy Venugopal, Doctor Suzanne Salveit, Doctor Sam Buckberry, Doctor Clare van Eyk, Doctor Michael Clark, Doctor Ira Devoson, Doctor Matilda Jackson, Doctor Khore Kumar	Targeted competitive	1/02/2023	31/01/2028	Genetics	Genetics, Genomics, Genetics, Genetics Not Elsewhere Classified, Clinical Sciences, Medical Genetics (Excl. Cancer Genetics)	\$	4,877,532.00
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	The University of Queensland	University	QLD	Personalising Innate Immunotherapy for Superior Treatment Outcomes with Large anticancer applicability (PISTOL)	This project will discover mechanisms to maximise tumoricidal functions of a novel off-the-shelf living drug, "Super Killer" NK cells. These cells are designed to detect and kill hard-to-cure metastatic solid cancers to prevent tumour spread and provide a safer therapy option than current treatments. This project will also use the knowledge of how cancer cells hide from immune cells, which can be leveraged to develop more effective and commercially available immunotherapy interventions.	Doctor Fernando de Souza Fonseca Guimarães	Doctor Fernando de Souza Fonseca Guimarães, Associate Professor Hatham Tuffaha, Doctor Hando Rhee, Professor Gabrielle Bell, Doctor Arutha Kulasinghe, Doctor Ahmed Mehdi, Doctor Seth Cheetham, Doctor Pui Wen Lam, Associate Professor Joy Wolfman, Doctor Jennifer Penduk Gosalvez	Targeted competitive	1/02/2023	31/01/2026	Medical Biotechnology	Medical Biotechnology, Medical Biotechnology Not Elsewhere Classified, Oncology And Carcinogenesis, Solid Tumours, Nanotechnology, Nanotechnology Not Elsewhere Classified	\$	990,020.97

Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	The University of Queensland	University	QLD	"Max Up" Trial – Maximising uptake of lung cancer screening and smoking cessation outcomes	As Cancer Australia works towards a national lung cancer screening program, knowledge gaps remain. Important unanswered questions are "How do we best help people at risk of lung cancer quit smoking?" and "to what extent will Quitline clients engage with screening?". Our research will answer these questions and help ensure lung cancer screening delivers the best health outcomes to people at risk of lung cancer, by detecting lung cancer early, and giving people the greatest chance to quit smoking.	Associate Professor Henry Marshall	Associate Professor Henry Marshall, Associate Professor Renee Manser, Associate Professor Marianne Weber, Professor Kwang Kwang, Associate Professor Annette McWilliams, Associate Professor Nicole Rankin, Professor Karen Canfell, Associate Professor Emily Stone, Professor Tanya Buchanan, Professor Fraser Birms, Professor Ian Yang, Professor Billie Bonevski, Associate Professor Catherine Seaton	Targeted competitive	1/02/2023	31/01/2026	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology Respiratory Diseases	\$	917,239.91
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	Griffith University	University	QLD	A biological nerve bridge device for repairing spinal cord injury in humans	This project will optimise an activated cellular nerve bridge that can be transplanted to repair acute and chronic spinal cord injury (SCI). The activated nerve bridges are a modification of our award-winning resting state cellular nerve bridges that have already demonstrated efficacy in repairing SCI.	Doctor Mo Chen	Doctor Mo Chen, Doctor Mariyam Murtaza, Doctor Yu-Ting Tseng, Doctor Runka Reshamwala	Targeted competitive	1/02/2023	31/01/2027	Biomedical Engineering	Biomedical Engineering, Medical Devices, Medical Biotechnology, Regenerative Medicine (incl. Stem Cells And Tissue Engineering), Biomedical Engineering, Biomaterials	\$	761,471.40
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	Monash University	University	VIC	Expanded umbilical cord blood cells for neuroprotection in extremely preterm infants	Being born preterm, especially extremely preterm, lays the foundation for life-long deficits in body movement, behaviour and learning. Parents of children with these developmental disorders request that research targets preventative therapies, particularly stem cell research. This program of preclinical studies will examine the necessary optimisation steps towards implement of an expanded umbilical cord blood cell therapy for preterm infants.	Doctor Courtney McDonald	Doctor Courtney McDonald, Doctor Tamara Yawno, Associate Professor Alit Malhotra, Doctor Tayla Penny, Doctor Madison Paton	Targeted competitive	1/02/2023	31/01/2027	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine, Paediatrics And Reproductive Medicine Not Elsewhere Classified	\$	590,134.71
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	Monash University	University	VIC	Zest – A personalised, digital intervention for sleep and wellbeing in Australian shift workers	Shift workers experience sleep disturbances and insomnia due to non-standard work hours and misalignment of circadian rhythms or "body-clock." Shift work is associated with enormously high risk of poor physical and mental health, including cardiovascular disease, type-1 diabetes, cancer, depression, suicidal ideation, accidents and injuries. The project will deliver a world's-first technology that revolutionises sleep health and lifestyle for more than 1.5 million Australian shift workers.	Doctor Prema Varna	Doctor Prema Varna, Doctor Jade Murray, Doctor Kylie King, Doctor Roisin McManey, Associate Professor Bei Bei, Doctor Tracey Sletten, Doctor Julia Stone, Doctor Svetlana Postnova, Doctor Lauren Isoler	Targeted competitive	1/02/2023	28/02/2026	Public Health And Health Services	Public Health And Health Services, Environmental And Occupational Health And Safety, Public Health And Health Services, Preventive Medicine, Psychology Psychology Not Elsewhere Classified	\$	805,255.87
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	Curtin University	University	WA	TRACKER: Biomarkers to predicting relapse in early stage hepatocellular carcinoma	Early detection is the best opportunity to improve outcomes in all cancer types. However, for liver cancer, "50% of patients even with early-stage cancer will relapse within two years of therapy. In this project by employing state-of-the-art technologies we will develop tissue and blood based diagnostic test to predict relapse in HCC which will help in guiding adjacent therapy in clinic thereby providing 'Right Drug at Right Time to Right Patient'.	Doctor Ankur Sharma	Doctor Ankur Sharma, Doctor Raluca Mahesan, Associate Professor Michael Wallace, Professor Shiv Sarin, Rohini Sharma, Doctor Saurabh Gupta, Longji Liu, Catherine Holliday, Doctor Archita Mishra, Pierce Chow, Doctor Jennifer Carroll, Professor Jason George, Professor Florent Ginchoux, Bicheng Yang, Professor Sarah-Jane Dawson	Targeted competitive	1/02/2023	31/01/2027	Clinical Sciences	Clinical Sciences, Gastroenterology And Hepatology	\$	980,081.41
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	Monash University	University	VIC	Better biomarkers for dementia diagnosis: NfL and Voice Acoustic analysis in Dementia Diagnosis (NAVADO)	There are no simple, accessible tests to detect all forms of dementia. This causes diagnostic delays, increases patient and family stress, and furthers health care inequities. Dementia therapies are on the horizon, meaning a simple test for dementia diagnosis represents a critical knowledge gap. We will examine taking a blood sample, voice recording, and early genetic testing in selected patients improves time to diagnosis and patient and family stress, and facilitating access to therapies.	Professor Amy Brodmann	Professor Amy Brodmann, Doctor Emile Wersan, Professor Adam Vogel, Doctor Julie Baird, Doctor Lan Gao, Professor Michelle Mielke, Professor Leonid Churlov	Targeted competitive	1/02/2023	31/01/2027	Clinical Sciences	Clinical Sciences, Clinical Sciences Not Elsewhere Classified	\$	1,589,171.41
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	Australian National University	University	ACT	Personalised medicine in the treatment of complex autoimmunity and autoinflammatory disease	This study will develop a platform to rapidly identify and validate the impact of genetic variants on the development of autoimmune and autoinflammatory disease, using a novel artificial intelligence assisted identification and a high capacity platform that will allow clinicians to respond in clinically meaningful timeframes.	Doctor Simon Jiang	Doctor Simon Jiang, Doctor Aron Chakera, Doctor Giles Walters, Associate Professor Katrina Randall, Doctor Thomas Andrews, Doctor Kathleen Morrisroe, Associate Professor Natasha Rogers, Doctor Vidi Athanassopoulou	Targeted competitive	1/02/2023	31/01/2027	Clinical Sciences	Clinical Sciences, Rheumatology And Arthritis	\$	1,553,568.84
Emerging Priorities and Consumer Driven Research	2017 Accelerated Research - Motor Neuron Disease Program	Cure for MND Foundation	Corporation	VIC	Clinical Trial of repurposed drugs for the treatment of Motor Neuron Disease	The project seeks to identify and trial one or more drugs that have already been approved for use in humans for other conditions that may have a successful indication in Motor Neuron Disease (MND). Consequently, this project aims to complete a Randomised Double-Blind Placebo-Controlled Phase II Trial in sporadic MND patients across up to 7 Australian sites.	Not applicable	Not available	Targeted non-competitive	22/06/2017	30/09/2020	Not available	Not available	\$	1,960,000.00
Emerging Priorities and Consumer Driven Research	2017 Accelerated Research - Teen Cancer Program	CanTeen	Corporation	NSW	The Australian Young Cancer Patient Clinical Trials Initiative	The purpose of the Accelerated Research Investment – Teen Cancer Program is to improve therapy and outcomes for Adolescents and Young Adult (AYA) cancer patients through new clinical trial activities for AYAs and greater access to innovative and cutting edge approaches with the aim of pursuing research breakthroughs. This will be achieved by providing funding to: increase the number of cancer patients participating in trials; manage the conduct of clinical trials for AYA cancer patients; and attract broader support for international collaboration on trial activity via co-funding models with other funders.	Not applicable	Not available	Targeted non-competitive	29/06/2017	30/09/2020	Not available	Not available	\$	5,000,000.00
Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Beat Cancer	Cancer Council SA	Corporation	SA	Cancer Council SA's Beat Cancer Project	The Beat Cancer Project funds cancer research initiatives including project grants, fellowships, infrastructure grants, travel grants and scholarships that work towards improving the quality of life and survival rates for people with cancer.	Not applicable	Not available	One-off/ad hoc	1/07/2019	31/12/2022	Not available	Not available	\$	3,000,000.00
Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Bone Marrow Failure Syndromes	Maddie Riewoldt Holdings Limited	Corporation	VIC	Clinical trials capacity building for patients with Bone Marrow Failure Syndromes in Australia	Following the establishment of critical foundations and the management of this through the Centre of Research Excellence in Bone Marrow Biology, Maddie's Vision now seeks to further leverage this talent pool and the research findings. The next stage is to develop clinical trial participation through a specific research funding pool directed at clinical research capacity within bone marrow failure syndromes. Enhanced clinical trial capacity in this much needed field of research will present opportunities to bring clinical trials from international centres to Australia through seed funding to support such facilities: research nurses, key clinical trial infrastructure, statistical support and/or to add value to existing clinical trials through the collection and analysis of correlative samples. Specific funding directed for these currently existing opportunities will facilitate the final piece of the Maddie's Vision research strategy. That is, basic science, translational and clinical trial coordinated.	Not applicable	Not available	One-off/ad hoc	23/01/2019	30/06/2023	Not available	Not available	\$	1,000,000.00
Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Congenital Heart Disease	Murdoch Children's Research Institute	Medical Research Institute	VIC	The Australian Genomics Cardiovascular Genetic Disorders Flagship	The Cardiovascular Genetic Disorders Flagship will provide genomic testing for up to 600 families with congenital heart disease, arrhythmia disorders and cardiomyopathies. It will pilot a model of clinical genomics where the functional resolution of variants of unknown significance (VUS) is part of a patient's clinical management pipeline; and will build evidence for the value of harnessing genomic technologies to improve the diagnosis and health management of Australians.	Not applicable	Not available	One-off/ad hoc	1/01/2019	30/06/2023	Not available	Not available	\$	6,000,000.00
Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Endometriosis	The Jean Hailes Foundation	Corporation	VIC	The NICST Network – National Endometriosis Clinical and Scientific Trials	The aim of this project is to build a national research platform that underpins a comprehensive national program of clinical, basic science and translational research relevant to the needs of Australian endometriosis sufferers, consistent with the research objectives in the draft National Action Plan for Endometriosis (NAPE). Specific achievements will include: (i) Development of a National Clinical Trials Network (CTN) that co-ordinates support for research organisations and conducts clinical trials for endometriosis treatments and services. (ii) Development of an Australian endometriosis collaborative research framework to support co-ordinated patient recruitment, consistent data collection and a national database and bio-repository developed from clinical trials and research projects for national and international research projects specific to endometriosis. (iii) Formation of a national collaborative network capable of responding to a targeted call for integrated endometriosis research focused on translational outcomes.	Not applicable	Not available	One-off/ad hoc	23/07/2018	31/12/2022	Not available	Not available	\$	2,500,000.00
Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Microbiome	St George and Sutherland Medical Research Foundation	Corporation	NSW	Studies on the role of the gut microbiome in health and disease	The project includes two linked studies that aim to put Australia at the forefront of research in the microbiome field. The first study aims to define the optimal Australian gut microbiome. We will study three groups: healthy elite athletes, healthy physically active lean individuals and healthy centenarians. The outcomes will include (1) the provision of a multi-omic healthy gut microbiome signatures (fingerprint) for use as a reference by all researchers in Australia and beyond. (2) defining of parameters for manipulation of a diseased microbiome and (3) providing a bank of the healthiest stool that could be used for faecal microbiota transplantation (FMT) and potential treatment of patients with various diseases. The second study (Moshenabadi) aims to study the role of the microbiome in pregnancy and its outcomes in the mothers and their babies. It is unique in starting at the preconception stage and following women for up to a year postpartum and their babies for the first few years of life. The study outcomes will include: (1) defining signatures of outcomes of pregnancy e.g. healthy, preeclampsia, diabetes, obesity, etc. (2) constructing multi-omic predictive signatures based on preconception microbiome; (3) using these predictive signatures to design studies aimed at pre-emptive manipulation of the microbiome at the preconception stage; (4) conducting the largest clinical trial designed to test the role of pre-emptive manipulation of the microbiome in pregnancy for the purpose of prevention of negative outcomes. This study will be a national treasure for Australia and for humanity.	Not applicable	Not available	One-off/ad hoc	1/01/2019	30/12/2022	Not available	Not available	\$	2,000,000.00

Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Motor Neuron Disease	Cure for MND Foundation	Corporation	VIC	National MND Precision Medicine and Clinical Trials Pipeline	The National MND Precision Medicine and Clinical Trials Pipeline will fund two phases: 1. Establish a Precision Medicine Program (PMP) for MND. Around 200 Australian MND patients will donate blood and tissue samples to generate innovative stem cell-based motor neurons to model MND "in the dish". These samples will be analysed and defined at a clinical, genetic, molecular, protein and metabolic level to improve disease classification of patients and encourage better selection and stratification of patients for enrolment in clinical trials, guided by disease signatures and favourable responses to drug screens. 2. Fund further multi-state clinical trials for MND, repurposing an existing drug to increase the number of patients able to access trials. Through competitive tender, a Clinical Research Organisation (CRO) will be identified to administer the trial in conjunction with principal clinical investigators. Up to a further 100 Australian MND patients will participate in the trial.	Not applicable	Not available	One-off/ad hoc	6/08/2018	30/06/2024	Not available	Not available	\$	6,000,000.00
Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Neurological (Cerebral Palsy Alliance)	Cerebral Palsy Alliance (NSW)	Corporation	NSW	Game Changing Research to Prevent, Treat and Cure Cerebral Palsy	This project is focused on 4 key research priorities set by Australians living with cerebral palsy and their families: 1. Making early diagnosis and treatment of cerebral palsy standard care in Australia; 2. Clinical trials of new interventions in high risk infants, including stem cells; 3. Feasibility and acceptability trial of Therasuit(R) intensive therapy; 4. New therapies to prevent cerebral palsy during pregnancy, including antenatal melanin to provide neuroprotection to the growth restricted fetus, and maternal creatine supplementation to protect babies from birth asphyxia.	Not applicable	Not available	One-off/ad hoc	26/07/2018	30/06/2020	Not available	Not available	\$	2,000,000.00
Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Neurological (Epilepsy Foundation)	Epilepsy Foundation (VIC)	Corporation	VIC	The Australian Epilepsy Research Fund	The Epilepsy Foundation has a commitment to supporting innovation and excellence in medical research. To this end, the Foundation has established the Australian Epilepsy Research Fund, launched in March, 2018. This grant represents the inaugural round of funding to be allocated through the Australian Epilepsy Research Fund (AERF). This funding will be allocated specifically to research aimed at finding a cure for rare genetic epilepsy disorders. We believe that research into rare genetic disorders and the opportunities afforded by increasing our knowledge of precision medicine are key emerging health priorities and also represent areas of current unmet need. Australia has contributed enormously to global efforts in unravelling the genetic and cellular basis of brain disorders. There is now an immediate opportunity to advance this knowledge towards clinical benefit. Investment in a specialised research program that focuses on pre-clinical development of diagnostics and therapeutics is required. Such activity is occurring sporadically across the nation but the lack of co-ordinated activity and sufficient funding base results in inefficient workflows, slowing the delivery of outcomes. The Epilepsy Foundation will manage the AERF and ensure that the funding is allocated to high quality research projects, and high quality researchers. To this end, the Foundation has engaged with some of the leading epilepsy researchers in Australia to form a governing committee for the AERF. This committee will determine how the funding acquired through this grant will be allocated. To date, \$500,000 has been granted for a project on precision medicine in Syngap-1-related disorders, to be run by Professor Steven Petrow from the Flinders Institute of Neuroscience. This project provides a clear example of the type of high quality projects that will be funded by the AERF and establishes a template for how projects will be chosen and assessed.	Not applicable	Not available	One-off/ad hoc	26/07/2018	30/06/2023	Not available	Not available	\$	2,000,000.00
Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Neurological (National Stroke Foundation)	National Stroke Foundation	Corporation	VIC	Australian Living Guidelines for Stroke Management and "Return to life, return to work": A targeted clinical research investment in stroke recovery for young survivors	The Living Clinical guidelines for Stroke Management project will draw on latest technologies and new ways of working to develop efficient "evidence surveillance" systems. These systems will continually identify new research, incorporate this research into living systematic reviews and rapidly update individual guideline recommendations whenever there is an important change in the evidence. The "Return to life, return to work" package will focus on clinical trials of recovery and rehabilitation interventions for stroke survivors.	Not applicable	Not available	One-off/ad hoc	23/07/2018	30/06/2023	Not available	Not available	\$	2,500,000.00
Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Priority-driven Collaborative Cancer Research Scheme - All Cancers	University of Melbourne	University	VIC	Role of the Nkp44-PDGF-DD axis in Glioblastoma	Glioblastoma (GBM) is the most common primary malignant brain tumour, carrying an extremely poor prognosis. This Activity is a study that will investigate and evaluate the potential to utilise the immune response to improve detection of, and possibly inhibit, the growth of GBM tumours. Using publicly available databases, the researchers of this project have discovered that a gene for a receptor expressed by important immune cells called Natural Killer (NK) cells is associated with the improved survival of some patients with brain cancer. This project will seek to confirm that this receptor is expressed as a protein on NK cells from these cancers, which then could be used to inform how to target this special pathway to treat patients with brain cancer. This work represents an essential step towards the development of immunotherapeutic strategies designed to specifically target pathways of growth factor immunosuppression in disease. The project aims to provide an essential step towards development of novel Chimeric Antigen Receptor -T-Cell (CAR-T) based immunotherapeutic strategies designed to target cancers that over-express growth factors.	Doctor Alexander Barrow	Not available	Targeted or restricted competitive	23/04/2019	31/12/2023	Not available	Not available	\$	573,689.20
Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Priority-driven Collaborative Cancer Research Scheme - All Cancers	University of Melbourne	University	VIC	Targeting invadopodia to treat glioblastoma	Brain cancer (glioblastoma) is a highly invasive cancer, killing approximately 1500 Australians annually. The researchers will target structures known as invadopodia which facilitate cancer cell invasion with FDA approved drugs not used for brain cancer patients. This project will screen to identify agents that will inhibit invadopodia, therefore interfering with the invasion process of cancer cells. The project aims to complement the current treatment regime of patients with FDA approved agents to improve survival.	Doctor Stanley Styli	Not available	Targeted or restricted competitive	23/04/2019	30/11/2023	Not available	Not available	\$	384,526.00
Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Priority-driven Collaborative Cancer Research Scheme - Childhood Cancers of Low Survival	Monash University	University	VIC	The PARC study: A phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) Relapsed/refractory Cancers of Children and Young Adults	Exciting new research shows that many cancer cells cannot survive without arginine (an amino acid), however normal cells can. A new drug (BCT-100), which causes arginine depletion, has shown promising results in laboratory models of childhood cancer and adult trials. The international PARC study is the first trial in the world to use BCT-100 in children and adolescents with a range of cancers with poor survival rates, offering Australian patients access to desperately needed new treatments.	Doctor Maria Kirby	Not available	Targeted or restricted competitive	23/04/2019	31/12/2022	Not available	Not available	\$	480,015.40
Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Prostate Cancer	The Movember Foundation	Corporation	VIC	Prostate Cancer Research Alliance (PCRA) - An Australian Government and Movember Foundation Collaboration	The Australian Government and the Movember Foundation (Movember) will fund three high quality, collaborative, multi-disciplinary Australian research teams with the scientific and clinical expertise to carry out research projects with a potential for near-term, transformative impact on the clinical management of prostate cancer.	Not applicable	Not available	One-off/ad hoc	25/10/2018	31/10/2023	Not available	Not available	\$	6,018,000.00
Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Rare Cancers	Olivia Newton-John Cancer Research Institute	Medical Research Institute	VIC	Expanding access to a phase I trial evaluating combination immunotherapy for treatment of rare gastrointestinal, neuroendocrine and gynaecological cancers for rural/regional and metropolitan patients	This project will support rare cancer research through expansion of a current clinical trial. The trial combines a new immunotherapy combination of ipilimumab and Nivolumab (ipil/ivo) drugs in patients with rare gastrointestinal, neuroendocrine and gynaecological cancers. The project will enable an additional 60 patients, including those located in rural/regional areas with rare cancers, to join the trial.	Not applicable	Not available	One-off/ad hoc	25/01/2019	31/12/2021	Not available	Not available	\$	1,000,000.00
Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Sanfilippo Syndrome	Sanfilippo Children's Foundation (NSW)	Corporation	NSW	Development of a personalised medicine approach for Australian children with Sanfilippo Syndrome (MPS II) utilising patient specific neuronal cell models	Every year in Australia, approximately 5 children are born with Sanfilippo Syndrome. When diagnosed, often years later, they and their families are confronted with the realisation of an incurable, terminal disease and the burden of a progressive neurological disorder which robs them of their physical and cognitive abilities, resulting in premature death by adolescence or early adulthood. The physical, emotional, social and financial toll on these families is extreme and the burden to Australian health services significant. This project provides an opportunity for life changing discoveries to significantly improve outcomes for Sanfilippo patients and their families, while strengthening the domestic research capacity and positioning Australia as a global leader in health and medical research. This project will apply pioneering medical breakthroughs to revolutionise pipelines for individualised therapeutic strategies in rare disease, improve clinical and economic efficiencies within the already burdened health system, and address a significant unmet need in the rare disease field. Patient-specific neurological disease models will be created and used to identify individualised therapies for Australian children with Sanfilippo Syndrome. It will accelerate medical research towards effective treatments for children with Sanfilippo Syndrome by: developing multi-purpose, functional neuronal cell models of Sanfilippo from individual patient's cells ("brain in a dish"); screening existing drugs that can be repurposed for Sanfilippo; supporting "fast-track" translation of targeted and individualised therapies to clinical trial (critical given the progressive disease course); establishing a collaborative network of expertise for Sanfilippo and building leading scientific capabilities in Australia.	Not applicable	Not available	One-off/ad hoc	18/02/2019	31/03/2023	Not available	Not available	\$	2,000,000.00
Emerging Priorities and Consumer Driven Research	2018 Accelerated Research - Stem Cells	University of Melbourne	University	VIC	Stem Cells Australia: translating stem cell research to medical application	Stem cell science has now advanced to the stage where it can be used to develop and test the effectiveness and safety of new gene therapies and drug treatments and also now offers novel ways to repair parts of the body through stem cell therapy. This research program aims to deliver novel stem cell based approaches to preventing or treating genetic defects that cause blindness and pioneering new approaches for the treatment of congenital heart disease. It will also support ongoing research programs aimed at developing new therapies for diseases such as Parkinson's disease, stroke, chronic kidney disease and dementia.	Not applicable	Not available	One-off/ad hoc	25/07/2018	31/12/2021	Not available	Not available	\$	3,000,000.00

Emerging Priorities and Consumer Driven Research	2019 Accelerated Research - Australian National Phenome Centre	Murdoch University	University	WA	Australian National Phenome Centre (Murdoch University) - Support for Establishment and Sustainability of Critical Infrastructure to Provide Transformational Phenomics Capacity for Australian Medical Research	The Australian National Phenome Centre (ANPC) vision is to create a world-class phenome centre, with strong global connections, directly supporting the development of precision medicine by the Australian research community. The project ensures that the Clinical and Population Health Division of the ANPC can be established at a scale which will support phenomic capacity keeping pace with genomic capacity in Australia, leveraging the significant investment being made in genomics. The potential benefits of combined omics analysis, such as cross-integration of genomic and metabolic phenotype data, are vast and exciting. The project supports acquisition of key scientific equipment for the ANPC, which, together with the support provided by Murdoch University to the ANPC, will allow for the ANPC to be sustainable.	Not applicable	Not available	One-off/ad hoc	28/03/2019	30/06/2020	Not available	Not available	\$	10,000,000.00
Emerging Priorities and Consumer Driven Research	2019 Accelerated Research - Drug Discovery Centre	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	National Drug Discovery Centre	The Walter and Eliza Hall Institute of Medical Research is expanding its early stage drug discovery capacity to dramatically increase the capacity for Australian researchers to undertake high throughput screening – a critical step in the translation of biomedical research discoveries into new drugs. This investment in the National Drug Discovery Centre will fill a known gap in the drug discovery pipeline in Australia and improve the translation of Australia's world class basic research outputs into drugs to treat diseases and improve the quality of life across the community. This investment has the potential to increase the opportunities, benefits and commercial returns to the intellectual property arising from Australian research discoveries.	Not applicable	Not available	One-off/ad hoc	27/03/2019	30/06/2023	Not available	Not available	\$	25,000,000.00
Emerging Priorities and Consumer Driven Research	2019 Accelerated Research - Juvenile Diabetes Research Foundation	JDRF Australia	Corporation	NSW	Australian Type 1 Diabetes Clinical Research Network (CRN)	The principle goal of the CRN is to positively impact the lives of people with type 1 diabetes through the support and translation of research. The three focus areas for the CRN are: 1. Trials: Increase the volume and impact of type 1 diabetes clinical research in Australia. 2. Translation: Support the translation and progress of early stage science. 3. Talent: Nurture current and future research leaders in type 1 diabetes.	Not applicable	Not available	One-off/ad hoc	28/03/2019	30/06/2024	Not available	Not available	\$	25,000,000.00
Emerging Priorities and Consumer Driven Research	2019 Accelerated Research - Leukodystrophy Flagship	Murdoch Children's Research Institute	Medical Research Institute	VIC	Maximo's Mission	Maximo's Mission will deliver more diagnoses, improved experiences and better outcomes for Australian children with leukodystrophies and other rare brain development disorders - through research and targeted precision treatments.	Not applicable	Not available	One-off/ad hoc	1/04/2019	30/06/2023	Not available	Not available	\$	3,000,000.00
Emerging Priorities and Consumer Driven Research	2019 Accelerated Research - Malaria Vaccine Trial	Griffith University	University	QLD	A vaccine for malaria: An Australian concept and development strategy	This project will focus on the pre-clinical development of a world-first whole parasite blood-stage malaria vaccine. Malaria results in >200 million cases and 450,000 deaths/yr. With existing control measures becoming increasingly less effective, the development of an effective malaria vaccine is critical. A single sub-unit malaria vaccine has been licensed; however it provides moderate, short term protection only. By including blood-stage proteins from the whole parasite formulated within novel liposomes to optimise immunogenicity and enable development of a cryopreserved (field deployable) vaccine formulation, our vaccine will be game-changing. This project will focus on three activities pertaining to the development of a field-deployable P. falciparum whole parasite blood-stage malaria vaccine: further optimisation of the vaccine formulation and vaccination regimen in pre-clinical models of malaria, vaccine stability studies and establishment of critical GMP-compliant manufacturing processes and GMP-grade reagents for future clinical vaccine development.	Not applicable	Not available	One-off/ad hoc	30/06/2019	31/12/2022	Not available	Not available	\$	500,000.00
Emerging Priorities and Consumer Driven Research	2019 Accelerated Research - Phenomics Capability	Australian National University	University	ACT	Phenomics Capability (Australian National University): The Phenomics Translation Initiative	The Phenomics Translation Initiative will transform phenomics capability for the benefit of the nation; building on decades of investment at The Australian National University and collaborators across Australia to expand the pipeline of human genomics to phenomics discovery and innovation. Key project activities include scale-up of clinically-derived bespoke disease models; development of pathway- and drug-specific biomarkers and companion diagnostics; evaluation and selection of novel therapies for rare and debilitating conditions; and preparation for 'N-of-1' clinical trials for patient with rare genomic variations and phenotypic profiles. Outcomes include development of new disease models, novel diagnostics and better treatment options for patients globally with diseases that are currently chronic, debilitating and incurable. Understanding mechanisms of disease, personalising therapy, and developing more effective treatments will improve quality of life for all Australians.	Not applicable	Not available	One-off/ad hoc	1/04/2019	30/03/2024	Not available	Not available	\$	10,000,000.00
Emerging Priorities and Consumer Driven Research	2019 Accelerated Research – Stillbirth Research Project – Centre of Research Excellence in Stillbirth	The University of Queensland	University	QLD	Preventing stillbirth: the Australian Safe Baby Bundle	Stillbirth is far too common – six Australian babies are stillborn each day and the psychosocial and economic consequences for families, their care providers and the health system are profound. Women who live with social disadvantage are at heightened risk for stillbirth. Aboriginal and Torres Strait Islander women and women from other culturally and linguistically backgrounds are at particular risk. As many as one-third of stillbirths may be preventable and priorities for stillbirth prevention are clear. Substandard care practices are frequent contributors and ensuring that evidence-based practice is uniformly implemented in all maternity settings is critical to reducing stillbirth rates. The Safe Baby Bundle is Australia's first comprehensive response to this urgent public health issue. The goal is to reduce the rate of stillbirth and to make best care available to all women when stillbirth occurs.	Not applicable	Not available	One-off/ad hoc	1/04/2019	30/06/2024	Not available	Not available	\$	3,000,000.00
Emerging Priorities and Consumer Driven Research	2019 Accelerated Research - The Australian Parkinson's Mission	University of New South Wales	University	NSW	The Australian Parkinson's Mission: Integrating genomics, biomarkers and patient cell phenotyping into disease modifying clinical trials to identify therapeutics to slow or stop disease progression	The Australian Parkinson's Mission (APM) aims to identify therapies that will slow or stop disease progression in people with Parkinson's disease (PD). APM is a collaborative of scientists, clinicians, pharma, and people with PD whose goal is to determine the causes of PD, identify effective therapeutics and fast track them to people with Parkinson's. To accomplish this, the five year project will employ a unique model of inter-connected and mutually reinforcing clinical trials, genomics and biomarker development and phenotyping of patient derived stem cells. A series of multi-arm, multi-drug clinical trials involving hundreds of patients will be conducted at multiple sites across Australia to test repurposed and new drugs that have been prioritised for testing by an international panel of PD experts. Blood RNA and metabolite biomarkers will be identified for their ability to accurately diagnose patients and detect drug efficacy with greater sensitivity than existing clinical measures.	Not applicable	Not available	One-off/ad hoc	1/04/2019	30/06/2025	Not available	Not available	\$	30,000,000.00
Emerging Priorities and Consumer Driven Research	2019 Autism Spectrum Disorder	Monash University	University	VIC	Autism Spectrum Disorders and Comorbid Disorders: Diagnosis and Treatment	Autism spectrum disorders (ASDs) are persistent neurodevelopmental conditions that frequently co-occur with other conditions such as ADHD. This comorbidity necessitates the identification of biomarkers across the ASD-ADHD spectrum that may aid differential diagnosis or lead to the identification of novel treatment options. This project will: (1) establish a landmark cohort of 1200 families across the ASD-ADHD spectrum and use cutting edge data science to identify novel subgroups; (2) use brain imaging to understand common and unique brain signatures; (3) apply cutting-edge genomics to identify common and unique genetic signatures; (4) implement a novel cognitive training programme to boost attention and executive function.	Not applicable	Not available	One-off/ad hoc	20/01/2020	30/06/2024	Not available	Not available	\$	2,500,000.00
Emerging Priorities and Consumer Driven Research	2019 Endometriosis Research	Deakin University	University	VIC	A Randomized Controlled Trial Comparing Yoga, Cognitive Behaviour Therapy and Education to Improve Quality of Life and Reduce Healthcare Costs in Endometriosis	Endometriosis is a chronic inflammatory disease affecting 700 000 Australians. In addition to pain, common symptoms include fatigue, anxiety, depression, and poor quality of life (QoL). Consistent with the National Action Plan for Endometriosis (NAPe) focus on improving QoL, this project will examine two mind-body interventions designed to enhance the mind's positive impact on the body in order to improve patient QoL. This trial aims to use gold-standard methodology to test whether one of the most popular treatments for chronic pain (yoga), and the most prescribed psychological therapy for chronic pain (to cognitive behaviour therapy), really do address the debilitating symptoms of endometriosis, to potentially alleviate the suffering of thousands of Australians.	Doctor Subhadra Evans	Targeted competitive	1/06/2020	30/06/2025	Other Medical And Health Sciences	Medical And Health Sciences Not Elsewhere Classified	\$	893,981.25	
Emerging Priorities and Consumer Driven Research	2019 Endometriosis Research	Monash University	University	VIC	Creating an evidence base for clinical care: A randomized controlled study examining the efficacy of the low FODMAP diet for the relief of gastrointestinal symptoms in endometriosis	Endometriosis is a common condition affecting up to 10% of women of reproductive age. Gastrointestinal (GI) complaints are common, affecting up to 90% of patients. There is large overlap between GI symptoms seen in irritable bowel syndrome (IBS) and endometriosis. Effective therapies are available for patients with IBS, with the low FODMAP diet, pioneered by our center, now first line. However, there is limited information as to whether it is helpful in patients suffering from similar GI symptoms secondary to endometriosis. The current project seeks to explore: 1) if low FODMAP diet therapy is effective in treating GI symptoms associated with endometriosis, 2) the potential role gut and vaginal microbiota plays in GI symptoms associated with endometriosis, 3) clinical, physiological and psychological parameters in patients with endometriosis associated with the presence of GI symptoms.	Associate Professor Jane Muir	Targeted competitive	1/06/2020	31/05/2025	Nutrition And Dietetics	Nutrition And Dietetics Not Elsewhere Classified	\$	948,619.20	
Emerging Priorities and Consumer Driven Research	2019 Endometriosis Research	Murdoch Children's Research Institute	Medical Research Institute	VIC	Long STEPP-A Longitudinal Study of Teenagers with Endometriosis, Period and Pelvic Pain in Australia to identify early risk factors, educational and management strategies that will lead to optimal health outcomes and appropriate health utilisation	The Longitudinal Study of Teenagers with Endometriosis, Period and Pelvic Pain (LongSTEPP-Australia) is novel project and the first of its kind due to its focus on adolescents, lending to the possibility of prevention of endometriosis through controlling pelvic pain and menstrual problems. There is limited education to ensure teenagers seek help for their period problems. This study intends to clarify through co-design the factors that are most important to teenagers, examine the impact of the various educational strategies by monitoring those where these programs are occurring; explore the psychosocial factors impacting on presentation and monitor management and health utilisation of teens presenting with endometriosis, period and pelvic pain to adolescent gynaecology units in public hospitals around Australia.	Professor Sonia Grover	Targeted competitive	1/06/2020	31/05/2026	Paediatrics And Reproductive Medicine	Obstetrics And Gynaecology	\$	1,963,118.00	

Emerging Priorities and Consumer Driven Research	2019 Endometriosis Research	University of Melbourne	University	VIC	Improving diagnosis and treatment of endometriosis	We aim to improve the quality of life for all women living with endometriosis through research-driven improvements to diagnosis and treatment. Our proposal has 3 major themes, (1) Better diagnosis of initial and recurrent endometriosis, (2) Improved outcomes for women with endometriosis-related pain, and (3) Development of evidence-based pathways to treat endometriosis-related infertility. The three themes contain a powerful mixture of clinical trials and laboratory based discovery research that will lead to improved outcomes in conjunction with a better understanding of factors that lead to the development and progression of endometriosis.	Professor Peter Rogers	Professor Peter Rogers, Associate Professor Martin Healey, Doctor Sarah Holdsworth-Carson, Doctor Jacqueline Donoghue, Associate Professor Helena Frawley, Doctor Claudia Cheng	Targeted competitive	1/06/2020	31/05/2025	Paediatrics And Reproductive Medicine	Obstetrics And Gynaecology	\$	3,929,233.50
Emerging Priorities and Consumer Driven Research	2019 Endometriosis Research	The University of Queensland	University	QLD	Genetic variants, Early Life exposures, and Longitudinal Endometriosis Symptoms study (GELLES)	The Genetic variants, Early Life exposures, and Longitudinal Endometriosis symptoms Study (GELLES) takes an innovative approach to address the evidence gaps and the limitations of previous Endometriosis studies. GELLES will compare women with and without endometriosis and identify the combinations of factors and patterns of symptoms linked with increased risk of endometriosis and longer time to diagnosis. The study will produce high quality evidence and provide new insights on the causal pathways and aetiology of this disease. GELLES researchers will work with end-users to ensure the new knowledge benefits consumers, including improved information on endometriosis, a new clinical tool for health professionals to assess the risk of endometriosis, and clinical guidelines to reduce the time required for diagnosis and accessing treatment.	Professor Gita Mishra	Professor Gita Mishra, Doctor Ingrid Rowlands, Doctor Sally-Anne Mortlock, Professor Jenny Doust, Professor Annette Dobson, Doctor Marina Kvasokoff	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Epidemiology	\$	1,856,540.00
Emerging Priorities and Consumer Driven Research	2019 Lung Cancer Genomics	Australian Genomic Cancer Medicine Centre Ltd	Corporation	NSW	ASPIRATION: assessing the impact of genomic profiling in lung cancer	There are several well-established, and an increasing number of, genomic alterations in metastatic non-squamous non-small cell lung cancer (mNSCLC) that are not adequately identified by current diagnostic testing. Comprehensive genomic profiling (CGP) has the capacity to identify actionable genomic alterations missed by current testing, potentially allowing patients to access personalised treatment with emerging targeted drugs currently available or in development. The ASPIRATION study will evaluate the clinical impact of CGP on the management of mNSCLC and assess the feasibility of implementation of CGP nationally.	Not applicable	Not available	One-off/ad hoc	5/02/2020	31/12/2024	Not available	Not available	\$	5,000,000.00
Emerging Priorities and Consumer Driven Research	2019 Male Infertility Research	University of New South Wales	University	NSW	Men and infertility over the lifecycle (MAIL)	One in 20 men suffer from infertility. We have assembled a world-class team of researchers and consumer advocates, to apply advanced epidemiological and analytical techniques to answer key questions in male reproductive health. Four integrated research streams have been designed to provide a complete picture of the reproductive and general health of men suffering from infertility and their children over the lifecycle, thereby identifying potential causes and targets for prevention and treatment. Translation activities include a publicly available IVF patient predictor tool & fertility clinic success rate website allowing individuals to estimate their chances of IVF successful, clinical practice guidelines and a clinical trials portal.	Not applicable	Not available	One-off/ad hoc	6/04/2020	30/06/2024	Not available	Not available	\$	4,600,000.00
Emerging Priorities and Consumer Driven Research	2019 Mental Health Pharmacogenomics	The Council of the Queensland Institute of Medical Research	Medical Research Institute	QLD	Australian Pharmacogenomics Diversity Project: Examining the evidence and improving the performance of pharmacogenomics in the Australian context	Psychiatric pharmacogenomic testing, if adopted in Australia, must be available to all Australians. Frequencies and effects of DNA variants vary between ethnic groups and the evidence-base is lacking to guide treatment decisions in Australian Aboriginal and Torres Strait Islander populations and the major non-European migrant groups within the Australian community. Our proposal addresses this lack of evidence and aims to increase the utility and efficacy of these tests for all Australians.	Professor Sarah Medland	Professor Sarah Medland, Professor Nicholas Martin, Mr Gregory Pratt, Professor Naomi Wray, Professor Ian Hickie, Associate Professor Maree Toombs, Associate Professor Louisa Gordon, Associate Professor Lucia Colodro-Conde, Doctor Enda Byrne, Associate Professor Penelope Lind	Targeted competitive	1/06/2020	31/05/2025	Clinical Sciences	Psychiatry (incl. Psychotherapy)	\$	1,371,571.30
Emerging Priorities and Consumer Driven Research	2019 Mental Health Pharmacogenomics	University of Melbourne	University	VIC	The PRESIDE (Pharmacogenomics in Depression) Trial: an RCT of pharmacogenomically-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care	Up to a half of patients with depression do not respond to their first antidepressant. This is partly due to genetic variation in the way people metabolise antidepressants. In this trial we will test the effect of using a genetic test to guide the choice and dose of antidepressant, comparing it with current best-practice prescribing. We will measure the effect of using this genetic test on improvement in symptoms of depression, reduced side-effects from antidepressants and healthcare costs.	Professor Jon Emery	Professor Jon Emery, Professor Jane Gunn, Doctor Chad Bouman, Professor Graeme Sulthers, Doctor Paddy (Pangalos) Chronidis, Associate Professor Victoria Palmer, Professor Cathrine Mihalopoulos, Professor Timothy Chen, Doctor Thomas Polasek	Targeted competitive	1/06/2020	31/08/2024	Public Health And Health Services	Primary Health Care	\$	1,390,401.00
Emerging Priorities and Consumer Driven Research	2019 Mental Health Pharmacogenomics	University of New South Wales	University	NSW	A multifaceted approach to the pharmacogenomic signatures of bipolar disorder for improving treatment outcomes	Bipolar Disorder is a debilitating psychiatric condition for which treatment response and clinical course is highly variable. Advanced genomics and biomarker analysis of patients with linked health record data over 15 years will address key knowledge gaps in treatment response and long-term treatment outcomes of this chronic condition. This project will enhance capacity for personalised medicine and classify subgroups for improved treatment to reduce the significant burden of this disease.	Associate Professor Janice Fullerton	Associate Professor Janice Fullerton, Professor Melissa Green, Professor Peter Schofield, Doctor Claudia Toma	Targeted competitive	1/06/2020	31/05/2025	Genetics	Genomics	\$	1,009,768.00
Emerging Priorities and Consumer Driven Research	2019 Mental Health Pharmacogenomics	University of New South Wales	University	NSW	An Australian Multicentre Double-Blinded Randomised Controlled Trial of Genotype-guided versus Standard Psychotropic Therapy in Moderately to Severely Depressed Patients Initiating Pharmacotherapy	Current drug treatment for depression is ineffective due to its one-size-fits-all approach. This project investigates the clinical and economic benefits of using individual pharmacogenomics and neuroimaging results to guide medication selection. Through artificial intelligence, it aims to combine pharmacogenomics and other datasets, to develop a user-friendly decision support tool that can be used at the bedside.	Doctor Kathy Wu	Doctor Kathy Wu, Professor Paul Fitzgerald, Professor Deborah Schofield, Professor Stuart Grieve, Professor Anthony Rodgers, Professor Anthony Harris, Doctor Rupendra Shrestha, Professor Sean Hood, Professor Timothy Usherwood, Doctor Fatemeh Vafaei	Targeted competitive	1/06/2020	31/05/2024	Other Medical And Health Sciences	Medical And Health Sciences Not Elsewhere Classified	\$	2,954,040.50
Emerging Priorities and Consumer Driven Research	2019 Multiple Sclerosis (MS) Flagship	University of Tasmania	University	TAS	The Multiple Sclerosis (MS) Flagship	The goal of the Menzies Institute for Medical Research Multiple Sclerosis (MS) Flagship is to perform high-quality, interdisciplinary, and consumer-engaged research designed to reduce the impact of MS on individuals, their families and society. To this end, this MRFF opportunity will support the MS Flagship to establish a stem cell bank designed to advance MS research, and support laboratory research into brain function, myelin repair, and the genes that underpin MS risk. They will also partner with consumers and stakeholders to develop an economic model to identify cost-effective treatments and interventions for MS, and develop education tools and online resources for people living with MS, including a symptom management App.	Not applicable	Not available	One-off/ad hoc	6/02/2020	30/06/2024	Not available	Not available	\$	10,000,000.00
Emerging Priorities and Consumer Driven Research	2019 Ovarian Cancer Research	Griffith University	University	QLD	A Phase II trial evaluating feasibility, safety and efficacy of an individually-tailored exercise intervention during chemotherapy for recurrent ovarian cancer	There is a pressing need to determine if exercise therapy is relevant for cancer cohorts with low-survival and high cancer- and treatment-related morbidity, such as is the case for women with recurrent ovarian cancer. This phase II trial will evaluate the feasibility, safety and effects of an exercise intervention during chemotherapy for recurrent OC, and in doing so will determine whether exercise is effective at improving the lives of those with advanced cancer.	Professor Sandra Hayes	Professor Sandra Hayes, Professor Andreas Obermayr, Professor Monika Janda, Professor Elizabeth Eakin, Doctor Catherine Shannon, Doctor Jeffrey Goh, Associate Professor Vanessa Beesley, Doctor Dimitrios Vagenas, Doctor Rosalind Spence	Targeted competitive	1/06/2020	31/05/2024	Oncology And Carcinogenesis	Oncology And Carcinogenesis Not Elsewhere Classified	\$	884,172.32
Emerging Priorities and Consumer Driven Research	2019 Ovarian Cancer Research	Monash University	University	VIC	Measuring adherence to best practice guidelines for the management of ovarian cancer in Australia to determine the extent to which variation in care influences clinical and patient-reported outcomes	That there is variation in the quality of care provided to women diagnosed with ovarian cancer in Australia is widely known. However, the impact of variation in care on key patient outcomes is unknown. A clinical quality registry such as the newly established National Gynaecology Registry can not only monitor how well clinical management aligns with agreed "best practice", but also can help drive changes in clinical practice to improve both clinical and patient-reported outcomes.	Professor John Zalberg	Professor John Zalberg, Associate Professor Robert Rome, Mrs Janice Antony, Professor Penelope Schofield, Associate Professor Alison Brand, Professor Gary Richardson, Associate Professor Rhonda Farrell, Professor Sue Evans, Ms Suzanne Hegarty, Associate Professor Aral Esmet	Targeted competitive	1/06/2020	31/05/2025	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	3,520,935.00
Emerging Priorities and Consumer Driven Research	2019 Ovarian Cancer Research	Monash University	University	VIC	Towards A New Era in Granulosa Cell Tumour Research: Patient Driven Outcomes, Genomics, Diagnostics & Therapeutics	Granulosa cell tumours (GCT) of the ovary are a unique subset of ovarian cancers which do not respond to conventional therapy. These studies will: i) characterise the patient experience; ii) identify mutations that lead to advanced disease which has a mortality of 80 percent; iii) characterise genes associated with advanced disease; iv) develop better diagnostics; and v) provide targeted approaches to treatment i.e. personalised medicine for women with GCT.	Professor Peter Fuller	Professor Peter Fuller, Doctor Simon Chu, Professor Thomas Jobling, Professor Victoria White, Associate Professor David Powell, Professor John Sike, Ms Natasha Armour	Targeted competitive	1/06/2020	31/05/2025	Oncology And Carcinogenesis	Oncology And Carcinogenesis Not Elsewhere Classified	\$	2,218,870.00
Emerging Priorities and Consumer Driven Research	2019 Ovarian Cancer Research	The Council of the Queensland Institute of Medical Research	Medical Research Institute	QLD	Ovarian cancer: Investigating Variation in care and survival. Aetiology and Risk factors to improve outcomes in Australia via National data linkage. The OVARIAN study	Many questions about ovarian cancer can only be answered with information from large and representative groups of women with ovarian cancer. We will capitalise on existing data that are routinely collected for healthcare and link these to create a data set with de-identified information for all women diagnosed with ovarian cancer in Australia and a comparable group of cancer-free women. This will allow us to answer questions about risk factors, diagnosis, variations in care and survival.	Professor Penelope Webb	Professor Penelope Webb, Doctor Paul Cohen, Associate Professor Susan Jordan, Associate Professor Louisa Gordon, Associate Professor Katrina Spillbury, Professor James Codde, Doctor Aime Powell, Associate Professor Peter Grant, Doctor Christopher Steer, Professor Colin Stewart	Targeted competitive	1/06/2020	31/05/2025	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	2,707,035.20
Emerging Priorities and Consumer Driven Research	2019 Ovarian Cancer Research	University of Melbourne	University	VIC	High throughput discovery of synergistic drug combinations for patients with low-grade serous ovarian cancer	Little is known about the best treatment strategies for women with low-grade serous ovarian cancers. We will systematically investigate novel drug combinations with a study of the key genetic determinants of response to these combinations in a large panel of patient-derived tumour cells. This innovative project is the first of its kind, and will highlight new treatment opportunities, and create immediate clinical drug development opportunities to significantly improve patient outcomes.	Doctor Dane Cheasley	Doctor Dane Cheasley, Associate Professor Kaylene Simpson, Professor Neville Hacker	Targeted competitive	1/06/2020	31/05/2024	Oncology And Carcinogenesis	Molecular Targets	\$	1,109,189.00
Emerging Priorities and Consumer Driven Research	2019 Ovarian Cancer Research	The University of Newcastle	University	NSW	Australian Program for Drug Repurposing for Treatment Resistant Ovarian Cancer Treatment	Drug repurposing is a method for identifying new uses for drugs that are outside the scope of the original medical use. We are proposing one of the most ambitious approaches to developing new ovarian cancer treatments ever undertaken by establishing the Australian program of drug repurposing for treatment resistant ovarian cancer. This will be a world first large-scale program of drug repurposing for ovarian cancer delivered by scientists, clinicians and ovarian cancer consumers working together.	Associate Professor Nikola Bowden	Associate Professor Nikola Bowden, Professor Jennifer Martin, Professor Deborah Marsh, Associate Professor Caroline Ford, Professor David Thomas, Professor Richard Innes, Doctor Michelle Wong-Brown, Ms Gill Stannard, Doctor Penny Reeves	Targeted competitive	1/06/2020	31/05/2025	Pharmacology And Pharmaceutical Sciences	Clinical Pharmacology And Therapeutics	\$	2,693,815.00
Emerging Priorities and Consumer Driven Research	2019 Ovarian Cancer Research	The University of Queensland	University	QLD	A new radio-imaging agent to guide targeted therapy for epithelial ovarian cancer	We aim to revolutionise care of advanced ovarian cancer. We will further develop a new agent, 100T7, that has dual functions for diagnosing and treating ovarian cancer. We discovered and have patented this unique agent and, in this study, will label it with a radioactive particle to determine its biodistribution in patient tumours and its safety. The study results have significant potential to increase options for advanced ovarian cancer not responsive to current treatments.	Associate Professor Paul Thomas	Associate Professor Paul Thomas, Professor John Hooper, Professor Trent Munro, Associate Professor David Wyld, Associate Professor Lewis Perrin, Doctor Rohan Louie, Professor Stephen Rose, Doctor Simon Puttick	Targeted competitive	1/06/2020	31/08/2024	Oncology And Carcinogenesis	Cancer Diagnosis	\$	1,893,306.20

Emerging Priorities and Consumer Driven Research	2019 Ovarian Cancer Research	The University of Queensland	University	QLD	Ovarian cancer early detection, monitoring and therapeutic intervention using extracellular vesicles	This project addresses the problems of late diagnosis, prediction of sensitivity or resistance to chemotherapy, and non-specific delivery of therapeutic agents to the tumour cells, in patients with ovarian cancer a critical challenge to global health. Information contained in these exosomes are reflective of the cellular alterations associated with cancer. This proposal will investigate the utility of exosomes as diagnostic markers, as well as novel anti-metastatic molecule delivery systems.	Doctor Carlos Salomon	Associate Professor Carlos Salomon, Doctor Amirali Popat, Doctor Muhammad Siddiqui, Professor Gregory Rice, Professor Yasuke Yamachi	Targeted competitive	1/06/2020	31/05/2024	Oncology And Carcinogenesis	Cancer Diagnosis	\$	1,213,467.50
Emerging Priorities and Consumer Driven Research	2019 Women in Sport Research	Victoria University	University	VIC	Changing Practice: Mental and Physical Health of Girls and Women	Despite the mental and physical, social, equity and economic benefits associated with girls and women involved as leaders and participants in sport, women are largely under-represented in leadership positions and fewer females participate in sport than males. The aim of this research is to change practices and increase the number of women and girls as leaders and participants in sport. The research will involve four sub-projects with separate aims: Aim 1: To identify factors to attract and retain women from CALD backgrounds as leaders in sport. Aim 2: To design and evaluate an intervention to change practices across sectors in the workplace to encourage more women in male-dominated leadership positions. Aim 3: To investigate community grass-roots sport participation for girls and women and their retention and drop-out patterns across the lifespan for two national sports. Aim 4: To collect comprehensive mental health and wellbeing data from women in semi and professional sports to assess and track mental health and evaluate existing initiatives.	Not applicable	Not available	One-off/ad hoc	29/01/2020	30/06/2023	Not available	Not available	\$	1,000,000.00
Emerging Priorities and Consumer Driven Research	2020 Australian Health Research Alliance: National Women's Health Research, Translation and Impact Network	Monash University	University	VIC	National Women's Health Research, Translation and Impact Network	There is a gap in women's health research and an under-representation of women in research. The Australian Government has prioritised strategies to address gender inequity across physical and mental health and the distinct challenges that are unique to women. The Australian Health Research Alliance (AHRA) will support workforce capacity building, leadership development, and broad research and translation in women's health. The Women's Health Research, Translation and Impact Network (VHRN) aims to support workforce capacity building nationally, in under-represented groups, including women and indigenous researchers to expand the knowledge base pertaining to women's health to realise improvements in women's health outcomes.	Not applicable	Not available	One-off/ad hoc	22/06/2020	31/12/2024	Not available	Not available	\$	5,000,000.00
Emerging Priorities and Consumer Driven Research	2020 Bushfire Impact Research	Australian National University	University	ACT	Building community resilience to promote mental health in bushfire-affected communities	This research will inform coping and resilience-building strategies to promote future bushfire preparedness, and develop recommendations to improve the capacity of health professionals to respond and deliver distress counselling and psychological support. The evidence will deliver both scientific advances in our understanding of how community resilience can be fostered in the context of bushfires, as well as practical benefits to affected communities in the coming months and years.	Professor Iain Walker	Professor Iain Walker, Professor Emily Lancsar, Professor Alison Calear, Doctor Stewart Sutherland, Doctor Lisa Marie Greenwell, Doctor Jo Leach, Doctor Rachael Rodney Harris, Dr Tegan Cuijys	Targeted competitive	1/06/2020	31/05/2023	Psychology	Social And Community Psychology	\$	295,037.60
Emerging Priorities and Consumer Driven Research	2020 Bushfire Impact Research	Australian National University	University	ACT	The short and long term impacts of bushfires on children and their caregivers mental health: Using the Longitudinal Study of Australian Children to understand the economic, family and community protective factors.	This project will document the long term impacts of bushfires on the mental health of children and adolescents and their caregivers using Australia's national study of children. It will provide information on economic, family, school and community factors that put children and adolescents and their caregivers more vulnerable or more resilient to bushfires to inform future preparedness, response and recovery.	Associate Professor Benjamin Edwards	Associate Professor Benjamin Edwards, Professor Matthew Gray	Targeted competitive	1/06/2020	31/05/2023	Psychology	Developmental Psychology And Ageing	\$	135,347.60
Emerging Priorities and Consumer Driven Research	2020 Bushfire Impact Research	Curtin University	University	WA	Supporting the ongoing wellbeing and resilience of Australia's first responders following the 2019/20 bushfires	The cumulative impact of exposure to traumatic events can negatively impact the wellbeing of first responders. The unprecedented intensity and severity of the 2019/20 bushfires may adversely impact many first responders. This study extends capacity building, leadership development, and broad research and translation in women's health. The Women's Health Research, Translation and Impact Network (VHRN) aims to support workforce capacity building nationally, in under-represented groups, including women and indigenous researchers to expand the knowledge base pertaining to women's health to realise improvements in women's health outcomes.	Associate Professor David Lawrence	Associate Professor David Lawrence, Mrs Wavne Rikkers, Doctor Miranda Van Hooff, Professor Sharon Lawn, Professor Stephen Houghton	Targeted competitive	1/06/2020	31/12/2023	Public Health And Health Services	Mental Health	\$	642,195.60
Emerging Priorities and Consumer Driven Research	2020 Bushfire Impact Research	University of Canberra	University	ACT	Supporting mental health through building resilience during and after bushfires: lessons from the 2019-20 bushfires in southern NSW and the ACT	This Stream 3 project will examine how to design bushfire preparedness and response strategies to support mental health through a focus on building resilience resources including fire preparedness and response strategies. We will do this through assessing whether people who have access to different types of resilience resources and bushfire communication, support and assistance show differing mental health outcomes when exposed to differing bushfire impacts (economic, social, and environmental).	Associate Professor Jacki Schirmer	Associate Professor Jacki Schirmer, Professor Douglas Paton, Associate Professor Petra Buegeft, Associate Professor Theophilie Niyonsenga	Targeted competitive	1/06/2020	30/11/2023	Public Health And Health Services	Mental Health	\$	322,234.60
Emerging Priorities and Consumer Driven Research	2020 Bushfire Impact Research	The University of New England	University	NSW	Enhancing social and emotional wellbeing healing through arts-based storytelling for Aboriginal communities of northern inland NSW bushfire affected areas	The aim of this project is to collaboratively develop and evaluate the impact of a co-designed arts-based storytelling mental health promotion workshop for Aboriginal people affected by the bushfires. The team, in collaboration with an Aboriginal Community Controlled Health Corporation as a partner, will engage with Aboriginal communities in the Northern Inland NSW region to build coping strategies and healing to manage distress that may have arisen during or after the bushfires.	Professor Kim Usher	Professor Kim Usher, Professor Rhonda Marriott, Doctor Vicki Lea Saunders, Associate Professor Nayaji Bhullar, Professor Geetha Ramnarathgala, Professor Myfanwy Maple	Targeted competitive	1/06/2020	31/05/2023	Other Medical And Health Sciences	Medical And Health Sciences Not Elsewhere Classified	\$	624,022.60
Emerging Priorities and Consumer Driven Research	2020 Bushfire Impact Research	Monash University	University	VIC	Physiological impacts of prolonged bushfire smoke exposure on first responders and outdoor workers	This project aims to investigate the physical health impacts of prolonged bushfire exposure during the 2019/20 bushfires on firefighters, other emergency services personnel and outdoor workers. It will link the cohort to hospital data, medicare benefits scheme data and compensation data. The findings will provide new information about short and medium term physical impacts, health service use and compensation claims to inform future policy and practice for these workers.	Professor Karen Walker-Bone	Professor Karen Walker-Bone, Associate Professor Deborah Glass, Professor Tim Driscoll, Doctor Ryan Hay, Doctor Fabienne Reisen	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Environmental And Occupational Health And Safety	\$	556,143.00
Emerging Priorities and Consumer Driven Research	2020 Bushfire Impact Research	The University of Newcastle	University	NSW	Bushfire Impact on Vulnerable Groups: the respiratory burden and effective community solutions	We will address the impact of prolonged bushfire smoke exposure on the vulnerable groups of pregnant and breastfeeding women with asthma, and adults with severe asthma using data and samples that we have collected during exposure and compare this to data and samples we will collect after the exposure has ended. The effects of prevention strategies will be assessed. The mechanisms will be studied in model systems. Results will be disseminated by our partner groups.	Professor Peter Gibson	Professor Peter Gibson, Doctor Megan Jensen, Professor Vanessa McDonald, Associate Professor Jay Horvat, Doctor Vanessa Murphy, Associate Professor Elizabeth Holland, Associate Professor Anne Vertigan	Targeted competitive	1/06/2020	31/05/2023	Cardiorespiratory Medicine And Haematology	Respiratory Diseases	\$	864,480.00
Emerging Priorities and Consumer Driven Research	2020 Bushfire Impact Research	University of New South Wales	University	NSW	A randomised controlled trial of mask use in control of respiratory outcomes during bushfire season	We will do a clinical trial to measure the protection offered by surgical masks and P2 respirators on asthma and lung disease during bushfires in Australia. The research addresses a gap in evidence about the use of face masks during bushfire smoke exposure to prevent exacerbations of asthma and other respiratory conditions. The research will be informed by consumers and driven by consumer engagement to ensure the findings can have the best health impact possible for affected communities.	Professor Raina Macintyre	Professor Raina Macintyre, Associate Professor Holly Seale, Associate Professor Smita Shah, Doctor Abrar Chughtai	Targeted competitive	1/06/2020	31/05/2023	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	473,135.00
Emerging Priorities and Consumer Driven Research	2020 Bushfire Impact Research	University of Technology Sydney	University	NSW	Defining and treating the physiological effects of bushfire smoke exposure	The physiological impacts of short and long-term inhalation of bushfire smoke (BFS) in different areas and if the effects resolve are unknown. We will define the effects (cell viability, inflammation, oxidative stress, mucus production, respiratory issues, lung function, gas exchange) in healthy human cells and tissues and in mouse models in vivo, and in asthma, emphysema and different age groups. We will determine safe exposures and assess the best therapies to prevent and treat the effects.	Professor Philip Hansbro	Professor Philip Hansbro, Professor Peter Wark, Professor Christine Jenkins, Professor Stephen Simpson, Doctor Chantal Donovan, Doctor Richard Kim, Doctor Alan Hsu, Professor Graham Neely, Associate Professor Garry Myers	Targeted competitive	1/06/2020	31/05/2023	Cardiorespiratory Medicine And Haematology	Respiratory Diseases	\$	1,087,404.00
Emerging Priorities and Consumer Driven Research	2020 Childhood Cancer Research	University of New South Wales	University	NSW	Improving outcomes for children with high risk cancer	Although combination chemotherapy has significantly improved survival rates for children with cancer, the outlook remains dismal for patients with aggressive high-risk disease. We have strong preclinical and clinical data highlighting specific vulnerabilities in poor outcome cancers that can be targeted as effective treatments. Our overall goal is to develop these new therapeutic opportunities to improve patient outcomes and provide prevention strategies for specific child cancer subtypes.	Professor Michelle Haber	Professor Michelle Haber, Professor Glenn Marshall, Professor Murray Norris, Mrs Chelsea Mayoh, Doctor Jamie Fletcher, Professor John Siles, Professor Guillaume Lessene	Targeted competitive	1/06/2021	31/12/2024	Oncology And Carcinogenesis	Molecular Targets	\$	1,497,517.83
Emerging Priorities and Consumer Driven Research	2020 Childhood Cancer Research	University of Melbourne	University	VIC	Studying the origins, maintenance and resistance mechanisms of poor prognosis paediatric leukaemia at single cell resolution to develop novel therapeutic approaches	Therapeutic resistance is a major barrier to curative treatment of acute leukaemia in children. However, we do not understand what drives this resistance to conventional chemotherapy and novel salvage therapies including cutting-edge cancer immunotherapies. Using a novel single cell approach we will examine the underlying biological mechanisms that drive this resistance. This information will be invaluable in developing new drugs to overcome this resistance.	Professor Mark Dawson	Professor Mark Dawson, Doctor Seong Lin Khaw, Doctor Ashley P Ng, Associate Professor Rachel Canver, Professor Simon Harrison, Associate Professor Jean Ollaro, Doctor Brendon Monahan	Targeted competitive	1/06/2021	31/05/2025	Oncology And Carcinogenesis	Cancer Cell Biology	\$	1,488,670.80
Emerging Priorities and Consumer Driven Research	2020 Childhood Cancer Research	University of Sydney	University	NSW	Alternative Lengthening of Telomeres (ALT): Target Discovery to Treatment	Osteosarcoma is the most common type of primary bone malignancy, with highest incidence in adolescence. Survival has shown little improvement over the last three decades. The majority (>60%) of osteosarcomas activate the Alternative Lengthening of Telomeres (ALT) pathway. We have discovered a weakness of ALT cells that we can exploit through the development of chemical inhibitors that are rapidly toxic to ALT cells. This approach will offer improved treatments for adolescent osteosarcomas.	Professor Hilda Pickett	Professor Hilda Pickett, Associate Professor Anthony Cesar, Doctor Yu Heng Lau, Professor Roger Reddel, Professor Sandro Consonati	Targeted competitive	1/06/2021	31/05/2024	Medicinal And Biomolecular Chemistry	Molecular Medicine	\$	1,484,000.00
Emerging Priorities and Consumer Driven Research	2020 Childhood Cancer Research	The University of Adelaide	University	SA	Adolescents with Acute Lymphoblastic Leukaemia: Focusing on the gut microbiota, its role in therapeutic response and potential as an effective adjunct therapeutic in this High-Risk group	Increasing age (>10 years) is a significant risk factor for poor outcome in ALL. Using patient samples our primary aim is to understand the impact of the gut microbiota and associated immune systems on therapeutic efficacy in adolescent ALL. Importantly, the gut microbiota is modifiable, as such we will explore whether these modifications, used safely in other disease, can be added to conventional treatment to significantly improve response and reduce toxicity in this very vulnerable group.	Professor Deborah White	Professor Deborah White, Professor David Lynn, Professor Andrew Zannettino, Associate Professor David Yeung, Doctor Stephen Blake, Doctor Michael Gibson, Doctor Laura Edell, Doctor Jacqueline Neill	Targeted competitive	1/06/2021	31/05/2024	Immunology	Tumour Immunology	\$	1,292,871.49
Emerging Priorities and Consumer Driven Research	2020 Childhood Cancer Research	University of New South Wales	University	NSW	Rationalised inclusion of HDAC inhibitors with standard-of-care chemotherapy to improve outcomes for primary and relapsed neuroblastoma	Neuroblastoma is the most common cancer in infants, frequently occurring in children under two years of age. Approximately half of all neuroblastoma patients present with high-risk disease, and receive intensive treatment including chemotherapy, surgery and radiotherapy. Despite this, the survival rate for high-risk neuroblastoma patients is still below 40-50%. Using advanced mathematical modelling we now propose to test a treatment regimen aimed at greatly improving this poor response rate.	Associate Professor David Croucher	Associate Professor David Croucher, Professor Yusef Khatib, Professor Frank Westermann, Professor Frank Spielman	Targeted competitive	1/06/2021	31/05/2024	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	614,017.00
Emerging Priorities and Consumer Driven Research	2020 Childhood Cancer Research	University of South Australia	University	SA	ADONH Neuroblastoma: Defining the Aetiology and underlying Biology of neuroblastoma to innovate and Shape new options for prevention, diagnosis and treatment	Neuroblastoma is a childhood cancer that typically affects children under the age of five, with a median age of diagnosis between one and two. It accounts for 15% of all childhood cancer deaths. For high-risk patients, the highly toxic treatment and the young age of the patients give rise to devastating developmental defects and other side effects. Our studies are aimed to improve diagnosis, lead to development of new therapies and better animal models for testing new therapeutics.	Professor Yeesim Khew-Goodall	Associate Professor Yeesim Khew-Goodall, Professor Gregory Goodall, Doctor Maria Kirby, Associate Professor Quentin Schwarz, Professor Jose Polo, Professor Ernst Wolvetang, Doctor Katherine Pflum, Doctor Sophie Jessop, Associate Professor Daniel Thomas	Targeted competitive	1/06/2021	30/09/2024	Oncology And Carcinogenesis	Cancer Cell Biology	\$	1,420,132.30

Emerging Priorities and Consumer Driven Research	2020 Childhood Cancer Research	St Vincent's Institute of Medical Research	Medical Research Institute	VIC	Reducing tumour incidence in adolescents with germ-line mutations in RECQL4	Our proposal will test a new candidate drug target that could potentially reduce disease and cancer formation for patients with mutations in a gene called RECQL4. RECQL4 mutations occur in a family cancer syndrome called Rothmund-Thomson Syndrome (RTS), where the children are at high risk of developing bone cancer during early adolescence. We have identified a new pathway that makes cells with RECQL4 mutation happen, and this grant will tell us how this happens and also develop inhibitors.	Professor Carl Walkley	Professor Carl Walkley, Doctor Jessica Hohen, Doctor Monique Smeets, Associate Professor Tiong Yang Tan	Targeted competitive	1/06/2021	31/05/2024	Oncology And Carcinogenesis	Cancer Cell Biology	\$	957,598.55
Emerging Priorities and Consumer Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	Swinburne University of Technology	University	VIC	Solving Unknown Primary cancer Earlier Diagnosis (SUPER-ED): A stepped wedge cluster randomised controlled trial implementing a new model of care to support earlier diagnosis	Cancer of unknown primary (CUP) is a rare condition where cancer has spread, but a primary tumour evades detection. Without standardised diagnostic tests, some CUP diagnoses may be erroneous, or time to diagnosis is too long. Initiated and guided by our consumer committee, we will develop a new model of care, to be tested and implemented through our Australia-wide CUP network of healthcare services, that will reduce time to diagnosis, lead to better treatments and improve patient experiences.	Professor Penelope Schofield	Professor Penelope Schofield, Professor Linda Mileschik, Doctor Anna Ugaldé, Associate Professor Richard Toshill, Associate Professor Stephen Quinn, Doctor Huai Wong, Doctor Owen Prall, Doctor Catherine Mitchell, Professor Nilmini Wickramasinghe, Doctor Clare Fedele	Targeted competitive	1/06/2021	31/05/2025	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	2,366,198.20
Emerging Priorities and Consumer Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	University of New South Wales	University	NSW	Microbial based biomarkers powered by artificial intelligence for early detection of liver cancer in Australia. The Australian Liver Cancer Microbiome Consortium	Liver cancer has dismal outcomes in Australia as it is often detected in its late stage. We and others have shown that gut microbiota related metabolic and immune responses signify cancer emergence. We aim to define and validate a liver cancer specific microbial based biomarker. We will apply artificial intelligence to extensive individual clinical and gut microbiome dataset to identify and validate a liver cancer specific biomarker for early diagnosis of liver cancer.	Associate Professor Amany Zekry	Associate Professor Amany Zekry, Professor Emad El-Omar, Doctor Fatemeh Vafaei, Professor Arcot Sowmya, Professor Geoffrey McCaughan, Professor Jeremy Nicholson, Professor Elaine Holmes, Professor Stuart Roberts, Doctor Jason Behary, Doctor Kim Park	Targeted competitive	1/06/2021	31/05/2026	Clinical Sciences	Gastroenterology And Hepatology	\$	3,989,421.75
Emerging Priorities and Consumer Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	Flinders University	University	SA	Shining Light into the "unknown" on Indigenous and non-Indigenous Australians with Cancer of Unknown Primary	Cancer of unknown primary (CUP) diagnosis is made after an exhaustive set of tests fail to identify a primary site of origin, but not everyone undergoes a uniform set of tests. In addition, CUP incidence/mortality disparity exists between the Indigenous and non-Indigenous Australians. This project aims to implement a uniform diagnostic pathway, accurately identify the primary site using a novel tissue of origin test and improve treatment options through genomic profiling for all Australians.	Professor Christos Karapetis	Professor Christos Karapetis, Professor Alex Brown, Doctor Ganessan Kichenadasse, Mr Gregory Pratt, Professor Hamish Scott, Professor Claire Vajdic, Doctor Nicola Waddell, Doctor Nada Corsini, Associate Professor Daniel Thomas, Associate Professor Anna Brown	Targeted competitive	1/06/2021	31/05/2026	Oncology And Carcinogenesis	Cancer Diagnosis	\$	2,401,509.40
Emerging Priorities and Consumer Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	University of South Australia	University	SA	Predicting and Preventing Ovarian Cancer: a machine learning approach	Ovarian cancer (OC) is the most fatal female reproductive cancer, with few known modifiable risk factors. We will analyse information from 273,000 women who were all free of cancer at baseline, and use a form of artificial intelligence to identify which factors predict their risk of cancer in the next 10-15 years. We will also use other large scale data and novel genetic approaches to identify mechanisms leading to OC and seek for biomarkers and drug targets which could help us to prevent OC.	Professor Elina Hypponen	Professor Elina Hypponen, Johanna Maepa, Associate Professor Sang Hong Lee, Associate Professor Ville-Peter Makinen	Targeted competitive	1/06/2021	31/08/2025	Public Health And Health Services	Preventive Medicine	\$	1,260,168.70
Emerging Priorities and Consumer Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	The University of Queensland	University	QLD	Implementing a Multivariate Index Assay for the Earlier Detection of Ovarian Cancer	We have developed a new type of test for the earlier detection of ovarian cancer. The test requires further validation to determine its clinical utility. This study will compare the performance of the new test with that of the current "gold-standard" to correctly identify women with early-stage ovarian cancer. This information is required to progress along the pathway to making the test available for clinical use.	Associate Professor Carlos Salomon	Associate Professor Carlos Salomon, Professor Gregory Rice, Professor Usha Menon, Professor Sunit Lahari, Professor Amanda Barnard, Associate Professor Hanne Suminen, Associate Professor Mahesh Choolani	Targeted competitive	1/06/2021	31/05/2025	Oncology And Carcinogenesis	Cancer Cell Biology	\$	2,664,278.15
Emerging Priorities and Consumer Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	University of Melbourne	University	VIC	Ready to screen. Targeting the high-risk population to improve lung cancer diagnosis	Lung cancer is the number one cause of cancer death worldwide. A screening test using low dose CT could save thousands of lives. We need to find the best ways to give people information about lung cancer screening so they can choose whether to take part. This project will test ways of inviting and educating people about lung cancer screening. The study will invite people via their family doctor and who are aged between 50 and 80 years and smoke cigarettes daily or quit less than 15 years ago.	Doctor Nicole Rankin	Doctor Nicole Rankin, Professor Christine Paul, Doctor Emily Stone, Associate Professor Joel Rhee, Professor Jennifer May, Professor Billie Bonenval, Professor Shalin Vinod, Doctor Daniel Barker, Doctor Michelle Bowill, Doctor Rachael Dodd	Targeted competitive	1/06/2021	31/05/2025	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	1,999,923.40
Emerging Priorities and Consumer Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	University of Western Australia	University	WA	The IC3 Trial: Identifying Cirrhosis and Liver Cancer in Primary Care	Many patients with a common liver cancer, hepatocellular carcinoma (HCC), have undiagnosed cirrhosis. These patients have missed the opportunity for surveillance that could detect HCC earlier and improve survival. We have established an accurate cirrhosis detection pathway and aim to examine its effect and cost on early HCC diagnosis and HCC surveillance compared to usual care. 2800 patients will be recruited across rural and urban general practices in Australia for this study.	Associate Professor Leon Adams	Associate Professor Leon Adams, Professor Jon Emery, Professor Gary Jeffrey, Professor Alexander Thompson, Associate Professor Simone Strasser, Professor Darrell Crawford, Associate Professor Louisa Gordon, Professor Christopher Reid, Associate Professor Michael Walters, Doctor Patty J Panagiotou Chondros	Targeted competitive	1/06/2021	31/08/2025	Clinical Sciences	Gastroenterology And Hepatology	\$	3,192,950.55
Emerging Priorities and Consumer Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	The University of Queensland	University	QLD	Lung cancer screening for early detection	Lung cancer is the biggest cause of cancer deaths and most cases sadly present at a late stage when it is no longer curable. Our research will focus utilise existing evidence to develop or improve approaches for the early diagnosis of lung cancer in order to detect and cure early lung cancer.	Professor Kwun Fong	Professor Kwun Fong, Professor Ian Yang, Doctor Henry Marshall, Professor Martin Tammemägi, Professor Stephen Lam, Associate Professor Maree Toombs, Associate Professor Renee Manser, Doctor Annette McWilliams	Targeted competitive	1/06/2021	31/05/2025	Cardiorespiratory Medicine And Haematology	Respiratory Diseases	\$	2,836,143.00
Emerging Priorities and Consumer Driven Research	2020 Medicinal Cannabis Clinical Trials	The University of Queensland	University	QLD	Medicinal Cannabis randomised multicentre double blind placebo-controlled trial to assess THC/CBD to relieve symptom burden in patients with cancer	People with advanced cancer experience a large range of distressing and difficult to manage symptoms. There has been much public interest in the use of medicinal cannabis to relieve the distress caused by these symptoms. In this trial, we will test the two main components of cannabis - THC and CBD - to determine if this makes patients feel better and improve their quality of life.	Professor Phillip Good	Professor Phillip Good, Professor Janet Hardy, Doctor Alison Hayward, Associate Professor Rebecca Olson, Associate Professor Rodan Guez, Professor Jennifer Philp, Professor Patsy Yates, Doctor Ruwani Mendis	Targeted competitive	1/06/2021	30/11/2025	Clinical Sciences	Clinical Sciences Not Elsewhere Classified	\$	1,526,798.49
Emerging Priorities and Consumer Driven Research	2020 Medicinal Cannabis Clinical Trials	Queensland University of Technology	University	QLD	A prospective multicentre randomised blinded two arm parallel trial of medicinal cannabis products for alleviating symptom burden in children with advanced cancer	We aim to investigate if giving medicinal cannabis (MC) to children receiving palliative care for advanced cancer, improves their symptoms such as pain. A prospective, randomised trial will assess the effectiveness, safety and side-effects of two (MC) products. We will also ask children and parents about their views on MC cannabis use. This study will contribute to the limited evidence around the role and safe use of MC in children, which can be used to inform future clinical trials.	Associate Professor Anthony Herbert	Associate Professor Anthony Herbert, Associate Professor Helen Haessler, Associate Professor Helen Irving, Professor Murray Mitchell, Professor Iain McGregor, Doctor Geoff Wallace, Associate Professor Natalie Bradford, Mr Michael Dulig, Doctor Alison Bowers	Targeted competitive	1/06/2021	31/05/2024	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	692,016.90
Emerging Priorities and Consumer Driven Research	2020 Medicinal Cannabis Clinical Trials	The University of Adelaide	University	SA	The CAnabinoids for CaNCer Therapy (CANCAN) Trial	Medicinal cannabis has been investigated for the management of cancer therapy symptoms. However, there is insufficient evidence to guide its use in clinical practice. The CANCAN trial will address this gap by exploring the use of personalised CBD/THC dosing to prevent common and impactful symptoms of treatment in advanced cancer.	Professor Timothy Price	Professor Timothy Price, Doctor Hannah Wardill, Associate Professor David Young, Professor Gregory Crawford, Professor Joanne Bowen, Professor Sagar Shukh, Doctor Scott Smith, Professor Guy Lutherook, Professor Andrew Zannettino, Mr Steve Whetton	Targeted competitive	1/06/2021	31/05/2026	Oncology And Carcinogenesis	Oncology And Carcinogenesis Not Elsewhere Classified	\$	1,486,715.40
Emerging Priorities and Consumer Driven Research	2020 Neurofibromatosis Research	Murdoch Children's Research Institute	Medical Research Institute	VIC	A randomised control trial of remote microphone listening devices in children with neurofibromatosis type 1 and central auditory deficits	Our project will investigate the efficacy of a remote microphone listening device in treating severe central auditory deficits that are experienced by 45% of children with the genetic syndrome NF1. There is no way to predict tumour severity which can range from <100 to thousands. We will conduct a large genome wide association study to identify genetic modifiers to understand disease variability and characterise potential treatment pathways.	Associate Professor Jonathan Payne	Associate Professor Jonathan Payne, Professor Rance, Professor Kathryn North, Professor Martin Delatycki, Doctor Gabriel Dabschek, Doctor Natalie Pride, Doctor Belinda Barton, Mrs Francesca Grini, Doctor Julien Zanin, Ms Alice Maier	Targeted competitive	1/06/2021	30/09/2025	Clinical Sciences	Clinical Sciences Not Elsewhere Classified	\$	599,283.40
Emerging Priorities and Consumer Driven Research	2020 Neurofibromatosis Research	Monash University	University	VIC	Defining NF1 clinical variation at the microscale to discover new therapeutic targets	Treatment of neurofibromatosis type 1 remains a significant challenge. Patients are diagnosed by detecting loss or changes in the neurofibromin gene. However, this genetic information is not enough to predict disease severity. We will apply new technologies to uncover how the neurofibromin protein is dysregulated at the atomic level and inside the cell. This project will enhance our ability to predict disease severity at diagnosis and discover new pathways for therapeutic intervention.	Doctor Andrew Ellisdon	Doctor Andrew Ellisdon, Doctor Michelle Hall, Associate Professor Raff Schittenhelm	Targeted competitive	1/06/2021	31/05/2024	Biochemistry And Cell Biology	Signal Transduction	\$	818,472.00
Emerging Priorities and Consumer Driven Research	2020 Neurofibromatosis Research	The University of Newcastle	University	NSW	The Neurofibromatosis type 1 (NF1) Cutaneous Neurofibroma Consortium: Identifying Genetic modifiers of disease burden to inform treatment pathways	Neurofibromatosis type 1 (NF1) is the most common neurogenetic condition. Adult patients report cosmetic disfigurement due to distressing fleshy skin tumours as the greatest burden of living with NF1. There is no way to predict tumour severity which can range from <100 to thousands. We will conduct a large genome wide association study to identify genetic modifiers to understand disease variability and characterise potential treatment pathways.	Associate Professor Tracy Dudding-Ilyth	Associate Professor Tracy Dudding-Ilyth, Professor Murray Cairns, Professor John Attis, Professor D Gareth Evans, Professor Rodney Scott, Professor Brian Lovell, Doctor Adrian Lim	Targeted competitive	1/06/2021	31/05/2024	Genetics	Gene Expression (Ind. Microarray And Other Genome-Wide Approaches)	\$	1,607,737.60
Emerging Priorities and Consumer Driven Research	2020 Neurofibromatosis Research	Murdoch Children's Research Institute	Medical Research Institute	VIC	Malignant Peripheral Nerve Sheath Tumour Genomics in Neurofibromatosis 1 (MaGen)	We aim to explore the genetic changes that lead to cancer in patients with Neurofibromatosis 1 (NF1). We are focusing on a cancer called Malignant Peripheral Nerve Sheath Tumour (MPNST). Our ultimate aim is to develop a test that leads to a blood test that diagnose cancer in patients with NF1. By doing this we hope to improve the lives of patients with NF1. We are working with doctors and scientists across Australia to develop this technology.	Doctor Gabriel Dabschek	Doctor Gabriel Dabschek, Associate Professor Jonathan Karpelowsky, Doctor Smadar Sahana-Edwin, Professor Katharine Drummond, Associate Professor Geoffrey McCowage, Doctor Leonard Golds, Professor Andy Pennington, Associate Professor Andrew Morokoff, Doctor James Whittle, Associate Professor Yemima Berman	Targeted competitive	1/06/2021	31/05/2024	Oncology And Carcinogenesis	Molecular Targets	\$	1,593,512.65
Emerging Priorities and Consumer Driven Research	2020 Paediatric Cancer	Monash University	University	VIC	The Victoria Paediatric Cancer Consortium: A Multi-institutional Partnership to Catalyze Advances in Childhood Cancer Research and Clinical Implementation	We propose the establishment of the Victorian Paediatric Cancer Consortium (VPCCC) that will leverage the unique research expertise and clinical capabilities across the Monash and Parkville precincts. VPCCC will focus on discovery research projects in next-generation precision oncology, tumour immunotherapy and epigenetics. This will be complemented by clinical programs aimed at improving patient survivorship by minimising adverse reactions to therapies and translating new discoveries.	Associate Professor Ron Firestein	Associate Professor Ron Firestein, Professor David Eisenstat, Associate Professor Rachel Conyers, Doctor Peter Downie, Associate Professor Jordan Hansford, Associate Professor Joseph Rosenbluh, Associate Professor Maria McCarthy, Doctor Jason Cain, Associate Professor Misty Jenkins, Professor Tracy Danaher	Targeted competitive	1/06/2021	31/05/2024	Oncology And Carcinogenesis	Cancer Genetics	\$	9,599,999.61

Emerging Priorities and Consumer Driven Research	2020 Primary Care Fracture Liaison Services Pilot Project	Osteoporosis Australia	Corporation	NSW	Primary Care Fracture Liaison (PCFLS) Pilot Project	The Primary Care Fracture Liaison (PCFLS) Pilot Project (the Project) will examine research questions concerning the effectiveness and benefits of establishing Fracture Liaison Services (FLSs) outside tertiary settings within primary care. Over two years, 50 Australian GP sites across two Tranches (1&2) will establish and implement an integrated FLS function within their practices. The specific objectives are to: assess the effectiveness of establishing the function of an FLS in GP practices; establish whether FLSs in the primary care setting improve the identification, diagnosis and management of patients with fragility fractures; identify and measure benefits to Australians with osteoporosis/osteopenia and fragility fractures as well as Australia's healthcare system generally, in taking this uniquely integrated approach; measure the effectiveness of current interventions undertaken by Australia's GPs; identify key clinical outcomes that matter most to patients suffering from osteoporosis and fragility fractures; and support behavioural change among GPs with a view to improving identification and management of osteoporosis at the primary health care 'frontline'.	Professor Peter Ebeling	Not available	One-off/ad hoc	30/06/2021	31/12/2024	Not available	Not available	\$	2,808,000.00
Emerging Priorities and Consumer Driven Research	2020 RESELECT Trial	Maddie Riewoldt Holdings Limited	Corporation	VIC	The RESELECT Trial	The RESELECT trial - Rescuing bone marrow function in patients with relapsed acquired Aplastic Anaemia and/or bone marrow failure post allogeneic stem Cell Transplantation is an interventional clinical trial that has the potential to improve both quality and quantity of life for Australian patients with very high risk bone marrow failure. The RESELECT trial will provide patients immediate access to novel therapies, whilst simultaneously developing a platform for the delivery of a pipeline of innovative treatments, including cutting edge cellular and gene therapies, for subsequent patient cohorts. It is an opportunity to make significant impact on the lives of Australian patients and families affected with Bone Marrow Failure Syndromes.	Not applicable	Not available	One-off/ad hoc	1/06/2020	30/06/2024	Not available	Not available	\$	1,020,000.00
Emerging Priorities and Consumer Driven Research	2020 Silirosis Research	The University of Queensland	University	QLD	Silirosis - Harnessing new ideas to conquer the re-emergence of an ancient lung disease - The SHIELD Study	An epidemic of fatal silicosis caused by inhaling dust from artificial stone products has engulfed Australia and other developed countries. SHIELD is a national, coordinated, multi-disciplinary response to the silicosis crisis. In multiple world firsts, SHIELD will: assess the potential of whole lung lavage to treat accelerated silicosis; test the ability of biologic markers to predict disease; and deploy cutting-edge technologies and innovations to bridge the 'kitchen bench-top to bedside' gap.	Professor Daniel Chambers	Professor Daniel Chambers, Professor Glen Westall, Associate Professor Nicole Goh, Associate Professor Tamara Corte, Doctor Simon Apts, Associate Professor Joseph Powell, Professor Steven Bozinovski, Doctor Katrina Newblin, Doctor Tracy Leong, Ms Celine Pattaroni	Targeted competitive	1/06/2021	31/05/2025	Cardiorespiratory Medicine And Haematology	Respiratory Diseases	\$	2,216,631.00
Emerging Priorities and Consumer Driven Research	2020 Silirosis Research	University of Sydney	University	NSW	Transforming diagnosis of silicosis: a novel AI approach	This project builds on a currently funded project establishing novel teaching tools to enhance silicosis diagnosis. The new work integrates artificial intelligence (AI) into the existing activity to achieve tailored education following clinicians' judgement of lung images; supported decision making for diagnosing silica-induced lung lesions; improved outcome predictions based on patient data. Diagnosis of silicosis will be transformed using the best of humans and machines.	Professor Patrick Brennan	Professor Patrick Brennan, Doctor Mo'ayyad Suleman, Doctor Ziba Gandomkar, Professor Dong Xu, Doctor Nigel Sommerfeld	Targeted competitive	1/06/2021	31/12/2024	Clinical Sciences	Radiology And Organ Imaging	\$	1,481,686.00
Emerging Priorities and Consumer Driven Research	2020 Silirosis Research	Monash University	University	VIC	The NLRP3 inflammasome as a potential biomarker and therapeutic target for silicosis	Inhalation of silica particles by artificial stone workers can lead to the development of silicosis disease and there are currently no available treatments. This project will identify new indications of disease risk, as well as anti-inflammatory drugs that can improve silicosis disease.	Associate Professor Michelle Tate	Associate Professor Michelle Tate, Associate Professor Ashley Mansel	Targeted competitive	1/06/2021	31/07/2024	Cardiorespiratory Medicine And Haematology	Respiratory Diseases	\$	645,763.70
Emerging Priorities and Consumer Driven Research	2020 Silirosis Research	University of Tasmania	University	TAS	The role of particle size in the pathogenesis of engineered stone-associated accelerated silicosis	The emergence of engineered stone associated silicosis in Australia is an occupational health disaster. We do not understand why this form of silicosis develops, is so severe or why it develops after only a few years of exposure to engineered stone dusts. This project aims to identify the types of engineered stones that are most hazardous to lung health and why the dusts generated cause such severe disease.	Professor Graeme Zosky	Professor Graeme Zosky, Doctor Sharyn Gaskin, Doctor Yong Song, Professor Dino Pisanelli, Doctor Jack Rivers-Auty	Targeted competitive	1/06/2021	31/05/2024	Cardiorespiratory Medicine And Haematology	Respiratory Diseases	\$	665,842.70
Emerging Priorities and Consumer Driven Research	2020 ZERO Childhood Cancer	University of New South Wales	University	NSW	Zero Childhood Cancer National Precision Medicine Program	We will expand the ZERO Childhood Cancer Program to all Australian children, adolescents and young adults with medium, high and very-high risk cancers, and evaluate the effectiveness of this comprehensive national precision medicine platform to improve health outcomes through genomic biomarker-driven matching of patients to optimal treatments and novel therapeutic clinical trials. Leveraging cutting edge computational and functional genomics, the project will accelerate biological and clinical discovery, identifying novel drug targets, and will enable industry engagement. Finally, it will assess the prevalence of hereditary cancer for Australian children and their families in at risk types, informing effective identification of at risk individuals.	Not applicable	Not available	One-off/ad hoc	22/06/2020	30/06/2025	Not available	Not available	\$	54,800,000.00
Emerging Priorities and Consumer Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	Monash University	University	VIC	A national functional diagnostic program for therapy development in congenital muscle disease	Skeletal muscle diseases such as congenital dystrophies/empropathies have one of the highest individual burdens of disease in Australia, with the Disability Adjusted Life Years lost being estimated to be higher than that of cancer and multiple sclerosis. The long term aim of this proposal is to develop an individual tailored precision medicine for child born with congenital muscle disease delivered through a better understanding of the molecular basis of disease and a national clinical consortium.	Peter Currie	Peter Currie, Robin Forbes, Peter Houweling, Paul Gregoire, Michelle Farrar, Michael Fahy, Megan McGrath, Gordon Lynch, Eppie Yiu, Enzo Porrello, Christina Mitchell, Catriona McLean, Avelina Raparella, Anita Cairns	Targeted competitive	1/04/2022	31/03/2027	Biochemistry And Cell Biology	Biochemistry And Cell Biology, Not Elsewhere Classified, Biochemistry And Cell Biology, Cellular Interactions (Incl. Adhesion, Matrix, Cell Wall)	\$	2,498,200.00
Emerging Priorities and Consumer Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	University of New South Wales	University	NSW	Advancing congenital and childhood-onset muscle disease diagnosis and treatment - a cross-disciplinary Australian collaboration	Congenital and childhood-onset muscle disorders cause significant physical disability and early death. Limited genetic diagnosis rates and lack of effective drug treatments adversely impact patient care. We aim to (1) Increase diagnosis rates by identifying previously unrecognised disease-causing variants in new and known genes (2) Confirm the abnormal impacts of these variants within cells, tissues and animal models (3) Establish a drug development consortium to develop effective treatments.	Emily Oates	Emily Oates, Stephen Loring, Robert Bryson-Richardson, Paul Cummings, Michaela Yuen, Marc Wilkins, Katharine Michie, Kate Quinlan	Targeted competitive	1/04/2022	31/03/2026	Clinical Sciences	Clinical Sciences, Medical Genetics (Excl. Cancer Genetics), Genetics, Neurogenetics	\$	2,499,988.00
Emerging Priorities and Consumer Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	Curtin University	University	WA	myAirHealth (myPATH): a digitally-enabled adaptive learning system to support quality care of young Australians living with chronic musculoskeletal (MSK) pain	myPATH is a novel digitally-enabled service model co-designed to support person-centred high value care of young Australians living with chronic musculoskeletal (MSK) pain. myPATH dynamic, interactive system will rapidly learn from young people what care they need, when they need it and what works best for them, helping young people take their health into their hands. myPATH will provide personalised right care at the right time and prompt healthy habits to improve young people's daily lives.	Helen Slater	Helen Slater, Susan Lord, Susan Murguly, Peter O'Sullivan, Niranjan Bidargaddi, Nadia-Rose Klem, Megan Burley, Marie Devereil, Kathy Lagar, Jennifer Simson, Jason Chua, Anne Smith, Andrew Briggs	Targeted competitive	1/04/2022	30/09/2027	Public Health And Health Services	Public Health And Health Services, Primary Health Care, Public Health And Health Services, Health Information Systems (Incl. Surveillance)	\$	1,474,044.60
Emerging Priorities and Consumer Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	Monash University	University	VIC	Children with Lower Limb Pain (CLLP): Working with families, community and health care provider's to improve outcomes	Chronic lower limb pain impacts up to 40% of the children and young people who have chronic musculoskeletal pain. Inconsistency in care often results in families feeling frustrated and alone, children and adolescents playing less with peers, and dropping out of school early. Our research will support families to receive consistent, evidence informed care and access management strategies no matter where they live in Australia, and no matter which type of health professional they see.	Cylie Williams	Cylie Williams, Verity Pacey, Vance Locke, Terrence Haines, Sue Brennan, Stephen Maloney, Nicole Williams, Mitchell Sarkies, Louise Tofts, Jane Munro, Enne Ihan, Elizabeth Sturges, Craig Munns	Targeted competitive	1/04/2022	31/03/2026	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine, Paediatrics, Clinical Sciences, Physiotherapy, Clinical Sciences, Podiatry	\$	1,809,204.97
Emerging Priorities and Consumer Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	University of Sydney	University	NSW	A3BC for Kids	A3BC for Kids aims to improve health outcomes for children and adolescents living with juvenile idiopathic arthritis (JIA). We will collect a broad range of self-reported, biological, environmental and health information from children with JIA across Australia, and, by using powerful research techniques we aim to provide the best treatment pathways for maximising symptom relief, disease control and quality of life, while minimising side effects, risks of ongoing medication exposure and costs.	Lyn March	Lyn March, Samuel Whittle, Rupendra Shrestha, Richard Saffery, Rangany Thomas, Rachelle Buchfelder, Melvina Nedland, Marissa Lassere, Manasi Mittinty, Kevin Murray, Jane Munns, Helen Keen, Davinder Singh-Grewal, Catherine Hill, Boris Novakovic	Targeted competitive	1/04/2022	31/03/2027	Clinical Sciences	Clinical Sciences, Rheumatology And Arthritis	\$	2,496,875.50
Emerging Priorities and Consumer Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	University of Melbourne	University	VIC	Force-reducing minimalist footwear for adolescents with chronic knee pain: a randomised clinical trial	Patellofemoral (front of knee) pain is the most common cause of chronic musculoskeletal pain in children and adolescents. Current treatments do not work and are not used by this group. Higher knee forces worsens symptoms, so force-reducing 'minimalist' shoes (lightweight and thin flexible soles) may be an effective treatment. We will be the first to assess if minimalist shoes improve symptoms, compared to 'motion control' shoes (arch support and cushioned soles), in adolescents with patellofemoral pain.	Kade Paterson	Kade Paterson, Rana Himman, Kim Bennell, Karen Lamb, Jo-Anne Manski-Hankveris, Adam Bryant	Targeted competitive	1/04/2022	31/03/2027	Clinical Sciences	Clinical Sciences, Physiotherapy, Clinical Sciences, Podiatry, Public Health And Health Services, Primary Health Care	\$	994,740.80
Emerging Priorities and Consumer Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	The University of Queensland	University	QLD	ACTIVE KNEECAPS! Targeted effective treatments for adolescent KNEECAP pain	Kneecap pain in adolescents is common, debilitating, and persistent, and can have serious long-term consequences, but there is uncertainty about which treatments are best due to a lack of evidence. The ACTIVE KNEECAPS! clinical trial will investigate whether shoe inserts or targeted physiotherapy can more effectively reduce kneecap pain in adolescents, compared to advice and education, and determine which treatment is more cost-effective over 1 year.	Natalie Collins	Natalie Collins, Tracy Comans, Nadine Foster, Michael Rathleiff, Mark Chaffield, Marieme van Middelkoop, Ray Crocker, Kathryn Mills, Wytton Menz, Guglielmo Viozesino, Gregoire Iven Mielke, Dawn Aitken, Danilo De Oliveira Silva, Christian Jantz	Targeted competitive	1/04/2022	31/03/2028	Clinical Sciences	Clinical Sciences, Physiotherapy, Clinical Sciences, Podiatry, Public Health And Health Services, Primary Health Care	\$	2,043,046.84
Emerging Priorities and Consumer Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	University of Sydney	University	NSW	JIA KidLink: Joint Venture to improve surveillance, clinical pathways and health outcomes of children with juvenile idiopathic arthritis	Juvenile idiopathic arthritis (JIA) can cause severe joint damage, chronic pain and permanent physical disability. Early diagnosis and treatment of JIA is vital to improve chances of remission. The JIA KidLink project will establish a national data linkage surveillance system of health service data, conduct clinical audits and consumer engagement, and identify costs of JIA to provide national ongoing data to improve early diagnosis, clinical pathways and health and well-being of children with JIA.	Natasha Nassar	Natasha Nassar, Sarah Norris, Samantha Lain, Ruth Colaguri, Rebecca James, Mark Friswell, Kirsten Howard, Jeffrey Chaitow, Helga Zogza, Francisco Schweuser, Anne Senner, Ann Louise Sharpe, Allison Tong	Targeted competitive	1/04/2022	31/03/2027	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine, Paediatrics	\$	1,597,811.40
Emerging Priorities and Consumer Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	University of Sydney	University	NSW	Pain Smart: Integrating education and clinical care for adolescents with pain	Like many chronic health conditions, chronic musculoskeletal pain often starts in adolescence but unlike obesity, substance use and mental health there are no broad-scale education initiatives aimed at preventing long term impacts of pain. Further, adolescents who experience disabling pain often do not receive effective care in the health system. Our project is testing a health education intervention delivered to adolescents alongside a managed care approach for those who experience pain.	Steven Kamper	Steven Kamper, Nicole Mathan, Michael Swain, Luke Woolfenden, Lisa Westbrook, Kris Rogers, Kelly Thompson, Joshua Pates, James McAulley, Christopher Williams, Blake Angeli, Alexandra Marinkovic	Targeted competitive	1/04/2022	31/12/2027	Clinical Sciences	Clinical Sciences, Rehabilitation And Therapy (Excl. Physiotherapy), Public Health And Health Services, Health Promotion	\$	1,242,434.80
Emerging Priorities and Consumer Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	The University of Queensland	University	QLD	Australian Cerebral Palsy Musculoskeletal Health Network	Cerebral palsy is the most common physical disability in Australian children. The early brain injury results in progressive movement problems (only 55% will walk, 30% will not sit), leading to problems with hip, spine deformity, major fractures, resulting in pain, loss of function and reduced participation. Our Consumer Network will guide us to form the Australian CP Musculoskeletal Health Network that will reduce the impact of hip, spine and bone fragility complications in children with CP.	Craig Munns	Craig Munns, Tracy Comans, Stewart Trost, Simon Paget, Roslyn Boyd, Robert Ware, Peter Pivovos, Natasha Nassar, Nadia Badawi, Leanne Sakewski, Kylie Tucker, Katherine Mary Langdon, Kate Willoughby, Judith Little, Joshua Burns	Targeted competitive	1/04/2022	31/12/2027	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine, Paediatrics, Clinical Sciences, Orthopaedics	\$	2,498,384.20

Emerging Priorities and Consumer Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	Murdoch Children's Research Institute	Medical Research Institute	VIC	Bridging Evidence Gaps - Developmental Dysplasia of the Hip (DDH)	The primary aim of this project is to establish a whole of state hip dysplasia registry (Nichtig) in Victoria, using prospectively collected data state wide and additional data from multiple clinical sites. The registry will also link in with an established international DDH registry, as well as a whole of state birth cohort (Geni), in order to identify and understand prognostic factors, best screening methods, and management and treatment for DDH.	Leo Donnan	Leo Donnan, Richard Angliss, Melissa Formosa, Melissa Wake, Mark O'Sullivan, Li Huang, Chris Harris, Cam Brockley, Brian Loh	Targeted competitive	1/04/2022	31/08/2026	Clinical Sciences	Clinical Sciences, Orthopaedics, Clinical Sciences - Surgery	\$	2,499,714.14
Emerging Priorities and Consumer Driven Research	2021 Chronic Neurological Conditions	University of New South Wales	University	NSW	Using technological innovations to provide equitable access to early identification of child developmental needs and integrated health and social care using a blended service delivery framework	We aim to create a responsive, equitable, and sustainable health pathway (CRESH-P) for children with developmental needs and their families through technologically innovative tools. This project will pursue three objectives: 1) Identify children with developmental needs early and intervene through the co-production of accessible and equitable models of care; 2) Co-design with consumers; 3) Evaluate the impact and implementation outcomes of CRESH-P and integrate new knowledge to address gaps.	Professor Valamma Eapen	Professor Valamma Eapen, Professor Andrew Page, Associate Professor Jane Kohlhoff, Professor Raghu Lingam, Associate Professor Jenny Downs, Professor Dreine Silva, Professor Virginia Schmid, Associate Professor Kenry Lawson, Doctor Daniel Liu, Doctor Adam Walker, Associate Professor Ann Dalich, Associate Professor Susan Woolfenden, Doctor Amy Finlay Jones, Professor Ian Katz, Associate Professor Shanti Raman	Targeted competitive	1/04/2022	31/03/2027	Clinical Sciences	Clinical Sciences, Psychiatry (incl. Psychotherapy)	\$	1,964,142.00
Emerging Priorities and Consumer Driven Research	2021 Chronic Neurological Conditions	The Bionics Institute of Australia	Medical Research Institute	VIC	Earlier intervention for infants with auditory neuropathy for lifelong benefit	Auditory neuropathy affects 10% of infants born with a hearing loss and is associated with severe difficulty distinguishing speech sounds. Currently, these infants are faced with greatly impaired language development and lifelong poor quality of life because we have to wait until they are around 2 years of age (too late for language development) to assess the severity of their neuropathy. Here, we use a novel brain imaging method to fast track early, appropriate, intervention for these infants.	Professor Colette McKay	Professor Colette McKay, Doctor Darren Mao, Professor Gary Rance	Targeted competitive	1/04/2022	31/03/2026	Neurosciences	Neurosciences, Sensory Systems, Medical Biotechnology, Medical Biotechnology Not Elsewhere Classified, Cognitive Science, Linguistic Processes (incl. Speech Production And Comprehension)	\$	392,940.00
Emerging Priorities and Consumer Driven Research	2021 Chronic Neurological Conditions	Monash University	University	VIC	Early, novel and accessible intervention for children with developmental regression	Approximately 20% of children lose skills, called developmental regression, as the onset of developmental delay. These children stop talking or walking as their parents watch in disbelief. We are establishing a first-of-its-kind research clinic to reduce >12 month waiting times. Our novel, online intervention, that can be tailored to each child's needs, will improve timely access to early intervention. We expect children to learn skills and parents to have improved health and quality of life.	Professor Katrina Williams	Professor Katrina Williams, Associate Professor Matthew Hunter, Doctor Alexandra Line, Doctor Jue Xie, Professor Patrick Olivier, Associate Professor Marie Yap, Associate Professor Helen Bourke-Taylor, Doctor Amanda Bignell, Doctor Wan Hua Sim, Professor Michael Fahy, Doctor Kirsten Furlay	Targeted competitive	1/04/2022	31/03/2027	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine, Paediatric	\$	1,995,974.54
Emerging Priorities and Consumer Driven Research	2021 Chronic Neurological Conditions	Monash University	University	VIC	Targeted Surveillance of Developmental Delay and Impairments for Young Children Born Very Preterm	Being born very preterm (two months early) is a leading cause for developmental delay and impairments in the community, yet there is no system for monitoring the development of these children. In order to reduce the burden of developmental impairments in children born very preterm, we will design a follow-up program that is targeted to the individual needs of the child and family. Parents and health professionals with lived experience will have a significant role in designing the program.	Professor Peter Anderson	Professor Peter Anderson, Doctor Nandakishor Desai, Ms Melinda Cruz, Professor Marimuthu Palaniswami, Amber Bates, Professor Helena Teele, Professor Jeanie Cheng, Doctor Jaane Ericicott, Doctor Alice Burnett, Associate Professor Gethan Roberts, Professor Alicia Spittle, Doctor Xinyang Huai, Professor Rod Hunt, Doctor Rheanna Mainzer, Professor Les Doyle	Targeted competitive	1/04/2022	31/03/2027	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine, Paediatric	\$	1,829,994.60
Emerging Priorities and Consumer Driven Research	2021 Chronic Neurological Conditions	Griffith University	University	QLD	Enhancing Quality of Life through an early Intervention co-developed with the autistic community (E-QoL-ITY)	People from the autistic community want research that finds ways to improve the happiness and health of autistic children. Sadly, none of the early interventions for young autistic children focus upon this. This project will bring together the autistic community, researchers and service providers. We will co-develop a survey and test the first ever early intervention to focus on getting young autistic children off to a happy, health start by improving their quality of life and wellbeing.	Associate Professor Dawn Adams	Associate Professor Dawn Adams, Associate Professor Martin Downes, Doctor Jessica Paynter, Associate Professor Marleen Westerveld, Doctor Jaqueline den Houten, Professor Simon, Professor Elizabeth Pellicano, Associate Professor David Trembath	Targeted competitive	1/04/2022	31/07/2025	Psychology	Psychology, Health, Clinical And Counselling Psychology, Psychology, Developmental Psychology And Ageing, Public Health And Health Services, Care For Disabled	\$	579,747.48
Emerging Priorities and Consumer Driven Research	2021 Chronic Neurological Conditions	Curtin University	University	WA	Developmental Delay: Enabling early and accurate detection of speech impairment through a web-based assessment application	The majority of children with Developmental Delay experience speech impairment. This affects how well they do at school and can make it hard to make friends. Accurate diagnosis is vital to receiving the right treatment. Using machine learning technology, this project will develop a mobile and automated assessment tool that measures and scores facial speech movements. This tool will help professionals make an accurate diagnosis of a speech impairment, leading to improved healthcare efficiencies.	Doctor Roslyn Ward	Doctor Roslyn Ward, Professor Katherine Husted, Doctor Yurko Khiladi, Doctor Neill Hennessy, Doctor Arvind Kumar Nannan, Doctor Petra Helmholz, Professor Derek Licht, Professor Gareth Baynam	Targeted competitive	1/04/2022	31/03/2025	Clinical Sciences	Clinical Sciences, Rehabilitation And Therapy (Excl. Physiotherapy), Cognitive Science, Linguistic Processes (incl. Speech Production And Comprehension), Public Health And Health Services, Community Child Health	\$	312,583.90
Emerging Priorities and Consumer Driven Research	2021 Chronic Neurological Conditions	The University of Queensland	University	QLD	Early Sleep Interventions to Improve Outcomes in Children with Neurodisability	This research involves children with neurodisability e.g., children with genetic syndromes. Sleep problems are very common in this group of children and can be severe and persistent, but few studies have been done specifically in this population. Poor sleep in children with neurodisability can make learning and behaviour even harder and also affects parent health and well-being. In this research we will explore new ways to diagnose and manage sleep problems in children with neurodisability.	Associate Professor Jasneek Chawla	Associate Professor Jasneek Chawla, Doctor Moya Vandelaar, Doctor Maree Milross, Doctor Natalie Pride, Professor Karen Waters, Professor Deborah Richards	Targeted competitive	1/04/2022	30/09/2025	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine, Paediatric	\$	1,614,882.40
Emerging Priorities and Consumer Driven Research	2021 Chronic Neurological Conditions	University of Sydney	University	NSW	We hear your voice! A consumer-codesigned program to customize, evaluate and implement speech recognition technology, for people with chronic degenerative neurologic diseases	Consumers have consistently nominated impaired speech as one of the most troublesome symptoms in chronic degenerative neurologic diseases (CDND), yet treatment is limited. Speech Recognition Technology (SRT) has had anecdotal success among people with Cerebral Palsy. This program aims to customize, evaluate and implement SRT, for people with CDND. SRT not only has the potential to improve verbal communication, but also opens the gateway to other voice-controlled assistive technologies.	Professor Clement Loy	Professor Clement Loy, Professor Matthew Kiernan, Associate Professor Craig Jin, Professor Armando Teixeira-Pinto, Professor Alcazar McEwan, Professor Allison Tong, Doctor Beena Ahmed, Doctor Kishore Kumar, Professor Kirrie Ballard, Professor Simon Lewis, Doctor Martin Howell, Mr Lewis Kaplan, Doctor Florence Chang	Targeted competitive	1/04/2022	31/03/2027	Neurosciences	Neurosciences, Neurology And Neuromuscular Diseases, Biomedical Engineering, Biomedical Engineering Not Elsewhere Classified	\$	1,990,688.40
Emerging Priorities and Consumer Driven Research	2021 Improving the Health and Wellbeing of Aboriginal and Torres Strait Islander Mothers and Babies	Charles Darwin University	University	NT	Birthing on Country: RISE SAFELY in rural, remote and very remote Australia	This First Nations led, co-designed and staffed MBFF study aims to establish exemplar birthing on Country maternal child health services in rural, remote and very remote Australia in 5 years. Our CIs have worked side-by-side with First Nations communities and stakeholders, building on 25 years of research, to develop the RISE SAFELY implementation framework. We will translate this into a community health safety maternity care, that use unprecedented success in an urban site, into three unique settings. We will increase protective factors for birthing women and babies across the first 1000 days, improve outcomes, focus on preventing preterm birth, and make a profound impact on Closing the Gap Target 2: Children are born healthy and strong.	Professor Yvette Roe	Professor Yvette Roe, Professor Sue Kildea, Associate Professor Lawurpa Mayplama, Professor Roanne West, Doctor Sarah Ireland, Associate Professor Ivana Gossop, Professor Sandra Campbell, Doctor Leila McCarthy, Professor Sue Kruske, Associate Professor Suzanne Moore	Open competitive	15/06/2022	15/05/2027	Not available	Not available	\$	4,998,540.00
Emerging Priorities and Consumer Driven Research	2021 Improving the Health and Wellbeing of Aboriginal and Torres Strait Islander Mothers and Babies	Institute for Urban Indigenous Health Ltd	Corporation	QLD	Birthing in Our Community: gold standard indigenous maternal infant health	Birthing in Our Community (BIOC) is an Indigenous-led Maternal Infant Health program designed and implemented in Brisbane. BIOC's outcomes, published in the Lancet Global Health (2021), show a 50% reduction in pre-term births, improvement in healthy weight babies, increased antenatal visits and an increase in exclusively breastfeeding at discharge. We will extend the reach of BIOC to three settings and follow cohorts of families (n=1800) to assess clinical outcomes and program acceptability. Further, we will evaluate scalability, sustainability, feasibility and cost effectiveness of this 'gold standard' program. Our goal is to build the evidence base to support adaptation and implementation of BIOC programs in urban Indigenous communities.	Mr Adrian Carson	Mr Adrian Carson, Professor James Ward, Ms Machelle Kosiak, Doctor Carmel Nelson, Associate Professor Federica Barzi, Associate Professor Steve Bell, Ms Kristie Watego, Ms Birri O'Dea, Professor Luke Connolly, Mr Alfred Davis, Doctor Jonathan Leitch, Ms Liz Wilkes	Open competitive	30/06/2022	29/06/2027	Not available	Not available	\$	4,999,156.00
Emerging Priorities and Consumer Driven Research	2021 Improving the Health and Wellbeing of Aboriginal and Torres Strait Islander Mothers and Babies	University of Melbourne	University	VIC	Replanting the Birthing Trees to Support First Nations Parents and Babies	This First Nations-led project aims to transform intergenerational cycles of trauma to support parents in achieving their hopes and dreams for a happy, safe and healthy family. We will do this by building infrastructure for culturally-safe, trauma-integrated, holistic, transdisciplinary perinatal care, critical in the first 2000 days. Based on rigorous co-design, this innovative program includes: a resource repository for parents, clinicians and decision-makers; support framework; integrated culturally-validated assessment tool; foster development resources; culturally and emotionally safe continuity-of-care implementation toolkit; and a therapeutic model to support families with complex social and emotional needs to stay together.	Professor Catherine Chamberlain	Professor Catherine Chamberlain, Professor Rhonda Marriott, Professor Marcia Langton, Associate Professor Paul Gray, Doctor Caroline Atkinson, Ms Jayanta Kishore, Doctor Koshy Canuto, Professor Helen Herman, Professor Sally Kendall, Professor Helen McLachlan, Professor Leonie Segal, Professor Susan Walker, Professor Helen Skouteris, Professor Della Fortner, Professor Jane Fisher, Emeritus Professor Judy Atkinson, Associate Professor Tracy Rebel, Ms Jayne Katz, Ms Valerie Ah Chee, Associate Professor Rex Walker, Doctor Jane Marie Eades, Doctor Debra Singh, Doctor Janine Mohamed, Associate Professor Campbell Paul, Ms Shawandrews, Ms Debra Bowman, Doctor Elise Davis, Doctor Kimberley Jones, Doctor Renee Folet, Doctor Ilias Kamitsis, Doctor Tess Bright, Doctor Kristen Smith, Doctor Vanessa Russ, Ms Pamela McAlman, Miss Gina Bunde, Mrs Alison Elliott, Professor Naomi Priest, Doctor Julie Andrews, Ms Slaye Stewart, Ms Abigail Dent, Ms Leah Johnston, Miss Tyarne-Paige Davis-Martin, Doctor Dave Carmody, Ms Adrienne Lipscomb, Mr Oliver Tye, Ms Kate Reynolds, Mrs Philippa Reppington, Ms Janinne Glidson	Open competitive	30/06/2022	29/06/2026	Not available	Not available	\$	4,999,905.00
Emerging Priorities and Consumer Driven Research	2021 Improving the Health and Wellbeing of Aboriginal and Torres Strait Islander Mothers and Babies	University of Western Australia (Kimberley Aboriginal Medical Services Limited)	University	WA	Optimisation of screening and management of hyperglycaemia in pregnancy	High blood glucose in pregnancy increases babies' risk of being born premature, by caesarean, larger/smaller than optimum, with low blood glucose levels, and difficulty breathing. This project will implement, evaluate and refine alternative screening for detecting high blood glucose in pregnancy at regional, state and national levels. We will use three-way learning between Aboriginal community members, health providers and researchers to co-design and trial self-management strategies for high blood glucose in pregnancy. This project will empower Aboriginal women and their families to make positive lifestyle choices aimed at improving birth outcomes and health for subsequent pregnancies and prevent or delay progression to chronic disease.	Mr Wayne Beddall	Mr Wayne Beddall, Ms Glenys Gillespie, Ms Kylie Hopkins, Ms Kathryn Johnstone, Mr John Joseph, Ms Conchita Boyler, Mr Ian Pratt, Professor David Atkinson, Ms Emma Carlin, Doctor Andrew Kiske, Doctor Emma Griffiths	Open competitive	30/06/2022	29/06/2027	Not available	Not available	\$	3,236,071.00

Emerging Priorities and Consumer Driven Research	2021 Improving the Health and Wellbeing of Aboriginal and Torres Strait Islander Mothers and Babies (English)	Children's Group Limited	Corporation	NT	Arehe ante areyele antamte areheleye ampe akewe ante atreyeyehelhe (Aremte). Women guiding women who are going to have babies	Ms Veronica Turner	Ms Veronica Turner, Professor Sheree Cairney, Ms Jen Lorains, Ms Jane Vadveelo, MK Turner, Mr William Tilmouth, Ms Cecily Djandjoneer, Doctor Sally Brinkman, Ms Felicity Hayes, Ms Purina Anderson, Ms Genise Williams, Ms Catherine Holmes, Ms Jackie Treves, Ms Kathy Thomson, Ms Shirley Djandjoneer, Ms Roanne Nabothlboro, Ms Jim Riddell, Ms Sorrell Abby	Open competitive	1/04/2022	29/06/2023	Not available	Not available	\$	200,000.00
Emerging Priorities and Consumer Driven Research	2021 Traumatic Brain Injury	Monash University	University	VIC	INFORMED: INegative approaches for Optimizing Recognition, Management and Education of concussion at the community sports level	Professor Biswadex Mitra	Professor Biswadex Mitra, Professor Melinda Fitzgerald, Doctor Sarah Hellewell, Doctor Michael Makdissi, Associate Professor Catherine Willmott, Associate Professor Riccardo Natch, Professor Karen Carenberghs, Doctor Zhi Chen, Associate Professor Sandy Shultz, Professor Meng Law, Professor Terence O'Brien, Doctor Stuart McDonald, Doctor Adam McKay, Professor Michael O'Sullivan, Professor Jenne Ponsford	Targeted competitive	1/06/2022	31/05/2025	Neurosciences	Neurosciences, Central Nervous System, Clinical Sciences, Emergency Medicine	\$	996,288.20
Emerging Priorities and Consumer Driven Research	2022 Effective Treatments and Therapies	University of New South Wales	University	NSW	Improving health outcomes by identifying biomarkers to delineate common mechanistic pathways and to monitor therapeutic effect of clinical trials in childhood dementia	Associate Professor Michelle Farrar	Associate Professor Michelle Farrar, Doctor Suhil Bandodkar, Miss Arlene D'Silva, Doctor Michel Tchan, Doctor Jinji Jingya Yan, Doctor Kaustav Bhattacharya, Doctor Shruja Patel, Professor Peter Shaw, Doctor Sheela Mohammad, Professor Russell Dale, Doctor Alexandra Johnson	Targeted competitive	1/01/2023	31/12/2026	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Neurosciences, Central Nervous System, Biomedical And Clinical Sciences, Medical Biochemistry And Metabolomics, Metabolic Medicine And Clinical Sciences, Medical Physiology, Cell Physiology	\$	595,955.60
Emerging Priorities and Consumer Driven Research	2022 Effective Treatments and Therapies	University of Sydney	University	NSW	RTTomics: Towards developing new treatments and therapies for Rett syndrome individuals using cortical brain organoids	Associate Professor Wendy Gold	Associate Professor Wendy Gold, Associate Professor Achyut Tolun, Doctor Anai Gonzalez Cordero, Doctor Mark Graham, Doctor Brian Gloss, Associate Professor Carolyn Ellaway, Doctor Chi Nam Ignatius Pang	Targeted competitive	1/03/2023	31/12/2026	Biological Sciences	Biological Sciences, Genetics, Gene Expression (incl. Microarray And Other Genome-Wide Approaches)	\$	595,972.93
Emerging Priorities and Consumer Driven Research	2022 Effective Treatments and Therapies	University of Tasmania	University	TAS	A new substrate reduction strategy to treat childhood demenias: Glucosylceramide synthase-targeting antisense oligonucleotides	Associate Professor Anthom Cook	Associate Professor Anthony Cook, Professor Stephen Wilton, Tyson Ware, Doctor May Aung-Hut, Doctor Craig McIntosh, Doctor Shan Perry, Professor Anna King, Professor Gareth Baynam, Doctor Matthew Walks, Professor Alex Hewitt	Targeted competitive	1/01/2023	31/12/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Medical Biotechnology, Gene And Molecular Therapy	\$	599,977.30
Emerging Priorities and Consumer Driven Research	2022 Effective Treatments and Therapies	The University of Adelaide	University	SA	Developing Nanoparticle Mediated Gene Transfer for Childhood Dementia	Doctor Nicholas Smith	Doctor Nicholas Smith, Professor Sanjay Garg, Professor Kim Hemley, Doctor Adelaide Lau	Targeted competitive	1/01/2023	31/03/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Medical Biochemistry And Metabolomics, Metabolic Medicine, Biomedical And Clinical Sciences, Medical Biotechnology, Gene And Molecular Therapy, Biomedical And Clinical Sciences, Medical Biotechnology, Nanomedicine	\$	302,148.00
Emerging Priorities and Consumer Driven Research	2022 Effective Treatments and Therapies	University of Melbourne	University	VIC	Developing an mRNA-based gene therapy strategy for Niemann-Pick Disease Type C1: a blueprint to treat childhood dementia	Doctor Ya Hui Hung	Doctor Ya Hui Hung, Professor Mark Waterfall, Doctor Carl Roulston, Doctor Rebecca Nisbet, Professor Ashley Bush, Doctor Laura Vella, Professor Colin Poulton	Targeted competitive	1/01/2023	31/12/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Medical Biotechnology, Gene And Molecular Therapy	\$	599,650.36
Emerging Priorities and Consumer Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	University of Sydney	University	NSW	Giving patients an EPIC-START: An evidence based, data driven model of care to improve patient care and efficiency in emergency departments	Professor Kate Curtis	Professor Kate Curtis, Professor Ramon Sheban, Doctor Amish Shetty, Doctor Helen Alkhouli, Associate Professor Christina Aggar, Wayne Vardell, Doctor Thomas Lung, Professor Margaret Fry, Doctor James Hughes, Associate Professor Ling Li, Associate Professor Michael Hogg, Doctor Margaret Murphy, Doctor Sarah Kourouche, Professor Julie Considine, Professor Timothy Shaw	Targeted competitive	1/04/2022	31/03/2027	Health Sciences	Health Sciences, Nursing, Acute Care	\$	2,847,592.24
Emerging Priorities and Consumer Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	Macquarie University	University	NSW	Working together: innovation to improve Emergency Department (ED) performance, and patient outcomes and experience for live complex consumer cohorts	Associate Professor Robyn Clay-Williams	Associate Professor Robyn Clay-Williams, Associate Professor Rebecca Mitchell, Associate Professor Reema Harrison, Associate Professor Peter Hibbert, Doctor Kate Churnace, Doctor Louise Ellis, Doctor Leanne Holt, Matthew Vukosovic, Professor Henry Cutler, Doctor Ramesh Walipoli, Associate Professor Yvonne Zuremka, Professor Jeffrey Braithwaite, Doctor Elizabeth Austin, Reza Ali, Doctor Donna Gillies	Targeted competitive	1/04/2022	31/03/2027	Health Sciences	Health Sciences, Health Services And Systems, Health Services And Systems Not Elsewhere Classified	\$	2,836,550.50
Emerging Priorities and Consumer Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	University of Sydney	University	NSW	Reshaping the management of low back pain in emergency departments	Professor Chris Maher	Professor Chris Maher, Doctor Eileen Rogan, Professor Leigh Kinman, Professor Kirsten Howard, Associate Professor Christopher Williams, Professor Lisa Harvey, Professor Vasi Nagathan, Professor Rachelle Buchinder, Doctor Gustavo Machado, Professor Kristen McCaffery, Professor Ian Harris, Doctor Nareg Ghinea, Professor Laurent Billet, Professor John Wiggers, Doctor James Edwards	Targeted competitive	1/04/2022	30/04/2026	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Clinical Sciences, Emergency Medicine	\$	2,818,123.56
Emerging Priorities and Consumer Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	Menzies School of Health Research	Medical Research Institute	NT	StreamlineED - improving the effectiveness and efficiency of Northern Territory (NT) Emergency Departments	Didier Palmer	Didier Palmer, Doctor Richard Johnson, Christine Watson, Doctor Sean Taylor, Doctor Sandra Brownlee, Doctor Gillian Gorton, Professor John Wakeman, Doctor Nicholas Fancourt, Doctor Stephen Gaurley, Mrs Rachel Buckley, Doctor Sandawana Majoni, Professor Alan Cass, Doctor Maria Heller, Doctor Deborah Russell, Anna Lithgow	Targeted competitive	1/04/2022	31/03/2027	Health Sciences	Health Sciences, Health Services And Systems, Health Services And Systems Not Elsewhere Classified	\$	2,917,464.19
Emerging Priorities and Consumer Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	Griffith University	University	QLD	Improved Respiratory Support in Remote Settings for Children: A Paediatric Acute Respiratory Intervention Study (PARIS), PARIS on Country	Doctor Donna Franklin	Doctor Donna Franklin, Associate Professor Catrina Felton-Buch, Doctor Andreas Schibler, Richard Hay, Associate Professor Martin Downes, Doctor Erika Borkeles, Associate Professor Ben Lawton, Professor Shu-Kay (Angus) Ng, Associate Professor Shane George, Doctor Alice Cairns, Sally West, Ms Malama Gray	Targeted competitive	1/04/2022	30/09/2027	Health Sciences	Health Sciences, Health Services And Systems, Rural And Remote Health Services	\$	1,630,153.35
Emerging Priorities and Consumer Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	Flinders University	University	SA	"There must be a better way": partnering with consumers to implement a digitally enabled geriatric urgent care unit to improve hospital flow	Associate Professor Craig Whitehead	Associate Professor Craig Whitehead, Professor Zee Adey-Wakeling, Professor Julie Radcliffe, Doctor Elizabeth Lynch, Diana Voss, Mr Andrew Partington, Doctor Mia Rahja, Associate Professor Kate Laver, Mr Shane D'Angelo, Professor Gillian Harvey, Doctor Timothy Le	Targeted competitive	1/04/2022	31/03/2024	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Clinical Sciences, Geriatrics And Gerontology, Health Sciences, Allied Health And Rehabilitation Sciences, Rehabilitation Health Sciences, Health Services And Systems, Allied Health Care	\$	1,116,756.25
Emerging Priorities and Consumer Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	South Australian Health and Medical Research Institute Limited	Medical Research Institute	SA	Using a State-wide Learning Health System for the Rapid Deployment, Evaluation and Translation of New Models of Care in South Australia to Reduce Pressure on Emergency Departments and Acute Care	Professor Derek Chew	Professor Derek Chew, Professor Paul Worley, Professor Jane Andrews, Professor Robert Padbury, Professor Andrew Bersten, Ms Kristina Labrakis, Doctor John MacMillan, Professor Danny Lew, Doctor Gerry O'Callaghan, Associate Professor Daniel Haastead, Professor Maria Crotty, Doctor Santosh Venghar, Professor Steven Wesselingh, Professor Maria Inacio, Professor Jonathan Karnon	Targeted competitive	1/04/2022	31/03/2027	Health Sciences	Health Sciences, Health Services And Systems, Health Systems, Biomedical And Clinical Sciences, Clinical Sciences, Emergency Medicine	\$	2,919,835.56
Emerging Priorities and Consumer Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	The University of Adelaide	University	SA	Improving Acute Atrial Fibrillation Management for better patient outcomes	Professor Prashanthan Sanders	Professor Prashanthan Sanders, Doctor Adrian Elliott, Doctor Jean Jacques Noubap, Doctor Melissa Middendorp, Professor Debra Rowett, Professor Dennis Lau, Doctor Christopher Wong, Doctor Gijo Thomas, Doctor Thiruvankumaran Gnanasekaran, Doctor Celine Gallagher, Professor Jerome Hendrick, Associate Professor Anand Ganasean	Targeted competitive	1/04/2022	31/03/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Cardiovascular Medicine And Haematology, Cardiology (incl. Cardiovascular Diseases)	\$	1,075,421.05

Emerging Priorities and Consumer Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	University of Tasmania	University	TAS	Implementing clinical Pathways for Acute Care in Tasmania (IMPACT)	Clinical pathways (CPs) are multidisciplinary tools enabling large-scale consistent practice of evidence-based medicine, and have the potential to improve patient care and reduce pressure on Emergency Departments. The effectiveness of CPs in Australia is not well known. IMPACT will utilise a consumer-driven approach to investigate barriers for CP use, develop a scalable and sustainable implementation strategy for CPs, and identify CP priorities to drive further excellence in health care.	Doctor Viet Tran	Doctor Viet Tran, Doctor Maria Unwin, Professor James Sharman, Doctor Ashley Loughman, Doctor James Stankovich, Professor Simon Brown, Associate Professor Emma Tawesley, Professor Anthony Lawler, Professor Simon Craig, Professor Graeme Zosky, Doctor Sarah Prior, Doctor Amanda Neil, Professor Janette Radford, Professor Blawade Mitra, Mr Giles Barrington	Targeted competitive	1/04/2022	30/04/2027	Health Sciences	Health Sciences, Health Services And Systems, Health Systems	\$	2,919,107.99
Emerging Priorities and Consumer Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	University of Western Australia	University	WA	OPERATE: Older Persons' Early Recognition Access and Treatment in Emergencies	Inefficient healthcare delivery and hospital overcrowding increases healthcare associated harm, particularly in older patients, and worsens pressures in Emergency Departments. The OPERATE program aims to implement, coordinate and evaluate strategies that provide health care for older people with functional decline or acute illness. These strategies target improving care at home rather than in hospital, streamlined ED and hospital care when necessary, and ensuring safe discharge and ongoing care.	Professor Antonio Celezna	Professor Antonio Celezna, Doctor Rosemary Saunders, Professor Simon Conroy, Associate Professor Richard Norman, Professor Meredith Borland, Associate Professor Paul Bailey, Doctor Kristie Harper, Associate Professor Glenn Avenells, Professor Judith Finn, Associate Professor David Mountain, Associate Professor Stephen Macdonald, Professor Mura Sin, Associate Professor Vinician Cavallieri de Oliveira, Doctor Hanh Ngo, Professor Christopher Etherton-Beer	Targeted competitive	1/04/2022	30/04/2027	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Clinical Sciences, Emergency Medicine, Biomedical And Clinical Sciences, Clinical Sciences, Geriatrics And Gerontology, Health Sciences, Health Services And Systems, Aged Health Care	\$	2,918,995.31
Emerging Priorities and Consumer Driven Research	2022 Mitochondrial Donation Pilot Program	Monash University	University	VIC	Introducing Mitochondrial Donation into Australia: The mitoHOPE (Healthy Outcomes Pilot and Evaluation) Program	In early 2022, the Australian government passed Mave's Law. This will allow the use of mitochondrial donation, a reproductive technology, to enable women at risk for passing on mitochondrial DNA disease to reduce their risk of having an affected child. The mitoHOPE program will perform a clinical trial to demonstrate that mitochondrial donation can be safely offered to Australian women; will improve its efficiency and will provide data justifying its ongoing use in the Australian health system.	Professor John Carroll	Professor John Carroll, Doctor Deepak Adhikari, Doctor Meenakshi Choudhary, Professor John Christodoulou, Professor David Coman, Professor Martin Delatycki, Associate Professor Carolyn Ellaway, Professor Michael Fahy, Associate Professor Ilias Goranitis, Doctor Christopher Gyngett, Doctor Karin Hammarberg, Doctor Tristan Hardy, Professor Mary Herbert, Associate Professor Ryan Hodges, Associate Professor Lisa Hui, Doctor Louise Hyslop, Doctor Benjamin Kamien, Doctor Janet Long, Associate Professor Karine Ludlow, Professor David Mackey, Professor Andrew Mallett, Professor Jeffrey Mann, Professor Catherine Mills, Professor Rebecca Robker, Professor Luk Rombauts, Professor Michael Ryan, Doctor Suzanne Salfweli, Professor Christopher Semsarian, Professor Robert Sparrow, Doctor Michel Tchan, Professor David Thorburn, Doctor Meaghan Wall, Doctor Matthew Wallis, Doctor Narelle Warren, Doctor Wai Yan Yau, Associate Professor Deirdre Zander-Fox, Professor Sophia Zoungas	Targeted competitive	Not available	Not available	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Clinical Sciences, Medical Genetics (Ext. Cancer Genetics), Biomedical And Clinical Sciences, Reproductive Medicine, Reproductive Medicine Not Elsewhere Classified, Biomedical And Clinical Sciences, Neurosciences, Neurosciences Not Elsewhere Classified	\$	15,000,000.00
Emerging Priorities and Consumer Driven Research	2022 Pancreatic Cancer Research	University of Melbourne	University	VIC	Overcoming inequity of opportunity for optimal pain and symptom management for Australians affected by pancreatic cancer	Patients with cancer have better quality of life and health outcomes when a specialist nurse is involved in their care. In Australia, there is considerable variation in access to specialist cancer nurses, especially for regional and rural patients and those diagnosed with less common cancers. Our randomised clinical trial will test a centrally-based, and consumer-informed model of nurse-led telehealth care to improve patient outcomes (pain and other symptoms) for patients with pancreatic cancer.	Professor Meenir Krishnasamy	Professor Meenir Krishnasamy, Associate Professor Karla Gough, Doctor Lisa Guccione, Associate Professor Vanessa Bessley, Doctor Jacqueline Richmond, Emeritus Professor Geoffrey Mitchell, Professor Michael Michael, Associate Professor Richard De Abreu Lourenco, Associate Professor Lara Lupton, Michelle Stewart, Associate Professor Haryana Dhillon, Professor Craig Underhill, Rob Blum, Doctor Erin Lang	Targeted competitive	1/03/2023	28/02/2026	Health Sciences	Health Sciences, Nursing, Acute Care, Health Sciences, Health Services And Systems, Implementation Science And Evaluation, Biomedical And Clinical Sciences, Oncology And Carcinogenesis, Solid Tumours	\$	1,239,777.00
Emerging Priorities and Consumer Driven Research	2022 Pancreatic Cancer Research	The University of Adelaide	University	SA	Faecal Microbiota Transplantation to improve pain, symptom management and treatment efficacy in patients with pancreatic cancer	Pancreatic cancer and its treatments (i.e. chemotherapy, surgery) cause pain and a range of gastrointestinal symptoms. Recent findings have shown that an imbalance in microbes living in the digestive system can lead to cancer, poor digestion and other gut issues. The current study will transfer micro-organisms from a healthy donor to a patient with pancreatic cancer to help restore appropriate digestion and alleviate pain and gastrointestinal discomfort.	Professor Guy Maddern	Professor Guy Maddern, Doctor Samuel Costello, Associate Professor Robert Bryant, Mr Thomas High, Professor Timothy Price, Associate Professor Hossein Afzali, Doctor Li Jian Kuan, Doctor Virginia Gaget	Targeted competitive	1/03/2023	30/04/2026	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Oncology And Carcinogenesis, Oncology And Carcinogenesis Not Elsewhere Classified	\$	1,521,832.00
Emerging Priorities and Consumer Driven Research	2022 Pancreatic Cancer Research	Monash University	University	VIC	Supplemental jejunal feeding to Improve Quality of Life (SuperQoL)	Troublesome symptoms such as pain, weight loss and diarrhoea are highly prevalent in people diagnosed with pancreatic cancer. These symptoms contribute to malnutrition, chemotherapy dose reductions, and reduced quality of life (QoL) and survival. Intensive nutrition support with tube feeding and adequate symptom control may reduce these symptoms. This project aims to develop and implement a study to assess the effectiveness of this intervention in improving symptoms and QoL in pancreatic cancer.	Doctor Daniel Croagh	Doctor Daniel Croagh, Doctor Kate Furness, Associate Professor Charles Piggin, Associate Professor Andrew Metz, Professor Terrence Haines, Doctor Sharon Carey, Professor David Kissane, Doctor Catherine Huggins, Associate Professor Michael Francis, Doctor Joanne Lundy, Ms Lauren Hanna, Diederick De Boe	Targeted competitive	1/03/2023	28/02/2026	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Nutrition And Dietetics, Clinical Nutrition	\$	1,668,079.00
Emerging Priorities and Consumer Driven Research	2022 Pancreatic Cancer Research	University of South Australia	University	SA	First-in-Human feasibility and safety trial of a theranostic agent for image-guided treatment and radiosensitisation of advanced pancreatic cancer	The project will investigate the safety and feasibility of precision image-guided radiotherapy with a novel theranostic magnetic resonance imaging agent specific to the tumour microenvironment of pancreatic cancer. It will assess pain relief and local control in a small cohort of patients with advanced pancreatic cancer.	Professor Benjamin Thierry	Professor Benjamin Thierry, Associate Professor Thomas Cox, Professor G. Lonnner Moseley, Associate Professor Ross Barbato, Doctor Mikaela Belfi Ono, Doctor Sweet Ping Ng	Targeted competitive	1/03/2023	28/02/2026	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Oncology And Carcinogenesis, Radiation Therapy	\$	1,273,047.00
Frontier Health and Medical Research	2018 Frontier Health and Medical Research (Cohort 1, Stage One)	Australian Lung Health Initiative Pty Ltd	Corporation	VIC	4D Functional diagnosis: a new frontier in lung health for children	This project delivers a groundbreaking lung healthcare technology that is safe, rapid, easy to use and provides detailed functional analysis for patients of any age, filling the critical unmet need for accurate and sensitive lung health assessment tools for young children. The five-year project brings together world-leading Australian scientists, engineers, manufacturers and medical researchers to revolutionise lung screening and treatment, based on the disruptive Australian 4D technology and low-dose imaging science. Devices developed from the project will deliver a substantial global health and economic impact, firmly establishing Australia at the forefront of lung science, while developing a new, local hi-tech industry.	Professor Andreas Fournas	Not available	Open competitive	1/07/2019	30/11/2020	Not available	Not available	\$	1,124,822.00
Frontier Health and Medical Research	2018 Frontier Health and Medical Research (Cohort 1, Stage One)	Burnet Institute	Medical Research Institute	VIC	EVE-M (Enhancing the Vaginal Environment and Microbiome) Initiative	The EVE-M initiative will formalise and build on our existing multidisciplinary team where we will work together with specialist advisors to generate industry aligned product development and commercialisation plans for a series of innovative technologies aimed at improving women's sexual and reproductive health. Development of EVE-M multipurpose prevention technologies will be underpinned by user-design approaches and composed of innovative materials delivering agents harnessing the beneficial properties of genital microbiota with the capacity to deliver other drugs including contraceptives. Our ultimate goal is to reduce the health burden and cost of bacterial vaginosis and sexually transmitted infections in Australia and globally.	Professor Gilda Tachedjian	Not available	Open competitive	1/07/2019	30/06/2020	Not available	Not available	\$	963,458.00
Frontier Health and Medical Research	2018 Frontier Health and Medical Research (Cohort 1, Stage One)	Florrey Institute of Neuroscience and Mental Health	Medical Research Institute	VIC	Precision Medicine in Epilepsy	Epilepsy is the most common serious neurological disorder of children, and one of the major neurological conditions affecting the general population. Diagnosis is initially difficult: less than half those with a first ever seizure will ultimately be found to have epilepsy (i.e. repeated seizures). In patients who do, the cause can be difficult to establish. New advanced brain imaging methods can help. We will bring together Australian and international leaders in epilepsy and brain imaging in a consortium unrivalled in this field. We will establish a program to improve the patient experience at every stage of their journey through diagnosis and treatment, utilising brain imaging methods not yet established in routine clinical practice.	Professor Graeme Jackson	Not available	Open competitive	1/07/2019	30/11/2020	Not available	Not available	\$	1,197,812.00
Frontier Health and Medical Research	2018 Frontier Health and Medical Research (Cohort 1, Stage One)	Monash University	University	VIC	An Innovative Public Health Program Against Mosquito-Borne Diseases	The World Mosquito Program (WMP) is a non-profit initiative working to protect global communities from mosquito-borne diseases like Zika, dengue and chikungunya. Pioneered by Australian researchers, our method uses a natural bacterium called Wolbachia to reduce the ability of mosquitoes to transmit these viruses. Long term monitoring shows our method is self-sustaining. This project will build on our considerable expertise to develop and test solutions enabling our Wolbachia method to be implemented at a scale allowing global rollout. The activities focus around two themes: mass production of quality mosquitoes suited to different ecologies and optimisation of cost-effective mosquito release modalities applicable to diverse geographies.	Professor Scott O'Neill	Not available	Open competitive	1/07/2019	30/06/2020	Not available	Not available	\$	1,175,625.00
Frontier Health and Medical Research	2018 Frontier Health and Medical Research (Cohort 1, Stage One)	Monash University	University	VIC	Cortical Frontiers: Commercialising Brain Machine Interfaces	Monash Vision Group has designed, manufactured and tested a multi-site brain stimulator that is approved for a Phase 1 clinical trial in 2019 (MVG-FH-P1). Although intended to restore vision, our device can be repurposed to provide stimulation of many neural functions. We have also developed a compatible recording interface. Stage 1 will identify the two most promising commercial applications of this technology by workshoping with clinicians and end users, before analysing business cases. We will plan clinical trials with the optimum partners, and build a detailed plan for Stage 2, which will include clinical trials supporting regulatory approvals, building two companies, and developing a scalable Australian manufacturing capability.	Professor Arthur Lowery	Not available	Open competitive	1/07/2019	30/11/2020	Not available	Not available	\$	1,046,625.00

Frontier Health and Medical Research	2018 Frontier Health and Medical Research (Cohort 1, Stage One)	Saluda Medical Pty Ltd	Corporation	NSW	Cerebral palsy treatment by closed loop electrical stimulation	Cerebral palsy is an incurable disease characterised by spasticity. Current pharmacological and surgical treatments offer limited relief but little or no functional improvements. Electrical stimulation of the spinal cord may have therapeutic benefits but has not been adopted in clinical practice due to limitations of current implants. We have developed a closed loop feedback technology which measures neural activity controlling muscles and applies electrical stimulation to the spinal cord that is always in the therapeutic range; it is the first self-adjusting implant. Our multidisciplinary team will clinically validate long-term efficacy of spinal cord stimulation to enable functional improvements in cerebral palsy patients.	Professor John Parker	Not available	Open competitive	1/07/2019	30/06/2020	Not available	Not available	\$	747,596.00
Frontier Health and Medical Research	2018 Frontier Health and Medical Research (Cohort 1, Stage One)	The University of Queensland	University	QLD	Therapeutic Ultrasound for the Treatment of Brain Disorders	Brain disorders have a major toll on society, both socially and economically. The aim of this multidisciplinary program is to catalyse our ground-breaking research in therapeutic ultrasound to deliver a first in world technological platform for the treatment of brain disorders including dementia. With the team's early stage therapeutic ultrasound device entering a phase 1 trial this year, a detailed Research and Implementation plan will be developed for Stage Two, towards developing an integrated final device and essential auxiliary technology, thereby building capacity in the emerging therapeutic ultrasound sector and creating opportunities for Australian service providers across the entire translational and commercialisation value chain.	Professor Juergen Goetz	Not available	Open competitive	1/07/2019	30/11/2020	Not available	Not available	\$	1,076,891.00
Frontier Health and Medical Research	2018 Frontier Health and Medical Research (Cohort 1, Stage One)	University of Melbourne	University	VIC	Using disruptive technologies to transform prehospital care for stroke	We have assembled a multidisciplinary research team to develop transformative prehospital technologies to improve treatments in the first GOLDEN HOUR after stroke. This will address outcome disparities between rural and urban Australia. Our alliance comprises stroke experts, engineers, computer scientists, paramedics, healthcare providers and NGOs. We will build on preliminary data in Stage 1, and deliver a strategic plan for Stage 2. Our program will reduce mortality and improve outcomes for stroke, a leading cause of death and disability. We will develop and test innovative new technologies and drive the commercialisation of our research, which will have a transformative impact on stroke care in Australia and globally.	Professor Geoffrey Dorman	Not available	Open competitive	1/07/2019	30/06/2020	Not available	Not available	\$	1,203,125.00
Frontier Health and Medical Research	2018 Frontier Health and Medical Research (Cohort 1, Stage One)	University of Technology Sydney	University	NSW	Disruptive technologies to trace, track & tackle antibiotic resistance	Antimicrobial resistance (AMR) represents the greatest health challenge facing humanity, forecast to cause 50 million deaths annually by 2050 at a cost of US\$100 trillion. OUTBREAk will be a cost-efficient, AI-powered, Australia-wide system for tracing, tracking, and tackling AMR. In protecting Australians from AMR infections, it will reduce hospital admissions and healthcare costs. It will also protect Australia's reputation as an exporter of safe, high quality meat, dairy and fresh produce. Sensor technologies, data, knowledge, and artificial intelligence developed during OUTBREAk's creation will position Australian companies at the forefront of the global digital health market which is expected to reach 223.7 billion USD by 2023.	Professor Steven Djordjevic	Not available	Open competitive	1/07/2019	30/11/2020	Not available	Not available	\$	1,166,210.00
Frontier Health and Medical Research	2018 Frontier Health and Medical Research (Cohort 1, Stage One)	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	c-FIND: CRISPR Frontier Infection Diagnostics to Detect Infection	There is an urgent and unmet health need globally for rapid and accurate diagnostics to identify infectious diseases and antimicrobial resistance to mitigate the devastating economic and population consequences of epidemics and pandemics and patient morbidity and mortality. Breakthrough CRISPR technology has entered a new frontier: development of new, accurate, rapid, near point-of-care CRISPR diagnostics. This has the potential to dramatically change the way infectious diseases are diagnosed, providing clinically significant answers in real-time. Using local expertise in biomedical research and clinical trials, the c-FIND programme will deliver health benefits to Australian patients and economic benefits to the Australian health system.	Professor Marc Pellegrini	Not available	Open competitive	1/07/2019	30/06/2020	Not available	Not available	\$	1,071,500.00
Frontier Health and Medical Research	2020 Frontier Health and Medical Research (Cohort 1, Stage Two)	University of Melbourne	University	VIC	The Stroke Golden Hour: delivering urgent stroke care to all Australians	Poor access of Australian stroke patients, particularly in rural and remote communities, to acute stroke therapy because of lack of brain imaging and expertise. Our program aims to solve this problem by developing lightweight brain scanners, to rapidly deliver pre-hospital stroke care by air and road ambulances to all Australians, underpinned by education and national telehealth platform. By increasing access to acute stroke care, we will gain over 235,000 years of healthy life by 2050 and deliver \$15.6 billion in economic benefit including 1700 new jobs.	Professor Geoffrey Donnan and Professor Stephen Davis	Not available	Targeted Competitive	21/06/2021	20/06/2026	Not available	Not available	\$	40,167,052.00
Frontier Health and Medical Research	2020 Frontier Health and Medical Research (Cohort 1, Stage Two)	Australian Lung Health Initiative Pty Ltd	Corporation	VIC	4D Functional Diagnosis: A new frontier in lung health for children	This project delivers ground-breaking lung scanners that are safe, rapid, and easy to use, enabling detailed functional analysis for patients of any age. Our team of world-leading Australian medical researchers, engineers, manufacturers, and doctors will revolutionise diagnosis and treatment of lung disease by combining novel imaging science with 4Dmedical's disruptive XV technology. These negligible-dose scanners will fill the critical unmet need for sensitive lung health assessment for young children, and can be immediately applied to COVID, delivering a substantial global health and economic impact that firmly establishes Australia at the forefront of lung science, while kick-starting a local, fast-growing, high-value, high-tech industry.	Professor Andreas Fournas	Not available	Targeted Competitive	1/07/2019	30/11/2020	Not available	Not available	\$	28,867,540.00
Frontier Health and Medical Research	2020 Frontier Health and Medical Research (Cohort 1, Stage Two)	University of Melbourne	University	VIC	The Australian Epilepsy Project	All Australians should have access to optimal treatment for epilepsy - a devastating, misunderstood, often hidden condition. 2.3 million Australians will have a seizure in their lifetime. Epilepsy costs Australia \$12.38/yr. Today, few have access to Australia's world-leading expertise and solutions currently locked in research centres. The Australian Epilepsy Project will transform lives by implementing a scalable national platform of AI-based expertise and clinical decision support, ensuring optimal care is delivered in a standardised way for all. Participants benefit day 1. Their curated data then contributes to big data, allowing continuously improving precision medicine: a model for globally sustainable brain & mental health.	Professor Graeme Jackson	Not available	Targeted Competitive	1/06/2021	31/05/2026	Not available	Not available	\$	30,080,129.00
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	Synchron Australia Pty Ltd	Corporation	VIC	The Brain-Machine Interface Frontier: Pioneering Endovascular Bionics	In August 2019, we demonstrated the world's first successful implantation of an endovascular neural interface, pioneering a new field of medicine. Using blood vessels, we safely delivered our device to the brain in a paralysed patient. Within months, he was able to control a computer with his mind. We are now poised to complete transformation of our paradigm shifting research into a clinical product, and through development and implementation of simulation capabilities, our endovascular device will become a globally recognised and internationally competitive platform across a broad range of neurological conditions.	Associate Professor Nicholas Ope	Not available	Open competitive	15/06/2021	14/09/2022	Not available	Not available	\$	996,000.00
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	Monash University	University	VIC	The Artificial Heart Frontiers Program	Over 23 million people suffer from heart failure around the globe, yet only six thousand a year receive a donor heart. Many patients turn to artificial hearts: large, noisy devices that too frequently fail, or confine the patient to hospital. Other patients have no options at all. Now, the Artificial Heart Frontiers Program will bring a new generation of artificial hearts to market. Our innovative implants are small, patient-friendly and reliable - outlasting all existing alternatives. They are powerful enough for an adult, yet small enough for a child. They are quiet, portable, and respond to active lifestyles, allowing patients to return to their families and jobs. This technology will revolutionise the lives of patients with heart failure.	Professor David Kaye	Not available	Open competitive	15/06/2021	14/09/2022	Not available	Not available	\$	999,570.00
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	University of Sydney	University	NSW	Australian Corneal Bioengineering: Novel Therapies to Fight Blindness	The cornea is the outermost structure of the eye. Disease or injury of the cornea, often leads to poor vision and in many cases, blindness. Corneal transplantation represents the current gold standard for the treatment of moderate to severe corneal disease. During corneal transplantation, donor corneas are used to replace the scarred or diseased tissue. However, only 1 cornea is available for every 70 potential patients globally representing a major ongoing concern. Our research group has established laboratory methods to create viable, bioengineered corneal tissue to replace donor corneas. With this grant, we aim to create a next-generation manufacturing facility to produce, store and allocate this tissue both locally and internationally.	Professor Gerard Sutton	Not available	Open competitive	15/06/2021	14/09/2022	Not available	Not available	\$	999,224.00
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	University of Sydney	University	NSW	Phage Australia	PHAGE AUSTRALIA: Integrating Australian Phage Biobanking and Therapeutic Networks and Delivering Solutions for Antimicrobial Resistance. Bacteriophage (phage) treatment offers a comprehensive solution to the problem of antimicrobial resistance. It is safer and more precise than antibiotics, with fewer side effects. Our primary goal is to establish bacteriophage therapy in a national framework of approved indications based on clinical trials and a sound understanding of the underlying biology. We will establish the supporting infrastructure for production, diagnostic support and clinical trials, linking academic, government and industry partners across Australia and overseas.	Professor Jonathan Iredell	Not available	Open competitive	15/06/2021	14/09/2022	Not available	Not available	\$	999,999.00
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	Australian Centre for E3 Therapeutics (ACE3T)	An exciting new protein degrader (PD) technology purposefully redirects the cell waste machinery, driven by E3 proteins, to destroy a specified protein, for the first time accessing previously 'undruggable' targets. The Australian Centre for E3 Therapeutics (ACE3T) will enable Australian researchers to access this emerging disruptive technology, generating Australia-based inventions & kick starting a new biotech sector. Application of PD technologies will have a broad impact on streamlining future drug discovery campaigns. With an initial focus on cancer and building on the strength of the Australian research sector, the ACE3T will develop new anti-cancer drugs with improved efficacy and fewer side effects, saving & improving many lives.	Professor John Silke	Not available	Open competitive	15/06/2021	14/09/2022	Not available	Not available	\$	999,999.00

Frontier Health and Medical Research	2021 Frontier Health and Medical Research	Snoretex Pty Ltd	Corporation	VIC	Novel, Innovative Modified Tetanus Toxin Drugs for Weak Muscle Conditions	There is no pharmacotherapy for disorders of low muscle tone or muscular flaccidity, such as obstructive sleep apnoea, urinary/faecal incontinence, pelvic floor weakness, MS and MND. Tetanus neurotoxin (TeNT) is related to botulinum neurotoxin (e.g. Botox, BoNT), but has the opposite effect of increasing muscle tone. Unlike BoNT, TeNT has not been used in medical applications due to human vaccinations and immunity, until now. Snoretex is a treatment made through modification of TeNT, bypassing the human immune response, making it a world-first drug able to enhance motor function and overcome muscle weakness in vaccinated humans and animals. This project will allow us to conduct the necessary steps to bring this exciting product to market.	Associate Professor Anthony Sasse	Not available	Open competitive	15/06/2021	14/09/2021	Not available	Not available	\$	994,509.00
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	University of New South Wales	University	NSW	EpiWatch – Artificial Intelligence Early-Warning System for Epidemics	If the catastrophic COVID-19 pandemic had been detected early in its genesis, before it had spread beyond Wuhan, it could have been stamped out entirely, and the pandemic prevented. Rapid epidemic detection is possible using algorithms and artificial intelligence to mine open source data, but has not been a focus of pandemic planning. We will develop a fully automated, intelligent system for rapid epidemic detection using open source data, building on a semi-automated prototype, Epiwatch. It will use AI, natural language processing, automated translation, report classification and prioritisation, risk analysis, geospatial information systems and a searchable user interface (Web and Apps). This will be a game changer in health security.	Professor Raina MacIntyre	Not available	Open competitive	15/06/2021	14/09/2022	Not available	Not available	\$	799,788.00
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	University of Western Australia	University	WA	Disruptive Technologies for Precision Medicine in Coronary Artery Disease	Coronary artery disease (CAD) is the single leading cause of death in Australia and the world. It is believed that two-thirds of heart attacks originate from plaques with less than 50% blockage of arteries in patients without symptoms. Coronary computed tomography angiography (CTCA) has emerged as a robust technique for CAD assessment. However, its true potential is yet to be realised. Many of the CTCA image analysis steps and clinical decisions are ideally suited for artificial intelligence (AI) methods. In our study, we will work across disciplines to develop, test, and deploy an AI-based risk prediction tool from CTCA scans, and personalise the management of patients with CAD across the full spectrum of the care continuum.	Professor Girish Dwivedi	Not available	Open competitive	15/06/2021	14/09/2022	Not available	Not available	\$	896,606.00
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	University of Sydney	University	NSW	New Frontiers in Personalised Prevention of Coronary Artery Disease	One Australian suffers a heart attack every 10 minutes. Until now, clinicians have been limited to modifiable risk factors, such as cholesterol and blood pressure levels, to predict heart attacks and guide prevention. But, up to 27% of patients with life-threatening attacks have no standard modifiable risk factors, and a proportion progress rapidly to recurrent events despite optimal management. Clearly there is more at play. We are a cross-disciplinary team of clinicians, researchers, and healthcare and industry leaders with a track record of translating innovation who are galvanised to: 1) identify urgently needed biomarkers of early plaque; 2) establish evidence-based clinical pathways; 3) discover game-changing new drug treatments.	Professor Gemma Fittree	Not available	Open competitive	15/06/2021	14/09/2022	Not available	Not available	\$	997,562.00
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	The University of Queensland	University	QLD	Earlier Diagnosis and Personalised Treatments for Endometriosis (EndoAIMM)	Endometriosis is poorly understood and affects 11% of women at an estimated cost to the Australia health system of \$9.7 billion each year. Women experience years of delay from onset of symptoms to diagnosis. Pharmaceutical management achieves variable success. Diagnosis requires surgery, and surgery does not cure the disease which often recurs. To disrupt this cycle, EndoAIMM will address the diagnostic and treatment challenges. New clinical tools for early diagnosis, as alternatives to diagnostic surgery, and personalised treatments will be developed by combining artificial intelligence, imaging, genomics and genomics. Commercialisation opportunities include software and diagnostics, new molecular tests, and targeted treatments.	Professor Grant Montgomery	Not available	Open competitive	15/06/2021	14/09/2022	Not available	Not available	\$	927,741.00
Genomics Health Futures Mission	2018 Mackenzie's Mission	Murdock Children's Research Institute	Medical Research Institute	VIC	Mackenzie's Mission: The Australian Reproductive Carrier Screening Project	Mackenzie Casella died aged 7 months from spinal muscular atrophy (SMA), a rare genetic condition. Mackenzie's parents, Rachael and Jonny Casella did not know they were carriers of SMA until after Mackenzie was born. They asked the question – why weren't we given the chance to find this out before becoming pregnant? The goal of Mackenzie's Mission is to work for a future in which no parent has to ask that question. Mackenzie's Mission: The Australian Reproductive Carrier Screening Project, aims to prepare the Australian healthcare system for population-wide reproductive carrier screening: screening 10,000 Australian couples before they conceive or in early pregnancy for ~500 genes associated with severely debilitating and often fatal genetic conditions affecting children. We will implement laboratory practices and protocols to deliver carrier screening at scale, with rapid results for couples. We will evaluate the screening outcomes, psychosocial impacts, ethical issues, possible barriers to successful uptake and health economic implications of the program. We will evaluate the views of Australians on carrier screening, and provide resources and tools to educate them, and empower them to make informed choices. We will follow the choices of couples found to be at high risk, and provide them with counselling and support through their choices.	Professor Edwin Kirk, Professor Martin Delatycki, and Professor Nigel Lang	Not available	One-off/ad hoc	9/11/2018	31/12/2022	Not available	Not available	\$	19,982,540.00
Genomics Health Futures Mission	2019 Investigator Grants	University of New South Wales	University	NSW	Developing synthetic DNA reference standards (sequins) to ensure accuracy in emerging genomic techniques	DNA sequencing can identify genetic mutations that cause disease. However, the process is challenging and technical errors can cause incorrect diagnoses. My research group has developed synthetic DNA controls (sequins) that mitigate such errors. I plan to expand this approach to create sequin controls for three cutting edge sequencing techniques that promise to revolutionise genomics. Sequins will improve the accuracy of these new techniques & facilitate their adoption into clinical practice.	Doctor Ira Deveson	Not applicable	Targeted competitive	1/01/2020	31/12/2024	Genetics	Genomics	\$	1,443,588.00
Genomics Health Futures Mission	2019 Investigator Grants	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	Statistical methods for analysing next generation sequencing data	The advancing genomic technologies will bring difficult and exciting challenges to the field of bioinformatics. There is a huge demand in statistical and bioinformatics solutions for analyzing and interpreting the data from the cutting-edge technologies. My research in the next five years will mainly involve developing statistical and bioinformatics strategies for analyzing such data. My solid background in bioinformatics and statistics will enable me to make great contribution to the field.	Doctor Yunshun Chen	Not applicable	Targeted competitive	1/01/2020	31/12/2024	Statistics	Biostatistics	\$	639,750.00
Genomics Health Futures Mission	2019 Investigator Grants	The University of Queensland	University	QLD	The history of the human genome and the mechanisms of genomic disease	I led a team aimed at developing computational and molecular approaches to better understand the relationship between changes in our DNA and changes in our health and well-being. I study how mutations drive tumours to form and how human genetic disease is related to mutations of the genome sequence. This fellowship will support my work on understanding how gene duplications affect the genome and what impact they have on health and disease.	Doctor Adam Ewing	Not applicable	Targeted competitive	1/01/2020	31/12/2024	Genetics	Genomics	\$	1,554,485.00
Genomics Health Futures Mission	2019 Pathogen Genomics	University of Melbourne	University	VIC	Precision Public Health in Australia through Integrated Pathogen Genomics	The PPHAGE multidisciplinary team will deliver a large scale integrated public health pathogen genomics research program, to demonstrate utility, cost-effectiveness, and capacity for translation of genomics into public health nationally. The program will deploy a national genomic platform (AusTrakka), for consistent analysis and reporting, and working with health departments and public health laboratories, will implement national genomics based responses to major infectious disease, focusing on respiratory and vaccine preventable diseases, foodborne diseases, sexually transmitted infections and antimicrobial resistance. Evaluation programs will determine cost-effectiveness and public health utility of PPHAGE.	Professor Benjamin Howden	Not available	Open competitive	1/01/2021	30/06/2024	Not available	Not available	\$	9,999,499.00
Genomics Health Futures Mission	2019 Pathogen Genomics	University of New South Wales	University	NSW	H2Seq: Viral genomics for public health interventions in HIV and HCV	Dramatic strides have been made in treatment and prevention of HIV and hepatitis C virus infections. The current challenge is elimination of these pathogens as public health risks by widespread implementation of improved prevention strategies, and highly effective antiviral drug treatments. This project will establish national networks, governance and infrastructure for improved public health metadata collection, sharing of existing viral sequence datasets, and deployment of high throughput viral sequencing and bioinformatic systems for "near real time" molecular epidemiological analyses. H2Seq will deliver actionable data to guide national and regional public health interventions, with cost-saving outcomes.	Professor Anthony Kelleher	Not available	Open competitive	1/01/2021	30/06/2024	Not available	Not available	\$	6,629,162.00
Genomics Health Futures Mission	2019 Pathogen Genomics	Monash University	University	VIC	Genomics, Digital Health and Machine Learning: the SuperbugAI Flagship	The SuperbugAI Flagship will integrate pathogen genomic data and electronic health care data to address the problem of antimicrobial resistance in the healthcare system. The research program will involve testing, clinical validation and implementation of a decision support system for precision medicine and AMR treatment and the creation of an AMR tracking and response system. This research will lead to earlier detection of AMR, personalised treatments for improved patient survival, and prevention of AMR outbreaks in the healthcare system.	Professor Anton Peleg	Not available	Open competitive	1/01/2021	30/06/2024	Not available	Not available	\$	3,403,772.00
Genomics Health Futures Mission	2019 Pathogen Genomics	University of Melbourne	University	VIC	META-GP: Delivering a Clinical Metagenomics Platform for Australia	Clinical metagenomic next-generation sequencing (mNGS) is a transformative approach in microbial diagnostics and patient care, because it can be used to detect and characterise all known pathogens - bacterial, viral, fungal, parasitic - in one single test. The ability to detect all known infections within a matter of hours is a paradigm shift in infectious diseases, and will ensure that clinical care is rapidly targeted where, when and how it is needed. The META-GP program will develop and implement clinical metagenomic diagnostics for infectious diseases in Australia. By the end of this programme, Australia will have the first accredited, nationally-accessible network of laboratories that can apply metagenomic approaches in patient care.	Associate Professor Deborah Williamson	Not available	Open competitive	2/01/2021	30/06/2024	Not available	Not available	\$	6,984,360.00

Genomics Health Futures Mission	2019 ProCan	University of Sydney	University	NSW	ProCan: The human cancer proteome project	ProCan is a multidisciplinary, large-scale cancer proteomics research program, using specialised technology (PCT SWATH-MS) to generate a comprehensive human cancer proteome database. ProCan's overall objective is to use cancer proteomics, genomics and related multi-omic big data analyses of tens of thousands of human cancer samples of all cancer types, which can be used in future to develop technologies and tools that significantly improve the precision of diagnosis and treatment of individual cancer patients. The current project represents two years of a longer (five-to-seven years) research program. Over the next two years, major steps will be undertaken toward ProCan's overall aims, including the acquisition, tissue-sectioning and histopathology review, and processing (including proteome deisotopomerisation) of more than 10,000 cancer samples - to produce the largest ever cancer proteome dataset of this kind. ProCan's software engineering and data science teams will begin the process of developing the platform, i.e., the technology and methodologies needed to analyse and interpret the data efficiently and effectively.	Not applicable	Not available	One-off/adj hoc	1/12/2018	30/11/2023	Not available	Not available	\$	20,400,000.00
Genomics Health Futures Mission	2019 Projects	Macquarie University	University	NSW	Cascade testing in intellectual disability: social and economic impact	Genomics provides significant opportunities to give children a healthier start to life. Severe Intellectual Disability (ID) is among the most important unmet challenges in health care due to its prevalence, life-long nature, and frequent recurrence within families. Families with a child with ID face many social and economic impacts, including: financial pressure, relationship strain, poorer parental health and uncertainty about family planning. We will quantify the social and financial costs to families of severe intellectual disability that is genetic in origin. We will then determine the extent to which clinical genomics with cascade testing can contribute to ameliorating these impacts.	Not applicable	Not available	Open competitive	30/06/2020	30/06/2023	Not available	Not available	\$	486,897.00
Genomics Health Futures Mission	2019 Projects	Monash University	University	VIC	Preventing mitochondrial disease using genomics	This project aims to increase public trust in genomic technologies used to diagnose and prevent mitochondrial disease by developing a best practice framework for their use and implementation in Australia. It will provide a comprehensive analysis of the ethical, legal and social issues that arise in this domain, foster understanding of mitochondrial disease and genomics in the medical and wider Australian community, and present a comprehensive view of current practice in reproductive genomics for mitochondrial disease. The best practice framework it develops will guide clinical practice and shape policy and regulation of the provision of reproductive genomics for mitochondrial disease.	Not applicable	Not available	Open competitive	30/06/2020	31/05/2023	Not available	Not available	\$	499,417.00
Genomics Health Futures Mission	2019 Projects	Monash University	University	VIC	Moratorium on Genetic Testing and Life Insurance: Monitoring the impact	The use of genetic test results in insurance raises ethical, legal & social concerns. Without adequate regulation, it could act as a barrier to genomic medicine in Australia. Recently, the Financial Services Council (FSC), peak body for life insurers, announced a moratorium on the requirement to disclose genetic results, for policies up to certain limits. The moratorium comes into effect July 2019. There will be a critical need to monitor its impact, including how it is received by stakeholders; effects on the uptake of genetic testing & research participation; & impacts on genetic discrimination. Our project will achieve these goals, to inform a planned 2022 regulatory review, & help Australia achieve appropriate long-term regulation.	Not applicable	Not available	Open competitive	30/06/2020	30/06/2023	Not available	Not available	\$	500,000.00
Genomics Health Futures Mission	2019 Projects	Murdoch Children's Research Institute	Medical Research Institute	VIC	A Centre for Ethics of Paediatric Genomics to improve Paediatric Care	This project will generate new knowledge about the ethical, legal and social implications of rapid genomic sequencing (RGS) in critically ill children. It will use both qualitative and quantitative research methods to improve understanding of the impact of RGS on patients, families, clinicians and health systems. It will apply ethical and legal principles to analyse key issues raised by RGS and develop evidence-based advice and guidelines to improve policy and practice. It will also establish a Centre for Ethics of Paediatric Genomics which will bring together national and international thought leaders in the field across ethical, legal, economical and clinical dimensions to further research and policy in the field of genomic medicine.	Not applicable	Not available	Open competitive	30/06/2020	31/03/2023	Not available	Not available	\$	463,471.00
Genomics Health Futures Mission	2019 Projects	Swinburne University of Technology	University	VIC	Towards a trusted genomic repository: Tackling commercialisation fears	The success of incorporating genomics into health care rests on the ability to reduce tension between public trust and industry involvement. Reasons for concern in incorporating genomics into health care will be uncovered by identifying public with distinct views on different aspects of commercialisation, thereby enabling tailored engagement and communication strategies. Contextualising the outputs within national and international obligations will provide an evidence base for targeted recommendations to promote trust.	Not applicable	Not available	Open competitive	30/06/2020	31/03/2023	Not available	Not available	\$	484,000.00
Genomics Health Futures Mission	2019 Projects	University of Melbourne	University	VIC	Achieving Equity in Genomic Health for Indigenous Australians	The aims of the project are to increase and ensure the benefits of genomics for Indigenous Australians by improving support for equity at both a health service and health system level. The project will achieve this by: 1. Co-designing and implementing measures to improve the extent to which provision of genomic health services meet the needs of Indigenous Australians. 2. Evaluating the impact of the measures on the accessibility, availability, affordability and acceptability of care. 3. Conducting a policy analysis to identify actions at a health systems level that will ensure the provision of genomic health services will continue to meet the needs of Indigenous Australians, as the field continues to develop.	Not applicable	Not available	Open competitive	30/06/2020	30/06/2023	Not available	Not available	\$	499,990.00
Genomics Health Futures Mission	2019 Projects	The University of Queensland	University	QLD	We need to talk: Genomics and disability	Scientific and medical developments in genomics are rapidly advancing with potentially profound impacts on people and society. For people with disability, the impacts of those developments can fundamentally alter their view of themselves and their perceived value in society. When scientific advances have existential impacts, affected individuals need to be involved in decisions about the direction of genomics and the medical, ethical and psychosocial implications. Through collaboration and co-design, this project seeks to articulate the ethical, legal and social issues of genomics and disability and the processes for effective bi-directional communication and engagement between multiple stakeholders including the disability community.	Not applicable	Not available	Open competitive	30/06/2020	30/06/2023	Not available	Not available	\$	497,213.00
Genomics Health Futures Mission	2019 Projects	University of Tasmania	University	TAS	Genome Editing: Formulating an Australian Community Response	This project builds on the best available science concerning the development and application of genomic technologies focussing on human health, applying the best available social science in order to promote meaningful public understanding and informed public debate. We begin by capturing current understandings among the public concerning genome editing, which given the novelty of the issue are not necessarily well-formed. Selected lay citizens will then engage with the science under good deliberative conditions, with the intention of developing a knowledgeable and reflective assessment of the issue. This assessment should then feed into and help create a broader citizen-centric public debate that informs future government policy.	Not applicable	Not available	Open competitive	30/06/2020	30/06/2022	Not available	Not available	\$	460,631.00
Genomics Health Futures Mission	2019 Projects	University of Tasmania	University	TAS	Returning Raw Genomic Data: Patient Autonomy or Legal Minefield?	Genomic sequencing for clinical and research purposes is now increasingly commonplace. There are considerable legal uncertainties around the rights of patients and research participants to access their raw genomic data, including ownership and privacy issues, tort liability and inter-jurisdictional complexities. This project will empirically assess requests for raw genomic data requests and subsequent use. This evidence will facilitate an applied approach to legal and ethical analysis, the results of which will be of significant benefit to patients, clinicians and researchers. Guidance will be provided through development of protocols for research and clinical practice and recommendations directed to policy makers.	Not applicable	Not available	Open competitive	30/06/2020	30/06/2023	Not available	Not available	\$	388,026.00
Genomics Health Futures Mission	2019 Projects	Queensland University of Technology	University	QLD	Genomic architecture of chronic disease in Australia's First Peoples	Aboriginal and Torres Strait Islander Australians are dying much younger than other Australians, in part due to an apparent genetic pre-disposition to chronic diseases. Better understanding of this genetic contribution has the potential to improve early detection and target prevention strategies. This project will use whole genome sequencing to define the genetic architecture of the Tjwi people and its association to various chronic diseases, helping to develop a precision medicine approach that will enable accurate diagnosis and inform targeted treatments. It will also train and build research and clinical capacity among collaborating partners and affected communities, creating international visibility in clinical genomics.	Not applicable	Not available	Open competitive	30/06/2020	31/08/2023	Not available	Not available	\$	1,368,256.00
Genomics Health Futures Mission	2019 Projects	University of Melbourne	University	VIC	SUPER-NEXT: Complete genome profiling for cancer of unknown primary	Defined by the absence of a cancer type diagnosis, cancer of unknown primary is a devastating disease with an exceptionally poor survival outcome. We will test two genomic approaches that will guide CUP treatment and help resolve missing cancer type diagnosis. We will use complete genome sequencing to capture all DNA changes in a patient's tumour cells to direct a more precise treatment. We will also test a new innovative approach that analyses DNA released from tumour cells into the patient's blood that will accelerate the return of genomic test results. Finally, we will assess whether analysis of tumour cells can guide better use of a new cancer imaging method. This study will drive broader adoption of genomics for all CUP patients.	Not applicable	Not available	Open competitive	30/06/2020	30/06/2023	Not available	Not available	\$	4,993,321.00

Genomics Health Futures Mission	2019 Projects	University of Melbourne	University	VIC	Precision Medicine for a Life-Threatening Infantile Epilepsy	Mutations in the sodium channel gene SCN2A cause a devastating epilepsy called early infantile SCN2A developmental and epileptic encephalopathy (DEE). Children under 3 months of age have uncontrolled seizures, profound impairment and a high risk of early death. We propose a first-in-man gene therapy trial using a novel SCN2A antisense oligonucleotide to reverse this severe disease, replicating our findings in mice. Our physiological studies will ensure patients whose sodium channels are overexcitable are selected for the trial. We will develop critical clinical and molecular biomarkers of disease as a baseline on which to assess trial outcomes. Then we will perform safety and dosing studies of our gene therapy in children with SCN2A-DEE.	Not applicable	Not available	Open competitive	30/06/2020	30/06/2023	Not available	Not available	\$	4,079,947.00
Genomics Health Futures Mission	2019 Projects	The University of Queensland	University	QLD	Whole Genome Sequencing in high-risk breast cancer patients	We will harness omics technology and national expertise to bring precision medicine to breast cancer care throughout Australia. This will be achieved by implementing Whole Genome Sequencing in patients with high-grade breast cancer undergoing neoadjuvant therapy in order to improve second-line therapeutic decision-making and outcomes.	Not applicable	Not available	Open competitive	30/06/2020	30/06/2023	Not available	Not available	\$	2,801,185.00
Genomics Health Futures Mission	2019 Projects	University of South Australia	University	SA	Genomic autopsy of perinatal death	The primary aim of this study is to determine what proportion of cases of stillbirth and perinatal death (PD) can be diagnosed by genomic analyses, such as whole exome sequencing (WES), whole genome sequencing (WGS), RNAseq, and/or SNP microarrays. The Australian definition of PD comprises fetal and newborn abnormalities that result in termination of pregnancy, death due to congenital abnormalities, death in utero, or death in the newborn period. Accurate diagnosis of the cause of PD is essential for appropriate counselling, including risk to future pregnancies in families. This study will inform public health policy recommendations for public health funding, including MBS, which will have significantly broader socioeconomic implications.	Not applicable	Not available	Open competitive	30/06/2020	30/06/2023	Not available	Not available	\$	3,401,790.00
Genomics Health Futures Mission	2019 Projects	Murdoch Children's Research Institute	Medical Research Institute	VIC	National rapid genomic diagnosis program for critically ill children	We will transform the care of critically ill children with genetic conditions in Australia by delivering a national program for rapid genomic diagnosis. We will evaluate whole genome sequencing (WGS) as a first-tier rapid test in the diagnostic setting, while scaling up rapid diagnosis across multiple centres in Australia, building research, clinical and diagnostic laboratory expertise and translational capability. This collaborative translational study will leverage substantial co-investment to maximize program outcomes. Comprehensive interdisciplinary evaluation of the program will produce a world-leading body of work, which will inform policy and practice in rapid paediatric genomics in Australia and other healthcare systems.	Not applicable	Not available	Open competitive	30/06/2020	31/05/2023	Not available	Not available	\$	4,848,331.00
Genomics Health Futures Mission	2019 Projects	The University of Queensland	University	QLD	Host gene expression signatures to diagnose sepsis in children	Sepsis is a leading cause of death and disability in adults and children, accounting for ca. 5000 deaths in Australia every year, and \$464M costs. This study aims to improve the diagnosis of sepsis through host transcriptomics. We will build on a unique prospective cohort of critically ill children presenting acutely with suspected sepsis to metropolitan, regional, and remote hospitals in Australia. We will discover host gene expression signatures characterizing dysregulated host response to bacterial infection and test these in a validation cohort. This project addresses a key priority in health and can lead to better treatment of sepsis, reduce unnecessary use of antibiotics, improve patient outcomes, with major cost saving potential.	Not applicable	Not available	Open competitive	30/06/2020	30/06/2023	Not available	Not available	\$	2,406,970.00
Genomics Health Futures Mission	2019 Projects	University of New South Wales	University	NSW	PreGen: Filling the Gap – antenatal genomics and newborn care	PreGen will assesses the utility of prenatal genomic testing to diagnose early and improve neonatal intensive care management. The outcomes of the PreGen project will be the development of Australian prenatal rapid genomic testing care standards and national laboratory accreditation, health economic utility of early genomics, understanding human malformation biology, and creating industry/academic partnerships to gain knowledge of childhood diseases, their causes, and treatments.	Not applicable	Not available	Open competitive	30/06/2020	30/06/2023	Not available	Not available	\$	4,828,094.00
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Murdoch Children's Research Institute	Medical Research Institute	VIC	A national large scale automated reanalysis program to increase rare disease diagnosis	Reanalyzing existing genomic data over time significantly increases diagnosis due to improvements in knowledge and analysis methods, but is currently limited due to reliance on manual processes. We will develop, apply, and evaluate a program for automating and scaling up the reanalysis process so that large numbers of rare disease patients can benefit nationally now and into the future.	Professor Zornitza Stark	Professor Zornitza Stark, Doctor Daniel MacArthur, Doctor Sebastian Lunke, Professor Amanda Spurdle, Doctor Simon Sadehn, Doctor Cliff Meldrum, Doctor Karin Kavanah, Doctor Denis Bauer, Associate Professor Ilias Goranitis, Doctor Chirag Patel	Targeted competitive	1/06/2021	31/07/2024	Clinical Sciences	Medical Genetics (Excl. Cancer Genetics)	\$	2,999,982.60
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	University of Melbourne	University	VIC	Precision Diagnosis for the Remaining 50% of Unsolved Developmental and Epileptic Encephalopathies	Devastating epilepsies known as developmental and epileptic encephalopathies are caused by abnormalities in over 300 genes, yet 50% of patients remain unsolved. Patients have uncontrolled seizures, profound impairment and a high risk of early death. We will employ innovative strategies and the latest technologies to reveal hidden causes in the remaining 50% of patients, and correlate these findings with their clinical symptoms, increasing diagnostic yield beyond 70% by 2025.	Associate Professor Michael Hildebrand	Associate Professor Michael Hildebrand, Professor Ingrid Schaffer, Associate Professor Peter Preucc, Professor Samuel Berkovic, Doctor Katherine Howell, Doctor Mark Bennett	Targeted competitive	1/06/2021	31/05/2025	Genetics	Neurogenetics	\$	2,992,144.21
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Murdoch Children's Research Institute	Medical Research Institute	VIC	Mitochondrial Diagnostic Network for Genomics and Omics	Mitochondrial Diseases (MDs) are the most common group of inherited metabolic disorders. They can be caused by changes in more than 300 different genes and affect any or all of our organ systems. New genomic (DNA) technologies have increased our ability to diagnose MDs from less than a quarter of patients to about a half. This study seeks to further improve the diagnostic rate by using new "Omics" technologies that can detect changes in thousands of RNAs, proteins and metabolites all at once.	Professor David Thorburn	Professor David Thorburn, Professor Carolyn Sue, Professor Aleksandra Filipovska, Professor Michael Ryan, Doctor David Stroud, Doctor Diana Stojanovski, Professor David Coman, Mr Sean Murray, Doctor Ryan Davis	Targeted competitive	1/06/2021	31/08/2025	Genetics	Genomics	\$	2,999,999.66
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Murdoch Children's Research Institute	Medical Research Institute	VIC	The Australian Undiagnosed Diseases Network (UDN Aus): An internationally networked national approach for transforming diagnosis for individuals living with rare diseases	Despite the advent of new gene sequencing technologies, half of individuals with rare genetic diseases remain without a diagnosis. In this project we will establish the Undiagnosed Diseases Network of Australia, bringing together a national crack team of medical specialists, diagnostic laboratories, computing experts and researchers to harness the latest genomic technologies, and emerging computer and laboratory-based tools to boost the diagnosis in these unsolved individuals to over 70%.	Professor John Christodoulou	Professor John Christodoulou, Professor Gareth Baynam, Associate Professor Susan White, Doctor Elizabeth Palmer, Mrs Azura Hemes, Professor Julie McGaughran, Doctor Timo Lassmann, Doctor Suzanne Salewsky, Associate Professor Tiyang Yang Tan, Doctor Matthew Wallis	Targeted competitive	1/06/2021	30/09/2024	Clinical Sciences	Medical Genetics (Excl. Cancer Genetics)	\$	2,974,134.60
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	James Cook University	University	QLD	The KidGen National Kidney Genomics Program – improving genomic outcomes for Australian families with genetic kidney disease	The KidGen National Kidney Genomics Program is an Australian national and translational genomics program addressing the need to urgently improve identification and diagnosis of inherited and genetic forms of kidney disease. Using an established national network of renal genetics clinics, we will apply cutting edge genomic approaches to improve the genetic diagnosis rate. This will be earlier and more efficient than ever before, and will inform clinical options and pathways for families.	Professor Andrew Mallett	Professor Andrew Mallett, Professor Stephen Alexander, Professor Melissa Little, Doctor Cas Simons, Professor Ian Smyth, Doctor Annel Mallawaarachchi, Associate Professor Catherine Guinan, Doctor Ira Devoson, Doctor Thomas Forbes, Doctor Kuhanthi Jayasinghe	Targeted competitive	1/06/2021	31/05/2026	Clinical Sciences	Nephrology And Urology	\$	2,999,537.40
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	University of Western Australia	University	WA	Closing the gap in diagnosis of neurological disorders including ataxias and neuropathies – a trans-Australia collaboration	Inherited brain, spinal cord or nerve diseases are chronically disabling and worsen over a patient's life. They severely affect quality of life and need for medical and non-medical support. The situation is made worse because many families remain genetically undiagnosed even after all known causes are tested. For patients and clinicians worldwide this is a critical setback. We will identify new causes of these diseases to provide diagnoses to these patients and improve their health and welfare.	Professor Nigel Laing	Professor Nigel Laing, Professor Marina Kennerison, Professor Philipp Lamont, Professor Oleg Vasic, Doctor Mark Davis, Associate Professor Robert Bryson-Richardson, Doctor Gaianna Ravenscroft, Doctor Gonzalo Perez Siles, Doctor Rousa Ghesai	Targeted competitive	1/06/2021	31/05/2025	Genetics	Neurogenetics	\$	2,996,253.50
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Murdoch Children's Research Institute	Medical Research Institute	VIC	New technologies for improved diagnosis of ataxia and the repeat expansion disorders	Identifying the genetic cause of disease in an individual is often the first step in the provision of appropriate clinical care. This diagnostic process is being revolutionised by our ability to sequence the entire human genome in a time and cost effective manner. This project will develop a tool to interrogate all known repeat expansions simultaneously, providing rapid diagnoses and better clinical care for individuals with neurogenetic disorders like ataxia, caused by repeat expansions.	Professor Paul Lockhart	Professor Paul Lockhart, Professor Martin Delatycki, Doctor Haloom Rafahi	Targeted competitive	1/06/2021	31/05/2023	Genetics	Neurogenetics	\$	653,299.00
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	University of Melbourne	University	VIC	Diagnosis, discovery and novel phenotype characterisation using multimodal genomics in patients with inherited bone marrow failure and related disorders	This project seeks to identify novel genetic causes of a group of rare diseases called 'inherited bone marrow failure syndromes'. Currently only ~50% of cases have a known genetic cause, required for a correct diagnosis, prognosis and for making treatment choices. We will study the genomes of 350 patients with this disease in order to identify novel causes of these diseases, improve the diagnostic rate, and assess the benefits of providing genomic testing to all patients with this disease.	Doctor Piers Blombery	Doctor Piers Blombery, Professor Erica Wood, Doctor Lucy Fox, Doctor Meaghan Wall, Professor Paul James, Associate Professor Anna Brown, Associate Professor William Stevenson, Professor David Ritchie, Professor Jillian Francis	Targeted competitive	1/06/2021	31/05/2025	Genetics	Genomics	\$	2,997,450.25
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	University of Melbourne	University	VIC	Evaluating clinically relevant biomarkers to improve early detection and treatment of head and neck cancer	Over the last thirty years, improvements in survival rates of head and neck cancer patients have remained modest and have been hampered by the late death of the disease. This project will sequence patient samples to identify signatures of malignancy that will be validated in unique laboratory models of the human disease. The findings will discover novel clinically relevant markers which will allow us to detect head and neck cancer earlier and lead to better treatment options for patients.	Doctor Charbel Darido	Doctor Charbel Darido, Professor Camille Farah, Doctor David Goode, Professor Stephen Jane, Doctor Michael Vacher, Doctor Simon Fox, Associate Professor Jermaine Coward, Doctor Glenn Francis	Targeted competitive	1/06/2021	30/09/2025	Biochemistry And Cell Biology	Cellular Interactions (Incl. Adhesion, Matrix, Cell Wall)	\$	2,231,954.50
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Monash University	University	VIC	Population genomic screening of young adults to prevent cancer in Australia	DNACancerScreen is a new national study offering preventive DNA testing to 10,000 otherwise healthy young adults to identify risk of two common cancers syndromes. The study will develop a low-cost DNA screening tool that is scalable to larger populations, and assess the acceptability and cost-effectiveness of offering this screening test to young adults in the Australian healthcare system, for cancer prevention.	Doctor Paul Lacaze	Doctor Paul Lacaze, Professor John McNeil, Professor John Zalcberg, Professor Al Tiller, Professor Roger Milne, Professor Paul James, Professor Martin Delatycki, Ms Mary-Anne Young, Doctor Kristen Nowak, Doctor Tu Nguyen-Dumont	Targeted competitive	1/06/2021	31/05/2025	Public Health And Health Services	Preventive Medicine	\$	2,968,057.20
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	University of Sydney	University	NSW	Genomic risk prediction and risk-tailored screening and early detection for common cancers	To reduce the burden of common cancers and help Australians live longer, healthier lives, we will produce evidence-based recommendations for effective and sustainable genomics informed risk-tailored cancer screening and early detection. We will generate a new testing regime of Australian genomic data; develop and validate genomic risk tools for the Australians population; identify and incorporate public preferences; determine 'best buy' risk-tailored screening and early detection strategies.	Professor Anne Cust	Professor Anne Cust, Doctor Julia Steinberg, Professor Karen Canfield, Doctor Alison Pearce, Doctor Dorothy Keefe, Doctor Daniel MacArthur, Doctor Michael Canavan, Doctor Gemma Bilbey, Doctor Martin McMahon, Professor Naom Wray	Targeted competitive	1/06/2021	31/05/2025	Public Health And Health Services	Preventive Medicine	\$	2,999,860.35

Genomics Health Futures Mission	2020 Genomics Health Futures Mission	University of Melbourne	University	VIC	Genetic mosaicism as a stable and robust blood DNA biomarker for precision risk assessment for cancer	To fully personalise cancer screening, we need to develop biomarkers that can be measured simply to identify those most at risk. This project will assess how analysis of small, non-inheritable gene changes, (somatic mosaicism) in blood cells can be used to measure cancer risk. Our data will support development of a simple blood test to enable targeted screening of people who are at risk of future cancer development due to acquired mutations over their lifetime.	Professor Ian Campbell	Professor Ian Campbell, Associate Professor Carolyn Nickson, Ms Lisa Devereux	Targeted competitive	1/06/2021	31/08/2025	Genetics	Genomics	\$	2,122,301.10
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	The University of Queensland	University	QLD	Improving genomic testing rates for inoperable lung cancer patients	Most lung cancer patients are diagnosed with advanced disease. Many patients undergo bronchoscopy instead of surgery to obtain cancer tissue to make a formal diagnosis and to perform genomic testing. This is to identify therapies that will be the most effective. This application addresses a current clinical problem, that for many patients the tumour biopsy does not yield sufficient tissue for genomic testing, denying the patient's chance to receive the optimum treatment for their cancer.	Associate Professor David Fielding	Associate Professor David Fielding, Associate Professor Peter Simpson, Doctor Katia Nones, Associate Professor Phan Nguyen, Associate Professor Daniel Steinfur, Doctor Nicola Wadell, Associate Professor Karin Steinke, Associate Professor Louisa Gordon, Associate Professor Gunter Hattler	Targeted competitive	1/06/2021	31/05/2025	Oncology And Carcinogenesis	Cancer Diagnosis	\$	2,492,446.30
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	University of Melbourne	University	VIC	Novel predictive disease modelling using liquid biopsies to improve outcomes in melanoma	Melanoma is the most aggressive type of skin cancer and treatment can be challenging. It is critical to predict which patients can be cured by surgery alone versus those at high risk of disease spreading. Many cancers including melanoma can release small fragments of their DNA into a patient's bloodstream (circulating tumour DNA or ctDNA). This project aims to develop and validate a ctDNA based blood test to detect residual disease after surgery to guide treatment and improve survival outcomes.	Professor Sarah-Jane Dawson	Professor Sarah-Jane Dawson, Associate Professor Shaheen Sandhu, Professor Paul Lorigan, Professor Caroline Dive, Doctor Stephen Wong, Doctor Dineika Chandrasekara, Associate Professor Victoria Atkinson, Professor Stephen Fox	Targeted competitive	1/06/2021	31/05/2026	Oncology And Carcinogenesis	Solid Tumours	\$	2,049,125.70
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Flinders University	University	SA	A liquid biopsy DNA methylation blood test for personalised treatment of patients with gastrointestinal cancers	Gastrointestinal cancers of the oesophagus, stomach and bowel are common in Australia and can have poor outcomes. There are currently no simple ways to monitor if the treatment for these cancers is working to ensure that people become cancer-free. We have developed a new blood test that can detect these cancers. We will now investigate the use of this test to be able to accurately monitor a patient's cancer treatment and detect any cancer relapses early, to ensure the best outcomes possible.	Associate Professor Erin Symonds	Associate Professor Erin Symonds, Professor Graeme Young, Professor David Watson, Professor Christos Karapetis, Professor Jonathan Karon, Professor Carlene Wilson, Professor Richard Woodman, Doctor Damian Hussey, Associate Professor Michael Michael, Doctor Jean Winter	Targeted competitive	1/06/2021	31/05/2025	Clinical Sciences	Gastroenterology And Hepatology	\$	1,980,810.10
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Macquarie University	University	NSW	Integrated Multimodal Precision Liquid biopsy to Enhance Melanoma and NSCLC Treatment (IMPLEMENT)	Recent advances in cancer therapy, including drugs known as immunotherapies, have improved patient outcomes, but many patients will not respond to these drugs. Currently we have no accurate method to predict patient response and we cannot easily monitor a patient's response over time. This study will develop a safe and simple blood test that can guide treatment choices, can monitor patient responses and allow clinicians to make immediate and informed treatment decisions.	Professor Helen Rizos	Professor Helen Rizos, Associate Professor Elin Gray, Doctor Jenny Lee, Professor Georgina Long, Professor Michael Millward, Doctor Louise Ellis, Professor Enrico Coiera, Doctor Steven Kao	Targeted competitive	1/06/2021	30/11/2025	Oncology And Carcinogenesis	Oncology And Carcinogenesis Not Elsewhere Classified	\$	2,031,178.80
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Murdoch Children's Research Institute	Medical Research Institute	VIC	The Australian Functional Genomics Network	Our genes carry the instructions for the development of a healthy body. Gene sequencing allows analysis of many genes at once and identifies many changes or variants, some of which cause disease. The Australian Functional Genomics Network will help establish which gene variants cause disease by matching a patient's clinician with the best and most appropriate researchers to fast track studies into new genes variants that may cause disease, leading to improved diagnosis and outcomes for patients.	Professor Andrew Sinclair	Professor Andrew Sinclair, Professor Ian Smyth, Doctor Nathan Palant, Professor Massimo Hillard, Professor Robyn Jamieson, Professor Nigel Laing, Doctor Chirag Patel, Professor Livia Hood, Professor Richard Harvey, Associate Professor Robert Bryson-Richardson, Doctor Tristan Hardy, Doctor Matthew Walls, Professor John Christodoulou, Professor Leonie Quinn, Associate Professor Tony Roscic, Associate Professor Josephine Boyles, Professor Zornitza Stark, Professor Patrick Tam, Professor Tiong Tan, Associate Professor Julian Heng, Associate Professor Tracy Oudling-Byth, Doctor Tessa Mattiske, Professor Gareth Baynam, Professor Bruce Bennetts, Professor Amanda Spurdle, Professor Ernst Wöhring, Professor Iazef Geiz, Professor Sally Dumeoole, Professor Paul Thomas, Doctor Elizabeth Palmer, Associate Professor Kristi Jones, Professor Hamish Scott, Associate Professor Kelly Smith, Doctor Daniel MacArthur, Professor Gary Hime, Professor Coral Warr	Targeted competitive	1/06/2021	30/11/2026	Genetics	Genetics Not Elsewhere Classified	\$	5,999,547.00
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of Sydney	University	NSW	RNA-4RD: Disease-agnostic, nationally-accessible pipelines of clinical RNA Diagnostics	Genetic disorders affect 1 in 100 individuals. A precise genetic diagnosis is the key to personalised healthcare, disease prevention, and sometimes a cure or treatment. For the 50% of families undiagnosed after DNA testing, the answer lies in their RNA. RNA-4RD will integrate RNA diagnostics into mainstream clinical practice, vastly improving diagnoses of families living with rare genetic diseases or inherited cancer predisposition and revolutionising their personalised health care options.	Professor Sandra Cooper	Professor Sandra Cooper, Doctor Natasha Brown, Mr Ben Lundie, Doctor Belinda Chong, Doctor Michael Buckley, Miss Emma Tadini, Professor Eduardo Eyras, Associate Professor Ilija Goranits, Doctor Mark Davis, Doctor Himanshu Goel, Associate Professor Tracy Oudling-Byth, Doctor Sarah Sandaradura, Professor Bruce Bennetts, Doctor Christopher Richmond, Doctor Peer Arts	Targeted competitive	1/06/2022	30/09/2025	Clinical Sciences	Clinical Sciences, Medical Genetics (Excl. Cancer Genetics)	\$	2,991,954.80
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	The University of Adelaide	University	SA	PERSYST: Pathogenic Evaluation of Recalcitrant Variants by Systematic Transactivation	Many patients with genetic disorders go undiagnosed. That is partly because one in three disease genes (1500) are not easily available for testing in routinely collected patient-derived tissue. Our research brings a breakthrough into this domain by harnessing the power of Nobel prize-winning genome editing technology to activate otherwise silent genes, in patient-derived tissues, so they become amenable to testing. This revolutionary technology has also potential therapeutic applications.	Professor Iazef Geiz	Professor Iazef Geiz, Doctor Cathryn Poulton, Doctor Clare van Eyk, Doctor Lachlan Jolly, Professor Samuel Berkovic, Professor David Connan, Professor Gareth Baynam, Professor Christopher Barnett, Professor Simon Barry, Associate Professor Irina Voineagu, Professor Ryan Lister, Associate Professor Michael Holdstock, Doctor Christian Pfleger, Professor Tong Yang Tan, Professor Ingrid Scheffer	Targeted competitive	1/06/2022	30/09/2027	Genetics	Genetics, Gene Expression (Incl. Microarray And Other Genome-Wide Approaches), Medical Biotechnology, Gene And Molecular Therapy	\$	2,996,428.00
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of New South Wales	University	NSW	High throughput functional genomics assays for ion channelopathies	Mutations in ion channel genes cause a wide range of devastating clinical diseases. Some of the more common channelopathies include polycystic kidney disease, cystic fibrosis, inherited arrhythmia syndromes (Long QT syndrome, Brugada syndrome) and genetic epilepsies. These conditions as a whole cause significant morbidity with reduced quality of life as well as shortened life expectancy. The assays we develop will help resolve more cases and facilitate development of new therapeutics.	Professor Jamie Vandenberg	Professor Jamie Vandenberg, Doctor Elizabeth Palmer, Doctor Kavitha Kothur, Doctor Shafigh Fritzer, Doctor Charles Cox, Doctor Chai Ng, Associate Professor Kathy Wu, Professor David Adams	Targeted competitive	1/06/2022	31/05/2026	Biochemistry And Cell Biology	Biochemistry And Cell Biology, Receptors And Membrane Biology, Clinical Sciences, Medical Genetics (Excl. Cancer Genetics), Genetics, Genetics Not Elsewhere Classified	\$	2,877,650.40
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	Advancing genetic diagnosis and health by leveraging high-throughput functional assay data into existing disease-agnostic variant platforms	Diagnosing genetic diseases is difficult because small changes can be harmful but we don't always know which ones. Researchers can now examine every change in a single gene, so we need an easy way to cross-reference experimental data with what is seen in the real-world. Our proposal will link two databases to share information efficiently, explore disease genes using this new technology, and offer workshops to help the clinical community understand and use lab results to improve patient health.	Doctor Alan Rubin	Doctor Alan Rubin, Associate Professor Christopher Wahn, Associate Professor Lea Starita, Professor Amanda Spurdle, Associate Professor Douglas Fowler, Associate Professor Anna Brown, Doctor Matthew Wakefield, Professor Hamish Scott, Doctor Cliff Meldrum, Professor Paul James, Doctor Belinda Phibson	Targeted competitive	1/06/2022	31/12/2025	Genetics	Genetics, Genomics	\$	2,573,362.20
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	The University of Queensland	University	QLD	TRIAGE: A disease agnostic computational and modelling platform to accelerate variant classification	Over a third of all patients with genetic testing do not have a known cause of disease. This research program implements new methods to reveal genes that are the likely cause of disease. We couple these predictions with disease-agnostic modelling to determine whether specific disease variants identified in patients are the cause of disease. Collectively, these approaches will facilitate accelerated classification of disease causing variants for any disease.	Associate Professor Nathan Palant	Associate Professor Nathan Palant, Doctor Tatiane Yanes, Professor Zornitza Stark, Associate Professor Jodie Ingles, Professor Richard Harvey, Professor Julie McCaughan, Professor Diane Farkis, Professor John Atherton, Doctor Adam Hill, Associate Professor Mikael Beiden, Professor Andrew Mallett, Doctor Richard Bagnall, Doctor Senia Shah, Doctor Alexander Combes, Professor Robert Bryson-Richardson	Targeted competitive	1/06/2022	30/11/2025	Genetics	Genetics, Developmental Genetics (Incl. Sex Determination), Biochemistry And Cell Biology, Cell Development, Proliferation And Death	\$	2,997,498.50
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of Melbourne	University	VIC	RDMassSpec: Mass-Spectrometry based Functional Genomics Platform for solving Rare Genetic Disorders	While individual rare diseases may be rare, collectively they are suffered by up to 2 million Australians. New genomic (DNA) technologies have transformed genetic diagnosis of rare diseases, however half of individuals still remain undiagnosed. DNA is the blueprint for protein, and proteins process the metabolites that sustain life. This study seeks to further improve the diagnostic rate by using new "omic" technologies that can detect changes in thousands of proteins and metabolites at once.	Doctor David Stroud	Doctor David Stroud, Professor Malcolm McCoville, Professor John Christodoulou, Daniela Hoxk, Doctor Katrina Bell, Doctor Cas Simons, Professor Daniel MacArthur, Professor Susan White, Professor David Thorburn, Doctor Nicole Van Bergen, Associate Professor Sebastian Lunke, Doctor James Pitt, Doctor Meaghan Wall	Targeted competitive	1/06/2022	31/08/2025	Genetics	Genetics, Genomics, Medical Biochemistry And Metabolomics, Medical Biochemistry: Proteins And Peptides (Incl. Medical Proteomics), Medical Biochemistry And Metabolomics, Medical Biochemistry And Metabolomics Not Elsewhere Classified	\$	2,998,604.40
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	The University of Adelaide	University	SA	Newborn screening model using integrated multi-omics in South Australia (NewbornStriSA)	Early diagnosis of genetic disorders in newborns gives these children the best chance of good health outcomes and of avoiding irreversible lifelong damage. The challenge is that there are thousands of potential genetic disorders and current screening models cannot detect them all. In this study, we will trial an approach that uses a number of complementary tools, looking at both DNA and metabolites, along with demographic and medical information to identify newborns at risk.	Associate Professor Karin Kasahara	Associate Professor Karin Kasahara, Mr Khoa Lam, Professor Tracy Merfin, Doctor Jennie Louise, Professor Christopher Barnett, Doctor Benjamin Saxon, Doctor Ago Bratkovic, Professor Hamish Scott, Doctor Nicholas Smith, Mr Enzo Ranieri, Doctor Jovanka King, Doctor Emile Mas, Doctor Carol Sly	Targeted competitive	1/06/2022	31/05/2025	Genetics	Genetics, Genomics, Medical Biochemistry And Metabolomics, Metabolic Medicine, Public Health And Health Services, Preventive Medicine	\$	2,941,351.00

Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of Sydney	University	NSW	gEnomicsANewborns: Integrating Ethics and Equity with Effectiveness and Economics for genomic newborn screening	Just because we can use genomics to sequence the DNA of newborn babies, it doesn't mean we should. Very soon we will be able to screen newborns for hundreds of conditions in addition to the 25 we currently screen for. Before we do this we need to understand what people across Australia think about the possible benefits and harms of genomics, and we need to make sure that the views of the community feed in to government decisions to make the genomic newborn screening publicly available.	Associate Professor Sarah Norris	Associate Professor Sarah Norris, Professor Kirsten Howard, Doctor Kristen Nowak, Professor Margaret Orlowski, Doctor Dylan Mordaunt, Professor Gareth Baynam, Associate Professor Kyle Mason, Sarah Norwith, Professor Kim Houslow, Ms Jo Watson, Associate Professor Catherine Bell, Professor Gail Garvey, Doctor Dindu Kariyawasam, Professor Jonathan Craig, Professor Stacy Carter	Targeted competitive	1/06/2022	31/10/2026	Clinical Sciences	Clinical Sciences, Medical Genetics (Excl. Cancer Genetics), Applied Ethics, Medical Ethics, Applied Economics, Health Economics	\$	2,117,960.40
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	Murdoch Children's Research Institute	Medical Research Institute	VIC	Assessing benefits of extended genomic newborn screening trialled on 100,000 infants from Generation Victoria	There are over 7,000 rare diseases with the average child receiving diagnosis at 4 years. Newborn screening using genomics could identify these children at a younger age and deliver new therapies at birth to offer the most chance of health benefits. We will test effectiveness of a novel genomic workflow called gNBS to detect harmful changes to genes on the whole-of-state birth cohort (GenV) of 100,000 infants. This will enable its implementation as a new model for genomic newborn screening.	Associate Professor David Godler	Associate Professor David Godler, Doctor Sheena Arora, Professor Jeanie Cheong, Professor David Amor, Doctor Mark Corbett, Professor Jozsef Geisz, Doctor Michael Field, Professor Katrina Williams, Professor Richard Saffery, Professor Melissa Wake, Doctor Quang Bui, Doctor James Pitt	Targeted competitive	1/06/2022	31/05/2027	Genetics	Genetics, Genomics	\$	2,999,919.80
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	Murdoch Children's Research Institute	Medical Research Institute	VIC	Genomic Newborn Screening for personalised lifelong healthcare in Australian babies	Almost every baby in Australia gets a "heel prick", collecting small spots of blood for Newborn Screening (NBS). This test finds diseases that can make the baby severely ill if not treated urgently. We will use new technology, called genome sequencing, to increase the number of diseases that can be detected by NBS from just a handful to over a hundred. At the same time, we will work with parents and doctors to ensure they know all that is necessary about this new test.	Associate Professor Sebastian Lunke	Associate Professor Sebastian Lunke, Doctor Alison Archibald, Associate Professor Ronda Greaves, Professor John Christodoulou, Doctor Lilian Downie, Associate Professor Stephanie Best, Professor Zornitza Stark, Associate Professor Ilias Goranitis, Doctor Christopher Gyngell, Professor Daniel MacArthur, Doctor Simon Saleh, Doctor Danyu Vears, Professor Martin Delatycki, Doctor Meaghan Wall, Professor Clara Gaff	Targeted competitive	1/06/2022	1/08/2027	Genetics	Genetics, Genomics, Applied Ethics, Ethical Use Of Biotechnology, Applied Economics (E.g. Nanotechnology), Applied Economics, Health Economics	\$	2,998,078.35
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of Sydney	University	NSW	Newborn GEN SEQ TRAIL: Newborn gEnomicSequencing in screening: TherapyReadyAndInformation for Life	Newborn screening (NBS) continues to be one of the most successful population health programmes, providing benefits to a target population through the early diagnosis of a serious and health condition, to enable early management and better health outcomes. The newborn Gen Seq TRAIL study will provide high-quality evidence to inform the integration of new models of genomic sequencing in NBS programs to be ready for new treatments and better health.	Professor Bruce Bennetts	Professor Bruce Bennetts, Doctor Gladys Ho, Tiffany Wotton, Associate Professor Adyee Tolun, Doctor Pak Long Cheong, Ms Kirsten Bagg, Associate Professor Kristi Jones, Won Tae Kim, Doctor Mark Davis, Professor Edwin Kirk, Doctor Natalie Twine, Doctor Karim Jamani Javid, Doctor Eva Chu, Doctor Kavitha Bhattacharya, Associate Professor Michelle Farrar	Targeted competitive	1/06/2022	30/09/2026	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine, Paediatrics	\$	2,954,189.32
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of Sydney	University	NSW	Ethical governance for clinical and genomic data	Rapid advances in genetic sequencing technologies are enabling large collections of genetic information – "genomic datasets" – to be set up and used to benefit human health. But what risks are there? Who should access them? How can we harness their benefits while maintaining public trust? This project will address the pressing ethical, legal and social aspects of these questions. It will develop and put into practice systems and processes to ensure genomic datasets are developed and used well.	Professor Ainsley Newson	Professor Ainsley Newson, Mrs Azure Hermes, Professor Jackie Leach Scully, Professor Wendy Lipworth, Associate Professor Marcus Smith, Doctor Kalinda Griffiths, Professor John Christodoulou, Professor Louisa Jorm, Professor Mark Taylor, Professor Zornitza Stark, Professor Julian Savulescu, Ms Heather Renton, Professor Alan Petersen, Professor Rachel Ankeny, Professor Margaret Orlowski, Professor Seumas Miller, Doctor Lisa Eckstein, Professor Ian Kerridge, Doctor Miranda Vidgen, Doctor Christopher Gyngell, Professor Daniel MacArthur, Professor Gareth Baynam, Professor Jozsef Geisz, Professor Oliver Hofmann, Associate Professor Jane Nielsen, Professor Louise Keogh, Professor Cameron Stewart, Ms Janette Mumford, Professor David Irving, Doctor Rebekah McWhirter, Professor Angus Dawson, Doctor Marie-Jo Brion, Doctor David Hansen, Doctor Marco Rizzi, Professor Alex Brown, Doctor Danyu Vears, Doctor Megan Pricot, Doctor Lisa Dine, Professor Dianne Nicol, Professor Jeannie Paterson, Professor Martin Delatycki, Professor Clara Gaff, Ms Monica Ferrie	Targeted competitive	1/06/2022	31/07/2027	Applied Ethics	Applied Ethics, Bioethics (Human And Animal), Genetics, Genetics Not Elsewhere Classified, Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	4,999,986.85
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	Australian National University	University	ACT	Pathways to benefits for Indigenous Australians in Genomic Medicine	Indigenous populations are not yet appropriately represented in genomic research. We have assembled a national consortium of Indigenous researchers, health services, institutions and industry to empower Indigenous leadership in genomics with a focus on 1) Governance; 2) Data Systems and Sovereignty; 3) Genomics Policy; and 4) Indigenous Genomic Capacity Development. Our network will enable equitable, culturally safe and responsive access to the benefits of genomic medicine for all Australians.	Professor Alex Brown	Professor Alex Brown, Mrs Azure Hermes, Mr Gregory Pratt, Professor David Lynn, Doctor Kalinda Griffiths, Professor Marcel Dinger, Doctor James Breen, Associate Professor Jodie Ingles, Rebecca D'Souza, Doctor Yasmine Soulimi, Doctor Kristen Nowak, Professor Julie McGaughan, Doctor Johanna Barclay, Doctor Shayne Bellingham, Professor Daniel MacArthur, Mr Glenn Pearson, Doctor Sharon Huebner, Professor Stephen Simpson, Professor Gareth Baynam, Doctor Nathan O'Callaghan, Associate Professor Odette Pearson, Ms Louise Lyons, Associate Professor Raymond Lovett, Professor David Thomas, Professor Jason Kovacic, Doctor Rebekah McWhirter, Doctor David Hansen, Professor Maurea Toombs, Associate Professor Mark Wentong, Doctor Simone Reynolds, Professor Ngare Brown, Mr Roe Rambaldini, Professor Elva Hyypponen, Professor Graham Mann, Doctor Shivashankar Hiriyur Nagaraj, Ms Kim Morey, Doctor Charlotte Slade, Doctor Hardip Patel, Doctor Karen Hawke, Professor Sarah Medland, Professor David James, Professor Ien Ying, Associate Professor Bastien Llamas, Associate Professor Misty Jenkins, Professor Clara Gaff, Doctor Vanessa Bryant, Doctor Timo Lasmann	Targeted competitive	1/06/2022	31/05/2027	Genetics	Genetics, Genomics, Public Health And Health Services, Aboriginal And Torres Strait Islander Health	\$	4,986,948.70
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of New South Wales	University	NSW	The Australian Genetic Diversity Database: towards a more equitable future for genomic medicine in Australia	Many severe diseases are caused by DNA changes that are very rare in the general population. Clinical laboratories thus need DNA data from many people to identify the specific cause(s) of each person's condition. Unfortunately, current DNA databases include mostly people from Europe, making it harder to diagnose patients from other ancestries. We propose a new DNA database of over 20,000 Australians that better reflects our diversity, ensuring more accurate diagnosis for all Australians.	Professor Daniel MacArthur	Professor Daniel MacArthur, Mrs Azure Hermes, Associate Professor Karin Kasala, Doctor Mona Saleh, Associate Professor Sarah Kummerfeld, Mr Ben Lundie, Doctor Azmeraw Amare, Doctor Loic Yengo, Associate Professor Stephanie Best, Professor Julian Savulescu, Associate Professor Jodie Ingles, Doctor Surena Karki, Associate Professor Ilias Goranitis, Doctor Rachel Thorpe, Ms Mary Ann Geromino, Associate Professor Alison McEwen, Professor Naomi Wray, Professor Gareth Baynam, Doctor Mark Davis, Doctor Ira Deveson, Professor David Irving, Professor Edwin Kirk, Associate Professor Sang Hong Lee, Professor Alex Brown, Mrs Tiffany Boughtwood, Professor Melissa Southey, Professor Joseph Powell, Michael Talkowski, Doctor Danyu Vears, Professor Bruce Bennetts, Doctor Cliff Meldrum, Professor Melissa Wake, Doctor Martin McNamara, Associate Professor Paul Lacaze, Professor Martin Delatycki, Associate Professor Beben Benyamin, Doctor Sonia Shah, Ms Mary-Anne Young, Associate Professor Sebastian Lunke, Heidi Kehm	Targeted competitive	1/06/2022	31/05/2027	Genetics	Genetics, Genomics, Clinical Sciences, Medical Genetics (Excl. Cancer Genetics), Applied Ethics, Medical Ethics	\$	9,996,894.20
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of New South Wales	University	NSW	Developing a long read nanopore sequencing platform for Indigenous genomics	Long-read nanopore sequencing is an emerging technology that promises to advance our understanding of genetic variation & improve diagnosis of genetic disease. We will develop an innovative nanopore sequencing platform for Indigenous Australian genomics. Through the analysis of diverse cohorts, clinical case studies and by establishing capabilities for portable sequencing in remote communities, we aim to extend the benefits of the latest advances in genomic technology to Indigenous Australians.	Doctor Ira Deveson	Doctor Ira Deveson, Doctor Amal Mallawaarachchi, Doctor Yasmine Soulimi, Doctor Hasindu Gamaarachchi, Professor Daniel MacArthur, Professor Gareth Baynam, Doctor Anne-Lutz Martin, Reis, Professor Graham Mann, Doctor Hardip Patel, Associate Professor Bastien Llamas	Targeted competitive	1/06/2022	31/05/2024	Genetics	Genetics, Genomics	\$	986,060.00

Genomics Health Futures Mission	2021 Genomics Health Futures Mission	Australian National University	University	ACT	Establishing epigenetic biomarkers in Indigenous Australians for precision health	Indigenous Australians have historically been severely disadvantaged when it comes to gaining equitable access to high quality healthcare, including with respect to the emerging field of Precision or "Personalised" medicine. Using a large cohort of Indigenous Australians, we aim to establish epigenetic profiles that can be used to develop accurate biomarkers that can target early prevention and management of diabetes and its complications.	Professor Alex Brown	Professor Alex Brown, Doctor James Breen, Professor Assam El-Osta, Associate Professor Natasha Howard, Doctor Scott Maxwell, Doctor Ishant Khurana, Doctor Boris Guernewig, Professor Ryan Lister, Doctor Sam Buckberry	Targeted competitive	1/06/2022	31/05/2024	Genetics	Genetics, Epigenetics (incl. Genome Methylation And Epigenomics), Public Health And Health Services, Aboriginal And Torres Strait Islander Health, Biochemistry And Cell Biology, Bioinformatics	\$	991,506.00
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	The Council of the Queensland Institute of Medical Research	Medical Research Institute	QLD	Ensuring genetics based prediction of glaucoma can benefit all Australians	Glaucoma is the most common cause of irreversible blindness worldwide. Early diagnosis and treatment can save sight. Glaucoma is one of the most heritable diseases, and genetic profiling can predict people at risk of blindness. However, most of these genetic scores have been developed only in Europeans. We will collect data from Australians with different ancestry. We will then derive genetic tests to ensure early diagnosis and prevent blindness in all Australians, regardless of ancestry.	Professor Stuart Macgregor	Professor Stuart Macgregor, Doctor Puya Garashkhani, Professor Alex Hewitt, Doctor Thanh Nguyen, Professor David Mackey, Professor Keith Martin, Doctor Deus Bigrimina, Professor Jamie Craig, Associate Professor Owen Nigg, Doctor Sandra Staffieri, Mrs Annie Gibbins	Targeted competitive	1/06/2022	31/05/2024	Ophthalmology And Optometry	Ophthalmology And Optometry, Vision Science	\$	997,796.80
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of Melbourne	University	VIC	Perioperative Pharmacogenomic Testing (PPGs): A Feasibility and Randomised Controlled Pilot Study	Pharmacogenomics is the study of how genetic variations affect patients drug responses (good-bad). This exciting emerging area has the potential to personalise medicine, improve safety, recovery and comfort after surgery. This is an important but poorly studied area. We aim to determine if perioperative pharmacogenomic testing is practical and whether changing a patient's anaesthetic drugs based on this testing can improve their quality of recovery and reduce complications after surgery.	Professor Bernhard Riedel	Professor Bernhard Riedel, Professor Alexander Henrot, Doctor Michelle Gersman, Professor Andrew Somogyi, Professor Colin Royce, Professor Carl Kirkpatrick	Targeted competitive	1/06/2022	31/05/2024	Clinical Sciences	Clinical Sciences, Anaesthesiology	\$	355,255.20
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	Australian National University	University	ACT	High throughput validation of genomic variants in Indigenous Australians and their contribution to kidney and immune disease	Indigenous Australians have some of the highest rates of chronic kidney disease (CKD) in the world. It has been estimated that one of the greatest risks for the development of CKD in these communities is genetics. This project is a national collaboration to understand and prove the genetic basis contributing to high rates of CKD. Through understanding the unique and shared basis for CKD in indigenous communities across Australia, we can improve detection and treatment for these groups.	Doctor Simon Jiang	Doctor Simon Jiang, Mrs Azure Hermes, Rakesh Pandey, Doctor Aron Chakera, Doctor Thomas Andrews, Doctor Vasi Athanasopoulos, Doctor Madhavan Sundaram	Targeted competitive	1/06/2022	31/05/2024	Clinical Sciences	Clinical Sciences, Nephrology And Urology	\$	975,502.80
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	The University of Queensland	University	QLD	Preparing Australia for use of genomics in prevention of heart-disease: Focus on South Asian Australians	Heart disease burden is higher in South Asians, but as they are under-represented in research studies, heart disease risk tools (used by GPs to identify high-risk individuals) underestimate risk in S.Asians. Newer risk tools that include genetic data are already being trialled in Australia, making it crucial to work towards an inclusive approach to disease prevention. Aim: Develop a culturally-sensitive framework for increasing participation of S.Asians in future health and genomics research.	Doctor Sonia Shah	Doctor Sonia Shah, Doctor Tatiane Yanes, Professor Katharine Walks, Doctor Rohan Maria Villan, Associate Professor Divya Mehta, Professor Julie McLaughlan, Professor Naomi Wray, Professor John Althorn, Professor Kim Kimura, Mr David Bunker, Doctor Heena Akbar, Ms Anjali Henderson	Targeted competitive	1/06/2022	31/12/2024	Genetics	Genetics, Genomics	\$	928,898.92
Global Health	2017 Antimicrobial Resistance Targeted Call For Research	Monash University	University	VIC	Stepped-wedge Trial to increase antibiotic Appropriateness in Residential aged care facilities and model Transmission of antimicrobial resistance (The START Research Program)	Residential aged care facilities (RACFs) represent a challenging and unique environment with significant drivers for the emergence and propagation of AMR. Our research to date has been instrumental in defining antimicrobial use and prescribing practices in Australian RACFs, including important barriers to antimicrobial stewardship and the prevalence of antimicrobial resistance. Our research directly led us to publish a "Case for Action" on "Antimicrobial Usage in Residential Aged-care facilities" accepted by the NHMRC Research Translation faculty in 2015. The critical unmet need defined in this case for action form the key elements of this call for research. Our multidisciplinary team will deliver on three key outcomes through the design and implementation of a multicentre, nurse-led antimicrobial intervention in a broad RACF network across multiple states in Australia. This intervention will be assessed using a stepped-wedge, cluster randomised controlled trial, with broad implications for practice and policy change. We will also study resident movement to and from RACFs using detailed network analyses, and characterise the spread of AMR organisms and resistance gene elements through use of advanced genomic and metagenomic technologies. We will use innovative methodologies to model AMR transmission that will be applicable to multiple settings, and by embedding these analyses within a randomised intervention trial, we will quantify the impact of improved antimicrobial use on AMR transmission in Australian RACFs.	Professor Anton Peleg	Professor Anton Peleg, Professor Terrence Haines, Professor Allen Cheng, Associate Professor Trisha Peet, Professor Kathryn Holt, Professor Sarah Milmer, Professor Yun-Hee Jeon, Associate Professor Andrew Stewardson, Doctor Tim Spelman	Restricted competitive	20/06/2018	31/12/2023	Clinical Sciences	Infectious Diseases	\$	1,826,398.82
Global Health	2017 Antimicrobial Resistance Targeted Call For Research	South Australian Health and Medical Research Institute Limited	Medical Research Institute	SA	Using metagenomics and the Registry of Ageing South Australians to understand carriage and transmission of antimicrobial resistance in the elderly	The GRACE study will address critical knowledge gaps in relation to antimicrobial resistance (AMR) in the residential aged care environment. Using a metagenomics-based strategy it will provide a comprehensive and highly detailed analysis the AMR dispersal in aged care residents, determine risk factors for carriage of resistant microbes, and identify modes of transmission. It will provide a basis for the development of specific strategies to limit the burden of resistant organisms in the residential aged care population, as well as a foundational assessment of the leading technology for long-term AMR surveillance. The study cohort will comprise of aged care residents, including those with cognitive impairment, across multiple sites in South Australia. Specifically, the study will address five fundamental questions: 1. What factors determine the types and levels of AMR carried by residents? 2. To what extent is there evidence of AMR transmission between residents? 3. Is interaction with RACF built environment likely to facilitate AMR transmission? 4. Do hospital visits for acute care significantly influence types and levels of AMR carriage? 5. To what extent do ageing-associated changes in gut microbiology influence AMR carriage?	Associate Professor Geraint Rogers	Professor Geraint Rogers, Professor Steven Wesseling, Professor David Gordon, Professor Maria Crotty, Associate Professor Maria Inacio, Associate Professor Craig Whitehead, Professor David Lynn, Professor Richard Woodman, Doctor Lito Papanicolas, Doctor Lex Leong	Restricted competitive	21/06/2018	31/12/2021	Medical Microbiology	Medical Bacteriology	\$	1,731,373.66
Global Health	2017 Antimicrobial Resistance Targeted Call For Research	The University of Queensland	University	QLD	Cluster randomised trial of a multimodal intervention to reduce antimicrobial use in residential aged care facilities	Antibiotic resistant Enterobacteriaceae have considerable health importance. Chief Investigators Paterson and Harris have just completed enrolment in the largest randomized controlled trial (RCT) yet performed on treatment options for priority 1 pathogens (Harris, 2015). In this 380 patient RCT on bloodstream infections for ESBL producing Enterobacteriaceae, the overall 30-day mortality was 7.6%. This approaches the 8% in-hospital mortality observed in patients presenting to hospital with acute myocardial infarction, emphasizing the significance of this infection. Mortality from infection with multidrug-resistant organisms in patients admitted to hospital from residential aged care facilities (RACFs) is likely to be even higher. With this background, the aim of this project is: To determine the prevalence of infection and colonisation with Multi-Drug Resistant (MDR) organisms (in particular, carbapenem resistant or ESBL-producing Enterobacteriaceae) in Brisbane RACFs; By molecular analysis, to determine the mechanisms of resistance and modes of spread of MDR organisms to and from RACFs and tertiary care hospitals; To determine if a multifaceted intervention reduces antibiotic use in RACFs.	Professor David Paterson	Professor David Paterson, Professor Len Gray, Professor Mark Schelenz, Professor Ruth Hullbard, Associate Professor Christopher Freeman, Ms Elaine Pascoe, Doctor Patrick Harris, Doctor Nancy Peel, Associate Professor Scott Beston, Doctor Ellen Burkett	Restricted competitive	26/06/2018	31/12/2023	Clinical Sciences	Infectious Diseases	\$	1,199,975.86
Global Health	2017 Antimicrobial Resistance Targeted Call For Research	University of South Australia	University	SA	Turning antimicrobial resistance in residential aged care inside-out from the patient to facility level	The WHO has identified drug-resistant bacterial infections as a global public health threat that needs urgent attention. Vulnerable populations are those such as residents in aged care facilities with contributing factors of aged-related physiology, underlying chronic conditions and the dense cohabitation. Infections are often difficult to diagnose due to co-morbidities and lack of on-site diagnostics, resulting in compromised antimicrobial stewardship and high levels of inappropriate antibiotic use. Hence residential aged care facilities (RACFs) are known reservoirs for antimicrobial resistance (AMR). Further, wastewater generated by these facilities contains high levels of pharmaceutical pollutants, thereby providing a hotspot of AMR selective pressure and resistance transfer to the environment. However, information about the extent of AMR in aged care, as well as the risk factors that contribute to the development and dissemination of AMR, are lacking. In this project we are using a multipronged One Health surveillance approach to provide much needed information on AMR in RACFs. Our study is underpinned by an extensive sampling regime that include the residents, the facilities and the wastewater generated by the facilities. The metatranscriptome of the samples are determined and combined with phenotypic and genotypic analysis of a biobank of organisms isolated from these samples. A survey of antibiotic/drug use in the RACF and chemical analysis of the wastewater further complements the data obtained. Participating RACFs were selected to provide a good coverage of variables (i.e. residency status, underlying devices and co-morbidities) and to allow the comparison between RACFs with/without antimicrobial stewardship programmes. Combined, this data will enable robust multivariate analysis of AMR risks associated with key system variables. These models will then be used to inform AMR risk assessments and guide future policy controls to curb the spread of AMR to, within and from RACFs. To our knowledge this is the only study of its kind to encompass such an extensive analysis of multiple factors contributing to the development and dissemination of antimicrobial resistance in aged care.	Doctor Henrietta Venter	Associate Professor Henrietta Venter, Professor John Turnidge, Doctor Michael Short, Professor Enzo Lombi, Doctor Guy Abel, Doctor David Roser, Professor Elizabeth Roughhead, Associate Professor Kay Price	Restricted competitive	26/06/2018	31/12/2023	Medical Microbiology	Medical Bacteriology	\$	1,142,251.65
Global Health	2017 National Security Against Pandemic Risk	Coalition for Epidemic Preparedness Innovations	Corporation	UK	National Security Against Pandemic Risk Program	Coalition for Epidemic Preparedness Innovations provides a dedicated source of predictable funding that will fuel an 'end-to-end' approach to vaccine development. Coalition for Epidemic Preparedness Innovations will do so by focusing on essential gaps in product development due to market failure. The initial focus will be to move new vaccines through development from pre-clinical to proof of principle in humans and the development of platforms that can be used for rapid vaccine development against unknown pathogens before an epidemic begins. Australia is well placed to become a regional Coalition for Epidemic Preparedness Innovations hub for this work and this contribution will provide a foothold in the program for future researcher engagement with the Coalition for Epidemic Preparedness Innovations agenda.	Not applicable	Not available	One-off/ad hoc	26/06/2018	31/03/2019	Not available	Not available	\$	2,000,000.00

Global Health	2019 Tackling Antimicrobial Resistance and Drug Resistant Tuberculosis in Pacific Island Countries	Burnet Institute	Medical Research Institute	VIC	Comprehensive community-based solutions to reduce MDRI transmission in a high incidence setting	Daru Island in Papua New Guinea (PNG) is the site of an unprecedented outbreak of drug-resistant tuberculosis. Our team has been working in partnership with PNG institutions and the local community with Australian government support to research this pressing health issue. Our proposed research seeks to implement a community-wide, comprehensive intervention to detect, treat and prevent tuberculosis and to determine its effectiveness in reducing the severity of this drug-resistant outbreak.	Professor Stephen Graham	Professor Stephen Graham, Doctor Suman Majumdar, Doctor Philipp DuCros, Doctor Gene Huang, Mr Geoffrey Chan, Doctor Jane Greig, Professor Leanne Robinson, Doctor Rowan Martin-Hughes	Targeted competitive	1/06/2020	31/05/2025	Public Health And Health Services	Preventive Medicine	\$	2,508,422.77
Global Health	2019 Tackling Antimicrobial Resistance and Drug Resistant Tuberculosis in Pacific Island Countries	University of Melbourne	University	VIC	Rapid detection of drug resistant tuberculosis using real-time sequencing	One of the major challenges in combating the tuberculosis epidemic in Papua New Guinea is rapid, affordable identification of drug resistance in order to ensure that appropriate treatment regimen is established early in the course of the disease. Unnecessary use of the latest line of anti-tuberculosis WHO class 5 drugs leads to the development of drug resistance, while use of drugs to which the bacterium is resistant leads to prolonged treatment and exposure of family members, leading to greater rates of transmission and increased mortality. Currently, rapid identification of rifampicin resistance has been made possible in-country through Gene-Xpert; however full characterisation of drug resistance is currently done out-of-country and takes months before results are known. It is possible to generate highly accurate predictions of drug resistance for many TB drugs from whole-genome sequencing; however, this is typically achieved by first culturing the bacterial isolate over several weeks. Real-time nanopore metagenomic sequencing is promising, but is prohibitively expensive due to the very small proportion of mycobacterial to human DNA in sputum. We have developed nanoparticles which can enrich mycobacterium directly from biological sample. We propose to use these nanoparticles in conjunction with real-time nanopore sequencing and streaming bioinformatics to characterise drug resistance in Papua New Guinea.	Professor Lachlan Coin	Professor Lachlan Coin, Doctor Rendi Moke, Doctor Arnold Banomigisa, Doctor Mark Blaskovich, Doctor Sanjaya KC, Professor Matthew Cooper	Targeted competitive	1/06/2020	31/07/2024	Medical Microbiology	Medical Bacteriology	\$	784,966.72
Global Health	2019 Tackling Antimicrobial Resistance and Drug Resistant Tuberculosis in Pacific Island Countries	University of Melbourne	University	VIC	Preparing Fiji for Pathogens with Critical Antimicrobial Resistance	This project will assess the capacity for hospitals in Fiji to manage outbreaks of pathogens with critical antimicrobial resistance. Baseline assessments will be made, then a program will be developed and implemented to ensure that hospitals are ready for these extreme challenges. The program will include use of cutting edge technology such as microbial genomics linked to epidemiology to help understand and contain any transmission of pathogens.	Professor Kirsty Buising	Professor Kirsty Buising, Professor Deborah Williamson, Professor Karin Thunsky, Professor Richard Snugnell, Associate Professor Nolen Bennett, Doctor Razi Naidu, Associate Professor Caroline Marshall, Associate Professor Leon Worth, Ms Ashdra Gautam, Ms Courtney Lane	Targeted competitive	1/06/2020	30/09/2023	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	823,055.25
Global Health	2019 Tackling Antimicrobial Resistance and Drug Resistant Tuberculosis in Pacific Island Countries	University of Sydney	University	NSW	Pathway to the Elimination of Antibiotic-Resistant Tuberculosis in the Pacific	Tuberculosis (TB) is the leading infectious disease killer on the planet. Urgent action is required to mitigate the threat of drug resistant (DR) TB in the Pacific, especially in TB hotspots such as Kiribati. Tarawa, the Kiribati capital, is one of the most densely populated places in the Pacific, with potential to act as a national/regional amplifier of the TB/DR-TB epidemic. If TB transmission is not interrupted, Tarawa is unlikely to implement a bold 'whole of population' TB elimination strategy. The overall project aims are to: 1) evaluate the effect of a community-wide active case finding program upon TB transmission and case notification in Tarawa, 2) provide Pacific-wide training and mentoring to improve DR-TB care and prevention, and 3) model the long-term cost-effectiveness and impact of different population-based elimination strategies, using data from Tarawa and other Pacific settings to inform regional and global TB control policy.	Professor Barend Marais	Professor Barend Marais, Emeritus Professor Warwick Britton, Professor Guy Marks, Professor Gregory Fox, Ms Amanda Christensen, Associate Professor Bernadette Saunders, Associate Professor James Trauer, Doctor Kerri Viney	Targeted competitive	1/06/2020	31/05/2025	Medical Microbiology	Medical Bacteriology	\$	4,248,555.26
Indigenous Health Research Fund	2019 Accelerated Research - Rheumatic Heart Disease	University of Western Australia	University	WA	Accelerating Development of a Group A Streptococcal Vaccine	This project will result in a Phase 2b efficacy trial of a Group A Streptococcus vaccine within 5 years. It will position Australia as the international leader in GAS vaccine development for the world. It will also attract benefits to Australia that, at a minimum, would include considerations for early introduction of a GAS vaccine, but will likely include economic benefits such as preferential pricing, possible equity, and even a manufacturing base in Australia.	Not applicable	Not available	One-off/ad hoc	30/06/2019	30/06/2024	Not available	Not available	\$	35,000,000.00
Indigenous Health Research Fund	2019 Indigenous Health Research	South Australian Health and Medical Research Institute Limited	Medical Research Institute	SA	Ngalayaa Boorai Gabara Budbut - supporting the heads and hearts of children: Responsive mental health care for Aboriginal and Torres Strait Islander adolescents	Our work has established that there are two key barriers to quality mental health care for Aboriginal adolescents: inadequate assessment of needs, and inadequate response. In response, this project will: i) formally validate culturally appropriate mental health assessment tools; ii) co-design a package of training and resources targeting care providers to promote timely and responsive care; iii) implement and evaluate this package of resources to inform a scalable model.	Professor Ngare Brown	Professor Ngare Brown, Associate Professor Peter Azopardi, Professor Debra Rickwood, Doctor Gladieta Pearson, Professor George Patton, Associate Professor Mark Wentong, Professor Jane Fisher	Targeted competitive	1/06/2020	30/11/2023	Public Health And Health Services	Aboriginal And Torres Strait Islander Health	\$	1,997,344.00
Indigenous Health Research Fund	2019 Indigenous Health Research	Flinders University	University	SA	Aboriginal Community-Led Diabetic Retinopathy Prevention: An Innovative Model of Eye Care for Understanding Risk and Early Detection	Diabetic retinopathy (DR) is a common cause of blindness among Aboriginal communities. Incomplete understanding of who's at risk, and poor access to screening and treatment programs is likely contributing. We will co-design a model of eye care that considers specific Aboriginal community need, identify eye care gaps, explore what factors cause DR blindness, implement new strategies that increase DR screening and treatment rates, and support Aboriginal people/systems that make this possible.	Professor Jamie Craig	Professor Jamie Craig, Doctor Tim Henderson, Doctor Natasha Howard, Associate Professor John Landers, Associate Professor John Vejjans, Doctor Justin Canuto, Mr Kurt Towers, Doctor Stewart Lake, Ms Kerri Reilly, Mr Jose Estevez	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Aboriginal And Torres Strait Islander Health	\$	1,436,870.80
Indigenous Health Research Fund	2019 Indigenous Health Research	Macquarie University	University	NSW	Improving care pathways for Otitis Media in Aboriginal children (0-12): A case study approach	Persistent and pervasive middle ear disease in Aboriginal children has life-long effects on health, education, employment and social and emotional well-being. While considerable funding, goodwill and the fundamental building blocks have been in place for many years, the success of programs has been limited. The study aims to explore the reasons for this, and to co-design, implement and evaluate an alternative approach to addressing this major public health problem.	Professor Catherine McMahon	Professor Catherine McMahon, Professor Elizabeth Pellicano, Mr Boe Rumboldi, Doctor Kylie Gwynne, Ms Samantha Harfous, Doctor Leanne Holt, Professor Harvey Coates, Doctor Neil Orr, Professor Andrew Smith, Doctor Liesa Clague	Targeted competitive	1/06/2020	31/05/2023	Other Medical And Health Services	Medical And Health Services Not Elsewhere Classified	\$	1,961,473.90
Indigenous Health Research Fund	2019 Indigenous Health Research	The University of Queensland	University	QLD	What Matters to Aboriginal and Torres Strait Islander Adolescents' Wellbeing: Developing a wellbeing measure for adolescents (WMJA Project)	This project will fill a critical gap in understanding the factors that are important to Indigenous adolescents' wellbeing. Based on these views and experiences, we will develop a national culturally relevant wellbeing measure. This new measure can be used in a range of mental health, health and education settings to increase transparency, responsiveness and relevance of clinical and health policy decision making to improve adolescent mental health and wellbeing.	Professor Gail Garvey	Professor Gail Garvey, Associate Professor Michelle Dickson, Professor Kirsten Howard, Professor Yvonne Cades James, Professor Rosanne Bainbridge, Doctor Darren Garvey, Professor Ioan Cunningham, Professor Patrick McGorry, Doctor Anna Williamson, Doctor Tamara Butler	Targeted competitive	1/06/2020	30/11/2023	Public Health And Health Services	Aboriginal And Torres Strait Islander Health	\$	1,896,841.30
Indigenous Health Research Fund	2019 Indigenous Health Research	Monash University	University	VIC	Reducing the burden of chronic kidney disease in the indigenous population - the PROPHETCKD study	Kidney disease is a major clinical problem in the Indigenous population particularly those with diabetes who often require dialysis or transplantation. This grant will further define the risk and rate of progression of kidney disease in a well characterised indigenous population from South Australia. Furthermore, promising new drugs already shown to protect the kidney in other populations will be tested in order to reduce the burden of kidney disease in Indigenous Australians	Professor Mark Cooper	Professor Mark Cooper, Ms Kim Morey, Professor Paul Zimmet, Mr Ricky Menta, Professor Karin Jandell-Dahm, Professor Assam El-Osta, Professor Stephen McDonald	Targeted competitive	1/06/2020	31/05/2023	Clinical Sciences	Nephrology And Urology	\$	1,995,895.00
Indigenous Health Research Fund	2019 Indigenous Health Research	University of Sydney	University	NSW	ACCESS: Aboriginal Community Controlled Ear health Support System: developing, embedding and evaluating best practice models of care	ACCESS is the result of a 16 year partnership between Aboriginal Community Controlled Health Services, health researchers, Aboriginal children, families and communities in NSW. ACCESS will enable the development, embedding and evaluation of a culturally safe Aboriginal Child Health Navigator service. This will form part of a comprehensive ear-health prevention and treatment model of care designed to be transferable to other Aboriginal services and translatable to other health conditions.	Associate Professor Hasantha Gunasekera	Associate Professor Hasantha Gunasekera, Mr Darryl Wright, Associate Professor Susan Woolforden, Mr Jamie Newman, Ms Sandra Bailey, Doctor Kathleen Falster, Professor Emily Banks, Professor Jonathan Craig, Professor Juanita Sherwood, Professor Armando Teixeira-Pinto	Targeted competitive	1/06/2020	30/11/2023	Paediatrics And Reproductive Medicine	Paediatrics	\$	887,186.00
Indigenous Health Research Fund	2019 Indigenous Health Research	University of New South Wales	University	NSW	Enabling Dads and Improving Indigenous Adolescent Mental Health	If men feel informed and empowered in their parenting, this will have a beneficial effect on the mental health of their adolescent children. Our aim is to apply a manualised, empirically rigorous and sustainable parenting intervention for Aboriginal and Torres Strait Islander men with the focus on improving the mental health of adolescents. We will test our ground-breaking intervention in 5 remote Aboriginal communities, where there is an urgent need to support adolescent mental health.	Associate Professor Susan Rees	Professor Susan Rees, Mr Lyndon Reilly, Doctor Mick Adams, Professor Derrick Slove	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Aboriginal And Torres Strait Islander Health	\$	1,684,560.00
Indigenous Health Research Fund	2019 Indigenous Health Research	The University of Queensland	University	QLD	IMHIP-Youth: A multi-disciplinary collaboration to embed and evaluate a model of social and emotional wellbeing care for Indigenous adolescents who experience detention	The proposal is to adapt, implement and evaluate a culturally informed Indigenous led in-reach to detention (IMHIP-Youth). The evaluation of IMHIP-Youth uses the Ngaa-bi-na-yi Indigenous Program Evaluation Framework.	Associate Professor Edward Heffernan	Associate Professor Edward Heffernan, Associate Professor Megan Williams, Associate Professor Scott Harden, Professor James Scott, Doctor Michael Watson, Associate Professor Stephen Stathis, Professor Stuart Kinner, Doctor Carla Meurk, Doctor Megan Steele, Mr Gregory Pratt	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Aboriginal And Torres Strait Islander Health	\$	1,988,280.32
Indigenous Health Research Fund	2019 Indigenous Health Research	The University of Queensland	University	QLD	Co-designed sleep health program to achieve better sleep and improved mental health symptoms in Indigenous adolescents	We will co-design and deliver a sleep health program for Indigenous adolescents and evaluate its feasibility, acceptability and effectiveness. This program is rooted in the Indigenous conceptualisation of sleep health, capacity building of Aboriginal youth workers and bringing together Indigenous community, mental health and primary care services, and advocacy partners to co-design a solution for improving the mental health of indigenous adolescents through healthy sleep.	Doctor Yagoot Fatima	Doctor Yagoot Fatima, Associate Professor Abdullah Maman, Professor Timothy Sloneer, Professor Romola Bucks, Professor Sarah Blunder, Doctor Stephanie Yiallouros, Professor Simon Smith, Professor Lisa McDavid	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Mental Health	\$	586,961.00
Indigenous Health Research Fund	2020 Indigenous Health Research	The University of Adelaide	University	SA	Working with Aboriginal families and health and social service providers to assess the feasibility of a novel care package to reduce cannabis and alcohol use and social stress in pregnancy	Aboriginal communities in South Australia have consistently said, they seek support to address harmful effects of cannabis and alcohol use and stress in pregnancy. This study will work with families and health and social service providers to co-design a culturally-responsive care package to improve women and their partner to address these issues. The study will generate new knowledge about the feasibility and acceptability of the package in two Aboriginal antenatal clinics in two hospitals to inform broader implementation.	Doctor Yvonne Clark	Doctor Yvonne Clark, Ms Karen Glover, Associate Professor Alice Rumboldi, Professor Stephanie Brown, Doctor a culturally-responsive care package to improve women and their partner to address these issues. The study will generate new knowledge about the feasibility and acceptability of the package in two Aboriginal antenatal clinics in two hospitals to inform broader implementation.	Targeted competitive	1/06/2021	31/08/2023	Public Health And Health Services	Aboriginal And Torres Strait Islander Health	\$	675,286.00
Indigenous Health Research Fund	2020 Indigenous Health Research	University of New South Wales	University	NSW	Understanding how cultural resilience impacts Aboriginal health & quality of life	The overall aim of this project is to strengthen cultural responsibility within regional health systems in NSW, by obtaining a measured and qualitative understanding of how existing cultural resilience initiatives impact health. The project will collaborate with Aboriginal Community Controlled Health Services in three regions to build a Model of Cultural Resilience, with the broader objective of translating this knowledge into a policy framework targeting institutional transformation.	Doctor Anyati Yashadhana	Doctor Anyati Yashadhana, Professor Evelyne de Lencoe, Doctor Brett Biles, Doctor Jonathan Kingsley, Mr Ted Fields, Ms Wendy Jopson, Professor Anthony Zwi, Doctor Margaret Raven, Mr Darren Green, Associate Professor Stephanie Topp	Targeted competitive	1/06/2021	31/05/2024	Public Health And Health Services	Aboriginal And Torres Strait Islander Health	\$	560,209.30

Indigenous Health Research Fund	2020 Indigenous Health Research	University of Sydney	University	NSW	Understanding the contribution of Aboriginal and Torres Strait Islander culture and wellbeing to health: Implementation of the What Matters 2 Adults wellbeing measure	The What Matters 2 Adults measure (WM2Adults) is a new wellbeing measure grounded in the values and preferences of Australia's First Peoples. We will implement WM2Adults, with the Cancer Institute NSW and cancer services, to determine the best way of using WM2Adults in clinical care to measure and address patients' wellbeing needs. This project will guide broad, evidence-based implementation of WM2Adults and improve understanding of the contribution of culture and health to wellbeing.	Professor Kirsten Howard	Professor Kirsten Howard, Professor Gail Garvey, Associate Professor Michelle Dickson, Doctor Kate Anderson, Professor David Roder, Robyn Martin, Mr Brendon Calmore, Jackie Jackson, Mr Nathan Jones, Professor David Carrow	Targeted competitive	1/06/2021	31/10/2023	Public Health And Health Services	Aboriginal And Torres Strait Islander Health	\$	998,036.60
Indigenous Health Research Fund	2020 Indigenous Health Research	University of Melbourne	University	VIC	Healing the Past by Nurturing the Future: Trauma-integrated perinatal care to improve health outcomes for Indigenous parents and infants in a rural setting	Indigenous communities are affected by complex trauma. The parenting transition is a critical life-course opportunity for 'healing the past by nurturing the future'. This Indigenous-led demonstration study builds rigorous evidence for the rural healthcare setting. We aim to develop, implement and evaluate the acceptability, feasibility, costs and preliminary effectiveness of providing trauma-informed primary care for rural Indigenous parents experiencing complex trauma to improve wellbeing.	Associate Professor Catherine Chamberlain	Associate Professor Catherine Chamberlain, Doctor Caroline Atkinson, Professor Helen Herman, Associate Professor Sandra Campbell, Associate Professor Raymond Lovett, Doctor Justin Canuto, Professor Lesnie Legall, Doctor Javine Mohamed, Doctor Michel McMahon, Doctor Elise Davis	Targeted competitive	1/06/2021	31/05/2025	Public Health And Health Services	Aboriginal And Torres Strait Islander Health	\$	1,499,041.20
Indigenous Health Research Fund	2020 Indigenous Health Research	University of Sydney	University	NSW	VOICE - Validating Outcomes by Including Consumer Experience: Developing a Patient Reported Experience Measure for Aboriginal and Torres Strait Islander people accessing primary health care	With strong Aboriginal and Torres Strait Islander leadership in all stages of development and implementation, the VOICE project will develop and validate an Indigenous-specific Patient Reported Experience Measure (PREM) for the primary health care (PHC) sector that is suitable for use in comprehensive PHC services, reflects the values and world views of Aboriginal and Torres Strait Islander people, and is consistent with the principles of Indigenous Data Sovereignty.	Associate Professor Megan Passy	Associate Professor Megan Passy, Ms Emma Walke, Professor Roxanne Bainbridge, Professor Ross Baile, Doctor Bronwyn Silver, Professor Sarah Larkins, Associate Professor Catrina Felton-Busch, Doctor Paul Burgess, Doctor Veronica Matthews, Erha Langham	Targeted competitive	1/06/2021	31/08/2025	Public Health And Health Services	Aboriginal And Torres Strait Islander Health	\$	1,430,917.85
Indigenous Health Research Fund	2020 Indigenous Health Research	The Sax Institute	Corporation	NSW	Indigenous Led Evaluation of Aboriginal Programs (ILEAP)	Aboriginal Community Controlled Health Services (ACCHS) offer innovative, culturally appropriate primary care programs to improve the health of Aboriginal people. These programs are rarely evaluated, resulting in little evidence of their effectiveness. This project will build evaluation capacity in the ACCHS sector and provide urgently needed evidence about what works in priority health areas: Aboriginal youth suicide and adult chronic disease by evaluating 3 ACCHS designed and led programs.	Ms Sandra Bailey	Ms Sandra Bailey, Mr Darrel Wright, Mr Jamie Newman, Mrs Christine Corby, Professor Timothy Usherwood, Doctor Anna Williamson, Doctor Michelle Bovill, Doctor Alice Knight, Doctor Martin McLennan, Associate Professor Timothy Dobbin	Targeted competitive	1/06/2021	31/05/2024	Public Health And Health Services	Aboriginal And Torres Strait Islander Health	\$	1,499,251.70
Indigenous Health Research Fund	2021 Indigenous Health Research	The University of Adelaide	University	SA	A silver fluoride intervention to improve the life trajectories of Indigenous young people and reduce dental disease across the life course	Indigenous children and young people experience profound levels of preventable dental diseases. Severe cases frequently require care under a hospital-based general anaesthetic. We plan to arrest active dental disease in Indigenous children/adolescents through an intervention involving silver fluoride (AgF). AgF application is a much less invasive alternative to needles, and drilling and filling, with many cost-benefits. There is particular utility among Indigenous children in remote locations.	Ms Joanne Hedges	Ms Joanne Hedges, Mr Simon Cooney, Mr Roman Zwolski, Ms Priscilla Larkins, Doctor Murray Mitty, Associate Professor Sanjewa Kularatna, Mr James Newman, Associate Professor Rachel Roberts, Ms Zeli Dodd, Ms Rae Fee, Professor Lisa Jameson	Targeted competitive	1/06/2022	31/01/2028	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health	\$	3,208,372.40
Indigenous Health Research Fund	2021 Indigenous Health Research	Flinders University	University	SA	Child Protection Services in Health: Fostering community led solutions to minimise trauma and change trajectories of pregnant Aboriginal women, their children and their families	Aboriginal families have been negatively affected by the ongoing removal of children and suffer high levels of trauma, grief, and loss. Health and social services have systems of care driven by negative ideas about Aboriginal people, including pregnant women and their ability to parent. Our research, led by Aboriginal people, will look at SA data, how health and social services are delivered and work with community to make sure that services treat trauma, support families and are appropriate.	Associate Professor Tamara Mackean	Associate Professor Tamara Mackean, Doctor Rhianon Pilkington, Doctor Jacqueline Beall, Ms Karen Glover, Mrs Margaret McCullum, Doctor Dylan Mordaunt, Mr Duncan Langford Glass, Professor John Lynch, Ms Catherine Turnbull, Ms Tessa Kong, Doctor Courtney Ryder, Professor Jonathan Karon	Targeted competitive	1/06/2022	31/05/2027	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health, Public Health And Health Services, Epidemiology, Paediatrics And Reproductive Medicine, Obstetrics And Gynaecology	\$	2,297,754.60
Indigenous Health Research Fund	2021 Indigenous Health Research	South Australian Health and Medical Research Institute Limited	Medical Research Institute	SA	Co-Designing a Coordinated, Sustainable and Supportive Patient Navigator Program to Improve Kidney Health Outcomes	Aboriginal and Torres Strait Islander people rely on each other and networks across Country to feel safe in the Australian health system. For many important as treatment journey is complex, confusing, and often frightening. This project seeks the best ways to integrate Patient Navigators (people with lived experience of kidney disease) into our health system to provide safe care and better outcomes for Aboriginal and Torres Strait Islander kidney patients.	Ms Kelli Owen	Ms Kelli Owen, Kate Tynell, Doctor Samantha Bateman, Neil Wilshire, Celia Alley, David Crocker, Lachlan Ross, Ms Rhanea Testakos, Doctor Kim O'Donnell, Amy Graham, Associate Professor Shigunaj Joudanan, Professor Stephen McDonald, Ms Heather Hall, Peter Henwood, Doctor Janet Kelly	Targeted competitive	1/06/2022	31/08/2024	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health, Clinical Sciences Nephrology And Urology	\$	986,773.80
Indigenous Health Research Fund	2021 Indigenous Health Research	Flinders University	University	SA	Knowledge interface co-design of a diabetes and metabolic syndrome intervention with and for Aboriginal and Torres Strait Islander peoples living on Ngarrindjeri country	Diabetes is a national health priority in Australia, and Aboriginal people are significantly impacted by higher diagnosis, hospitalisation and death. The Cooring Diabetes Collaborative will change these terrible health impacts through a newly developed program to reverse diabetes. We will do this with local Aboriginal people, health professionals, doctors, experts on holistic eating and on ways to measure this. Aboriginal people will trial the program for evaluation and uptake in Australia.	Doctor Courtney Ryder	Doctor Courtney Ryder, Mr Darrel Cameron, Joseph Wang, Doctor Shahid Ullah, Cathi Kerigan, Associate Professor Billingsley Kaambwa, Doctor Brooke Speth, Sharon Perkins, Stephen Stranks, Professor Paul Worley, Doctor Annabelle Wilson	Targeted competitive	1/06/2022	31/05/2024	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health	\$	756,621.00
Indigenous Health Research Fund	2021 Indigenous Health Research	James Cook University	University	QLD	Strong Community, Strong Health: Exploring opportunities for chronic disease prevention in the Torres Strait	Chronic disease represents a significant risk to the health and wellbeing of Australia's First Nations peoples. This project will partner with Torres Strait communities to co-develop diet and activity tools and map enablers and barriers to health in the Torres Strait. This project will address gaps in information about diet and physical activity practices of people living in the Torres Strait, raise awareness in communities of chronic disease risks, and inform future interventions.	Professor Edward Strivens	Professor Edward Strivens, Doctor Yvonne Homby-Turner, Doctor Kathryn Meldrum, Ms Melissa Kilburn, Doctor Gavin Miller, Professor Ray Mahoney, Betty Jaggi, Professor Sarah Larkins, Mrs Rachel Quigley, Doctor Karla Canuto, Doctor Dymna Leonard, Mr Torres Webb, Associate Professor Sarah Russell, Doctor Sean Taylor, Mrs Yvonne Wallace	Targeted competitive	1/06/2022	31/05/2024	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health, Public Health And Health Services, Health Promotion, Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	473,642.00
Indigenous Health Research Fund	2021 Indigenous Health Research	The University of Queensland	University	QLD	Type 2 diabetes prevalence and management in patients attending an Aboriginal and Torres Strait Islander Health Service in Southeast Queensland over a twelve-year period: factors associated with good management and low risk of hospitalisation	Statistics show that by 55 years of age, at least one in three Indigenous Australians will have diabetes. Diabetes can cause serious heart and kidney problems for which people need to go to hospital, but there are ways to reduce the risk of having such problems. We aim to learn if the Inala Indigenous Health Service can do better for people with diabetes. We also would like to know if the number of people developing diabetes is increasing, and if more resources are needed to prevent diabetes.	Associate Professor Federica Barzi	Associate Professor Federica Barzi, Doctor Prabha Lakshmi, Mr Stephen Harfield, Professor Noel Hayman, Professor James Ward, Associate Professor Geoffrey Spurling, Professor Anthony Russell	Targeted competitive	1/06/2022	31/05/2024	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health, Public Health And Health Services, Primary Health Care, Statistics, Biostatistics	\$	392,285.00
Indigenous Health Research Fund	2021 Indigenous Health Research	Menzies School of Health Research	Medical Research Institute	NT	Examining the impact of extreme temperature on primary healthcare services utilisation in remote Central Australia to inform adaptation strategies	There is limited information on the impact of extreme hot weather on remote clinic utilisation. This project aims to generate an evidence base on the impact of exposure to extreme heat on primary health care service utilisation in Central Australia. This evidence will inform the collaborative development of adaptation strategies by communities and the primary health care sector to reduce the impacts of extreme temperatures on health outcomes.	Professor John Wakeman	Professor John Wakeman, Associate Professor Linda Ford, Doctor Mohammad Radwanur Talukder, Doctor Supriya Mathew, Associate Professor Kerstin Zander, Doctor Abdulvalibagh Baghinian, Doctor Sophie Pascoe, Doctor Deborah Russell	Targeted competitive	1/06/2022	31/05/2024	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health, Public Health And Health Services, Environmental And Occupational Health And Safety, Public Health And Health Services, Primary Health Care	\$	480,027.60
Indigenous Health Research Fund	2021 Indigenous Health Research	Curtin University	University	WA	Improving coverage, confidence and knowledge about COVID-19 vaccination among Aboriginal Women of child-bearing age in Western Australia	This Aboriginal-led research aims to improve the COVID-19 vaccination program for Aboriginal women in two Aboriginal health services in Western Australia. Appropriate access and effectiveness (via timely vaccine uptake) of COVID-19 vaccination for First Nations women of childbearing age during preconception, pregnancy and/or are breastfeeding in Western Australia is urgently needed.	Doctor Anne Eades	Doctor Anne Eades, Professor Julianne Coffin, Professor Sandra Eades, Doctor Samantha Carlson, Associate Professor Kate Attwell, Professor Christopher Blyth, Doctor Martyn Symons, Ms Lesley Nelson, Doctor Hui Ming Lu, Doctor Zoe Bradford, Tiana Cubong, Doctor Sharynne Hamilton	Targeted competitive	1/06/2022	31/05/2024	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health, Public Health And Health Services, Health Promotion, Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	805,458.80
Indigenous Health Research Fund	2021 Indigenous Health Research	University of Western Australia	University	WA	Building a Culturally Safe Mental Health System for Aboriginal and Torres Strait Islander Young People	Aboriginal and Torres Strait Islander young people face a disparity in mental health systems as these systems do not operate in a culturally safe way. We will establish evidence-based ways to improve cultural safety in mental health services for Aboriginal and Torres Strait Islander young people and their families. We will map child and family experiences in mental health services, and develop guidelines for those services to improve cultural safety.	Professor Helen Milroy	Professor Helen Milroy, Mr Michael Mitchell, Doctor Marshall Watson, Associate Professor Matthew Coleman, Professor Sean Hood, Professor Michael Small, Doctor Ais Woodard, Professor Anghel Lin, Professor Pat Dudgeon, Doctor Shradha Kashyap, Doctor Jemma Collova	Targeted competitive	1/06/2022	31/05/2024	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health, Public Health And Health Services, Mental Health	\$	713,520.00
Indigenous Health Research Fund	2021 Indigenous Health Research	The University of Queensland	University	QLD	Multidisciplinary co-design of innovative, client-centred models for Indigenous mental health services in South East Queensland	Longstanding mental health inequalities between Indigenous and non-Indigenous peoples exist in Australia. Our aim is to improve Indigenous clients' timely access to culturally appropriate, safe health care services for the prevention, treatment and management of mental health issues. We will co-produce new models of mental health care across community-controlled and mainstream services in ways that privilege the knowledges and lived experiences of Indigenous clients.	Professor Roxanne Bainbridge	Professor Roxanne Bainbridge, Mr Karva Watson, Ms Hayley Williams, Professor James Ward, Doctor Sandra Dominici, Doctor Alze Ferrari, Professor Yan Liu, Mr Randall Frazer, Mr Shea Spearing, Professor Harvey Whiteford, Associate Professor Shuchi Surtani	Targeted competitive	1/06/2022	31/05/2024	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health	\$	999,912.20
Indigenous Health Research Fund	2021 Indigenous Health Research	University of Technology Sydney	University	NSW	Our Wisdom, Our Ways supporting Aboriginal Women carers using a strengths based approach to the development of carer and clinician resources that support the carer to continue to care	First Nations women and Elders overwhelmingly bear the burden of care to their children, grandchildren, families and others. COVID-19 has placed significant stressor on First Nation women carers and those requiring care. Through this project we seek to develop, distribute and evaluate in partnership first time resources for carers and clinical teams supporting the mental health and wellbeing for First Nations women carers and Elders on Wiradjuri Country - Our Wisdom, Our Ways.	Associate Professor Faye McMillan	Associate Professor Faye McMillan, Miss Patricia Morris, Anna Gannon, Jane Havelka, Miss Ella Havelka, Mrs Lorraine Tye, Jasmine Williams	Targeted competitive	1/06/2022	30/11/2024	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health	\$	479,465.00
Medical Research Commercialisation	2017 BioMedTech Horizons Program (Round 1)	MTPConnect	Corporation	VIC	BioMedTech Horizons (Round 1)	The purpose of the BioTech Horizons Program is to provide a pathway to innovation, stimulating those discoveries in the first 'valley of death' along the research pipeline that have merit, but are struggling to progress past the proof-of-concept stage due to funding generally not being available. Initial investments will be in precision medicine and 3D anatomical printing. The BioTech Horizons Program is intended to build Australia's ability to move more cutting-edge ideas and breakthrough discoveries towards proof-of-concept and commercialisation. The Program will focus on the adoption of new technologies and solutions for health challenges.	Not applicable	Not available	One-off	27/10/2017	30/11/2021	Not available	Not available	\$	10,000,000.00
Medical Research Commercialisation	2018 Biomedical Translation Bridge	MTPConnect	Corporation	VIC	MTPConnect Biomedical Translation Bridge: Catalytic Partnerships Unlocking Commercialisation	This Program will support early stage innovative health and medical research conducted in Australia that is well positioned for development through to proof-of-concept.	Not applicable	Not available	Open competitive	18/02/2019	30/06/2022	Not available	Not available	\$	22,300,000.00
Medical Research Commercialisation	2019 BioMedTech Horizons Program (Rounds 2 & 3)	MTPConnect	Corporation	VIC	BioMedTech Horizons (Rounds 2&3)	BioMedTech Horizons (BMTH) is the Australian Federal Government's program that has committed \$35M to fund the proof-of-concept to commercial development of biomedical and medical technologies (biomedtech) and thereby positioned these technologies to attract private capital investment or achieve other commercial outcomes. The BMTH Program is being delivered as a part of the Australian Government's \$20B Medical Research Future Fund, which aims to transform health and medical research to improve lives, build the economy and contribute to health system sustainability through targeted strategic investment.	Not applicable	Not available	Ad hoc	29/03/2019	31/12/2022	Not available	Not available	\$	35,000,000.00

Medical Research Commercialisation	2020 Early Stage Translation and Commercialisation Support	MRFC Pty Ltd	Corporation	VIC	The MRCF's Commercialisation Incubator (#1)	The MRCF's Commercialisation Incubator (MRCF CI) will identify 20-25 promising early-stage Australian biomedical technologies, providing funding and hands-on expertise to guide development of these assets through to the point of investment or partnership-readiness. MRCF CI will provide an important bridge to overcome the existing funding gap in the early-stage biomedical ecosystem, addressing the need for translationally-focused funding, and also providing research teams with access to significant hands-on development, management, intellectual property and commercialisation expertise. The MRCF will assist successful projects in securing follow-on funding, helping them to grow into the next generation of Australian biomedical companies.	Doctor Chris Nave	Doctor Michael Bettess, Doctor Katherine Jackman, Doctor Ingrid Wahlqvist, Doctor Stephen Thompson, Doctor Chris Nave	Open competitive	30/06/2021	30/06/2024	Not available	Not available	\$	19,750,000.00
Medical Research Commercialisation	2020 Early Stage Translation and Commercialisation Support	MRFC Pty Ltd	Corporation	VIC	The MRCF's Commercialisation Incubator (#2)	The MRCF's Commercialisation Incubator (MRCF CI) will identify at least 11 clinical-stage novel therapeutic development programs, or novel drug repurposing programs, providing funding and hands-on expertise to guide development of these assets through to the completion of phase 1 clinical safety, or clinical proof-of-concept, studies positioning the SMEs to secure follow-on funding or partnering for continued clinical development and commercialisation. MRCF CI will provide funding capacity and clinical research teams with access to hands-on development, management, IP and commercialisation expertise. The MRCF will assist successful projects secure follow-on funding, helping them grow into the next generation of Australian biomed companies.	Doctor Chris Nave	Doctor Bob Soh, Doctor Melissa McBurnie, Doctor Prashanth Rajan, Doctor Melissa Byrne, Doctor Stephen Thompson, Doctor Chris Nave	Open competitive	30/06/2021	30/06/2024	Not available	Not available	\$	19,750,000.00
Medical Research Commercialisation	2020 Early Stage Translation and Commercialisation Support	MTPConnect	Corporation	VIC	MedVentures - Medical Devices Research Commercialisation Program	The Clinical Translation and Commercialisation - Medtech (CTC-M) Program, delivered through MTPConnect, will identify and develop high-quality medical device projects with commercial potential by supporting translation through early clinical development. Leveraging a track record of MRFF program execution, MTPConnect will deliver CTC-M with commercialisation partners the Medical Device Partnering Program, the Medical Technology Association of Australia, Cicada Innovations, infrastructure partner Therapeutic Innovation Australia and education partner Queensland University of Technology. CTC-M's program of interactive mentoring will provide SMEs with access to the expertise and infrastructure need for their projects to succeed.	Doctor Daniel Grant	Doctor Daniel Grant, Mr Stuart Dignam, Doctor Erin McAllium, Doctor Gerard Gibbs, Doctor Vishal Srivastava, Professor Karen Reynolds, Doctor Merrilyn Clancy, Doctor Dharmica Mishra, Professor Lyn Griffiths, Doctor Stuart Newman	Open competitive	30/06/2021	31/07/2025	Not available	Not available	\$	19,750,000.00
Medical Research Commercialisation	2020 Early Stage Translation and Commercialisation Support	ANDHealth Limited	Corporation	VIC	Delivering Research, Impact and Health Outcomes in Digital Health (DRIOD)	ANDHealth is Australia's only organisation dedicated to growing a world class digital health sector based on the development & commercialisation of evidence based, clinically proven digital health. DRIOD will fund the delivery of Australia's most successful digital health commercialisation program, ANDHealth, with "90% of MRFF funding directly invested into up to 25 selected SMEs via project funding and highly specialised support. SMEs will be further supported by industry development, leading resources and content creation as an annual event series, to ensure that the industry beyond selected SMEs continues to grow and that Australia's capacity and capability to undertake research in this increasingly important area is enhanced.	Ms Brownyn Le Grice	Ms Brownyn Le Grice, Ms Grace Leathan, Mr Damien Miller, Ms Claire Newstead-Sinclair, Doctor Annabel Tan, Ms Tayla Steckoll, Mr Max Streadler, Ms Rita Morgenstern, Doctor Chris Medli	Open competitive	30/06/2021	31/07/2025	Not available	Not available	\$	19,750,000.00
Medical Research Commercialisation	2021 BioMedTech Incubator	MRFC Pty Ltd	Corporation	VIC	The Brandon BioCatalyst and ANDHealth BioMedTech Incubator	The Brandon BioCatalyst and ANDHealth BioMedTech Incubator (BMTI) is a national program focused on accelerating the commercialisation of early-stage Australian life science technologies. The BMTI will identify at least 10 and up to 15 SMEs developing Australian biomedtech innovations. SMEs will be provided with access to investment capital, commercial guidance, international expert networks, and hands-on support and mentorship to drive the translation and commercialisation of new drugs, devices, diagnostics and digital technologies. In addition to program oversight, SMEs will be supported to secure follow-on funding and facilitate their continued development to ultimately improve patient outcomes and generate jobs and income for the sector.	Doctor Chris Nave	Doctor Chris Nave	Open competitive	Not available	Not available	Not available	Not available	\$	50,000,000.00
Million Minds Mental Health Research Mission	2018 Million Minds Mission	Curtin University	University	WA	Our Journey, Our Story: Building bridges to improve Aboriginal youth mental health and wellbeing	This project will implement and evaluate a culturally validated framework that harnesses the leadership of Aboriginal Elders and youth to alter the way mental health services work with and for Aboriginal youth and their families. Co-designed culturally secure ways of working will be implemented in youth mental health services so that more Aboriginal youth access mainstream services; services better meet needs; community perceptions of services improve, resulting in better health and wellness.	Associate Professor Michael Wright	Associate Professor Michael Wright, Professor Alex Brown, Professor Pat Dudgeon, Mr Rob McPhee, Professor Julianne Coffin, Mr Glenn Pearson, Associate Professor Ashleigh Lin, Doctor Elizabeth Newnham, Professor Elizabeth Gellhood, Ms King Barulev	Targeted competitive	1/06/2019	31/05/2024	Public Health And Health Services	Aboriginal And Torres Strait Islander Health	\$	2,459,030.00
Million Minds Mental Health Research Mission	2018 Million Minds Mission	Deakin University	University	VIC	Leveraging digital technology to reduce the prevalence and severity of eating disorders in Australia	Many individuals use social media rather than traditional treatments for their eating disorder (ED) related concerns. Unfortunately, social media about EDs is often inaccurate or intentionally pro-ED. Our project seeks to identify these at risk of EDs by the social media content they post, and offer proven treatment solutions for them. As our treatments are digitally based (i.e., on apps and web platforms), they may offer a scalable and cost-effective alternative to current treatment options.	Associate Professor Matthew Fuller-Tyskiewicz	Associate Professor Matthew Fuller-Tyskiewicz, Emeritus Professor Susan Paxton, Doctor Scott Griffiths, Doctor Sam McLean, Associate Professor Zali Yager, Associate Professor Rachel Rodgers, Professor Catherine Mihalopoulos, Professor Denise Meyer, Professor Alexandra Parker, Associate Professor Truyen Tran	Targeted competitive	1/06/2019	31/05/2024	Psychology	Health, Clinical And Counselling Psychology	\$	1,342,548.00
Million Minds Mental Health Research Mission	2018 Million Minds Mission	Monash University	University	VIC	The Kids are Not Okay: Emergency Department management of acute mental health crises in children and young people	There has been an alarming recent increase in emergency department (ED) mental health presentations (self-harm, depression, and behavioural disorders) by children and adolescents. Our research will help us understand why these high-risk vulnerable patients attend the ED, and their outcomes after discharge; test the effectiveness of a safety planning Smartphone app to manage suicidal thoughts; and determine the best medications to use for severe agitation and/or acute behavioural disturbance.	Professor Simon Craig	Professor Simon Craig, Professor Franz Babi, Associate Professor Glenn Melvin, Professor Katherine Lee, Professor Vicki Anderson, Professor Harriet Huzick, Associate Professor Rohan Borschmann, Associate Professor Michael Gordon, Professor Meredith Borland, Professor Kylie Gray	Targeted competitive	1/06/2019	31/05/2025	Clinical Sciences	Psychiatry (Incl. Psychotherapy)	\$	4,996,126.75
Million Minds Mental Health Research Mission	2018 Million Minds Mission	University of Melbourne	University	VIC	Bringing family, community, culture and country to the centre of health care: culturally appropriate models for improving mental health and wellbeing in Aboriginal and Torres Strait Islander young people	Our 5-year program will partner with Aboriginal young people, their families, community, and health services in WA and Victoria to design and test approaches that integrate mental health care with health, education and culture and embed connection to culture and country in usual care. We will add knowledge on suicide risk factors, and Aboriginal university students' wellbeing, train future leaders in youth mental health research and care and translate findings into policy and practice.	Professor Sandra Eades	Professor Sandra Eades, Professor Lena Sanci, Associate Professor Alastair Vance, Professor Shaun Ewen, Professor Emily Banks, Professor Jane Pirika, Associate Professor Daniel McAulay, Doctor Janet McGaw, Professor George Patton, Professor Cathrine Mihalopoulos	Targeted competitive	1/06/2019	31/05/2025	Public Health And Health Services	Mental Health	\$	4,998,863.80
Million Minds Mental Health Research Mission	2018 Million Minds Mission	University of Southern Queensland	University	QLD	Translating evidence-based interventions into population-level digital models of care for child and adolescent mental health	Anxiety, depression and substance use are common and problematic for many youth. Although effective treatments exist, very few young people receive help. This research translates knowledge about evidence-based practice into real world solutions that young people want to use, that are accessible, and low cost. This project examines the effectiveness of a digital, population-level model of care for delivering assessment and intervention to young people experiencing common mental health problems.	Associate Professor Sonja March	Professor Sonja March, Associate Professor Caroline Donovan, Professor Britt Klein, Professor David Kavanagh, Professor Alison Cleary, Associate Professor Vanessa Cobham, Professor Leanne Hides, Emeritus Professor Susan Spence, Associate Professor Lana Farrell, Doctor Sanjeeva Kularatna	Targeted competitive	1/06/2019	31/12/2024	Public Health And Health Services	Mental Health	\$	4,996,350.50
Million Minds Mental Health Research Mission	2018 Million Minds Mission	University of Sydney	University	NSW	MAINSTREAM Centre for Health System Research & Translation in Eating Disorders: detection and intervention system focused knowledge to drive better outcomes in mainstream care for eating disorders	Eating disorders impact over one million Australians and have an increased death rate. Historically there has been significant under-investment in treatment and research, which over the next decade will be reversed through unprecedented Medicare and state health investment. This project will equip the national health system with a platform to monitor early detection and intervention, assess the impact of new interventions, and develop scalable models of care for mainstream health settings.	Doctor Sarah Maguire	Doctor Sarah Maguire, Professor Stephen Touss, Professor Natasha Nassar, Doctor Michelle Cunich, Professor Ian Hickie, Professor Janice Russell, Associate Professor Suzanne Madden, Associate Professor Warren Ward, Ms Danielle Maloney, Ms Claire Duffey	Targeted competitive	1/06/2019	31/05/2024	Public Health And Health Services	Mental Health	\$	3,670,400.00
Million Minds Mental Health Research Mission	2018 Million Minds Mission	University of Western Australia	University	WA	Generating Indigenous patient-centred, clinically and culturally capable models of mental health care	The program will develop Indigenous mental health service models to support Indigenous access to, and the effectiveness of, clinical treatment and cultural healers in all service settings; support mainstream services to work better across cultural and experiential differences; and integrate mental health, alcohol and drug, suicide, and social and cultural support service responses through multidisciplinary teams. It will develop Indigenous-specific assessment tools for use in the models.	Professor Pat Dudgeon	Professor Pat Dudgeon, Professor Helen Milroy, Professor Jill Milroy, Professor Thomas Calma, Associate Professor Michael Wright, Doctor Graham Gee, Professor Shaun Ewen, Professor Sean Hood, Associate Professor Roz Walker, Professor Michael Small	Targeted competitive	1/06/2019	31/05/2024	Public Health And Health Services	Mental Health	\$	4,991,608.00
Million Minds Mental Health Research Mission	2019 Suicide Prevention	Murdoch Children's Research Institute	Medical Research Institute	VIC	Suicide prevention among men in early fatherhood: Determining the effectiveness of Working Out Dads, a group-based peer support intervention to reduce fathers' mental health difficulties compared to usual care	One of the highest rates of suicide among men coincides with a key life stage when many become fathers and are raising young children. Effective interventions to improve men's mental health during early fatherhood are an integral part of a comprehensive suicide prevention strategy to reduce the number of male suicides in Australia. This randomised controlled trial will determine the effectiveness, cost-effectiveness and scalability of the Working Out Dads (WOD) program, a suicide prevention intervention targeting men in early fatherhood. WOD is an innovative 6-week group-based peer support intervention to: (a) reduce fathers' mental health difficulties and suicidal ideation, (b) reduce barriers to help-seeking, (c) increase social support, and (d) reduce unmet need for mental health services. This real-world effectiveness trial will generate high quality evidence about a targeted suicide prevention intervention that can be implemented and scaled up in community-based services working with families of young children. This will provide greatly improved opportunities for early and effective provision of mental health care to men at risk of suicide in early fatherhood.	Associate Professor Rebecca Giallo	Associate Professor Rebecca Giallo, Doctor Amanda Cooklin, Professor Jan Nicholson, Doctor Liana Leach, Doctor Jimmah Ride, Professor Brian Oldenburg, Doctor Anna Grobler, Professor Stephanie Brown, Doctor Catherine Wood, Professor Craig Garfield	Targeted competitive	1/06/2020	31/10/2024	Public Health And Health Services	Mental Health	\$	951,918.00
Million Minds Mental Health Research Mission	2019 Suicide Prevention	University of Melbourne	University	VIC	Preventing suicide in boys and men	Males account for 75% of all suicides. Conformity to 'dominant' masculine norms like self-reliance is associated with reduced help-seeking in boys and men. If they do seek help, they often find that services are not well matched to their way of dealing with problems. This research will trial 5 interventions that are designed to encourage male help-seeking by challenging certain dominant masculine norms, and take the form of workshops, training and a media campaign delivered to men and boys where they 'mix, live and play'. It will also trial 2 additional interventions that are designed to ensure that if men and boys do seek help from providers like telephone crisis support workers and psychologists, these providers can offer services that meet their needs. The findings from the trials will then be used to inform a modelling exercise which identifies how effective and cost-effective interventions might be optimised, synthesised and scaled up.	Professor Jane Pirika	Professor Jane Pirika, Professor George Patton, Professor John Giffie, Professor Nicole Reasley, Professor Catherine Mihalopoulos, Professor Anthony LaMontagne, Associate Professor Simon Rice, Doctor Zac Sedler, Doctor Kylie King, Doctor Stewart Vella	Targeted competitive	1/06/2020	31/05/2025	Public Health And Health Services	Mental Health	\$	5,623,082.80

Million Minds Mental Health Research Mission	2019 Suicide Prevention	University of New South Wales	University	NSW	Developing a Comprehensive Care Pathway For those at Risk of Suicide But Not in Care: The Under the Radar Project	As many as 60% of those who die by suicide are not in care. Many are on the internet, and state this as their preferential route to seek help. This project aims to describe and understand this group in more depth, to outline their preferences for care, and to develop, with them, using the internet as the first point of contact, a collaborative, consumer-led, comprehensive care model that introduces digital, peer support and face to face services. The co-design process will include clinicians, peer support workers, policy and organisational leadership. Following this, the model will be evaluated relative to treatment as usual. Outcomes will be usability, value, effectiveness (relaxation, attempts, self-harm, suicide) and cost effectiveness.	Professor Helen Christensen	Professor Helen Christensen, Associate Professor Samuel Harvey, Professor Gregory Carter, Professor Sweeth Venkatesh, Professor Katherine Boydell, Professor Henry Cuffler, Professor Ian Kneebone, Associate Professor Toby Newton-John, Doctor Jin Han, Doctor Kit Huchvale	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Mental Health	\$	3,729,420.50
Million Minds Mental Health Research Mission	2020 Mental Health Research	University of Sydney	University	NSW	Growing Minds Australia- A National Trials Strategy to Transform Child and Youth Mental Health Services	We will establish Growing Minds Australia, a child and youth clinical trials network that improve methods for identifying signs of mental health problems in children and youth, identify non-responders to treatments and evaluate methods for addressing their ongoing needs; improve the focus on the physical health of MH problems, and improve access to evidence-based programs through a national approach to improving mental health literacy, and reducing stigma.	Professor Mark Dadds	Professor Mark Dadds, Professor Vicki Anderson, Emeritus Professor Bruce Tonge, Professor Katrina Williams, Professor Vakamma Eapen, Professor Philip Ward, Professor Melissa Green, Associate Professor David Hawes, Professor Michael Kohn, Professor Michael Sawyer, Associate Professor Kristin Laurens, Mr Stephen Hearns, Doctor Nick Kowalewko, Associate Professor Marie Yap, Professor Caroline Hunt, Professor Vaughan Carr, Peter Fonagy, Professor Elizabeth Elliott, Doctor Lucy Tully, Professor Kimberlie Dean, Professor Louisa Degenhardt, Jacqueline Emery, Associate Professor Sobieras, Doctor Laura Hart, Mr Warren Cam, Professor Patrick Olivier, Emeritus Professor Anthony Iom, Professor Frank Oberklaid, Professor Sharon Goldfeld, Associate Professor Tim Silk, Professor Eva Kimani, Professor Mark Bellgrove, Professor Matthew Sanders, Professor Ronald Rapee, Doctor Stacy Tzoumakis, Associate Professor David Efros, Doctor Jaime Northam, Associate Professor Jackie Curtis, Professor Louise Newman, David Clark, Associate Professor Blake Dear, Professor Melanie Zimmer-Gembeck, Doctor Frances Lee Doyle, Professor Ngare Brown, Associate Professor Dianne Shanley, Professor Justin Kenardy, Professor Olivia Mangan, Professor Anna Manning, Professor Michael Berk, Professor Nicholas Martin, Professor Murat Yucel, Associate Professor Rebecca Mottelin, Doctor Michael Millard, Professor Catherine Mihalopoulos, Professor Greg Ward, Professor Daniel Lubman, Professor Chee Ng, Professor Osvaldo Almeida, Professor Jerome Sarris, Associate Professor Adrienne O'Neil, Professor Kate Hoy, Professor Jim Lagopoulos, Professor Anthony Rodgers, Professor Cherrie Ann Galletly, Professor Vassio Apostolopoulos, Professor Katherine Mills, Professor Mark Nelson, Professor David Forbes, Professor John McGrath, Professor Sophia Zoungas, Professor Philip Batterham, Professor Jayashri Kulkarni, Professor Denise Meyer, Sarah Russell, Professor Helen Christensen, Associate Professor Olivia Dear, Professor Sean Hood, Professor Susan Russell, Professor Jane Gunn, Professor Gin Malhi, Professor Stephen Touyz, Professor Christos Pantelis, Professor Richard Bryant, Professor Michael Kyrios, Associate Professor Samuel Harvey, Professor Suresh Sundram, Professor Dan Siskind, Professor Sweeth Venkatesh, Professor Frances Kay-Lambkin, Professor Anthony Harris, Doctor Alyna Turner, Professor Colleen Loos, Professor Christopher Davey, Professor Nicholas Glozier, Professor Richard Asherson, Professor Michael O'Donoghue, Professor	Open competitive	1/05/2021	30/04/2026	Public Health And Health Services	Mental Health	\$	11,930,126.00
Million Minds Mental Health Research Mission	2020 Mental Health Research	Deakin University	University	VIC	Mental Health Australia General Clinical Trial Network (MAGNET)	With a vision of unlocking innovative, world-class clinical trials to deliver new and better mental health treatment and support, the Mental Health Australia General Clinical Trial Network (MAGNET) is a truly cooperative, inclusive mental health research alliance. At a national scale, MAGNET will shift our approach to mental health trials, generating much needed new therapies, lived experience leadership, and strategies to enhance treatment access and the health of communities across Australia.	Professor Michael Berk	Professor Michael Berk, Professor Nicholas Martin, Professor Murat Yucel, Associate Professor Rebecca Mottelin, Doctor Michael Millard, Professor Catherine Mihalopoulos, Professor Greg Ward, Professor Daniel Lubman, Professor Chee Ng, Professor Osvaldo Almeida, Professor Jerome Sarris, Associate Professor Adrienne O'Neil, Professor Kate Hoy, Professor Jim Lagopoulos, Professor Anthony Rodgers, Professor Cherrie Ann Galletly, Professor Vassio Apostolopoulos, Professor Katherine Mills, Professor Mark Nelson, Professor David Forbes, Professor John McGrath, Professor Sophia Zoungas, Professor Philip Batterham, Professor Jayashri Kulkarni, Professor Denise Meyer, Sarah Russell, Professor Helen Christensen, Associate Professor Olivia Dear, Professor Sean Hood, Professor Susan Russell, Professor Jane Gunn, Professor Gin Malhi, Professor Stephen Touyz, Professor Christos Pantelis, Professor Richard Bryant, Professor Michael Kyrios, Associate Professor Samuel Harvey, Professor Suresh Sundram, Professor Dan Siskind, Professor Sweeth Venkatesh, Professor Frances Kay-Lambkin, Professor Anthony Harris, Doctor Alyna Turner, Professor Colleen Loos, Professor Christopher Davey, Professor Nicholas Glozier, Professor Richard Asherson, Professor Michael O'Donoghue, Professor	Open competitive	1/05/2021	31/01/2027	Psychology	Health, Clinical And Counselling Psychology	\$	11,998,907.76
National Critical Research Infrastructure	2019 Applied Artificial Intelligence Research in Health	Centre For Eye Research Australia Limited	Medical Research Institute	VIC	Artificial intelligence to detect eye and cardiovascular diseases	Using the advanced deep learning system that has been developed and validated by the team as a basis, this project brings together medical research institutes, technical developers, industry, consumer organisations, government policy and service providers to develop, translate and prove an all-in-one AI system (A-Eye) that aims to create innovative solutions for multiple health disciplines and needs, including an opportunistic screening model, diagnosis standardisation and a cross-disciplinary model of risk prediction for cardiovascular diseases. An "Eye and Systemic Disease AI Open Platform" will be created to enable resource sharing and workforce development to maximize the impact of AI on linking ocular imaging and systemic diseases.	Not applicable	Not available	Open competitive	30/06/2020	29/06/2023	Not available	Not available	\$	4,988,487.00
National Critical Research Infrastructure	2019 Applied Artificial Intelligence Research in Health	St Vincent's Institute of Medical Research	Medical Research Institute	VIC	Transforming Breast Cancer Screening with Artificial Intelligence	We propose to better use mammography to prevent women dying from breast cancer, in a way that improves detection, lowers harms, reduces costs, causes less stress and can be quickly put into practice. We will apply AI to our large digital datasets with a personalised view incorporating a woman's risk profile and expectations through a co-created approach in an operating screening service. We will build on our leading research to develop an AI software as a service for screening that will transform the current "one-size-fits-all" BreastScreen Australia model. It establishes an exemplar for broad AI deployment in healthcare and a global AI opportunity creating value from the 20 year public investment in population health and screening data.	Not applicable	Not available	Open competitive	30/06/2020	29/06/2023	Not available	Not available	\$	2,260,100.00
National Critical Research Infrastructure	2019 Applied Artificial Intelligence Research in Health	University of Sydney	University	NSW	Explainable machine learning to improve youth mental health care	Mental disorders are the leading cause of disability and death among young people. A key challenge for mental health care is to develop new tools that are useful for guiding clinical decisions about the appropriate interventions for individuals presenting for care. This project will: (i) use explainable machine learning and simulation to infer the causal relationship between mental health outcomes over time; (ii) use dynamic simulation modelling to test and probabilistically quantify the impacts of interventions on outcomes; and (iii) co-design an ethical clinical decision-support tool that identifies how to target assessment and interventions to optimise outcomes for individuals presenting to health services.	Not applicable	Not available	Open competitive	30/06/2020	29/06/2023	Not available	Not available	\$	3,107,627.00
National Critical Research Infrastructure	2019 Applied Artificial Intelligence Research in Health	University of Sydney	University	NSW	Translating AI to Support Clinical Excellence in Neuro Diseases	Software-generated 'artificial neural networks' have demonstrated a remarkable capacity for (generic) image recognition, with error rates of only 1-2%. Despite the clear potential for this technology to transform health delivery, particularly through advances in medical imaging, AI research and implementation has remained the preserve of research institutes and technology companies with limited domain knowledge or access to real-world data. TRANSCEND seeks to redress this imbalance by building a novel, hybrid AI learning ecosystem that links a premiere research institute (University of Sydney) and industry specialist (Sydney Neuroimaging Analysis Centre) with health provider networks (iMED Radiology and clinical neurology partners) to generate clinically-relevant biomarkers of disease progression for the common, disabling neurological condition, multiple sclerosis. The MSBASE-XNAT imaging repository and i-MED clinical radiology site data will respectively form the key components of a unique central-federated AI learning environment, yielding algorithms that, validated in a clinical neurology environment, will set a benchmark in diagnostic MS imaging; track subclinical progression of the disease; direct therapeutic strategy; and mine hitherto untapped quantitative imaging data. Our novel approach will enable new AI research and technologies within the health sector, while preserving patient privacy and data security.	Not applicable	Not available	Open competitive	30/06/2020	29/06/2023	Not available	Not available	\$	4,016,415.00
National Critical Research Infrastructure	2019 Applied Artificial Intelligence Research in Health	University of New South Wales	University	NSW	Optimising treatments in mental health using AI	Mental health disorders are prevalent, affect people in every workplace, and cause great distress to students and their parents. A major problem is that most treatments in mental health are only partially effective. We don't know which interventions, or which components of therapies provide the vital, active ingredients, and why they work for some but not for others. We will use artificial intelligence (AI) to uncover which treatments for for anxiety and depression work quickly, and for whom. If AI can advance a solution towards shortening the prolonged period where people are provided with non-optimal treatment for their condition, the social, personal and economic costs would be enormous.	Not applicable	Not available	Open competitive	30/06/2020	29/06/2023	Not available	Not available	\$	4,995,434.00

National Critical Research Infrastructure	2019 Rural, Regional and Remote Clinical Trial Enabling Infrastructure	Border Medical Oncology Research Unit	Medical Research Institute	NSW	RevITALISE Project Bridging the metro - regional trials gap by 2025	RevITALISE key activities: 1) adding Mildura Base Hospital and Latrobe Regional Hospital as new sites to Regional Trials Network Victoria 2) expand existing sites 3) introduce 7 unique projects across the network resulting in increased number of trials & improved recruitment. The key outcomes: 1) increase trial participation in Regional Rural and Remote (RRR) areas by 2025 creating equitable access and outcomes 2) Improving models of care for indigenous, palliative and supportive care patients 3) establishing new research programs in older patients 4) Improving research literacy in the regional workforce with the establishment of a Regional Research Teaching Hub 5) Improving access to registry and immunotherapy trials.	Craig Underhill	Not available	Open competitive	1/05/2021	1/05/2026	Not available	Not available	\$	18,583,563.00
National Critical Research Infrastructure	2019 Rural, Regional and Remote Clinical Trial Enabling Infrastructure	Department of Health, Queensland	State government entity/local health district	QLD	The Australian Teletrial Program - access to clinical trials closer to home	This program brings clinical trials closer to the homes of regional, rural and remote (RRR) patients by implementing the Australian Teletrial Model (ATM) across Australia. The program creates Regional Clinical Trial Coordinating Centres (RCCCs) to support clinical trials to adopt a scaled-up ATM. The RCCCs are supported by policy cohesion ensuring national regulatory harmonisation, equipment and logistics, education and prompts, recruitment boosting initiatives, including primary care. The program is driven by clinical implementation science. The impact and evaluation will measure success based on equitable numbers of regional, rural and remote patients on clinical trials, increased workforce capacity and patient outcomes.	Karen Thompson	Not available	Open competitive	5/10/2021	4/10/2026	Not available	Not available	\$	75,240,166.00
National Critical Research Infrastructure	2019 Rural, Regional and Remote Clinical Trial Enabling Infrastructure	Ministry of Health, NSW	State government entity/local health district	NSW	Improving access to innovative healthcare in RRR NSW and ACT	This proposal led by NSW Health (Moi) and ACT Health will address clinical trials inequality for 1.8M people in rural regional and remote (RR) NSW. We will achieve our aim through partnerships and initiatives including a new model of delivery. "Virtual clinical trials", enhance traditional approaches to trials; community engagement; providing R3 based skilled staff to support trials delivery, and professional education. Moi will coordinate and embed the proposal within the health system, with strong governance, and active collaboration with other infrastructure projects to achieve national cohesion. Outcomes will be sustainable trial infrastructure that brings health, scientific and economic benefits to R3 areas in NSW, and wider Australia.	Anita van der Meer	Not available	Open competitive	1/04/2022	31/03/2027	Not available	Not available	\$	30,548,184.00
National Critical Research Infrastructure	2020 Enhancing Clinical Trials Networks Capabilities	Australian Clinical Trials Alliance	Corporation	VIC	Embedding clinical trials for "better health through best evidence"	Through the program, Embedding clinical trials for "better health through best evidence", the Australian Clinical Trials Alliance (ACTA) will strengthen the capability of the investigator-led clinical trial sector towards a self-learning health system. ACTA will undertake to facilitate cross-sector collaboration and embed evidence-based care in the health system for more effective clinical trials research and improved health outcomes.	Professor John Zalberg	Not available	One-off/ad hoc	21/10/2020	7/12/2021	Not available	Not available	\$	5,000,000.00
National Critical Research Infrastructure	2021 mRNA Clinical Trial Enabling Infrastructure	Monash University	University	VIC	Development of novel mRNA products for clinical trials	The project will build on Monash's experience in design, development and manufacture of mRNA products, to build a pipeline of new products fit for clinical development. To meet this objective we will establish a dedicated laboratory for pre-clinical mRNA product manufacture, staffed by three experienced mRNA technologists. The unit will provide high quality mRNA products to biomedical researchers to undertake proof-of-concept (POC) studies, followed by further pre-clinical studies to establish optimised formulations and appropriate doses for Phase 1 clinical studies. The 4-year project will complete POC studies for >10 indications and will result in 3 products ready for manufacture using IDT Australia's GMP manufacturing facility.	Professor Colin William Pouton	Professor Colin William Pouton, Associate Professor Traude Helene Behlharz, Professor John Carroll, Professor Christopher John Hamilton Porter, Associate Professor Chen Davidovich, Associate Professor Angus Philip Rayner Johnston, Associate Professor Natalie Leanne Trevisan, Doctor Hareth Al Wassiti	Targeted competitive	Not available	Not available	Not available	Not available	\$	5,000,000.00
National Critical Research Infrastructure	2021 mRNA Clinical Trial Enabling Infrastructure	University of Melbourne	University	VIC	RNA Powered Antiviral Antibodies	Monoclonal antibodies (mAbs) are the fastest growing therapeutic class in medicine today. Leveraging emerging RNA technology as a production and delivery vehicle, the project will overcome current barriers to the therapeutic use of mAbs to address the substantial unmet need and sizeable markets for the treatment of viral infectious diseases, including future pandemics. Our program will deliver new mRNA based therapeutic candidates into a proven ecosystem of pre-clinical and clinical development, with great potential to aid Australia's growth into a powerhouse of mRNA based drug manufacturing. This will position Australia as a leader in a novel product category with extensive application across infectious disease, immunology and oncology.	Professor Damian Purcell	Professor Damian Purcell, Professor Sharon Lewin, Professor Frank Canoso, Doctor Julie McQuay, Doctor Adam Kenneth Wheatley, Doctor Sarah Londrigan, Professor Linfa Wang, Professor Jason Mackenzie, Doctor Danielle Anderson, Professor Deborah Williamson, Doctor Vincent Dominique Andre Corbin, Professor Joe Jacobs, Associate Professor Isabelle Koutler, Professor Riccardo Bolzetti, Professor Dale Godfrey, Associate Professor James Hamilton McMahon	Targeted competitive	Not available	Not available	Not available	Not available	\$	5,000,000.00
National Critical Research Infrastructure	2021 mRNA Clinical Trial Enabling Infrastructure	Southern RNA Pty Ltd	Corporation	QLD	Translational ecosystem for clinical development of mRNA modalities	There is currently an unmet need in Australia for facilities and services to develop mRNA vaccines from preclinical to clinical, from genetic material production to manufacture of the vaccine. This project will establish an end-to-end RNA Development and Manufacturing Ecosystem in Queensland based on a partnership between QIMR Berghofer, the University of Queensland, Griffith University and industry partners Southern RNA, Cyta, Providence Therapeutics/Northern RNA and Springfield City Group. At completion, this project will have invested in mRNA manufacture and formulation infrastructure in Queensland to support the development of the new generation of mRNA modalities, and will have progressed multiple mRNA vaccines to clinical studies.	Doctor Romain Guillaume Bertrand Troppe	Doctor Romain Guillaume Bertrand Troppe, Associate Professor Timothy Robert Mercer, Professor Nigel Alan McMillan, Professor Andreas Schirmer, Mr Gary Heaney, Ms Natalie Martin Orozco, Doctor Jagannathan Bilakanti, Professor Frank Gannon, Doctor Aleksandra Pastrak	Targeted competitive	Not available	Not available	Not available	Not available	\$	5,000,000.00
National Critical Research Infrastructure	2021 mRNA Clinical Trial Enabling Infrastructure	Bridgeway Australia Biotech Pty Ltd	Corporation	NSW	Developing enabling technologies for manufacture of precision mRNA vaccines	Australia currently lacks domestic manufacturing of mRNA products under accredited pharmaceutical GMP. This MRFF grant will strengthen linkages between commercial lead BioCina Pty Ltd, industry partner Cyta, as well as expand discovery research in microfluidic chip parallel manufacturing of mRNA based therapeutic vaccines with world-class experts from the University of Adelaide. Outcomes of this grant will extend the mRNA manufacturing and analytical capabilities of BioCina's GMP facility to all clinical phases and commercial supply and deliver new to market automated microfluidics technology for manufacture of mRNA therapeutic vaccines, which will fill a significant technology gap in the personalised mRNA vaccines market.	Doctor Jan Bekker	Doctor Jan Bekker, Doctor Lukas Gerstweiler, Doctor Rini Akmalawati, Professor David Milton Lewis, Professor Chun Xia Zhao, Associate Professor Abel Santos, Professor Robert John Falconer, Doctor Richard van Wigen, Doctor Gerben Zondag, Professor Brendon Coventry, Professor Tim O'Meara	Targeted competitive	Not available	Not available	Not available	Not available	\$	5,000,000.00
National Critical Research Infrastructure	2021 mRNA Clinical Trial Enabling Infrastructure	University of New South Wales	University	NSW	BRIDGE: Bringing RNA Innovations through the Developmental Gap Effectively	This Consortium co-ordinates and builds upon existing infrastructure and developmental expertise to streamline a developmental pathway for RNA molecules. These molecules will be taken through 4 steps: 1) identification of lead candidate 2) cGMP/cGMP-like manufacture 3) Clinical trial-enabling studies 4) Early phase clinical trials. Key components of this process include: compliance with regulatory agency requirements for pharmaceutical development; stage-gating of budgetary allocations; protection and enhancement of intellectual property; enhancement of existing capabilities; active fund raising. The primary objective is to allow inventors and host institutions to undertake rigorous, efficient product development in an academic setting.	Professor Anthony D Kelleher	Professor Anthony D Kelleher, Professor Mark Thomas Sullivan, Doctor Charlotte Rose Lemech, Professor Gail Matthews, Professor Matthew Owen Law, Doctor Louise Ann Evans, Professor Paul Thordarson, Doctor Chantelle Lisa Evelyn Alenstiel, Professor Christopher Carl Goodnow, Doctor Deborah Lily Burnett, Mr Andrew Douglas Warden	Targeted competitive	Not available	Not available	Not available	Not available	\$	5,000,000.00
Preventive and Public Health Research	2017 Boosting Preventive Health Research Program	The Sax Institute	Corporation	NSW	Accelerating Pathways to Prevention through The Australian Prevention Partnership Centre	It is widely recognised that many opportunities to reduce the burden of disease through prevention are currently missed. The purpose of the Accelerating Pathways to Prevention through The Australian Prevention Partnership Centre program is to identify the best opportunities for significant and immediate impact on prevention efforts, to undertake the research that could accelerate action and to bring together key players to advance and sustain action.	Not applicable	Not available	Targeted non-competitive	23/06/2017	30/06/2021	Not available	Not available	\$	10,000,000.00
Preventive and Public Health Research	2018 Keeping Australians Out of Hospital	Baker Heart and Diabetes Institute	Medical Research Institute	VIC	Reduction of Heart Failure Readmission in Resource Constrained Environments: Supporting Nurse-led Disease Management by Risk-Guidance and eHealth	Patients with Heart failure often require admission to hospital. Unfortunately, repeat admission is frequent within 1-3 months – a process that is inconvenient and stressful for the patient and expensive for the health system. Many of these readmissions can be prevented using a nurse-led disease management program. This study seeks to improve the efficiency of these programs by identifying the patients who are most likely to benefit, and by optimizing patient engagement using a digital coach.	Professor Thomas Marwick	Professor Thomas Marwick, Associate Professor Melinda Carrington, Doctor Quan Huynh, Doctor Jaewon-Randall, Professor Rakesh Negishi, Professor Graeme Maguire, Mr Michael Pervan, Doctor Judith Hammond, Doctor Paul Macintyre, Doctor Kevin Ng	Targeted competitive	1/07/2019	30/06/2022	Cardiorespiratory Medicine And Haematology	Cardiology (incl. Cardiovascular Diseases)	\$	287,662.90
Preventive and Public Health Research	2018 Keeping Australians Out of Hospital	La Trobe University	University	VIC	Reducing inappropriate knee joint replacement surgery and hospital burden	Knee osteoarthritis affects 2.1 million Australians. 53,673 knee replacement surgeries were performed in 2017-18. Education, exercise and weight management should be provided to all patients, and knee replacement surgery only considered if this approach is not successful. Most people in Australia with knee osteoarthritis are not provided appropriate care prior to surgery. This study will test whether access to appropriate care can prevent or delay surgery.	Doctor Christian Barton	Doctor Christian Barton, Associate Professor Michelle Dowsey, Professor Peter Chong, Associate Professor Zandra Adami, Professor Anne Smith, Professor Kay Crossley, Doctor Jason Wallis, Associate Professor Ilana Ackerman, Doctor Samantha Bunzl, Doctor Joanne Kemp	Targeted competitive	1/06/2019	28/02/2025	Public Health And Health Services	Preventive Medicine	\$	1,337,750.00
Preventive and Public Health Research	2018 Keeping Australians Out of Hospital	Monash University	University	VIC	Transforming pulmonary rehabilitation to reduce hospital admissions in COPD	Pulmonary rehabilitation is an effective treatment for chronic lung disease, but is delivered to less than 10 percent of people who would benefit. Our new home-based rehabilitation model was effective in a clinical trial, but is not yet available in practice. We will test the widespread implementation of home-based pulmonary rehabilitation across 14 centres in 5 Australian states. If successful, this will improve access to care, reduce hospital visits and improve wellbeing for people with chronic lung disease.	Professor Anne Holland	Professor Anne Holland, Professor Christine McDonald, Professor Ajay Mahal, Professor Natasha Lamm, Doctor Narelle Cox, Associate Professor Graham Hepworth, Doctor Paul O'Halloran	Targeted competitive	1/06/2019	31/08/2024	Cardiorespiratory Medicine And Haematology	Respiratory Diseases	\$	1,220,668.40
Preventive and Public Health Research	2018 Keeping Australians Out of Hospital	Macquarie University	University	NSW	Harvesting implementation science, complexity science and evidence-based care to Keep Australians Out of Hospital: leveraging seven natural experiments in New South Wales	Seven NSW-wide, multi-agency projects, underpinned by the latest evidence-based clinical approaches, are starting to deliver more effective, affordable and safer care. Our proposed collaboration between NSW Health agencies and the AHI and MUCHE represents an ideal partnership. Drawing on valuable insights and data from these in-train interventions, we will develop novel, adaptive implementation models to keep people out of hospital.	Professor Jeffrey Braithwaite	Professor Jeffrey Braithwaite, Professor Johanna Westbrook, Professor Richard Day, Professor Jean-Frederic Levesque, Associate Professor Rebecca Mitchell, Professor Frances Rapport, Professor Henry Cutler, Doctor Yoanne Tran, Associate Professor Robert Clae-Williams	Targeted competitive	1/06/2019	31/05/2023	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	1,505,612.00

Preventive and Public Health Research	2018 Keeping Australians Out of Hospital	Queensland University of Technology	University	QLD	An early detection program to prevent unnecessary hospital admissions of aged care residents	The Early Detection of Deterioration in Elderly residents program is aimed at improving the medical care and management of aged care residents. It involves training nursing staff to detect and manage early signs of deterioration with the aim of avoiding unnecessary, costly and stressful transfers to hospital. We will implement this program in 12 aged care facilities to determine its effectiveness and cost-effectiveness with the aim of embedding this new model of care into everyday practice.	Professor Gillian Harvey	Professor Nicholas Graves, Professor Trudy Dwyer, Professor Gillian Harvey, Associate Professor Lynne Parkinson, Doctor Hannah Carter, Doctor King Lee, Associate Professor Florin Oprea, Doctor Elizabeth Cyarto, Doctor Claudia Meyer, Associate Professor Jeffrey Rowland	Targeted competitive	1/06/2019	30/09/2023	Public Health And Health Services	Aged Health Care	\$	1,898,519.30
Preventive and Public Health Research	2018 Keeping Australians Out of Hospital	Queensland University of Technology	University	QLD	LOCAL Assessment and Triage Evaluation of NAFLD (LOCATE-NAFLD)	Non-alcoholic fatty liver disease is the most common type of chronic liver disease in Australia, affecting approximately 30 percent of the adult population. It reduces quality of life and places significant time and cost burden on the public health system. We propose to conduct a nurse-led community assessment service in urban and regional Queensland, which will reduce burden on the hospital system and provide patients with better options for managing their disease.	Professor Adrian Barnett	Professor Adrian Barnett, Professor James O'Brien, Doctor Sheila Patel, Doctor Jason Kwong, Doctor Paul Yates, Doctor Jay Ramchand, Associate Professor Joshua Byrnes	Targeted competitive	1/06/2019	31/08/2022	Clinical Sciences	Gastroenterology And Hepatology	\$	969,193.00
Preventive and Public Health Research	2018 Keeping Australians Out of Hospital	University of Melbourne	University	VIC	The Enhance care study: multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer	Unnecessary suffering and frequent hospitalisations despite preferring care at home is the experience of thousands of Australians. Early palliative care is a high value proposition – improving health outcomes for patients with advanced cancer, AND at lower cost with reduced hospitalisation. Yet early palliative care is not routinely available. This multi-site study will implement early palliative care in three cancer centres and assess the impact on acute hospital use at the end of life.	Professor Jennifer Philip	Professor Jennifer Philip, Associate Professor Vijaya Sundararajan, Professor Anna Nowak, Professor Meir Krishnamoorthy, Doctor Nicole Rankin, Doctor Anna Collins, Professor Maarten IJzerman, Professor Gregory Crawford, Associate Professor Brian Le, Ms Robyn Hudson	Targeted competitive	1/06/2019	30/06/2023	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	1,061,521.50
Preventive and Public Health Research	2018 Keeping Australians Out of Hospital	University of Melbourne	University	VIC	The Resilience to Seasonal Illness and Increased Emergency admissions CaRe (RESILIENCE) Study	Despite our best efforts, including hospital avoidance programs, the problem of peaks in hospital admissions during winter and heatwaves is worsening as more Australians become chronically ill. In a world-first study involving 300 patients with heart disease and other chronic illnesses at high risk of repeated admissions to hospital 'seasonal frequent flyers', we will trial a unique intervention that builds their 'resilience' to changes in the weather and, therefore, keep them out of hospital.	Professor Louise Burrell	Professor Louise Burrell, Professor Simon Stewart, Doctor Sheila Patel, Doctor Jason Kwong, Doctor Paul Yates, Doctor Jay Ramchand, Associate Professor Joshua Byrnes	Targeted competitive	1/06/2019	31/05/2023	Public Health And Health Services	Health And Community Services	\$	1,284,327.00
Preventive and Public Health Research	2018 Keeping Australians Out of Hospital	University of Melbourne	University	VIC	There's no place like home: national scale up of the paediatric low risk febrile neutropenia program	Children undergoing cancer treatment are at an increased risk of infection. This is managed by hospital admission for antibiotics which can be disruptive for the child and their family and expensive for the healthcare system. While many need admission, almost half can be safely managed at home. This project will set up a program for home-based management of fever in children with cancer at low risk for infection. This program is proven to improve quality of life and decreases costs of care.	Doctor Gabrielle Haensler	Doctor Gabrielle Haensler, Professor Karin Thursky, Professor Monica Savin, Associate Professor Lisa Hall, Professor Tracey O'Brien, Professor Franz Babl, Associate Professor Richard De Azavedo, Associate Professor Julia Clark, Professor Meredith Borland, Doctor Brendan McMullan	Targeted competitive	1/06/2019	31/05/2023	Clinical Sciences	Infectious Diseases	\$	1,237,016.00
Preventive and Public Health Research	2018 Keeping Australians Out of Hospital	University of Technology Sydney	University	NSW	Translation of best practice osteoporosis refracture prevention: stopping fragility fractures to keep Australians out of hospital	Older people who break bones after only minor injuries may be at risk of further fractures. If those with more fragile bones are identified, they can be treated to improve their bone health, and prevent new fractures and hospital stays. Evidence shows what treatments to use but many services struggle to deliver this effectively and sustainably. This study tests an approach to develop, trial and cost locally-tailored solutions as a way to improve patient outcomes and value of care for Australians	Professor Lin Perry	Professor Lin Perry, Professor Jacqueline Center, Professor Ian Harris, Associate Professor Roderick Clifton-Blyth, Doctor Geraldine Hassett, Professor Tuan Nguyen, Professor Elizabeth McIntyre, Associate Professor Christopher White, Doctor Steven Frost	Targeted competitive	1/06/2019	31/05/2023	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	897,729.90
Preventive and Public Health Research	2018 Keeping Australians Out of Hospital - Preventative Health Research in Rural and Regional Communities (Tasmania)	University of Tasmania	University	TAS	Preventative Health Research in Rural and Regional Communities (Tasmania)	An ageing Australia will increasingly impact social, health and economic activity, as exemplified in complex disorders such as dementia. Obesity is also increasing at a rapid rate and is a major antecedent risk factor for a range of chronic illnesses. Both conditions will be a particular challenge for rural and regional communities as they have the highest rates of related risk factors and chronic illness, and also relatively reduced access to specialist medical services and preventative health programs. This proposal focusses on dementia and obesity in north-west Tasmania, developing innovative initiatives to manage and reduce risk of these conditions, which will reduce medical procedures overall including presentations to hospital. The program involves two major projects: the Island Study Linking Ageing and Neurodegenerative Disease (ISLAND) and the Critical Age Periods for Impacting Obesogenic Lifestyles (CAPITOL) study. The ISLAND study will involve a pragmatic clustered randomised controlled trial on interventions for major potentially modifiable risk factors for dementia, including obesity, physical activity, diabetes, smoking, hypertension, depression and cognitive stimulation/education, most of which are antecedents to chronic illness. The CAPITOL study will facilitate a transdisciplinary professional network to build a community-specific, sustainable approach to supporting children and families in relation to physical health and wellbeing. This project will identify enabling contextual factors which influence engagement in healthy physical play practices; foster buy-in from families (at multiple entry points); improve school readiness through enhancing outcomes for children (0-8 years) in the AECd domain of physical health and wellbeing; and generate sustainable communities of practice. North-west Tasmania is an ideal 'test-bed' to develop preventative health strategies that are relevant and scalable to other Australian rural and regional communities.	Professor James Vickers	Professor James Vickers, Professor Andrew Hills, Associate Professor Lynette Goldberg, Professor Nuala Byrne, Doctor Maree Farrow, Professor Roger Hughes, Doctor Shannon Kleckovich, Doctor Kiran Ahuja, Doctor Helen Courtney-Pratt, Doctor Kira Patterson	Closed non-competitive	27/03/2019	31/03/2023	Public Health And Health Services	Preventive Medicine	\$	2,400,000.00
Preventive and Public Health Research	2019 Keeping Australians Out of Hospital - Preventative Health Research in the Australian Capital Territory (ACT)	University of Canberra	University	ACT	Environmental and social determinants of health in the Australian Capital Territory: program interventions aimed at reducing the burden of disease and avoidable hospital admissions	This Grant aims to support the University of Canberra's to boost preventative health measures through the translation of research into health care practice.	Professor Rachel Davey	Professor Rachel Davey, Professor Mark Daniel, Associate Professor Margaret Cargo, Associate Professor Suzanne Carroll, Associate Professor Theophile Nyemanga, Associate Professor Nicole Freyre, Associate Professor Sam Kosari	Closed non-competitive	5/04/2019	30/10/2024	Public Health And Health Services	Preventive Medicine	\$	4,000,000.00
Preventive and Public Health Research	2019 Preventive and Public Health Research	Deakin University	University	VIC	TeleFIT - A personalized, telehealth exercise and lifestyle risk factor management program to reduce falls and fracture risk in older adults: A 12-month hybrid effectiveness-implementation trial	Fragility fractures occur every 3.4 min in Australia. Exercise can reduce fracture risk, but access to best practice programs and trained professionals are key barriers. This study will evaluate whether a multifaceted, telehealth model of service delivery including exercise, behaviour change support, education, nutrition and online peer-support, can improve multiple fracture risk factors in older people, and whether this approach is translatable into clinical practice and feasible for scale-up.	Professor Robin Daly	Professor Robin Daly, Professor Kim Bennett, Associate Professor David Scott, Professor Peter Ebeling, Professor Andrea Maier, Professor Lora Giangregorio, Professor Rana Himman, Associate Professor Jennifer Watts, Doctor Harriet Koorts, Doctor Catherine Mills	Targeted competitive	1/06/2020	31/10/2024	Clinical Sciences	Rehabilitation And Therapy (Excl. Physiotherapy)	\$	1,393,504.50
Preventive and Public Health Research	2019 Preventive and Public Health Research	Edith Cowan University	University	WA	Developing a novel approach to improve diet and lifestyle	Most Australians do not meet fruit and vegetable intake and physical activity recommendations. New non-invasive measures of structural vascular disease strongly predict heart disease and stroke deaths and all-cause mortality, independent of other risk factors. Our primary aim is to determine if an individual's knowledge of their level of structural vascular disease can lead to an increase in fruit and vegetable intake.	Professor Jonathan Hodgson	Professor Jonathan Hodgson, Associate Professor Joshua Lewis, Professor John Schousboe, Professor Richard Woodman, Associate Professor Ben Jackson, Professor James Dimmock	Targeted competitive	1/06/2020	31/05/2023	Nutrition And Dietetics	Public Nutrition Intervention	\$	295,803.50
Preventive and Public Health Research	2019 Preventive and Public Health Research	La Trobe University	University	VIC	Exploring the impact of caseload midwifery on preterm birth among vulnerable and disadvantaged women: a multi-centre randomised controlled trial	Premature babies can have poorer short and long-term health outcomes, and this is especially the case for infants of women who are socially disadvantaged. How care is provided can impact health outcomes. Caseload midwifery is a model of care where women have continuity from a 'known' midwife during pregnancy, labour, birth and after the birth. This trial will compare the effectiveness of caseload midwifery socially disadvantaged women on preterm birth, other health outcomes, and costs.	Professor Helen McLachlan	Professor Helen McLachlan, Professor Della Foster, Doctor Stefan Kane, Professor Jane Sandell, Doctor Touran Shafiei, Doctor Rocco Cuzzilla, Professor Alan Shiel, Doctor Cattram Nguyen, Doctor Michelle Newton, Professor Michael Kingsley	Targeted competitive	1/06/2020	31/05/2024	Nursing	Midwifery	\$	1,598,496.00
Preventive and Public Health Research	2019 Preventive and Public Health Research	Menzies School of Health Research	Medical Research Institute	NT	A life course approach to reduce intergenerational diabetes risk in remote Northern Australia through improved systems of care and consumer engagement	Our established partnership of researchers, health services and policy makers across Australia aims to improve diabetes-related health outcomes in Aboriginal and Torres Strait Islander communities, starting as early as possible in life. This proposal aims to improve management of diabetes in pregnancy and post-partum follow-up of women, in order to reduce future risk of chronic conditions of obesity, diabetes and heart disease in Aboriginal and Torres Strait Islander mothers and their children.	Professor Louise Maple-Brown	Professor Louise Maple-Brown, Doctor Christine Connors, Doctor Leisa McCarthy, Professor Jeremy Oats, Ms Sumaria Corpus, Doctor Anna-Gerardina McLean, Professor Harold McIntyre, Doctor Karla Canalis, Doctor Renae Kirkham, Professor Jonathan Shaw	Targeted competitive	1/06/2020	31/05/2026	Clinical Sciences	Endocrinology	\$	2,923,325.00
Preventive and Public Health Research	2019 Preventive and Public Health Research	Monash University	University	VIC	Healthy lifestyle in Preconception, Pregnancy and Postpartum HIPP - Personalised Medicine meets Public Health	Reproductive healthcare is fragmented, not personalised and doesn't integrate healthy lifestyle, a major priority in the first 2000 days, leading to burgeoning obesity and disease burden. Here we build on our current work, networks and community framework to identify and target those at high risk, co-design models of care and undertake implementation and impact research and translation of evidence into practice and policy to optimise health for mothers and children.	Professor Helena Teede	Professor Helena Teede, Professor Helen Skouteris, Associate Professor Jacqueline Boyle, Associate Professor Lisa Moran, Professor Robert Norman, Professor Andrew Hills, Associate Professor Zafina Ademi, Professor James Dunbar, Professor Shakila Thangaratinam, Doctor Joanne Entcott	Targeted competitive	1/06/2020	31/05/2025	Public Health And Health Services	Preventive Medicine	\$	2,551,476.40
Preventive and Public Health Research	2019 Preventive and Public Health Research	Queensland University of Technology	University	QLD	Effectiveness of an early childhood intervention to promote healthy child development and prevent chronic health conditions such as obesity in families attending community playgroups. The program will address the underlying risk factors for chronic disease by helping parents take effective steps to improve their child's dietary, physical activity, screen time, and sleep behaviours.	This project will test the impact of an early childhood intervention to promote healthy child development and prevent chronic health conditions such as obesity in families attending community playgroups. The program will address the underlying risk factors for chronic disease by helping parents take effective steps to improve their child's dietary, physical activity, screen time, and sleep behaviours.	Professor Stewart Trost	Professor Stewart Trost, Professor Rebecca Kolley, Associate Professor Hayley Christian (nee Cull), Doctor Rebecca Byrne, Associate Professor Kate Williams	Targeted competitive	1/06/2020	31/12/2023	Public Health And Health Services	Community Child Health	\$	870,950.01
Preventive and Public Health Research	2019 Preventive and Public Health Research	The University of Adelaide	University	SA	The Begin Better Randomised Trial	We will identify whether weight loss before pregnancy improves pregnancy and birth outcomes for overweight or obese women who are planning pregnancy, while evaluating health economic implications and social factors contributing to access and utilisation of the weight loss intervention. Findings will provide evidence to support investment in health promotion prior to conception care at a population level, inform health policies globally, and provide a strategy to tackle child obesity.	Professor Jodie Dodd	Professor Jodie Dodd, Doctor Amanda Poprzeczny, Doctor Jennie Louise, Associate Professor Amy Keir, Doctor Charabell Pham, Associate Professor Rachel Laws, Professor Annette Briley, Professor Deborah Turnbull, Professor Karen Campbell, Doctor Megan Mitchell, Doctor Melissa Oxlad	Targeted competitive	1/06/2020	31/05/2025	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine Not Elsewhere Classified	\$	2,790,917.40
Preventive and Public Health Research	2019 Preventive and Public Health Research	The University of Adelaide	University	SA	A pragmatic randomised controlled trial to test whether incentives and carbon monoxide monitoring help pregnant women quit smoking	Smoking during pregnancy causes irreversible, long-term harm to the developing baby. Currently women are offered counselling for smoking cessation with limited success. We will test whether more pragmatic control quit smoking tests if incorporating financial incentives and carbon monoxide prenatal care or when financial incentives are offered. We will look at the costs to the health system of smoking and incentives, and we will explore community acceptability of incentives.	Associate Professor Lisa Smithers	Professor Lisa Smithers, Professor Gustaaf Dekker, Professor John Lynch, Professor Lily Gurnis, Professor Stefanie Schurer, Ms Josephine Teller	Targeted competitive	1/06/2020	31/05/2025	Clinical Sciences	Clinical Sciences Not Elsewhere Classified	\$	987,207.50

Preventive and Public Health Research	2019 Preventive and Public Health Research	The University of Adelaide	University	SA	Time-Restricted EATING to reduce the risk of developing type 2 diabetes (TREAT)	Two million Australians are at risk of developing type 2 diabetes mellitus. This may be partly due to modern human lifestyles which are linked with eating for a prolonged period each day. Preliminary data by the CS show that time restricted eating (TRE, 8-10 h/day for up to 8 wk) improves glucose tolerance by 36% in people with obesity. This study will now test whether TRE is effective to improve glycaemic control and can be sustainable in humans longer term.	Associate Professor Leonie Heilbronn	Associate Professor Leonie Heilbronn, Professor John Hawley, Doctor Amy Hutchison, Doctor Brooke Devlin, Doctor Evelyn Parr	Targeted competitive	1/06/2020	31/05/2024	Nutrition And Dietetics	Nutritional Physiology	\$	1,012,420.00
Preventive and Public Health Research	2019 Preventive and Public Health Research	University of Melbourne	University	VIC	Prenatal environments, offspring neurodevelopment and epigenetic programming	Child development is sensitive to exposures during pregnancy. This includes maternal oral intakes, including plastic residues. In animal studies, plastics affect brain development gene activity. This human project will identify which prenatal factors are associated with adverse child neurodevelopment (low cognition, poor attention and autism disorders) and the extent that they operate through epigenetic programming, that is, by switching genes on or off. This will guide future recommendations.	Professor Anne-Louise Ponsonby	Professor Anne-Louise Ponsonby, Doctor Boris Novakovic, Professor Deborah Dewey, Professor Peter Sly	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Epidemiology	\$	748,010.00
Preventive and Public Health Research	2019 Preventive and Public Health Research	University of Melbourne	University	VIC	Telerehabilitation for early intervention to improve neurodevelopmental outcomes of infants born preterm and their parents' well-being: a randomised controlled trial	This randomised controlled trial will compare an innovative physiotherapy led intervention for preterm infants that utilizes telerehabilitation and focuses on early development, environmental enrichment and supporting parent-infant interaction with standard care. Our goal is to improve motor, thinking, language and behavioural outcomes of the babies, along with improving parental well-being.	Associate Professor Alicia Spitale	Professor Alicia Spitale, Professor Peter Anderson, Professor Stacy Dusing, Doctor Karl Treyraud, Professor Rod Hunt, Professor Katherine Lee, Doctor Li Huang, Professor Angela Morgan, Professor Anne Holland	Targeted competitive	1/06/2020	31/05/2025	Paediatrics And Reproductive Medicine	Foetal Development And Medicine	\$	1,819,841.50
Preventive and Public Health Research	2019 Preventive and Public Health Research	University of Melbourne	University	VIC	A Precision Medicine approach to improving developmental outcomes for Aboriginal and Torres Strait Islander children	Aboriginal children are among the most disadvantaged nationally. Yet, many early childhood programs have no proof that they make a difference to Aboriginal children's development. We will produce the first culturally appropriate developmental outcome measure for Aboriginal children: ASQ-STEPS. ASQ-STEPS will be a way of measuring the impact of early childhood programs and of measuring individual children's development. This will help tailor programs to promote Aboriginal children's development.	Doctor Anita D'Aprano	Doctor Anita D'Aprano, Associate Professor Patricia Eadie, Doctor Daniel Cloney	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Aboriginal And Torres Strait Islander Health	\$	945,266.50
Preventive and Public Health Research	2019 Preventive and Public Health Research	The University of Newcastle	University	NSW	Building the capacity of community mental health services to provide preventive care to people with a mental health condition	People with a mental health condition have a higher prevalence of key modifiable risk factors such as poor nutrition and inadequate physical activity, resulting in an inequitable burden of chronic disease. This research will support people with a mental health condition to engage in healthy behaviours by implementing practice change in community mental health services across 3 health districts in NSW. This will lead to improved health outcomes for people with a mental health condition.	Professor Jennifer Bowman	Professor Jennifer Bowman, Doctor Kate Bartlem, Professor David Castle, Professor Sharon Lawn, Doctor Elizabeth Campbell, Doctor Penny Kewes	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Health And Community Services	\$	1,365,093.00
Preventive and Public Health Research	2019 Preventive and Public Health Research	University of Sydney	University	NSW	Can a pre-conception weight loss program improve maternal and infant outcomes for women with overweight or obesity? A pragmatic randomised controlled trial (PCT)	Half of Australian women are overweight or obese at the start of pregnancy resulting in pregnancy and delivery complications plus significant risks of later obesity and cardiovascular disease for their children. Optimising women prior to pregnancy may offer the best chance of protecting the next generation. This study will assess whether weight loss using a meal replacement diet program for overweight and obese women planning pregnancy can improve outcomes for both mother and baby.	Professor Adrienne Gordon	Professor Adrienne Gordon, Professor Janette Brand Miller, Professor William Tarnow-Mordi, Professor Amanda Sallis, Professor Jon Hyett, Doctor Ariarne Sweeting, Doctor Frances Garden, Associate Professor Beverly Mulhauser, Associate Professor Tania Markovic, Doctor Bradley de Vries	Targeted competitive	1/06/2020	31/05/2025	Paediatrics And Reproductive Medicine	Obstetrics And Gynaecology	\$	1,920,566.00
Preventive and Public Health Research	2019 Preventive and Public Health Research	University of Sydney	University	NSW	Physical activity promotion by health professionals to increase physical activity: two hybrid type II implementation effectiveness cluster randomised controlled trials in hospital outpatient settings	This project aims to enhance physical activity counselling and referral by health professionals to suitable sport and exercise opportunities as part of clinical care for people with physical disabilities, defined as difficulty walking due to any health conditions. Two intervention packages have been developed to support health professionals to promote physical activity. This project will evaluate these two packages with cluster randomised trials using effectiveness-implementation designs.	Doctor Leanne Hassett	Doctor Leanne Hassett, Professor Catherine Sherrington, Doctor Marina de Barros Pinheiro, Professor Kirsten Howard, Mr Matthew Jennings, Professor Colin Greaves, Professor Jennifer Allison, Associate Professor Jeff Walkley, Doctor Abigail Haines	Targeted competitive	1/06/2020	31/05/2023	Public Health And Health Services	Preventive Medicine	\$	480,078.20
Preventive and Public Health Research	2019 Preventive and Public Health Research	University of Sydney	University	NSW	Developing and evaluating an interactive web-based Healthy Beginnings program for preventing obesity in the first years of life	Risk factors for childhood obesity are established in the first 2000 days. This study aims to translate, develop and test the acceptability measured by participant engagement, motivation and health behaviour change program, Healthy Beginnings, through an interactive web-based platform. The study contains 2 stages using qualitative and quantitative approaches: intervention development targeting third trimester to 12 months of age (Phase 1) and intervention testing (Phase 2).	Associate Professor Li Ming Wen	Associate Professor Li Ming Wen, Professor Louise Baur, Doctor Sarah Eidel, Professor Robert Cohen, Doctor Hulan Xu, Doctor Limin Buchanan, Doctor Rachel Jones	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Health Promotion	\$	670,031.00
Preventive and Public Health Research	2019 Preventive and Public Health Research	University of Canberra	University	ACT	A good start in life for young children: reducing vulnerability and health inequity	The project will evaluate an integrated multi-sector, multi-component programme of interventions for improving the health and wellbeing of children who are at the highest risk of developmental vulnerability. We will reduce children's problems, promote healthy child development, enhance family and community environments. In partnership with our local community and service providers, we will provide potential for scaling up and capacity building that will have national significance.	Professor Rachel Davey	Professor Rachel Davey, Associate Professor Margaret Cargi, Professor Michelle Lincoln, Professor Christine Phillips, Associate Professor Jane Herbert, Doctor Jacqueline McKechnie	Targeted competitive	1/06/2020	31/07/2025	Public Health And Health Services	Preventive Medicine	\$	868,846.28
Preventive and Public Health Research	2019 Preventive and Public Health Research	University of South Australia	University	SA	Healthy Choices: Co-designed community programs to enhance healthy lifestyle choices for people with chronic conditions	This project will implement and evaluate a community-based health service where university exercise and nutrition students partner with people with chronic conditions. Together they will learn about the specific condition/s and develop goals and individual and group programs. These programs will foster better health habits (including better diets and sustainable physical activity) that will improve the participants' health and well-being.	Professor Susan Hillier	Professor Susan Hillier, Professor Timothy Olds, Professor Carol Maher, Doctor Tiffany Gill, Professor Adrian Easton, Doctor David Khudja, Professor Robert Adams, Professor Catherine Hill	Targeted competitive	1/06/2020	31/05/2025	Clinical Sciences	Rehabilitation And Therapy (Excl. Physiotherapy)	\$	780,670.00
Preventive and Public Health Research	2019 Preventive and Public Health Research	University of Tasmania	University	TAS	Developing benchmarks and a smart online tool for assessing walkability in regional and rural communities: Supporting rural Australians to live healthy, active lives	Rural adults are less active and suffer more chronic disease than urban adults. The built environment (roads, housing, footpaths) can hinder or support physical activity, but we lack a way to easily measure 'walkability' in rural areas. This means it's hard to decide what to prioritise to better support active lifestyles. This project will explore walkability benchmarks and work collaboratively to co-design an online walkability assessment tool to help decide priority actions in rural areas.	Associate Professor Verity Cleland	Associate Professor Verity Cleland, Professor Anna Timperio, Doctor Kim Jose, Associate Professor Melanie Daven	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	570,968.50
Preventive and Public Health Research	2019 Preventive and Public Health Research	University of Technology Sydney	University	NSW	The impact of neonatal care on long-term healthcare needs and outcomes	This project will examine how newborn care affects healthcare needs and costs over the first five years of a child's life.	Doctor Serena Yu	Doctor Serena Yu, Professor Ket Lui, Associate Professor Lynn Sinclair, Professor David Fielding, Doctor Vanessa Searl, Professor Rosalie Vasey	Targeted competitive	1/06/2020	30/11/2023	Econometrics	Econometric And Statistical Methods	\$	163,840.00
Preventive and Public Health Research	2019 Preventive and Public Health Research	University of Wollongong	University	NSW	Peer support for breastfeeding for Aboriginal women	This study involves using Aboriginal peer support workers to support Aboriginal women to initiate breastfeeding and to breastfeed over the first 6 months of life, by using face to face visits, and phone and video-chat. The study will involve six Aboriginal maternal and infant health services in NSW, where we will recruit 720 mother and baby pairs over a 5 year period. We also plan to interview Aboriginal women and their health carers to assess the support they received for breastfeeding.	Associate Professor Rowena Ivers	Associate Professor Rowena Ivers, Associate Professor Michelle Dickson, Professor Karen Charlton, Professor Lisa Jackson Pulver, Associate Professor Christine Catling, Professor Michael Dibley, Doctor Miranda Buck, Associate Professor Patrick Kelly	Targeted competitive	1/06/2020	30/11/2025	Nutrition And Dietetics	Public Nutrition Intervention	\$	1,530,350.01
Preventive and Public Health Research	2019 Preventive and Public Health Research	Victoria University	University	VIC	Optimising the dose of exercise to promote improvements of cerebrovascular function and health in middle-aged adults	Exercise as a medical intervention can be an effective way to prevent many diseases. For example, exercise reduces the risk of dementia, which is linked with healthy brain blood flow. However, the correct prescription is critical to optimise the beneficial effects of exercise. This project aims to discover how different 'doses' of exercise affect brain vascular function and health, and translate this new knowledge into more individualised exercise prescriptions to better prevent dementia.	Doctor James Broatch	Doctor James Broatch, Professor David Bishop, Professor Amy Brodtmann	Targeted competitive	1/06/2020	31/05/2025	Human Movement And Sports Science	Exercise Physiology	\$	847,130.00
Preventive and Public Health Research	2019 Targeted Health System and Community Organisation Research (Round 1)	Monash University	University	VIC	Assessing diagnostic accuracy for melanoma with compared to without access to Melanoma Surveillance Photography in high-risk individuals	Skin cancer is Australia's most common and most expensive cancer, but costs vary greatly depending on the stage at diagnosis. Taking a set of total body photographs to use as a reference during skin checks, has shown the potential to improve the accuracy of diagnosis. If confirmed, this would lead to earlier detection, improved survival, better quality of life and lower treatment costs. The financial implications, should total body photographs be reimbursed by Medicare, are not fully understood.	Associate Professor Victoria Mar	Associate Professor Victoria Mar, Professor Anne Cust, Professor H. Peter Soyer, Professor Rachael Morton, Professor Rory Wolfe, Associate Professor Pascale Gutierrez, Mr Paul White, Professor Monika Janda, Doctor Paul Fairburn, Professor John Kelly	Targeted non-competitive	1/06/2019	31/10/2023	Public Health And Health Services	Health Information Systems (Incl. Surveillance)	\$	2,416,998.00
Preventive and Public Health Research	2019 Targeted Health System and Community Organisation Research (Round 1)	University of Western Australia	University	WA	Evaluation of clinical pathways and patient outcomes for breast MRI in preoperative assessment and staging of breast cancer: Establishing when MRI improves patient outcomes and when it does not	Essentially we will try to answer two questions: 1. "Can MRI reassure both the clinician and the patient as to the benignity of the ill-defined features seen on the mammogram/Ultrasono". And 2. "In which groups of women with newly diagnosed breast cancer can MRI improve treatment planning thus lead to better clinical and patient outcomes".	Professor Christobel Saunders	Professor Christobel Saunders, Professor Nehmat Houssami, Professor Gregory Mann, Professor Andrew Spillane, Doctor Patsy Soon, Associate Professor Donna Taylor, Professor Max Barbara, Doctor Michele Reintals, Doctor Colman Taylor, Professor Rachael Morgan	Targeted non-competitive	1/06/2019	31/05/2023	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	2,072,217.00
Preventive and Public Health Research	2019 Targeted Health System and Community Organisation Research (Round 2)	The University of Adelaide	University	SA	Mobile X-ray services provided within residential aged care facilities	An avoidable trip to the hospital can be a distressing experience for aged care residents and their families. For many, the trip is for a diagnostic x-ray following a fall or when abdominal or chest discomfort is experienced. From the 1st of May 2019, Medicare funding to support mobile x-ray services to residential aged care facilities for selected circumstances will exist. This research will assess the benefits of this aged care as well as inform modifications to ensure future sustainability.	Professor Guy Maddem	Professor Guy Maddem, Associate Professor Maria Inacio, Professor Renuka Vivanathan, Professor Jonathan Karnon	Targeted competitive	1/07/2019	30/06/2023	Other Medical And Health Sciences	Medical And Health Sciences Not Elsewhere Classified	\$	1,970,000.00
Preventive and Public Health Research	2019 Targeted Health System and Community Organisation Research (Round 2)	University of Tasmania	University	TAS	ANCHOR Project: health economics and epidemiology of myalgic encephalomyelitis/chronic fatigue syndrome	ME/CFS is a complex condition with debilitating health, social and economic impacts. Little is understood in Australia regarding the prevalence or health economic aspects of the condition. We will conduct four studies which will: i) estimate prevalence of ME/CFS in primary care settings; ii) determine the social and economic burden of ME/CFS to patients and carers, iii) quantify the costs to government and society, and iv) establish the burden of disease associated with ME/CFS for Australia.	Doctor Barbara de Graaff	Doctor Barbara de Graaff, Doctor Julie Campbell, Associate Professor Heidi Nicholl, Associate Professor Martin Hemmer, Doctor Karen Wills, Professor Andrew Palmer	Targeted competitive	1/07/2019	31/12/2022	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	155,000.00
Preventive and Public Health Research	2019 Targeted Health System and Community Organisation Research (Round 3)	Australian National University	University	ACT	Tools to value health change in paediatric populations	Our multidisciplinary team will deliver a program of methodological and applied research that will provide the Pharmaceutical Benefits Advisory Committee and other Commonwealth and State funders of health care with a consistent basis to compare interventions in paediatric populations. Results will allow a broader use of the quality adjusted life year framework to inform policy and resource allocation in a population for which the current evidence has been unable to facilitate broad uptake.	Professor Emily Lancsar	Professor Emily Lancsar, Professor Kirsten Howard, Professor Stavros Petrou, Doctor Elisabeth Huynh, Doctor Martin Howden, Doctor Joanna Cairns, Associate Professor Alison Hayes, Professor Jonathan Craig, Professor Germaine Wong, Professor Cam Donaldson	Targeted competitive	1/06/2020	30/09/2024	Applied Economics	Health Economics	\$	2,215,268.00
Preventive and Public Health Research	2019 Targeted Health System and Community Organisation Research (Round 3)	University of Sydney	University	NSW	Modelling five-year patterns in cancer incidence, staging and related health services	Health system costs for cancer are escalating as the population ages and new high-cost technologies are developed. Predicting changes in cancer trends will be critical to ensuring healthcare subsidies are based on the best evidence and targeted to patient need. Under this research scheme, Cancer Council NSW will build on its leading work in modelling complex cancer trends and related interventions.	Professor Karen Canfield	Professor Karen Canfield, Doctor Eleonora Feletto, Doctor Marianne Weber, Doctor Michael Caruana, Doctor Philip Hayward, Doctor Tracy-Lee Lala, Professor Xun Feng, Mr David Goldsbury, Doctor Pietro Procopio, Doctor Julia Steinberg	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Preventive Medicine	\$	3,585,390.00

Preventive and Public Health Research	2019 Targeted Health System and Community Organisation Research (Round 3)	University of Melbourne	University	VIC	Predicting the population health economic impact of current and new Cancer Treatments (PRIMCAT)	Listing of new cancer treatments in the Pharmaceutical Benefits Scheme (PBS) and Medical Benefits Schedule has become a complicated undertaking, because of the uncertainty in the number of patients who may actually benefit from treatment and the financial implication for the health system. PRIMCAT will use a data-driven modelling approach to answer these questions for three nominated cancers (colorectal, melanoma and NSCLC) and for two pan-cancer mutations Ahead of time in the PBS and MBS.	Doctor Fanny Franchini	Doctor Fanny Franchini, Professor Yuting Zhang, Professor Peter Gibbs, Professor Sallie-Anne Pearson, Doctor Koen Degeir, Doctor Fanny Franchini, Professor Benjamin Solomon, Professor Grant McArthur, Professor Stephen Fox, Associate Professor Lewis Dantal	Targeted competitive	1/06/2020	30/11/2023	Applied Economics	Health Economics	\$	2,322,794.95
Preventive and Public Health Research	2019 Targeted Health System and Community Organisation Research (Round 3)	University of Melbourne	University	VIC	Measuring and valuing changes in child health to facilitate robust decision making	Decisions about health care rely on evidence that treatments work and are value for money. This project will produce better ways of measuring child health outcomes, so we have better evidence. Our results will help decision makers to 'weigh up' improved outcomes for adults and children when making spending decisions. Our research team are world leading experts in child health and measuring outcomes. We will provide a practical set of tools to help make good decisions about children's health care.	Professor Nancy Devlin	Professor Nancy Devlin, Associate Professor Richard Norman, Professor Rosalie Viney, Professor Julie Ratcliffe, Associate Professor Kim Dalziel, Associate Professor Brendan Mulhern, Professor Harriet Hiscock, Professor Deborah Street, Associate Professor Gane Chen	Targeted competitive	1/06/2020	30/11/2023	Applied Economics	Health Economics	\$	2,352,349.50
Preventive and Public Health Research	2019 Targeted Health System and Community Organisation Research (Round 3)	University of Sydney	University	NSW	Evidence on the clinical effectiveness and cost-effectiveness of digital breast tomosynthesis in identifying breast cancer compared to standard imaging in populations at risk of breast cancer	A multi-study research program on DIGITAL BREAST TOMOSYNTHESIS (DBT) will be done in public and private health services, to generate evidence on whether DBT is effective and cost-effective in diagnosing breast cancer compared to other imaging (mammography, ultrasound) in three groups of patients at risk of breast cancer: those with breast symptoms, or with previous breast cancer, or with a family history of breast cancer. Findings from this project will assist decisions on public funding of DBT.	Professor Nehmat Housami	Professor Nehmat Housami, Associate Professor Catherine Bell, Associate Professor Carolyn Nickson, Professor Armando Teixeira-Pinto, Professor Lisa Askie, Doctor Darren Lockie, Doctor Naomi Noguchi	Targeted competitive	1/06/2020	31/05/2024	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	1,422,683.00
Preventive and Public Health Research	2019 Targeted Health System and Community Organisation Research (Round 3)	Monash University	University	VIC	Epidemiological modelling to deliver better care for Australian patients with myeloma	Myeloma is an incurable cancer that accounts for approximately 10% of all blood cancers diagnosed in Australia. Treatment is combination drug therapy with or without high dose chemotherapy and autologous stem cell transplantation, depending on patient age and comorbidities. This research will use data collected in a specific myeloma registry to estimate the numbers of patients who require therapy at different stages of their disease in Australia.	Associate Professor Zoe McQuilten	Associate Professor Zoe McQuilten, Associate Professor Dennis Petrie, Professor Andrew Spencer, Professor Erica Wood, Professor Anthony Harris, Doctor Laura Finning	Targeted competitive	1/06/2020	31/05/2023	Cardiorespiratory Medicine And Haematology	Haematology	\$	459,847.00
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	La Trobe University	University	VIC	Repurposing valproate for the treatment of colorectal cancer	Colorectal cancer is a major cause of cancer related deaths for which there is an urgent need to develop new treatments. The drug valproate has been used to treat epilepsy and mood disorders for over 50 years. We have found that valproate can profoundly increase the anti-tumour activity of a class of drugs known as EGFR inhibitors in laboratory models of colon cancer. We will now test the activity of this drug combination in a phase II clinical trial in patients with advanced colon cancer.	Professor Niall Tebbutt	Professor Niall Tebbutt, Professor John Mariadason, Associate Professor Jeanne Tie, Doctor Katrin Siquist, Professor Timothy Price, Doctor matthew burge	Targeted competitive	1/06/2021	31/05/2024	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	751,884.70
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	University of Melbourne	University	VIC	Repurposing BCL-2 inhibitors for immune manipulation to improve outcomes in allogeneic stem cell transplantation	Allogeneic (donor) stem cell transplantation is a curative therapy for blood cancers. Not everyone can safely have a transplant as the toxicity of the pre-transplant chemotherapy is too toxic. We have discovered in mouse models that by using the existing drug venetoclax we can reduce the intensity of the preparative chemotherapy. This makes the transplant safer yet as effective. In this project we will undertake this same approach in a clinical trial of patients undergoing transplantation.	Professor David Ritchie	Professor David Ritchie, Doctor Rachel Koldej	Targeted competitive	1/06/2021	31/05/2024	Immunology	Transplantation Immunology	\$	599,595.60
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	University of Sydney	University	NSW	MOTIVATE C: The Methodical evaluation and Optimisation of Targeted Interventions for Accessing Treatment of Early stage hepatitis C	Hepatitis C treatment is now well tolerated and highly effective, yet uptake in Australia remains low. Australia is trying to eliminate hepatitis C, whereas interventions are required to increase treatment uptake of those infected with the virus. Financial incentives offer a simple, yet potentially effective, solution. This study will evaluate the effect of random allocation of financial incentives to improve treatment uptake in patients with hepatitis C.	Professor Thomas Snelling	Professor Thomas Snelling, Associate Professor Joseph Doyle, Doctor Wendy Cheng, Professor Margaret Hellard, Doctor Alisa Pedrana, Professor Joshua Davis, Mr Mark Jones, Associate Professor Penelope Abbott, Associate Professor Jane Davies, Professor Kirsten Howard	Targeted competitive	1/06/2021	30/11/2025	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	2,126,775.89
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	University of New South Wales	University	NSW	A Prospective Randomised Controlled Trial of Adults with Perianal Fissulising Crohn's Disease and Optimised Therapeutic Infliximab Levels: PROACTIVE Trial	The study aims to optimise treatment in adults suffering with Crohn's perianal fistulae. The study will compare individualised to standard dosing of current best care medication, infliximab. Individualised dosing will use routinely collected blood drug levels to guide the dose of infliximab given, with the aim to achieve higher blood drug level targets. This new approach is expected to enhance fistula healing, reduce symptom burden, and improve costs; but these benefits have yet to be assessed.	Associate Professor Susan Connor	Associate Professor Susan Connor, Associate Professor Nik Ding, Associate Professor Miles Sparrow, Associate Professor Peter De Cruz, Professor Alisa Hart, Associate Professor Heidi Vande Castele, Doctor Jord Rimola, Mr Basil D'Souza, Professor Danny Lew, Doctor Frances Garden	Targeted competitive	1/06/2021	31/05/2026	Clinical Sciences	Gastroenterology And Hepatology	\$	834,374.30
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	The University of Queensland	University	QLD	A novel use of sterile water for injection to relieve pain in labour	Medical pain relief options for labour have changed little in 50 years. While epidurals are effective other options such as opioids or (laughing) gas are often ineffective and all come with unwanted side-effects. Our placebo-controlled trial will test the use of injections of sterile water to relieve contraction pain in labour; proven by our team as safe and effective for back pain in labour. If successful the trial will provide a simple and safe choice for labour pain relief.	Doctor Nigel Lee	Doctor Nigel Lee, Professor Sue Kildea, Professor Lena Martensson, Associate Professor Yu Gao, Professor Leone Callaway, Doctor Belinda Barnett	Targeted competitive	1/06/2021	31/05/2024	Nursing	Midwifery	\$	302,942.48
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	University of New South Wales	University	NSW	A Phase III randomised placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine ("Ice") dependence	Crystalline methamphetamine ("Ice") is a growing concern in Australia. There are no approved medications that can be used to treat dependence on this drug. This clinical trial will examine whether mirtazapine, a newly identified treatment agent for methamphetamine use, can be used safely and effectively in routine clinical care to manage methamphetamine dependence in Australia.	Associate Professor Rebecca Mcketin	Associate Professor Rebecca Mcketin, Professor Michael Farrell, Professor Louisa Degenhardt, Professor Gregory Dore, Professor Steven Shoptaw, Associate Professor Peter Kelly, Doctor Alysa Turner, Doctor Philip Clare, Doctor Shalini Arunogiri, Ms Samantha Colledge	Targeted competitive	1/06/2021	31/05/2025	Public Health And Health Services	Mental Health	\$	4,899,579.86
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	University of Sydney	University	NSW	Cost-Utility Comparison of Down-Titration Strategies for Safer and More Efficient Use of Biologics in Adults with Rheumatoid Arthritis and Psoriatic Arthritis	Rheumatoid arthritis and psoriatic arthritis can cause severe pain, joint destruction, disability and early death. Biologic drugs can improve these arthritis health outcomes but may also have serious side effects, are very costly and are not cures. Drug-free remission is the next best outcome. This trial aims to identify the optimum dosing strategies for safer and more efficient biologic drug use to help more people with rheumatoid and psoriatic arthritis achieve a drug-free remission.	Professor Lyn March	Professor Lyn March, Professor Rachelle Buchbinder, Professor Marissa Laserna, Professor Susanna Proudman, Professor Rangely Thomas, Professor Deborah Schofield, Doctor Meiling Xue, Associate Professor Mihir Wechalekar, Doctor Samuel Whittle, Doctor Premnani Srinivasan	Targeted competitive	1/06/2021	31/05/2026	Clinical Sciences	Rheumatology And Arthritis	\$	2,720,942.80
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	Melanoma Institute Australia	Medical Research Institute	NSW	NADINA Phase 3 trial comparing response driven neo-adjuvant combination of pilsimab + nivolumab versus adjuvant nivolumab	Standard care for melanoma spread to lymph nodes is surgery followed by 1 year of drug to prevent recurrence. A drug used in many cancers, immunotherapy, cost Australia \$688 million in 2020. This study will test a safe and cost-effective way to prevent recurrence with just 6 weeks of immunotherapy before surgery. If the tumour is destroyed, major surgery and more drug therapy can be avoided. A shorter course of drug therapy will reduce healthcare costs by nearly 50%.	Professor Georgina Long	Professor Georgina Long, Professor Richard Scolyer, Professor Grant McArthur, Associate Professor Alexander Menzies, Professor Andrew Spillane, Associate Professor Matteo Carlos, Associate Professor David Gyorik, Associate Professor Robyn Saw, Associate Professor Serigne Lo, Professor Rachael Morton	Targeted competitive	1/06/2021	31/05/2025	Oncology And Carcinogenesis	Cancer Therapy (Excl. Chemotherapy And Radiation Therapy)	\$	2,023,376.40
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	Monash University	University	VIC	Benchmarking for healthy stores in remote Aboriginal and Torres Strait Islander communities	How food is promoted, priced and made available in food retail has considerable impact on consumer behaviour and subsequently population health. In partnership with government and Aboriginal health services, the remote retail sector and policy-makers, we will codesign and test the feasibility and effectiveness of an innovative benchmarking approach to support healthy food stores in remote Aboriginal and Torres Strait Islander communities and identify the pathway to set benchmarking into policy.	Associate Professor Julie Brimblecombe	Associate Professor Julie Brimblecombe, Doctor Emma McMahon, Doctor Leila McCarthy, Doctor Megan Ferguson, Professor Brownyn Fredericks, Ms Nicole Turner, Professor Amanda Lee, Professor Joanna Battstone, Associate Professor Christina Pollard, Professor Louise Maple-Brown, Adam Sainsbury	Targeted competitive	1/06/2021	31/05/2026	Nutrition And Dietetics	Public Nutrition Intervention	\$	1,450,376.89
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	The University of Queensland	University	QLD	School Readiness child outcomes of early neuroprotection/early neurorehabilitation for infants at high risk of Cerebral Palsy in the first 2,000 days	Cerebral Palsy (CP) is a life-long complex condition that affects movement and learning due to early brain injury. Children with CP are significantly delayed on their School Readiness (in domains of cognition, health, motor, physical activity, communication) than their healthy peers. Our extended follow-up of early interventions at age of 4 years will determine if new treatments can prevent the brain injury and repair those with CP using neuro-rehabilitation leading to better academic outcomes.	Professor Roslyn Boyd	Professor Roslyn Boyd, Professor Iona Nowak, Doctor Catherine Morgan, Associate Professor Leanne Sakzewski, Associate Professor Michael Fahey, Professor Robert Ware, Associate Professor Tracy Connors, Doctor Koa Whittingham, Professor Stewart Trost, Doctor Kerstin Pannek	Targeted competitive	1/06/2021	31/05/2025	Paediatrics And Reproductive Medicine	Paediatrics	\$	1,451,738.18
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	The University of Newcastle	University	NSW	Effectiveness and cost effectiveness of a time-efficient school-based physical activity intervention for adolescents living with disability	Adolescents with disability are less active than their typically developing peers. They also have more co-occurring physical and mental health conditions. Brief but intense exercise is a potent and potentially affordable prevention strategy. Our aim is to test the effectiveness and cost effectiveness of this approach in adolescents with disability. This project has the potential to change school practice by providing a vulnerable group with a new opportunity to be physically active at school.	Professor David Lubans	Professor David Lubans, Professor Nora Shields, Professor Charles Hillman, Professor Chris Lonsdale, Associate Professor Narelle Eather, Doctor Jordan Smith, Doctor Michael Noel, Doctor Penny Reeves, Mr Angus Leahy	Targeted competitive	1/06/2021	31/05/2024	Public Health And Health Services	Preventive Medicine	\$	712,779.71
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	La Trobe University	University	VIC	Exploring the impact of midwife-led group antenatal care on caesarean section rates and infant health: a multi-site randomised controlled trial	Midwife-led group antenatal care and education is where women have pregnancy check-ups, and childbirth and parenting education in groups of about ten women at the same stage of pregnancy, instead of individuals and separate childbirth education. We don't know if it is effective or if it causes harm, so we will test if the midwife-led group care (compared to having individual appointments) improves outcomes for mothers and babies such as fewer caesarean births and more healthy babies.	Professor Della Forster	Professor Della Forster, Doctor Stefan Kane, Professor Helen McLauchlan, Associate Professor Susan Jacobs, Doctor Touran Shafiei, Doctor Catrann Nguyen, Doctor Tram Nguyen	Targeted competitive	1/06/2021	31/05/2026	Nursing	Midwifery	\$	1,284,106.01
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	The University of Queensland	University	QLD	Mothers and their Children's Healthcare Experience Study (MATCHES)	This study collects new data on the experience of preventive healthcare by mothers and children, from before conception, through pregnancy and early childhood. This will generate the new knowledge needed to address issues with the effectiveness and delivery of current maternal and child preventive care. In collaboration with doctors, nurses, and the community, the study will make detailed recommendations to improve preventive healthcare, including for disadvantaged women and children.	Professor Gita Mishra	Professor Gita Mishra, Professor Jenny Doust, Doctor Katrina Moss, Professor Deborah Luntan, Doctor Lisa Buckley, Professor Kathleen Baird, Associate Professor Anthony Herbert, Associate Professor Seema Mishra, Professor Annette Dobson, Professor Craig Olsson	Targeted competitive	1/06/2021	31/05/2025	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	659,448.80
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	University of South Australia	University	SA	A multi-site guideline implementation randomised controlled trial to improve physical activity and screen time in Out of School Hours Care	This study aims to lift the standards of physical activity and screen time offerings in Out of School Hours Care services throughout Australia, by implementing and evaluating newly developed Australian OSHC-sector guidelines for physical activity and screen time. The guidelines will be evaluated in a rigorous trial in OSHC services in SA, NSW and WA, prior to national release.	Professor Carol Maher	Professor Carol Maher, Associate Professor Hayley Christian (nee Cutti), Professor Adrian Estleman, Doctor Nicole Nathan, Professor Richard Rosekrantz, Associate Professor Lucy Lewis, Doctor Dylan Cliff, Doctor Rachel Milne, Doctor Rachel Curtis	Targeted competitive	1/12/2021	30/11/2024	Public Health And Health Services	Community Child Health	\$	1,451,734.59

Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	Monash University	University	VIC	The protective effect of maternal immunisation on obstetric outcomes: characterising the underlying mechanisms and impact on newborn immune function	Preterm birth is a serious complication of pregnancy contributing to long term disability in children. Despite advances in maternity care there has been little reduction in the rate of preterm birth in the last 30 years. Along with protecting against influenza or pertussis infection, vaccination in pregnancy has shown promise in protecting women and babies from preterm birth and may positively alter the immune system of the baby. This project aims to understand how vaccines may do this.	Associate Professor Michelle Giles	Associate Professor Michelle Giles, Professor Tobias Kollmann, Doctor Mary-Ann Davey, Doctor Nelly Amenyegbe	Targeted competitive	1/06/2021	31/05/2025	Paediatrics And Reproductive Medicine	Obstetrics And Gynaecology	\$	1,146,489.15
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	Murdoch Children's Research Institute	Medical Research Institute	VIC	Infant2Child: Optimising nutrition in early life to reduce childhood dental caries	Dental caries (tooth decay) is the commonest disease worldwide and affects 40% of Australian pre-school children. By repurposing an already successful early life dietary and feeding intervention to address the biggest cause of early childhood caries – high sugar intake, and understand how sugar influences oral bacteria to cause caries, this study will deliver urgently needed improvements in childhood oral health, with benefits throughout the life course.	Doctor Mihiri Silva	Doctor Mihiri Silva, Associate Professor Rachel Laws, Doctor Margarita Moreno-Betancur, Professor Stuart Dasher, Doctor Miaobing Zheng, Professor Martin Hall, Professor David Burger, Doctor Anur Singh, Associate Professor Nicky Kipitakis, Associate Professor Kim-Anh LÃ Cao, Sarah Marshall	Targeted competitive	1/06/2021	31/05/2026	Dentistry	Paedodontics	\$	1,267,826.21
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	University of Melbourne	University	VIC	HipHealth: an exercise and weight loss telehealth program to improve outcomes for Australians living with hip osteoarthritis	Hip osteoarthritis is a common problem leading to chronic pain and disability and high rates of joint replacement surgery. This project aims to improve the health and well-being of Australians with hip osteoarthritis by implementing and evaluating an education, exercise and weight loss program (HipHealth) delivered remotely by physiotherapists and dietitians. The program will be firstly tested in the private health insurance setting with view to future scale-up in this and other settings.	Professor Kim Bennell	Professor Kim Bennell, Professor Rana Himman, Doctor Kalpana Sumthiran, Doctor Catherine Keating, Professor Julie Simpson, Professor Anthony Harris, Professor Jillian Francis, Doctor Michelle Hall, Doctor Belinda Lawford	Targeted competitive	1/06/2021	31/05/2026	Clinical Sciences	Physiotherapy	\$	1,124,557.63
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	Monash University	University	VIC	Optimising the delivery of antenatal interventions in public healthcare: Improving equity, access and engagement for better maternal and neonatal health outcomes	Increasing proportion of young women are commencing pregnancy overweight or obese. Research demonstrates that lifestyle interventions improve health during pregnancy and are cost effective, yet scale up into routine pregnancy care remains limited. Here we address this critical gap, supported by stakeholder and community engagement, by developing and enhancing digital technology to increase accessibility, usability and engagement across two Australian healthcare settings.	Doctor Cheryce Harrison	Doctor Cheryce Harrison, Professor Helena Teede, Professor Jennifer McIntosh, Associate Professor Emily Calander, Doctor Kirsten Palmer, Doctor Joanne Ericott, Professor Daphne Pym, Associate Professor Lisa Moran, Professor Ben W. Mol, Doctor Siow Lim	Targeted competitive	1/06/2021	30/09/2025	Public Health And Health Services	Preventive Medicine	\$	1,450,942.83
Preventive and Public Health Research	2020 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	University of Sydney	University	NSW	A Systems approach to enhancing community-based medication review	This proposal will enhance the quality use of medicines in primary care by building better systems for pharmacists and GPs to work together by establishing multi-disciplinary Medication Therapeutics Committees in Primary Health Networks (PHNs) and through better integration of professional pharmacy services. At the patient level, individuals at high risk of medication harm will be recruited to receive a medication review and other support services after discharge. At the system level, quality use of medicine indicators will be monitored and pharmacists and GPs supported to provide optimal medication management. A stepped-wedge cluster randomised trial will be used with the main hypothesis being a reduction in hospital readmissions.	Professor Timothy Chen	Professor Timothy Chen, Associate Professor Tracey Lea Luba, Associate Professor Fiona Robinson, Associate Professor Charles Demaro, Associate Professor Danijela Griglic, Doctor Emily Saarnan, Doctor Rose Cairns, Doctor Carl Schneider, Doctor Kenji Fujita, Doctor Joanna Moulton, Doctor Keri Luetich, Doctor Alexandra Bennett, Professor Parker Magin, Professor Asad Patanwala, Professor David Lyle, Professor Ian Coombes, Professor Sarah Hilmer	Open competitive	30/06/2021	29/06/2025	Not available	Not available	\$	2,432,288.00
Preventive and Public Health Research	2020 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	University of Sydney	University	NSW	Pharmacy-based screening and quality use of medicines in kidney disease	Chronic Kidney Disease (CKD) is a growing public health concern with over 1.7 million Australians unaware that they have indicators of CKD. Community pharmacists in Australia are a largely untapped health resource for the identification and management of patients with CKD. The overall goal is to screen people for CKD via community pharmacies and provide a quality use of medicine service which includes identifying medications that are potentially inappropriate (as per the kidney function) and/or nephrotoxic and provide recommendations to optimise use of medications. The benefits include reduced medication-related harm, improved public knowledge and awareness of CKD risk factors, and expanded public health roles for community pharmacists.	Doctor Ronald Castello	Doctor Ronald Castello, Associate Professor Judy Mullin, Associate Professor Sanjoy Vaghalkar, Associate Professor Lukas Kairalis, Associate Professor Kamal Sud, Doctor Wubshet Tesfaye, Doctor Nasir Ghies, Doctor Anh Tran, Doctor Rita McMoraw, Doctor Connie Van, Professor Ines Krass, Professor David Johnson	Open competitive	30/06/2021	29/06/2025	Not available	Not available	\$	1,894,075.00
Preventive and Public Health Research	2020 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	Monash University	University	VIC	The ALLIANCE trial	The ALLIANCE trial will improve the health and wellbeing of Australian women by promoting safe and effective use of contraceptive medicines amongst those at high risk (women seeking the emergency contraceptive pill (ECP) or early medical abortion (EMA) in settings such as rural and regional communities. It will determine whether expanding community pharmacist's scope of practice to deliver a reliable consultation involving high quality, structured, patient centred, effectiveness-based contraceptive counselling and a referral to a contraceptive provider results in increased use of subsequent effective contraception amongst these women and reduced unintended pregnancy, thereby addressing a key goal of the National Women's Health Strategy.	Professor Danielle Mazza	Professor Danielle Mazza, Associate Professor Kevin McGeehan, Doctor Saleera Hussaini, Doctor Jody Church, Ms Stefanie Johnston, Professor Jane Tompary, Professor Sharon Cameron, Professor Deborah Bateson	Open competitive	30/06/2021	29/06/2025	Not available	Not available	\$	2,493,400.00
Preventive and Public Health Research	2020 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	University of Sydney	University	NSW	Safer medicines To reduce falls and fractures for Osteoporosis (RSTOP)	This project will evaluate a coordinated and integrated referral pathway for a pharmacist-led medication review for consumers with osteoporosis that have sustained a minimal trauma fracture. This intervention aims to decrease falls risk and refracture by reducing the use of medicines that lead to falls and improve the use of anti-osteoporosis medicines for bone strength. Individuals will be identified via Osteoporosis Refractive Prevention (ORP) services at 7 clinical sites across NSW and Victoria. The recommendations of the pharmacists' review will be shared with the ORP specialists, the consumers' primary care providers and a lay summary will be shared with the consumer to empower them to discuss their shared-care plan with their GP and pharmacist.	Associate Professor Rebekah Moles	Associate Professor Rebekah Moles, Associate Professor Kathryn Gibson, Associate Professor Christopher Yates, Associate Professor Stephen Barnett, Associate Professor Patrick Bolton, Associate Professor Christopher White, Associate Professor Justine Naylor, Doctor Carter Stephen, Doctor Benjamin Bagger, Doctor Steven Frost, Doctor Kate Luckie, Doctor Matthew Jennings, Doctor Thanh Tran, Doctor Ayoana Kelly, Doctor Lei Si, Doctor Gabor Major, Doctor Dana Blum, Doctor Geraldine Hassett, Ms Jenny Ly, Professor Mark Kotowicz, Professor Jacqueline Carter, Professor Gustavo Duque, Professor Lin Perry, Professor Peter Ebeling	Open competitive	30/06/2021	29/06/2025	Not available	Not available	\$	2,337,170.00
Preventive and Public Health Research	2020 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	The University of Queensland	University	QLD	Activating pharmacists to reduce medication related problems: ACTMED	This innovative project takes a whole-of-system approach to identify and reduce serious medication safety problems (MRPs) most likely to cause hospitalisations, morbidity and mortality. Based in primary care, initiated by pharmacists and actioned within an integrated primary care framework, interventions will be co-designed and supported through new IT modules, an actionable dashboard and financial incentives. Using a pre-specified list of clinical indicators, individuals at risk of serious MRPs will be identified through clinical records that are compatible with My Health Record, enabling future national scalability. A co-design process will incorporate all consumer preferences, including Aboriginal and Torres Strait Islander peoples.	Doctor Jean Spinks	Doctor Jean Spinks, Associate Professor Dennis Petrie, Associate Professor Josh Byrnes, Doctor Laura Fanning, Doctor Fiona Kelly, Doctor Kerry Hall, Professor Lisa Hixon, Professor Douglas Boyle, Professor Amanda Wheeler, Professor Robert Ware	Open competitive	30/06/2021	29/06/2025	Not available	Not available	\$	2,498,824.00
Preventive and Public Health Research	2020 Targeted Translation Research Accelerator	MTPConnect	Corporation	VIC	MTPConnect Diabetes and Cardiovascular Accelerator initiative	The MTPConnect Diabetes and Cardiovascular Accelerator (Accelerator) will provide a three pillar program to improve the management and treatment of diabetes and cardiovascular disease (D&CVD). The Accelerator will: 1) establish research centres for diabetes and cardiovascular disease, 2) establish a contestable funding program to support D&CVD research projects, and 3) promote the effective clinical and commercial translation of novel therapeutics and devices for D&CVD. The Accelerator, guided by an expert Board appointed by the Minister for Health, will work in partnership with leading D&CVD groups to improve the health and wellbeing of local, national and international communities through research, education and clinical practice.	Not applicable	Not available	Open competitive	29/06/2020	31/01/2025	Not available	Not available	\$	47,000,000.00
Preventive and Public Health Research	2021 Chronic Respiratory Conditions	University of New South Wales	University	NSW	The Breathlessness Rapid Evaluation And Therapy (BREATHE) Project	Breathlessness affects around 2 million Australians and causes greater risk of hospital admission, impaired quality of life and loss of work capacity. It is often poorly assessed in primary care, diagnosis is delayed and management is not tailored to patients' needs. Breathlessness has many causes but management can be accurate, personalised and efficient. We have developed a computerised pathway for diagnosis and evidence based management, and will test its effectiveness in primary care.	Professor Christine Jenkins	Professor Christine Jenkins, Doctor Allison Humphries (nee Martin), Associate Professor Gian Luca Di Tanna, Professor David Peris, Associate Professor Charlotte Hespe, Associate Professor Clare Anon, Professor Stephen Ian, Associate Professor Zoe McKeough, Doctor Anthony Sunjaya, Professor Guy Marks, Doctor Devansetty Praveen, Ms Caroline Polak-Sowerell	Targeted competitive	1/01/2023	28/02/2029	Clinical Sciences	Clinical Sciences, Clinical Sciences Not Elsewhere Classified	\$	1,878,738.80
Preventive and Public Health Research	2021 Chronic Respiratory Conditions	The University of Newcastle	University	NSW	Minimising Oral Corticosteroid use in Asthma using Treatable Traits	We aim to test the effectiveness of a new individualised treatment approach, we call Treatable Traits, and assess acceptance of this approach with people with asthma. A trait is a characteristic belonging to a person, that can be behavioural, physical, psychosocial or genetic. For a trait to be included in our approach it has to be something that can be changed, or 'treated'. We assess each person to identify the traits then personalise their treatment plan, to treat these traits.	Professor Vanessa McDonald	Professor Vanessa McDonald, Associate Professor Elizabeth Holliday, Professor Philip Bardin, Professor Alvar Agusti Garcia Navarro, Professor Luke Wolfenden, Professor Peter Gibson, Professor Anne Verigan, Doctor Dennis Thomas, Professor Richard Beasley, Associate Professor McLaughlin, Professor John Upham, Associate Professor John Blakey, Doctor John Farley, Doctor Penny Reeves, Professor Ian Pavord	Targeted competitive	1/01/2023	31/12/2028	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology Respiratory Diseases	\$	1,813,800.20
Preventive and Public Health Research	2021 Chronic Respiratory Conditions	Flinders University	University	SA	A novel targeted approach to deliver treatable-trait based precision medicine for obstructive sleep apnoea	>1 million Australians have obstructive sleep apnoea (OSA). In addition to disrupted sleep, OSA has serious health, safety, & economic consequences. Current treatment approaches do not consider an individual's specific needs leading to patient frustration and significant untreated disease. Our research program will generate new diagnostic and clinical tools to provide a range of effective personalised alternative OSA targeted treatments to improve patient health and satisfaction.	Professor Danny Eckert	Professor Danny Eckert, Associate Professor Andrew Vakulin, Doctor Angela D'Rozario, Doctor Camilla Hoyos, Professor Peter Catcheside, Associate Professor Craig Phillips, Associate Professor Keith Wong, Professor Robert Adams, Doctor Bastien Lechat, Professor Brendon Yee, Professor Ronald Grunstein, Associate Professor Ching Li-Chai-Cotter, Associate Professor Sutapa Mukherjee, Associate Professor Niranjan Bidargaddi	Targeted competitive	1/03/2023	29/02/2028	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology Respiratory Diseases	\$	1,999,634.00

Preventive and Public Health Research	2021 Chronic Respiratory Conditions	Curtin University	University	WA	Treating Pulmonary Pseudomonas infections with Bacteriophage Therapy (TERMINATE- TRIALS)	Bacterial infections resistant to drugs that kill bacteria (antimicrobials) are a global health crisis. With few new antimicrobials being developed, other approaches are needed. Bacteriophages are viruses that only infect specific bacterial species. Using a precision medicine approach, we will identify, prepare and deliver phages tailored to individual's need. We will treat patients with antimicrobial-resistant lung infections with inhaled phage and monitor its effects.	Associate Professor Anthony Kicic	Associate Professor Anthony Kicic, Professor Stephen Skid, Doctor Luke Garratt, Professor Hakim Chin, Professor Mark Nicol, Professor Barbara Chang, Doctor Sandra Agudelo Romero, Professor Tobias Kollmann, Doctor See Tai, Associate Professor Alexander Jarman	Targeted competitive	1/01/2023	31/12/2026	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology Respiratory Diseases	\$	1,972,631.60
Preventive and Public Health Research	2021 Chronic Respiratory Conditions	The University of Newcastle	University	NSW	Personalising the management of obesity-associated asthma using medical nutrition therapy and physical activity prescription: The IDEAL Study	Obesity is present in 42% of Australian adults with asthma and is associated with poorer asthma outcomes. It is a treatable trait, however there is insufficient evidence to guide its treatment. We will test the first individualised obesity management approach in people with asthma, which will address nutritional and physical activity inadequacies, while considering patient preferences, behaviours, and comorbidities. We will determine impact on asthma, with findings informing policy and practice.	Doctor Hayley Scott	Doctor Hayley Scott, Doctor Evan Williams, Professor Anne Dixon, Doctor Alexandra Brown, Doctor Sarah Vallenborgs, Doctor Bronwyn Berthoin, Associate Professor See Lin Young, Associate Professor Jay Horvat, Doctor Natasha Weaver, Professor Lisa Wood	Targeted competitive	1/01/2023	31/12/2027	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology Respiratory Diseases	\$	1,474,151.15
Preventive and Public Health Research	2021 Chronic Respiratory Conditions	Flinders University	University	SA	A treatable traits framework for chronic respiratory disease in rural and regional Aboriginal communities	Managing chronic lung disease (CLD) via a "treatable traits" approach allows care to be tailored to the health needs of the individual. Regional Aboriginal communities have amongst the highest burden of CLD in Australia but providing treatable traits models of care is hampered by limited health infrastructure and differences in clinical needs. We will co-design treatable traits models with regional Aboriginal communities in New South Wales and South Australia as a template for national roll-out.	Professor Geraint Rogers	Professor Geraint Rogers, Doctor Guy Cameron, Ms Lisa Flynn, Associate Professor Odette Pearson, Professor Jodie Simpson, Professor Peter Wark, Doctor Elissa Elvidge, Ms Karen Baker, Paul Duncan, Professor Caroline Miller, Professor Steven Wesslingh, Doctor Steven Taylor	Targeted competitive	1/01/2023	31/12/2028	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology Respiratory Diseases	\$	1,997,629.00
Preventive and Public Health Research	2021 Chronic Respiratory Conditions	University of Western Australia	University	WA	Treatable Traits in Interstitial Lung Disease (ITRILD) Study: The New Frontier	Interstitial Lung Disease (ILD) is a major cause of morbidity and mortality that has different causes. We propose to identify specific clinical characteristics of ILD called treatable traits. Our study will test if specifically addressing these treatable traits improves patient outcomes and is cost-effective. In addition, we will also discover new treatable traits using cutting-edge technologies for future development. We suggest our study will significantly improve management of ILD.	Professor Yubem Moodley	Professor Yubem Moodley, Doctor Emily Jeffery, Doctor Alan Teoh, Associate Professor Nicole Goh, Professor Andrew Palmer, Associate Professor Vinicius Cavalheri de Oliveira, Professor Joseph Powell, Doctor John Macdonald, Professor Daniel Chambers, Associate Professor Yet Khor, Professor Joanne Dickinson, Associate Professor Tamara Corte, Associate Professor Kristin Ganey, Professor Philip Hambro, Doctor Tim Luckett	Targeted competitive	1/01/2023	31/05/2028	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology Respiratory Diseases	\$	1,999,323.20
Preventive and Public Health Research	2021 Chronic Respiratory Conditions	Monash University	University	VIC	Primary Breathe AUS: A primary care technology-enabled intervention to improve symptom self-management for people with chronic respiratory illness	Breathlessness is a common, distressing symptom experienced by people with lung conditions. It is hard to treat as it persists despite treating the lung condition. A few hospital teams have developed effective ways to support patients to improve their breathing, but access to this care is limited. Using technology (websites, Apps, telehealth), this research will test whether this breathlessness care can be effectively provided in primary care to enable more people with lung diseases to benefit.	Associate Professor Natasha Smallwood	Associate Professor Natasha Smallwood, Professor Jonathan Mant, Associate Professor Christian Osadnik, Doctor Anna Spathis, Associate Professor Daniel Stauden, Doctor Priti (Paragita) Chondri, Associate Professor Rebecca Dieter, Associate Professor Yet Khor, Professor Karen Willis, Professor Grant Russell, Associate Professor Jo-Anne Manak-Nankens, Professor Lena Sanci, Professor Sintha Bosnic-Antkewich, Doctor Kerry Hancock, Professor Jennifer Philip	Targeted competitive	1/01/2023	31/12/2028	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology Respiratory Diseases, Public Health and Health Services, Primary Health Care	\$	1,977,834.10
Preventive and Public Health Research	2021 Chronic Respiratory Conditions	University of Sydney	University	NSW	A randomised clinical trial of a digital self-management package for people with interstitial Lung Disease (the REBUILD-SM trial)	This trial will address a major unmet need identified by people with interstitial lung disease, for disease-specific self-management and support. We will study the efficacy and cost-effectiveness of our self-management program delivered via our smartphone application in a randomised clinical trial (REBUILD-SM trial). We hypothesise that REBUILD-SM will improve quality of life for people living with ILD, through better self-efficacy and reduced symptom burden and anxiety.	Associate Professor Tamara Corte	Associate Professor Tamara Corte, Doctor Ingrid Cox, Associate Professor Nicole Goh, Professor Andrew Palmer, Professor Yubem Moodley, Doctor Liliana Laranjo, Professor Daniel Chambers, Associate Professor Luke Kribbs, Professor Anthony Kicic, Professor Anne Holland, Associate Professor Ian Glasziou, Doctor Narelle Cox, Associate Professor Lauren Troy	Targeted competitive	1/01/2023	31/05/2029	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology Respiratory Diseases	\$	1,999,997.08
Preventive and Public Health Research	2021 Chronic Respiratory Conditions	University of Sydney	University	NSW	Lungs for life: Using wearable oximetry and a virtual ward to improve outcomes of infants with bronchopulmonary dysplasia (BPD)	We will use a wearable oximeter and digital health package that was extensively used globally for home care of adult patients in the COVID-19 pandemic to improve the health of infants with bronchopulmonary dysplasia (BPD), who are at risk of hypoxia (low oxygen levels). Over 4 years, we will enrol 224 Australian infants with BPD to usual care or home oximetry with the primary outcome of decreasing hospitalisation by improving oxygenation and improving patient compliance to medical care.	Professor Ju Lee Oei	Professor Ju Lee Oei, Professor Alistair McEwan, Doctor Evelyn Lee, Professor Dominic Fitzgerald, Doctor Himanshu Popat, Doctor Mark Tracy, Professor Jane Pilrow, Doctor Sandya Khanna, Associate Professor Shannon Simpson, Professor Anne Chang, Associate Professor Donna Haritz, Doctor Andrew Wilson, Doctor Carolyn Mazariego, Mrs Kylie Russell, Robert Halliday	Targeted competitive	1/01/2023	30/06/2028	Paediatrics And Reproductive Medicine	Paediatrics And Reproductive Medicine, Paediatrics	\$	1,918,884.78
Preventive and Public Health Research	2021 Consumer-Led Research	University of Sydney	University	NSW	The Natural Helper approach to culturally responsive healthcare	The purpose is to understand if patients from culturally and linguistically diverse (CALD) backgrounds experience greater engagement with chronic disease self-management when they receive mentoring from a culture-specific peer, compared to those who do not. We expect CALD patients who receive mentoring from someone with lived experience will be better equipped to adopt recommended behaviours and this will result in higher activation and self-efficacy, better coping and greater quality of life.	Doctor Bernadette Brady	Doctor Bernadette Brady, Associate Professor Catherine Said, Associate Professor Claire Ashton-James, Associate Professor Justine Naylor, Doctor Clarice Tang, Doctor David Lim, Doctor Geraldine Jassat, Mr Joseph Descaillie, Mr Matthew Jennings, Ms Baldwin Sudis, Ms Bonnie Ikeda, Ms Samia Sayad, Professor Gavin Williams, Professor Kathryn Hefelhaage, Professor Sarah Dennis	Targeted competitive	1/01/2023	31/12/2025	Clinical Sciences	Clinical Sciences, Clinical Sciences Not Elsewhere Classified, Other Medical And Health Sciences, Medical And Health Sciences Not Elsewhere Classified	\$	576,851.10
Preventive and Public Health Research	2021 Consumer-Led Research	Flinders University	University	SA	Harneising the power of co-design to develop digital solutions and improve health self-efficacy after stroke	Our team will design a way of using digital technology (eg website, app, phone messaging) to help survivors of stroke and access to get information to manage their health and wellbeing. After designing the digital solution, we will ask survivors and carers to test it, to make sure it is easy to use. We will refine it if there are problems. We will then test the digital solution on different groups of survivors and carers to see who the solution looks likely to help. This will guide future research.	Doctor Elizabeth Lynch	Doctor Elizabeth Lynch, Associate Professor Anne Huthichinson, Doctor Anna Kneedwell, Doctor Ester Klimkeit, Doctor Jo River, Doctor Mark Pearson, Doctor Tracy Smith, Mr Don Dennett, Mrs Lenette Ruttle, Ms Mary Roberts, Professor David Currow, Professor Gerben Keijzers, Professor Marie Williams, Professor Meera Agar	Targeted competitive	1/01/2023	31/12/2025	Public Health And Health Services	Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	599,874.14
Preventive and Public Health Research	2021 Consumer-Led Research	University of Technology Sydney	University	NSW	Co-designing with consumers, carers and other stakeholders a self-management plan for breathlessness crises from chronic obstructive pulmonary disease (COPD)	Breathlessness 'crises' are terrifying events that disempower people with COPD ('consumers') and their carers. This project will co-design with consumers, carers and clinicians a written self-management 'plan' to help consumers and carers bring breathlessness crises under control. Feasibility testing will refine the plan and develop tools to get it into practice. The Lung Foundation Australia will promote the plan in online, printed and app formats through its networks and educational program.	Doctor Tim Luckett	Doctor Tim Luckett, Associate Professor Joel Rhee, Doctor Ann Hutchinson, Doctor Anna Kneedwell, Doctor Ester Klimkeit, Doctor Jo River, Doctor Mark Pearson, Doctor Tracy Smith, Mr Don Dennett, Mrs Lenette Ruttle, Ms Mary Roberts, Professor David Currow, Professor Gerben Keijzers, Professor Marie Williams, Professor Meera Agar	Targeted competitive	1/01/2023	31/12/2025	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology Respiratory Diseases	\$	397,111.74
Preventive and Public Health Research	2021 Consumer-Led Research	Monash University	University	VIC	HeartPath- Targeting self-efficacy and health literacy through patient education to prevent recurrent heart events in Australians with heart disease	The aim of HeartPath is to test the effectiveness and implementation of a co-designed website to help heart disease patients and their families actively manage risk factors and overall health. Specifically, we aim to improve comprehensive health literacy skills of patients and families. We believe that by improving comprehensive health literacy, patients and families will have more confidence and knowledge to undertake heart disease risk factor management leading to a healthier and longer life.	Doctor Susan Cartledge	Doctor Susan Cartledge, Caryl Hennequin, Associate Professor Dion Stob, Associate Professor Janet Bray, Doctor Alison Beauchamp, Doctor Barbara Murphy, Doctor Ella Zhang, Doctor Li Li, Doctor Ling Zhang, Ms Rebecca Nourse, Professor Adrienne O'Neil, Professor Andrea Driscoll, Professor Julie Redfern, Professor Robyn Gallagher, Professor Rory Wolfe	Targeted competitive	1/01/2023	31/10/2026	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology Cardiology (incl. Cardiovascular Diseases), Public Health And Health Services, Health Promotion	\$	598,381.24
Preventive and Public Health Research	2021 Consumer-Led Research	University of Melbourne	University	VIC	MINDCARE: Co-producing a dementia risk reduction program for CALD communities to improve health self-efficacy	The MindCare project aims to raise awareness of modifiable lifestyle factors that can reduce the risk of developing dementia in culturally and linguistically diverse (CALD) communities, and thus increase health self-efficacy and empower consumers to take action to improve their health and reduce their risk of dementia. The program will be co-created with consumers from Vietnamese-, Hindi-, Greek-, and Arabic-speaking communities, and delivered via community-based educators.	Doctor Josefina Antoniadou	Doctor Josefina Antoniadou, Associate Professor Tuan Anh Nguyen, Doctor Ardostorene Gilbert, Doctor Antonia Thodis, Doctor Joanne Enticott, Doctor Katrin Gerber, Mrs Dilnaz Billimoria, Ms Thu Ha Dang, Professor Bianca Brighenti, Professor Razi Levinger, Professor Robyn Woodward-Kron	Targeted competitive	1/01/2023	31/12/2025	Public Health And Health Services	Public Health And Health Services, Health Promotion	\$	599,932.06
Preventive and Public Health Research	2021 Consumer-Led Research	Flinders University	University	SA	Development and Evaluation of Used Experience Peer Support Intervention for Mental Health Service Users in Primary Care	Primary care services provide crucial mental health support to many Australians, but demand is overwhelming. Many Australians many fall through system gaps, leaving their mental health unaddressed. Lived experience peer support has been used in many mental healthcare contexts, but not in primary care. Peers walk alongside consumers to improve their self-efficacy and personal recovery. Peer support will improve access, engagement and support for people with mental ill-health in primary care.	Professor Sharon Lawn	Professor Sharon Lawn, Bill Gye, Associate Professor Billingsley Kaambwa, Associate Professor Tania Shelby-James, Caroline Phegan, Doctor Louise Byrne, Doctor Helen Rattray, Doctor Sam Manger, Doctor Shabli Ullah, Doctor Vivian Isaac, Mr Geoff Harris, Ms Christine Kane, Professor Paul Worley	Targeted competitive	1/01/2023	31/12/2025	Public Health And Health Services	Public Health And Health Services, Primary Health Care, Public Health And Health Services, Mental Health	\$	599,663.76
Preventive and Public Health Research	2021 Consumer-Led Research	University of Sydney	University	NSW	DRIV-8: A co-designed personalised App to navigate and accelerate my mental health recovery	Using findings from preliminary research and a rigorous co-design process, we will develop and test the usefulness and impact of the DRIVING my own mental health recovery (DRIV-8) App. DRIV-8 will transform a widely-used and well-tested self-assessment (RAS-8) Recovery Assessment Scale - Domains and Stages), from an outcome measure into a self-directed process to support mental health consumers to navigate and drive their own recovery assessment, goal setting and action planning.	Associate Professor Nicola Hancock	Associate Professor Nicola Hancock, Associate Professor Justin Karlan, Doctor Anne Honey, Doctor Grenville Rose, Doctor Naesam Ahmadpour, Mr Mark Orr, Ms Helen Glover, Professor Lorraine Smith	Targeted competitive	1/01/2023	31/12/2025	Public Health And Health Services	Public Health And Health Services, Mental Health	\$	556,676.50
Preventive and Public Health Research	2021 Consumer-Led Research	University of Technology Sydney	University	NSW	Our Recovery - A mental health, evidence-based online program to optimise pain self management in the community	People living with chronic pain require support to manage their condition over the long term, yet our current healthcare system is unable to provide that support. This project will develop and test an innovative, community-based online support program for chronic pain. Our Recovery, Co-designed and led by consumers, the Our Recovery program will support people to live well with chronic pain using the best research evidence. Program outcomes will be compared with usual care for chronic pain.	Professor Toby Newton-John	Professor Toby Newton-John, Associate Professor Anne Grunseit, Associate Professor Kris Rogers, Doctor Bronwyn Lemnox Thompson, Doctor Colleen Johnston-Devine, Doctor Hemakumar Devam, Ms Angie Chen-Hawkins, Ms Jolanta Bellon, Professor Donald Nease, Professor Steven Kamper	Targeted competitive	1/01/2023	31/12/2026	Public Health And Health Services	Public Health And Health Services, Health And Community Services	\$	591,639.40

Preventive and Public Health Research	2021 Consumer-Led Research	The University of Queensland	University	QLD	Bridging the Digital Divide: Building Health Self-Efficacy through Communication-Accessible Online Environments	Many essential health and support services are now primarily accessible through the internet. While this increases access for many, it can be a barrier for people with disability. Language skills (reading, writing, understanding) are essential for internet use. This is a problem for stroke survivors who have aphasia (impaired language/communication). We will develop technology, training and guidelines that make the internet accessible to people with communication disability.	Doctor Sarah Wallace	Doctor Sarah Wallace, Doctor Anne Hill, Doctor Ciara Shiggins, Doctor Sonia Brownsett, Doctor Kirstine Shrivastava, Doctor Peter Worby, Mr Philip Jameson, Mrs Kim Barron, Professor Alex Haslam, Professor David Copland, Professor Janet Wiles, Professor Leanne Jantke	Targeted competitive	1/01/2023	30/06/2025	Clinical Sciences	Clinical Sciences, Rehabilitation And Therapy (Excl. Physiotherapy), Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	537,750.00
Preventive and Public Health Research	2021 Consumer-Led Research	Monash University	University	VIC	Consumer and Community Involvement: Implementation Research for Impact (CCIR)	We propose an innovative research program to build consumer and community networks; develop a digital hub using state of the art methods to harness innovative co-design and information technology expertise to create, evaluate, refine and deliver the Hub. We will generate new knowledge to enable behaviour change towards genuine CUE and will integrate knowledge from these activities in health research case studies and develop an implementation resources to enable national scale-up.	Professor Helena Teede	Professor Helena Teede, Ms Ainslie Cahill, Professor Carol Hodgson, Ms Debra Langridge, Doctor Sandra Reeder, Professor Kerrie Doyle, Associate Professor Alan Dorin, Professor Mark Parsons, Associate Professor Leah Hea, Doctor Angela Jones, Professor Diana Egerton-Warburton	Targeted competitive	1/01/2023	31/01/2025	Public Health And Health Services	Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	999,128.90
Preventive and Public Health Research	2021 Consumer-Led Research	University of Western Australia	University	WA	Good paths for healthy hearts: bringing choice and flexibility to long-acting penicillins for rheumatic heart disease	Rheumatic heart disease (RHD) disproportionately affects Indigenous Australians. For 70 years there has been only one treatment to prevent RHD and adherence rates are low. This study recognises that to prevent RHD strategies must be culturally acceptable. Using both-way conversations with consumers leading trial design, we will implement two novel ways to deliver long acting penicillin with the aim of providing greater choice and flexibility for the patient, their carers and the community.	Associate Professor Laurens Manning	Associate Professor Laurens Manning, Associate Professor Joshua Francis, Ms Vicki Wade, Professor Jonathan Carapetis, Professor Anna Ralph, Doctor Emma Haynes, Doctor Renae Barry, Associate Professor Marisa Gilles, Doctor Jennifer Yan, Mr Glenn Pearson, Associate Professor Judith Katznelson	Targeted competitive	1/01/2023	30/06/2026	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health	\$	999,230.40
Preventive and Public Health Research	2021 Consumer-Led Research	University of Tasmania	University	TAS	Privileging the spirit, voices, and culture of Aboriginal people in dementia care: Education for non-Aboriginal healthcare providers	Aboriginal people with dementia must receive culturally respectful and safe care. The Royal Commission into Aged Care Quality and Safety has expressed concern that many non-Aboriginal staff are unfamiliar with such care. Working with Aboriginal Elders from TAS, VIC, NSW, and WA, we will co-create new knowledge to educate non-Aboriginal healthcare providers, initially through a free online university unit, then scaled up for nationwide availability through a free Massive Open Online Course.	Associate Professor Lynette Goldberg	Associate Professor Lynette Goldberg, Doctor Kylie Radford, Doctor Tanya Schramm, Associate Professor Alison Canty, Professor Dawn Besarab, Doctor Jennifer Evans, Associate Professor Tony Barnett, Doctor Manesh Kuruvilla, Mrs Dianne Baldock, Associate Professor Dina Loufiduc, Associate Professor Jade Cartwright, Doctor Kate Smith, Mrs Lauren Poules, Associate Professor Clair Andersen	Targeted competitive	1/01/2023	31/12/2025	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health	\$	989,089.80
Preventive and Public Health Research	2021 Consumer-Led Research	University of Sydney	University	NSW	Adolescent-led transformation of preventive and public health research using citizen science	Chronic diseases are among the most significant health threats facing today's teenagers. Yet, few studies have engaged adolescent consumers in the research process. We ask, "Why aren't teenage voices included in preventive and public health research?" To this, our project will use low-cost digital tools to engage teenagers in all phases of the research cycle. This research will improve their understanding of and interest in research, enhance research agendas and improve health outcomes.	Doctor Stephanie Partridge	Doctor Stephanie Partridge, Associate Professor Seema Mirshah, Professor Ollie Jay, Professor Philmyrath Phangavan, Doctor Katrina Chumpon, Professor Julie Redfern, Doctor Louise Thornton, Doctor Hoi Lun Cheng, Doctor Anna Singleton, Doctor Lauren Gardner, Doctor Karice Hyun	Targeted competitive	1/01/2023	31/12/2025	Public Health And Health Services	Public Health And Health Services, Health Promotion, Nutrition And Dietetics, Public Nutrition Intervention, Public Health And Health Services, Mental Health	\$	799,815.10
Preventive and Public Health Research	2021 Consumer-Led Research	University of Melbourne	University	VIC	A Citizen Science Project to co-create 'BigaAgAr' a Preventive Experiential, Arts, Cultural Evidence (PEACE) model for implementing at-scale in primary care and community	For Australia to see effective solutions to current health inequities faced in priority populations such as Aboriginal and Torres Strait Islander people and people who live with severe mental ill-health, there is an urgent need for Preventive, Experiential, Arts and Cultural Evidence models for practice. The PEACE citizen project uses crowdsourcing, co-design of augmented and virtual reality models tested in the big anxiety festival to co-create evidence for future implementation at-scale.	Professor Victoria Palmer	Professor Victoria Palmer, Professor SarbDoxora Eades, Professor Kelsey Hegarty, Katie Lamb, Associate Professor Michelle Barfield, Philip Orcher, Mr Josh Moorhouse, Ms Elise Dettmann, Professor Jill Bennett, Doctor Jennifer Bibb, Doctor Oliver Black	Targeted competitive	1/01/2023	31/12/2025	Public Health And Health Services	Public Health And Health Services, Primary Health Care	\$	934,035.60
Preventive and Public Health Research	2021 Maternal Health and Healthy Lifestyles	Cancer Council Victoria	Corporation	VIC	Improved labelling of ready-made infant & toddler foods to empower healthier parental choices: a scalable policy intervention	Early nutrition is vital to lifelong health. Many readymade commercial infant/toddler foods contain unhealthy added sugars. Placing 'added sugar' warning labels on such foods and restricting on-pack marketing claims could help parents to identify and access healthier options for their infants/toddlers. This project will test the efficacy of these interventions through research with parents. Should they prove effective, they could be made mandatory, achieving national reach and widespread impact.	Associate Professor Helen G Dixon	Associate Professor Helen G Dixon, Doctor Ashleigh Haynes, Doctor Belinda Chelsea Morley, Doctor Ntheli Jacobs Silva, Andrea Lea Rhodes, Ms Jennifer Rae McCann, Professor Melanie A Wakefield, Doctor Lindsey Taillie, Professor Helen Skouteris, Associate Professor Bridget Kelly	Targeted competitive	1/01/2023	31/12/2025	Nutrition And Dietetics	Nutrition And Dietetics, Public Nutrition Intervention, Public Health And Health Services, Clinical And Counselling Psychology	\$	349,041.63
Preventive and Public Health Research	2021 Maternal Health and Healthy Lifestyles	University of Western Australia	University	WA	Scaling-up the 'Play Active' program to improve children's physical activity in early childhood education and care — a multi-state hybrid effectiveness-implementation trial	Physically active play is critical during the early years of life for physical and mental health. Young children enjoy being active while playing. Yet, many young children do not get enough daily physical activity to support their health and development. With our national and state partners we are scaling-up the Play Active program to evaluate the benefits and costs of supporting children's services throughout Australia to boost 100,000's of children's daily active play.	Associate Professor Hayley Emma Christian	Associate Professor Hayley Emma Christian (nee Cutt), Doctor Matthew Philip McLaughlin, Doctor Andrea Grace Nathan, Professor Carol Ann Maher, Professor Jasper Schipperijn, Professor Patti-Jean (PJ) Naylor, Doctor Ian Li, Professor Stewart Graeme Trust, Associate Professor Kevin Murray	Targeted competitive	1/01/2023	30/04/2027	Public Health And Health Services	Public Health And Health Services, Health Promotion	\$	1,727,513.22
Preventive and Public Health Research	2021 Maternal Health and Healthy Lifestyles	The University of Queensland	University	QLD	Closing the final gaps in maternal and infant health: the Deadly Fit Mums program	The Deadly Fit Mums (DFM) program is an Aboriginal community-led exercise and nutrition program offered to Indigenous pregnant mothers and to other mothers pregnant with an Indigenous baby. Mothers participating to DFM will be cared for by a team of health professionals assisting with various mother's health requirements and wishes during and after pregnancy. With this study we are hoping to show that DFM will help mothers to have a healthy pregnancy and a healthy Indigenous baby.	Associate Professor Federica Barzi	Associate Professor Federica Barzi, Associate Professor Stephen Andrew Bell, Kristie Auelon Watago, Associate Professor Abdullah Al Mamun, Professor Amanda Joan Lee, Doctor Jonathan Lettich, Katrina Ghidella, Professor James Steven Ward, Associate Professor Camell L Nelson, Doctor Keane Wheeler, Doctor Victor Madaubuchi Oguma, Doctor Joemar Calderon Maravilla	Targeted competitive	1/01/2023	31/12/2026	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health	\$	1,806,991.40
Preventive and Public Health Research	2021 Maternal Health and Healthy Lifestyles	The University of Adelaide	University	SA	Implementation of an omega-3 precision nutrition strategy to prevent preterm birth	Our clinical trials have demonstrated that the simple nutritional intervention of treating women who are low in omega-3 can prevent 1 in 7 babies from the medical crisis of being born before 34 weeks of gestation. Premature birth, can account for up to 85% of all medical complications and neonatal deaths. This project will show whether we can achieve the same reductions in preterm birth seen in clinical trials using an omega-3 precision nutrition strategy in the community.	Doctor Karen Patricia Best	Doctor Karen Patricia Best, Associate Professor Luke Edward Grzeskowiak, Professor Robert Alan Gibson, Doctor Penelope Susan Coates, Associate Professor Alice Rumbold, Professor John Phillips Newnham, Ms Karen Michelle Glover, Associate Professor Hossein Alali, Professor Philippa Fairfax Middleton, Doctor Lisa Nicole Yelland, Doctor Lucy Alice Simmonds, Jennifer Gould, Professor Maria Makrides	Targeted competitive	1/01/2023	31/03/2027	Nutrition And Dietetics	Nutrition And Dietetics, Public Nutrition Intervention	\$	1,366,712.80
Preventive and Public Health Research	2021 Maternal Health and Healthy Lifestyles	Deakin University	University	VIC	A randomised controlled trial to assess the impact of Baby-EATS, a scalable digital health intervention targeting infant feeding and weight in children aged 0-2 years	This study seeks to test the impact of Baby-EATS, a digital health program to support childcare educators and parents with improving nutrition and reducing excessive weight gain in children aged 8to 2 years old. This initiative was developed to address the needs of parents, childcare providers and health services for timely and evidence-based nutrition support for young children. To ensure translation and impact, Baby-EATS was intentionally designed to be amenable for population-wide adoption.	Associate Professor See Lin Yoong	Associate Professor See Lin Yoong, Doctor Rachel Louise Sutherland, Professor Helen Truby, Doctor Alice Grady, Doctor Christopher Oldmanford, Mrs Jaithri Ananthapavan, Professor Luke Woolfenden, Professor John H Wiggers, Professor Nilmini Sureshthra Wickramasinghe	Targeted competitive	1/01/2023	30/06/2027	Public Health And Health Services	Public Health And Health Services, Community Child Health, Public Health And Health Services, Preventive Medicine, Nutrition And Dietetics, Public Nutrition Intervention	\$	1,377,504.90
Preventive and Public Health Research	2021 Maternal Health and Healthy Lifestyles	Flinders University	University	SA	"Escape the vape": Designing health communications for prevention of e-cigarette use in young people	This research will develop health messages and resources to prevent the uptake of vaping amongst young adults and adolescents, reducing the risk of harm these emerging products present.	Professor Billie Bonevski	Professor Billie Bonevski, Doctor Shahid Ullah, Doctor Michelle Isabel Longeneil, Professor Simone Frances Pettigrew, Doctor Ashleigh Guillaumier, Doctor Joanne Dove, Professor Janet Hook, Professor Leanne Hides, Associate Professor Susan R Woolfenden, Professor James Arnold Smith, Professor Richard Peter Edwards, Doctor Joshua Tisse	Targeted competitive	1/01/2023	31/03/2026	Public Health And Health Services	Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	854,636.30
Preventive and Public Health Research	2021 Maternal Health and Healthy Lifestyles	University of Sydney	University	NSW	A new scalable eHealth approach to prevent e-cigarette use among adolescents: The OurFutures Vaping program	The use of electronic-cigarettes (vapes) among adolescents has drastically increased in recent years, making it a public health priority. Effective and scalable prevention approaches are urgently needed to reduce the short- and long-term harms associated with vaping. This study will evaluate the efficacy and cost-effectiveness of the first school-based eHealth preventive intervention targeting e-cigarette use among young Australians; the OurFutures Vaping program.	Professor Nicola Newton	Professor Nicola Newton, Associate Professor Becky Freeman, Professor Catherine Mitsakoglou, Associate Professor Lexine Sapinski, Doctor Jennifer Debenham, Professor Hayden McRobbie, Associate Professor Nicole Lee, Associate Professor Matthew Sunderland, Professor Steve Allcott, Doctor Jami Leung, Doctor Louise Thornton, Doctor Lauren Gardner, Doctor Emily Stockings, Associate Professor Nyanda Medrisse, Doctor Katrina Champion	Targeted competitive	1/01/2023	31/12/2026	Public Health And Health Services	Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	1,979,022.00
Preventive and Public Health Research	2021 Maternal Health and Healthy Lifestyles	The University of Newcastle	University	NSW	Getting quality evidence to policy makers and practitioners more quickly: Applying novel methods to identify effective, scalable interventions to prevent e-cigarette use in youth	The establishment of evidence surveillance systems to identify and synthesise research evidence as soon as it is available is recommended to inform responses to emerging health threats. We will establish such a system to identify and 'recruit' trials of e-cigarette prevention interventions targeting youth to harmonise key measures and to share their trial data for pooled analyses. The research will provide a powerful, flexible and timely analyses of global evidence to guide decision making.	Professor Luke Woolfenden	Professor Luke Woolfenden, Doctor Andrew John Milat, Associate Professor See Lin Yoong, Professor Emily Banks, Doctor Rebecca Kate Hodder, Doctor Anna Rene Seidler, Sam McGobb	Targeted competitive	1/01/2023	31/12/2026	Public Health And Health Services	Public Health And Health Services, Health Promotion, Public Health And Health Services, Preventive Medicine, Public Health And Health Services, Public Health And Health Services Not Elsewhere Classified	\$	1,862,283.00
Preventive and Public Health Research	2021 Maternal Health and Healthy Lifestyles	University of Sydney	University	NSW	Scalable approaches to reducing alcohol and other drug use among traumatised young people: A RCT examining the safety, effectiveness, and cost-effectiveness of an integrated cognitive-behavioural therapy delivered via telehealth	Substance use disorders are chronic debilitating disorders that typically emerge prior to the age of 25 against a background of significant psychological trauma. This RCT responds to an urgent need for scalable evidence-based interventions that target both substance use and the underlying trauma to prevent chronic psychological, neurological and physical health problems that may persist into adulthood.	Professor Katherine L Mills	Professor Katherine L Mills, Doctor Natalie Louise Peach, Professor Frances Joy Kay-Lambkin, Professor Vanessa Cobham, Doctor Shalini Anungwi, Professor Sean Gregory Peris, Doctor Mary Lou Chatterton, Professor Sudee E Back, Associate Professor Sarah Benda, Professor Kathleen T Brady	Targeted competitive	1/01/2023	31/12/2027	Psychology	Psychology, Health, Clinical And Counselling Psychology	\$	1,886,854.20

Preventive and Public Health Research	2021 Maternal Health and Healthy Lifestyles	University of Sydney	University	NSW	Health4Life Parents & Teens: a co-designed and scalable eHealth intervention to reduce modifiable cancer risk factors among socio-economically disadvantaged adolescents	This study aims to co-design a parent-based intervention that is as effective as possible in modifying lifestyle cancer risk factors among low SES adolescents, and that can be delivered with the least possible burden. The parent-based program is a tailored educational program to raise the effectiveness of the combined Health4Life Parents & Teens Program in reducing overall cancer risk among low SES youth across NSW.	Doctor Katrina Elizabeth Champion	Doctor Katrina Elizabeth Champion, Associate Professor Cath Chapman, Doctor Stephanie Ruth Partridge, Professor Tracy Burrows, Doctor Louise Kyle Thornton, Professor Nicola Clare Alice Newton, Professor Bonnie Spring, Associate Professor Belinda Jane Parmenter, Associate Professor Matthew Sunderland, Professor Maree Rose Tessoni, Professor Louise Alison Blair, Professor Timothy Slade, Professor Cathrine Mihalopoulos, Doctor Lauren Anne Gardner, Professor David Revalds Lubans	Targeted competitive	1/01/2023	31/08/2027	Public Health And Health Services	Public Health And Health Services, Preventive Medicine	\$	1,624,922.28
Preventive and Public Health Research	2021 Maternal Health and Healthy Lifestyles	The University of Newcastle	University	NSW	The Gulbana (Coolamon) Project: A state-wide, co-designed model of care supporting Aboriginal mothers to be smoke-free in pregnancy and beyond	Significantly more Aboriginal women smoke during pregnancy compared to non-Aboriginal women. Group-based smoking cessation programs have been shown to increase quitting by 50%-130% in the general population but have never been evaluated in Aboriginal communities. We will co-design, embed in Aboriginal Community Controlled Health Services, and evaluate a group-based smoking cessation program. This project will contribute to significant improvements in inter-generational health and well being.	Doctor Michelle Kennedy (nee Bowill)	Doctor Michelle Kennedy (nee Bowill), Associate Professor Luke J Burchill, Doctor Mary Bellenger, Professor Sandra J Fades, Doctor Tameka McFadyen, Jessica Bennett, Doctor Raglan Maddox, Professor Catherine K Chamberlain, Professor Alexandra Lynda Conboy Martiniuk, Doctor Jamie Bryant	Targeted competitive	1/01/2023	31/12/2026	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health	\$	1,996,981.10
Preventive and Public Health Research	2021 Optimising the Clinical Use of Immunoglobulins	Monash University	University	VIC	Generating evidence to improve use of immunoglobulin replacement to reduce infections in blood cancers: the RATIONAL Platform Trial	Patients with blood cancers often have low levels of antibodies needed to fight infections, both due to their underlying blood cancer and also due to their cancer treatments. In this study, we will evaluate two commonly provided treatments - replacement of antibodies with a blood product (called immunoglobulin) and antibiotic therapy - to determine which treatments are most effective at reducing infections and which patients are most likely to benefit from the treatments.	Associate Professor Zoe McQuilten	Associate Professor Zoe McQuilten, Associate Professor Dennis Petrie, Associate Professor Eliza Hawkes, Associate Professor John Reynolds, Associate Professor Philip Orsini, Doctor Laura Fanning, Doctor Robert Wrenkover, Professor Andrew Spencer, Professor C. Orla Morrissey, Professor David Paterson, Professor Erica Wood, Professor Jason Roberts, Professor Simon Staworth, Professor Stephen Mulligan, Professor Stephen Opat	Targeted competitive	1/04/2022	31/03/2027	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology Haematology	\$	3,984,139.00
Preventive and Public Health Research	2021 Optimising the Clinical Use of Immunoglobulins	University of Sydney	University	NSW	antiCD20 treatment to rationalise the use of IVIG in CDP	We will conduct the first trial in an uncommon, but expensive to treat, peripheral nerve disease, to determine whether targeting lymphocytes with a monoclonal antibody therapy will allow better treatment and less drug use than the very expensive drug currently used, immunoglobulin. With this we will evaluate available possible marker of disease and discover new ones to help tailor treatments to individual patient needs in this disease.	Professor David Brown	Professor David Brown, Associate Professor Fabienne Brillot, Associate Professor Joanne Reed, Associate Professor Kathy Poutoumou, Associate Professor Marc Rutenberg, Doctor Sarah Saxon, Doctor Sudarshan Ramakrishnan, Professor Anthony Kelleher, Professor Golo Ahlenstiel, Professor Matthew Kieran, Professor Ostojic Vucic	Targeted competitive	1/04/2022	31/03/2027	Clinical Sciences	Clinical Sciences, Clinical Sciences Not Elsewhere Classified	\$	2,891,769.00
Preventive and Public Health Research	2021 Optimising the Clinical Use of Immunoglobulins	Monash University	University	VIC	evidence synthesis to inform the optimal use of Immunoglobulin (The VALUE-Ig Study)	Immunoglobulin (Ig) therapy can be effective at preventing infections or controlling immune system response. However there is weak evidence to guide treatment decisions such as who should have Ig and how long they should stay on Ig. This project will use health data on Australian Ig therapy patients to ensure Ig is used judiciously to avoid wasted valuable resources but always available to those patients for whom it provides a cost-effective benefit.	Associate Professor Dennis Petrie	Associate Professor Dennis Petrie, Associate Professor Annelie van der Wal, Associate Professor Eliza Hawkes, Associate Professor Philip Orsini, Associate Professor Stephen Reddel, Associate Professor Zoe McQuilten, Doctor Adam Zing, Doctor Katherine Buzzard, Doctor Laura Fanning, Professor Andrew Spencer, Professor Anthony Harris, Professor Erica Wood, Professor Stephen Opat	Targeted competitive	1/04/2022	31/03/2025	Applied Economics	Applied Economics, Health Economics, Oncology And Carcinogenesis, Haematological Tumours, Neurosciences, Neurology And Neuromuscular Diseases	\$	1,723,772.00
Preventive and Public Health Research	2021 Optimising the Clinical Use of Immunoglobulins	University of Sydney	University	NSW	Australian ODP National Registry: Dissecting Phenotypes and Immunoglobulin Usage Requirements	Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune neuropathy producing severe disability and representing the second most common indication for the use of immunoglobulin treatment in Australia. Despite this, there remains a lack of markers to identify treatment response and disease activity, which are clearly necessary to target treatment to appropriate patients and important to improve efficient use of immunoglobulin in Australia.	Associate Professor Susanna Park	Associate Professor Susanna Park, Associate Professor Lynette Kiers, Associate Professor Robert Henderson, Doctor Mahina Kapor, Doctor Nidhi Gang, Professor Bruce Taylor, Professor Cindy Lin, Professor Deborah Street, Professor Matthew Bellgard, Professor Matthew Kieran, Professor Michael Barnett, Professor Ostojic Vucic, Professor Stephen Goodall	Targeted competitive	1/04/2022	31/03/2025	Neurosciences	Neurosciences, Neurology And Neuromuscular Diseases	\$	812,889.00
Preventive and Public Health Research	2022 Effective Treatments and Therapies	University of Sydney	University	NSW	Active Women over 50: an effectiveness-implementation randomised controlled trial	Women aged 50+ are a priority for targeted physical activity programs, since capacity starts to decline at this age, and women aged 50+ have unique barriers to becoming active. The Active Women over 50 program combines website information, health coaching, Facebook group and SMS or email motivational messages, to promote physical activity. This research will test the effectiveness, cost-effectiveness and implementation potential of this virtually delivered physical activity promotion program.	Professor Anne Tiedemann	Professor Anne Tiedemann, Professor Phyllyrath Phongsavan, Ms Geraldine Wallbank, Professor Nehmat Housami, Doctor Dominika Kwesnicka, Associate Professor Simon Newham, Associate Professor Leanne Hassett, Doctor Marina de Barros Pinheiro, Doctor Abigail Haynes, Professor Catherine Sherrington	Targeted competitive	1/01/2023	31/12/2026	Health Sciences	Health Sciences, Public Health, Health Promotion	\$	1,210,256.79
Preventive and Public Health Research	2022 Effective Treatments and Therapies	University of New South Wales	University	NSW	CAPACITY: A telehealth, effectiveness-implementation hybrid trial to increase physical activity in adults with chronic low back pain	Adults with chronic low back pain are 30% less likely to meet physical activity guidelines compared to those without pain and are thus more likely to develop chronic disease. The aim of the CAPACITY trial is to test whether a patient-centred intervention comprised of tailored pain education and goal setting helps adults with chronic low back pain increase physical activity and reduce blood pressure. If effective, CAPACITY could be widely implemented to improve health in people with chronic pain.	Doctor Matthew Jones	Doctor Matthew Jones, Doctor Aidan Cashin, Professor G. Lorimer Moseley, Professor Manuela Ferreira, Professor Lorraine Smith, Professor Kathryn Refshaugh, Doctor Adrian Traeger, Professor James McAuliffe, Professor Stephen Goodall, Associate Professor Belinda Parmenter, Associate Professor Christopher Williams, Associate Professor Ruth Peters, Professor Emmanuel Stamatakis, Professor Aletta Schutte	Targeted competitive	1/01/2023	31/12/2026	Health Sciences	Health Sciences, Allied Health And Rehabilitation Science, Allied Health And Rehabilitation Science Not Elsewhere Classified	\$	1,384,135.99
Preventive and Public Health Research	2022 Effective Treatments and Therapies	The University of Newcastle	University	NSW	Improving activity-sleep patterns to enhance glucose control in higher risk mid aged adults	We lack robust evidence for the impact of interventions targeting improvements in both activity and sleep to reduce chronic disease risk. Using a 3-arm Randomised Control Trial (RCT) this project will test the efficacy of a novel digital physical activity and sleep health intervention -'Balanced'-to maximise improvements glucose control among mid aged adults (45-64 years) who are physically inactive and have poor sleep health relative to a physical activity only intervention and a control group.	Professor Mitch Duncan	Professor Mitch Duncan, Doctor Grace Vincent, Professor Gary Witter, Professor Sally Ferguson, Associate Professor Christopher Kline, Doctor Anna Rayward	Targeted competitive	1/01/2023	30/04/2025	Health Sciences	Health Sciences, Public Health, Health Promotion	\$	909,691.84
Preventive and Public Health Research	2022 Effective Treatments and Therapies	University of Wollongong	University	NSW	PANDA Trial: Physical Activity in Nature for Cardiometaabolic Diseases in People Aged 45+	Contact with nature might be key to promoting regular physical activity in people with heart disease and diabetes. Our national survey indicates 72% of physically inactive Australians aged 45+ with cardiometaabolic diseases would accept a nature prescription yet there are none on offer. We aim to co-design and test a nature prescription intervention that enables this target group to spend more time in nature and thereby reap the rewards of sustained physical activity for cardiometaabolic health.	Professor Thomas Astell-Burt	Professor Thomas Astell-Burt, Doctor Katarzyna Olkon, Professor Lenneet Veerman, Professor Lorna Moatam, Professor Elizabeth Halcomb, Professor Evangelos Pappas, Professor Marijka Batterham, Doctor Sonali Gnanamanthran, Professor Glendenn Mahony, Associate Professor Stewart Vella, Associate Professor Rowena Ivers, Doctor Monique Francois, Professor Julie Redfern, Associate Professor Xiaojie Feng	Targeted competitive	1/01/2023	30/06/2027	Health Sciences	Health Sciences, Public Health, Preventative Health Care	\$	1,491,204.51
Preventive and Public Health Research	2022 Effective Treatments and Therapies	Griffith University	University	QLD	STOP FRACTURE! Strength Training for Optimum Prevention of Fracture. Refocussing A Clinical paradigm That Underutilises Recognised Effective Therapy	Osteoporosis is a growing and costly problem that dramatically reduces quality of life, leads to loss of independence and increases risk of death. Usual treatment is drugs, but many patients won't take them. Many use exercise as alternative therapy, but only certain exercise is effective. We aim to reduce osteoporotic fracture by implementing pathways of referral to a known effective exercise program, thereby supporting health care providers and their patients.	Professor Belinda Beck	Professor Belinda Beck, Associate Professor Peter Wong, Doctor Ping Zhang, Professor Jacqueline Center, Doctor Oliver Frank, Professor Lyn March, Associate Professor Martin Downes, Ms Robyn Speerin	Targeted competitive	1/01/2023	31/12/2026	Health Sciences	Health Sciences, Public Health, Preventative Health Care	\$	1,484,165.09
Preventive and Public Health Research	2022 Effective Treatments and Therapies	The University of Queensland	University	QLD	Implementation and scale-up of a consumer co-designed physical activity promotion program for people with moderate-to-profound disabilities	Our project will test a physical activity promotion program for people living with disability. We will modify our best practice physical activity promotion tool, and evaluate whether the program successfully empowers people with moderate-to-profound disability to engage in physical activities which are enjoyable, safe and health enhancing. Training modules will enable health professionals working in urban, regional, and rural settings to deliver the program at scale in their own communities.	Professor Stewart Trost	Professor Stewart Trost, Doctor Emma Beckman, Associate Professor Sean Tweedy, Doctor Spiros Gomerall, Doctor Jessica Hill, Professor John Cairney, Doctor Iain Dutta, Doctor Kelly Clancy, Professor Jennifer Fleming, Doctor Jonas Fookien	Targeted competitive	1/01/2023	28/02/2027	Health Sciences	Health Sciences, Sports Science And Exercise, Exercise Physiology, Health Sciences, Public Health, Health Promotion, Health Sciences, Health Services And Systems, People With Disability	\$	590,868.88
Preventive and Public Health Research	2022 Effective Treatments and Therapies	University of Sydney	University	NSW	Walk with Ease Australia	We will develop, evaluate, and implement a sustainable, community-driven walking program for people with OA. The Walk with Ease program is proven to reduce pain and improve function in people with moderate to severe levels of pain. This program will be adapted for the Australian setting by partnering with state-based arthritis consumer groups to co-design the delivery of a program that will focus on engagement, adherence, and long-term sustainability.	Professor David Hunter	Professor David Hunter, Associate Professor Nicole Rankin, Professor Rana Nimman, Professor Guglielmo Viorozzi, Doctor Sarah Kobayashi, Associate Professor Dawn Aitken, Doctor Christian Barton, Professor Kim Bennell, Ms Vicki Doung, Mr Daniel White, Professor Leigh Callahan, Professor Elena Losina, Doctor Jillian Eyles, Professor Emmanuel Stamatakis	Targeted competitive	1/01/2023	30/06/2027	Health Sciences	Health Sciences, Health Services And Systems, Health And Community Services	\$	591,279.58
Preventive and Public Health Research	2022 Effective Treatments and Therapies	University of Melbourne	University	VIC	Implementation of a co-designed, community led exercise program to reduce falls in older people from culturally and linguistically diverse communities: a pilot trial	Falls are the second leading cause of disability in older people. There is strong evidence that exercise reduces falls, however most older people do not meet physical activity guidelines. We are co-designing a program to increase the uptake of exercise to reduce falls with older people from Italian, Arab and Chinese communities. This pilot trial will test the feasibility of delivering and evaluating this co-designed program.	Associate Professor Catherine Said	Associate Professor Catherine Said, Doctor Lidia Engel, Associate Professor Frances Batchelor, Ms Emily Ramage, Doctor Cassie McDonald, Associate Professor Michele Callaway, Professor Bianca Brinjari, Doctor Sara Vagrin, Doctor Marlene Kiac, Doctor Marina de Barros Pinheiro, Professor Wen Lim	Targeted competitive	1/01/2023	30/09/2026	Health Sciences	Health Sciences, Allied Health And Rehabilitation Science, Physiotherapy, Biomedical And Clinical Sciences, Clinical Sciences, Genetics And Gerontology, Health Sciences, Public Health, Injury Prevention	\$	586,939.18

Preventive and Public Health Research	2022 Effective Treatments and Therapies	Curtin University	University	WA	Talking together, walking together: developing, implementing and validating community-led physical activity programs in diverse Aboriginal populations	Regular physical activity is important to good health, but many Aboriginal adults don't undertake enough physical activity for health benefits, increasing their risk of conditions like heart disease and diabetes. "Talking together, walking together" will empower Aboriginal communities to develop and implement new programs that improve access to and participation in physical activity. Because the programs will be community-led, they will be designed to meet local needs and priorities.	Professor Andrew Maiorana	Professor Andrew Maiorana, Doctor Tagay Esghin, Doctor Joanna Moulin, Associate Professor Eleanor Gossard, Associate Professor Joanne McKeough, Associate Professor Judith Katzenellenbogen, Associate Professor Christina Pollard, Doctor Jonathan Lee, Doctor Ian Lim, Ms Angela Jacques, Doctor Marshall Makale, Doctor Emma Hawkes	Targeted competitive	1/01/2023	31/12/2026	Indigenous Studies	Indigenous Studies, Aboriginal and Torres Strait Islander Health And Wellbeing, Aboriginal and Torres Strait Islander Sport And Physical Activity	\$	571,856.58
Preventive and Public Health Research	2022 Effective Treatments and Therapies	University of South Australia	University	SA	Small Steps towards personalised dementia prevention	Only 19% of the Australian public have a good understanding of dementia risk factors. Physical activity is a promising and affordable dementia prevention strategy. What people need is assistance, to enable them to make healthier choices whilst also giving them the opportunities to keep constant the behaviours they cannot, or prefer not, to change. We will co-design, implement and evaluate a first of its kind personalised dementia prevention physical activity intervention, called Small Steps.	Doctor Ashleigh Smith	Doctor Ashleigh Smith, Professor Timothy Olds, Associate Professor Kate Laver, Professor Alison Goates, Doctor Michelle Rogers, Associate Professor Ross Smith, Doctor Tynan Stanford, Doctor Alexandra Wade, Associate Professor Hannah Keage, Doctor Doreen Dunneil	Targeted competitive	1/01/2023	31/12/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Clinical Sciences, Geriatrics And Gerontology	\$	588,352.18
Preventive and Public Health Research	2022 Effective Treatments and Therapies	The Council of the Queensland Institute of Medical Research	Medical Research Institute	QLD	Improving quality of life in adults with severe mental illness	People with severe mental illness (SMI) have lower quality of life, and die 10-30 years earlier than the general population, caused by preventable diseases such as cardiovascular disease and diabetes. Exercise can prevent and manage these diseases, however, exercise intervention is not currently offered routinely in mental health services. This trial will investigate the effectiveness and cost-effectiveness of exercise intervention for improving quality of life outcomes in people with SMI.	Doctor Justin Chapman	Doctor Justin Chapman, Doctor Ursula Arnaoutskaya, Professor Dan Skidnd, Doctor Marianne Wyder, Doctor Yong Yi Lee, Doctor Kylie Burke, Doctor Eva Malacova, Professor Alison Yung, Professor James Scott, Doctor Nicole Korman, Professor Amanda Wheeler	Targeted competitive	1/01/2023	31/12/2026	Health Sciences	Health Sciences, Health Services And Systems, Mental Health Services, Health Sciences, Sports Science And Exercise, Exercise Physiology	\$	591,249.38
Preventive and Public Health Research	2022 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	University of Melbourne	University	VIC	PRECISION- Pharmacogenomic medicines optimisation for people with cancer	PRECISION is a multi-trial, multi-centre, mixed-methods program that will discover, translate, implement and evaluate an evidence-based approach to pharmacogenomic (PGx) medicines optimisation in adult and paediatric cancer cohorts. Conducting two clinical trials and using implementation science methods we will assess feasibility, acceptability, needs, cost effectiveness and scalability of PGx-guided medicines optimisation to enable safer and more effective use of medicines for people with cancer. Three program streams of clinical trials, implementation, and discovery, will simultaneously investigate multiple clinical and research questions whilst focused on confirming the feasibility of PGx in cancer care.	Doctor Marliese Alexander	Doctor Marliese Alexander, Mr Senthil Lingaratnam, Associate Professor Safiera Hussaini, Associate Professor Leslie Sheffield, Professor Andrew Somogyi, Professor Michael Michael, Professor Shereen Loi, Professor John Seymour, Associate Professor Stephanie Best, Associate Professor Richard De Abreu Lourenco, Associate Professor Rachel Conyers, Professor Paul James, Doctor Laura Jones, Professor Mervyn Kishinevsky, Doctor Peter Galetis, Professor Jennifer Martin, Professor Carl Kirkpatrick, Professor Ian Campbell, Associate Professor Craig Underhill, Doctor Sam Harris, Professor Jennifer Philip, Associate Professor Tim Speelman, Doctor Chiao Xin Lim, Ms Sarah Glewis, Ms Jennifer Devine	Open competitive	Not available	Not available	Not available	Not available	\$	1,500,000.00
Preventive and Public Health Research	2022 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	The University of Queensland	University	QLD	Pharmacogenomics for better treatment of fungal infections in cancer	PRAGMATIC will deliver a high-quality and cost-effective approach to optimise the quality of care of cancer patients. This research will support pharmacists working to the full scope of practice, applying their expertise in using diagnostic and therapeutic innovations to provide patient-centred care. We will achieve this by conducting a randomised clinical trial in cancer patients (aged ≥2 years) and prescribed voriconazole, in which we will compare the effectiveness of genomic-testing plus a genotype-based dosing guideline (ARM 1), with genomic-testing plus software-informed dose optimisation (ARM 2), coupled with an implementation project to ensure the future scalability of the interventions by tailoring them to each study setting.	Professor Jason Roberts	Professor Jason Roberts, Professor Johannes Aellenaar, Professor Monica Slavin, Doctor Suzanne Parker, Mr Julian Lindsay, Mr Mark Chatfield, Doctor Adam Irwin, Doctor Michelle Cunich, Doctor Natasha Roberts, Mr Philip Kelly, Ms Helen Ishagah, Mr Tony Lai, Ms Amy Legg, Doctor Jacobus Ungerer	Open competitive	Not available	Not available	Not available	Not available	\$	1,499,982.00
Preventive and Public Health Research	2022 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	University of Sydney	University	NSW	Timely post discharge medication reviews in rural and regional Australia	After hospital discharge, over 90% of Australians have at least one medication-related problem. The Timely post-discharge medication review to Improve Continuity – Transitions Of Care stewardship (TIC TOC) study aims to evaluate the effectiveness of a virtual community and hospital practitioner collaboration to improve medication management for high-risk patients at discharge from regional and rural hospitals. This project will identify a sustainable and scalable way to reduce hospital readmissions due to medication related complications.	Doctor Jonathan Penn	Doctor Jonathan Penn, Doctor Many Angley, Associate Professor Rebekah Molen, Ms Deirdre Cridde, Associate Professor Rohan Elliott, Ms Deborah (Debbie) Rigby, Professor Smeeth Shalib, Associate Professor Frank Santillano, Doctor Stephen Carter, Doctor Charly Budgen, Doctor Kim-Huang Nguyen, Doctor Paul Yates, Ms Katie Phillips, Mr Jerry Yik, Associate Professor Faye McMillan, Mrs Deborah (Debbie) Hawthorne, Doctor Michelle Penn, Ms Gorden Fleming, Ms Anna Packer, Doctor Andrew Hawthorne, Ms Linda Krogh, Doctor Simon Poon, Doctor Alexander Khentzos, Doctor Jillian Khentzos	Open competitive	Not available	Not available	Not available	Not available	\$	1,499,128.00
Preventive and Public Health Research	2022 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	The University of Queensland	University	QLD	Optimising medicine information handover after discharge (REMAIN HOME 2.0)	A disconnect of medication related patient information from hospital to primary care health providers contributes to preventable hospital readmissions nationwide. We will co-design an intervention, with consumers and stakeholders, to address this unmet need by advancing 3 strategies: (1) Hospital pharmacist navigators to coordinate community-based medicine reconciliation; (2) Medication management programs with patient-selected pharmacies and general practices; and (3) A digital medicine handover solution to prevent 30-day readmissions caused by medication-related harm. Project outcomes involve reduced hospital readmissions and improved patients' medicine handover through delivery of the intervention after discharge from hospital.	Associate Adjunct Professor Hendrika Hattingh	Associate Adjunct Professor Hendrika Hattingh, Professor Elizabeth Manias, Doctor Tin Fei Sim, Doctor Holly Ford, Doctor Faith Yong, Professor Melissa Batten, Professor Ian Scott, Professor Gerben Keijzers, Professor Claire Jackson, Professor Mark Morgan, Professor Barbara Mullan, Associate Professor Richard Norman	Open competitive	Not available	Not available	Not available	Not available	\$	1,498,330.00
Preventive and Public Health Research	2022 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	The University of Queensland	University	QLD	Reducing hospital re-admission for high-risk CARDiology patients	RECARD study will optimise medication management of cardiovascular patients (those with a heart attack or heart surgery), by safely transitioning them from the hospital to community care, through designing and delivering an evidence based transition of care (ToC) service. This study will work closely with patients, their families, community and hospital clinicians, to design the new service model. We will build on existing indigenous cardiac care programs to enhance impact through a culturally appropriate service, that is tailored to patient needs. The ToC service will then be tested across 3 hospitals in Queensland, and evaluated for how effective it is in reducing medication harm related hospital re-admissions and cost effectiveness.	Associate Professor Michael Barras	Associate Professor Michael Barras, Doctor Nazanin Falconer, Associate Professor William Cottrell, Doctor Kelvin Robertson, Associate Professor William Wang, Associate Professor Shelley Wilkinson, Doctor Jared Miles, Professor John Atherton, Doctor Contance Snowell, Ms Vivian Bryce, Professor Ian Coombes, Ms Sue Carson, Doctor Andrew Jones, Associate Professor Laurence Macdonald	Open competitive	Not available	Not available	Not available	Not available	\$	1,499,818.00
Preventive and Public Health Research	2022 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	University of South Australia	University	SA	Establishing the PHARMA-Care quality monitoring program in aged care homes	Our team will develop, validate, implement, cost, and disseminate an innovative national quality framework to support pharmacists to improve medicines use in residential aged care facilities (RACFs). We will interview stakeholders to understand their needs, synthesise existing quality use of medicines indicators, and establish a co-designed framework. Agreed quality indicators will be evaluated using novel population-based datasets and implemented in RACFs. Our multidisciplinary team will co-create a national implementation plan with costings to guide rapid translation. The PHARMA-Care quality monitoring program will equip aged care teams with robust evidence to improve the safe and effective use of medicines and optimise resident outcomes.	Doctor Janet Sluggett	Doctor Janet Sluggett, Professor Maria Inacio, Professor Gillian Caughey, Doctor Jyoti Khadka, Professor Gregory Peterson, Professor Steven Wesselingh, Doctor Andrew Safford, Associate Professor Lisa Kallish Elliott, Doctor Shane Jackson, Associate Professor Peter Hilbert, Doctor Monica Carlons, Ms Megan Curll, Associate Professor Solomon Yu, Associate Professor Malcolm Clark, Doctor Jodie Hillen, Doctor Natalie Soultby	Open competitive	Not available	Not available	Not available	Not available	\$	1,499,093.00
Preventive and Public Health Research	2022 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	Macquarie University	University	NSW	Leveraging informatics to optimise medication reviews and outcomes in RAC	This project will design, deliver, and evaluate an innovative electronic medication management review (eMAR) portal – a one-stop platform which will (i) use predictive risk algorithms to identify residents at increased risk of poor outcomes due to medication-related problems who would most benefit from an eMAR, and (ii) deliver a transparent communication process by which eMAR requests, recommendations, actions, and outcomes can be monitored by pharmacists, GPs, residents and families, and RAC staff. The cost-effectiveness of our approach will be evaluated relative to current practice. This integrated system-based approach will make optimal use of medication reviews for a safer, quality, and effective use of medicines in RAC.	Doctor Karla Seaman	Doctor Karla Seaman, Doctor Magdalena Raban, Professor Henry Culler, Doctor Nasir Waber, Professor Johanna Westbrook, Associate Professor Rosemary Saunders, Doctor Sandan Silva, Doctor Guangyang, Doctor Alwanah Canale, Doctor Amy Nguyen, Doctor Rachel Urwin, Doctor Tim Tse, Doctor Bosco Wu	Open competitive	Not available	Not available	Not available	Not available	\$	1,479,329.00
Preventive and Public Health Research	2022 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	Monash University	University	VIC	Maximising Embedded pharmacists in aged Care Medication Advisory Committees	Our project evaluates an innovative system-level knowledge broker role for embedded pharmacists to improve the quality use of medications. This project provides a nationally scalable process for implementing the Australian Commission on Safety and Quality in Health Care (ACSQHC) 2022 Guiding Principles for Medication Management in Residential Aged Care. This is achieved through developing and validating resident focused indicators. Embedded pharmacists will use the indicators to deliver, monitor and evaluate quality improvement initiatives. Our project also involves implementing and evaluating an innovative national quality improvement collaborative (MEGA-MAC) which will act as a real-time clinical network to support embedded pharmacists.	Professor John Bell	Professor John Bell, Doctor Amanda Cross, Doctor Kate Laver, Professor Terrence Haines, Professor Sarah Hilmer, Doctor Atish Manek, Doctor Alexandra Bennett, Doctor Angelita Martin, Ms Lynette Quirke, Doctor Mary Ann Kuhl	Open competitive	Not available	Not available	Not available	Not available	\$	1,499,612.00
Preventive and Public Health Research	2022 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	University of Canberra	University	ACT	Implementation and scale up of on-site pharmacist in residential aged care	Our team conceptualised the on-site pharmacist in aged care model and has conducted the first pilot and cluster randomised controlled trial in Australia to test the efficacy, effectiveness and local implementation of this model. The Commonwealth Government announced \$345M in funding to implement community and on-site pharmacists into residential aged care from 2023. In this project we will test the scale up of the model under 'real world' conditions and in a variety of settings (e.g. urban, regional, rural and remote aged care facilities) that will represent contexts and environments that will be encountered in national implementation. The outcomes will inform solutions to improve the long-term success and sustainability of the model.	Associate Professor Sam Kosari	Associate Professor Sam Kosari, Professor Mark Naughton, Professor Rachel Davey, Doctor Jane Warner, Associate Professor Nasser Bagheri, Adjunct Professor Pooresh Dawda	Open competitive	Not available	Not available	Not available	Not available	\$	1,498,638.00

Preventive and Public Health Research	2022 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	University of Western Australia	University	WA	Pharmacist Review to Optimize Medicines in Residential Aged Care: PROMPT-AC	Limitations in current medicines management practices in residential aged care facilities (RACFs) were highlighted in the Royal Commission into Aged Care Quality and Standards, which led to the recommendation to embed pharmacists within RACFs. Our research will develop capacity for evidence based practice and research in RACFs at a crucial time as pharmacists transition into new roles embedded in RACFs. We will undertake an intervention to establish, embed and evaluate a virtual Community of Practice combined with a structured program for training and support to ensure translation and sustainability of the findings with an intervention to support pharmacists medicines reviews by pharmacists using an app with integrated decision support.	Doctor Amy Page	Open competitive	Not available	Not available	Not available	Not available	Not available	\$	1,499,766.00
Primary Health Care Research	2019 Primary Health Care Research	Monash University	University	VIC	The ORENT study: Improving Rural and regional access to long acting reversible contraceptive and medical abortion through nurse-led models of care, Tasksharing and telehealth	Women in rural and regional areas have higher rates of unintended pregnancies and difficulty accessing the most effective forms of contraception (implants and intrauterine devices) and medical abortion. The ORENT study will trial the effectiveness of nurse-led models of care at increasing access to these services. We will co-design the nurse-led models with consumers and stakeholders and support their implementation using education, academic detailing and a virtual community of practice.	Professor Danielle Mazza	Targeted competitive	1/06/2020	31/10/2025	Public Health And Health Services	Primary Health Care	\$	1,928,519.00	
Primary Health Care Research	2019 Primary Health Care Research	The University of Adelaide	University	SA	Translation of culturally informed diabetes training for Aboriginal Health Practitioners on Aboriginal patient outcomes: a cluster randomised trial of effectiveness	Diabetes affects many Indigenous Australians who as a result, experience preventable illnesses and death. Well managed diabetes can prevent or delay poor or fatal outcomes. The current certificate III and IV health worker and practitioner curriculum allocates less than one day to diabetes. This project will assess if a co-designed culturally informed diabetes training program for Aboriginal Health Practitioners improves diabetes patient health outcomes.	Doctor Odette Pearson	Targeted competitive	1/06/2020	31/05/2025	Public Health And Health Services	Aboriginal And Torres Strait Islander Health	\$	1,299,036.03	
Primary Health Care Research	2019 Primary Health Care Research	The University of Newcastle	University	NSW	Addressing the evidence gap on medical nutrition therapy for primary and secondary prevention of cardiovascular disease in regional and rural communities	This project evaluates cost-effectiveness of evidence-based models of medical nutrition therapy (MNT) provision in rural and regional primary healthcare. We will test novel technology based MNT to improve program reach and access to nutrition interventions, dietetic expertise, and communication of results to GPs, while addressing cost. Project impact assessment will inform translation of relevant findings to policy and practice across Australia.	Professor Clare Collins	Targeted competitive	1/06/2020	31/05/2023	Nutrition And Dietetics	Nutrition And Dietetics Not Elsewhere Classified	\$	1,028,236.00	
Primary Health Care Research	2019 Primary Health Care Research	The University of Queensland	University	QLD	Transforming access, relational care, and primary health care in an urban Aboriginal and Torres Strait Islander population through patient-centred medical homes: a prospective observational cohort study using mixed methods	The Aboriginal Community Controlled Health Sector has been at the forefront in addressing the challenge of providing quality primary health care services to rapidly growing populations affected by complex health care needs. Through a collaboration between researchers and service providers this study will contribute new knowledge for the broader primary health care system on how a model of care based on multidisciplinary teams and relationships can improve access to care and health and wellbeing.	Professor James Ward	Targeted competitive	1/06/2020	31/05/2025	Public Health And Health Services	Primary Health Care	\$	1,209,747.50	
Primary Health Care Research	2019 Primary Health Care Research	University of South Australia	University	SA	Using big data to create evidence-based primary health care service delivery and policy for the Australian aged care sector - a nationwide study	Using the Registry of Senior Australians, we will study the use of primary care services by the vulnerable Australians who have accessed aged care services. Our study will produce the information necessary to inform practice and make policy recommendations related to access, differences in services, and best quality in care for these older individuals. If implemented these recommendations can help shape, define and inform standards related to primary care service access and quality for aged care.	Associate Professor Maria Inacio	Targeted competitive	1/07/2020	30/06/2024	Public Health And Health Services	Primary Health Care	\$	1,435,801.00	
Primary Health Care Research	2020 Primary Health Care Research	Flinders University	University	SA	A hybrid, implementation-effectiveness trial of a nurse-enabled, shared-care Model between primary and acute care for prostate Cancer Survivors (The MOSES Trial)	The MOSES Trial will implement and evaluate an integrated, model of follow-up care shared between the acute cancer service and general practice across Queensland, South Australia and Victoria. In partnership with the Prostate Cancer Foundation of Australia specialist nurses, we will maximise the scalability of this best-practice care model using a range of implementation strategies, ultimately transforming how care is delivered to thousands men with prostate cancer.	Professor Raymond Chan	Targeted competitive	1/05/2021	30/04/2025	Public Health And Health Services	Primary Health Care	\$	1,625,286.65	
Primary Health Care Research	2020 Primary Health Care Research	University of Sydney	University	NSW	Health4Me: Improving adolescent physical activity and nutrition behaviours via primary care	Physical activity and nutrition are pillars of good physical and mental health, yet, are among the most significant health challenges facing today's young people. In Australia, over 90% of adolescents own a mobile phone, yet there are limited digital health programs to improve youth health in primary care. To address this, we will test a scalable text-messaging program for young people. This research could ultimately better integrate services for young people in primary care across Australia.	Doctor Stephanie Partridge	Targeted competitive	1/05/2021	30/04/2025	Public Health And Health Services	Primary Health Care	\$	511,750.50	
Primary Health Care Research	2020 Primary Health Care Research	Flinders University	University	SA	Improving the social and emotional wellbeing of Aboriginal and Torres Strait Islander men in South Australia	Aboriginal and Torres Strait Islander men carry the worst health and social outcomes within Australian society. Despite significant investment and policy focus on women's health, and men's health in general, the area of Aboriginal and Torres Strait Islander men's social and emotional wellbeing has remained relatively ignored. This project will address a community identified priority by shifting away from describing the challenges to providing solutions for the primary health care ecosystem.	Doctor Justin Canuto	Targeted competitive	1/05/2021	30/04/2026	Public Health And Health Services	Aboriginal And Torres Strait Islander Health	\$	1,255,051.40	
Primary Health Care Research	2020 Primary Health Care Research	Bond University Limited	University	QLD	Activating primary care COPD patients with Multi-morbidity (APCOM) study	Chronic Obstructive Pulmonary Disease (COPD) is a common chronic condition that can progress to disability and death. Self-management support for people with COPD can reduce exacerbations and improve quality of life but many programs are not effective as they fail to recognise the impact of other long term conditions. This study will evaluate the effectiveness, cost-effectiveness and uptake of a self-management intervention that is tailored to individual need and recognises multimorbidity.	Professor Nicholas Zwar	Targeted competitive	1/05/2021	30/06/2025	Public Health And Health Services	Primary Health Care	\$	977,628.15	
Primary Health Care Research	2020 Primary Health Care Research	Curtin University	University	WA	Improving diet quality of patients living with obesity: A randomised controlled trial to build effective dietetic service delivery in a primary health care setting	There are very few publicly available weight management services led by dietitians the experts in dietary advice: leaving 30% of Australians living with obesity limited treatment options. To address this gap, General Practitioners (GPs) will be able to offer their patients referral to a digital weight management trial led by clinical dietitians who will deliver cutting edge, high quality, cost-effective dietetic care for weight management.	Professor Deborah Kerr	Targeted competitive	1/05/2021	30/04/2024	Nutrition And Dietetics	Nutrition And Dietetics Not Elsewhere Classified	\$	1,060,354.10	
Primary Health Care Research	2020 Primary Health Care Research	Australian National University	University	ACT	Optimising primary health care in Australia: multi-method whole-of-population investigation of the impact of telehealth on uptake and quality of care	In 2020, telehealth was made available to everyone in Australia, in response to COVID-19. To provide evidence to improve primary health care in Australia, the project will investigate the effect of telehealth on quality of primary care, including accessibility, safety, continuity and appropriateness. For the whole population, we will analyse Medicare data linked to health, social and economic information, complemented by interviews and workshops engaging patient and clinician perspectives.	Associate Professor Rosemary Korda	Targeted competitive	1/05/2021	31/07/2024	Public Health And Health Services	Primary Health Care	\$	1,520,219.65	
Primary Health Care Research	2021 Primary Health Care Digital Innovations	Monash University	University	VIC	Co-designing and evaluating the effectiveness of a digital parenting intervention with peer-coaching for parents of adolescents with emerging mental health problems	This project aims to develop (through co-design) and evaluate a new trained peer workforce of parents with lived experience of caring for adolescents with mental health problems, to provide video-conferencing coaching support for parents engaging in the evidence-based Partners in Parenting online program due to concerns about emerging mental health problems in their adolescent. This new program fills a crucial gap in family-individual primary healthcare services for adolescent mental health.	Associate Professor Marie Yap	Targeted competitive	1/01/2023	30/06/2027	Public Health And Health Services	Public Health And Health Services, Primary Health Care, Public Health And Health Services, Mental Health, Psychology, Health, Clinical And Counselling Psychology	\$	1,599,056.00	
Primary Health Care Research	2021 Primary Health Care Digital Innovations	University of New South Wales	University	NSW	The NOTUS trial (Non-pharmacological Treatment for chronic low back pain Using digital health technology)	Low back pain is the most prevalent musculoskeletal condition and has been the leading cause of long-term disability globally for 30 years. The NOTUS Trial is a hybrid effectiveness-implementation trial to test the effectiveness of a prescribable mobile app for chronic low back pain in primary care. If successful, the NOTUS trial will reduce pain and disability of people with chronic low back pain and inform the development of future digital interventions for the management of chronic disease.	Professor James McAuley	Targeted competitive	1/01/2023	31/12/2027	Public Health And Health Services	Public Health And Health Services, Primary Health Care	\$	1,614,405.00	
Primary Health Care Research	2021 Primary Health Care Digital Innovations	University of New South Wales	University	NSW	Identifying primary care opportunities to enhance HPV vaccination and cervical screening for priority population groups	This project will help eliminate cervical cancer fairly in Australia by reducing barriers to access (green cervical cancer prevention services) and increasing primary care engagement. We will focus on five community groups who exhibit an unacceptably high burden from cervical cancer. We will build a new digital health tool using existing data. We will translate the evidence generated by the tool to improved clinical practices, educational resources, national policies, and outcomes for patients.	Professor Claire Vajdic	Targeted competitive	1/01/2023	31/12/2027	Public Health And Health Services	Public Health And Health Services, Primary Health Care, Statistics, Applied Statistics, Other Medical And Health Sciences, Medical And Health Sciences Not Elsewhere Classified	\$	1,583,120.00	
Primary Health Care Research	2021 Primary Health Care Digital Innovations	The University of Queensland	University	QLD	Digital Health Transformation of Rural Primary Health Care Through an Innovative Digital Indigenous Primary Health Care Delivery Model: DI-INSPIRED	The positive impact of digital transformation in primary care is being realised in a multitude of settings worldwide. Such transformation has streamlined workflows in health care settings optimising patient outcomes and arguably reducing costs. Most of these successes have been demonstrated in metropolitan areas where such transformation is easier to enable, implement and evaluate. However, its impact when integrated within a primary care setting in remote Indigenous communities is unknown.	Associate Professor Srinivas Kondeamany Chennakesavan	Targeted competitive	1/01/2023	31/12/2027	Public Health And Health Services	Public Health And Health Services, Primary Health Care	\$	926,568.00	
Primary Health Care Research	2021 Primary Health Care Digital Innovations	Queensland University of Technology	University	QLD	3D digital solutions for diabetes related foot ulcer offloading treatment	Annually, approximately 50,000 Australians are impacted by diabetes-related foot ulcers (DFU) with the impact of DFUs dramatically increasing in regional/Indigenous communities costing ~\$1.6B. We will develop and deploy low-cost dynamic foot scanning technologies to enable the 3D scanning and 3D printing of low-cost, patient-specific, personalised DFU offloading insoles to improve DFU treatment outcomes and provide equitable access to regional communities.	Professor Maria Woodruff	Targeted competitive	1/01/2023	30/11/2026	Biomedical Engineering	Biomedical Engineering, Medical Devices, Clinical Sciences, Podiatry, Public Health And Health Services, Primary Health Care	\$	810,102.00	

Primary Health Care Research	2021 Primary Health Care Digital Innovations	University of Sydney	University	NSW	Making it easier for Aboriginal and Torres Strait Islander primary health care services to screen for risky drinking and provide tailored feedback: adapting the Grog Survey App	Alcohol screening and brief intervention are effective ways to reduce risky drinking and related harms in general populations. Yet, it is challenging and complex to detect risky drinking in First Nations Australians. This study will deliver a valid, reliable and acceptable digital alcohol screening and brief intervention tool for First Nations Australians, which is integrated into a commonly-used practice software system. This is something not currently available.	Associate Professor Kylie Lee	Associate Professor Kylie Lee, Doctor James Congrave, Associate Professor Scott Wilson, Professor Noel Hayman, Professor Katherine Congrave, Associate Professor Nikki Percival, Professor Tanya Chikritzis, Professor Angela Dawson, Doctor Marguerite Tracy, Associate Professor Kristen Morley, Doctor Michael Doyle, Doctor Michelle Fitts, Teagan Weatherall	Targeted competitive	1/01/2023	31/12/2028	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health	\$	3,466,749.00
Primary Health Care Research	2021 Primary Health Care Research	Curtin University	University	WA	OP Movement	Children with cerebral palsy often spend more than 96% of their day seated or lying down. Not moving can lead to poor health outcomes. In partnership with children with cerebral palsy, their families, and health care workers we will develop and test wearable sensors. This sensor will monitor the movement of children with cerebral palsy who are unable to walk. By using technology and working together in the community we will improve the health of children with cerebral palsy.	Professor Catherine Elliott	Professor Catherine Elliott, Doctor Dayna Pool, Doctor Sarah Redman, Professor Rachael Moorin, Associate Professor Ben Jackson, Doctor Soeban Reid, Associate Professor Amy Campbell, Professor Leon Straker, Professor Stewart Trott, Professor Christine Imms, Professor Jane Valentine, Ewan Cameron, Doctor Ashleigh Thornton, Associate Professor Mark Peterson, Associate Professor Olaf Verschuere	Targeted competitive	1/06/2022	31/05/2027	Public Health And Health Services	Public Health And Health Services, Care For Disabled, Public Health And Health Services, Primary Health Care, Paediatrics And Reproductive Medicine, Paediatrics	\$	1,538,149.96
Primary Health Care Research	2021 Primary Health Care Research	Bond University Limited	University	QLD	Wearables Integrated Technology to support healthy behaviours in people with Type 2 Diabetes (Wear-IT)	Exercise and dietary behaviours are vital to controlling type 2 diabetes and preventing complications from this disease. This study will combine information from wearable technologies, including physical activity trackers, with health information from the patient's medical record to help people with type-2 diabetes to set goals and monitor progress on physical activity, blood sugar and blood pressure control. Participants will be supported to achieve goals by their GP and Practice Nurse.	Professor Nicholas Zwar	Professor Nicholas Zwar, Professor Robert Samon-Fisher, Professor Katharine Wallis, Doctor Breanne Hobden, Professor Christopher Doran, Gideon Meyerowitz-Katz, Doctor Kean-Seng Lim, Doctor Kristy Fakes, Professor Glendon Mabery, Professor Elizabeth Halcob, Doctor Christopher Oldmeadow	Targeted competitive	1/06/2022	31/05/2026	Public Health And Health Services	Public Health And Health Services, Primary Health Care	\$	1,093,405.00
Primary Health Care Research	2021 Primary Health Care Research	University of New South Wales	University	NSW	Transforming blood pressure control in primary care using the next generation of wearable blood pressure devices: the NEXTGEN-BP randomised trial	The proposed NEXTGEN-BP randomised parallel-group, open-label multicentre trial aims to assess the effectiveness of a novel wearable cuffless BP care strategy in adults with hypertension to reduce clinic BP in primary care compared to usual care at 12 months follow-up. Our secondary objectives are to assess this novel strategy's acceptability to patients and general practitioners; cost-effectiveness; effect on BP medication adherence and tolerability.	Professor Aletta Schutte	Professor Aletta Schutte, Ms Ruth Freed, Doctor Sonali Gnannethiran, Belinda Bennett, Doctor Emily Atkins, Associate Professor Gian Luca Di Tanna, Professor David Peiris, Professor Anusha Patel, Doctor Isabella Tan, Associate Professor Charlotte Hespe, Doctor Niamh Chapman, Professor James Sharran, Associate Professor Damir Gajic, Doctor Hui Ming Liu, Professor Markus Schlaich	Targeted competitive	1/06/2022	31/05/2026	Cardiorespiratory Medicine And Haematology	Cardiorespiratory Medicine And Haematology, Cardiology (Incl. Cardiovascular Diseases)	\$	1,936,263.10
Primary Health Care Research	2021 Primary Health Care Research	Flinders University	University	SA	Equitable access to full blood evaluation testing at the point-of-care in remote primary health	This project will provide access to the most common blood test performed in Australia to some of the most remote communities, with test results available in 10 minutes compared to 4-7 days. The blood test helps early diagnosis of severe infection, or sepsis, the major focus of this project. More broadly, the project will also measure how this rapid blood test may benefit the general health and access to care for remote populations, particularly Aboriginal and Torres Strait Islander people.	Doctor Brooke Spenth	Doctor Brooke Spenth, Professor Mark Shephard, Doctor Shahid Ullah, Professor Richard Reed, Professor Billie Bonevski, Doctor Andrea McVitt, Doctor Tina Noutsos, Doctor Jacqueline Stephens, Professor Chris Rissel, Rodney Ormond, Doctor Annabelle Wilson, Professor Jonathan Kaman, Professor Simon Finfer, Doctor Sean Taylor, Professor James Smith	Targeted competitive	1/06/2022	31/01/2028	Public Health And Health Services	Public Health And Health Services, Aboriginal And Torres Strait Islander Health, Public Health And Health Services, Primary Health Care	\$	2,996,294.25
Rapid Applied Research Translation	2017 Rapid Applied Research Translation (Round 1)	Monash University	University	VIC	Monash Partners Rapid Translation Projects - Component A	1. Expanded analysis of the Victorian Cardiac Outcome Registry (VCOR) 2015-2017 to address barriers and improve patient outcomes in the era of field-triage. 2. Using data linkage to reduce avoidable hospitalisation in vulnerable groups including the elderly. 3. Implementation of an Enhanced Recovery After Surgery (ERAS) Program for Hip and Knee Replacement Surgery. 4. Ensuring HIV positive people are retained in care for best health outcomes. 5. Towards integrated care: improving patient and frontline staff engagement and experience of ambulatory care across the care continuum. 6. Improving access to primary care for vulnerable patients. 7. Improving access to new treatments for patients with Myeloma through a new clinical trials platform. 8. Reducing the evidence practice gap in preventing rehospitalisation and recurrences following stroke. 9. Identifying the determinants of narcotic and radiological imaging overuse for low back pain in community-based women. 10. A large scale approach to improving lung cancer care and health outcomes: assessment of best practice using a clinical quality registry. 11. A new model of health-care for co-morbid diabetes and chronic kidney disease. 12. Victorian Obstetric Anal Sphincter Injury (OASIS). National System Level Initiatives: 13. Health Systems Improvement and Sustainability Framework and Health Technology Assessment. 4. Building capacity in data driven healthcare improvement. 15. An Indigenous Research Network and capacity building.	Not applicable	Not available	Targeted non-competitive	2/01/2018	31/12/2018	Not available	Not available	\$	2,222,222.00
Rapid Applied Research Translation	2017 Rapid Applied Research Translation (Round 1)	The University of Queensland	University	QLD	Collaborative research into national system level initiatives/ - Component B	Aligned with the Australian Medical Research and Innovation Strategy 2016-2021 and Australian Medical Research and Innovation priorities 2016-2018, the aim is to increase health system innovation and responsiveness to emerging challenges across new technology, communicable diseases, and an ageing population. BDHP will collaborate across the Australian Health Research Alliance (AHRA) to improve health outcomes, cutting across systems level challenges nationally through integration of research, education and health care and building capacity in agreed priority initiatives. Research is recognised as the optimal strategy to prepare for emerging challenges and drive health system safety and quality, ensure intervention effectiveness and prevent and treat conditions. This proposal addresses the MHF priorities: i) clinical pathways and care, collaborating across the continuum of care, ii) clinical variation underpinned by data driven health care improvement and iii) improving the health of vulnerable groups. To do this the Centres provide collaborative governance models within each Centre and across the AHRA. BDHP will lead capacity building in initiative one through its expertise in implementation and knowledge translation with a special focus on the hospital - primary care interface. BDHP will engage in building capacity in data driven health care improvement through expertise and experience in electronic medical records to enhance the quality and efficiency of care. Building on existing efforts and integrated digital hospital platform, it will refine and expand its pioneering techniques in linking patient process measures to patient outcomes and translating them into continuum of care workflows. BDHP will engage in building capacity in community involvement in research and indigenous led research. MHF support for these priorities will enable excellent researchers to drive innovative treatments through rapid translation to health impact, contributing to a sustainable health system, cutting across the health system. It aligns with BDHP's Strategic Plan 2015-2020 and State Government vision for research and translation of knowledge into practice and care.	Not applicable	Not available	Targeted non-competitive	2/01/2018	31/12/2018	Not available	Not available	\$	222,222.00
Rapid Applied Research Translation	2017 Rapid Applied Research Translation (Round 1)	University of Melbourne	University	VIC	Melbourne Academic Centre for Health Rapid Translation Projects - Component A	A. Precision medicine for EE: An integrated translational program with three components: 1. Gene discovery: to identify and characterise novel EE genes in cohort >700 patients through whole genome and whole exome sequencing 2. Functional studies: in vitro, in vivo and stem cell models to understand the impact of genetic mutations on protein function and identify novel pathways 3. Novel drug discovery platforms: pre-clinical studies of the impact of repurposed drugs and novel compounds on models of EE. B. EMPOWER-GR: The project will address the challenge of physical deconditioning in patients with acute disease and highest risk of physical limitations, by counteracting sarcopenia through: 1. Diagnostics 2. Intervention - RCTs for nutritional and exercise interventions 3. Understanding of basic biological mechanisms 4. Implementation in geriatric rehabilitation settings 5. Dissemination - encouraging screening, diagnostics and intervention in collaboration with national and international stakeholders. C. Retinal photography & AI: This project will assess the impact of the new AI-based GP retinal screening model in identifying three types of eye disease (glaucoma, diabetic retinopathy and age related macular degeneration). Investigators have developed a web-based system that incorporates an artificial intelligence (AI)-based automatic grading algorithm on retinal imaging with proven efficiency and accuracy. The project will assess the impact, feasibility, and cost-effectiveness of this model in a randomised trial. D. Thunderstorm Asthma: This project proposes to establish potential and identify novel risk factors for severe asthma during this epidemic to inform future clinical interventions. Hospital and population-based case-control studies will confirm and quantify risk factors. It will also investigate treatment strategies by undertaking a clinical trial of sublingual grass-pollen desensitisation tablets in patients with allergic asthma. A prediction model will be developed to identify patients at risk, which will inform platforms for Health Services Research, clinical and public health translation.	Not applicable	Not available	Targeted non-competitive	20/03/2018	30/06/2018	Not available	Not available	\$	2,222,222.00

Rapid Applied Research Translation	2017 Rapid Applied Research Translation (Round 1)	University of Sydney	University	NSW	Sydney Health Partners Rapid Translation Projects - Component A	The Sydney Health Partners Rapid Applied Research Translation Program will scale up innovation in health care and accelerate the delivery of improved health outcomes by addressing the leading causes of death and disability in our populations. The individual projects are embedded in our Local Health Districts (LHDs), led by clinicians serving more than 2.7 million people, and supported by the world leading research capabilities of the University of Sydney and nine independent research institutes. Projects in cancer, cardiovascular disease and musculoskeletal disorders will cross the spectrum from acute emergency care to chronic disease management amongst disadvantaged groups in the community developing, improving and implementing clinical pathways, harmonising data to address variations in clinical practice and outcomes, all with the objective of enhancing care that is both patient centred and value based. A smaller but important part of the program will address how the vast potential of genomics can be utilised in mainstream health using genetic eye disease and breast cancer biomarkers as examples. The projects are responsive to locally identified needs, but the outcomes will have application well beyond our own community. For example, hepatitis C (and associated liver cancer) is a national challenge that requires localised responses. Australia fails to meet international targets largely because established hospital-based programs do not reach high prevalence groups. We are proposing an innovative community-based model of care that can deliver higher rates of vaccination and provide opportunities for addressing many other health issues affecting vulnerable populations. Following a rigorous evaluation process, we selected projects on the basis of their alignment with the objectives of the Rapid Applied Research Translation Program, their feasibility and potential impact on the broader health system and the health of the community, and on their ability to deliver meaningful outcomes in a finite time.	Not applicable	Not available	Targeted non-competitive	12/01/2018	31/12/2018	Not available	Not available	\$	2,222,222.00
Rapid Applied Research Translation	2017 Rapid Applied Research Translation (Round 1)	University of Western Australia	University	WA	Collaborative research into national system level initiative/s - Component B	Aligned with the Australian Medical Research and Innovation Strategy 2016-2021 and Australian Medical Research and Innovation priorities 2016-2018, this "project" aims to increase health system innovation and responsiveness to emerging challenges across new technology, communicable diseases, and an ageing population. We propose i) unprecedented collaboration across all stakeholders and ii) nationwide system level activities (component B). Research is recognised as the optimal strategy to prepare for emerging challenges and drive health system safety and quality, ensure intervention effectiveness and prevent and treat conditions. Our proposal addresses MRFF priority areas both health research and its translation by i) clinical pathways and care, collaborating across the continuum of care, ii) clinical variation underpinned by data driven health care improvement and iii) improving the health of vulnerable groups. To do this we offer collaborative governance models within our AIRTC and across the Australian Health Research Alliance. In component B we will work with the AIRRA to improve health outcomes, cutting across systems level challenges nationally through integration of research, education and health care by building capacity in agreed priority areas. WAHTN will co-lead with Sydney Health Partners the consumer and community involvement initiative, focusing on building capacity for data driven health care improvement, and engage in building capacity in community involvement in research and health care innovation, in health services research and in Indigenous led research. WAHTN will also engage in other AIRRA initiatives described by other Alliance members. MRFF support for these strategic priorities will enable excellent researchers, and drive innovative treatments through rapid translation to health impact, contributing to a sustainable health system, cutting across the health system. WAHTN represents a "Whole of State" approach to advancing health care and to embedding research as a core activity of the health care system.	Not applicable	Not available	Targeted non-competitive	2/01/2018	31/12/2018	Not available	Not available	\$	222,222.00
Rapid Applied Research Translation	2017 Rapid Applied Research Translation (Round 1)	Central Australian Aboriginal Congress Aboriginal Corporation	Corporation	NT	Collaborative research into national system level initiative/s - Component B	The proposed project will build further capacity for, and support the application of, Aboriginal community engagement in translational health research. While most of the project activities will be carried out in Central Australia, the learnings from the project will be shared with NHMRC accredited Centres to inform appropriate Aboriginal community engagement in other parts of the country. The three main components of the project are: (1) Seed funding for innovative and high priority research (\$100,000). Two research projects have been selected to receive a small contribution towards project development and implementation: the 'HTLV-1 mother to child transmission study', and 'Assessing the effectiveness of the Aboriginal community controlled health services sector study'. These research studies are aligned with the platform areas of the CA AHSC and the MRFF objectives. (2) Aboriginal research engagement officer(s) (\$72,222). The CA AHSC Partner have considerable expertise in Aboriginal community engagement within the region. The part-time employment of one or more Aboriginal research engagement officers will ensure development of effective and streamlined channels for Partners and other community organisations to engage in the five platform areas of the CA AHSC. (3) Support towards administration of the CA AHSC (\$50,000). There is need to accelerate the administration of the CA AHSC as a Centre for Innovation in Regional Health. The newly developed Chief Operating Officer role will allow for better coordination of planning, priority setting, and development of policies and procedures by the CA AHSC. This includes greater capacity to: coordinate annual priority setting processes with community partners; develop organisational policies (including as related to community engagement); and participate in national dialogue and initiatives with the Australian Health Research Alliance (AHRA). The above project elements will be integrated into the national initiatives identified by the AHRA: Consumer and Community Involvement; and the Indigenous Research Network.	Not applicable	Not available	Targeted non-competitive	2/01/2018	31/12/2018	Not available	Not available	\$	222,222.00
Rapid Applied Research Translation	2017 Rapid Applied Research Translation (Round 1)	The University of Newcastle	University	NSW	Collaborative research into national system level initiative/s - Component B	The development of a national framework for assessment of new health technologies and models of care is aligned with the Australian Medical Research and Innovation Strategy 2016-2021 and Australian Medical Research and Innovation Priorities 2016-2018. The focus of this national initiative aims to increase health system innovation and responsiveness to emerging challenges across new technology and changing models of health care and provide evidence for value-based health care decision making. We propose unprecedented collaboration across all NSWRRP stakeholders and AIRRA nationwide system level activities to develop a national framework in health economics assessment that considers clinical, economic and social indicators. Our initiative addresses MRFF priority areas across both health research and its translation - i) clinical pathways and care, collaborating across the continuum of care, ii) clinical variation underpinned by data driven health care improvement and iii) improving the health of vulnerable groups. To do this we will work within the collaborative governance models of our CRH and across the Australian Health Research Alliance centres. We will work with the AIRRA by developing of a national health systems improvement and sustainability framework and building capacity in agreed priority areas. NSW Regional Health Partners will co-lead this work with the Sydney Partnership for Health Education Research and Enterprise (SPHERE) and Brisbane Diamantina Health Partners. NSWRRP will also engage in other AIRRA initiatives, specifically in ii) building capacity in Indigenous led research, iii) contributing to the steering committees for building capacity in data driven care improvement and iv) developing the implementation sciences required to change behaviours within our communities and health services. NSWRRP will support these strategic national priorities to enable clinicians and researchers to drive innovative treatments through rapid translation to health impact, contributing to a sustainable innovative health system. These initiatives will be underpinned by community and consumer engagement.	Not applicable	Not available	Targeted non-competitive	2/01/2018	31/12/2018	Not available	Not available	\$	222,222.00

Rapid Applied Research Translation	2017 Rapid Applied Research Translation (Round 1)	South Australian Health and Medical Research Institute Limited	Medical Research Institute	SA	South Australian Health and Medical Research Institute Rapid Translation Projects - Component A	The SA Academic Health Science and Translation Centre (SA Centre) Rapid Translation Projects outlined in this application address each of the SA Centre priority areas, focusing not only on health issues of greatest clinical concern such as Aboriginal Health, colorectal cancer and cardiac rehabilitation, but also on the issues associated with the successful implementation of a State-wide translational health 'pipeline' to help bridge the gaps that lie between the different stages of translating new, evidence-based discoveries into standard healthcare practice. The SA Centre has identified nine translational research projects that are aligned with the MRFF Priority areas. These projects cover key health areas – cardiac rehabilitation (Project 4), pre-term birth (Project 7), diabetes (Project 2), colorectal cancer (Project 3) and stroke (Project 9) – as well as focusing on data and registry science in the areas of mental health (Project 6), ageing (Project 5) and joint replacement (Project 8). In addition, the SA Centre will have a specific focus on chronic disease in Aboriginal communities (Project 1). These projects focus on the integration of research, education and clinical care by building capacity across the three sectors. Through its whole-of-State approach, and the co-location with the South Australian Health and Biomedical Precinct, the SA Centre is collaboratively driving the implementation of these targeted research and translation projects in its priority areas, which in a short period of time will achieve significant outcomes. At a national level, the SA Centre will work with the Australian Health Research Alliance to build capacity in agreed national priority areas: data driven health care improvement, health services research and Indigenous led research. The provision of support from the MRFF for this translational program of research will enhance the conduct of excellent health and medical research leading to rapid translation for improved health care delivery.	Not applicable	Not available	Targeted non-competitive	22/12/2017	31/12/2018	Not available	Not available	\$	2,222,222.00
Rapid Applied Research Translation	2017 Rapid Applied Research Translation (Round 1)	University of New South Wales	University	NSW	Collaborative research into national system level initiative/s - Component B	Aligned with the Australian Medical Research and Innovation Strategy 2016-2021 and Australian Medical Research and Innovation priorities 2016-2018, this "project" aims to increase health system innovation and responsiveness to emerging challenges across new technology, communicable and non-communicable diseases, and an ageing population. We propose i) unprecedented collaboration across all stakeholders and ii) nationwide system level activities (component B). Research is recognised as the optimal strategy to prepare for emerging challenges and drive health system safety and quality ensuring intervention effectiveness. Research translation is then required to prevent and treat conditions. Our proposal addresses MRFF priority areas across - i) clinical pathways and care, collaborating across the continuum of care, ii) clinical variation underpinned by data driven health care improvement and iii) improving the health of vulnerable groups. To do this we offer collaborative governance models within our AHRC and across the Australian Health Research Alliance. In component B we will work with the AHRA to improve health outcomes, cutting across systems level challenges nationally through integration of research, education and health care by developing a national health systems improvement and sustainability framework and building capacity in agreed priority areas. The Sydney Partnership for Health Education Research (SPHER) and Enterprise will co-lead the national health systems improvement and sustainability framework development in partnership with Brisbane Diamantina and NSW Regional Health Partners. SPHERE will also engage in other AHRA initiatives described by other alliance members, specifically building capacity in community involvement in research and innovation, building capacity in Indigenous led research and building capacity in data driven care improvement. The establishment within SPHERE of Clinical Academic Groups such as Aboriginal Health & Wellbeing and the cross-cutting themes in Health Informatics and Health System Improvement and their associated allocation of SPHERE funding will provide in kind support to these national initiatives.	Not applicable	Not available	Targeted non-competitive	2/01/2018	31/12/2018	Not available	Not available	\$	222,222.00
Rapid Applied Research Translation	2018 Rapid Applied Research Translation (Round 2.1)	South Australian Health and Medical Research Institute Limited	Medical Research Institute	SA	Health Translation SA – MRFF Rapid Applied Research Translation, Stage 2.1	The SA Centre Translational Research projects outlined in this application address SA Centre priority areas and issues associated with the successful implementation of a State-wide translational health 'pipeline' to help bridge the gaps that lie between the different stages of translating new, evidence-based discoveries into standard healthcare practice. The SA Centre has identified eight projects, listed below, that are aligned with MRFF priority areas and focus on key health areas - colorectal cancer (Project 1), stroke (Project 3), diabetes (Project 8), Aboriginal health (Project 4 and 6), mental health (Project 7). These projects focus on integration of research, education and clinical care by building capacity across the three sectors. Additionally, they all consider the interface between policy makers, consumers and other key stakeholders and are focused on driving impact across the state. The SA Centre is collaboratively driving the implementation of these targeted research and translation projects in its priority areas, which in a short period of time will achieve significant outcomes. Project 1 Improving wait times between a positive faecal immunochemical test (FIT) and diagnostic colonoscopy <120 days for all (Lead: Dan Worthley) Project 2 Translating evidence-based chronic breathlessness intervention services to South Australia: personal, clinical and cost effectiveness (Lead: Kyle Johnston) Project 3 Acting fast to increase time-critical stroke treatments to all South Australians (Lead: Susan Hillier) Project 4 Safely sleeping Aboriginal babies in South Australia – doing it together (Lead: Julian Grant) Project 5 Healthy South: Testing the feasibility of the rapid translation of Health in All Policies (HiAP) ideas to create healthy urban environments, create health promoting health services and stem the non-communicable disease epidemic in the Southern area of Adelaide (Lead: Fran Baum) Project 6 Engaging with Aboriginal People to Improve Kidney Care and Outcomes in South Australia (Lead: Janet Kelly) Project 7 Implementing a decision support tool to facilitate early access to community-based care for people with severe mental illness (Lead: Niranjan Bidargaddi) Project 8 Initiation of a novel in-hospital intervention for patients with Type 2 diabetes (Lead: Gary Witter) At a national level, the SA Centre will work with other Centres in the Australian Health Research Alliance to build capacity in agreed priority areas. The provision of research support from the Australian Medical Research and Innovation Strategy 2016-2018, these grant activities aim to increase health system innovation and responsiveness to emerging challenges across new technology, communicable diseases, and an ageing population. We propose i) unprecedented collaboration across all stakeholders, ii) high impact strategic, prioritised translational research projects and iii) nationwide system level activities. Research is recognised as the optimal strategy to prepare for emerging challenges and drive health system safety and quality, ensure intervention effectiveness and prevent and treat conditions. Our proposal addresses MRFF priority areas across i) clinical pathways and care, collaborating across the continuum of care, ii) clinical variation underpinned by data driven health care improvement and iii) improving the health of vulnerable groups. To do this we offer collaborative governance models within our AHRC and across the Australian Health Research Alliance. Our Translational Research projects will: advance treatment of life threatening infections in cancer patients; translate a model for elimination of Hepatitis C into practice; improve quality and safety outcomes following cardiothoracic surgery; implement a patient centred model of care across the care continuum for patients with dementia and delirium; enhance communication and primary health care for residents of aged care facilities with limited English proficiency; bring primary health and social services to vulnerable communities; and enhance home based care for jaundiced infants. We will also build capacity for data driven health care improvement through health data research incubator hubs and develop data harmonisation and clinical research facilitation road maps to support clinical research. In the National System Level Initiatives, we will work with AHRA to improve health outcomes, cutting across systems level challenges nationally through integration of research, education and health care by building capacity in agreed priority areas. Monash Partners will lead in building capacity in data driven health care improvement, and engage in strengthening consumer and community involvement in health research, in building capacity for Health Systems Improvement and Sustainability, and in Indigenous led research and Mound Care.	Not applicable	Not available	One-off/ad hoc	9/01/2019	31/12/2022	Not available	Not available	\$	2,000,000.00
Rapid Applied Research Translation	2018 Rapid Applied Research Translation (Round 2.1)	Monash University	University	VIC	Monash Partners Advanced Health Translation Centre - MRFF Rapid Applied Research Translation, Stage 2.1	Aligned with the Australian Medical Research and Innovation Strategy 2016-2018, these grant activities aim to increase health system innovation and responsiveness to emerging challenges across new technology, communicable diseases, and an ageing population. We propose i) unprecedented collaboration across all stakeholders, ii) high impact strategic, prioritised translational research projects and iii) nationwide system level activities. Research is recognised as the optimal strategy to prepare for emerging challenges and drive health system safety and quality, ensure intervention effectiveness and prevent and treat conditions. Our proposal addresses MRFF priority areas across i) clinical pathways and care, collaborating across the continuum of care, ii) clinical variation underpinned by data driven health care improvement and iii) improving the health of vulnerable groups. To do this we offer collaborative governance models within our AHRC and across the Australian Health Research Alliance. Our Translational Research projects will: advance treatment of life threatening infections in cancer patients; translate a model for elimination of Hepatitis C into practice; improve quality and safety outcomes following cardiothoracic surgery; implement a patient centred model of care across the care continuum for patients with dementia and delirium; enhance communication and primary health care for residents of aged care facilities with limited English proficiency; bring primary health and social services to vulnerable communities; and enhance home based care for jaundiced infants. We will also build capacity for data driven health care improvement through health data research incubator hubs and develop data harmonisation and clinical research facilitation road maps to support clinical research. In the National System Level Initiatives, we will work with AHRA to improve health outcomes, cutting across systems level challenges nationally through integration of research, education and health care by building capacity in agreed priority areas. Monash Partners will lead in building capacity in data driven health care improvement, and engage in strengthening consumer and community involvement in health research, in building capacity for Health Systems Improvement and Sustainability, and in Indigenous led research and Mound Care.	Not applicable	Not available	One-off/ad hoc	11/01/2019	30/06/2021	Not available	Not available	\$	1,978,561.00

Rapid Applied Research Translation	2018 Rapid Applied Research Translation (Round 2.1)	The University of Queensland	University	QLD	Brisbane Diamantina Health Partners – MRFF Rapid Applied Research Translation, Stage 2.1	The BDHP Translational Research Program 2018-2019 will fund nine translational research projects that will deliver health system improvements, better patient outcomes and cost efficiencies for the health system. All projects align with MRFF Priorities and with those of BDHP health service partners and Queensland Health. The projects focus on the integration of health, education and clinical care and build workforce capacity and will lead to more efficient health services, better models of care and improved clinical practice. Projects address knowledge gaps in health, addressing cardiac and cancer-related burdens of disease, health issues impacting vulnerable groups including older and indigenous people, as well as obesity, diabetes, sepsis, and melanoma. The proposed projects, selected through a rigorous assessment process, led by clinician-researchers are across the hospital-community care continuum and the translational research spectrum. They all demonstrate appropriate research methodology and design, have objectives and outputs that can be delivered within the R&T timeframe and show high levels of consumer and community involvement. In consultation and collaboration with the other eight Translation Centres, BDHP will also continue to actively participate in key National System Level Initiatives (NSLI). The four initiatives: Health Systems Improvement and Sustainability Framework, Data Drive Healthcare Improvement, Indigenous Research Network and Capacity Building, and Community Involvement in Health Research, will be progressed into 2019. BDHP will continue to co-lead the Health Systems Improvement and Sustainability initiative with NSW Regional Health Partners and SPHERE. In addition, BDHP will participate in several new areas identified by the Australian Health Research Alliance (AHRA), including Wound Care, Aged Care and Women's Health. BDHP will co-lead with Western Australian Health Translation Network (WAHTN) the Wound Care initiative and BDHP is coordinating the Aged Care Translation Research and Impact Network.	Not applicable	Not available	One-off/ad hoc	30/01/2019	30/06/2023	Not available	Not available	\$	2,000,000.00
Rapid Applied Research Translation	2018 Rapid Applied Research Translation (Round 2.1)	University of Melbourne	University	VIC	Melbourne Academic Centre for Health – MRFF Rapid Applied Research Translation, Stage 2.1	Transformative Translational Research (TTR): Through a targeted call for grants aligned to MACH and MRFF priorities, rigorous peer review (scientific quality, team, alignment, feasibility, breadth and scale of partnership, inclusion of primary care), and assessment of likely impact by MACH health decision makers (ECOs), the MACH has selected seven multi-site projects. A1 – BIVARD: Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (TASTE) An ECR-led clinical trial to identify if early administration of oral thrombolytic agent, tenecteplase prior to hospital can improve outcomes from stroke, and reduce costs compared to standard care of IV alteplase in hospital. A2 – BURCHILL: Closing the gap on indigenous cardiovascular (CV) health: Improving community outcomes through high impact policy relevant research. An ECR-Indigenous clinician researcher led primary care health data project to determine barriers to implementation of evidence-based cardiovascular (CV) to Indigenous Australians compared to rest of the community. A3 – DEANE: Liberal Glucose Control in critically ill patient with pre-existing type 2 Diabetes (LUCID): a phase III multi-centre parallel group randomised clinical trial. An ECR led multicentre randomised clinical trial to improve management of hyperglycaemia in type II diabetes patients in critical care, so that interventions occur only a higher blood glucose level. This trial aims to reduce hypoglycaemia and other complications of diabetes and ICU stay in this population. A4 – DUGUE: Integrating Osteoporosis in Primary Care: The Osteoporosis Risk and Management (ORMA) Project. This health services research study and fellowship seeks to evaluate effectiveness of scale up of a new, tested and osteoporosis e-technology platform in primary care to improve detection, management, and knowledge about osteoporosis by GPs. A5 – HISDOCK: Improving the care of children with frequent asthma admissions through partnerships with hospitals, GPs, and families. This health services/data research study and fellowship aims to reduce unnecessary, costly asthma re-admissions to paediatric and mixed adult/child emergency departments in children by analysis of health data to identify modifiable health system, primary care, and family factors associated with asthma re-admissions. A6 – NELSON: Future Health Today Project Co-ordinator of Bioscience. This cross-institutional research and fellowship will test the potential of short-term translational research projects that address MRFF priorities aligned with the priorities of our health service partners. The projects will improve clinical pathways, build capacity in the clinical workforce, and test a number of care options that seek to shift care away from hospitals and into the home, providing significant benefits to patients as well as cost-savings to the health system. Several projects aim to address known health inequalities among marginalised members of our communities, for example, people with rare diseases, people with severe mental illness, people with Hep C, and Indigenous children. The individual projects are embedded in our Local Health Districts (LHDs), led by clinicians serving more than 2.7 million people and supported by the world leading research capabilities of the University of Sydney and nine independent research institutes. Projects across the spectrum from acute care to chronic disease management and community-based interventions amongst disadvantaged and/or marginalised groups. They will develop, implement and improve clinical pathways, leverage existing data to inform and improve clinical practice and outcomes, and drive more patient-centred care. A smaller but important part of the program will support proof of concept projects that test the potential of genomics to guide diagnosis and treatment decisions for patients with chronic disease, families with rare diseases and those at increased risk of colon cancer. The proposed R&T projects are diverse in subject, target population and stage of the research continuum, however they have in common that they: Map closely to AMRAB/MRFF priorities; Involve scale through multidisciplinary and multi-institutional involvement to take advantage of the large population catchment served by SHP partners; Have a clear research question and strong design and evaluation including meaningful 12-month objectives and deliverables; Have an explicit implementation pathway; Have been selected following a rigorous assessment process. Following an open call, funding applications were ranked and triaged by our health service partners for alignment with local health priorities, then reviewed by an expert panel on the following criteria: alignment with MRFF priorities; feasibility; potential impact on the broader health system and the health of the community; and the project's ability to.	Not applicable	Not available	One-off/ad hoc	27/03/2019	30/06/2021	Not available	Not available	\$	1,678,100.00
Rapid Applied Research Translation	2018 Rapid Applied Research Translation (Round 2.1)	University of Sydney	University	NSW	Sydney Health Partners – MRFF Rapid Applied Research Translation, Stage 2.1	The Sydney Health Partners Rapid Translation Research Program 2018-19 will fund a program of short-term translational research projects that address MRFF priorities aligned with the priorities of our health service partners. The projects will improve clinical pathways, build capacity in the clinical workforce, and test a number of care options that seek to shift care away from hospitals and into the home, providing significant benefits to patients as well as cost-savings to the health system. Several projects aim to address known health inequalities among marginalised members of our communities, for example, people with rare diseases, people with severe mental illness, people with Hep C, and Indigenous children. The individual projects are embedded in our Local Health Districts (LHDs), led by clinicians serving more than 2.7 million people and supported by the world leading research capabilities of the University of Sydney and nine independent research institutes. Projects across the spectrum from acute care to chronic disease management and community-based interventions amongst disadvantaged and/or marginalised groups. They will develop, implement and improve clinical pathways, leverage existing data to inform and improve clinical practice and outcomes, and drive more patient-centred care. A smaller but important part of the program will support proof of concept projects that test the potential of genomics to guide diagnosis and treatment decisions for patients with chronic disease, families with rare diseases and those at increased risk of colon cancer. The proposed R&T projects are diverse in subject, target population and stage of the research continuum, however they have in common that they: Map closely to AMRAB/MRFF priorities; Involve scale through multidisciplinary and multi-institutional involvement to take advantage of the large population catchment served by SHP partners; Have a clear research question and strong design and evaluation including meaningful 12-month objectives and deliverables; Have an explicit implementation pathway; Have been selected following a rigorous assessment process. Following an open call, funding applications were ranked and triaged by our health service partners for alignment with local health priorities, then reviewed by an expert panel on the following criteria: alignment with MRFF priorities; feasibility; potential impact on the broader health system and the health of the community; and the project's ability to.	Not applicable	Not available	One-off/ad hoc	30/01/2019	30/06/2021	Not available	Not available	\$	1,992,000.00
Rapid Applied Research Translation	2018 Rapid Applied Research Translation (Round 2.1)	University of Western Australia	University	WA	Western Australian Health Translation Network – MRFF Rapid Applied Research Translation, Stage 2.1	The Transformative Translational research projects outlined in this application align with the Australian Medical Research and Innovation Strategy 2016-2021 and Australian Medical Research and Innovation priorities 2016-2018, and focus on the integration of research, education and clinical care by building capacity across these three key areas. WAHTN will undertake a number of rapid translational research projects during the 2019 calendar year that build capacity in the clinical workforce and improve clinical pathways. The four key projects will focus on: Early career development; by offering Early Career Research Fellowships open to all health professionals with an emphasis on collaboration, leveraged funding and measurement of impact on improved patient outcomes (Project 1). Increasing research education and training capacity; by undertaking a review of current contextualised research training across the AHRA Centres, and their partners, to map relevant research on-line education needs (Project 2). Enhancing researcher access to cohort data; through development of a software platform to support governance, discovery and translation from large health datasets (Project 3). Addressing the important clinical area of men's health; through analyses into the associations of endogenous sex hormones with key health outcomes using pooled data from nine cohort studies samples from ~20,000 men across Australia, Europe and USA (Project 4). For a detailed description of each project see Section 3, Criterion 1 of this application and the activity plan in Table A. In addition to the rapid translational research projects, WAHTN will continue to actively participate in key National System Level Initiatives (NSLI), in consultation and collaboration with the other AHRA Centres. These projects will build upon the four initiatives commenced in 2018 namely: Health System Improvement and Sustainability Framework; Data Driven Health Care; Indigenous Research Capacity Building; and Consumer and Community Involvement in Health Research. WAHTN will also participate in several new initiatives identified by AHRA, these include Wound Care, Aged Care and Women's Health. WAHTN will co-lead with Brisbane Diamantina Health Partners the newly developed Wound Care initiative and will continue to co-lead the Consumer and Community Involvement in Health Research initiative with Sydney Health Partners. These four initiatives are areas of national research strength in WA, and	Not applicable	Not available	One-off/ad hoc	30/01/2019	28/02/2021	Not available	Not available	\$	1,972,000.00

Rapid Applied Research Translation	2018 Rapid Applied Research Translation (Round 2.1)	Central Australian Aboriginal Congress Aboriginal Corporation	Corporation	NT	Researcheremmy Wappayalawanga Central Australia Academic Health Science Network – MRFF Rapid Applied Research Translation, Stage 2.1	Summary: 1 Significant improvement in quality of care in Aboriginal primary health care through developing tools to develop/enhance non-clinical CPs. 2 Aboriginal Primary Health services will be the focus of consolidating/evaluating the delivery of Trauma Informed Care at all levels within their organisations. 3 A cohort of 800 Indigenous residents has been recruited to Baker's HTLV-1 community survey. It will partner with those already engaged to a Longitudinal Study, expanding to WA's Nganyanjara region. 4 Research has often been imposed on Aboriginal people with little meaningful exchange of knowledge/understanding. To assist Aboriginal communities, services and board members in improving understanding/benefits/outcomes of research, to become partners in driving research. 5 Reports of youth crime and risky behaviour in Alice Springs have increased. There is an absence of young people's voices and input into understanding the issues and identifying solutions for young people most at risk. 6 Effective communications between health staff and patients across the Central Australia Health Service is a critical element in improving health outcomes. It is designed to provide sustained improvement in intercultural communication into policy/practice. 7 Aboriginal people experience of very high levels of psychological distress is unacceptably elevated compared with non-Indigenous. The project involves establishing a prototype SEWB assessment instrument that is culturally relevant and safe. 8 The need for an effective primary health care system is urgent in remote Aboriginal communities in order to "close the health gap". This aims to measure the impact of short-term health staff in the remote Nganyanjara Health Service; co-design and implement a comprehensive, affordable, culturally safe and evidence-based workforce strategy. 9 The burden of disease and mortality rate increases with increasing remoteness—there is a need for effective primary health care services, but also for effective emergency services which give remote residents access to life-saving care. A dedicated Medical Retrieval and Consultation Centre was launched in 2018. This study will evaluate the timeliness, efficiency and impact of Centre. 10 Disparities between Aboriginal and non-Aboriginal Australians with diabetes are most striking in young people. Obesity is a key risk for type 2 diabetes—addressing this is vital in reducing risk of complications. 3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35-36-37-38-39-40-41-42-43-44-45-46-47-48-49-50-51-52-53-54-55-56-57-58-59-60-61-62-63-64-65-66-67-68-69-70-71-72-73-74-75-76-77-78-79-80-81-82-83-84-85-86-87-88-89-90-91-92-93-94-95-96-97-98-99-100-101-102-103-104-105-106-107-108-109-110-111-112-113-114-115-116-117-118-119-120-121-122-123-124-125-126-127-128-129-130-131-132-133-134-135-136-137-138-139-140-141-142-143-144-145-146-147-148-149-150-151-152-153-154-155-156-157-158-159-160-161-162-163-164-165-166-167-168-169-170-171-172-173-174-175-176-177-178-179-180-181-182-183-184-185-186-187-188-189-190-191-192-193-194-195-196-197-198-199-200-201-202-203-204-205-206-207-208-209-210-211-212-213-214-215-216-217-218-219-220-221-222-223-224-225-226-227-228-229-230-231-232-233-234-235-236-237-238-239-240-241-242-243-244-245-246-247-248-249-250-251-252-253-254-255-256-257-258-259-260-261-262-263-264-265-266-267-268-269-270-271-272-273-274-275-276-277-278-279-280-281-282-283-284-285-286-287-288-289-290-291-292-293-294-295-296-297-298-299-300-301-302-303-304-305-306-307-308-309-310-311-312-313-314-315-316-317-318-319-320-321-322-323-324-325-326-327-328-329-330-331-332-333-334-335-336-337-338-339-340-341-342-343-344-345-346-347-348-349-350-351-352-353-354-355-356-357-358-359-360-361-362-363-364-365-366-367-368-369-370-371-372-373-374-375-376-377-378-379-380-381-382-383-384-385-386-387-388-389-390-391-392-393-394-395-396-397-398-399-400-401-402-403-404-405-406-407-408-409-410-411-412-413-414-415-416-417-418-419-420-421-422-423-424-425-426-427-428-429-430-431-432-433-434-435-436-437-438-439-440-441-442-443-444-445-446-447-448-449-450-451-452-453-454-455-456-457-458-459-460-461-462-463-464-465-466-467-468-469-470-471-472-473-474-475-476-477-478-479-480-481-482-483-484-485-486-487-488-489-490-491-492-493-494-495-496-497-498-499-500-501-502-503-504-505-506-507-508-509-510-511-512-513-514-515-516-517-518-519-520-521-522-523-524-525-526-527-528-529-530-531-532-533-534-535-536-537-538-539-540-541-542-543-544-545-546-547-548-549-550-551-552-553-554-555-556-557-558-559-560-561-562-563-564-565-566-567-568-569-570-571-572-573-574-575-576-577-578-579-580-581-582-583-584-585-586-587-588-589-590-591-592-593-594-595-596-597-598-599-600-601-602-603-604-605-606-607-608-609-610-611-612-613-614-615-616-617-618-619-620-621-622-623-624-625-626-627-628-629-630-631-632-633-634-635-636-637-638-639-640-641-642-643-644-645-646-647-648-649-650-651-652-653-654-655-656-657-658-659-660-661-662-663-664-665-666-667-668-669-670-671-672-673-674-675-676-677-678-679-680-681-682-683-684-685-686-687-688-689-690-691-692-693-694-695-696-697-698-699-700-701-702-703-704-705-706-707-708-709-710-711-712-713-714-715-716-717-718-719-720-721-722-723-724-725-726-727-728-729-730-731-732-733-734-735-736-737-738-739-740-741-742-743-744-745-746-747-748-749-750-751-752-753-754-755-756-757-758-759-760-761-762-763-764-765-766-767-768-769-770-771-772-773-774-775-776-777-778-779-780-781-782-783-784-785-786-787-788-789-790-791-792-793-794-795-796-797-798-799-800-801-802-803-804-805-806-807-808-809-810-811-812-813-814-815-816-817-818-819-820-821-822-823-824-825-826-827-828-829-830-831-832-833-834-835-836-837-838-839-840-841-842-843-844-845-846-847-848-849-850-851-852-853-854-855-856-857-858-859-860-861-862-863-864-865-866-867-868-869-870-871-872-873-874-875-876-877-878-879-880-881-882-883-884-885-886-887-888-889-890-891-892-893-894-895-896-897-898-899-900-901-902-903-904-905-906-907-908-909-910-911-912-913-914-915-916-917-918-919-920-921-922-923-924-925-926-927-928-929-930-931-932-933-934-935-936-937-938-939-940-941-942-943-944-945-946-947-948-949-950-951-952-953-954-955-956-957-958-959-960-961-962-963-964-965-966-967-968-969-970-971-972-973-974-975-976-977-978-979-980-981-982-983-984-985-986-987-988-989-990-991-992-993-994-995-996-997-998-999-1000-1001-1002-1003-1004-1005-1006-1007-1008-1009-1010-1011-1012-1013-1014-1015-1016-1017-1018-1019-1020-1021-1022-1023-1024-1025-1026-1027-1028-1029-1030-1031-1032-1033-1034-1035-1036-1037-1038-1039-1040-1041-1042-1043-1044-1045-1046-1047-1048-1049-1050-1051-1052-1053-1054-1055-1056-1057-1058-1059-1060-1061-1062-1063-1064-1065-1066-1067-1068-1069-1070-1071-1072-1073-1074-1075-1076-1077-1078-1079-1080-1081-1082-1083-1084-1085-1086-1087-1088-1089-1090-1091-1092-1093-1094-1095-1096-1097-1098-1099-1100-1101-1102-1103-1104-1105-1106-1107-1108-1109-1110-1111-1112-1113-1114-1115-1116-1117-1118-1119-1120-1121-1122-1123-1124-1125-1126-1127-1128-1129-1130-1131-1132-1133-1134-1135-1136-1137-1138-1139-1140-1141-1142-1143-1144-1145-1146-1147-1148-1149-1150-1151-1152-1153-1154-1155-1156-1157-1158-1159-1160-1161-1162-1163-1164-1165-1166-1167-1168-1169-1170-1171-1172-1173-1174-1175-1176-1177-1178-1179-1180-1181-1182-1183-1184-1185-1186-1187-1188-1189-1190-1191-1192-1193-1194-1195-1196-1197-1198-1199-1200-1201-1202-1203-1204-1205-1206-1207-1208-1209-1210-1211-1212-1213-1214-1215-1216-1217-1218-1219-1220-1221-1222-1223-1224-1225-1226-1227-1228-1229-1230-1231-1232-1233-1234-1235-1236-1237-1238-1239-1240-1241-1242-1243-1244-1245-1246-1247-1248-1249-1250-1251-1252-1253-1254-1255-1256-1257-1258-1259-1260-1261-1262-1263-1264-1265-1266-1267-1268-1269-1270-1271-1272-1273-1274-1275-1276-1277-1278-1279-1280-1281-1282-1283-1284-1285-1286-1287-1288-1289-1290-1291-1292-1293-1294-1295-1296-1297-1298-1299-1300-1301-1302-1303-1304-1305-1306-1307-1308-1309-1310-1311-1312-1313-1314-1315-1316-1317-1318-1319-1320-1321-1322-1323-1324-1325-1326-1327-1328-1329-1330-1331-1332-1333-1334-1335-1336-1337-1338-1339-1340-1341-1342-1343-1344-1345-1346-1347-1348-1349-1350-1351-1352-1353-1354-1355-1356-1357-1358-1359-1360-1361-1362-1363-1364-1365-1366-1367-1368-1369-1370-1371-1372-1373-1374-1375-1376-1377-1378-1379-1380-1381-1382-1383-1384-1385-1386-1387-1388-1389-1390-1391-1392-1393-1394-1395-1396-1397-1398-1399-1400-1401-1402-1403-1404-1405-1406-1407-1408-1409-1410-1411-1412-1413-1414-1415-1416-1417-1418-1419-1420-1421-1422-1423-1424-1425-1426-1427-1428-1429-1430-1431-1432-1433-1434-1435-1436-1437-1438-1439-1440-1441-1442-1443-1444-1445-1446-1447-1448-1449-1450-1451-1452-1453-1454-1455-1456-1457-1458-1459-1460-1461-1462-1463-1464-1465-1466-1467-1468-1469-1470-1471-1472-1473-1474-1475-1476-1477-1478-1479-1480-1481-1482-1483-1484-1485-1486-1487-1488-1489-1490-1491-1492-1493-1494-1495-1496-1497-1498-1499-1500-1501-1502-1503-1504-1505-1506-1507-1508-1509-1510-1511-1512-1513-1514-1515-1516-1517-1518-1519-1520-1521-1522-1523-1524-1525-1526-1527-1528-1529-1530-1531-1532-1533-1534-1535-1536-1537-1538-1539-1540-1541-1542-1543-1544-1545-1546-1547-1548-1549-1550-1551-1552-1553-1554-1555-1556-1557-1558-1559-1560-1561-1562-1563-1564-1565-1566-1567-1568-1569-1570-1571-1572-1573-1574-1575-1576-1577-1578-1579-1580-1581-1582-1583-1584-1585-1586-1587-1588-1589-1590-1591-1592-1593-1594-1595-1596-1597-1598-1599-1600-1601-1602-1603-1604-1605-1606-1607-1608-1609-1610-1611-1612-1613-1614-1615-1616-1617-1618-1619-1620-1621-1622-1623-1624-1625-1626-1627-1628-1629-1630-1631-1632-1633-1634-1635-1636-1637-1638-1639-1640-1641-1642-1643-1644-1645-1646-1647-1648-1649-1650-1651-1652-1653-1654-1655-1656-1657-1658-1659-1660-1661-1662-1663-1664-1665-1666-1667-1668-1669-1670-1671-1672-1673-1674-1675-1676-1677-1678-1679-1680-1681-1682-1683-1684-1685-1686-1687-1688-1689-1690-1691-1692-1693-1694-1695-1696-1697-1698-1699-1700-1701-1702-1703-1704-1705-1706-1707-1708-1709-1710-1711-1712-1713-1714-1715-1716-1717-1718-1719-1720-1721-1722-1723-1724-1725-1726-1727-1728-1729-1730-1731-1732-1733-1734-1735-1736-1737-1738-1739-1740-1741-1742-1743-1744-1745-1746-1747-1748-1749-1750-1751-1752-1753-1754-1755-1756-1757-1758-1759-1760-1761-1762-1763-1764-1765-1766-1767-1768-1769-1770-1771-1772-1773-1774-1775-1776-1777-1778-1779-1780-1781-1782-1783-1784-1785-1786-1787-1788-1789-1790-1791-1792-1793-1794-1795-1796-1797-1798-1799-1800-1801-1802-1803-1804-1805-1806-1807-1808-1809-1810-1811-1812-1813-1814-1815-1816-1817-1818-1819-1820-1821-1822-1823-1824-1825-1826-1827-1828-1829-1830-1831-1832-1833-1834-1835-1836-1837-1838-1839-1840-1841-1842-1843-1844-1845-1846-1847-1848-1849-1850-1851-1852-1853-1854-1855-1856-1857-1858-1859-1860-1861-1862-1863-1864-1865-1866-1867-1868-1869-1870-1871-1872-1873-1874-1875-1876-1877-1878-1879-1880-1881-1882-1883-1884-1885-1886-1887-1888-1889-1890-1891-1892-1893-1894-1895-1896-1897-1898-1899-1900-1901-1902-1903-1904-1905-1906-1907-1908-1909-1910-1911-1912-1913-1914-1915-1916-1917-1918-1919-1920-1921-1922-1923-1924-1925-1926-1927-1928-1929-1930-1931-1932-1933-1934-1935-1936-1937-1938-1939-1940-1941-1942-1943-1944-1945-1946-1947-1948-1949-1950-1951-1952-1953-1954-1955-1956-1957-1958-1959-1960-1961-1962-1963-1964-1965-1966-1967-1968-1969-1970-1971-1972-1973-1974-1975-1976-1977-1978-1979-1980-1981-1982-1983-1984-1985-1986-1987-1988-1989-1990-1991-1992-1993-1994-1995-1996-1997-1998-1999-2000-2001-2002-2003-2004-2005-2006-2007-2008-2009-2010-2011-2012-2013-2014-2015-2016-2017-2018-2019-2020-2021-2022-2023-2024-2025-2026-2027-2028-2029-2030-2031-2032-2033-2034-2035-2036-2037-2038-2039-2040-2041-2042-2043-2044-2045-2046-2047-2048-2049-2050-2051-2052-2053-2054-2055-2056-2057-2058-2059-2060-2061-2062-2063-2064-2065-2066-2067-2068-2069-2070-2071-2072-2073-2074-2075-2076-2077-2078-2079-2080-2081-2082-2083-2084-2085-2086-2087-2088-2089-2090-2091-2092-2093-2094-2095-2096-2097-2098-2099-2100-2101-2102-2103-2104-2105-2106-2107-2108-2109-2110-2111-2112-2113-2114-2115-2116-2117-2118-2119-2120-2121-2122-2123-2124-2125-2126-2127-2128-2129-2130-2131-2132-2133-2134-2135-2136-2137-2138-2139-2140-2141-2142-2143-2144-2145-2146-2147-2148-2149-2150-2151-2152-2153-2154-2155-2156-2157-2158-2159-2160-2161-2162-2163-2164-2165-2166-2167-2168-2169-2170-2171-2172-2173-2174-2175-2176-2177-2178-2179-2180-2181-2182-2183-2184-2185-2186-2187-2188-2189-2190-2191-2192-2193-2194-2195-2196-2197-2198-2199-2200-2201-2202-2203-2204-2205-2206-2207-2208-2209-2210-2211-2212-2213-2214-2215-2216-2217-2218-2219-2220-2221-2222-2223-2224-2225-2226-2227-2228-2229-2230-2231-2232-2233-2234-2235-2236-2237-2238-2239-2240-2241-2242-2243-2244-2245-2246-2247-2248-2249-2250-2251-2252-2253-2254-2255-2256-2257-2258-2259-2260-2261-2262-2263-2264-2265-2266-2267-2268-2269-2270-2271-2272-2273-2274-2275-2276-2277-2278-2279-2280-2281-2282-2283-2284-2285-2286-2287-2288-2289-2290-2291-2292-2293-2294-2295-2296-2297-2298-2299-2300-2301-2302-2303-2304-2305-2306-2307-2308-2309-2310-2311-2312-2313-2314-2315-2316-2317-2318-2319-2320-2321-2322-2323-2324-2325-2326-2327-2328-2329-2330-2331-2332-2333-2334-2335-2336-2337-2338-2339-2340-2341-2342-2343-2344-2345-2346-2347-2348-2349-2350-2351-2352-2353-2354-2355-2356-2357-2358-2359-2360-2361-2362-2363-2364-2365-2366-2367-2368-2369-2370-2371-2372-2373-2374-2375-2376-2377-2378-2379-2380-2381-2382-2383-2384-2385-2386-2387-2388-2389-2390-2391-2392-2393-2394-2395-2396-2397-2398-2399-2400-2401-2402-2403-2404-2405-2406-2407-2408-2409-2410-2411-2412-2413-2414-2415-2416-2417-2418-2419-2420-2421-2422-2423-2424-2425-2426-2427-2428-2429-2430-2431-2432-2433-2434-2435-2436-2437-2438-2439-2440-2441-2442-2443-2444-2445-2446-2447-2448-2449-2450-2451-2452-2453-2454-2455-2456-2457-2458-2459-2460-2461-2462-2463-2464-2465-2466-2467-2468-2469-2470-2471-2472-2473-2474-2475-2476-2477-2478-2479-2480-2481-2482-2483-2484-2485-2486-2487-2488-2489-2490-2491-2492-2493-2494-2495-2496-2497-2498-2499-2500-2501-2502-2503-2504-2505-2506-2507-2508-2509-2510-2511-2512-2513-2514-2515-2516-2517-2518-2519-2520-2521-2522-2523-2524-2525-2526-2527-2528-2529-2530-2531-2532-2533-2534-2535-2536-2537-2538-2539-2540-2541-2542-2543-2544-2545-2546-2547-2548-2549-2550-2551-2552-2553-2554-2555-2556-2557-2558-2559-2560-2561-2562-2563-2564-2565-2566-2567-2568-2569-2570-2571-2572-2573-2574-2575-2576-2577-2578-2579-2580-2581-2582-2583
------------------------------------	---	---	-------------	----	--	---

Rapid Applied Research Translation	2018 Rapid Applied Research Translation (Round 2.2)	The University of Queensland	University	QLD	Brisbane Diamantina Health Partners – MRFF Rapid Applied Research Translation, Stage Two	Transformative Translational Research: Funding is sought for six research projects for inclusion in the BDHP Transformative Translational Research Program 2019 – 2021. The proposed projects will deliver health system improvements, better patient outcomes and cost efficiencies for the health system. The projects align with MRFF, BDHP and Queensland Department of Health, priorities. They meet the requisite objectives and desired outcomes outlined in the current MRFF guidelines, addressing specific knowledge gaps in health, demonstrating clinical significance with potential for scalability and building workforce capacity. The projects also demonstrate scientific robustness and appropriate research methodology and design. Further, they demonstrate strong transdisciplinary collaboration and meaningful consumer and community involvement. The proposed projects, selected through a rigorous two-stage assessment process, are led by clinician-researchers across the hospital-community care continuum and the translational research spectrum, with deliverable objectives and outputs within the RART timeframe. National System Level Initiatives: Funding is sought to support BDHP's continued consultation and collaboration with the other eight Translation Research Centres to further the National System Level Initiatives (NSLI). BDHP will again actively participate in the four key NSLs and the recently identified Wound Care initiative. The four NSLI - Health Systems Improvement and Sustainability Framework, Data Driven Healthcare Improvement, Indigenous Research Network and Capacity Building, and Community Involvement in Health Research will be progressed into 2020. BDHP will continue with the work program as: co-lead for the Health Systems Improvement and Sustainability Framework initiative with Mandulu Budyari Gungal and the NSW Regional Health Partners; co-lead for the Wound Care initiative with the Western Australian Health Translation Network (WAHTN). In addition, BDHP will also continue to participate in the areas of Aged Care and Women's Health, as identified by the Australian Health Research Alliance (AHRA). BDHP coordinates the Aged Care Translation Research and Impact Network. Collaborative work programs across all the initiatives will engage community and consumers and integrate system-wide learning.	Not applicable	Not available	One-off/ad hoc	1/07/2019	30/06/2023	Not available	Not available	\$	4,110,000.00
Rapid Applied Research Translation	2018 Rapid Applied Research Translation (Round 2.2)	University of Melbourne	University	VIC	Melbourne Academic Centre for Health – MRFF Rapid Applied Research Translation, Stage Two	YIR Activities - YIR EXPANSION activities: The EXPANSION activities for each of these projects will build on translational research to strengthen patient outcomes and enhance the national scalability and implementation across the AHRA network. This opportunity is offered for EXPANSION activities only and not for existing project activities. A1 – BIVARD: EXPANSION - Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (TASTE) A2 – BUNCHILL: EXPANSION - Closing the gap on Indigenous cardiovascular (CV) health: improving community outcomes through high impact policy relevant research. A3 – DEANE: EXPANSION - Liberal glucose Control in critically ill patients with pre-existing type 2 Diabetes (LUCID): a phase III multi-centre parallel group randomised clinical trial A4 – DIQUE: EXPANSION - Integrating Osteoporosis in Primary Care: The Osteoporosis Risk and Management (ORAM) Project A5 – HISCOCK: EXPANSION - Improving the care of children with frequent asthma admissions through partnerships with hospitals, GPs, and families. A6 – NELSON: EXPANSION - Future Health Today Project Co-design of Prototypes - New investigator-led projects A8 – BIGDTMANN: Preventing post-stroke dementia and brain atrophy with exercise: The Post Ischaemic Stroke Cardiovascular Exercise Study (PICES) A9 – CASTLE: Evaluating the impact of a psychological intervention to reduce the severe stress and psychological morbidity of people with chronic kidney disease: The Kidney Optimal Health Program (KOHPP); Stage 2 A10 – EKINCI: Can flash glucose monitoring improve blood glucose control in Indigenous Australians with type 2 diabetes? A11 – LAUTENSCHLAGER: Physical Activity in Aged Mental Health Services: Physical activity guidelines implementation for aged mental health community team consumers A12 – MULLIGOM: Clinical Decision Support Integrated with e-Screening for Postnatal Depression A13 – MILNER: Clinical and community service provision for people with disabilities: Investigating the perspectives of the health care workforce and their clients A14 – REDDINGHILL: Hips on Track: A state-wide approach to preventing hip dislocation for young people with cerebral palsy A15 – VELAKOULIS: Clinical utility of plasma neurofilament light chain in the diagnostic screening of psychiatric and neurological disorders A16 – ZIEGLER: The ZIEGLER project A17 – ANDERSON: Developing precision medicine The proposed activities include original transformative translational research, capacity building to address key gaps in innovation pathways, and research infrastructure development to leverage and extend existing resources, particularly health data. The proposal delivers scalable solutions to health service problems to benefit patients. We also include participation in national system-level activities in partnership with other AHRTCs. Sydney Health Partners leads the AHRA work on innovative consumer and community involvement in research (along with the Western Australian Health Translation Network), and the AHRA initiative in better use of data to improve health outcomes (along with Monash Partners and the Melbourne Academic Centre for Health). We also have representation on the following initiatives: Health System Improvement and Sustainability, Women's Health, Indigenous Researcher Capacity, Wound Care, and Aged Care. Collectively these activities address Australian Medical Research Advisory Board priorities for 2016-2018 and 2018-2020, and meet the Grant Opportunity Guidelines. Original projects have been chosen based on alignment with the priorities of the MRFF RART program and our health services, scientific validity and the ability for successful outcomes to be translated rapidly into the health system. They are multidisciplinary and each project involves collaboration across multiple health settings. These range from acute health services to aged care facilities, primary care and the general community. Our grant activities have been structured into two broad categories: improving care and health outcomes (with a focus on chronic disease in the community, and several vulnerable groups); and capacity building and infrastructure development including local and national projects in unprecedented collaboration with all other AHRA member Centres. For the next round, our partners have elected to include projects on Type 2 diabetes in two understudied populations: young adults and pregnant women. Diabetes is the fastest growing chronic condition in Australia, affecting around 1.7 million people. Several transformative translational projects target diabetes care, aiming to improve the attendance of diabetic adolescents at specialist clinics, providing increased access to gold standard care, and working to reduce the risk of Type 2 diabetes among the young adult population.	Not applicable	Not available	One-off/ad hoc	1/07/2019	30/06/2022	Not available	Not available	\$	4,431,900.00
Rapid Applied Research Translation	2018 Rapid Applied Research Translation (Round 2.2)	University of Sydney	University	NSW	Sydney Health Partners – MRFF Rapid Applied Research Translation, Stage Two	Professor Don Nutbeam	Not available	One-off/ad hoc	1/07/2019	30/06/2024	Not available	Not available	\$	4,118,000.00	
Rapid Applied Research Translation	2018 Rapid Applied Research Translation (Round 2.2)	University of Western Australia	University	WA	Western Australian Health Translation Network – MRFF Rapid Applied Research Translation, Stage Two	he projects in this application align with the Australian Medical Research and Innovation (AMRI) Strategy 2016-2021 and address the AMRI Priorities 2016-2018 and/or 2018-2020. Transformative Translational Research: Health Service Translational Research Projects. Twelve research projects will be funded across a range of clinical topics. The projects are initiated and endorsed by WA Health Service Providers (HSP) and required to have: broad collaboration across WAHTN partner organisations; matched partner funding; measurable impact; and scalability. The two stage selection process involved projects being reviewed by WAHTN HSPs and the top four from each HSP then being assessed by an independent review panel. This ensures the successful projects will deliver scalable solutions to health service problems and directly benefit patients, while also aligning with the requisite MRFF and AMRI Priorities. Targeted Translational Research Fellowships will be offered through an open call process to WAHTN partner organisations. Funding will be provided for three 12-18 month Fellowships in the targeted areas of Antimicrobial Resistance, Wound Care and Indigenous Health. These are key areas of interest to the WA health and medical research sector with obvious alignment to the MRFF and AMRI Priorities. These Fellowships are designed to integrate research, education and clinical care by building capacity in the clinical workforce and improving clinical pathways. The areas of Wound Care and Indigenous Health also have obvious integration and synergy with two of the current NSLs. National System Level Initiatives: CCI and Wound Care are areas of particular research strength in WA and resonate with the WAHTN membership. WAHTN will take a leading role on these two projects, while also continuing to actively participate in the remaining NSLI. Networks and advocacy activities led by other AHRA Centres. CCI in Health Research. WAHTN will co-chair this initiative with SHP. A Project Plan has been agreed by AHRA members who will continue to work collaboratively to achieve it. The plan targets four key areas of work. WAHTN will coordinate the activity across the AHRA centres and take the lead on Project 1: Development of minimum standards of good practice. In addition, WAHTN will work with two of its key enabling platforms to create a number of relevant tool sources like CCI online modules. Wound Care. WAHTN will co-lead this initiative with BDHP. The	Not applicable	Not available	One-off/ad hoc	1/07/2019	30/06/2023	Not available	Not available	\$	4,138,000.00

Rapid Applied Research Translation	2018 Rapid Applied Research Translation (Round 2.2)	The University of Newcastle	University	NSW	NSW Regional Health Partners – MRFF Rapid Applied Research Translation, Stage Two	The research projects proposed for 2019-2021 form a cohesive and focused program of work with three focus areas: end of life, health economics and building researcher capacity (see diagram A). 1. Enhanced Palliative Care Community Team Model: Lack of healthcare support prevents many patients from dying at home, particularly in rural communities. The project will pilot an 'enhanced' palliative care multidisciplinary community team model able to rapidly respond to dying patients' increased care needs. The model will be piloted in two matched urban and two matched rural sectors providing an analysis of the economic benefits. 2. Advanced Care Planning: Rural Australians have poorer access to End of Life Care (EOLC) than other Australians. Advanced Care Planning can improve the quality, continuity and efficiency of EOLC, however local data shows use by health professionals is low. The project uses strategies to improve the development, quality, access, use and compliance with plans and uses a mixed methods study design to assess effectiveness. 3. Perioperative Shared Decision Making in the Older Adult Population: Some surgery is considered 'futile', leading to health burdens on patients and increased costs to the health system. This project will implement a multidisciplinary shared decision-making clinic for high risk adults considering surgery aiming to provide more appropriate care for surgical candidates nearing the end of their life. 4. Palliative Care Research Capacity Building Central Coast: This project provides accelerated research skills training for palliative care clinicians via the development of strategic research projects to support the agreed local vision for end of life care. It reflects current evidence by placing emphasis on strategic organisational alignment and mentoring relationships. 5. Practice Based Primary Care Research Network: A practice-based research network (PBRN) will be established. The PBRN will address the research capacity gap in primary care. Seed funding for member-selected research projects will be provided and a wound care clinical trial will be undertaken. 6. Embedded Economist: A health economist will be employed to work with our five health partners. They will spend several months with each providing dedicated support. The economist will work with each partner to improve evidence-based decision making. The economist will be supported by a research assistant and a study co-ordinator for research. 7. Health Translation SA has identified Transformative Translational Research projects that align with MRFF priorities and focus on key South Australian and national health areas including Aboriginal Health, Ageing, Data Access and Analytics, Health Services Interface and Mental Health. These projects represent key health challenges and priorities identified as strengths and needs in South Australia. The activities demonstrate mobilising 'across partner' projects that lead to solutions to current health services challenges and where health services, academics and community sectors pragmatically and effectively co-design and deliver solutions that address some of the real issues facing the health system and patients in South Australia. HTSA is collaboratively driving the implementation of these targeted research and translation projects, which in a short period of time will achieve significant outcomes. Aboriginal Health Project - Strengthening Aboriginal Capacity in Health Research Translation and Development in South Australia (SACTD) (Lead: Professor Alex Brown) Ageing Project - STARR SA, State Action on Avoidable Rethospitalisations and Unplanned Admissions: An Integrated Knowledge Translation project across SA (Lead: Professor Maria Crotty) Data Access and Data Analytics Project - Health Informatics Hub including an exemplar Health Services Interface Data Project (Lead: Health Translation SA) Mental Health Project - Needs based community mental health services: implementing timely and needs based interventions in the community by applying algorithms to transactional health care data (Lead: A/Professor Niranjan Bidagaddi) Nationally HTSA will work collaboratively with other Centres in the Australian Health Research Alliance (AHRA) in five agreed national priority areas. The provision of support from the MRFF for these National System Level Initiatives (NSLI), as listed below, will advance health services and research and the rapid translation of knowledge into improved health care across the country. NSLI 1: Health Systems Improvement and Sustainability Framework and health technology assessment platform - Health Systems Embedded Economic NSLI 2: Building capacity in data driven health care improvement NSLI 3: An Indigenous Research Network and Capacity Building NSLI 4: Consumer and Community Involvement NSLI 5: Wound Care. HTSA leads the national Indigenous Research Network and Capacity Building Initiative NSLI 2) and will support the MRFF Priorities, the Australian Medical Research and Innovation Priorities 2016-2020, areas of improving models and pathways of care, reducing unwarranted clinical variation, addressing healthcare needs of vulnerable groups, improving primary care research and implementing public health interventions in our population. In 2017, Marildu implemented a rigorous annual internal productivity review process to maintain focus on priority areas and to drive project performance to milestones, outcomes and impacts. The focus of this RART grant program is on the conduct of translational research and research translation in MRFF priority areas and the establishment of strategic programs that enable and support the translation of research outcomes into clinical practice and health policy. Marildu is a purpose build translational research and research translation vehicle comprising 16 Clinical Academic Groups (CAGs), each supported by cross-cutting enabling platforms that focus on clinical academic workforce capacity building, clinical trials, health informatics, implementation science and knowledge translation and integrated value-based healthcare. The CAGs span the major burdens of disease in our region; are cross-disciplinary and cross-institutional; are embedded within our four healthcare partners; conduct local healthcare provider and national MRFF priority-driven translational research projects across the partnership. 12 CAGs have been fully operational for 21 months and their initial 18 months of project activity has undergone external peer review in July 2018. Four new CAGs have been accredited and have progressed planning with project activities about to commence. Individual CAG projects and relevant platform activities are described in detail below. The four new CAGs, and the 12 foundation CAGs are scheduled to be performance appraised against MRFF and internal priority key performance indicators in November 2019. The strategic platforms i.e. Implementation Science, Knowledge Translation, Clinical Trials Support and Enablement, and Clinical Workforce Development platforms have been established by Marildu and are designed to support CAGs to deliver transformational projects that will have impact on local healthcare.	Not applicable	Not available	One-off/ad hoc	1/07/2019	31/12/2023	Not available	Not available	\$	4,110,000.00
Rapid Applied Research Translation	2018 Rapid Applied Research Translation (Round 2.2)	South Australian Health and Medical Research Institute Limited	Medical Research Institute	SA	Health Translation SA – MRFF Rapid Applied Research Translation, Stage Two	Health Translation SA has identified Transformative Translational Research projects that align with MRFF priorities and focus on key South Australian and national health areas including Aboriginal Health, Ageing, Data Access and Analytics, Health Services Interface and Mental Health. These projects represent key health challenges and priorities identified as strengths and needs in South Australia. The activities demonstrate mobilising 'across partner' projects that lead to solutions to current health services challenges and where health services, academics and community sectors pragmatically and effectively co-design and deliver solutions that address some of the real issues facing the health system and patients in South Australia. HTSA is collaboratively driving the implementation of these targeted research and translation projects, which in a short period of time will achieve significant outcomes. Aboriginal Health Project - Strengthening Aboriginal Capacity in Health Research Translation and Development in South Australia (SACTD) (Lead: Professor Alex Brown) Ageing Project - STARR SA, State Action on Avoidable Rethospitalisations and Unplanned Admissions: An Integrated Knowledge Translation project across SA (Lead: Professor Maria Crotty) Data Access and Data Analytics Project - Health Informatics Hub including an exemplar Health Services Interface Data Project (Lead: Health Translation SA) Mental Health Project - Needs based community mental health services: implementing timely and needs based interventions in the community by applying algorithms to transactional health care data (Lead: A/Professor Niranjan Bidagaddi) Nationally HTSA will work collaboratively with other Centres in the Australian Health Research Alliance (AHRA) in five agreed national priority areas. The provision of support from the MRFF for these National System Level Initiatives (NSLI), as listed below, will advance health services and research and the rapid translation of knowledge into improved health care across the country. NSLI 1: Health Systems Improvement and Sustainability Framework and health technology assessment platform - Health Systems Embedded Economic NSLI 2: Building capacity in data driven health care improvement NSLI 3: An Indigenous Research Network and Capacity Building NSLI 4: Consumer and Community Involvement NSLI 5: Wound Care. HTSA leads the national Indigenous Research Network and Capacity Building Initiative NSLI 2) and will support the MRFF Priorities, the Australian Medical Research and Innovation Priorities 2016-2020, areas of improving models and pathways of care, reducing unwarranted clinical variation, addressing healthcare needs of vulnerable groups, improving primary care research and implementing public health interventions in our population. In 2017, Marildu implemented a rigorous annual internal productivity review process to maintain focus on priority areas and to drive project performance to milestones, outcomes and impacts. The focus of this RART grant program is on the conduct of translational research and research translation in MRFF priority areas and the establishment of strategic programs that enable and support the translation of research outcomes into clinical practice and health policy. Marildu is a purpose build translational research and research translation vehicle comprising 16 Clinical Academic Groups (CAGs), each supported by cross-cutting enabling platforms that focus on clinical academic workforce capacity building, clinical trials, health informatics, implementation science and knowledge translation and integrated value-based healthcare. The CAGs span the major burdens of disease in our region; are cross-disciplinary and cross-institutional; are embedded within our four healthcare partners; conduct local healthcare provider and national MRFF priority-driven translational research projects across the partnership. 12 CAGs have been fully operational for 21 months and their initial 18 months of project activity has undergone external peer review in July 2018. Four new CAGs have been accredited and have progressed planning with project activities about to commence. Individual CAG projects and relevant platform activities are described in detail below. The four new CAGs, and the 12 foundation CAGs are scheduled to be performance appraised against MRFF and internal priority key performance indicators in November 2019. The strategic platforms i.e. Implementation Science, Knowledge Translation, Clinical Trials Support and Enablement, and Clinical Workforce Development platforms have been established by Marildu and are designed to support CAGs to deliver transformational projects that will have impact on local healthcare.	Not applicable	Not available	One-off/ad hoc	1/07/2019	30/06/2024	Not available	Not available	\$	4,110,000.00
Rapid Applied Research Translation	2018 Rapid Applied Research Translation (Round 2.2)	University of New South Wales	University	NSW	Marildu Budyanj Gurnal Sydney Partnership for Health Education Research and Enterprise (SPHERE) – MRFF Rapid Applied Research Translation, Stage Two	This application outlines an innovative program of research and translation activities addressing the MRFF Priorities, the Australian Medical Research and Innovation Priorities 2016-2020, areas of improving models and pathways of care, reducing unwarranted clinical variation, addressing healthcare needs of vulnerable groups, improving primary care research and implementing public health interventions in our population. In 2017, Marildu implemented a rigorous annual internal productivity review process to maintain focus on priority areas and to drive project performance to milestones, outcomes and impacts. The focus of this RART grant program is on the conduct of translational research and research translation in MRFF priority areas and the establishment of strategic programs that enable and support the translation of research outcomes into clinical practice and health policy. Marildu is a purpose build translational research and research translation vehicle comprising 16 Clinical Academic Groups (CAGs), each supported by cross-cutting enabling platforms that focus on clinical academic workforce capacity building, clinical trials, health informatics, implementation science and knowledge translation and integrated value-based healthcare. The CAGs span the major burdens of disease in our region; are cross-disciplinary and cross-institutional; are embedded within our four healthcare partners; conduct local healthcare provider and national MRFF priority-driven translational research projects across the partnership. 12 CAGs have been fully operational for 21 months and their initial 18 months of project activity has undergone external peer review in July 2018. Four new CAGs have been accredited and have progressed planning with project activities about to commence. Individual CAG projects and relevant platform activities are described in detail below. The four new CAGs, and the 12 foundation CAGs are scheduled to be performance appraised against MRFF and internal priority key performance indicators in November 2019. The strategic platforms i.e. Implementation Science, Knowledge Translation, Clinical Trials Support and Enablement, and Clinical Workforce Development platforms have been established by Marildu and are designed to support CAGs to deliver transformational projects that will have impact on local healthcare.	Not applicable	Not available	One-off/ad hoc	1/07/2019	30/06/2022	Not available	Not available	\$	4,110,000.00
Rapid Applied Research Translation	2018 Rapid Applied Research Translation (Round 2.2)	Central Australian Aboriginal Congress Aboriginal Corporation	Corporation	NT	Researcherchemy Wappayalawangka Central Australia Academic Health Science Network	Within MRFF priorities and grant guidelines, CAHSN has determined its main areas of effort: Workforce and capacity building, emphasising Aboriginal research community; Policy research/evaluation; Health services research; Health determinants/risk factors; Chronic/communicable diseases. Summary: 1. Significant improvement in quality of care in Aboriginal primary health care through developing tools to develop/enhance non-clinical KPIs. 2. Aboriginal Primary Health services will be the focus of consolidating/evaluating the delivery of Trauma Informed Care at all levels within their organisations. 3. A cohort of 800 Indigenous residents has been recruited to Baker's HTLV-1 community survey. It will partner with those already engaged to a longitudinal study, expanding to WA's Nganyatjarra region. 4. Research has often been imposed on Aboriginal people with little meaningful exchange of knowledge/understanding. To assist Aboriginal communities, services and board members in improving understanding/benefits/outcomes of research, to become partners in driving research. 5. Reports of youth crime and risky behaviour in Alice Springs have increased. There is an absence of young people's voices and input into understanding the issues and identifying solutions for young people most at risk. 6. Effective communications between health staff and patients across the Central Australia Health Service is a critical element in improving health outcomes. It is designed to provide sustained improvement in intercultural communication into policy/practice. 7. Aboriginal people experience of very high levels of psychological distress is unacceptably elevated compared with non-Indigenous. The project involves establishing a prototype SEWB assessment instrument that is culturally relevant and safe. 8. The need for an effective primary health care system is urgent in remote Aboriginal communities in order to 'close the health gap'. This aims to measure the impact of short-term health staff in the remote Nganyatjarra Health Service; co-design and implement a comprehensive, affordable, culturally safe and evidence-based workforce strategy. 9. The burden of disease and mortality rate increases with increasing remoteness – there is a need for effective primary health care services, but also for effective emergency services which	Not applicable	Not available	One-off/ad hoc	1/08/2020	30/06/2023	Not available	Not available	\$	4,000,000.00

Rapid Applied Research Translation	2020 Rapid Applied Research Translation	University of New South Wales	University	NSW	Scaling up infectious disease point-of-care testing for Indigenous people	Diagnostic testing with timely return of results is critical for infectious disease management and prevention but is not uniformly accessible for Indigenous people in rural and remote settings. Delays in testing and return of results can lead to serious adverse health consequences including hospitalizations, cancer, and death. Building on ten years of experience and stakeholder engagement, we will scale up infectious disease point-of-care testing nationally in primary care services. We will use implementation research to evaluate their uptake, acceptability, effectiveness, cost-effectiveness, and sustainability. In parallel we will strengthen the critical support systems essential to integration into healthcare practice.	Professor Rebecca Guy	Professor Rebecca Guy, Doctor Adam Bartlett, Doctor Alison Marshall, Professor Andrew Lloyd, Professor Andrew Valley, Associate Professor Angela Kelly-Hanks, Doctor Annapurna Nori, Ms Annie Tansey, Associate Professor Asha Bowen, Doctor Behnaz Hajizadeh, Doctor Belinda Hengel, Professor Carla Treloar, Doctor Caroline Watts, Doctor Chris Coulter, Doctor Clare Bradley, Doctor Daniel Judge, Associate Professor David Regan, Doctor David Speers, Associate Professor David Whitley, Doctor Dawn Casey, Professor Deborah Williamson, Professor Donna Mak, Doctor Dylan Barbi, Doctor Evan Cunningham, Professor Gill Matthews, Scientia Professor Greg Dore, Professor Greg Fox, Associate Professor Handan Wand, Ms Jackie Thomas, Associate Professor James Wood, Doctor Janessa Pickering, Professor Jason Grebely, J/Belle Foster, Doctor Jeffrey Cannon, Scientia Professor John Kaldor, Doctor Josh Hanson, Associate Professor Julie Broffert, Doctor Julia Vnuk, Professor Katherine Boydell, Doctor Lisa Valley, Associate Professor Lisa Whop, Doctor Lise Lafferty, Doctor Louise Causse, Doctor Manoj Gunathilake, Doctor Marianne Martiniello, Professor Marion Saville, Professor Mark Shephard, Doctor Mervyn Smith, Ms Michael Luchie, Associate	Open competitive	14/02/2022	13/02/2027	Not available	Not available	\$	9,967,326.00
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	The George Institute for Global Health	Medical Research Institute	NSW	Implementing holistic burn care through a culturally safe integrated model	For optimum recovery, burn injuries need to be treated with appropriate ongoing burn care. There is a gap in access to culturally safe burn care for Aboriginal and Torres Strait Islander children, contributing to longer stays in hospital. We will implement a co-designed, evidence-based culturally safe integrated model of burn care, involving upskilling of community-based health providers in NSW Aboriginal Community Controlled Health Services and the creation of a hub and spoke care network. We will conduct a rigorous mixed methods evaluation to assess program implementation. Benefits include provision of culturally responsive, localised burn care with integration between services, leading to improved burn management and cost effectiveness.	Doctor Julieann Coombes	Doctor Julieann Coombes, Professor Andrew Holland, Soobhan Connolly, Anne Darton, Doctor Courtney Ryder, Gill Schierhout, Huimin Liu, Karl Briscoe, Doctor Kate Hunter, Keriah Bennett-Brook, Nicole Turner, Stephen Jan	Open competitive	20/01/2022	30/06/2026	Not available	Not available	\$	2,410,958.00
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	St Vincent's Institute of Medical Research	Medical Research Institute	VIC	Pathway to use of immunotherapy in clinical practice for type 1 diabetes	Type 1 diabetes (T1D) is a common autoimmune disease with onset usually in childhood or young adulthood that has been treated with insulin for over 99 years. Insulin is not a cure and T1D treatment remains burdensome. The recent development of numerous drugs that affect the immune system means that the treatment of T1D is poised to be transformed. However, many barriers remain before immunotherapy becomes part of routine clinical care. We will form a multi-disciplinary panel to address challenges such as better biomarkers, education and change within the workforce, and meeting the requirements of the TGA. We will provide centralised expert advice on immunotherapy for patients and clinicians across MACH-based hospitals.	Professor Thomas Kay	Professor Thomas Kay, Doctor Bala Krishnamurthy, Professor Rob Anderson, Associate Professor Elif Binci, Professor Fergus Cameron, Professor Helen Thomas, Associate Professor John Wentworth, Professor Len Harrison, Doctor Michelle So, Professor John Gorman, Professor Philip Clarke, Professor Richard MacIsaac, Associate Professor Shane Hamblin, Associate Professor Spiros Fourlanos, Associate Professor Stuart Manning	Open competitive	14/02/2022	3/11/2026	Not available	Not available	\$	2,676,000.00
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	Florrey Institute of Neuroscience and Mental Health	Medical Research Institute	VIC	Building Australia's First Young Stroke Service	Young Australians with stroke (aged 18-45 years) are often misdiagnosed and underserved in the current health system. New, evidence-based acute diagnostic and management approaches and interventions that improve return to work, cognition and taking control of recovery have potential to improve lives and reduce stroke burden on individuals and the Australian community. The current gap is translation. Our innovative, digitally-enabled young stroke service will overcome geographic service boundaries, streamline fragmented services and responsively meet our user's needs, fostering the individual's ability to engage in and direct their care long term, including those with communication and cognitive challenges as a result of their stroke.	Professor Julie Bernhardt	Professor Julie Bernhardt, Professor Amy Brothmann, Professor Chris Bladin, Doctor Dana Wong, Associate Professor Emma Power, Doctor Karen Benschmann, Doctor Kate Hayward, Professor Kathleen Gray, Doctor Lisa Murphy, Professor Maria Crotty, Professor Natasha Laminin, Doctor Toni Witsiel, Professor Vincent Thijs	Open competitive	1/02/2022	31/12/2026	Not available	Not available	\$	9,932,108.00
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	The Garvan Institute of Medical Research	Medical Research Institute	NSW	P-OMICs-flow: Integrating precision oncology into clinical programs	Our team of international experts combines precision medicine, implementation science, clinical informatics, cancer genetics, oncology, consumer experience, and patient-reported outcomes to lead a world-first transformational research program to support the rapid adoption of precision medicine into routine health care. Through P-OMICs-flow – a novel precision medicine oncology clinic – we will leverage off three key Australian medical oncology and cancer genetics precision medicine trials, to drive evidence-based implementation of the P-OMICs-flow model of care at Prince of Wales Hospital, compare outcomes against comparative hospitals, and co-design and pilot test a scale-up model to enable local adaptations and national roll-out.	Associate Professor Natalie Taylor	Associate Professor Natalie Taylor, Ms April Morrow, Professor David Goldstein, Professor David Thomas, Doctor Frank Lin, Professor Jane Young, Associate Professor Katherine Tucker, Ms Kathryn Leamey, Associate Professor Liz Schroeder, Doctor Mandy Ballinger, Ms Margaret Gough, Doctor Milita Zahedi, Professor Phyllis Butow, Professor Sandy Middleton	Open competitive	28/02/2022	27/01/2027	Not available	Not available	\$	5,868,917.00
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	COVU Global Pty Ltd	Corporation	QLD	Transforming Wound Care through Telehealth in Aged Care	This project responds to an urgent call to further develop telehealth to increase access to wound care in residential aged care facilities (RACFs), especially for residents residing care in place and rural settings. A suite of digital tools including mobile imaging will be developed, tested and integrated into an existing secure telehealth video call platform, enabling data visualisation of patient assessments including wound and vital sign changes, clinical decision making support, transdisciplinary consultation and access to educational materials. Following review of implementation in metropolitan and rural RACFs, a cluster randomised trial will evaluate clinical efficacy, acceptability and impact on patient quality of life.	Associate Professor Georgina Luscombe	Associate Professor Georgina Luscombe, Doctor Annie Banbury, Doctor Lars Petersson, Mr Luke Griewe, Professor Meredith Makinham, Doctor Michelle Banker Johnson, Ms Michelle Pitt, Doctor Oliver Salvado, Associate Professor Ruth Webster, Doctor Silvia Pfeiffer, Professor Tim Shaw	Open competitive	28/02/2022	28/01/2027	Not available	Not available	\$	6,499,695.00
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	Central Australian Aboriginal Congress Aboriginal Corporation	Corporation	NT	Aboriginal prosperity through community driven translational research	An Aboriginal-led integrated program of culturally responsive research and knowledge translation is delivering better health and social outcomes to Aboriginal people of Central Australia and Barkly regions, through three streams of activity: 1) Translating Culture through Research: Two way learning that integrates Aboriginal and western knowledge systems to improve health services and outcomes. 2) Health Services and Workforce Capacity: Research to establish culturally responsive and evidence based models of service delivery, enhanced workforce capacity and evaluation. 3) Chronic Diseases: Translational research interventions throughout the life cycle to prevent and manage diabetes and heart failure.	Doctor Leisa McCarthy	Doctor Leisa McCarthy, Mr Chris Perry, Ms Danielle Dwyll, Doctor Deb Russell, Ms Donna Ah Chee, Ms Erin Lew Ratt, Ms Heather Burton, Ms Irene Nangala, Mr Jeff Hutcombe, Doctor Jocelyn Davies, Doctor John Boffa, Professor John Condon, Professor John Humphreys, Professor John Wakeman, Professor Jonathan Shaw, Ms Karina Demasi, Associate Professor Kylie Dingwall, Doctor Liz Moore, Ms Lorna Murakami-Gold, Professor Louise Maple-Brown, Ms Louise Martin, Doctor Michelle Pitt, Ms Monica Robinson Nangala, Doctor Richard Johnson, Professor Robyn Aitken, Ms Sarah Brown, Professor Sher Cairney, Ms Sonia Hines, Professor Steve Guthridge, Doctor Supriya Mathew, Professor Tom Marwick, Professor Tricia Nagel, Ms Walbira Murray, Doctor Yuenjin Zhao	Open competitive	10/02/2022	28/02/2026	Not available	Not available	\$	9,760,245.00
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	Menzies School of Health Research	Medical Research Institute	NT	Top End Partners: translational research to improve health outcomes (TOP R)	TOP R is an initiative of Top End Partners, an academic health science center located in the Northern Territory. TOP R's themes reflect core Northern Territory priorities and our unique expertise: Aboriginal Health and Health Security, Five transformative, translational research projects are presented with significant potential for scalable impact. Our goals through these projects are to improve patients' experience and outcomes in health care, roll out a new wellbeing measurement for Aboriginal and Torres Strait Islander people, provide a healthy start to life, strengthen chronic condition management via a novel clinical decision making tool, and implement an effective COVID-19 quarantine and isolation model of care.	Professor Alan Cass	Professor Alan Cass, Mr Allan Anderson, Ms Allison Grierson, Ms Angela Brannelly, Doctor Anita D'Agrano, Professor Anna Ralph, Associate Professor Anne Lovell, Doctor Asanga Abernethy, Doctor Athira Rohi, Ms Christina Fitzpatrick, Ms Colleen Voss, Doctor Curtis Roman, Ms Danielle Aquino, Professor Dianna Stephens, Professor Gill Garvey, Professor Gary Robinson, Ms Gillian Gorman, Ms Heather D'Antonio, Ms Joanne Gibson, Professor Kristen Howard, Ms Lisa Vermeulen, Ms Lucretia Johns, Professor Lynn Kemp, Mr Mark Paining, Ms Michelle Evison-Rose, Doctor Radwan Talukder, Ms Raelene Brunette, Ms Rarrityway Melaine Herdman, Ms Rebecca Cooney, Associate Professor Sajiv Cherian, Doctor Sean Taylor, Ms Vicki Kerrigan	Open competitive	1/02/2022	31/12/2026	Not available	Not available	\$	5,802,202.00

Rapid Applied Research Translation	2020 Rapid Applied Research Translation	Western Alliance Health Research Ltd	Corporation	VIC	Delivering enhanced healthcare at home for older people in rural Australia	Driven by our healthcare and consumer partner needs DELIVER will apply existing knowledge, co-design new initiatives, and embed health interventions that support enhanced delivery of virtually enabled home-based care for older people in rural areas. DELIVER is uniquely placed to build and evaluate a sustainable research capacity building model across western Victoria. Through this we will rapidly identify, prioritise and test local solutions to address the key challenges facing home-based care for older people in rural areas. Throughout the project and beyond, DELIVER will have embedded best practice into routine care in western Victoria and developed a blueprint for scaling this model nationally.	Professor Anna Peeters	Professor Anna Peeters, Professor Adam Elshaug, Associate Professor Ann Borda, Doctor Anna Ugaldes, Associate Professor Anna Wong Shee, Professor Bodil Rasmussen, Mr Craig Wilford, Ms Fiona Mitchell, Ms Hannah Belk, Doctor Joanne Erticott, Associate Professor Joanne Porter, Associate Professor Kevin McKinnon, Doctor Laura Alkton, Doctor Louise Greenstock, Professor Martin Hensher, Associate Professor Michele Callisaya, Doctor Olivia King, Professor Steven Alender, Ms Sue Williams, Professor Terry Haines, Associate Professor Vincent Versace, Professor Warren Payne, Professor Wendy Chapman	Open competitive	1/02/2022	31/12/2026	Not available	Not available	\$	9,067,407.00
Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	The University of Queensland	University	QLD	Improving surveillance infrastructure for Indigenous primary health care	The ATLAS+ proposal will enable expansion of the reach and scope of the ATLAS sentinel surveillance network, currently comprising 32 Aboriginal Community-Controlled Health Organisations (ACCHOs) nationally. We will double the number of ACCHOs participating and add new primary care providers and geographical regions to the network. We will expand the scope of the infrastructure beyond sexually transmissible infections and blood-borne viruses, to include vaccine-preventable diseases and chronic conditions. ATLAS+ will increase the quality and capacity of our surveillance and reporting systems and will further support ACCHOs to improve clinical care. ATLAS+ will also prioritise capacity development to strengthen Indigenous Data Sovereignty.	Doctor Clare Bradley	Doctor Clare Bradley, Associate Professor Federica Barzi, Associate Professor Adrian Bickertafte, Doctor Dianna Pearson, Doctor Susan Jacup, Doctor Kalinda Griffiths, Professor Rebecca Gay, Professor James Ward, Professor Helen Marshall	Open competitive	30/06/2021	29/06/2024	Not available	Not available	\$	1,990,329.00
Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	South Australian Health and Medical Research Institute Limited	Medical Research Institute	SA	Registry of Senior Australians: Improving Care and Outcomes in Aged Care	The Registry of Senior Australians (ROSA) is a nationwide aged and health care data linkage platform and outcomes monitoring system developed by SAHMRI. Our project will create a 'big data' platform through extension and expansion of ROSA infrastructure to keep pace with emerging issues (e.g. COVID-19) and continue our ground-breaking research on lay, and currently unknown, residential aged care impacts with new datasets (immunisation, rehabilitation and social welfare data). With project partners, we will embed ROSA into routine aged care monitoring and build the sector's digital health literacy. Project outcomes will position ROSA as the only national data solution for evidence-based policy and practice change in residential aged care.	Professor Steve Wesselingh	Professor Steve Wesselingh, Associate Professor Maria Inacio, Associate Professor Gillian Gough, Associate Professor Keith Evans, Ms Megan Corlis, Professor Maria Crotty, Professor Craig Whitehead	Open competitive	30/06/2021	29/06/2024	Not available	Not available	\$	1,966,031.00
Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	University of Melbourne	University	VIC	Platform to Enhance Prostate Cancer Shared care Integration (PEPSI)	The number of cancer survivors requiring long term medical care is increasing. Shared care models are essential to manage these patients effectively. Western Health runs a shared care model for prostate cancer, but it is resource intensive and not sustainable. We propose to innovate and improve shared care by linking data across primary and tertiary settings using a cloud-based platform which is technology agnostic. The platform features treatment algorithms, secure communication and collects standardised data. We aim to demonstrate that this platform enables the safe and effective care of patients in the community, leading to better outcomes, significant hospital avoidance, comprehensive data collection and cost saving.	Professor Helen O'Connell	Professor Helen O'Connell, Associate Professor Shane Hamblin, Associate Professor Matt Corcoran, Associate Professor Edmund Tse, Doctor Gauri Yankaran, Doctor Karyn Alexander, Doctor Henry Yao, Doctor Ines Rio, Doctor Zina Valaydon, Doctor Shirley Wong, Ms Cindy Ogilusko, Professor Peter Gibbs	Open competitive	30/06/2021	29/06/2024	Not available	Not available	\$	1,995,611.00
Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	Monash University	University	VIC	Optimising health information exchange during aged care transfers	Cross-sector care coordination is a perennial problem for Residential Aged Care (RAC). COVID-19 experiences have seen rapid movement of residents between sectors (RAC facilities, primary care, hospital, ambulance) often en masse, with little or no accompanying information. Despite there being more electronic health data than ever before, information pertaining to RAC remains siloed and is not effectively shared between sectors. We will develop and test a national solution for integrated data sharing that puts the resident at the centre of care and meets the data and system requirements of multiple end users. Outcomes include improved quality and safety of care for RAC residents and health systems savings through increased efficiencies.	Associate Professor Nadine Andrew	Associate Professor Nadine Andrew, Associate Professor Anna Barker, Associate Professor Richard Beare, Associate Professor Chris Moran, Doctor Jue Xie, Doctor Katrina Long, Professor Patrick Olivier, Professor Velanda Srikanth, Professor Karen Smith, Professor Irene Blackburn, Professor Keith Hill, Professor Simon Bell, Professor: Terry Haines	Open competitive	30/06/2021	29/06/2024	Not available	Not available	\$	1,949,557.00
Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	The University of Adelaide	University	SA	ImagingAI: Diagnosing endometriosis with imaging and AI	This project will provide a cost-effective, accessible, and accurate method to non-invasively diagnose endometriosis. Artificial intelligence using endometriosis ultrasound and MRI images will develop diagnostic algorithms that estimate the likelihood that an individual has endometriosis. Images uploaded by in-built software in imaging machines, will be analysed by this algorithm in real time on a cloud-based digital platform. Integrating with the National Endometriosis Scientific and Clinical Trial and delivering National Action Plan for Endometriosis Priorities and Research Goals, this tool will improve 'access to simpler and less invasive diagnostic tests and treatments' for those negatively impacted by endometriosis.	Associate Professor Mary Louise Hull	Associate Professor Mary Louise Hull, Associate Professor David Gonzalez-Chica, Associate Professor George Condous, Doctor Jodie Avery, Doctor Rebecca O'Hara, Doctor Steven Knox, Ms Aisha Singh, Ms Carina Perreault, Professor Gustavo Carneiro, Professor Jason Abbott	Open competitive	30/06/2021	29/06/2024	Not available	Not available	\$	1,990,998.00
Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	Kimberley Aboriginal Medical Services Limited	Corporation	WA	Regional collaboration to create a Kimberley Health Evidence Data Platform	This project aims to improve the health and wellbeing of Aboriginal people through the development of a linked data platform in the Kimberley region of Western Australia, with a focus on primary health care. The Kimberley Health Evidence Data Platform will be utilised to inform regional research priorities, improve research data availability, guide health service provision and enable effective tracking and evaluation of regional health targets. Delivered in partnership between all Aboriginal Community Controlled Health Services and government primary health care providers in the Kimberley, along with experienced researchers, this project will involve extensive interagency collaboration that builds on existing regional governance structures.	Mr Mick Gooda	Mr Mick Gooda, Associate Professor Julia Marley, Doctor Kimberley Sear, Doctor Emma Griffiths, Doctor David Hendricks, Doctor Loraine Anderson, Mr Justin Manuel, Mr Rob McPhee, Mrs Erin Stenske, Ms Lucy Falocchio, Professor David Atkinson	Open competitive	30/06/2021	29/06/2024	Not available	Not available	\$	1,027,835.00
Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	Monash School of Health Research	Medical Research Institute	NT	Territory Integrated Care: Primary health data Linkage Using Software	Territory Kidney Care (TKC) is a digital health tool which consolidates electronic health records (EHR) from public hospitals, government-operated primary care services and participating Aboriginal medical services. EHR data from disparate systems is linked to drive point of care clinical decision-making and improve individual and population health. Currently, TKC supports the identification and management of chronic kidney disease (CKD). The proposed TKC PLUS project will build on the TKC prototype and expand the scope to NT private general practitioner practices and include other preventable chronic diseases. Key aims are to facilitate the integration of health care in the NT including two-way sharing of clinical information.	Ms Gillian Gorham	Ms Gillian Gorham, Doctor Asanga Aleyaratne, Professor Alan Cass, Doctor Naderaj Kangaharan, Doctor Julie Franzon, Doctor Paul Burgess, Doctor Adam Whitehead, Mr Jeff Robson, Doctor Winnie Chen, Doctor Pratik George, Mr Paul Kamler	Open competitive	30/06/2021	29/06/2024	Not available	Not available	\$	1,962,185.00
Research Data Infrastructure	2021 Research Data Infrastructure	Monash University	University	VIC	National Transfusion Research Data Infrastructure Initiative	Blood transfusions, used wisely, save lives, but carry risks & costs – Australia spends \$1.3 billion annually on blood products. It is essential that we know how to use them appropriately. However, Australia lacks infrastructure to provide fundamental data on how blood is used (who needs it, where, how, how much, & why); outcomes for transfused patients, including adverse events ("haemovigilance"); and costs to our health system. The National Transfusion Research Data Infrastructure Initiative will use novel approaches and methods to link data from our national blood service with pre-hospital, hospital, haemovigilance & clinical registry data, and generate a new national transfusion dataset as a resource for policy, practice & research.	Professor Erica Wood	Professor Erica Wood, Associate Professor Zoe McCullough, Professor Carol Hodgson, Doctor Lisa Higgins, Doctor Shelley Cox, Doctor James Daly, Professor David Rowley, Doctor Adam Irving, Doctor Susan Morgan, Mr Simon Benson, Mr Christopher Berry, Ms Linley Bielby, Doctor Karina Brady, Doctor Fiona Chen, Doctor Kim Huynh, Mr Neil Waters, Doctor Cameron Wellard, Mrs Shannah Anderson	Open competitive	30/06/2022	30/05/2026	Not available	Not available	\$	2,999,557.00
Research Data Infrastructure	2021 Research Data Infrastructure	University of New South Wales	University	NSW	EndoLinked: Identifying fertility outcomes for women with endometriosis	EndoLinked will determine: The reproductive and maternal outcomes for women with, compared to without endometriosis in Australia; the neonatal outcomes for infants born to women with endometriosis; the impact of no versus single versus multiple surgeries for endometriosis prior to undertaking fertility treatments. These questions will provide evidence for clinical care and counselling for women with endometriosis and inform the RANZCOG Endometriosis Clinical Practice Guidelines. EndoLinked will address identified evidence-gaps in the National Action Plan for Endometriosis (NAPE) in these areas.	Professor Jason Abbott	Professor Jason Abbott, Professor Gita Mishra, Associate Professor Amanda Henry, Doctor Ingrid Rowlands, Doctor Cecelia Ng	Open competitive	30/06/2022	30/05/2026	Not available	Not available	\$	689,236.00
Research Data Infrastructure	2021 Research Data Infrastructure	University of New South Wales	University	NSW	Next-gen clinical registries: common data models, AI & cloud computing	We will create and deploy a software framework (NextCR, comprising software code, documentation, training materials) that organisations can use to establish and operate highly secure, cloud-based next-generation clinical registries. It will address new national requirements for clinical quality registries in domains including endometriosis, cardiovascular disease and cancer. It will use advanced software engineering and AI methods to transform near real-time data drawn directly from electronic medical records (EMRs) and other electronic data, including imaging. NextCR registries will provide highly-detailed, research-ready clinical data, leveraging international Common Data Models and terminologies to maximise data interoperability.	Professor Louisa Jorm	Professor Louisa Jorm, Professor Stephen Graves, Professor Richard de Steiger, Professor Ian Harris, Associate Professor Sue-Yuan Ooi, Doctor Jennifer Yu, Associate Professor Blanca Gallego Lujan, Professor Geoff Delaney, Associate Professor Winston Law, Doctor Timothy Churches, Doctor Georgina Kennedy, Doctor Sebastiano Barbieri, Doctor Oscar Perez Concha, Professor Jean-Frederic Lavoie	Open competitive	30/06/2022	31/05/2026	Not available	Not available	\$	2,645,724.00
Research Data Infrastructure	2021 Research Data Infrastructure	The University of Queensland	University	QLD	Digital Infrastructure For Improving First Nations Maternal & Child Health	The DIFFERENCE project will deliver the largest connected First Nations data infrastructure to ensure the best possible start to life for First Nations Australians. Building on strong partnerships prioritising First Nations data sovereignty and governance, it will develop a data linkage platform with a nationally agreed health data set for First Nations child and maternal health outcomes, and interagency standards—all one-to-keep closing the gap in maternal and perinatal health disparities between First Nations and non-First Nations mums and infants. This project will also generate sophisticated Machine Learning analytics to foster iterative quality improvement and will adopt international standards to support scalability.	Associate Professor Clair Sullivan	Associate Professor Clair Sullivan, Associate Professor Jason Ferris, Doctor Nabha Resi Reddy, Professor Saleem Kumar, Doctor Dominique Gorse, Professor Steven McPhail, Doctor Michael Lawley, Doctor Paul Schlegel, Professor James Wai Wai, Associate Professor Guido Zuccato, Associate Professor Carmel Nelson, Doctor Lyle Turner, Ms Birri O'Dea, Ms Jayne Barclay	Open competitive	30/06/2022	29/06/2026	Not available	Not available	\$	2,999,587.00

Research Data Infrastructure	2021 Research Data Infrastructure	University of Melbourne	University	VIC	Appropriate Antimicrobial Use: Scaling Surveillance Using Digital Health	Antimicrobial resistance is a major global challenge. This research collaboration brings a multidisciplinary team of antimicrobial stewardship experts from human and animal health with digital health experts to establish a new research platform for antimicrobial appropriateness surveillance. We will use large existing databases of manual surveys and electronic medical records. Natural language processing, machine learning algorithms, and common data models for antimicrobial use metrics and infection indications will be developed to support automation and scaling of antimicrobial prescribing surveys. The platform will facilitate data aggregation and linkage for the first time across all areas of health, and will improve healthcare delivery.	Professor Karen Thursky	Professor Karen Thursky, Doctor Rodney James, Ms Remadevi Pathmanaban, Doctor Steve Christou, Doctor Courtney Ierano, Associate Professor Noleen Bennett, Associate Professor Leon Worth, Associate Professor Jo-Anne Marnik-Nenkovic, Professor Kristy Buijing, Doctor Ruby Breen, Professor Glenn Browning, Professor James Gilkinson, Doctor Kirsten Bailey, Doctor Laura Hardefeldt, Professor Wendy Chapman, Doctor Daniel Capurro, Doctor Mike Conway, Doctor Douglas Pires, Doctor Viada Rozova, Professor Monica Slavin, Ms Anna Khantina	Open competitive	30/06/2022	31/05/2026	Not available	Not available	\$	2,962,654.00
Researcher Exchange and Development Within Industry	2019 Researcher Exchange and Development Within Industry	MTPConnect	Corporation	VIC	The MTPConnect REDI Program	MTPConnect, an independent, not-for-profit organisation, drives connectivity, innovation, productivity and competitiveness in Australia's medtech, biotech and pharma (MTP) sector. MTPConnect's REDI program leverages a national alliance of proven education and training partners to systematically address current gaps in workforce skills, identify new/unknown gaps and meet the challenge of developing and retaining world-class talent who have industry experience in research translation, clinical development and commercialisation. Our program of industry-relevant training, industry placements and embedded industry fellowships will support researchers, clinicians and industry and government participants and drive the sector's future growth.	Doctor Daniel Grant	Not available	Open competitive	29/05/2020	31/12/2023	Not available	Not available	\$	32,000,000.00
Stem Cell Therapies Mission	2020 Stem Cell Therapies	University of Melbourne	University	VIC	Identifying novel therapeutic targets in leukaemia stem cells	Many cancers, including AML, are sustained by a small population of cancer stem cells that possess the ability to self renew indefinitely and regenerate the cancer after therapy. Our ability to develop treatments that eradicate these leukaemia stem cells (LSC) has been hampered by the inability to grow them effectively in the lab to study and understand them. We have recently identified a unique method to grow LSC resulting in the ability to find new treatments for this often incurable cancer.	Professor Mark Dawson	Professor Mark Dawson, Doctor Brendon Monahan, Associate Professor Paul Stupples	Targeted competitive	1/06/2020	31/05/2023	Oncology And Carcinogenesis	Haematological Tumours	\$	894,180.00
Stem Cell Therapies Mission	2020 Stem Cell Therapies	University of Melbourne	University	VIC	Translating patient stem cells into personalized screens for age-related macular degeneration	We aim to develop a screening platform for patient stem cell-derived retinal cells, using artificial intelligence to model diseases of the retina in a dish; subsequently screen for 2,900 drugs able to reverse those identified disease specific phenotypes; and test the 10 best compounds on a large bank of patient stem cell-derived retinal cells. The best compounds will be further advanced for clinical translation.	Professor Alice Pebay	Professor Alice Pebay, Professor Alex Hewitt, Associate Professor Kaylene Simpson, Doctor Grace Lidgerwood, Professor Robyn Guymer, Professor Erica Fletcher	Targeted competitive	1/06/2020	31/12/2023	Ophthalmology And Optometry	Ophthalmology	\$	881,906.60
Stem Cell Therapies Mission	2020 Stem Cell Therapies	University of Melbourne	University	VIC	Next generation stem cell therapy for Parkinson's disease	A promising experimental therapy for Parkinson's disease is the use of stem cells that in order to replace the cells lost during the disease process. A challenge for this approach is that upon transplantation into the brain, in addition to the therapeutic cell types, there will also be unwanted cell types such as those that can form tumours. This proposal seeks to establish a novel strategy for removing those cells prior to transplantation.	Associate Professor Lachlan Thompson	Associate Professor Lachlan Thompson, Professor Clare Parish, Professor Colin Pouton	Targeted competitive	1/06/2020	30/11/2022	Neurosciences	Central Nervous System	\$	952,873.50
Stem Cell Therapies Mission	2020 Stem Cell Therapies	Curtin University	University	WA	Optimizing a preclinical model for bioprinting skin aimed at repairing skin loss in patients	This project seeks to develop new treatments for skin loss in patients caused by injury or disease, using the emerging and transforming technology of 3D bioprinting and skin stem cell biology. The project driven by a team of Australian investigators with extensive basic science and clinical expertise uses the pig as a large animal skin repair model to translate recent discoveries into innovative treatments for patients.	Associate Professor Prithinder Kaur	Associate Professor Prithinder Kaur, Professor Fiona Wood, Professor Gordon Wallace, Associate Professor Mark Fear, Doctor Abbas Shafiee, Doctor Zhilian Yue, Cameron Ferris	Targeted competitive	1/06/2020	31/05/2022	Biomedical Engineering	Biomaterials	\$	737,689.50
Stem Cell Therapies Mission	2020 Stem Cell Therapies	Monash University	University	VIC	Discovering new drugs for epilepsy using personalised medicine	Epilepsy is a serious neurological condition that affects millions of people around the world. For many people with epilepsy the current drugs are ineffective which means their seizures are not able to be controlled. This project attempts to find new drugs for these patients, by testing drugs in human patient cells in a dish. We believe this project will enable us to test thousands of drugs rapidly and find new drugs that can be given to patients with epilepsy.	Professor Patrick Kwan	Professor Patrick Kwan, Doctor Benjamin Kello, Doctor Chris Langmead, Doctor Katie Ayres, Doctor Alexander Harris	Targeted competitive	1/06/2020	31/05/2022	Neurosciences	Central Nervous System	\$	556,460.60
Stem Cell Therapies Mission	2020 Stem Cell Therapies	Monash University	University	VIC	Developing novel cellular therapies and tissue engineering approaches for the treatment of muscle injury and wasting disorders using tissue resident muscle stem cells	We propose to develop novel cellular therapies and tissue engineering approaches for the treatment of a muscle injury and wasting disorders using tissue resident muscle stem cells or satellite cells. Our ultimate aim is to accelerate the development of safe, effective and affordable muscle stem cell-based therapies, in an attempt to lessen the disease burden of muscle wasting disorders.	Professor Peter Currie	Professor Peter Currie, Associate Professor Mikael Martinsson, Professor Laurence Meagher	Targeted competitive	1/06/2020	31/05/2022	Other Medical And Health Sciences	Medical And Health Sciences Not Elsewhere Classified	\$	824,480.00
Stem Cell Therapies Mission	2020 Stem Cell Therapies	Monash University	University	VIC	Human Amniotic Epithelial Stem Cells as Novel Treatment for Autoimmune Vasculitis	Autoimmune vasculitis is a serious disease affecting small blood vessels. Current treatments are partially effective and produce serious side effects from which many patients die. So, safer, effective therapies are needed. Human amniotic stem cells (hAECs) represent a novel, safe and affordable therapy for this disease. Using animal models and patients' cells, we will identify hAECs as an appealing new treatment for vasculitis, paving the way for their progress into clinical trials.	Professor Stephen Holdsworth	Professor Stephen Holdsworth, Doctor Dragana Odobasic, Doctor Poh Yi Gan, Doctor Kim Maree O'Sullivan	Targeted competitive	1/06/2020	30/11/2022	Clinical Sciences	Nephrology And Urology	\$	588,396.00
Stem Cell Therapies Mission	2020 Stem Cell Therapies	Monash University	University	VIC	Engineering a solution to non-alcoholic steatohepatitis through tuning substrate stiffness	Fatty liver disease affects up to 25% of the Australian population and has been identified in children as young as 10 years of age. When the disease progresses to a severe, inflammatory form, it significantly increases the incidence of liver scarring and primary liver cancer. There is no treatment for the disease to date. We propose to bioengineer a solution that uses cells from the amniotic sac to create a novel cost-effective regenerative medicine for this disease.	Associate Professor Rebecca Lim	Associate Professor Rebecca Lim, Professor William Sievert, Professor Euan Wallace, Associate Professor Jessica Frith, Doctor David Greening, Doctor Gina Kusuma	Targeted competitive	1/06/2020	31/05/2022	Medical Biotechnology	Regenerative Medicine (Incl. Stem Cells And Tissue Engineering)	\$	472,680.00
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	Murdoch Children's Research Institute	Medical Research Institute	VIC	Evaluating safety and efficacy of bioengineered heart tissue for congenital heart repair	Heart disease is the leading cause of death in infants in Australia. To date, few studies have explored the potential for stem cells in the setting of childhood heart disease. This project aims to evaluate the safety and effectiveness of bioengineered heart tissue in a pre-clinical model of paediatric heart failure. If successful, this approach could radically transform patient outcomes and improve the quality of life of children affected by heart disease.	Associate Professor Enzo Porrello	Associate Professor Enzo Porrello, Associate Professor James Hudson, Professor Christian Brizard, Associate Professor Michael Cheung, Professor Igor Konstantinov, Associate Professor David Elliott, Professor Richard Harvey, Associate Professor Salvatore Pepe, Associate Professor Joseph Smolich, Associate Professor James Chong	Targeted competitive	1/06/2021	30/11/2023	Cardiorespiratory Medicine And Haematology	Cardiology (Incl. Cardiovascular Diseases)	\$	998,838.15
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	University of Melbourne	University	VIC	Stem cell therapies for digestive disease	Digestive diseases caused by damage to the nerves in the gut are extremely debilitating and have a major impact on the physical and mental wellbeing of sufferers. Current drug and surgical treatments do not cure the disease or provide long term relief from symptoms. New treatments for digestive diseases involving enteric neuron damage or loss are urgently needed. We aim to accelerate the development of a safe and effective stem cell-based therapy to restore gut function in these patients.	Doctor Lincoln Stamp	Doctor Lincoln Stamp, Associate Professor Sebastian King, Professor John Furness, Doctor Marlene Hao, Professor Nicholas Talley, Professor Joel Bernstein	Targeted competitive	1/06/2021	31/12/2023	Medical Biotechnology	Regenerative Medicine (Incl. Stem Cells And Tissue Engineering)	\$	583,614.00
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	University of Sydney	University	NSW	Induced pluripotent stem cell derived cardiomyocytes: a new therapy for "no-option" end-stage heart failure	Heart failure costs in Australia are over \$1 Billion p.a. with 50% mortality within 1 year (stage IV disease). This arises from the heart's limited capacity for self-repair. This project builds on our team's previous work with novel stem cell derived heart muscle, to take this treatment into proof-of-concept clinical trial in patients with "no option" end-stage heart failure.	Associate Professor James Chong	Associate Professor James Chong, Professor Peter Gray, Professor Alan Truscott, Professor Bob Graham, Doctor Nathan Palpanet, Doctor Nicholas Timmins, Doctor Andrew Prowse, Professor Yuji Shiba	Targeted competitive	1/06/2021	31/12/2026	Cardiorespiratory Medicine And Haematology	Cardiology (Incl. Cardiovascular Diseases)	\$	4,978,360.66
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	Monash University	University	VIC	Locally administered extracellular vesicles for perianal fistulising Crohn's disease	Perianal fistulas in Crohn's disease are debilitating and difficult to treat. Stem cells can heal fistulas but are expensive and need specialized facilities. Alternatively, the tiny messenger particles that stem cells produce and use to communicate with their environment may also be effective. These improve disease in animals similar to our live stem cells and are easier to manufacture. Hence we propose a human trial using the messenger particles in 10 patients to assess safety and healing.	Associate Professor Gregory Moore	Associate Professor Gregory Moore, Doctor Charlotte Keung, Associate Professor Rebecca Lim, Professor William Sievert, Doctor Thang Chien Nguyen	Targeted competitive	1/06/2021	28/02/2025	Clinical Sciences	Gastroenterology And Hepatology	\$	935,629.60
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	The University of Adelaide	University	SA	A Precision Medicine-Based Approach to Treat Craniosynostosis in Children	Children with craniosynostosis or premature fused coronal sutures show signs of craniofacial defects and increased intracranial pressure leading to neurological deficits. To date, surgical intervention during postnatal growth is the only available treatment option to ensure optimal brain and craniofacial development. Our research identifies drug-specific chemical inhibitors to prevent premature fusion of cranial sutures, as novel non-surgical targeted therapies to treat craniosynostosis.	Professor Stan Gronthos	Professor Stan Gronthos, Professor Peter Anderson, Professor Krasimir Varlev	Targeted competitive	1/06/2021	31/05/2024	Clinical Sciences	Orthopaedics	\$	441,370.75
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	Murdoch Children's Research Institute	Medical Research Institute	VIC	New therapies preventing heart damage during chemotherapy	Using heart muscle cells produced in the laboratory we are looking for drugs that stop the damage that occurs during chemotherapy. We are testing how these drugs function to protect heart muscle cells using miniature human hearts called organoids. Importantly, we are using approved drugs enabling us to quickly move toward the clinic for trials designed to establish if these compounds work in patients to protect the hearts of children undergoing chemotherapy.	Associate Professor David Elliot	Associate Professor David Elliott, Professor Jonathan Beall, Associate Professor Enzo Porrello, Associate Professor Mirana Ramalison, Doctor Benjamin Parker, Associate Professor James Hudson, Associate Professor Rachel Conyers, Professor David Eisenstat, Associate Professor Michael Cheung, Associate Professor Salvatore Pepe	Targeted competitive	1/06/2021	31/05/2024	Cardiorespiratory Medicine And Haematology	Cardiology (Incl. Cardiovascular Diseases)	\$	879,205.45
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	University of Melbourne	University	VIC	iPSC clinical trials - population wide screening of patient iPSCs to reassess high value drug targets for motor neuron disease	Motor Neuron Disease (MND) is rapid and fatal disease that affects 1000's of Australians every year. Emerging research suggests that previous clinical trials may have missed drugs that were effective only for a subset of patients. We aim to use stem cells from people with MND to reassess all previously tested drugs in a virtual clinical trial. The project seeks to rapidly determine which patients may benefit from each drug to find new treatments for MND.	Doctor Christopher Bye	Doctor Christopher Bye, Associate Professor Bradley Turner, Professor Ostojic Vucic, Professor Matthew Kiernan, Christina Azodi, Professor Naomi Wray, Doctor Samantha Beattie, Doctor Tharanga Dhamadasa, Professor Kevin Talbot	Targeted competitive	1/06/2021	31/05/2024	Neurosciences	Central Nervous System	\$	1,000,000.00

Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	The University of Queensland	University	QLD	Transforming the paradigm of epilepsy care with precision medicine	Nearly 1 million Australians will develop epilepsy and for or more than 30% of patients, finding effective drug treatment is a long journey of "trial and error". By using organoid models derived from a patient's own cells to identify effective and secure drugs in the dish and combining this with software, we will identify effective drugs for patients faster and more precisely. This will improve patient health outcomes, facilitate evidence-based drug selection, and reduce health care costs.	Professor Ernst Wolvetang	Professor Ernst Wolvetang, Professor Patrick Kwan, Associate Professor Lata Vadlamudi, Professor Terence O'Brien, Doctor Zongyuan Ge, Doctor Alison Anderson, Doctor Mohammed Shaker, Doctor Ana Antonic-Baker, Doctor Hannah Leeson	Targeted competitive	1/06/2021	31/05/2024	Neurosciences	Central Nervous System	\$	999,807.95
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	University of Wollongong	University	NSW	Novel SMART AAV vectors for gene therapy for Friedreich's Ataxia	Friedreich's ataxia (FRDA) is an inherited disease caused by mutations in Frataxin gene leading to a significant loss of Frataxin protein levels in the body. Reduced Frataxin levels leads to cell degeneration, particularly within heart tissue and the nervous system. Gene therapy is currently at the forefront as a potential approach to successfully treat FRDA. This proposal will use human stem cells as a platform to significantly advance current technologies in gene therapy to treat FRDA.	Associate Professor Mirella Dottor	Associate Professor Mirella Dottor, Associate Professor Leszek Lisowski, Professor Martin Delatycki, Doctor Shang Lin, Professor Elizabeth Vincin, Professor Alice Peabay, Doctor Samuel Nayler, Associate Professor Louise Corben	Targeted competitive	1/06/2021	31/05/2024	Medical Biotechnology	Regenerative Medicine (incl. Stem Cells And Tissue Engineering)	\$	982,861.60
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	University of Sydney	University	NSW	Stem Cell Derived-Retinal Organoids to Test Novel Genetic Therapies	Genetic blinding eye diseases are the leading cause of blindness in working-age adults. Patients have a poor prognosis with high disease burden. Most have no cure and testing of novel therapies is often conducted in systems not reflective of the human retina. Our stem cell-based screening assay, using proven disease biomarkers, will enable the testing of genetic therapies in human eye cells. This project will significantly progress forward the testing of new treatments for these conditions.	Doctor Anal Gonzalez Cordero	Doctor Anal Gonzalez Cordero, Professor Robyn Jamieson, Doctor Livia Carvalho, Professor Ian Alexander, Professor John Grigg	Targeted competitive	1/06/2021	31/05/2023	Ophthalmology And Optometry	Ophthalmology	\$	498,419.00
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	Murdoch Children's Research Institute	Medical Research Institute	VIC	Stem cell models of glomerular kidney disease for understanding disease and developing treatments	While we can now identify disease-causing mutations in more than 50% of children presenting with inherited kidney disease, there are no treatments for these conditions. In this study, we will use human stem cells gene edited to model a series of mutations in the NPHS2 gene known to cause the severe early onset kidney disease, nephrotic syndrome. By recreating mini kidneys from these stem cells, we can screen known and novel compounds to find treatments for this life threatening condition.	Professor Melissa Little	Professor Melissa Little, Doctor Aude Dorison, Associate Professor Catherine Quinlan, Doctor Thomas Forbes	Targeted competitive	1/06/2021	31/05/2024	Biochemistry And Cell Biology	Cell Development, Proliferation And Death	\$	934,253.30
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	University of South Australia	University	SA	Identification and assessment of new treatment options for the childhood cancer Neuroblastoma	Neuroblastoma is a devastating childhood cancer that is the leading cause of cancer related death in children under the age of five. Current therapies for high-risk patients are highly damaging and often lead to profound life-long side effects. Our work aims to understand the biological origin of this disease and to develop new personalized therapies for high-risk neuroblastoma patients.	Associate Professor Quenten Schwarz	Associate Professor Quenten Schwarz, Associate Professor Yesim Khew-Goodall, Professor Gregory Goodall, Professor Maria Karam, Doctor Jamie Fletcher, Doctor Katherine Pillman, Doctor Maria Kirby, Doctor Sophie Jessop	Targeted competitive	1/06/2021	31/07/2024	Oncology And Carcinogenesis	Cancer Cell Biology	\$	982,101.20
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	Murdoch Children's Research Institute	Medical Research Institute	VIC	Insights into CDKL5 neuronal regulation: pathways to improving neurological outcomes for CDKL5 Deficiency Disorder	CDKL5 Deficiency Disorder is a debilitating seizure disorder affecting young children, with no effective treatments. Our research will use several pioneering techniques to unravel CDKL5 function to a level never before attempted. We will study molecular pathways using human brain cells grown in a 3D environment to better mimic the human brain. In addition, a high-throughput drug screening program will be used to identify potential targeted therapies for children with CDD.	Doctor Nicole Van Bergen	Doctor Nicole Van Bergen, Doctor Anita Quigley, Doctor Alexander Harris, Professor John Christodoulou, Doctor Benjamin Rollo, Professor Robert Kapia	Targeted competitive	1/06/2021	30/09/2024	Biochemistry And Cell Biology	Cell Neurochemistry	\$	854,205.00
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	The University of Adelaide	University	SA	Engineered human stem cells for mutation-specific eradication of myofibrosis	Myofibrosis is a poorly understood cancer of bone marrow that eventually evolves into leukaemia. We have developed new tools by engineering stem cells to mimic driver genes in myofibrosis that can be used to test novel treatments and help us to understand how and why this disease occurs. Our technology has already led to a mutation-specific lead biological and a drug class strategy that we will test as a pre-clinical data package for phase I trials in Australia.	Associate Professor Daniel Thomas	Associate Professor Daniel Thomas, Doctor Andreas Reinisch, Associate Professor David Ross, Associate Professor Jeffrey Babon, Doctor Denis Yvorogov, Doctor Pramod Nair, Doctor Rhannon Morris	Targeted competitive	1/06/2021	31/05/2024	Cardiorespiratory Medicine And Haematology	Haematology	\$	853,274.50
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	Macquarie University	University	NSW	Improving decisions about access to stem cell interventions	This research will generate guidelines, and recommendations for determining when access to stem cell based interventions (SCBIs) should be confined to clinical trials, when SCBIs should be offered through clinical innovation, and when they should be offered as standard clinical practice. It will also generate principles for communication to help patients understand their options. This will facilitate better governance decisions and help patients make informed and values-based decisions.	Associate Professor Wendy Lipworth	Associate Professor Wendy Lipworth, Professor Cameron Stewart, Professor Megan Munise, Professor Ian Kerridge, Doctor Tania Lyagh, Doctor Claire Hooper, Professor Alan Petersen, Doctor Claire Tanner, Doctor Christopher Gyngell, Doctor Christopher Rudge	Targeted competitive	1/06/2021	30/11/2024	Applied Ethics	Bioethics (Human And Animal)	\$	799,543.40
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	The University of Adelaide	University	SA	Developing an Evidence-based Model for Building Trust in Australian Stem Cell Research and Therapies	This project seeks to explore the ethical, social, and legal issues associated with models for more open science in the context of Australian stem cell research with particular focus on stakeholder expectations for a stem cell commons. It will investigate what such a commons could contain or require, whether and how it could result in more inclusive and equitable research and clinical applications for better aligned with maximal public benefit, and how it could help to foster greater public trust.	Professor Rachel Ankeny	Professor Rachel Ankeny, Professor Dianne Nicol, Professor Joan Leach, Professor Christine Wells	Targeted competitive	1/06/2021	31/07/2024	Applied Ethics	Bioethics (Human And Animal)	\$	995,406.75
Stem Cell Therapies Mission	2021 Stem Cell Therapies	University of Melbourne	University	VIC	Cartilage based stem cell therapies for joint deformity and facial disfigurement. A framework for point-of-care manufacturing and delivery (ARISTOCART)	ARISTOCART is proposing first of its kind in Australia research that will allow live stem cells to be 3D printed and used as a material for treatments. The aim of this innovative solution not only for repairing cartilage loss which leads towards painful joint deformity but also facial disfigurement from ear and nose absence or loss. This national collaboration will use technology that will revolutionize the way we think about personalized care, patient involvement and scientific advancements.	Professor Peter Choong	Professor Peter Choong, Doctor Claire Tanner, Professor David Castle, Professor Gordon Wallace, Doctor John Gardner, Professor Jonathan Clark, Professor Nora Shields, Doctor Sharon Sagnella, Professor Simon Moulton, Doctor Samantha Bonni, Professor Philip Clarke, Doctor Serena Duchi, Doctor Tim Spelman, Associate Professor Payal Mukherjee, Doctor Chris Schilling, Associate Professor Ruta Gupta, Professor Michelle Downey, Doctor Cathal O'Connell, Doctor Joseph Dusseldorp, Doctor Johnson Chung, Associate Professor Stephen Beirne, Doctor Sanjeev Gambhir, Emma Ruahkuroke, Associate Professor Claudia Di Bella, Doctor Andrew Ronchi	Targeted competitive	1/06/2022	30/09/2027	Medical Biotechnology	Medical Biotechnology, Regenerative Medicine (incl. Stem Cells And Tissue Engineering)	\$	6,999,671.10
Stem Cell Therapies Mission	2021 Stem Cell Therapies	Cartherics Pty Ltd	Corporation	VIC	Gene modified pluripotent stem cells to generate and empower innate immune cells against poor-prognosis cancers	Standard treatments often do not stop patients dying of common and widely spread solid cancers. A new kind of cell and gene therapy can drive individual patients' immune systems to get rid of widespread blood cancers. But this immunotherapy does not yet work so well for common solid cancers. We aim to beat this problem by creating banks of 'off-the-shelf' functionally enhanced killer immune cells to treat many patients and can also engage the patient's own immune system in tumour destruction.	Professor Michael Brown	Professor Michael Brown, Doctor Runzhe Shu, Doctor Pollyanna Goh, Nicholas Boyd, Doctor Peter Hudson, Professor Alan Trounson, Professor Richard Boyd, Professor Peter Currie, Jennifer Hollands, Associate Professor Mikael Martino, Doctor David Liu, Doctor Ian Nisbet, Associate Professor Nicholas Clemen, Professor Graham Leschke, Walid Asar, Maureen Howard, Doctor Vera Evtimov	Targeted competitive	1/06/2022	31/05/2027	Medical Biotechnology	Medical Biotechnology, Regenerative Medicine (incl. Stem Cells And Tissue Engineering)	\$	5,376,696.00
Stem Cell Therapies Mission	2021 Stem Cell Therapies	University of Melbourne	University	VIC	Necessary steps to advance a pluripotent stem cell-derived tissue repair therapy to the clinic for stroke	Despite great hope for stem cell therapies for stroke, clinical trials to date have largely failed due to a focus on safety at the expense of evidence of preclinical efficacy. We recently showed that human stem cell grafts could restore limb function in a stroke model. This study will now perform a series of iterative, necessary preclinical optimisation, safety and functionality testing of a stem cell product suitable for a Phase I clinical trial in stroke patients.	Professor Clare Parish	Professor Clare Parish, Doctor Charlotte Ermine, Professor Lachlan Thompson, Professor Clive May	Targeted competitive	1/06/2022	31/05/2026	Neurosciences	Neurosciences, Central Nervous System, Medical Biotechnology, Regenerative Medicine (incl. Stem Cells And Tissue Engineering), Neurosciences, Cellular Nervous System	\$	2,065,971.00
Stem Cell Therapies Mission	2021 Stem Cell Therapies	University of Sydney	University	NSW	Development of photoreceptor cell therapy to treat blindness	This research lays the foundation of retinal cell therapy for the treatment of blinding eye diseases caused by the degeneration of the light-sensing cells in the eye. A renewable source of human stem cells will be created from which transplantable photoreceptor cells will be produced for regenerative therapy of the retina. This pre-clinical process development enables translational research in stem cell medicine and cell therapy and offers a path to clinical trials of retinal cell therapy.	Doctor Anal Gonzalez Cordero	Doctor Anal Gonzalez Cordero, Associate Professor Matthew Simunovic, Professor Roger Reddel, Professor John Grigg, Doctor Kate Hetherington, Associate Professor Ngire Dwoad, Professor Patrick Tam, Professor Hale Zreig, Professor Robyn Jamieson, Associate Professor Perygi Yang, Professor Claire Wakefield	Targeted competitive	1/06/2022	31/05/2027	Ophthalmology And Optometry	Ophthalmology And Optometry, Ophthalmology	\$	2,566,652.72
Stem Cell Therapies Mission	2021 Stem Cell Therapies	Monash University	University	VIC	Pre-clinical evaluation of selective adenosine A1 receptor positive allosteric modulators for the treatment of Drug-resistant epilepsy	Current drugs for epilepsy have limited efficacy because of over-reliance on a few animal models of provoked seizures to randomly screen compounds in preclinical development, resulting in many 'me-too' drugs that have limited modes of actions. This project will utilise our stem cell derived neural and heart platforms to develop a brand new class of compounds and test them in an animal model of drug-resistant epilepsy. Upon project completion the compounds will be ready for clinical trialling.	Professor Patrick Kwan	Professor Patrick Kwan, Professor Peter Scammells, Doctor Lauren May, Professor Chris Langmead, Doctor Pablo Guillen Espinosa, Professor Arthur Christopoulos, Doctor Jo-Anne Baltos, Doctor Ana Antonic-Baker, Doctor Karen Gregory, Professor Terence O'Brien, Doctor Sara Howden, Doctor Huseyin Sumar, Doctor Benjamin Rollo, Associate Professor David Elliott, Doctor Anh Thi Ngoc Nguyen	Targeted competitive	1/06/2022	31/05/2027	Neurosciences	Neurosciences, Central Nervous System	\$	3,849,003.60
Stem Cell Therapies Mission	2021 Stem Cell Therapies	Griffith University	University	QLD	Drug discovery for schizophrenia using patient-derived stem cells	Schizophrenia is a debilitating life-long disease. Annually, it costs the Government about \$4M and the community almost \$5M. There are few medications for schizophrenia. We will use stem cells from people with schizophrenia to discover new therapies by screening Drugs already approved for use in other diseases. Those that reverse differences we find in the schizophrenia stem cells will yield novel drugs that have the potential to be innovative therapeutics to benefit all Australians.	Doctor Alexane Cristino	Doctor Alexane Cristino, Professor Michael Berk, Professor Ken Walker, Professor Vicki Avery, Emeritus Professor Alan Maday-Sim	Targeted competitive	1/06/2022	30/09/2025	Biochemistry And Cell Biology	Biochemistry And Cell Biology, Cellular Interactions (incl. Adhesion, Matrix, Cell Wall)	\$	1,425,156.50
Stem Cell Therapies Mission	2021 Stem Cell Therapies	University of Western Australia	University	WA	Eyes and Ears: a human retinal and inner ear organoid platform for pre-clinical screening of novel therapeutics for Usher Syndrome	Usher syndrome (USH) is a cruel and incurable disease that robs patients of both sight and hearing. In this project, we bring together experts in eye and ear clinical care and research to develop new treatments for USH. Our clinicians will prepare our USH patients for inclusion in upcoming clinical trials. In parallel, our scientists will grow retinal and inner ear tissues from patient stem cells in the lab, and use them to evaluate the promising new USH treatments being developed by our team.	Doctor Samuel McLenahan	Doctor Samuel McLenahan, Doctor Daniel Brown, Professor Stephen Wilton, Associate Professor Fred Chen, Doctor Yee Man Elaine Wong, Associate Professor Hans Al-Salam, Doctor Livia Carvalho, Professor Marcus Atlas	Targeted competitive	1/06/2022	31/05/2025	Medical Biotechnology	Medical Biotechnology, Gene And Molecular Therapy, Ophthalmology And Optometry, Ophthalmology, Clinical Sciences, Otorhinolaryngology	\$	2,215,017.62

Stem Cell Therapies Mission	2022 Stem Cell Therapies	University of Sydney	University	NSW	Transforming corneal stem cell-based therapies with innovative bioengineered technologies	Our group was first to discover a novel method of stem cell transplantation using contact lenses to treat corneal blindness. The cornea is the eye's window and stem cells ensure its clarity for vision. To improve the success of our stem cell treatment so that it can reach the clinic and restore sight, our team of experts will use patient-derived biomaterials to support stem cells during transplantation. Whilst our educational and policy experts ready the sector for corneal stem cell therapies.	Professor Stephanie Watson	Professor Stephanie Watson, Doctor Timothy Hughes, Professor Nick Di Girolamo, Doctor Gurvir Singh, Associate Professor Laura Downie, Associate Professor James Guy Lyons, Doctor Maria Cabrera Aguiar, Professor Megan Munroe, Doctor Yagambha Ramaswamy, Doctor Himani Kanab, Doctor Helmut Thissen.	Targeted competitive	1/02/2023	31/01/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Ophthalmology And Optometry, Ophthalmology, Engineering, Biomedical Engineering, Biomaterials	\$	567,683.00
Stem Cell Therapies Mission	2022 Stem Cell Therapies	University of Sydney	University	NSW	Purification and cryopreservation of an allogeneic stem cell-derived photoreceptor cell product	This research lays the foundation of retinal cell therapy for the treatment of blinding eye diseases caused by the degeneration of the light-sensing cells in the eye. A renewable source of human stem cells will be created from which transplantable photoreceptor cells will be produced for regenerative therapy of the retina. This pre-clinical process development enables translational research in stem cell medicine and cell therapy and offers a path to clinical trials of retinal cell therapy.	Doctor Anal Gonzalez Cordero	Doctor Anal Gonzalez Cordero, Associate Professor Nigam Elwood, Professor Patrick Tam, Hani Jeun Kim, Associate Professor Pengyi Yang	Targeted competitive	1/02/2023	31/01/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Medical Biotechnology, Regenerative Medicine (incl. Stem Cells)	\$	515,340.00
Stem Cell Therapies Mission	2022 Stem Cell Therapies	St Vincent's Institute of Medical Research	Medical Research Institute	VIC	PAGETURN: Pioneering Application of Gene Editing in Transplant Using RNA	We will apply cutting edge gene editing technologies in blood stem cells, to prevent children and young adults from dying from bone marrow failure syndromes. We aim to: 1) consolidate Australian gene editing capabilities, 2) demonstrate proof-of-principle corrective gene editing in blood stem cells, 3) trial a feasible, curative, blood stem cell product, and 4) determine the clinical framework for implementation of a therapy.	Associate Professor Andrew Deans	Associate Professor Andrew Deans, Professor Alex Hewitt, Doctor Lucy Fox, Doctor Paula Rio, Doctor Piers Blombery, Doctor Kirsten Fairfax, Professor Colin Pouton, Professor David Ritchie, Associate Professor Wayne Crismani, Associate Professor Rachel Conyers, Associate Professor Jorg Heierhorst, Professor Tracy Bryan	Targeted competitive	1/02/2023	31/03/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Medical Biotechnology, Gene And Molecular Therapy, Biomedical And Clinical Sciences, Paediatrics, Paediatrics Not Elsewhere Classified, Biological Sciences, Biochemistry And Cell Biology, Synthetic Biology	\$	979,980.00
Stem Cell Therapies Mission	2022 Stem Cell Therapies	St Vincent's Institute of Medical Research	Medical Research Institute	VIC	Bio-engineering vascularized skin flaps for complex wound reconstruction	Serious 'difficult to heal' skin wounds are repaired by harvesting thick 3-dimensional pieces of skin from other sites on the patient to cover and heal the wound. This surgery is complex creating a second wound on the patient, involves frequent complications and is costly. This project will engineer in the laboratory human skin flaps derived from the patient's own cells which will eliminate skin flap harvest and reduce patient complications, pain and costs.	Associate Professor Geraldine Mitchell	Associate Professor Geraldine Mitchell, Doctor Anne King, Doctor Cathal O'Connell, Doctor Kirya Yap, Emeritus Professor Wayne Morrison	Targeted competitive	1/02/2023	31/07/2025	Engineering	Engineering, Biomedical Engineering, Tissue Engineering	\$	710,793.20
Stem Cell Therapies Mission	2022 Stem Cell Therapies	Monash University	University	VIC	Intracerebral delivery of Neuropeptide Y through hiPSC-derived progenitors (NPY-hiPSC- NPs) as a disease-modifying treatment for drug-resistant epilepsy	Epilepsy is a serious brain condition and seizure cannot be controlled despite the best available treatments in ~30% patients. The underlying mechanisms of drug resistance are poorly understood. We aim to investigate whether stem cells can be used as vehicles to deliver Neuropeptide Y, that can suppress seizures in drug-resistant epilepsy. This study will provide novel insights into how epilepsy develops, and form the basis for the development of novel disease modifying treatment strategies.	Professor Terence O'Brien	Professor Terence O'Brien, Doctor Benjamin Rollo, Professor Patrick Kwan, Associate Professor Nigel Jones, Professor Margaret Morris, Doctor Ana Antonic-Baker	Targeted competitive	1/02/2023	31/01/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Neurosciences, Cellular Nervous System	\$	671,512.00
Stem Cell Therapies Mission	2022 Stem Cell Therapies	The Walter and Eliza Hall Institute of Medical Research	Medical Research Institute	VIC	A novel stem cell-derived manufacturing platform for next-generation dendritic cell vaccines	Dendritic cells (DCs) are immune sentinels that alert then rid the body of 'foreign' components, including cancer. However, no clinical trials in cancer patients have ever been undertaken with the 'right' kind of DCs because not enough of them can be made. Our novel method can generate >100 times more of the 'right' kind of DCs from a patient's stem cells. In this proposal, we will adapt their generation so it meets approval for use in a Phase I anti-cancer immunotherapy trial.	Associate Professor Shalin Naik	Associate Professor Shalin Naik, Doctor Cindy Audiger, Associate Professor Jane Olaro, Professor Simon Harrison, Professor Stephen Nutt	Targeted competitive	1/02/2023	31/05/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Immunology, Cellular Immunology, Biomedical And Clinical Sciences, Immunology, Tumour Immunology, Biomedical And Clinical Sciences, Oncology And Carcinogenesis, Solid Tumours	\$	909,695.60
Stem Cell Therapies Mission	2022 Stem Cell Therapies	Centre for Eye Research Australia Limited	Medical Research Institute	VIC	Development of a photoreceptor regenerative therapy to treat blindness	Photoreceptors are the light-sensing cells in the retina, and their loss in many diseases leads to incurable blindness. Using human retinal stem cells, this project will identify a set of specific genes to stimulate cell reprogramming and regenerate photoreceptors. We will also test the feasibility of this regenerative approach in a rodent disease model. Our findings will allow us to develop a novel reprogramming therapy to stimulate retinal regeneration and restore vision in blinding patients.	Associate Professor Raymond Ching-Bong Wong	Associate Professor Raymond Ching-Bong Wong, Doctor Thomas Edwards, Yuh Han Loh, Professor Colin Martin, Associate Professor Chi Liu, Doctor Shang Lim	Targeted competitive	1/02/2023	31/01/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Ophthalmology And Optometry, Ophthalmology, Biomedical And Clinical Sciences, Medical Biotechnology, Regenerative Medicine (incl. Stem Cells), Biomedical And Clinical Sciences, Medical Biotechnology, Gene And Molecular Therapy	\$	587,569.30
Stem Cell Therapies Mission	2022 Stem Cell Therapies	University of New South Wales	University	NSW	Bioengineered tissue models to identify new antiarrhythmics for atrial fibrillation	We will use sophisticated engineered tissue models of atrial fibrillation (AF) as the basis of a new high throughput screen for better and safer drugs for AF. Our models incorporate genetic and environmental modifiers by combining heart muscle cells with fibroblasts (involved in scarring of the heart) and signalling from adipocytes (fat cells), allowing detailed examination of the pathology of AF, and development of pharmacological treatments for this potentially fatal disorder.	Doctor Adam Hill	Doctor Adam Hill, Doctor David Tsai, Doctor Valentin Romanov, Andrew Grace, Jessica Farr, Doctor Sara Ballou, Professor Jamie Vandenberg, Doctor Jordan Thorpe, Professor Diane Fafini, Doctor Matthew Perry, Associate Professor Eddy Kizana, Professor Nigel Lovell	Targeted competitive	1/02/2023	30/04/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Cardiovascular Medicine And Haematology, Cardiology (incl. Cardiovascular Diseases), Engineering, Biomedical Engineering, Biomechanical Engineering	\$	979,564.92
Stem Cell Therapies Mission	2022 Stem Cell Therapies	The University of Queensland	University	QLD	Moon's Mission: creating a replicable therapeutic framework for hereditary spastic paraplegia	Patients with the hereditary spastic paraplegia SPG5 develop spasticity, progressive weakness of lower limbs and neurological defects during early childhood but no treatment exists. Using advanced patient specific stem cell derived brain organoid models we will test the safety and efficacy of viral gene therapy and benchmark this approach against traditional mouse models. Importantly, this pre-clinical testing framework can then be replicated for other genetic brain diseases.	Professor Ernst Wolvetang	Professor Ernst Wolvetang, Professor David Caman, Professor Matthias Klugmann, Doctor Hannah Leeson, Doctor Dominik Froehlich, Doctor Connie Ross, Professor Richard Leverter, Professor Elizabeth Gillan	Targeted competitive	1/02/2023	31/01/2025	Biological Sciences	Biological Sciences, Genetics, Neurogenetics, Biomedical And Clinical Sciences, Pharmacology And Pharmaceutical Sciences, Clinical Pharmacology And Therapeutics	\$	940,424.52
Stem Cell Therapies Mission	2022 Stem Cell Therapies	Flinders University	University	SA	Pre-clinical iPSC neuron screen of repurposed drugs for children with a form of dementia	There is no cure for the fatal childhood dementia Sanfilippo syndrome, and distressing symptoms destroy the quality of their short lives. We will use a state-of-the-art screening platform with patient-derived iPSC-neurons to rapidly identify repurposed drugs that can correct neuronal dysfunction. This will accelerate clinical trials to address symptoms, improve quality of life for children with Sanfilippo and their families, and establish an innovative model for other childhood dementias.	Associate Professor Cedric Bardy	Associate Professor Cedric Bardy, Doctor Zarina Greenberg, Doctor Nicholas Smith, Doctor Lisa Meltzer, Professor Kim Hemsley, Doctor Christopher Bye, Professor Mark Hutchison	Targeted competitive	1/02/2023	31/01/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Neurosciences, Cellular Nervous System	\$	738,228.02
Stem Cell Therapies Mission	2022 Stem Cell Therapies	St Vincent's Institute of Medical Research	Medical Research Institute	VIC	Repurposing Clinical Grade Medications for Treatment of Friedrich Ataxia Heart Disease	Friedreich ataxia (FRDA) is a genetic disorder and heart disease is the leading cause of premature death in FRDA patients. There is currently no treatment for FRDA heart disease. We will use patient-specific stem cells to create a FRDA heart disease model-in-a-dish to achieve a better understanding of disease development and progression. This study will establish a pre-clinical human model of FRDA heart disease, for discovery of new therapies and to facilitate pre-clinical trials.	Doctor Shiang Lim	Doctor Shiang Lim, Associate Professor Marek Napierala, Associate Professor Kaylene Simpson, Doctor Jarmon Lees, Doctor David McCarthy, Associate Professor Louise Corben	Targeted competitive	1/02/2023	30/06/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Cardiovascular Medicine And Haematology, Cardiology (incl. Cardiovascular Diseases)	\$	812,364.52
Stem Cell Therapies Mission	2022 Stem Cell Therapies	Murdoch Children's Research Institute	Medical Research Institute	VIC	Novel human stem cell based models of genetic cardiomyopathy as a platform for disease modelling and therapeutic development	Heart Disease is the leading cause of death worldwide, taking a life every 20 seconds. This is a huge burden for patients, families, and global healthcare systems. There is great need to create new and more effective treatments for these patients with heart disease. The goal of this application is to develop and validate new human stem cells models of genetic heart disease to understand the root cause of these diseases. In time, this will lead to the creation of new and effective therapies.	Doctor James McNamara	Doctor James McNamara, Professor Enzo Porrello, Associate Professor David Elliott, Doctor Benjamin Parker, Associate Professor Mirza Ramialison, Professor Zornitza Stark, Professor Perry Elliott, Associate Professor Luis Lopez	Targeted competitive	1/02/2023	30/06/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Cardiovascular Medicine And Haematology, Cardiology (incl. Cardiovascular Diseases)	\$	732,251.00
Stem Cell Therapies Mission	2022 Stem Cell Therapies	The University of Adelaide	University	SA	Bioengineering a Superior Humanized Haematopoietic Niche Derived from Mesenchymal Stem Cells for Pre-Clinical Avatar Cancer Trials	Breakthroughs in cancer therapies has been slowed in recent years due to the lack of appropriate disease models utilised for studying disease and effective treatments prior to pre-clinical studies. We have developed a reproducible model for human blood cancers using human stem cells from bone marrow tissue. Our model enables prediction and testing of novel therapies for poor prognosis blood cancers.	Associate Professor Daniel Thomas	Associate Professor Daniel Thomas, Doctor Andreas Reinisch, Doctor Chloe Thompson-Peach, Associate Professor Jason Powell, Professor Susan Branford, Doctor Agnieszka Arthur, Professor Stuart Pison, Professor Timothy Hughes, Associate Professor David Ross, Doctor Laura Edney	Targeted competitive	1/02/2023	31/07/2025	Biomedical And Clinical Sciences	Biomedical And Clinical Sciences, Medical Biotechnology, Regenerative Medicine (incl. Stem Cells)	\$	854,593.92
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury	Murdoch Children's Research Institute	Medical Research Institute	VIC	Can predictive markers assist in early detection of children at risk for persisting symptoms and their response to prevention and intervention?	In the context of wide media attention, child concussion is of increasing community concern, despite limited empirical evidence regarding its real consequences. Our research will identify mechanisms underpinning persisting symptoms and link these predictive markers to recovery profiles and to individual responses to prevention and treatment.	Professor Vicki Anderson	Professor Vicki Anderson, Professor Franz Babl, Professor Vera Ignatovic, Professor Gavin Davis, Professor Karen Barlow, Mr Stephen Heaps, Doctor Michael Takagi	Targeted competitive	1/06/2020	31/05/2024	Clinical Sciences	Clinical Sciences Not Elsewhere Classified	\$	1,975,723.00
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury	The University of Adelaide	University	SA	Forecasting Impairment and Neurodegenerative Disease risk following Traumatic Brain Injury (TBI-TBI): A computational neurology-driven method to predict long-term prognosis	Traumatic brain injury (TBI) can be associated with persistent memory and decision making impairments and motor dysfunction. TBI also increases risk of developing neurodegenerative diseases, including dementia and Parkinson's disease. There are currently no clinical tools to predict who is most at risk of long-term impairments. This project will use both innovative brain imaging techniques and novel blood injury markers to understand disease progression in order to improve prognosis.	Associate Professor Lyndsey Collins-Prairo	Associate Professor Lyndsey Collins-Prairo, Professor Mark Jenkins, Doctor Irina Baetu, Doctor Adam Wells, Professor Samuel Gandy, Associate Professor Rene Turner, Doctor Frances Corrigan, Adel Helmy, Doctor Murthy Mitty	Targeted competitive	1/06/2020	31/05/2024	Neurosciences	Neurology And Neuromuscular Diseases	\$	1,987,160.00
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury	The University of Queensland	University	QLD	PREDICT-TBI - Prediction and Diagnosis using Imaging and Clinical Biomarkers Trial in Traumatic Brain Injury: the value of Magnetic Resonance Imaging	PREDICT-TBI will evaluate the use of magnetic resonance imaging (MRI), combined with other candidate biomarkers, to predict patient recovery after traumatic brain injury. Biomarkers are indicators that help identify injury severity and predict outcome. An innovative artificial intelligence model will analyse several biomarkers in combination and follow them over time for a detailed picture of this complex condition. The results will facilitate shared decision making with patients and families.	Doctor Fatima Nasrallah	Doctor Fatima Nasrallah, Professor David Reutens, Doctor Shekhar Chandra, Doctor James Walsham, Professor Trevor Russell, Associate Professor Sandesh R, Doctor Daria Ross, Doctor Craig Winter, Doctor Sivagnanesel Senthanar, Doctor Judith Bellapart	Targeted competitive	1/06/2020	31/05/2024	Clinical Sciences	Clinical Sciences Not Elsewhere Classified	\$	1,765,000.00

Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	Curtin University	University	WA	An informatics approach to predict outcomes and monitor intervention efficacy following moderate to severe traumatic brain injury	Moderate to severe traumatic brain injury (TBI) can be devastating for those affected. We will design a way to confidentially gather data on treatment and outcomes of TBI in all States and Territories in Australia, including those in rural, remote and Aboriginal communities. This information will help to personalise care for individuals who experience TBI and b) determine which treatments work best for specific symptoms and individuals, to improve the lives of Australians with TBI.	Professor Melinda Fitzgerald	Professor Melinda Fitzgerald, Doctor Leanne Hassett, Doctor Adam Wells, Doctor Gary Mitchell, Doctor Robert McManus, Professor David Menon, Professor James Harrison, Professor Kate Curtis, Professor Stephen Rose, Professor Meng Law, Professor Terence O'Brien, Professor Paul Maria Parietel, Professor Andrew Holland, Associate Professor Jennifer Cullen, Professor Natasha Lamin, Professor Vicki Anderson, Professor James Vickers, Professor Gavin Williams, Professor Jennifer Fleming, Professor Leanne Togher, Professor Grahame Simpson, Professor Belinda Gabbie, Professor Tamara Owensworth, Professor Elizabeth Kendall, Professor Skye McDonald, Professor Jennie Pondford, Professor Michael Reade, Professor Daniel Fatovich, Professor Zoeli Balogh, Professor Mark Fitzgerald, Professor David Cooper, Professor Peter Cameron, Professor Sandra Lades, Professor Elizabeth Armstrong, Associate Professor Sandy Shultz, Associate Professor Kirsten Vallmuur, Associate Professor Dinesh Varma, Associate Professor Adam Scheinberg, Associate Professor Lyndsey Collins-Prairie, Associate Professor Anthony Delaney, Associate Professor Rosalind Jeffree, Doctor Sandra Braaf, Doctor Rowena Mobbs, Doctor Bridgette Somerville, Doctor Elaine Huxtable, Doctor	Targeted competitive	1/06/2021	31/05/2023	Neurosciences	Central Nervous System	\$	499,815.70
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	University of Sydney	University	NSW	From injury to long-term physical activity for people living with traumatic brain injury	This project aims to enhance participation in physical activity for Australians living with moderate-to-severe traumatic brain injury through the adaptation and translation of the newly released WHO physical activity guidelines for people living with disability. This project will identify the current patient journey from injury to community-reintegration, identifying who, where and how physical activity is prescribed, identifying examples of evidence-based care and where service gaps exist.	Doctor Leanne Hassett	Doctor Leanne Hassett, Professor Catherine Sherrington, Associate Professor Sean Tweedy, Professor Luke Wolfenden, Professor Mary, Professor Kirsten Howard, Doctor Abigail Haynes	Targeted competitive	1/06/2021	31/05/2023	Clinical Sciences	Rehabilitation and Therapy (Excl. Physiotherapy)	\$	406,506.00
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	Monash University	University	VIC	PRECISION-TBI – Promoting evidence-based, data driven care for critically ill moderate-to-severe TBI patients	Our aim is to establish a consumer-enriched, clinician-driven, neurocritical care research collaborative across all major neurotrauma centres in Australia and New Zealand, so as to improve the health and social outcomes for m-STBI patients. We will achieve this, by completing the following: 1. Identifying key knowledge gaps via a bi-national Delphi process; 2) collecting highly granular data on current practice; and 3) establishing the infrastructure to test novel interventions in future RCTs.	Professor Andrew Udy	Professor Andrew Udy, Professor David Cooper, Associate Professor Rosalind Jeffree, Professor Rinaldo Bellomo, Professor Alistair Nichol, Professor Terence O'Brien, Doctor Judith Bellapara, Professor David Menon, Doctor Robert McManus, Professor Melinda Fitzgerald	Targeted competitive	1/06/2021	31/05/2025	Neurosciences	Central Nervous System	\$	499,477.70
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	Monash University	University	VIC	The Australian Traumatic Brain Injury National Data (ATBIND) Project	The Australian Government is investing \$50 million over 10 years to better predict recovery outcomes after a traumatic brain injury and to identify the most effective care and treatments. These goals will be difficult to achieve without baseline data, which is currently lacking. This project will provide current national data on the incidence of those with moderate to severe brain injury, as well as identifying existing treatment variables, shortfalls and associated outcomes.	Professor Gerard O'Reilly	Associate Professor Gerard O'Reilly, Professor Mark Fitzgerald, Professor Kate Curtis, Yesul Kim, Nick Rushworth, Professor Biswadev Mitra, Associate Professor John Lee, Doctor Catherine Huxtable, Doctor Courtney Ryder, Associate Professor Delia Hendrie	Targeted competitive	1/06/2021	31/05/2023	Clinical Sciences	Surgery	\$	365,995.00
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	Monash University	University	VIC	Exercise therapy for mild traumatic brain injury (mTBI) and persistent post-concussion symptoms (PPCS) across the lifespan	Mild traumatic brain injuries (mTBI) result in debilitating impairments that can persist for months. The clinical management of these injuries is difficult because there are no treatments to improve recovery in patients across the lifespan. This project will test whether an aerobic exercise intervention, that is beneficial in adolescents, can also improve recovery in adults with mTBI patients. We will also develop protocols that can be accessed and used in clinical settings across Australia.	Professor Terence O'Brien	Professor Terence O'Brien, Professor John Leddy, Associate Professor Catherine Willmott, Professor Biswadev Mitra, Associate Professor Sandy Shultz, Doctor Zhen Chen, Doctor Stuart McDonald, Associate Professor Andrew Morokoff, Professor Karen Caveneyberghs	Targeted competitive	1/06/2021	31/05/2024	Neurosciences	Neurology And Neuromuscular Diseases	\$	499,705.00
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	University of Tasmania	University	TAS	Transforming Awareness, Literacy & Knowledge of Traumatic Brain Injury (TALK-TBI)	This project assesses current Australian awareness of traumatic brain injury (TBI) to identify gaps in community knowledge that can lead to poor outcomes for individuals living with TBI. We will use innovative educational tools that include stories of lived experience and visual arts to broaden Australians' understanding of TBI. Education will cover the spectrum of injury from mild through to moderate-severe as well as the journey from the initial injury through to moving back into community.	Doctor Jenna Ziebell	Doctor Jenna Ziebell, Doctor Peta Cook, Doctor Kathleen Doherty, Doctor Claire Eccleston, Doctor Tanya Schramm, Professor Melinda Fitzgerald, Doctor Christine Padgett, Professor Anna King, Professor James Vickers	Targeted competitive	1/06/2021	31/05/2025	Public Health And Health Services	Health Promotion	\$	999,998.00
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	University of Tasmania	University	TAS	Clinical practice guidelines for the management of psychosocial disorders following adult traumatic brain injury	Disorders of psychosocial functioning are common following adult TBI, which result in long-term emotional difficulties and behaviours of concern. They represent a significant barrier to reintegration and engagement in meaningful life goals. Successful management of these disorders is critically important to recovery. This project will develop de novo clinical practice guidelines for the management of psychosocial disorders in adults with TBI.	Doctor Cynthia Horan	Doctor Cynthia Horan, Professor Skye McDonald, Emeritus Professor Jacqui Douglas, Professor Tamara Owensworth, Associate Professor Grahame Simpson, Doctor Dana Wong, Doctor Travis Wearne, Professor Angela Morgan	Targeted competitive	1/03/2022	28/02/2024	Clinical Sciences	Rehabilitation And Therapy (Excl. Physiotherapy)	\$	448,051.00
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	The University of Queensland	University	QLD	Australian Clinical Practice Guidelines for the Assessment and Management of Mild Traumatic Brain Injury and Post-Concussion Symptoms	Clinical practice guidelines (CPG) provide clinicians with the information they need to care for people with mild traumatic brain injury (mTBI) and post-concussion symptoms. Up-to-date CPGs tailored to the Australian setting are more likely to be used. This project will develop a contextual CPG to facilitate best practice care for people with mTBI. Its recommendations will account for Australian circumstances and at-risk populations, including Aboriginal and Torres Strait Islander peoples.	Professor Karen Barlow	Professor Karen Barlow, Professor Jennie Pondford, Professor Fran Babi, Associate Professor Paul McCrory, Professor Vicki Anderson, Professor Gavin Davis, Doctor Julia Treleven, Professor John Over, Doctor Gill Cowen, Professor Rebecca Kimble	Targeted competitive	1/03/2022	30/04/2024	Public Health And Health Services	Public Health And Health Services Not Elsewhere Classified	\$	497,834.00
Traumatic Brain Injury Mission	2021 Traumatic Brain Injury	Curtin University	University	WA	AUS-mTBI: designing and implementing the health informatics approaches to enhance treatment and care for people with mild TBI	Mild TBI (or concussion) can lead to continuing symptoms and isn't well managed. The AUS-mTBI national consortium will build online platforms including an App, to facilitate collection of mild TBI data from people across Australia. The team will analyse that data and identify the factors that predict optimal outcomes. The team will then feed this information back into our platforms, to create an accessible, evidence-based resource to guide care and improve outcomes for people with mild TBI.	Professor Melinda Fitzgerald	Professor Melinda Fitzgerald, Doctor Jonathan Buller, Associate Professor Paul McCrory, Professor Karen Barlow, Associate Professor Lyndsey Collins-Prairie, Doctor Jesse Young, Doctor Sarah Hellewell, Professor Kirsten Vallmuur, Mr Alexander King, Associate Professor Peter Bragge, Associate Professor Grahame Simpson, Associate Professor John Gilroy, Professor Natasha Lamin, Professor Daniel Fatovich, Doctor Michael Makitsis, Professor Patrick Kwan, Professor Christopher Levi, Associate Professor Zongyuan Ge, Professor Gavin Davis, Professor Belinda Gabbie, Professor Paul Parietel, Mr George Charalambous, Professor Fran Babi, Professor Kate Curtis, Professor Karen Caveneyberghs, Ms Jennifer Cullen, Associate Professor Sandy Shultz, Patricia Ratajczak, Professor Vicki Anderson, Associate Professor Delia Hendrie, Professor Terence O'Brien, Doctor Fatima Nasrallah, Professor Elizabeth Armstrong, Professor John Over, Professor Leanne Togher, Nick Rushworth, Professor Jennifer Fleming, Professor Biswadev Mitra, Doctor Gary Mitchell, Doctor Stuart McDonald, Professor Michael Reade, Maayken van den Berg, Professor Jennie Pondford, Jodie-Kate Williams, Doctor Jenna Ziebell, Gill Cowen, Professor Alison Hutchisson, Associate Professor Elaine Huxtable, Associate Professor	Targeted competitive	1/06/2022	31/05/2025	Neurosciences	Neurosciences, Central Nervous System	\$	2,999,658.00